
<html lang="en"     class="pb-page"  data-request-id="bdc77691-b7b3-4509-a792-111284d98611"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c00744;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update" /></meta><meta name="dc.Creator" content="Tizhi  Wu" /></meta><meta name="dc.Creator" content="Zhen  Qin" /></meta><meta name="dc.Creator" content="Yucheng  Tian" /></meta><meta name="dc.Creator" content="Jubo  Wang" /></meta><meta name="dc.Creator" content="Chenxi  Xu" /></meta><meta name="dc.Creator" content="Zhiyu  Li" /></meta><meta name="dc.Creator" content="Jinlei  Bian" /></meta><meta name="dc.Description" content="Cyclin-dependent kinase 9 (CDK9), which regulates transcriptional elongation, is an attractive therapeutic target for many cancers, especially for cancers driven by transcriptional dysregulation. I..." /></meta><meta name="Description" content="Cyclin-dependent kinase 9 (CDK9), which regulates transcriptional elongation, is an attractive therapeutic target for many cancers, especially for cancers driven by transcriptional dysregulation. I..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 31, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00744" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00744" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00744" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00744" /></link>
        
    
    

<title>Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00744" /></meta><meta property="og:title" content="Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0028.jpeg" /></meta><meta property="og:description" content="Cyclin-dependent kinase 9 (CDK9), which regulates transcriptional elongation, is an attractive therapeutic target for many cancers, especially for cancers driven by transcriptional dysregulation. In particular, CDK9 promotes RNA polymerase II pause/release, a rate-limiting step in normal transcriptional regulation that is frequently dysregulated in cancers. Emerging evidence indicates that selective CDK9 inhibition or degradation may provide a therapeutic benefit against certain cancers. Indeed, the development of CDK9 modulators (inhibitors and degraders) has attracted great attention, with several molecules currently under clinical development. This review provides an overview of recent advances in CDK9 modulators in general, with special emphasis on compounds under clinical evaluation and new emerging strategies, such as proteolysis targeting chimeras (PROTACs)." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Cyclin-dependent kinase 9 (CDK9), which regulates transcriptional elongation, is an attractive therapeutic target for many cancers, especially for cancers driven by transcriptional dysregulation. In particular, CDK9 promotes RNA polymerase II pause/release, a rate-limiting step in normal transcriptional regulation that is frequently dysregulated in cancers. Emerging evidence indicates that selective CDK9 inhibition or degradation may provide a therapeutic benefit against certain cancers. Indeed, the development of CDK9 modulators (inhibitors and degraders) has attracted great attention, with several molecules currently under clinical development. This review provides an overview of recent advances in CDK9 modulators in general, with special emphasis on compounds under clinical evaluation and new emerging strategies, such as proteolysis targeting chimeras (PROTACs)." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0028.jpeg" /></meta><meta name="twitter:title" content="Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00744"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00744">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00744&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00744&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00744&amp;href=/doi/10.1021/acs.jmedchem.0c00744" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 13228-13257</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00626" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00776" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Tizhi Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tizhi Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tizhi++Wu">Tizhi Wu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhen Qin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhen Qin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhen++Qin">Zhen Qin</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yucheng Tian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yucheng Tian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yucheng++Tian">Yucheng Tian</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jubo Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jubo Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jubo++Wang">Jubo Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chenxi Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chenxi Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chenxi++Xu">Chenxi Xu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhiyu Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiyu Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>Tel: +8613951678592. Email: <a href="/cdn-cgi/l/email-protection#017b696878746d68416271742f6465742f626f"><span class="__cf_email__" data-cfemail="9ae0f2f3e3eff6f3daf9eaefb4fffeefb4f9f4">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiyu++Li">Zhiyu Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6492-9511" title="Orcid link">http://orcid.org/0000-0001-6492-9511</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jinlei Bian</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinlei Bian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>Tel: +8615151865295. Email: <a href="/cdn-cgi/l/email-protection#086a6169666264486b787d266d6c7d266b66"><span class="__cf_email__" data-cfemail="b8dad1d9d6d2d4f8dbc8cd96dddccd96dbd6">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinlei++Bian">Jinlei Bian</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4552-1195" title="Orcid link">http://orcid.org/0000-0003-4552-1195</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00744&amp;href=/doi/10.1021%2Facs.jmedchem.0c00744" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 13228–13257</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 31, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 May 2020</li><li><span class="item_label"><b>Published</b> online</span>31 August 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00744" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00744</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D13228%26pageCount%3D30%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTizhi%2BWu%252C%2BZhen%2BQin%252C%2BYucheng%2BTian%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D22%26contentID%3Dacs.jmedchem.0c00744%26title%3DRecent%2BDevelopments%2Bin%2Bthe%2BBiology%2Band%2BMedicinal%2BChemistry%2Bof%2BCDK9%2BInhibitors%253A%2BAn%2BUpdate%26numPages%3D30%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D13257%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00744"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3164</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00744" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tizhi&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Zhen&quot;,&quot;last_name&quot;:&quot;Qin&quot;},{&quot;first_name&quot;:&quot;Yucheng&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Jubo&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Chenxi&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Zhiyu&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jinlei&quot;,&quot;last_name&quot;:&quot;Bian&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;13228-13257&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00744&quot;},&quot;abstract&quot;:&quot;Cyclin-dependent kinase 9 (CDK9), which regulates transcriptional elongation, is an attractive therapeutic target for many cancers, especially for cancers driven by transcriptional dysregulation. In particular, CDK9 promotes RNA polymerase II pause/release, a rate-limiting step in normal transcriptional regulation that is frequently dysregulated in cancers. Emerging evidence indicates that selective CDK9 inhibition or degradation may provide a therapeutic benefit against certain cancers. Indeed, the development of CDK9 modulators (inhibitors and degraders) has attracted great attention, with several molecules currently under clinical development. This review provides an overview of recent advances in CDK9 modulators in general, with special emphasis on compounds under clinical evaluation and new emerging strategies, such as proteolysis targeting chimeras (PROTACs).&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00744&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00744" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00744&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00744" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00744&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00744" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00744&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00744&amp;href=/doi/10.1021/acs.jmedchem.0c00744" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00744" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00744" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00744%26sid%3Dliteratum%253Aachs%26pmid%3D32866383%26genre%3Darticle%26aulast%3DWu%26date%3D2020%26atitle%3DRecent%2BDevelopments%2Bin%2Bthe%2BBiology%2Band%2BMedicinal%2BChemistry%2Bof%2BCDK9%2BInhibitors%253A%2BAn%2BUpdate%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D22%26spage%3D13228%26epage%3D13257%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/22" title="Go to Volume 63, Issue 22"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/jmcmar.2020.63.issue-22/20201125/jmcmar.2020.63.issue-22.largecover.jpg" alt="Go to Volume 63, Issue 22"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cyclin-dependent kinase 9 (CDK9), which regulates transcriptional elongation, is an attractive therapeutic target for many cancers, especially for cancers driven by transcriptional dysregulation. In particular, CDK9 promotes RNA polymerase II pause/release, a rate-limiting step in normal transcriptional regulation that is frequently dysregulated in cancers. Emerging evidence indicates that selective CDK9 inhibition or degradation may provide a therapeutic benefit against certain cancers. Indeed, the development of CDK9 modulators (inhibitors and degraders) has attracted great attention, with several molecules currently under clinical development. This review provides an overview of recent advances in CDK9 modulators in general, with special emphasis on compounds under clinical evaluation and new emerging strategies, such as proteolysis targeting chimeras (PROTACs).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55014" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55014" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Today, cancer remains one of the leading causes of death and a serious threat to human health worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> From the microscopic point of view, the unlimited abnormal proliferation of cells is the main feature of tumorigenesis and development.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In multicellular organisms, cell proliferation and differentiation are regulated by the cell cycle.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Dysregulation of the cell cycle and increased resistance to apoptosis are the main causes of tumors.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> As members of the serine/threonine kinase family, cyclin-dependent kinases (CDKs) are major drivers of cell cycle regulation mechanisms, promoting DNA synthesis and mitosis by phosphorylation of key substrates.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> The abnormal activation of CDKs promotes dysregulation of the cell cycle and uncontrolled proliferation of cells, leading to the development of malignant cancer.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Accordingly, targeting CDKs has been considered as an effective strategy for developing anticancer drugs.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a></div><div class="NLM_p">The biological activity of CDKs is tightly associated with another family of regulatory proteins called cyclins.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> They bind together to form functional heterodimeric complexes responsible for the regulation of various cellular vital functions, including proliferation, differentiation, apoptosis, and DNA damage repair.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> While CDKs levels remain constant throughout the cell cycle, the levels of cyclins vary according to the protein synthesis and proteasome degradation rates, ensuring that CDKs are not activated until needed.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Depending on their function, CDKs are divided into cell cycle CDKs (including CDK1, CDK2, CDK4, CDK6) and transcriptional CDKs (including CDK7–9, CDK11–13, CDK19) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Cell cycle CDKs play significant roles in the synchronization of cell cycle progression, while transcriptional CDKs are mainly involved in mechanisms of transcriptional regulation (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Recently, the recognition of transcriptional addiction as a potential vulnerability in various cancer types has led to an increasing interest in transcriptional CDKs.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> As a key activator in transcriptional regulation, CDK9 has attracted special attention from medicinal chemists.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biological Functions of Representative CDKs and Their Corresponding Cyclins</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">classification</th><th class="colsep0 rowsep0" align="center">CDK<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cyclin</th><th class="colsep0 rowsep0" align="center">functions</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="5" align="left">cell cycle CDKs</td><td class="colsep0 rowsep0" align="left">CDK1</td><td class="colsep0 rowsep0" align="left">cyclins A and B</td><td class="colsep0 rowsep0" align="left">regulate G2 and M phase and control entry into mitosis<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="left">cyclins A and E</td><td class="colsep0 rowsep0" align="left">phosphorylate RB<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a>, activate transcription factors E2F, and govern DNA replication<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK3</td><td class="colsep0 rowsep0" align="left">cyclin C</td><td class="colsep0 rowsep0" align="left">phosphorylate RB and regulate G1 phase<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK4/6</td><td class="colsep0 rowsep0" align="left">cyclin D</td><td class="colsep0 rowsep0" align="left">mediate the phosphorylation and inactivation of RB and regulate entry into the S phase<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK5</td><td class="colsep0 rowsep0" align="left">cyclin D</td><td class="colsep0 rowsep0" align="left">regulate neuronal process, promote angiogenesis, and increase expression of cyclins and other CDKs<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="7" align="left">transcriptional CDKs</td><td class="colsep0 rowsep0" align="left">CDK7</td><td class="colsep0 rowsep0" align="left">cyclin H</td><td class="colsep0 rowsep0" align="left">regulate the initiation and elongation of transcription and activate CDKs<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK8</td><td class="colsep0 rowsep0" align="left">cyclin C</td><td class="colsep0 rowsep0" align="left">a subunit of the mediator complex that functions as a transcriptional regulator<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK9</td><td class="colsep0 rowsep0" align="left">cyclins T and K</td><td class="colsep0 rowsep0" align="left">promote transcription elongation<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK11</td><td class="colsep0 rowsep0" align="left">cyclins L1 and L2</td><td class="colsep0 rowsep0" align="left">play significant roles in mRNA transcription, mitosis, and cell apoptosis<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK12</td><td class="colsep0 rowsep0" align="left">cyclin K</td><td class="colsep0 rowsep0" align="left">phosphorylate the CTD<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> of RNA polymerase II and regulate mRNA processing<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK13</td><td class="colsep0 rowsep0" align="left">cyclin K</td><td class="colsep0 rowsep0" align="left">regulate mRNA processing and gene expression<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK19</td><td class="colsep0 rowsep0" align="left">cyclin C</td><td class="colsep0 rowsep0" align="left">control mediator structure and function and phosphorylate transcription factors<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">CDKs, cyclin-dependent kinases.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">RB, retinoblastoma proteins.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">CTD, C-terminal repeat domain.</p></div></div></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Role of CDKs and their corresponding cyclins in the regulation of cell cycle and transcription. Cell cycle-related CDKs: Binding of CDK4/6 to cyclin D releases the E2F transcription factor and starts the cell cycle by phosphorylating the retinoblastoma protein (Rb). Inhibitors of CDK4 (INK4) proteins (p15<sup>INK4B</sup>, p16<sup>INK4A</sup>, p18<sup>INK4C</sup>, and p19<sup>INK4D</sup>) inhibit CDK4/6 activation. The CDK2-cyclin E complex maintains the phosphorylation of Rb, while the CDK2-cyclin A complex regulates DNA replication in the S phase, and their activities are modulated by the CDK inhibitors P21<sup>CIP1</sup> and P27<sup>KIP1</sup>. CDK1 formed an active complex with cyclin A or cyclin B that can prevent Rb phosphorylation and regulate the progression of the late S phase and entire G2 phase. Checkpoint signaling kinases such as CHK1 and WEE1 can inactivate CDK1. Transcription-related CDKs: As a component of the transcription factor IIH (TFIIH), CDK7 is mainly responsible for the initiation of transcription. CDK8 phosphorylates the CTD of RNAPII and activates transcription by forming the mediator complex with cyclin C and mediator complex subunits (Med12 and Med13). In addition, CDK8 can inhibit transcription initiation by phosphorylation of the cyclin H of TFIIH. The CDK9–cyclin T complex phosphorylates the negative elongation factor (NELF) complex, DRB-sensitivity inducing factor (DSIF), and the Ser2 of the CTD of RNAPII, which leads to the removal of elongation blocks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">CDK9 specifically regulates gene transcription elongation and mRNA (mRNA) maturation.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> When CDK9 was first isolated, it was designated as PITALRE for its characteristic amino acid motif (Pro-Ile-Thr-Ala-Leu-Arg-Glu).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Subsequently, a study of the human immunodeficiency virus (HIV) confirmed that CDK9 was a significant component of the positive transcription elongation factor b (P-TEFb) complex that phosphorylates the carboxyl-terminal domain (CTD) of RNA polymerase II (RNAPII)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Many studies have demonstrated that a dysregulated CDK9 signaling system is prominent in a variety of hematologic malignancies and solid tumor cell lines, and CDK9 inhibition can result in growth inhibition and apoptosis in cancer cells.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Therefore, targeting CDK9 is an appealing strategy for treating cancers, and an increasing number of researchers are devoted to the development of CDK9 inhibitors. However, most CDK9 inhibitors, especially those in clinical development, are broad-spectrum inhibitors due to the highly conserved structure of CDKs,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> which may result in unpredictable side effects.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Several CDK9 inhibitors have already been halted from clinical studies due to serious side effects, which may be associated with their poor selectivity (e.g., roniciclib).<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> Thus, the improvement of the selectivity of CDK9 inhibitors may be beneficial to patients.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> In this review, we provide an overview of the biological and structural characteristics of CDK9 and describe its main functions in various cancers. Additionally, our attention is mainly focused on the discussion of design strategies for the development of selective CDK9 inhibitors by studying the discovery process of representative CDK9 modulators reported in recent years from the perspective of medicinal chemistry. It should be noted that this review does not discuss in detail those inhibitors that have been discussed in detail in a previous review.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  The Biology of CDK9 and Its Role in Cancer</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24163" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24163" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1.  The Biology of CDK9</h3><div class="NLM_p">The gene encoding human CDK9 is located near the telomeric end of the long arm of chromosome 9 at position q34.1.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The two different promoters present in the <i>CDK9</i> gene lead to the generation of two CDK9 isoforms, one is the best characterized short form 42 kDa protein (CDK9<sub>42</sub>) originally identified as PITALRE, and the other is the less characterized long-form 55 kDa protein (CDK9<sub>55</sub>).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Compared to CDK9<sub>42</sub>, CDK9<sub>55</sub> has an additional 117 amino acid residues at the N terminus.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The protein levels of the two isoforms are different, and CDK9<sub>42</sub> is more highly expressed in cells. In addition, both exhibit differences in subcellular localization, regulation, and tissue distribution.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> CDK9<sub>42</sub> is mainly distributed in the cytoplasm and nucleus, and CDK9<sub>55</sub> is mainly found in the nucleolar region.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Studies have demonstrated that CDK9<sub>42</sub> participates in global transcriptional regulation, while CDK9<sub>55</sub> is mainly involved in DNA repair and genome integrity through different functions.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> It is worth noting that more expression and function patterns of CDK9<sub>55</sub> are still not fully explored, while CDK9<sub>42</sub> is currently the most studied and main driver of transcription.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p"><i>In vivo</i>, the formation of the CDK9–cyclin (including cyclinT1, T2a, T2b, and K) complex and the phosphorylation of the key Thr186 residue is required for the activation of CDK9.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In addition, bromodomain-containing protein 4 (BRD4) and CDK7 are reported to regulate CDK9 activity.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> As a part of P-TEFb, CDK9 stimulates transcriptional elongation by the phosphorylation of the RNAPII CTD, which consists of a 7-amino acid tandem repeat.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In order to promote the transcriptional elongation, CTD needs to be hyperphosphorylated.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Ser2 and Ser5 are the main phosphorylation sites for CDK9 and CDK7, respectively.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The phosphorylation of Ser5 by CDK7 activates RNAPII, thereby stimulating the transcription of RNA. The transition into the productive elongation phase results from the phosphorylation of Ser2 by the CDK9–cyclin complex.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a></div><div class="NLM_p">CDK9 precisely regulates the elongation of RNA transcription (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref24 ref41'); return false;" href="javascript:void(0);" class="ref ref24 ref41">(24,41)</a> After being released from the preinitiation complex, RNAPII starts elongating but pauses at the promoter-proximal region due to the effect of the negative elongation factors (NELF) and DRB-sensitivity inducing factor (DSIF), which also blocks the initiation of new RNAPII molecules.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In the presence of BRD4, the CDK9–cyclin T complex is recruited to the promoter region, phosphorylating DISF, NELF, and the Ser2 of RNAPII CTD. The phosphorylation causes the release of the NELF complex and converts DISF into a positive factor, leading to the removal of elongation blocks. Then, RNAPII begins transitioning into the elongation phase and also stimulates the initiation of new RNAPII molecules.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Role of CDK9 in mRNA transcription. CDK7 phosphorylates the CTD of RNAPII for transcription initiation, promoting the release of RNAPII from the preinitiation complex (PIC). The NELF complex and DSIF lead to the formation of the paused transcription complex. With the help of bromodomain-containing protein 4 (BRD4), the CDK9–cyclin T complex is recruited and phosphorylates DISF, NELF, and the CTD of RNAPII, which releases the paused RNAPII into the productive elongation phase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2.  The Role of CDK9 in Cancer</h3><div class="NLM_p">CDK9 plays a significant role in the regulation of global transcription, especially in the transcription of the apoptosis regulator myeloid cell leukemia 1 (Mcl-1) and the downstream protooncogene MYC involved in cell growth and cell cycle progression, which control proliferation and survival of tumor cells.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> As a result, the dysregulation of CDK9 signaling is prominent in various cancer cells, including hematological malignancies and solid tumors (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Mechanistically, CDK9 inhibition blocks phosphorylation at Ser2 of the RNAPII CTD and induces downregulation of MYC as well as Mcl-1 protein levels, which were confirmed in various hematological malignancies, including adult T-cell leukemia/lymphoma (ATL),<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> acute myeloid leukemia (AML),<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> chronic lymphocytic leukemia (CLL),<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> multiple myeloma (MM),<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and natural killer (NK) cell leukemias/lymphomas.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> It has been reported that the selective CDK9 inhibitor BAY-1143572 significantly decreased ATL tumor infiltration in the liver and bone marrow of treated mice, suggesting that selective CDK9 inhibitors may have the potential to treat ATL.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The successful use of CDK9 inhibitors in the treatment of solid tumors has also been reported for prostate cancer,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> gastric cancer,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> ovarian cancer,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and human head and neck squamous cell carcinoma (HNSCC).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In addition, high expression of CDK9 was observed in chordoma cell lines and chordoma tissue.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Both CDK9 inhibition and silencing resulted in the growth inhibition of chordoma cells, suggesting that CDK9 represents an emerging potential target in chordoma therapy.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> Importantly, recent research demonstrated that CDK9 inhibition reactivated epigenetically silenced genes in cancer, leading to the restoration of tumor suppressor gene expression, cell differentiation, and activation of endogenous retrovirus genes.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> All of these studies suggest that CDK9 is a promising therapeutical target in cancer treatment.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Main CDK9-Related Effects or Mechanisms in Various Cancer</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">tissue</th><th class="colsep0 rowsep0" align="center">cancer</th><th class="colsep0 rowsep0" align="center">CDK9-related effects or mechanisms</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="left">hepatocellular carcinoma (HCC)</td><td class="colsep0 rowsep0" align="left">Inhibition of CDK9 is able to induce cell apoptosis in HCC cell lines.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">nonsmall-cell lung cancer (NSCLC)</td><td class="colsep0 rowsep0" align="left">Inhibition of CDK9 results in the suppression of cell cycle progression, colony formation, as well as cell proliferation and induces apoptosis in NSCLC lines. Additionally, because CDK9 inhibition leads to reduced mRNA and the protein levels of cFlip<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> as well as Mcl-1, the CDK9 inhibitor combined with TRAI<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> can potently kill cells in a panel of mostly TRAIL-resistant NSCLC lines.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">stomach</td><td class="colsep0 rowsep0" align="left">gastric cancer</td><td class="colsep0 rowsep0" align="left">MicroRNA-613 with protein levels obviously reduced in gastric cancer tissue and cells is able to repress proliferation and migration of gastric cancer by inhibiting CDK9 expression.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">breast</td><td class="colsep0 rowsep0" align="left">triple-negative breast cancer (TNBC)</td><td class="colsep0 rowsep0" align="left">Inhibition of CDK9 reduces the levels of cyclin B1 and MYC in TNBC cell lines.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ovary</td><td class="colsep0 rowsep0" align="left">ovarian cancer</td><td class="colsep0 rowsep0" align="left">Inhibition of CDK9 significantly decreases cell growth and viability by suppressing the phosphorylation of RNAPII and inducing apoptosis in ovarian cancer cells.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">prostate</td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="left">Ser81 phosphorylation by CDK9 is a core event in the regulation of AR, which controls the nuclear retention, chromatin binding, transactivation of specific gene expression, and transcriptional activity of AR. Overexpression of CDK9–cyclinT leads to an increased Ser81 phosphorylation in cells.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">blood</td><td class="colsep0 rowsep0" align="left">multiple myeloma (MM)</td><td class="colsep0 rowsep0" align="left">Inhibition of CDK9 significantly induces cell apoptosis and suppresses the transcription of antiapoptotic protein Mcl-1 in MM cells.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia (AML)</td><td class="colsep0 rowsep0" align="left">Overexpression of CDK9 promotes the cell proliferation of antiapoptotic protein Mcl-1, which is necessary for the survival and sustained growth of AML cells. In addition, the inhibition of CDK9 can result in apoptosis of AML cells.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">adult T-cell leukemia/lymphoma (ATL)</td><td class="colsep0 rowsep0" align="left">In ATL, inhibition of CDK9 results in the suppression of phosphorylation at Ser2 of the RNAPII CTD and induces downregulation of c-Myc as well as Mcl-1 protein levels.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">chronic lymphocytic leukemia (CLL)</td><td class="colsep0 rowsep0" align="left">In CLL, inhibition of CDK9 results in the suppression of phosphorylation of RNAPII and inhibition of RNA synthesis and induces downregulation of Mcl-1 and X-linked inhibitor of apoptosis protein levels.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref46 ref56'); return false;" href="javascript:void(0);" class="ref ref46 ref56">(46,56)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">natural killer (NK) cell leukemias/lymphomas</td><td class="colsep0 rowsep0" align="left">In NK-cell leukemias/lymphomas, the selective CDK9 inhibitor is able to prevent the phosphorylation of Ser2 of the CTD in RNAPII, which brings about downregulation of c-Myc and Mcl-1 protein levels, promoting growth inhibition and apoptosis of NK-cell leukemias/lymphomas.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lymph</td><td class="colsep0 rowsep0" align="left">aggressive MYC-driven B cell lymphoma</td><td class="colsep0 rowsep0" align="left">Inhibition of CDK9 suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B cell lymphoma.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">head and neck</td><td class="colsep0 rowsep0" align="left">human head and neck squamous cell carcinoma (HNSCC)</td><td class="colsep0 rowsep0" align="left">In HNSCC cells, CDK9 overexpression leads to radioprotection, while CDK9 depletion obviously enhanced the radiosensitivity of HNSCC cells.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colon</td><td class="colsep0 rowsep0" align="left">colorectal cancer</td><td class="colsep0 rowsep0" align="left">CDK9 inhibitors show significant cytotoxicity in HCT116 and HT29 cells and promote depolarization of mitochondrial membrane, resulting in caspase-independent apoptosis.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bone</td><td class="colsep0 rowsep0" align="left">chordoma</td><td class="colsep0 rowsep0" align="left">Inhibition of CDK9 significantly suppresses cell growth and proliferation in chordoma cell lines.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">neuro</td><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="left">Blocking the activity of CDK2 and CDK9 results in potent antiproliferative effect and induce cell death in a panel of neuroblastoma cell lines.</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">cFlip, cellular FLICE-like inhibitory protein.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">3.  CDK9 Inhibitors in Clinical Evaluation for Cancer Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To our knowledge, 16 CDK9 inhibitors have been or are currently being in various stages of clinical development for cancer treatment (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Among them, four inhibitors, namely, P-276–00 (<b>3</b>), ZK-304709 (<b>5</b>), BAY-1000394 (<b>6</b>) and SNS-032 (<b>13</b>), have been discontinued, while others, including Alvocidib (<b>1</b>), TP-1287 (<b>2</b>), P-1446 (<b>4</b>), BAY-1143572 (<b>7</b>), BAY-1251152 (<b>8</b>), TG-02 (<b>9</b>), (R)-Roscovitine (<b>10</b>), Fadraciclib (<b>11</b>), Dinaciclib (<b>12</b>), AT7519 (<b>14</b>), BTX-A51 (<b>15</b>), and AZD-4573 (<b>16</b>), are active in various clinical trials.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> These compounds can be mainly divided into two categories according to their structures, namely, flavones and base analogues (such as aminopyrimidine, aminopyridine, and a nitrogen-containing fused heterocycle). Among the flavone derivatives, compound <b>3</b> has advanced into phase III trials (the last phase of the trials), while the other three are still in early phase clinical trials, i.e., <b>1</b> in phase II, <b>2</b> in phase I, and <b>4</b> in phase I (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The other compounds are all in phase I or phase II. Although most of these inhibitors (<b>1</b>–<b>6</b> and <b>9</b>–<b>15</b>) show potent but nonselective inhibition of CDK9 enzymatic activity, with IC<sub>50</sub> values in the nM range.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Several of them have been confirmed to have potent antitumor activity by targeting CDK9, such as compounds <b>1</b>, <b>3</b>, and <b>9</b> (see <a class="ref internalNav" href="#sec4_2_1" aria-label="sections 4.2.1">sections 4.2.1</a> and <a class="ref internalNav" href="#sec4_2_2" aria-label="4.2.2">4.2.2</a>). However, due to the lack of selectivity, most nonselective CDK9 inhibitors may result in adverse effects, which limit their further clinical application in cancer treatment.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> In a phase II study of compound <b>1</b> for patients with CLL, 100% of patients suffered from side effects, and 87% were at high risk.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Due to adverse effects, such as nausea and vomiting, compound <b>5</b> was prematurely discontinued in a phase I study for patients with advanced solid tumors.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> A phase Ib/II study of compound <b>6</b> combined with chemotherapy in patients with extensive-disease small-cell lung cancer showed the promising efficacy of the compound.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> However, 42 patients (97.7%) suffered from side effects, such as nausea and vomiting, and 16.3% of the patients experienced serious adverse events. Due to its unacceptable adverse effects, the phase II study of compound <b>6</b> was discontinued.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The multitargeted CDK inhibitor <b>12</b> was involved in three-phase II clinical studies in which more than 75% of the patients had adverse effects, although the compound exhibited single-agent potency in patients suffering from multiple myeloma.<a onclick="showRef(event, 'ref64 ref65 ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref64 ref65 ref66 ref67">(64−67)</a> The enrollment in a phase I study of compound <b>13</b>, a potent inhibitor targeting CDK 2, 7, and 9, was terminated due to toxicity problems during dose escalation. All patients in this study suffered from side effects, including fatigue, nausea, diarrhea, and abdominal pain.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Besides adverse effects, many CDK9 inhibitors showed no clear objective responses in patients. No complete response was observed in more than half of 12 phase I studies of compound <b>1</b> and three phase II trials of compound <b>12</b>.<a onclick="showRef(event, 'ref24 ref65 ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref24 ref65 ref66 ref67">(24,65−67)</a> Although the drug level in the expected therapeutic range was achieved and target engagement was confirmed, there was no objective response in the treatment of AML with compound <b>8</b>,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> a selective CDK9 inhibitor which is currently in an active clinical trial.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Overall, clinical trials for the treatment with various CDK9 inhibitors have revealed many detrimental effects, and most of them remain unsuccessful. Improvement in the selectivity and antitumor activity of CDK9 inhibitors can lead to the availability of a successful treatment for cancer patients.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. CDK9 Inhibitors That Have Been or Are Currently Being Tested in Clinical Trials</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0026.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> values were achieved through a kinase-based assay.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">The information is from the web of Clarivate Analytics Integrity (<a href="https://integrity.clarivate.com" class="extLink">https://integrity.clarivate.com</a>).</p></div></div><div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">4.  Design Strategies and Structural Types of CDK9 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25287" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25287" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Due to the essential role of CDK9 in cancers, considerable medicinal chemistry efforts have been devoted to the design of highly potent CDK9 inhibitors. Among these inhibitors, several have been or are currently being evaluated in various clinical trials. Recently, an increasing amount of medicinal chemistry effort is focused on the development of novel CDK9 inhibitors with diverse structural scaffolds to achieve better selectivity, higher potency, and superior safety profile.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">4.1.  Structural Features and Binding Sites in CDK9</h3><div class="NLM_p">CDK family members share high sequence and structural similarity. Among them, CDK9 is similar in structure to CDK2, and both share 40% sequence identity,<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> which makes it challenging to design selective CDK9 inhibitors. Structurally, like other kinases, CDK9 is composed of a C-terminal lobe, mainly containing α-helixes, and a smaller N-terminal lobe, mainly comprised of β-sheet and one α-helix. The N-terminal lobe comprises the residues 16–108, while the C-terminal lobe comprises the residues 109–330 of the CDK9 protein.<a onclick="showRef(event, 'ref34 ref70'); return false;" href="javascript:void(0);" class="ref ref34 ref70">(34,70)</a></div><div class="NLM_p">Functional domains of CDK9 mainly include a glycine-rich G loop, an αC-helix, and a hinge in the N-terminal, as well as an activation loop and a catalytic loop in the C-terminal (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The glycine-rich G loop comprising the consensus sequence GXGXXGXV is capable of interacting with triphosphate chain, while the αC-helix is the main region where CDK9 combines with its cyclin partners, such as cyclin T and K.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The hinge is a key region of the CDK9 binding sites. The hydrogen bonds between ligands and the hinge residue Asp104, as well as Cys106, in the CDK9 protein, are essential for the ligand activity (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). For example, the core scaffold of CDK9 inhibitors in clinical trials forms hydrogen bonds with the residues in the hinge region, which significantly contribute to their CDK9 potency (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The activation loop (T loop) is the location of a threonine residue whose phosphorylation is essential for the enzymatic activity, which in CDK9 is Thr186. In addition, the residues Asp149, Lys151, and Thr191 of CDK9 form the catalytic loop, which directly participates in the transphosphorylation reaction.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Notably, some less conserved regions in CDK9 binding sites, including the hydrophobic region, the solvent-exposed region, may provide an opportunity to design selective CDK9 inhibitors.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure analysis of CDK9/cyclin T (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>). According to the crystal structure, the structural features of CDK9 mainly include a glycine-rich G loop, an αC-helix and a hinge in the N-terminal, as well as an activation loop and catalytic loop in the C-terminal. The interactions with amino acid residues in the hinge significantly contribute to the potent inhibition of CDK9. Some less conserved regions, including a hydrophobic region, a solvent-exposed region, and the G loop, may provide an opportunity to design selective inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CDK9 inhibitors that have been or are currently being evaluated in various clinical trials. Atoms participating in binding to the hinge region of the active site are shown in red with dashed lines for putative hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">4.2.  CDK9 Nonselective Inhibitors</h3><div class="NLM_p">Most CDK9 inhibitors have poor selectivity over other CDKs due to the high homology of these proteins in the catalytic domain. Structurally, CDK9 nonselective inhibitors can be divided into three categories based on the group binding with the hinge residues, namely flavonoids, aminopyrimidine, and nitrogen-containing fused heterocycle compounds.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">4.2.1.  CDK9 Inhibitors Bearing the Flavonoid Scaffold</h4><div class="NLM_p">Flavopiridol (<b>1</b>), a synthetic flavonoid from a plant native to Indian, was developed for the potential treatment of cancer.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> As the first CDK inhibitor entering clinical studies, compound <b>1</b> is a potent CDK inhibitor with broad specificity for most CDK family members, including CDK1, CDK2, CDK4, CDK5, and CDK9 (IC<sub>50</sub> = 20, 15, 19, 14, and 3 nM, respectively).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> In fact, compound <b>1</b> showed maximum suppression of CDK9 and interfered with RNAPII activation and associated transcription.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Some studies reported that <b>1</b> exhibited anti-inflammatory via CDK9 and NFκB-dependent signaling,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> and CDK9 was the most relevant target of compound <b>1</b>.<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73,74)</a> The crystal structure of <b>1</b>-CDK9 revealed the formation of hydrogen bonds from the 4-<i>O</i> oxygen and 5-<i>O</i> hydroxyl of compound <b>1</b> to hinge residues Cys106 and Asp104 in CDK9, respectively. Additionally, the 3-<i>O</i> hydroxyl of <b>1</b> interacts with Asp167 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A) and this interaction contributes to its potent inhibitory effect on CDK9 kinase activity. The compound <b>1</b> can potently induce apoptosis of CLL cells <i>in vitro</i> and is effective for the treatment of liver cancer, breast cancer as well as prostate cancer. Indeed, it has already been approved as an orphan drug for CLL.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Since this drug binds avidly to plasma proteins, higher serum concentrations were required for clinical antileukemia activity than those suggested by <i>in vitro</i> studies, leading to significant toxicity, including high rates of major tumor lysis syndrome, cytokine release syndrome and secretory diarrhea.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> However, a new clinical study of flavopiridol and venetoclax in patients with relapsed/refractory AML is being conducted and is currently in the recruitment stage.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) The crystal structure of flavopiridol (<b>1</b>) and CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>). The hydrogen bonds are depicted by red dotted lines. (B) The development of CDK9 inhibitors with a flavonoid scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The water solubility of compound <b>1</b> is poor under neutral or basic conditions (both 0.02 mg/mL at pH 6.8 and pH 8.7), hampering the development of the oral formulation. Thus, a phosphate prodrug TP-1287 (<b>2</b>) was designed and synthesized to improve solubility and oral bioavailability (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The prodrug <b>2</b> was shown to have a good water solubility (9.5 mg/mL at pH 6.8 and 9.3 mg/mL at pH 8.7), displaying high oral bioavailability (%<i>F</i> = 182.3, compared to intravenous <b>1</b>) with an efficient conversion to the parent compound <b>1</b> in mouse pharmacokinetic (PK) studies. Furthermore, <b>2</b> achieved excellent antitumor efficacy in a xenograft model, exhibiting 109.1% tumor growth inhibition at a dose of 7.5 mg/kg. This orally delivered CDK9 inhibitor <b>2</b> has recently advanced into clinical trials for the treatment of solid tumors.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p">Bharate et al. designed a series of flavonoid derivatives based on compound <b>1</b>, with the aim of improving oral bioavailability.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> After several rounds of structure–activity relationship (SAR) discussions, the replacement of the chlorophenyl group in <b>1</b> with a 2,6-dichlorostyryl group led to compound IIIM-290 (<b>17</b>), which displays excellent potency against CDK9 (IC<sub>50</sub> = 1.9 nM), strong cellular antiproliferation activity in leukemia cells (GI<sub>50</sub> = 0.5 and 0.9 μM for MOLT-4 and HL60 cell lines, respectively) and potent growth inhibition of tumors in pancreatic, colon, and leukemia xenograft nude mouse models (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). In addition, <b>17</b> exhibited good physicochemical and PK properties (water solubility = 20.31 μg/mL, Log <i>P</i> = 3.09, Cl = 55.4 mL/min/kg, oral bioavailability = 70.7%). However, <b>17</b> lacked selectivity over other CDKs, especially CDK2 (IC<sub>50</sub> = 16 nM).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><div class="NLM_p">Recently, Nada Ibrahim et al. reported the discovery of a new series of compound <b>1</b> analogues targeting CDK9 by introducing sugars, amino acids, and heterocycle groups on the ring C of compound <b>1</b>.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Cell viability assays of ovarian cancer lines demonstrated that the analogues bearing sugars or amino acids displayed poor cytotoxic activity, while the derivatives containing heterocycle potently inhibited tumor cell growth with submicromolar IC<sub>50</sub> values. Among them, compound <b>18</b>, containing benzimidazole, exhibited the best antiproliferative activity and showed high cytotoxic potency in seven tumor cell lines (including ovarian cancer, gastric adenocarcinoma, breast cancer, prostate cancer, pancreatic cancer, colon carcinoma, and leukemia cell lines) with six of seven IC<sub>50</sub> values being within 100 nM, which are comparable to those of compound <b>1</b>. However, <b>18</b> displayed slightly reduced inhibitory activity against CDK9, and the CDK9 selectivity was still not good enough (IC<sub>50</sub> = 64, 1725, and 1093 nM for CDK9, CDK2, and CDK5, respectively).<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div><div class="NLM_p">Rearrangement of the six-membered piperidine of flavopiridol to a five-membered ring pyrrolidine resulted in the clinical pan-CDK inhibitor P-276–00 (<b>3</b>). The compound turned out to be more selective for CDK4, CDK1, and CDK9 with IC<sub>50</sub>s < 100 nM, and less selective for non-CDK kinases.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> However, studies have shown that CDK9 is the major target of compound <b>3</b> in multiple myeloma cells.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In addition, <i>in vitro</i> studies have shown that the antiproliferation and pro-apoptotic activity of compound <b>3</b> in human lung, colon, breast, and leukemia cell lines was at least two times higher than that of <b>1</b>. Unfortunately, a phase II study to evaluate the efficacy and safety of <b>3</b> in mantle cell lymphoma was terminated due to a lack of objective responses.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> The introduction of a trifluoromethyl group at the para position of the benzene ring in compound <b>3</b> led to another clinical CDK inhibitor, namely, voruciclib (<b>4</b>), with higher potency against CDK9, CDK4, and CDK6 (IC<sub>50</sub> = 1.68, 3.96, and 2.92 nM, respectively) as well as less non-CDK off-target liability than <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Compound <b>4</b> could significantly induce apoptosis in various tumor cells, such as chronic lymphocytic leukemia cells, nonsmall-cell lung cancer cells, and human colon cancer cells.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Meanwhile, recent studies demonstrated that <b>4</b> was capable of potentiating the potency of paclitaxel and doxorubicin in cells overexpressing ATP-binding cassette transporters. These transporters are major obstacles impeding the effect of cancer chemotherapy. Thus, <b>4</b> has a potential application prospect in combination with antitumor drugs for cancer chemotherapy and is currently in phase I clinical study (recruitment phase).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p">Wogonin (<b>19</b>) is a natural product isolated from the plant <i>Scutellaria baicalensis</i>, and its structure is similar to that of compound <b>1</b>. The natural product has been shown to be a potent CDK9 inhibitor (IC<sub>50</sub> = 190 nM).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> However, its activity and selectivity against CDK9 need to be further improved. Our group recently disclosed a series of wogonin derivatives to investigate the effect of substituents at the 8-methoxy group and B ring of <b>19</b> on the CDK9 activity and selectivity by structure-based drug design (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> In order to evaluate the effect on its selectivity for CDK9, different electron-withdrawing or -donating groups were introduced into the B ring of <b>19</b>, which led to compound <b>20</b> with significant improvement in the selectivity against CDK9 over CDK2. With the aim of improving the enzymatic potency, different polar and nonpolar groups were introduced into the <i>O</i>8 of compound <b>20</b>. Among them, compound <b>21</b> was a potent CDK9 inhibitor with an IC<sub>50</sub> value of 19.9 nM, and showed a 45-fold selectivity over CDK2 (IC<sub>50</sub> = 913 nM), demonstrating a clearly improved CDK9 inhibitory activity and selectivity compared to compound <b>19</b>. The cellular antiproliferative studies suggested that compound <b>21</b> had potent antiproliferative activity against a panel of 14 tumor cell lines, preferentially against MV4–11 (IC<sub>50</sub> = 20 nM), but displayed low toxicity against normal cell lines (IC<sub>50</sub> = 15 and 22 μM for HEK293 and L02, respectively).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Design of CDK9 inhibitor <b>21</b> with high activity and selectivity based on the natural product wogonin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Molecular docking studies were performed to understand the interaction pattern of the representative compound <b>21</b> in the active site of CDK9 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The carbonyl group of <b>21</b> forms a hydrogen bond with Cys106 in the hinge region, while the NH group of the <i>O</i>8-pyrazole ring forms another important hydrogen bond with Ala153 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A), which contribute to the high CDK9 inhibitory activity of <b>21</b>. In addition, we found that the steric hindrance of Lys89 at the inlet of the ATP-binding pocket made it difficult for <b>21</b> to adopt a stable conformation and bind tightly to CDK2 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). The corresponding amino acid in CDK9 is Gly112, which is more favorable for accommodating the piperazinyl group of <b>21</b> and results in good selectivity versus CDK2.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) The docking model of compound <b>21</b> and CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>). (B) The docking model of compound <b>21</b> and CDK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCP">4BCP</a>). The hydrogen bonds are depicted by red dotted lines. The steric hindrance of Gly112 and Lys89 is shown on the surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">4.2.2.  CDK9 Inhibitors Bearing the Aminopyrimidine Scaffold</h4><div class="NLM_p">The structure-based optimization of pyrimidine-based inhibitors resulted in the clinical candidate TG02 (<b>9</b>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), a potent inhibitor of CDKs, Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Although compound <b>9</b> is a pan-CDK inhibitor, CDK9 is considered as a primary target of this compound, which potently inhibited CDK9 with an IC<sub>50</sub> value of 3 nM.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Notably, the macrocyclic scaffold of <b>9</b> is rare among all CDK inhibitors, especially CDK9 inhibitors. The macrocycle, with a basic nitrogen in <b>9</b>, forms a salt bridge with the Asp86 in CDKs, which contributes to its high potency.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Researchers have suggested that macrocyclization is essential to present the pharmacophore elements in the required conformation for binding to the protein by lowering the conformational energy penalty.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Compound <b>9</b> could inhibit the growth of various cancers, including AML (IC<sub>50</sub> = 18–39 nM), colon carcinoma (IC<sub>50</sub> = 40–305 nM), prostate carcinoma (IC<sub>50</sub> = 43–84 nM), breast carcinoma (IC<sub>50</sub> = 65–164 nM), lung carcinoma (IC<sub>50</sub> = 110 nM), nonsmall-cell lung cancer (IC<sub>50</sub> = 242–258 nM), and small-cell lung cancer (IC<sub>50</sub> = 95–139 nM).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Research has demonstrated that the antitumor activity of <b>9</b> in the AML is mediated by the dephosphorylation of RNAPII leading to depletion of survival molecules, such as Mcl-1 and XIAP, with subsequent activation of BAX, culminating in apoptosis.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Given its excellent antitumor activity and drug-like properties, <b>9</b> progressed into clinical development for advanced leukemias and multiple myeloma in 2010. Currently, there are three ongoing clinical studies of <b>9</b>, at the moment in the recruiting phase, for a brain tumor, glioblastoma, and high-grade gliomas, respectively.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p">Recently, Wang et al. disclosed the synthesis and biological evaluation of a series of 5-chloro-pyrimidine-2,4-diamine derivatives that exhibited potent inhibition of CDK9, culminating in the discovery of <b>28</b>, a novel dual CDK6 and 9 inhibitor.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The enzymatic activity screening in the in-house compound library led to the hit <b>22</b> with a pyrimidine diamine core. Hit <b>22</b> showed moderate inhibitory effects on CDK6 and CDK9 but bound more tightly to CDK2 (IC<sub>50</sub> = 6.65, 3.43, and 0.03 μM, respectively). With the aim of improving the potency against CDK6/9 and selectivity over CDK2, a series of pyrimidine diamine derivatives were designed and synthesized starting from hit <b>22</b> through structure-based drug design.</div><div class="NLM_p">The docking study of <b>22</b> was first performed to analyze its key interactions with CDK6/9. Two hydrogen bonds were formed between 2-amino pyrimidine and key residues (Val101 and Cys106 in CDK6/9, respectively). In addition, the <i>o</i>-methyl phenyl moiety of <b>22</b> occupied the hydrophobic pockets in the CDK6/9 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). According to the docking results, the structural optimization was performed step by step. First, the replacement of the pyridine ring of <b>22</b> with various phenyl, substituted phenyl, and other heterocycles produced compound <b>23</b> with slightly improved potency. Subsequently, the detailed SAR studies were conducted to evaluate the effects of the N position, the distance between the pyridine and pyrimidine, and the substitution of the pyridine ring on the enzymatic potency, culminating in the discovery of compound <b>24</b> bearing <i>N</i>-methylpiperazine. Compared to compound <b>23</b>, compound <b>24</b> exhibited much better potency for CDK6/9 and selectivity over CDK2. Unfortunately, the change of length between the phenyl and pyrimidine groups proved to be disappointing. Then, the authors undertook to explore the influence of the substitution of the phenyl ring to improve the enzyme inhibitory activity. Although the incorporation of bulk hydrophobic groups resulted in higher CDK6 inhibitory activity, the affinity of most compounds for CDK9 decreased significantly (<b>25</b>, <b>26</b>, and <b>27</b>). The extensive SAR study eventually led to compound <b>28</b> with an acetylamino group at the meta position of the phenyl (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Compared to compound <b>24</b>, compound <b>28</b> exhibited improved CDK9 potency and a balancing effect on CDK6/9, as well as slight inhibition of CDK3/5/11 at 1 μM, suggesting its good preference for CDK6/9. The acetylamino group in <b>28</b> was considered to interact with key residues in the hydrophilic region of CDK6/9 (Lys43 and Asp163 in CDK6; Lys48 and Asp167 in CDK9), which contributed to an increase of the activity against CDK6/9 100-fold higher than that of compound <b>22</b>.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Development of CDK9 inhibitor <b>28</b> with high activity and selectivity based on compound <b>22</b>. According to the docking model of compound <b>48</b>-CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>), two hydrogen bonds were formed between 2-amino pyrimidine and the key residue Cys106 (the interactions between compound <b>22</b> and CDK6 are not shown). The hydrogen bonds are depicted by red dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">4.2.3.  CDK9 Inhibitors Bearing the Nitrogen-Containing Fused Heterocycle Scaffold</h4><div class="NLM_p">Variolins (<b>29</b>, IC<sub>50</sub> < 0.04 and 0.21 μM for CDK9 and CDK2, respectively) and meriolins (<b>30</b>, both IC<sub>50</sub> < 10 μM for CDK9 and CDK2) are natural products with CDK inhibitory activity, including against CDK9 and CDK2.<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a> Hybridizing the structure of these two compounds generated a 3-pyrimidinylazaindole derivative (<b>31</b>, IC<sub>50</sub> < 0.03 μM for CDK9 and CDK2), with better activity against CDK9 and CDK2. Furthermore, this derivative exhibited an antiproliferative activity in tumor cell lines and significant growth inhibition in a mouse LS174T (colorectal carcinoma) xenograft cancer model.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> However, compound <b>31</b> had poor physicochemical and PK properties, limiting its further clinical applications. Recently, Umed et al. reported the synthesis and biological evaluation of a new generation of analogues with a 3-pyrimidinylazaindole scaffold.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Binding-mode analysis of <b>31</b>-CDK2 and <b>31</b>-CDK9 complexes revealed that 7-azaindole was the key pharmacophore as the moiety formed two hydrogen bonds with the hinge residues Cys106 and Asp104 in CDK9 (Leu83 and Glu81 in CDK2) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). The introduction of hydrogen bond acceptors, hydrogen bond donors, or hydrophobic groups was feasible for the substitution at the 5-positions of ring A and the amino group of ring C. Thus, extensive structural modifications were carried out at these two moieties to improve the physicochemical and PK properties while retaining the potency for CDK2 and CDK9, culminating in the discovery of the potent CDK9 and CDK2 inhibitor <b>32</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). <i>In vivo</i> assays suggested that <b>32</b> strongly inhibited CDK9 and CDK2 with IC<sub>50</sub> values of 24 nM and 5.5 nM, respectively, and displayed high inhibition of cell proliferation in HCT-116 (IC<sub>50</sub> = 0.2 μM) and SH-SY5Y cells (IC<sub>50</sub> = 0.8 μM). After the treatment with <b>32</b> in mouse triple-negative breast cancer (TNBC), a significant tumor growth inhibition (90%) was observed, indicating its potential to be a development candidate against TNBC.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Discovery of compound <b>32</b>. The docking models of <b>31</b>-CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>) and <b>31</b>-CDK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>) reveal that 7-azaindole of <b>31</b> forms two hydrogen bonds with the hinge residues Cys106 and Asp104 in CDK9 (Glu81 and Leu83 in CDK2). The hydrogen bonds are depicted by red dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2018, Li et al.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> disclosed the identification of compound <b>35</b> (IC<sub>50</sub> = 12 nM for CDK9), derived from the hybridization of ribociclib (<b>34</b>) and vorinostat (<b>33</b>), which was a histone deacetylase (HDAC) inhibitor (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). In addition to CDK9, <b>35</b> showed significant inhibitory activity against CDK4 (IC<sub>50</sub> = 8.8 nM) and HDAC (IC<sub>50</sub> = 12 nM). It is worth noting that this compound displayed a clearly enhanced suppression against CDK9 compared to ribociclib (IC<sub>50</sub> = 197 nM for CDK9). The docking model revealed that a new hydrogen bond was formed between <b>35</b> and residue Thr29 of CDK9 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> B). In addition, treatment with <b>35</b> in the 4T1 model with an oral dose of 90 mg/kg, a higher tumor growth inhibition was observed compared to vorinostat and ribociclib at the same dose, suggesting that compound <b>35</b> can generate excellent tumor regression <i>in vivo</i>.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) The design of selective CDK9 inhibitors by structural hybridization. (B) The overlay docking model of <b>34</b> and <b>35</b> in CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF">4BCF</a>). (C) The overlay docking model of <b>34</b> and <b>39</b> in CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>). The hydrogen bonds are depicted by red dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2019, Wang et al. described a series of novel, highly potent, and selective CDK9 inhibitors with inhibitory activity against cancer stem cells (CSCs).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Similar to the study by Li et al.,<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> they designed various merged molecules by combining the pyrrolo-[2,3-<i>d</i>] pyrimidines-2-amine in <b>34</b> with isothiocyanate from sulforaphane (<b>36</b>), which is a known natural compound targeting CSCs and can potently inhibit tumorigenesis and metastatic progression (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). Compound <b>37</b> (IC<sub>50</sub> = 11, 148, and 145 nM for CDK9, 4, and 6, respectively) is a representative example of these merged molecules, exhibiting selectivity over other CDKs and suppressing tumor growth.</div><div class="NLM_p last">Compound <b>39</b> is also a hybrid derivative from <b>34</b> and cabozantinib (<b>38</b>), which is a vascular endothelial growth factor 2 inhibitor (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A).<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Compound <b>39</b> was reported to potently inhibit CDK9 with an IC<sub>50</sub> value of 12 nM and exhibited high selectivity over other CDKs. Moreover, it effectively induced apoptosis in cancer cells, such as breast cancer and lung cancer cell lines. Noteworthy, compared to <b>34</b> (IC<sub>50</sub> = 197 and 13 nM for CDK9 and CDK4, respectively), <b>39</b> showed significant improvement in selectivity against CDK9 over CDK4 (IC<sub>50</sub> = 12 and 142 nM for CDK9 and CDK4, respectively). The docking model revealed a new hydrogen bond between the Asn116 residue in CDK9 and the 4-(3-fluorobenzyloxy) group of <b>39</b>, compared to the positive control <b>34</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C).</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">4.3.  Efforts on the Development of Selective CDK9 Modulators</h3><div class="NLM_p">In recent years, medicinal chemists have gradually turned their attention to the development of selective CDK9 inhibitors. Among the selective CDK9 inhibitors, three of them have progressed into clinical trials, including BAY-1143572 (<b>7</b>), BAY-1251152 (<b>8</b>), and AZD-4573 (<b>16</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Furthermore, it is important to mention that the proteolysis targeting chimeras (PROTACs) strategy has been used to design selective CDK9 small molecule degraders. This technology could promote further understanding of the mechanism of CDK9 in tumorigenesis and development.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">4.3.1.  Selective CDK9 Inhibitors Bearing the Aminopyridine (or Aminotriazine) Scaffold</h4><div class="NLM_p">BAY-985 (<b>40</b>) bearing an <i>N</i>-triazine core was found to be a potent and highly selective CDK9 inhibitor (CDK9, IC<sub>50</sub> = 11 nM; other CDKs, IC<sub>50</sub> > 1078 nM) and exhibited good antiproliferative activity in HeLa cells (IC<sub>50</sub> = 1 μM) and MOLM-13 cells (IC<sub>50</sub> = 280 nM).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> However, the unfavorable physicochemical and DMPK (drug metabolism and pharmacokinetic) properties of <b>40</b>, such as low water solubility of 11 mg/L at pH6.5, short half-life (<i>t</i><sub>1/2</sub> = 0.7 h), and low bioavailability of 10%, limited the further development of this compound.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The docking experiment was performed to investigate the binding mode of <b>40</b>-CDK9 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a><b>A</b>) revealed two hydrogen bonds formed between the hinge region of CDK9 and the triazine core, as well as the aniline NH, respectively. The benzyl sulfonamide moiety interacted with Glu107 and was directed toward the exit of the ATP-binding pocket. The benzyl sulfonamide group was believed to significantly contribute to the low water solubility of <b>40</b> due to its polarity, high number of heteroatoms, and multiple hydrogen-bonding interactions. Thus, efforts were focused on the modification of the benzyl sulfonamide group to improve solubility while maintaining good potency. A series of sulfone groups were used to replace the benzyl sulfonamide, resulting in compound <b>41</b> (IC<sub>50</sub> = 24 and 1608 nM for CDK9 and CDK2, respectively). It exhibited similar potency against CDK9 and selectivity over CDK2 compared with <b>40</b> (IC<sub>50</sub> = 11 and 1078 nM for CDK9 and CDK2, respectively). Notably, both compounds <b>42</b> (IC<sub>50</sub> = 49 and 588 nM for CDK9 and CDK2, respectively), in which an additional methylene group was introduced to <b>41</b>, and compound <b>43</b> (IC<sub>50</sub> = 32 and 608 nM for CDK9 and CDK2, respectively), in which the methylene group from <b>41</b> was removed, displayed a clear reduction of selectivity over CDK2 and activity against CDK9.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) The development of BAY-1143572 (<b>7</b>) and BAY-1251152 (<b>8</b>) based on compound <b>40</b>. According to the docking model of <b>40</b>-CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG">4BCG</a>), two hydrogen bonds were formed between the hinge region of CDK9 and the triazine core as well as the aniline NH group. The benzyl sulfonamide moiety interacted with Glu107 and was directed toward the exit of the ATP-binding pocket. The hydrogen bonds are depicted by red dotted lines. (B) The structure of AZ-5576 (<b>44</b>) and AZD-4573 (<b>16</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, it was disappointing that <b>41</b> showed a lower water solubility of 4 mg/L compared to <b>40</b>. A rather steep SAR about CDK9 selectivity and activity was observed when the structure on the right side of <b>40</b> was modified. Ultimately, the introduction of the uncommon benzyl sulfoximine group into <b>40</b> led to the discovery of compound <b>7</b>. Compared with <b>40</b>, compound <b>7</b> clearly exhibited a better overall profile <i>in vitro</i> and <i>in vivo</i>, similar inhibitory activity against CDK9 (IC<sub>50</sub> = 6 nM), and higher selectivity (other CDKs, IC<sub>50</sub> > 890 nM). The kinase selectivity assay demonstrated that only the GSK3 enzyme displayed submicromolar inhibition of non-CDK kinases with the treatment of compound <b>7</b> (IC<sub>50</sub> = 45–87 nM). More importantly, <b>7</b> displayed a good water solubility of 479 mg/L, low blood clearance, and a moderate bioavailability of 54% in rats <i>in vivo</i> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A). In <i>in vivo</i> efficacy studies, <b>7</b> could significantly inhibit the growth of MOLM-13 and MV4–11 tumor xenografts and promote almost complete tumor remission at a dose of 12 mg/kg for 14 days in an MV4–11 leukemia mouse model. Due to the promising overall profile, <b>7</b> was selected as a candidate compound to enter a clinical trial for advanced cancer and leukemia.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><div class="NLM_p">In order to fully investigate future treatment options using selective CDK9 inhibitors based on compound <b>7</b>, extensive lead optimization efforts were made to find the novel CDK9 inhibitor <b>8</b>.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Compared to <b>7</b>, compound <b>8</b> exhibited improved enzymatic activity (IC<sub>50</sub> = 3 nM against CDK9) and cytotoxic activity (IC<sub>50</sub> = 29 nM against MOLM13 cells), increased selectivity over CDK2, as well as high permeability. Compound <b>8</b> was shown to potently suppress tumor growth in xenograft models and turned out to be another CDK9 inhibitor with high selectivity in the clinical development study. Unfortunately, more information about the discovery of <b>8</b> was not disclosed.</div><div class="NLM_p">AZ-5576 (<b>44</b>), a potent, highly selective, and orally bioavailable CDK9 inhibitor, has an aminopyridine scaffold. This compound inhibited CDK9 protein activity with IC<sub>50</sub> values < 5 nM and suppressed Ser2-phosphorylation of RNAPII in cells with an IC<sub>50</sub> of 96 nM.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> A rapid dose-dependent decrease in pSer2-RNAPII with concomitant loss of Mcl-1 mRNA protein was observed after short-term treatment with <b>44</b> of the MV4–11 cell lines, which led to the cleavage and activation of caspase 3, as well as a decrease in cell viability. This compound could inhibit the growth of human leukemia cells with an IC<sub>50</sub> of 50–100 nM. Further structure-based drug optimization was performed based on the scaffold of compound <b>44</b> to improve its physicochemical and PK properties suitable for an intravenous agent with short target engagement, which ultimately resulted in the identification of <b>16</b>.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Compound <b>16</b> showed potent inhibitory activity against CDK9 (IC<sub>50</sub> < 3 nM) with high selectivity over other CDKs (CDK1 = 370 nM, CDK2 > 10 μM, CDK4 > 10 μM, CDK7 = 1.1 μM) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B). Kinase selectivity profiling demonstrated that <b>16</b> had a 100-fold higher selectivity for CDK9 compared to 8 of 14 top kinases. Compound <b>16</b> had a 25-fold higher cellular selectivity over other CDKs in the MCF7 cells, while exhibiting rapid induction of apoptosis broadly across hematologic cancer cell lines (GI<sub>50</sub> = 23 nM). Short-term treatment with <b>16</b> led to the depletion of Mcl-1 in a dose- and time-dependent manner, which was considered as the mechanism of <b>16</b>-induced tumor cell death.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Compound <b>16</b> had good water solubility suitable for intravenous administration. The half-life of <b>16</b> was less than 1 h in rat, dog, and monkey. A tolerated dose-dependent response was observed in the MV4–11 tumor xenografts after weekly treatment of 5 or 15 mg/kg of <b>16</b>, dosed IP BID q2h on consecutive days. Moreover, the 15 mg/kg dose led to tumor regression in all mice, which lasted for more than 125 days. In addition, the combination of <b>16</b> and venetoclax achieved highly durable regression in all treated animals; the latter is a BCL2 inhibitor approved by the United States Food and Drug Administration (U.S. FDA) for treatment of CLL.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Therefore, as a selective CDK9 inhibitor, <b>16</b> was advanced into a clinical trial for the treatment of hematological malignancies. Unfortunately, the specific discovery process of <b>16</b> was not disclosed.</div><div class="NLM_p">The pyrimidine analogue <b>45</b> could potently inhibit CDK9 with an 80-fold higher selectivity versus CDK2 (<i>K</i><sub>i</sub> = 7 and 568 nM for CDK9 and CDK2, respectively).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Two cocrystal structures of <b>45</b> bound to CDK9 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG">4BCG</a>) as well as CDK2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCP">4BCP</a>) were obtained to explain the observed preference (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), revealing that <b>45</b> shares a similar binding conformation in both kinases. However, due to the steric hindrance between the 1,4-diazepane moiety of <b>45</b> and Lys89 in CDK2, the binding process of <b>45</b> and CDK2 produces an “inward” or “outward” conformation, which is not observed in the CDK9, indicating that the CDK2 binding pocket is too crowded for <b>45</b>. Although <b>45</b> has similar modes of action with CDK9 and CDK2, there are still some obvious differences. On the one hand, the binding of <b>45</b> to CDK9 induces the lowering of the glycine-rich loop into the ATP-binding site, which does not occur in CDK2. On the other hand, different from the apo structure of CDK9, the backbone of the hinge region in CDK9 shifts from the position where <b>45</b> is located to accommodate the binding of <b>45</b>, which contributes to the formation of the hydrogen bond between C2-NH of the pyrimidine and Cys106 at an optimal length of 2.8 Å. Both differences suggest that compared to CDK2, the CDK9 protein has a more flexible ATP-binding pocket to accommodate the binding of <b>45</b>.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Cocrystal structures of <b>45</b> bound to CDK9 (A and C, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG">4BCG</a>) and CDK2 (B and D, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCP">4BCP</a>). The steric hindrance of Lys89 leads to compound <b>45</b> showing “inward” or “outward” conformations in CDK2 (D), which does not exist in CDK9 (C). The hydrogen bonds are depicted by red dotted lines. The steric hindrance of Gly112 and Lys89 is shown on the surface and depicted by yellow dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While compound <b>45</b> had a high selectivity over most CDKs, with an IC<sub>50</sub> value of 92 nM for CDK7.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> In order to discover a CDK9 inhibitor with higher selectivity than <b>45</b>, Liu et al. performed the docking studies between <b>45</b> and CDK7/9 to find the motivation to explore the selectivity between CDK7 and CDK9.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The analysis of binding modes indicated that the flexibility of the CDK9 P-loop and the shallow hydrophobic pocket formed by the Gly112 and His108 residues may be exploited to enhance the preference for CDK9 over CDK7. Furthermore, they postulated that changing the CN group of <b>45</b> to the Cl atom was beneficial for the improvement of the CDK9 affinity. Based on these analyses, a detailed SAR study was conducted starting from compound <b>45</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). Some biological evaluations were performed to better study the SAR, including the biochemical assay with CDK9, cellular antiproliferative potency in MV4–11, MEC-1 as well as Chinese hamster lung (CHL) cells, which was used to monitor the cytotoxicity of the inhibitors. The initial design was made to replace the CN group with a Cl atom. Compound <b>46</b> (IC<sub>50</sub> > 10 μM) completely lost the potency for CDK9, while the activity of compounds <b>47</b> and <b>48</b> was restored (IC<sub>50</sub> = 0.56 and 0.24 μM, respectively). However, all of them showed no inhibitory activity in tumor cells. Changing the phenyl to the 4-fluoro benzoyl group (<b>49</b>, IC<sub>50</sub> = 2.3 μM for CDK9) gave rise to a large activity loss against CDK9 and led to a certain cytotoxicity (IC<sub>50</sub> = 0.93 μM for CHL), suggesting that a more flexible group may be suitable at this position. Therefore, the introduction of 4-amino cyclohexyl was performed and led to compound <b>50</b>, which exhibited good inhibitory activity against CDK9 (IC<sub>50</sub> = 0.022 μM) and MV4–11 cells (IC<sub>50</sub> = 0.55 μM). Moreover, an adequate selectivity over CHL was also observed (IC<sub>50</sub> = 3.5 μM). Accordingly, extensive modifications at the position of 4-amino cyclohexyl were performed. Most of the acyl substitutions resulted in activity loss against CDK9 and tumor cells. However, aliphatic substitutions brought about an obvious increase in CDK9 inhibitory activity. Among them, methoxylethane substitution in <b>51</b> (IC<sub>50</sub> = 0.002 μM) demonstrated excellent suppression of the CDK9 activity, although it showed weak inhibitory activity in tumor cells.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Development of CDK9 inhibitor <b>58</b> with high activity and selectivity based on compound <b>45</b> and the structure of compound <b>59</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the aim to improve cell antiproliferative activity of compound <b>51</b>, a new round of structural optimization was performed to focus on its NH group of the aminothiazole moiety. Compound <b>52</b> (IC<sub>50</sub> = 0.101 μM), obtained by replacing tetrahydropyran of <b>51</b> with a hydrogen atom, showed a 50-fold drop in the activity for CDK9. The hydrophobic CF<sub>3</sub> group substitution in <b>53</b> (IC<sub>50</sub> = 0.017 μM) restored the kinase activity, which promoted the introduction of various hydrophobic rings in the same position. Although most of them had good CDK9 activity, none of them displayed good cytotoxic activity (<b>54</b>, <b>55</b>, <b>56</b>). When the tetrahydrofuran group was introduced (<b>57</b>), it potently inhibited CDK9 (IC<sub>50</sub> = 0.09 μM) and displayed good selectivity for tumor cells compared to normal cells. Furthermore, changing tetrahydrofuran to tetrahydropyran carbonitrile (<b>58</b>) led to excellent CDK9 inhibitory activity (IC<sub>50</sub> = 0.002 μM), potent antiproliferative efficacy (GI<sub>50</sub> = 0.012 and 0.037 μM for MV4–11 and MEC-1, respectively) as well as low cytotoxicity (GI<sub>50</sub> = 1.2 μM for CHL). Compound <b>58</b> displayed the best in the biological evaluations. A selectivity higher than 1000-fold was observed for <b>58</b> when tested against CDK7 and other CDK members, including CDK1/2/3/5/8/11. Additionally, <b>58</b> exhibited outstanding selectivity for CDK in over 468 kinases/mutants in the kinase profiler panel. As for the <i>in vitro</i> antitumor activity, <b>58</b> could potently suppress cell proliferation in various solid tumor and leukemia cell lines with a GI<sub>50</sub> ranging from 1 to 44 nM. Compound <b>58</b> exhibited good bioavailability in rats, mice, and dogs (<i>F</i> = 45.1, 45.0, and 39.1%, respectively) and completely inhibited tumor progression on day 14 of treatment with <b>58</b> (10, 20, and 30 mg/kg/day), with no obvious cytotoxicity.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p">A docking study of <b>58</b>-CDK9 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG">4BCG</a>) was performed to gain a better insight into the binding mechanism (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A). The results demonstrated that there were two key hydrogen bonds formed between the aminopyridine of <b>58</b> and the hinge residue Cys106 in CDK9. In addition, another three hydrogen bonds were formed between the aminothiazole moiety and Asp167 in the activation loop, the oxygen atom of the methoxyethylamine moiety and nearby Asp109, as well as the CN group and Thr29 in the P-loop, respectively. Since compound <b>58</b> displays 1700-fold selectivity over CDK7 (IC<sub>50</sub> = 17,200 nM), this binding mode is superimposed onto CDK7 kinase to explain the selectivity (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>B). On the one hand, the hydrogen bond of the methoxyethylamine moiety does not exist due to the steric hindrance of the Val100 residue around the hinge region of CDK7, but the corresponding residue in CDK9 is Gly122, which has a smaller volume, avoiding such an impact. On the other hand, the Gly21 of CDK7 replaces the Thr29 in the CDK9 P-loop, leading to a lack of the capability to interact with the CN group of <b>58</b>. Thus, the formation of five hydrogen bonds between <b>58</b> and CDK9 may contribute to its high activity and selectivity.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) The binding mode of compound <b>58</b> and CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG">4BCG</a>). (B) The overlay model of CDK7 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UA2">1UA2</a>) and <b>58</b>-CDK9.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>59</b>, developed by Novartis, shares a similar structure with <b>58</b>, where the thiazole ring in <b>58</b> is replaced with the pyridine ring of <b>59</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). It can also potently inhibit CDK9 (IC<sub>50</sub> < 0.5 nM) and displays excellent selectivity over CDK7 (IC<sub>50</sub> > 10 μM). Compound <b>59</b> exhibited outstanding proliferation inhibitory activity in MOLT4 cells (IC<sub>50</sub> = 9 nM). In addition, the compound was effective for the treatment of tumor, inflammation, HIV infection, and cardiac hypertrophy.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">4.3.2.  Selective CDK9 Inhibitors Bearing the Aminopyrimidine Scaffold</h4><div class="NLM_p">Recently, Xu et al. reported another aminopyrimidine <b>61</b> showing significant selectivity against CDK9 over other CDKs (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>A).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Initially, they identified compound <b>60</b> (IC<sub>50</sub> = 184, 1211, and 27 000 nM for CDK9, CDK2, and CDK7, respectively) bearing a coumarin scaffold, which showed moderate CDK9 inhibitory activity, 7-fold and 146-fold higher selectivity over CDK2 and CDK7, respectively. According to the docking model, besides the two hydrogen bonds between the aminopyridine of compound <b>60</b> and the hinge residue Cys106 of CDK9, the coumarin group in <b>60</b> forms a hydrogen bond with Asp109 of CDK9, which account for the CDK9 activity of <b>60</b>. In order to find novel and selective CDK9 inhibitors, a detailed SAR study was performed to focus on the modification of pyrimidine and coumarin in compound <b>60</b>, culminating in the discovery of compound <b>61</b>. Compared with <b>60</b>, compound <b>61</b> showed significantly improved CDK9 activity and selectivity, with an IC<sub>50</sub> value of 2 nM against CDK9 and 100-fold and 3000-fold higher selectivity over cell cycle CDKs (CDK1–6) and transcriptional CDKs (CDK7, CDK8, and CDK19), respectively. Xu et al. suggested that the high selectivity of compound <b>61</b> against CDK9 mainly results from the smaller volume of the Gly112/Ala111 in CDK9 than that of the residues at the same position of other CDKs,<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> which also accounts for the selectivity of compounds <b>21</b>, <b>45</b>, and <b>58</b>. The steric hindrance of these residues in other CDKs, such as the residues Lys89/Lys88 of CDK2 and the residues Thr102/Arg101 of CDK4, prevents the interaction between the CDK protein and the bulky coumarin bearing 3-acetyl and 4-morpholino in compound <b>61</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>B,C). Compound <b>61</b> displayed good drug-like properties, such as potent antiproliferative activity in various tumor cells, slight hERG toxicity, and obvious tumor growth suppression in an MV4–11 mouse xenograft model. However, the PK properties of compound <b>61</b> are not good, such as the short half-life of approximately 0.23 h, which is required for further improvement.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. (A) The discovery of a selective CDK9 inhibitor. (B) The docking model between compound <b>61</b> and CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG">4BCG</a>). (C) The docking model between compound <b>61</b> and CDK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCP">4BCP</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">4.3.3.  Selective CDK9 Inhibitors Bearing A Nitrogen-Containing Fused Heterocycle Scaffold</h4><div class="NLM_p">Phillips et al.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> reported the discovery and characterization of two selective CDK9 inhibitors, namely, A-1467729 (<b>62</b>) and A-1592668 (<b>63</b>), which contains a nitrogen-containing fused heterocycle scaffold (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). Compound <b>62</b> was identified through SAR studies and shown to have a 1000-fold higher selectivity against CDK9 (IC<sub>50</sub> = 1.2 nM) over CDK1, 2, 7, and 8, and exhibited a more potent affinity to CDK4 and CDK6 with 12-fold and 240-fold higher selectivity, respectively. At the cellular level, <b>62</b> showed potent inhibition of the phosphorylation of RNA PII (IC<sub>50</sub> = 27.6 nM). In addition, a significant cell killing activity was observed in the H929 and MV4–11 cell lines treated with <b>62</b> (IC<sub>50</sub> = 39 and 42 nM, respectively). However, PK studies in rats suggested a Clp of 2.1 L/h/kg via the tail vein at a concentration of 2 mg/kg <b>62</b>, which was unsuitable for <i>in vivo</i> pharmacodynamic study. In order to reduce the clearance to within 20% of liver blood while retaining the activity against CDK9, additional structural optimization was performed. The introduction of a carboxylic acid group led to <b>63</b> with decreased clearance (Clp = 0.63 L/h/kg). Importantly, both the affinity toward CDK9 (IC<sub>50</sub> = 2.6 nM) and selectivity over other CDKs (>100-fold) were retained. Moreover, similar cell inhibition by <b>63</b> in the Mcl-1-dependent cell lines (IC<sub>50</sub> = 40 and 138 nM for H929 and MV4–11 cells, respectively) was also observed in the comparison with <b>62</b>. As a result, <b>63</b> progressed into further studies related to CDK9 inhibition. Notably, the combination of <b>63</b> and BCL2 inhibitor venetoclax significantly induced cell apoptosis in the OCI-Ly1 199R and SC-1 199R cell lines, which developed acquired resistance to venetoclax. This combined administration could give rise to greater tumor growth inhibition than the single administration in the SU-DHL-4 xenograft model.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Report of the selective CDK9 inhibitors A-1467729 (<b>62</b>) and A-1592688 (<b>63</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">4.3.4.  Selective CDK9 Inhibitors Bearing Various Scaffolds Claimed in Patents</h4><div class="NLM_p">There are some selective CDK9 inhibitors whose development processes were not disclosed, especially those reported in patents. However, they also show good inhibitory activity and selectivity against CDK9 as well as novel structures. Thus, we will briefly describe them in this section (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of compounds <b>64</b>–<b>69</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Like the macrocyclic CDK9 inhibitor <b>9</b> in a clinical study, a new macrocyclic derivative, <b>64</b>, identified by Bayer exhibits potent CDK9 inhibitory activity.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Compound <b>64</b> is a highly potent and selective CDK9 inhibitor (IC<sub>50</sub> = 2.1 nM), exhibiting a 500-fold higher selectivity over CDK2 (IC<sub>50</sub> = 1,240 nM). Furthermore, changing the fluorine atom in the para position of phenyl to the meta position leading to compound <b>65</b> with a significant increase in the selectivity over CDK2 (IC<sub>50</sub> = 7,520 nM) while maintaining the CDK9 activity (IC<sub>50</sub> = 3.4 nM). However, <b>65</b> shows a drop in cell activity compared to <b>64</b> (IC<sub>50</sub> = 126 and 8.2 nM in MOLM-13 cells, respectively). Compound <b>64</b> has excellent PK properties, like the maximum calculated oral bioavailability based on the stability data in rat hepatocyte and its half-life, which are as high as 93% and 6.9 h, respectively.</div><div class="NLM_p">Compound <b>66</b> exhibits outstanding inhibitory activity against CDK9 (IC<sub>50</sub> = 1 nM) and high selectivity over CDK2 (IC<sub>50</sub> = 8560 nM). Additionally, <b>66</b> shows significant antiproliferative activity in MOLM-13 and HeLa cell lines (IC<sub>50</sub> = 46 and 38 nM, respectively).<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The treatment with the pyrrolo-pyrimidine derivative <b>67</b> can lead to potent CDK9 inhibition (IC<sub>50</sub> = 13 nM), which shares a similar structure with the pyrrolo-pyridine derivative <b>63</b>.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Excellent CDK9 inhibitory activity is also observed for dipyridyl compounds <b>68</b> and <b>69</b> (IC<sub>50</sub> = 3 and <8 nM, respectively).<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Unfortunately, to the best of our knowledge, neither their selectivity nor their discovery process has been reported to date.</div><div class="NLM_p last">In fact, the development of kinase inhibitors (including CDK9 inhibitors) mainly currently relies on the target-based screening, which has resulted in numerous failures in clinical studies due to the poor link between the actual state of diseases and the biological targets.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Thus, phenotypic drug discovery has again captured the attention of medicinal chemists.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> In addition, new biological techniques, such as PROTACs, provide a novel and potential approach to develop CDK9 modulators.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Next, we will focus on the discussion of these two approaches currently used in the discovery of selective CDK9 modulators.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">4.3.5.  The Application of Phenotypic Screening in the Development of CDK9 Inhibitors</h4><div class="NLM_p">Phenotypic screening is a biological experiment involving a series of small molecules, peptides, and other substances to find agents that induce a desired phenotypic outcome (such as the inhibition of cellular proliferation), which is currently the main strategy used by medicinal chemists for the initial development of drugs.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Unlike targeted screening, phenotypic screening directly evaluates the ability of compounds to modulate disease-related phenotypes and identify active compounds with unknown targets and mechanisms of action. This more “holistic”, target-naive screening approach may identify initial hits that are more relevant and useful start points for medicinal chemistry optimization.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Some researchers believe that the knowledge of the molecular pathways and targets required for specific disease-associated phenotypes, along with the ability to use more disease-relevant cell models, can increase the chance of finding drugs with novel mechanisms of action and clinical efficacy.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The existing CDK inhibitors have some disadvantages, including low activity, poor physical and chemical properties, and poor selectivity. Thus, an effective phenotypic screening method may provide a novel and promising strategy to develop CDK inhibitors, including CDK9 inhibitors.<a onclick="showRef(event, 'ref87 ref115'); return false;" href="javascript:void(0);" class="ref ref87 ref115">(87,115)</a></div><div class="NLM_p">Epigenetic reprogramming in cancer leads to heritable changes in gene expression, such as the silencing of tumor suppressor genes.<a onclick="showRef(event, 'ref28 ref116'); return false;" href="javascript:void(0);" class="ref ref28 ref116">(28,116)</a> Reversing epigenetic modifications by drugging the epigenome represents a useful tool in the field of epigenetic therapy. However, epigenetic treatment options remain limited clinically.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> The YB5 cell-based system derived from the human colon cancer cell line, SW48, as a platform for epigenetic drug screening, was used by Zhang et al.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> to perform high-throughput phenotypic screening of the NDL-3040 natural compound library (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>), leading to an aminothiazole derivative <b>70</b> (HH1). In YB5, <b>70</b> can effectively activate the GFP gene, which is silenced by an epigenetic mechanism. However, there is no drug with aminothiazole structure among the known epigenetic drugs, facilitating the identification of CDK9 as a new regulator of gene silencing. As a result, 77 aminothiazole derivatives were designed and synthesized, and the best active compound <b>71</b> was screened using the YB5 cell-based system. The evaluations using the kinase activity assay showed that <b>71</b> was at least 22 times more selective for CDK9 (IC<sub>50</sub> = 5 nM) over other CDK family members. Some studies suggest that the reactivation of silenced genes requires cell division to help reset the chromatin.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Therefore, optimizing lead compounds by GFP gene expression may be a promising strategy for identifying potent CDK9 inhibitors.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. (A) Drug screening workflow utilizing YB5 as a phenotypic-based screening system. (B) Development of the novel CDK9 inhibitor <b>71</b> by gene expression-based SAR discovery.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Similarly, a high-through phenotypic screening was used to find potent inhibitors of the heat shock factor 1 (HSF1) stress pathway, which proved to be CDK9 inhibitors with high selectivity.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> The 4,6-disubstituted pyrimidine <b>73</b> with potent inhibition of the HSF1-stress pathway exhibits a 78-fold higher selectivity for CDK9 over other CDKs (except CDK5, 43-fold). Importantly, whether it is the 4,6-disubstituted pyrimidine derivatives (<b>72</b>, <b>73</b>, <b>74</b>, <b>75</b>) or other compounds with entirely different chemical structures (<b>12</b> and <b>13</b>), there is a good correlation between their CDK9 activity and the inhibition of the HSF1 pathway (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), indicating that CDK9 inhibition may be involved in the suppression of the HSF1-stress pathway suppression. Although the identification of compounds <b>71</b> and <b>73</b> as selective CDK9 inhibitors was not the initial purpose, their evolutions are driven through the phenotypic marker. Thus, phenotypic screening and optimization on the basis of the HSF1-stress pathway and epigenetic reprogramming might provide a new approach to develop specific CDK9 inhibitors.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. 4,6-Disubstituted pyrimidine derivatives obtained by using the HSF1-stress pathway as a phenotypic-based screening system. The CDK9 inhibitor dinaciclib (<b>12</b>) and SNS-032 (<b>13</b>) also showed potent inhibition of the HSF1-stress pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">4.3.6.  The Application of PROTAC Strategy in the Development of CDK9 Degraders</h4><div class="NLM_p">PROTACs are heterobifunctional small molecules that are aimed at achieving selective degradation of the target proteins.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Typically, PROTACs are mainly composed of one moiety that binds the target of interest, another that binds a ubiquitin (E3) ligase, and a linker connecting these two moieties.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> The normal physiological function of the ubiquitin-protease system is responsible for clearing mutated, denatured, or harmful proteins from cells. With the help of PROTACs, E3 ligase combined with ubiquitin-conjugating enzymes (E2) and the activated ubiquitin molecules recognizes the target proteins and ubiquitinates them, which ultimately results in the degradation of target proteins by the proteasome. (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref121 ref122 ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref121 ref122 ref123 ref124">(121−124)</a> Recently, the first PROTAC anticancer candidate has entered clinical trials,<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> suggesting the feasibility and efficacy of the PROTAC strategy in the development of antitumor drugs.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Composition and degradation mechanism of PROTACs. The PROTAC molecule (<b>78</b>) is composed of a CDK9 inhibitor and a small molecule binding to E3 ligase, followed by polyubiquitination and proteasome degradation of CDK9.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Due to the high homology of the CDK family, the development of selective CDK9 inhibitors is challenging. A recent study showed that lysine residues with appropriate surface exposure have an important effect on ubiquitination and proteasomal degradation.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> This may provide a new approach to develop small molecules selectively targeting CDKs since there are some differences in the distribution and shape of lysine residues on the surface among different CDKs.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Indeed, to date, many researchers have reported the identification of selective CDKs degraders, including CDK9 degraders.<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(127,128)</a></div><div class="NLM_p">Compound <b>78</b> is the first reported PROTAC molecule that selectively induces CDK9 cleavage. A series of aminopyrazole analogues were designed and screened for CDK activity, which led to the identification of compound <b>76</b> with selectivity for CDK5 and CDK9 over CDK2.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> The degrader <b>78</b> was generated by conjugating compound <b>76</b> and thalidomide (<b>77</b>) using an alkane chain containing 4 carbon atoms (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Western blot analysis demonstrated that compound <b>78</b> could strongly degrade CDK9 (DC<sub>50</sub> = ∼8 μM, the value estimated from the reported data). Importantly, although the parental compound <b>76</b> displayed good inhibition against CDK5, the PROTAC <b>78</b> did not cause a clear change in the levels of CDK5, CDK2, and other kinases, such as FAK, AKT, and IKKβ, suggesting that the PROTAC molecule was a selective CDK9 degrader. Researchers believe that the selectivity of the compound might stem from the absence of a proximal lysine residue in these kinases that can be ubiquitinated.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> In addition, a more significantly reduced level of Mcl-1 induced by degrader <b>78</b> was observed compared with parent <b>76</b>.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structures of compounds <b>76</b>–<b>80</b>. The DC<sub>50</sub> values are estimated from the reported data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2018, our laboratory reported the discovery of wogonin-based PROTACs against CDK9, which is the first report on the application of flavonoid natural products in PROTACs targeting CDK9.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Among them, compound <b>79</b> can selectively degrade CDK9 in a concentration-dependent manner and potently inhibit proliferation of MCF-7 cells at low concentration (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).</div><div class="NLM_p last">SNS-032 (<b>13</b>) is a potent pan-CDK inhibitor with IC<sub>50</sub> values of 480, 38, 340, 62, and 4 nM for CDK1, CDK2, CDK5, CDK7, and CDK9, respectively, which was also used to design a degrader (<b>80</b>) by connecting thalidomide through a polyethylene glycol linker (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref104 ref129'); return false;" href="javascript:void(0);" class="ref ref104 ref129">(104,129)</a> Compound <b>80</b> could induce rapid and specific cleavage of CDK9 in wildtype and CRBN MOLT4 cells. Although the CDK9 cleavage induced by <b>80</b> was CRBN-dependent up to a concentration of 5 μM, the levels of other CDKs were hardly changed at a concentration of 50 μM, suggesting the design of a PROTAC molecule significantly improved the preference of the parental compound <b>13</b>. Additionally, <i>in vitro</i> antiproliferative assay of MOLT4 cells demonstrated that the CDK9 degrader <b>80</b> (IC<sub>50</sub> = 50 nM) had a more potent inhibitory activity than parent <b>13</b> (IC<sub>50</sub> = 173 nM).</div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">5.  Summary and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72273" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72273" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">CDK9 plays a vital role in transcription regulation, and the CDK9-mediated transcription of MYC and Mcl-1 is required for the growth and survival of tumor cells. Thus, the dysregulation of the CDK9 pathway is widespread in a variety of hematological malignancies, solid tumor cell lines, and other diseases, making CDK9 signaling a potential and attractive therapeutic target. An increasing number of CDK9 inhibitors have been discovered, and some have progressed into clinical studies. The pan-CDK inhibitor flavopiridol actually has good antitumor activity through the inhibition of the CDK9 pathway and has been approved by the FDA as an orphan drug for the treatment of lymphocytic leukemia. However, the use of flavopiridol may come with serious toxicities, limiting its further clinical development, which suggests the need for careful development and monitoring of novel CDK9 inhibitors with high selectivity.</div><div class="NLM_p">From the perspective of the CDK9 protein structure, there are some essential amino acid residues in the ATP-binding pocket of CDK9, which contribute to the activity and selectivity of CDK9. First, the interactions with the residues Cys106, Asp104, Asp164, and Thr29 in CDK9 significantly account for the kinase inhibitory activity, especially the hinge residue Cys106. Second, a less crowded environment is observed at the exit of the ATP pocket of the CDK9 protein because CDK9 Gly112/Ala111 replaces the bulkier Lys89/Lys88 in CDK2, suggesting that the ATP cavity of CDK9 may accommodate larger ligands. In addition, the shallow hydrophobic pocket, containing the His108 and Gly112 of CDK9, is replaced with the raised pocket formed by Thr96 and Val100 in CDK7, indicating that a carefully selected small hydrophobic moiety could be utilized to study the selectivity between CDK7 and CDK9. Importantly, the steric hindrance from the bulky residues at the same position was also conserved in other CDKs, such as the residues Thr104/Arg101 of CDK4, which accounted for the selectivity of several CDK9 inhibitors with high selectivity (including compounds <b>21</b>, <b>45</b>, <b>58</b>, and <b>61</b>). Accordingly, making full use of the Gly112/Ala111 residues in CDK9 may offer an opportunity to enhance the CDK9 inhibitor selectivity. Meanwhile, the formation of halogen bonds with the gatekeeper or hinge residue of CDK9, such as Phe103 and Asp104, may promote a higher selectivity and binding affinity. In addition, the whole conformation of the CDK9 protein has high plasticity and can be adapted to a ligand with a more flexible framework.<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(130,131)</a></div><div class="NLM_p">From the perspective of the structure of the inhibitors, we divided the structure of CDK9 inhibitors reported in recent years into six categories according to their core skeleton, namely, flavonoids, aminopyridine (aminotriazine), aminopyrimidine, fused heterocycle, bipyridine, and aminothiazole (aminopyrazole) (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). Among them, currently, inhibitors with flavonoids, aminopyridine (aminotriazine), or aminopyrimidine cores are typical CDK9 inhibitors, and most CDK9 inhibitors in clinical trials belong to these types. However, compared with CDK9 inhibitors reviewed by Sonawane et al.,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> there is almost no CDK9 inhibitor with a new scaffold reported in the past five years. The binding models of these inhibitors to the CDK9 active site are depicted in <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>. The structural requirements of CDK9 inhibitors consist of three parts, namely, parts A, B, and C (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>). Part A is the core scaffold of CDK9 inhibitors, which forms hydrogen bonds with the hinge residues of CDK9. This part is required to ensure the CDK9 inhibitory activity. Part C, which extends into the hydrophilic region, may serve to further improve the kinase activity, while part B adjacent to the solvent-exposed region usually serves to improve selectivity and physicochemical properties. According to the superimposition of each class of CDK9 inhibitors (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00744/suppl_file/jm0c00744_si_001.pdf" class="ext-link">Figure S1</a>), their main differences are concentrated in parts B and C. Notably, an increasing number of studies exploring the optimization of part B have been recently reported.<a onclick="showRef(event, 'ref80 ref103 ref106 ref132'); return false;" href="javascript:void(0);" class="ref ref80 ref103 ref106 ref132">(80,103,106,132)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Overview of the structure of CDK9 inhibitors discussed in this review, which are divided into six categories according to their core scaffold, including flavonoids, aminopyridine (aminotriazine), aminopyrimidine, fused heterocycles, bipyridine, and aminothiazole (aminopyrazole). Compounds marked in blue are currently in clinical studies, while those marked in red are discontinued.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Binding mode of inhibitors in the ATP pocket of CDK9, which consists of A (cyan), B (blue), and C (turquois). CDK9 inhibitors including flavonoids, aminopyridine, aminopyrimidine, and a fused heterocycle are shown and color-coded by their binding mode. Part A is the core scaffold of CDK9 inhibitors and forms hydrogen bonds with the hinge residues of CDK9 (the interaction area is indicated in pink). Part C, extending into the hydrophilic region, may be used to further improve kinase activity, while part B, the adjacent solvent-exposed region, is usually used to improve the selectivity and physicochemical properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The main drug design strategies discussed in this review are listed in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. According to the list, the structure-based drug design is the main approach to develop CDK9 inhibitors, probably due to the rapid development of computer technology and the disclosure of many CDK9 structure crystals (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The ligand-binding crystallography has an extremely positive effect on the design and synthesis of novel selective CDK inhibitors. However, the most serious challenge for computer-aided technologies applied in the structure-based design strategy is that it cannot accurately simulate the complexity of biological systems,<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> which explains the poor selectivity of some CDK9 inhibitors and, to some extent, the lack of CDK9 inhibitors with novel scaffolds. Thus, some novel strategies, such as PROTAC or other approaches that do not rely or rely less on computer technology, are currently used in the development of CDK9 inhibitors or degraders. Small-molecule PROTACs targeting CDK9 can potently degrade CDK9 protein with high selectivity, while phenotypic screening may generate a specific CDK9 inhibitor with novel scaffolds. Moreover, the structural hybrid strategy is also widely used to develop CDK9 inhibitors based on known compounds.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Overview of the Design Strategies of CDK9 Modulators Examined in This Review</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">design strategy</th><th class="colsep0 rowsep0" align="center">compd<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">CDK9 (IC<sub>50</sub>/nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">other CDKs or targets (IC<sub>50</sub>/nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="7" align="left">structure-based drug design</td><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">CDK2 (5), CDK7 (37)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char="."><4</td><td class="colsep0 rowsep0" align="left">CDK1(370)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char=".">19.9</td><td class="colsep0 rowsep0" align="left">CDK2 (913)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="left">CDK6 (41), CDK2 (>640)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="left">CDK2 (24)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">CDK7 (1720)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">CDK2 (>300)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">lead optimization (SAR study)</td><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="left">CDK1 (25), CDK2 (180) CDK4 (90), CDK5 (210), CDK6 (210)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char=".">64</td><td class="colsep0 rowsep0" align="left">CDK2 (1725), CDK5 (1093)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="left">CDK4 (162), CDK6 (101)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">physicochemical properties-guided optimization</td><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="left">CDK1, CDK2</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="left">other CDKs (>890), GSK3 (45–87)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="left">CDK2 (16)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">structural hybridization</td><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">CDK4 (8.8), HDAC1 (12)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left">CDK4 (148), CDK6 (145)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">CDK4 (142)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">phenotypic screening</td><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="left">CDK5 (610)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">PROTAC strategy</td><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">high selectivity over other CDKs</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">high selectivity over other CDKs</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>80</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">high selectivity over other CDKs</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Those compounds claimed in patents are not included.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">The IC<sub>50</sub> values were achieved through a kinase-based assay.</p></div></div></div><div class="NLM_p">The main objective of improving the preference of CDK9 inhibitors is to reduce or avoid their potential side effects. However, recently, dual or multiple inhibitors have been reported to possess unique advantages. Several studies have suggested that the response to mutations in downstream factors, such as in the Rb-E2F signaling pathway, contributes to the resistance of cancer cells to CDK4/6 inhibitors.<a onclick="showRef(event, 'ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref134 ref135">(134,135)</a> More importantly, a close association has been observed between the overexpression of CDK9 and clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Thus, the identification of multiple inhibitors might emerge as a potential strategy to overcome resistance to signal-targeting therapeutics. In fact, the development of multitarget inhibitors against CDK9 kinase has achieved encouraging results, such as dual CDK2/9 inhibitor <b>32</b>, as well as multitarget inhibitor <b>35</b> against CDK4/9 and HADC<sub>1</sub>. The CDK9 inhibitor BTX-A51 (<b>15</b>), which is in clinical trials for the treatment of human leukemia, also inhibits CDK7 and casein kinase 1A1.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Just recently, Wang et al. has disclosed the identification of a dual CDK6/9 inhibitor that significantly suppresses tumor growth in a xenograft mouse model without obvious toxicity.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> In addition, the combination therapies have also exhibited improved anticancer activity compared to the single inhibitors of CDK9. The combination of AZD-4573 (<b>16</b>) with acalabrutinib, an inhibitor of bruton tyrosine kinase (BTK), resulted in enhanced antitumor activity in BTK inhibitor-sensitive <i>in vivo</i> models.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> A combination of BAY-1143572 (<b>7</b>) with 5-fluorouracil exhibited synergistic antitumorigenic effects against esophageal adenocarcinoma.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Another recent study demonstrates that CDK9 inhibitors can act synergistically with bromodomain and extraterminal (BET) inhibitors in preclinical models of MLL-rearranged acute leukemia.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> A new clinical study of venetoclax and flavopiridol in patients with relapsed/refractory AML is in the phase of recruitment,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> indicating the potential of CDK9 inhibitors in combination therapies. These studies demonstrate that the development of multitarget inhibitors or the application of combination therapies may also be good choices to expand the clinical application of CDK9 inhibitors.</div><div class="NLM_p last">In summary, the design of drugs and inhibitors to target CDK9 is a promising strategy for the development of antitumor drugs. More and more researchers are focusing on the discovery of CDK9 inhibitors. However, many of the found CDK9 inhibitors have not met the requirements for entry into clinical trials due to their poor physicochemical properties, high toxicity, and lack of specificity. Thus, the discovery and application of the latest effective design strategies will benefit the discovery of superior CDK9 inhibitors for clinical treatment to future successful FDA drug approvals.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00744" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33734" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33734" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00744?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00744</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">The superimposition of the dominant conformation of CDK9 inhibitors in the binding site of CDK9 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00744/suppl_file/jm0c00744_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00744/suppl_file/jm0c00744_si_001.pdf">jm0c00744_si_001.pdf (255.51 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00744" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63548" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63548" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiyu Li</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6492-9511" title="Orcid link">http://orcid.org/0000-0001-6492-9511</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c4beacadbdb1a8ad84a7b4b1eaa1a0b1eaa7aa"><span class="__cf_email__" data-cfemail="d7adbfbeaea2bbbe97b4a7a2f9b2b3a2f9b4b9">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinlei Bian</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4552-1195" title="Orcid link">http://orcid.org/0000-0003-4552-1195</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#503239313e3a3c103320257e3534257e333e"><span class="__cf_email__" data-cfemail="abc9c2cac5c1c7ebc8dbde85cecfde85c8c5">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tizhi Wu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhen Qin</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yucheng Tian</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jubo Wang</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chenxi Xu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>J.B.and T.W. are responsible for writing the whole manuscript. Z.L., J.B., Z.Q., Y.T., J.W., and C.X. were in charge of verification and revisions.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38374" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38374" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Tizhi Wu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=BIO-d7e3760-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tizhi Wu</b> got his Bachelor’s degree from the Nanjing University of Chinese Medicine in 2017. He is currently a postgraduate student at the Department of Medicinal Chemistry, China Pharmaceutical University, under the supervision of Professor Zhiyu Li. His research is mainly focused on the design, synthesis, and biological evaluation of potent and selective CDK9 inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Zhen Qin</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=BIO-d7e3765-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zhen Qin</b> got his Bachelor’s degree from Shenyang Pharmaceutical University in 2019. She is currently a postgraduate student at the Department of Medicinal Chemistry, China Pharmaceutical University, under the supervision of professor Zhiyu Li. Her research mainly focuses on the synthesis of potent and selective CDK9 inhibitors.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Yucheng Tian</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=BIO-d7e3770-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yucheng Tian</b> got his Bachelor’s degree from the China Pharmaceutical University of Medicinal Chemistry in 2018. He is currently a postgraduate student at the Department of Medicinal Chemistry, China Pharmaceutical University, under the supervision of Professor Zhiyu Li. His research mainly focuses on the structural optimization and biological evaluation of Mcl-1 inhibitors.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Jubo Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=BIO-d7e3775-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jubo Wang</b> achieved his Ph.D. at China Pharmaceutical University in 2019. Currently, he is conducting postdoctoral research under the supervision of Professor Zhiyu Li. His research topic is mainly focused on the design, synthesis, and biological evaluation of potent and selective CDK9 inhibitors.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Chenxi Xu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=BIO-d7e3780-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Chenxi Xu</b> is currently a college student and will get her Bachelor’s degree from China Pharmaceutical University soon.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Zhiyu Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=BIO-d7e3785-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zhiyu Li</b> graduated from China Pharmaceutical University with his Bachelor’s and Master’s degrees in 1988. He received his Ph.D. in medicinal chemistry at the same institute in 2000. Currently, he is the director and a full professor of the Department of Medical Chemistry, School of Pharmacy, at CPU. He has published more than 50 papers in peer-reviewed journals and owns approximately 30 granted patents. His major research interests focus on the discovery and development of targeted anticancer drugs.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Jinlei Bian</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=BIO-d7e3790-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jinlei Bian</b> received his Bachelor’s degree from China Pharmaceutical University, where he also obtained his Ph.D. in Medicinal Chemistry under the supervision of Professor Qi-Dong You. He is currently a member of the Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University. He works as a medicinal chemist, and his main research topics focus on the following: (i) rational design of modulators targeting tumor metabolism and (ii) the chemical biology study of CDKs.</p></figure></div><div class="ack" id="ACK-d7e3812-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge financial support from the National Natural Science Foundation of China (81872746 and 81703347), the National Natural Science Foundation of Jiangsu Province of China (BK20170743 and BK20171393), a National Innovation and Entrepreneurship Training Program For College Students (201910316030S), the “Double First-Class” University Project (CPU2018GY07), and the State Key Laboratory of Drug Research and Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX18_0770).</p></div><table summary="" class="NLM_def-list" id="dl2"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">CDKs</td><td class="NLM_def"><p class="first last">cyclin-dependent kinases</p></td></tr><tr><td class="NLM_term">RB</td><td class="NLM_def"><p class="first last">retinoblastoma proteins</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">CTD</td><td class="NLM_def"><p class="first last">C-terminal repeat domain</p></td></tr><tr><td class="NLM_term">P-TEFb</td><td class="NLM_def"><p class="first last">the positive transcription elongation factor B</p></td></tr><tr><td class="NLM_term">RNAPII</td><td class="NLM_def"><p class="first last">RNA polymerase II</p></td></tr><tr><td class="NLM_term">NELF</td><td class="NLM_def"><p class="first last">negative elongation factors</p></td></tr><tr><td class="NLM_term">DSIF</td><td class="NLM_def"><p class="first last">DRB-sensitivity inducing factor</p></td></tr><tr><td class="NLM_term">BRD4</td><td class="NLM_def"><p class="first last">bromodomain-containing protein 4</p></td></tr><tr><td class="NLM_term">Mcl-1</td><td class="NLM_def"><p class="first last">myeloid cell leukemia 1</p></td></tr><tr><td class="NLM_term">INK4</td><td class="NLM_def"><p class="first last">inhibitors of CDK4</p></td></tr><tr><td class="NLM_term">TFIIH</td><td class="NLM_def"><p class="first last">transcription factor IIH</p></td></tr><tr><td class="NLM_term">PIC</td><td class="NLM_def"><p class="first last">the preinitiation complex</p></td></tr><tr><td class="NLM_term">ATL</td><td class="NLM_def"><p class="first last">adult T-cell leukemia/lymphoma</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">Fms-like tyrosine kinase-3</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">CHL</td><td class="NLM_def"><p class="first last">Chinese hamster lung cell</p></td></tr><tr><td class="NLM_term">PROTACs</td><td class="NLM_def"><p class="first last">proteolysis-targeting chimeras</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">bruton tyrosine kinase</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extraterminal</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall-cell lung cancer</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">androgen receptor</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">HNSCC</td><td class="NLM_def"><p class="first last">human head and neck squamous cell carcinoma</p></td></tr><tr><td class="NLM_term">cFlip</td><td class="NLM_def"><p class="first last">cellular FLICE-like inhibitory protein</p></td></tr><tr><td class="NLM_term">TRAIL</td><td class="NLM_def"><p class="first last">tumor necrosis factor-related apoptosis-inducing ligand</p></td></tr><tr><td class="NLM_term">NK</td><td class="NLM_def"><p class="first last">natural killer</p></td></tr><tr><td class="NLM_term">CSCs</td><td class="NLM_def"><p class="first last">cancer stem cells</p></td></tr><tr><td class="NLM_term">MLL</td><td class="NLM_def"><p class="first last">mixed-lineage leukemia</p></td></tr><tr><td class="NLM_term">T loop</td><td class="NLM_def"><p class="first last">activation loop</p></td></tr><tr><td class="NLM_term">DMPK</td><td class="NLM_def"><p class="first last">drug metabolism and pharmacokinetic</p></td></tr><tr><td class="NLM_term">U.S. FDA</td><td class="NLM_def"><p class="first last">United States Food and Drug Administration</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87218" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87218" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 140 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedewa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manassaram-Baptiste, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saslow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wender, R. C.</span></span> <span> </span><span class="NLM_article-title">Cancer screening in the united states, 2019: a review of current American cancer society guidelines and current issues in cancer screening</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.3322/caac.21557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.3322%2Fcaac.21557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30875085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BB3cbksV2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=184-210&issue=3&author=R.+A.+Smithauthor=K.+S.+Andrewsauthor=D.+Brooksauthor=S.+A.+Fedewaauthor=D.+Manassaram-Baptisteauthor=D.+Saslowauthor=R.+C.+Wender&title=Cancer+screening+in+the+united+states%2C+2019%3A+a+review+of+current+American+cancer+society+guidelines+and+current+issues+in+cancer+screening&doi=10.3322%2Fcaac.21557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening</span></div><div class="casAuthors">Smith Robert A; Andrews Kimberly S; Manassaram-Baptiste Deana; Brooks Durado; Fedewa Stacey A; Saslow Debbie; Wender Richard C</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-210</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society publishes a summary of its guidelines for early cancer detection, data and trends in cancer screening rates, and select issues related to cancer screening.  In this issue of the journal, the current American Cancer Society cancer screening guidelines are summarized, and the most current data from the National Health Interview Survey are provided on the utilization of cancer screening for men and women and on the adherence of men and women to multiple recommended screening tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkwie6IygDLeIHSmpohpd0fW6udTcc2eZPZgMTB56A2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbksV2qtw%253D%253D&md5=e04fa8bf340b2cfda11d03cdf2afa95a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21557%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DAndrews%26aufirst%3DK.%2BS.%26aulast%3DBrooks%26aufirst%3DD.%26aulast%3DFedewa%26aufirst%3DS.%2BA.%26aulast%3DManassaram-Baptiste%26aufirst%3DD.%26aulast%3DSaslow%26aufirst%3DD.%26aulast%3DWender%26aufirst%3DR.%2BC.%26atitle%3DCancer%2520screening%2520in%2520the%2520united%2520states%252C%25202019%253A%2520a%2520review%2520of%2520current%2520American%2520cancer%2520society%2520guidelines%2520and%2520current%2520issues%2520in%2520cancer%2520screening%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2019%26volume%3D69%26issue%3D3%26spage%3D184%26epage%3D210%26doi%3D10.3322%2Fcaac.21557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tutone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almerico, A. M.</span></span> <span> </span><span class="NLM_article-title">Recent advances on CDK inhibitors: an insight by means of in silico methods</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">142</span>),  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2017.07.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=300-315&issue=142&author=M.+Tutoneauthor=A.+M.+Almerico&title=Recent+advances+on+CDK+inhibitors%3A+an+insight+by+means+of+in+silico+methods&doi=10.1016%2Fj.ejmech.2017.07.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.067%26sid%3Dliteratum%253Aachs%26aulast%3DTutone%26aufirst%3DM.%26aulast%3DAlmerico%26aufirst%3DA.%2BM.%26atitle%3DRecent%2520advances%2520on%2520CDK%2520inhibitors%253A%2520an%2520insight%2520by%2520means%2520of%2520in%2520silico%2520methods%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D15%26issue%3D142%26spage%3D300%26epage%3D315%26doi%3D10.1016%2Fj.ejmech.2017.07.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duronio, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span> <span> </span><span class="NLM_article-title">Signaling pathways that control cell proliferation</span>. <i>Cold Spring Harbor Perspect. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">a008904</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a008904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1101%2Fcshperspect.a008904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=23457258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVCit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=a008904&author=R.+J.+Duronioauthor=Y.+Xiong&title=Signaling+pathways+that+control+cell+proliferation&doi=10.1101%2Fcshperspect.a008904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling pathways that control cell proliferation</span></div><div class="casAuthors">Duronio, Robert J.; Xiong, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">a008904/1-a008904/12</span>CODEN:
                <span class="NLM_cas:coden">CSHPEU</span>;
        ISSN:<span class="NLM_cas:issn">1943-0264</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Cells decide to proliferate or remain quiescent using signaling pathways that link information about the cellular environment to the G1 phase of the cell cycle.  Progression through G1 phase is controlled by pRB proteins, which function to repress the activity of E2F transcription factors in cells exiting mitosis and in quiescent cells.  Phosphorylation of pRB proteins by the G1 cyclin-dependent kinases (CDKs) releases E2F factors, promoting the transition to S phase.  CDK activity is primarily regulated by the binding of CDK catalytic subunits to cyclin partners and CDK inhibitors.  Consequently, both mitogenic and antiproliferative signals exert their effects on cell proliferation through the transcriptional regulation and ubiquitin-dependent degrdn. of cyclins and CDK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprCm1Z75UpSrVg90H21EOLACvtfcHk0lhwi15npes6xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVCit7k%253D&md5=6f5a3dcca0bb636f013af03783d1fccd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a008904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a008904%26sid%3Dliteratum%253Aachs%26aulast%3DDuronio%26aufirst%3DR.%2BJ.%26aulast%3DXiong%26aufirst%3DY.%26atitle%3DSignaling%2520pathways%2520that%2520control%2520cell%2520proliferation%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2013%26volume%3D5%26spage%3Da008904%26doi%3D10.1101%2Fcshperspect.a008904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1535-7163.MCT-12-0286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=22821149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2265-2273&issue=10&author=G.+Siemeisterauthor=U.+Luckingauthor=A.+M.+Wengnerauthor=P.+Lienauauthor=W.+Steinkeauthor=C.+Schatzauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=BAY1000394%2C+a+novel+cyclin-dependent+kinase+inhibitor%2C+with+potent+antitumor+activity+in+mono-+and+in+combination+treatment+upon+oral+application&doi=10.1158%2F1535-7163.MCT-12-0286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application</span></div><div class="casAuthors">Siemeister, Gerhard; Luecking, Ulrich; Wengner, Antje M.; Lienau, Philip; Steinke, Wolfram; Schatz, Christoph; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2265-2273</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulated activity of cyclin-dependent kinases (CDK) results in loss of cell-cycle checkpoint function and increased expression of antiapoptotic proteins, which has been directly linked to the mol. pathol. of cancer.  BAY 1000394 inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC50 values in the range between 5 and 25 nmol/L.  Cell proliferation was inhibited at low nanomolar concn. in a broad spectrum of human cancer cell lines.  In cell-based assays, the inhibition of phosphorylation of the CDK substrates retinoblastoma protein, nucleophosmin, and RNA polymerase II was shown.  Cell-cycle profiles were consistent with inhibition of CDK 1, 2, and 4 as shown in cell-cycle block and release expts.  The physicochem. and pharmacokinetic properties of BAY 1000394 facilitate rapid absorption and moderate oral bioavailability.  The compd. potently inhibits growth of various human tumor xenografts on athymic mice including models of chemotherapy resistance upon oral dosing.  Furthermore, BAY 1000394 shows more than additive efficacy when combined with cisplatin and etoposide.  These results suggest that BAY 1000394 is a potent pan-CDK inhibitor and a novel oral cytotoxic agent currently in phase I clin. trials.  Mol Cancer Ther; 11(10); 2265-73. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBMnyCrxDjqbVg90H21EOLACvtfcHk0lhwi15npes6xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK&md5=c175eacd5440b59b113a78a61a89a4b5</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0286%26sid%3Dliteratum%253Aachs%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DLucking%26aufirst%3DU.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSteinke%26aufirst%3DW.%26aulast%3DSchatz%26aufirst%3DC.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DBAY1000394%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520with%2520potent%2520antitumor%2520activity%2520in%2520mono-%2520and%2520in%2520combination%2520treatment%2520upon%2520oral%2520application%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D10%26spage%3D2265%26epage%3D2273%26doi%3D10.1158%2F1535-7163.MCT-12-0286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnum, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, M. J.</span></span> <span> </span><span class="NLM_article-title">Cell cycle regulation by checkpoints</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1170</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-0888-2_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2F978-1-4939-0888-2_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24906307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2cfgsFeqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1170&publication_year=2014&pages=29-40&author=K.+J.+Barnumauthor=M.+J.+O%E2%80%99Connell&title=Cell+cycle+regulation+by+checkpoints&doi=10.1007%2F978-1-4939-0888-2_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle regulation by checkpoints</span></div><div class="casAuthors">Barnum Kevin J; O'Connell Matthew J</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cell cycle checkpoints are surveillance mechanisms that monitor the order, integrity, and fidelity of the major events of the cell cycle.  These include growth to the appropriate cell size, the replication and integrity of the chromosomes, and their accurate segregation at mitosis.  Many of these mechanisms are ancient in origin and highly conserved, and hence have been heavily informed by studies in simple organisms such as the yeasts.  Others have evolved in higher organisms, and control alternative cell fates with significant impact on tumor suppression.  Here, we consider these different checkpoint pathways and the consequences of their dysfunction on cell fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3b8IASWHSOg8IxFYvehhofW6udTcc2ebMAIj25-ulerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfgsFeqtA%253D%253D&md5=b5572013941fc639faddf9d9813ec0e3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-0888-2_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-0888-2_2%26sid%3Dliteratum%253Aachs%26aulast%3DBarnum%26aufirst%3DK.%2BJ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DM.%2BJ.%26atitle%3DCell%2520cycle%2520regulation%2520by%2520checkpoints%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2014%26volume%3D1170%26spage%3D29%26epage%3D40%26doi%3D10.1007%2F978-1-4939-0888-2_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of cyclin-dependent protein kinase inhibitors</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1042/EBC20170040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1042%2FEBC20170040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29118092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC1M7pt1Gmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=439-452&issue=5&author=M.+P.+Martinauthor=J.+A.+Endicottauthor=M.+E.+M.+Noble&title=Structure-based+discovery+of+cyclin-dependent+protein+kinase+inhibitors&doi=10.1042%2FEBC20170040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of cyclin-dependent protein kinase inhibitors</span></div><div class="casAuthors">Martin Mathew P; Endicott Jane A; Noble Martin E M</div><div class="citationInfo"><span class="NLM_cas:title">Essays in biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">439-452</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The cell fate-determining roles played by members of the cyclin-dependent protein kinase (CDK) family explain why their dysregulation can promote proliferative diseases, and identify them as potential targets for drug discovery in oncology and beyond.  After many years of research, the first efficacious CDK inhibitors have now been registered for clinical use in a defined segment of breast cancer.  Research is underway to identify inhibitors with appropriate CDK-inhibitory profiles to recapitulate this success in other disease settings.  Here, we review the structural data that illustrate the interactions and properties that confer upon inhibitors affinity and/or selectivity toward different CDK family members.  We conclude that where CDK inhibitors display selectivity, that selectivity derives from exploiting active site sequence peculiarities and/or from the capacity of the target CDK(s) to access conformations compatible with optimizing inhibitor-target interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqZGQ3bfUY0XELvajU9pjPfW6udTcc2ebMAIj25-ulerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7pt1Gmtg%253D%253D&md5=7795a97e063f43e77499e9a03020d6cb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1042%2FEBC20170040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FEBC20170040%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26atitle%3DStructure-based%2520discovery%2520of%2520cyclin-dependent%2520protein%2520kinase%2520inhibitors%26jtitle%3DEssays%2520Biochem.%26date%3D2017%26volume%3D61%26issue%3D5%26spage%3D439%26epage%3D452%26doi%3D10.1042%2FEBC20170040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, E. L.</span></span> <span> </span><span class="NLM_article-title">Targeting breast cancer with CDK inhibitors</span>. <i>Curr. Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">443</span>, <span class="refDoi"> DOI: 10.1007/s11912-015-0443-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs11912-015-0443-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25716100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2MrptVantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=443&issue=5&author=E.+L.+Mayer&title=Targeting+breast+cancer+with+CDK+inhibitors&doi=10.1007%2Fs11912-015-0443-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting breast cancer with CDK inhibitors</span></div><div class="casAuthors">Mayer Erica L</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">443</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dysregulation of the cell cycle is a classic hallmark of cancer growth and metastatic potential.  Re-establishing cell cycle control through CDK inhibition has emerged as an attractive option in the development of targeted cancer therapy.  Three oral agents selectively targeting CDK4/6 have been developed: palbociclib, abemaciclib, and LEE011.  Preclinical models show optimal activity in hormone receptor positive breast cancer, which may display biologic features suggesting particular dependence on the CDK4/cyclin D1/Rb interaction.  Palbociclib has been studied in a randomized phase 2 clinical trial in metastatic hormone receptor positive breast cancer in which the combination of palbociclib and endocrine therapy significantly prolonged progression-free survival over endocrine therapy alone.  The toxicity profile of palbociclib and the other CDK 4/6 inhibitors in early phase I and II trials has been predominantly hematologic, characterized by limited neutropenia, as well as variable gastrointestinal toxicity.  Multiple phase II and III studies are ongoing with all three agents, and are designed to explore the role of CDK 4/6 inhibition in metastatic hormone receptor positive breast cancer.  The next wave of studies will examine further clinical and scientific topics, including the role of CDK 4/6 inhibition in the neo/adjuvant setting, the combination of CDK 4/6 inhibitors with other targeted therapies, and the activity of CDK 4/6 inhibitors in the HER2 positive subset of breast cancer, as well as in other cancer subtypes.  Should ongoing study confirm benefits and tolerability of CDK 4/6 inhibition, combination therapy with endocrine agents may become a new standard of care for hormone receptor positive breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBpxScH0UYfUh5eUSa2oe_fW6udTcc2ebMAIj25-ulerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrptVantw%253D%253D&md5=01eda5d08847dab9cc5386e44daa00a9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs11912-015-0443-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-015-0443-3%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DE.%2BL.%26atitle%3DTargeting%2520breast%2520cancer%2520with%2520CDK%2520inhibitors%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2015%26volume%3D17%26issue%3D5%26spage%3D443%26doi%3D10.1007%2Fs11912-015-0443-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vora, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinzon-Ortiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ccr.2014.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25002028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFans7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=136-149&issue=1&author=S.+R.+Voraauthor=D.+Juricauthor=N.+Kimauthor=M.+Mino-Kenudsonauthor=T.+Huynhauthor=C.+Costaauthor=E.+L.+Lockermanauthor=S.+F.+Pollackauthor=M.+Liuauthor=X.+Y.+Liauthor=J.+Leharauthor=M.+Wiesmannauthor=M.+Wartmannauthor=Y.+Chenauthor=Z.+A.+Caoauthor=M.+Pinzon-Ortizauthor=S.+Kimauthor=R.+Schlegelauthor=A.+Huangauthor=J.+A.+Engelman&title=CDK+4%2F6+inhibitors+sensitize+PIK3CA+mutant+breast+cancer+to+PI3K+inhibitors&doi=10.1016%2Fj.ccr.2014.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors</span></div><div class="casAuthors">Vora, Sadhna R.; Juric, Dejan; Kim, Nayoon; Mino-Kenudson, Mari; Huynh, Tiffany; Costa, Carlotta; Lockerman, Elizabeth L.; Pollack, Sarah F.; Liu, Manway; Li, Xiaoyan; Lehar, Joseph; Wiesmann, Marion; Wartmann, Markus; Chen, Yan; Cao, Z. Alexander; Pinzon-Ortiz, Maria; Kim, Sunkyu; Schlegel, Robert; Huang, Alan; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-149</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast cancer.  However, clin. results of single-agent PI3K inhibitors have been modest to date.  A combinatorial drug screen on multiple PIK3CA mutant cancers with decreased sensitivity to PI3K inhibitors revealed that combined CDK 4/6-PI3K inhibition synergistically reduces cell viability.  Lab. studies revealed that sensitive cancers suppress RB phosphorylation upon treatment with single-agent PI3K inhibitors but cancers with reduced sensitivity fail to do so.  Similarly, patients' tumors that responded to the PI3K inhibitor BYL719 demonstrated suppression of pRB, while nonresponding tumors showed sustained or increased levels of pRB.  Importantly, the combination of PI3K and CDK 4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions in PIK3CA mutant xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwXkjWvgTQGrVg90H21EOLACvtfcHk0ljyAGAnqU55vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFans7rE&md5=493e85e43bf363ffcf301968df772b85</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DVora%26aufirst%3DS.%2BR.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DHuynh%26aufirst%3DT.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DPollack%26aufirst%3DS.%2BF.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%2BY.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DZ.%2BA.%26aulast%3DPinzon-Ortiz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DCDK%25204%252F6%2520inhibitors%2520sensitize%2520PIK3CA%2520mutant%2520breast%2520cancer%2520to%2520PI3K%2520inhibitors%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26issue%3D1%26spage%3D136%26epage%3D149%26doi%3D10.1016%2Fj.ccr.2014.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boye, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grallert, B.</span></span> <span> </span><span class="NLM_article-title">Consequences of abnormal CDK activity in S phase</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">973</span>, <span class="refDoi"> DOI: 10.1080/15384101.2016.1152423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F15384101.2016.1152423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26918805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFeit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=963-973&issue=7&author=S.+Andaauthor=C.+Rotheauthor=E.+Boyeauthor=B.+Grallert&title=Consequences+of+abnormal+CDK+activity+in+S+phase&doi=10.1080%2F15384101.2016.1152423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Consequences of abnormal CDK activity in S phase</span></div><div class="casAuthors">Anda, Silje; Rothe, Christiane; Boye, Erik; Grallert, Beata</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">963-973</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cyclin Dependent Kinases (CDKs) are important regulators of DNA replication.  In this work we have investigated the consequences of increasing or decreasing the CDK activity in S phase.  To this end we identified S-phase regulators of the fission yeast CDK, Cdc2, and used appropriate mutants to modulate Cdc2 activity.  In fission yeast Mik1 has been thought to be the main regulator of Cdc2 activity in S phase.  However, we find that Wee1 has a major function in S phase and thus we used wee1 mutants to investigate the consequences of increased Cdc2 activity.  These wee1 mutants display increased replication stress and, particularly in the absence of the S-phase checkpoint, accumulate DNA damage.  Notably, more cells incorporate EdU in a wee1- strain as compared to wildtype, suggesting altered regulation of DNA replication.  In addn., a higher no. of cells contain chromatin-bound Cdc45, an indicator of active replication forks.  In addn., we found that Cdc25 is required to activate Cdc2 in S phase and used a cdc25 mutant to explore a situation where Cdc2 activity is reduced.  Interestingly, a cdc25 mutant has a higher tolerance for replication stress than wild-type cells, suggesting that reduced CDK activity in S phase confers resistance to at least some forms of replication stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro8l9RISwz0rVg90H21EOLACvtfcHk0ljyAGAnqU55vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFeit74%253D&md5=79f38e52076ea0bd77b5268e4d2c48a7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1080%2F15384101.2016.1152423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2016.1152423%26sid%3Dliteratum%253Aachs%26aulast%3DAnda%26aufirst%3DS.%26aulast%3DRothe%26aufirst%3DC.%26aulast%3DBoye%26aufirst%3DE.%26aulast%3DGrallert%26aufirst%3DB.%26atitle%3DConsequences%2520of%2520abnormal%2520CDK%2520activity%2520in%2520S%2520phase%26jtitle%3DCell%2520Cycle%26date%3D2016%26volume%3D15%26issue%3D7%26spage%3D963%26epage%3D973%26doi%3D10.1080%2F15384101.2016.1152423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumarasiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK6 in cancer: state of the art and new insights</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3220</span>– <span class="NLM_lpage">3230</span>, <span class="refDoi"> DOI: 10.1080/15384101.2015.1084445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F15384101.2015.1084445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26315616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=3220-3230&issue=20&author=S.+Tadesseauthor=M.+Yuauthor=M.+Kumarasiriauthor=B.+T.+Leauthor=S.+Wang&title=Targeting+CDK6+in+cancer%3A+state+of+the+art+and+new+insights&doi=10.1080%2F15384101.2015.1084445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK6 in cancer: State of the art and new insights</span></div><div class="casAuthors">Tadesse, Solomon; Yu, Mingfeng; Kumarasiri, Malika; Le, Bich Thuy; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3220-3230</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 6 (CDK6) plays a vital role in regulating the progression of the cell cycle.  More recently, CDK6 has also been shown to have a transcriptional role in tumor angiogenesis.  Up-regulated CDK6 activity is assocd. with the development of several types of cancers.  While CDK6 is over-expressed in cancer cells, it has a low detectable level in non-cancerous cells and CDK6-null mice develop normally, suggesting a specific oncogenic role of CDK6, and that its inhibition may represent an ideal mechanism-based and low toxic therapeutic strategy in cancer treatment.  Identification of selective small mol. inhibitors of CDK6 is thus needed for drug development.  Herein, we review the latest understandings of the biol. regulation and oncogenic roles of CDK6.  The potential clin. relevance of CDK6 inhibition, the progress in the development of small-mol. CDK6 inhibitors and the rational design of potential selective CDK6 inhibitors are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV1uu9UWb3XrVg90H21EOLACvtfcHk0ljyAGAnqU55vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsbrN&md5=eefeeab43ed50693886447c122e5002d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1084445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1084445%26sid%3Dliteratum%253Aachs%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DB.%2BT.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520CDK6%2520in%2520cancer%253A%2520state%2520of%2520the%2520art%2520and%2520new%2520insights%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26issue%3D20%26spage%3D3220%26epage%3D3230%26doi%3D10.1080%2F15384101.2015.1084445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span> <span> </span><span class="NLM_article-title">Phylogenetic analysis of CDK and cyclin proteins in premetazoan lineages</span>. <i>BMC Evol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1186/1471-2148-14-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1186%2F1471-2148-14-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24433236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsFKlsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=10-16&issue=1&author=L.+Caoauthor=F.+Chenauthor=X.+Yangauthor=W.+Xuauthor=J.+Xieauthor=L.+Yu&title=Phylogenetic+analysis+of+CDK+and+cyclin+proteins+in+premetazoan+lineages&doi=10.1186%2F1471-2148-14-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Phylogenetic analysis of CDK and cyclin proteins in premetazoan lineages</span></div><div class="casAuthors">Cao, Lihuan; Chen, Fang; Yang, Xianmei; Xu, Weijin; Xie, Jun; Yu, Long</div><div class="citationInfo"><span class="NLM_cas:title">BMC Evolutionary Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10/1-10/16, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">BEBMCG</span>;
        ISSN:<span class="NLM_cas:issn">1471-2148</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The mol. history of animal evolution from single-celled ancestors remains a major question in biol., and little is known regarding the evolution of cell cycle regulation during animal emergence.  In this study, we conducted a comprehensive evolutionary anal. of CDK and cyclin proteins in metazoans and their unicellular relatives.  Results: Our anal. divided the CDK family into eight subfamilies.  Seven subfamilies (CDK1/2/3, CDK5, CDK7, CDK 20, CDK8/19, CDK9 and CDK10/11) are conserved in metazoans and fungi, with the remaining subfamily, CDK4/6, found only in eumetazoans.  With respect to cyclins, cyclin C, H, L, Y subfamilies, and cyclin K and T as a whole subfamily, are generally conserved in animal, fungi, and amoeba Dictyostelium discoideum.  In contrast, cyclin subfamilies B, A, E, and D, which are cell cycle-related, have distinct evolutionary histories.  The cyclin B subfamily is generally conserved in D. discoideum, fungi, and animals, whereas cyclin A and E subfamilies are both present in animals and their unicellular relatives such as choanoflagellate Monosiga brevicollis and filasterean Capsaspora owczarzaki, but are absent in fungi and D. discoideum.  Although absent in fungi and D. discoideum, cyclin D subfamily orthologs can be found in the early-emerging, non-opisthokont apusozoan Thecamonas trahens.  Within opisthokonta, the cyclin D subfamily is conserved only in eumetazoans, and is absent in fungi, choanoflagellates, and the basal metazoan Amphimedon queenslandica.  Conclusions: Our data indicate that the CDK4/6 subfamily and eumetazoans emerged simultaneously, with the evolutionary conservation of the cyclin D subfamily also tightly linked with eumetazoan appearance.  Establishment of the CDK4/6-cyclin D complex may have been the key step in the evolution of cell cycle control during eumetazoan emergence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopxivYNpVsqLVg90H21EOLACvtfcHk0ljns5UfoM8yCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsFKlsL0%253D&md5=9220ce7f96250958f4c040dda377c99d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2F1471-2148-14-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2148-14-10%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DL.%26atitle%3DPhylogenetic%2520analysis%2520of%2520CDK%2520and%2520cyclin%2520proteins%2520in%2520premetazoan%2520lineages%26jtitle%3DBMC%2520Evol.%2520Biol.%26date%3D2014%26volume%3D14%26issue%3D1%26spage%3D10%26epage%3D16%26doi%3D10.1186%2F1471-2148-14-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galbraith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, J. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of transcriptional cyclin-dependent kinases</span>. <i>Transcription.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/21541264.2018.1539615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F21541264.2018.1539615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30409083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKjs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=118-136&issue=2&author=M.+D.+Galbraithauthor=H.+Benderauthor=J.+M.+Espinosa&title=Therapeutic+targeting+of+transcriptional+cyclin-dependent+kinases&doi=10.1080%2F21541264.2018.1539615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of transcriptional cyclin-dependent kinases</span></div><div class="casAuthors">Galbraith, Matthew D.; Bender, Heather; Espinosa, Joaquin M.</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-136</span>CODEN:
                <span class="NLM_cas:coden">TRANH2</span>;
        ISSN:<span class="NLM_cas:issn">2154-1272</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  The fact that many cancer types display transcriptional addiction driven by dysregulation of oncogenic enhancers and transcription factors has led to increased interest in a group of protein kinases, known as transcriptional cyclin dependent kinases (tCDKs), as potential therapeutic targets.  Despite early reservations about targeting a process that is essential to healthy cell types, there is now evidence that targeting tCDKs could provide enough therapeutic window to be effective in the clinic.  Here, we discuss recent developments in this field, with an emphasis on highly-selective inhibitors and the challenges to be addressed before these inhibitors could be used for therapeutic purposes.: CAK: CDK-activating kinase;CDK: cyclin-dependent kinase;CMGC group: CDK-, MAPK-, GSK3-, and CLK-like;CTD: C-terminal repeat domain of the RPB1 subunit of RNA polymerase II;DRB: 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole;mCRPC: metastatic castration-resistant prostate cancer;NSCLC: non-small cell lung cancer;P-TEFb: pos. elongation factor b;RNAPII: RNA polymerase II;S2: serine-2 of CTD repeats;S5: serine-5 of CTD repeats;S7: serine-7 of CTD repeats;SEC: super elongation complex;tCDK: transcriptional cyclin-dependent kinase;TNBC: triple-neg. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptgAOjkQMqqbVg90H21EOLACvtfcHk0ljns5UfoM8yCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKjs7vP&md5=1700138890acfc08ad2ab2a81f62c476</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F21541264.2018.1539615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2018.1539615%26sid%3Dliteratum%253Aachs%26aulast%3DGalbraith%26aufirst%3DM.%2BD.%26aulast%3DBender%26aufirst%3DH.%26aulast%3DEspinosa%26aufirst%3DJ.%2BM.%26atitle%3DTherapeutic%2520targeting%2520of%2520transcriptional%2520cyclin-dependent%2520kinases%26jtitle%3DTranscription.%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D118%26epage%3D136%26doi%3D10.1080%2F21541264.2018.1539615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korolchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moukhametzianov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span> <span> </span><span class="NLM_article-title">CDK1 structures reveal conserved and unique features of the essential cell cycle CDK</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/ncomms7769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fncomms7769" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1-12&issue=1&author=N.+R.+Brownauthor=S.+Korolchukauthor=M.+P.+Martinauthor=W.+A.+Stanleyauthor=R.+Moukhametzianovauthor=M.+E.+M.+Nobleauthor=J.+A.+Endicott&title=CDK1+structures+reveal+conserved+and+unique+features+of+the+essential+cell+cycle+CDK&doi=10.1038%2Fncomms7769"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fncomms7769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7769%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%2BR.%26aulast%3DKorolchuk%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DStanley%26aufirst%3DW.%2BA.%26aulast%3DMoukhametzianov%26aufirst%3DR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26atitle%3DCDK1%2520structures%2520reveal%2520conserved%2520and%2520unique%2520features%2520of%2520the%2520essential%2520cell%2520cycle%2520CDK%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26issue%3D1%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fncomms7769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherukupalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleti, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayyad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampannavar, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merugu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachamalla, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpoormath, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 4,6-disubstituted pyrazolo[3,4-d]pyrimidine analogues: cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation</span>. <i>J. Mol. Struct.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1176</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1016/j.molstruc.2018.08.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.molstruc.2018.08.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWis7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1176&publication_year=2019&pages=538-551&author=S.+Cherukupalliauthor=B.+Chandrasekaranauthor=R.+R.+Aletiauthor=N.+Sayyadauthor=G.+A.+Hampannavarauthor=S.+R.+Meruguauthor=H.+R.+Rachamallaauthor=R.+Banerjeeauthor=R.+Karpoormath&title=Synthesis+of+4%2C6-disubstituted+pyrazolo%5B3%2C4-d%5Dpyrimidine+analogues%3A+cyclin-dependent+kinase+2+%28CDK2%29+inhibition%2C+molecular+docking+and+anticancer+evaluation&doi=10.1016%2Fj.molstruc.2018.08.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 4,6-disubstituted pyrazolo[3,4-d]pyrimidine analogues: Cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation</span></div><div class="casAuthors">Cherukupalli, Srinivasulu; Chandrasekaran, Balakumar; Aleti, Rajeshwar Reddy; Sayyad, Nisar; Hampannavar, Girish A.; Merugu, Srinivas Reddy; Rachamalla, Harikrishna Reddy; Banerjee, Rajkumar; Karpoormath, Rajshekhar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Structure</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">538-551</span>CODEN:
                <span class="NLM_cas:coden">JMOSB4</span>;
        ISSN:<span class="NLM_cas:issn">0022-2860</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cyclin-dependent kinases (CDKs) play a crucial role in cell cycle progression and are validated targets of cancer therapy.  Pyrazolopyrimidines are versatile scaffolds, which have been exploited for developing potential anticancer agents.  We herein report the synthesis and in vitro CDK2/cyclin E kinase inhibitory activity of 34 novel 4,6-disubstituted pyrazolo [3,4-d]pyrimidines.  The structure-activity relationship (SAR) studies revealed that compds. with thiopentane/thiophenethyl group at C-6 and heteroatom-contg. bicyclic moiety (benzofuran) at C-4 exhibited good CDK2 inhibitory activity.  Further, the binding energies obtained for the active compds. from in silico mol. docking studies with CDK2 were found to be in consonance with the obsd. SAR and exptl. results.  In addn., some of the synthesized compds. showed anti-proliferative activity against K-562 (chronic myelogenous leukemia) and MCF-7 (breast adenocarcinoma) cell lines in micromolar ranges.  Further, the cytotoxicity studies on CHO cell line revealed that all the compds. are non-toxic to normal cells and are safe.  Thus, the research findings revealed the anticancer potential of 4,6-disubstituted pyrazolo [3,4-d]pyrimidine derivs. which could be further considered for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpukE_bBmZt-LVg90H21EOLACvtfcHk0ljrALAgmPR4sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWis7%252FJ&md5=2c3f2ca5d72af3e4614ad3a214cf1104</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.molstruc.2018.08.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molstruc.2018.08.104%26sid%3Dliteratum%253Aachs%26aulast%3DCherukupalli%26aufirst%3DS.%26aulast%3DChandrasekaran%26aufirst%3DB.%26aulast%3DAleti%26aufirst%3DR.%2BR.%26aulast%3DSayyad%26aufirst%3DN.%26aulast%3DHampannavar%26aufirst%3DG.%2BA.%26aulast%3DMerugu%26aufirst%3DS.%2BR.%26aulast%3DRachamalla%26aufirst%3DH.%2BR.%26aulast%3DBanerjee%26aufirst%3DR.%26aulast%3DKarpoormath%26aufirst%3DR.%26atitle%3DSynthesis%2520of%25204%252C6-disubstituted%2520pyrazolo%255B3%252C4-d%255Dpyrimidine%2520analogues%253A%2520cyclin-dependent%2520kinase%25202%2520%2528CDK2%2529%2520inhibition%252C%2520molecular%2520docking%2520and%2520anticancer%2520evaluation%26jtitle%3DJ.%2520Mol.%2520Struct.%26date%3D2019%26volume%3D1176%26spage%3D538%26epage%3D551%26doi%3D10.1016%2Fj.molstruc.2018.08.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of NFAT3 by CDK3 induces cell transformation and promotes tumor growth in skin cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2835</span>– <span class="NLM_lpage">2845</span>, <span class="refDoi"> DOI: 10.1038/onc.2016.434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fonc.2016.434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27893713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCnu7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=2835-2845&issue=20&author=T.+Xiaoauthor=J.+J.+Zhuauthor=S.+Huangauthor=C.+Pengauthor=S.+Heauthor=J.+Duauthor=R.+Hongauthor=X.+Chenauthor=A.+M.+Bodeauthor=W.+Jiangauthor=Z.+Dongauthor=D.+Zheng&title=Phosphorylation+of+NFAT3+by+CDK3+induces+cell+transformation+and+promotes+tumor+growth+in+skin+cancer&doi=10.1038%2Fonc.2016.434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of NFAT3 by CDK3 induces cell transformation and promotes tumor growth in skin cancer</span></div><div class="casAuthors">Xiao, T.; Zhu, J. J.; Huang, S.; Peng, C.; He, S.; Du, J.; Hong, R.; Chen, X.; Bode, A. M.; Jiang, W.; Dong, Z.; Zheng, D.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2835-2845</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The nuclear factor of activated T cells (NFAT) family proteins are transcription factors that regulate the expression of pro-inflammatory cytokines and other genes during the immune response.  Although the NFAT proteins have been extensively investigated in the immune system, their role in cancer progression remains controversial.  Here, we report that NFAT3 is highly expressed in various skin cancer cell lines and tumor tissues.  Knockdown of endogenous NFAT3 expression by short hairpin RNA (shRNA) significantly inhibited tumor cell proliferation, colony formation and anchorage-independent cell growth.  Furthermore, results of the mammalian two-hybrid assay showed that cyclin-dependent kinase 3 (CDK3) directly interacted with NFAT3 and phosphorylated NFAT3 at serine 259 (Ser259), which enhanced the transactivation and transcriptional activity of NFAT3.  The phosphorylation site of NFAT3 was crit. for epidermal growth factor (EGF)-stimulated cell transformation of the HaCaT immortalized skin cell line and mutation of NFAT3 at Ser259 led to a redn. of colony formation in soft agar.  We also found that overexpressing wildtype NFAT3, but not mutant NFAT3-S259A, promoted A431 xenograft tumor growth.  Importantly, we showed that CDK3, NFAT3 and phosphorylated NFAT3-Ser259 were highly expressed in skin cancer compared with normal skin tissues.  These results provided evidence supporting the oncogenic potential of NFAT3 and suggested that CDK3-mediated phosphorylation of NFAT3 has an important role in skin tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4PbBstnK9LLVg90H21EOLACvtfcHk0ljrALAgmPR4sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCnu7vO&md5=01d3620d159057585f5d2177309f36e3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fonc.2016.434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2016.434%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DBode%26aufirst%3DA.%2BM.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DD.%26atitle%3DPhosphorylation%2520of%2520NFAT3%2520by%2520CDK3%2520induces%2520cell%2520transformation%2520and%2520promotes%2520tumor%2520growth%2520in%2520skin%2520cancer%26jtitle%3DOncogene%26date%3D2017%26volume%3D36%26issue%3D20%26spage%3D2835%26epage%3D2845%26doi%3D10.1038%2Fonc.2016.434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaganathan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overstreet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, E.</span></span> <span> </span><span class="NLM_article-title">Improving breast cancer therapy with CDK4/6 inhibitors</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2014.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.clbc.2014.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25457990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2MzkslCisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=379-380&author=H.+Jaganathanauthor=K.+Overstreetauthor=E.+Reed&title=Improving+breast+cancer+therapy+with+CDK4%2F6+inhibitors&doi=10.1016%2Fj.clbc.2014.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Improving breast cancer therapy with CDK4/6 inhibitors</span></div><div class="casAuthors">Jaganathan Hamsa; Overstreet Karen; Reed Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Clinical breast cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">379-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsa0Hvb5m_-GHOrQ6qeX-mfW6udTcc2ea8wkiX12cySLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzkslCisw%253D%253D&md5=7212a5d3482aef9e55605bbb7c743251</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2014.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2014.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DJaganathan%26aufirst%3DH.%26aulast%3DOverstreet%26aufirst%3DK.%26aulast%3DReed%26aufirst%3DE.%26atitle%3DImproving%2520breast%2520cancer%2520therapy%2520with%2520CDK4%252F6%2520inhibitors%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D379%26epage%3D380%26doi%3D10.1016%2Fj.clbc.2014.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shupp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestell, R. G.</span></span> <span> </span><span class="NLM_article-title">Biological functions of CDK5 and potential CDK5 targeted clinical treatments</span>. <i>Oncotarget.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">17373</span>– <span class="NLM_lpage">17382</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.18632%2Foncotarget.14538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28077789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC1c7kslOqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=17373-17382&issue=10&author=A.+Shuppauthor=M.+C.+Casimiroauthor=R.+G.+Pestell&title=Biological+functions+of+CDK5+and+potential+CDK5+targeted+clinical+treatments&doi=10.18632%2Foncotarget.14538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biological functions of CDK5 and potential CDK5 targeted clinical treatments</span></div><div class="casAuthors">Shupp Alison; Casimiro Mathew C; Pestell Richard G</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">17373-17382</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin dependent kinases are proline-directed serine/threonine protein kinases that are traditionally activated upon association with a regulatory subunit.  For most CDKs, activation by a cyclin occurs through association and phosphorylation of the CDK's T-loop.  CDK5 is unusual because it is not typically activated upon binding with a cyclin and does not require T-loop phosphorylation for activation, even though it has high amino acid sequence homology with other CDKs.  While it was previously thought that CDK5 only interacted with p35 or p39 and their cleaved counterparts, Recent evidence suggests that CDK5 can interact with certain cylins, amongst other proteins, which modulate CDK5 activity levels.  This review discusses recent findings of molecular interactions that regulate CDK5 activity and CDK5 associated pathways that are implicated in various diseases.  Also covered herein is the growing body of evidence for CDK5 in contributing to the onset and progression of tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIIzpNr4o8O-RS7coPn-RtfW6udTcc2eZZRzIs4EwDuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7kslOqug%253D%253D&md5=a18a8cf007ba65b165d690e4a7f6bb1a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14538%26sid%3Dliteratum%253Aachs%26aulast%3DShupp%26aufirst%3DA.%26aulast%3DCasimiro%26aufirst%3DM.%2BC.%26aulast%3DPestell%26aufirst%3DR.%2BG.%26atitle%3DBiological%2520functions%2520of%2520CDK5%2520and%2520potential%2520CDK5%2520targeted%2520clinical%2520treatments%26jtitle%3DOncotarget.%26date%3D2017%26volume%3D8%26issue%3D10%26spage%3D17373%26epage%3D17382%26doi%3D10.18632%2Foncotarget.14538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK7 increases the stability of snail to promote the dissemination of colorectal cancer</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1442</span>– <span class="NLM_lpage">1452</span>, <span class="refDoi"> DOI: 10.1038/s41418-018-0222-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fs41418-018-0222-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30451989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegtrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1442-1452&issue=8&author=Y.+Zhouauthor=L.+Luauthor=G.+Jiangauthor=Z.+Chenauthor=J.+Liauthor=P.+Anauthor=L.+Chenauthor=J.+Duauthor=H.+Wang&title=Targeting+CDK7+increases+the+stability+of+snail+to+promote+the+dissemination+of+colorectal+cancer&doi=10.1038%2Fs41418-018-0222-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer</span></div><div class="casAuthors">Zhou, Yan; Lu, Linlin; Jiang, Guanmin; Chen, Zhuojia; Li, Jiexin; An, Panpan; Chen, Likun; Du, Jun; Wang, Hongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1442-1452</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Targeted inhibition of cyclin-dependent kinase 7 (CDK7) via its covalent inhibitor THZ1 can suppress the growth of various cancers, while its roles on colorectal cancer (CRC) remain obscure.  Here we report that the expression of CDK7 is upregulated in CRC cells and tissues.  THZ1 exhibits high potency and selectivity against CRC cells both in vitro and in vivo via induction of cell apoptosis rather than cell cycle disruption.  Intriguingly, THZ1 treatment increases the ability of epithelial mesenchymal transition (EMT) and in vivo metastasis to liver of CRC cells.  Mechanistical studies reveal that THZ1 increases the expression of Snail, while not other EMT-transcription factors, via enhancing its protein stability rather than mRNA expression or translation.  By screening Snail stability related factors via qRT-PCR, results indicate THZ1 and si-CDK7 decrease the expression of protein kinase D1 (PKD1) in CRC cells.  Down regulation of PKD1 mediates THZ1 up regulated Snail via dephosphorylation of Snail Ser 11 and prevention of proteasome mediated degrdn.  Clin. anal. confirms that CDK7 is significantly (p < 0.05) neg. correlated with the expression of mesenchymal markers including FN1, VIM, and MMP2.  CRC patients whose tumors expressing less CDK7/SNAI1 or PKD1/SNAI1 showed significant (p < 0.05) poorer overall survival (OS) rate as compared with those with greater levels.  Collectively, our data suggest that targeted inhibition of CDK7 can trigger the metastasis of CRC during cancer development via PKD1/Snail axis, which imposes great challenge that inhibition of CDK7 is a potential approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy89Fkw4m-F7Vg90H21EOLACvtfcHk0ljfxonMHnzNXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegtrzJ&md5=6674d36ade83d70a05060d69632d3737</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fs41418-018-0222-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41418-018-0222-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DAn%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DTargeting%2520CDK7%2520increases%2520the%2520stability%2520of%2520snail%2520to%2520promote%2520the%2520dissemination%2520of%2520colorectal%2520cancer%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2019%26volume%3D26%26issue%3D8%26spage%3D1442%26epage%3D1452%26doi%3D10.1038%2Fs41418-018-0222-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective CDK8 inhibitors through FBDD approach</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4488</span>– <span class="NLM_lpage">4492</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.07.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bmcl.2017.07.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28802632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlarsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4488-4492&author=X.+C.+Hanauthor=M.+Jiangauthor=C.+G.+Zhouauthor=Z.+Zhouauthor=Z.+H.+Xuauthor=L.+S.+Wangauthor=A.+V.+Maywegauthor=R.+Niuauthor=T.+G.+Jinauthor=S.+Yang&title=Discovery+of+potent+and+selective+CDK8+inhibitors+through+FBDD+approach&doi=10.1016%2Fj.bmcl.2017.07.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective CDK8 inhibitors through FBDD approach</span></div><div class="casAuthors">Han, Xingchun; Jiang, Min; Zhou, Chengang; Zhou, Zheng; Xu, Zhiheng; Wang, Lisha; Mayweg, Alexander V.; Niu, Rui; Jin, Tai-Guang; Yang, Song</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4488-4492</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A fragment library screen was carried out to identify starting points for novel CDK8 inhibitors.  Optimization of a fragment hit guided by co-crystal structures led to identification of a novel series of potent CDK8 inhibitors which are highly ligand efficient, kinase selective and cellular active.  Compd. I was progressed to a mouse pharmacokinetic study and showed good oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLEnv4NnOEZ7Vg90H21EOLACvtfcHk0ljfxonMHnzNXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlarsrrM&md5=23b49ed1f18b508afde0847db8027a81</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.07.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.07.080%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%2BC.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DC.%2BG.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DZ.%2BH.%26aulast%3DWang%26aufirst%3DL.%2BS.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DNiu%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DT.%2BG.%26aulast%3DYang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520CDK8%2520inhibitors%2520through%2520FBDD%2520approach%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4488%26epage%3D4492%26doi%3D10.1016%2Fj.bmcl.2017.07.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franco, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boffo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">CDK9: a key player in cancer and other diseases</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">1273</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1002/jcb.26293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1002%2Fjcb.26293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28722178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1SksbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=1273-1284&issue=2&author=L.+C.+Francoauthor=F.+Moralesauthor=S.+Boffoauthor=A.+Giordano&title=CDK9%3A+a+key+player+in+cancer+and+other+diseases&doi=10.1002%2Fjcb.26293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9: A key player in cancer and other diseases</span></div><div class="casAuthors">Franco, Lia Carolina; Morales, Fatima; Boffo, Silvia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1273-1284</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cyclin-Dependent Kinase 9 (CDK9) is part of a functional diverse group of enzymes responsible for cell cycle control and progression.  It assocs. mainly with Cyclin T1 and forms the Pos. Transcription Elongation Factor b (p-TEFb) complex responsible for regulation of transcription elongation and mRNA maturation.  Recent studies have highlighted the importance of CDK9 in many relevant pathol. processes, like cancer, cardiovascular diseases, and viral replication.  Herein we provide an overview of the different pathways in which CDK9 is directly and indirectly involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-mhEa2vTa8LVg90H21EOLACvtfcHk0lg8y7D-rM19Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1SksbzI&md5=769d1349ea4079406fd15ec6746d2522</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fjcb.26293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.26293%26sid%3Dliteratum%253Aachs%26aulast%3DFranco%26aufirst%3DL.%2BC.%26aulast%3DMorales%26aufirst%3DF.%26aulast%3DBoffo%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCDK9%253A%2520a%2520key%2520player%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2018%26volume%3D119%26issue%3D2%26spage%3D1273%26epage%3D1284%26doi%3D10.1002%2Fjcb.26293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dos
Santos Paparidis, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canduri, F.</span></span> <span> </span><span class="NLM_article-title">The emerging picture of CDK11: genetic, functional and medicinal aspects</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170815102036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.2174%2F0929867324666170815102036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28814241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC1cfovFOntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=880-888&issue=8&author=N.+F.+Dos%0ASantos+Paparidisauthor=F.+Canduri&title=The+emerging+picture+of+CDK11%3A+genetic%2C+functional+and+medicinal+aspects&doi=10.2174%2F0929867324666170815102036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Emerging Picture of CDK11: Genetic, Functional and Medicinal Aspects</span></div><div class="casAuthors">Dos Santos Paparidis Nikolas Ferreira; Canduri Fernanda</div><div class="citationInfo"><span class="NLM_cas:title">Current medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">880-888</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinase 11 is a relatively neglected member of the transcriptional CDKs subfamily, despite possibly being the most versatile CDK in this group.  Different CDK11 variants are known to play essential roles in major cellular processes as mRNA transcription (CDK11p110), mitosis (CDK11p58), and apoptosis (CDK11p46 and CDK11p60).  Each CDK11 species targets a particular set of substrates related to its functional background, but all isoforms originate from the CDC2L gene complex in human chromosome 1p36.2.  CDK11p110 is synthesized through regular cap-dependent translation of CDK11 mRNA, whereas CDK11p58 translation is initiated through an IRES, and occurs only at G2 and M phases.  CDK11p46 and CDK11p60, in turn, are the products of caspase cleavage of the larger isoforms during apoptosis.  L-type cyclins are the main partners of CDK11, although CDK11p58 species interacts specifically with cyclin D3.  The link between CDK11 dysfunction and cancer has been known for a long time, and critical roles in the proliferation of different cancer cell lines have been assigned to CDK11.  This review summarizes more than 25 years of studies that unraveled CDK11 genetic and functional aspects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3qfv6I-cXX2Gmni0r9GoKfW6udTcc2eZ0fzHpA0-corntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfovFOntA%253D%253D&md5=e16097c1b50b5c24f91f734ef28d21b7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170815102036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170815102036%26sid%3Dliteratum%253Aachs%26aulast%3DDos%2BSantos%2BPaparidis%26aufirst%3DN.%2BF.%26aulast%3DCanduri%26aufirst%3DF.%26atitle%3DThe%2520emerging%2520picture%2520of%2520CDK11%253A%2520genetic%252C%2520functional%2520and%2520medicinal%2520aspects%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2018%26volume%3D25%26issue%3D8%26spage%3D880%26epage%3D888%26doi%3D10.2174%2F0929867324666170815102036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriplani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moseley, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Fatah, T. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhusudan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhaka, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natrajan, R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of CDK12 protein expression as a potential novel biomarker for dna damage response-targeted therapies in breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1535-7163.MCT-17-0760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29133620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Gitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=306-315&issue=1&author=K.+Naidooauthor=P.+T.+Waiauthor=S.+L.+Maguireauthor=F.+Daleyauthor=S.+Haiderauthor=D.+Kriplaniauthor=J.+Campbellauthor=H.+Mirzaauthor=A.+Grigoriadisauthor=A.+Tuttauthor=P.+M.+Moseleyauthor=T.+M.+A.+Abdel-Fatahauthor=S.+Y.+T.+Chanauthor=S.+Madhusudanauthor=E.+A.+Rhakaauthor=I.+O.+Ellisauthor=C.+J.+Lordauthor=Y.+Y.+Yuanauthor=A.+R.+Greenauthor=R.+Natrajan&title=Evaluation+of+CDK12+protein+expression+as+a+potential+novel+biomarker+for+dna+damage+response-targeted+therapies+in+breast+cancer&doi=10.1158%2F1535-7163.MCT-17-0760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer</span></div><div class="casAuthors">Naidoo, Kalnisha; Wai, Patty T.; Maguire, Sarah L.; Daley, Frances; Haider, Syed; Kriplani, Divya; Campbell, James; Mirza, Hasan; Grigoriadis, Anita; Tutt, Andrew; Moseley, Paul M.; Abdel-Fatah, Tarek M. A.; Chan, Stephen Y. T.; Madhusudan, Srinivasan; Rhaka, Emad A.; Ellis, Ian O.; Lord, Christopher J.; Yuan, Yinyin; Green, Andrew R.; Natrajan, Rachael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">306-315</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors.  However, CDK12 has also been proposed as an oncogene in breast cancer.  We therefore aimed to assess the frequency and distribution of CDK12 protein expression by IHC in independent cohorts of breast cancer and correlate this with outcome and genomic status.  We found that 21% of primary unselected breast cancers were CDK12 high, and 10.5% were absent, by IHC.  CDK12 positivity correlated with HER2 positivity but was not an independent predictor of breast cancer-specific survival taking HER2 status into account; however, absent CDK12 protein expression significantly correlated with a triple-neg. phenotype.  Interestingly, CDK12 protein absence was assocd. with reduced expression of a no. of DDR proteins including ATR, Ku70/Ku80, PARP1, DNA-PK, and γH2AX, suggesting a novel mechanism of CDK12-assocd. DDR dysregulation in breast cancer.  Our data suggest that diagnostic IHC quantification of CDK12 in breast cancer is feasible, with CDK12 absence possibly signifying defective DDR function.  This may have important therapeutic implications, particularly for triple-neg. breast cancers.  Mol Cancer Ther; 17(1); 306-15. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK7g_s8kIxRrVg90H21EOLACvtfcHk0lg8y7D-rM19Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Gitw%253D%253D&md5=66790735980e31d1736272e2c20be108</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0760%26sid%3Dliteratum%253Aachs%26aulast%3DNaidoo%26aufirst%3DK.%26aulast%3DWai%26aufirst%3DP.%2BT.%26aulast%3DMaguire%26aufirst%3DS.%2BL.%26aulast%3DDaley%26aufirst%3DF.%26aulast%3DHaider%26aufirst%3DS.%26aulast%3DKriplani%26aufirst%3DD.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DMirza%26aufirst%3DH.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DMoseley%26aufirst%3DP.%2BM.%26aulast%3DAbdel-Fatah%26aufirst%3DT.%2BM.%2BA.%26aulast%3DChan%26aufirst%3DS.%2BY.%2BT.%26aulast%3DMadhusudan%26aufirst%3DS.%26aulast%3DRhaka%26aufirst%3DE.%2BA.%26aulast%3DEllis%26aufirst%3DI.%2BO.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DYuan%26aufirst%3DY.%2BY.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26aulast%3DNatrajan%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520CDK12%2520protein%2520expression%2520as%2520a%2520potential%2520novel%2520biomarker%2520for%2520dna%2520damage%2520response-targeted%2520therapies%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D306%26epage%3D315%26doi%3D10.1158%2F1535-7163.MCT-17-0760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fant, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taatjes, D. J.</span></span> <span> </span><span class="NLM_article-title">Regulatory functions of the mediator kinases CDK8 and CDK19</span>. <i>Transcription.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1080/21541264.2018.1556915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F21541264.2018.1556915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30585107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BB3cnlsFKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=76-90&issue=2&author=C.+B.+Fantauthor=D.+J.+Taatjes&title=Regulatory+functions+of+the+mediator+kinases+CDK8+and+CDK19&doi=10.1080%2F21541264.2018.1556915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory functions of the Mediator kinases CDK8 and CDK19</span></div><div class="casAuthors">Fant Charli B; Taatjes Dylan J</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">76-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Mediator-associated kinases CDK8 and CDK19 function in the context of three additional proteins: CCNC and MED12, which activate CDK8/CDK19 kinase function, and MED13, which enables their association with the Mediator complex.  The Mediator kinases affect RNA polymerase II (pol II) transcription indirectly, through phosphorylation of transcription factors and by controlling Mediator structure and function.  In this review, we discuss cellular roles of the Mediator kinases and mechanisms that enable their biological functions.  We focus on sequence-specific, DNA-binding transcription factors and other Mediator kinase substrates, and how CDK8 or CDK19 may enable metabolic and transcriptional reprogramming through enhancers and chromatin looping.  We also summarize Mediator kinase inhibitors and their therapeutic potential.  Throughout, we note conserved and divergent functions between yeast and mammalian CDK8, and highlight many aspects of kinase module function that remain enigmatic, ranging from potential roles in pol II promoter-proximal pausing to liquid-liquid phase separation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQbbey-l8f0QpJitSxOdIlfW6udTcc2eaJIOhfBejSerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnlsFKksQ%253D%253D&md5=356eb2f7adf7ec40e8fcd0a02cdaed69</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1080%2F21541264.2018.1556915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2018.1556915%26sid%3Dliteratum%253Aachs%26aulast%3DFant%26aufirst%3DC.%2BB.%26aulast%3DTaatjes%26aufirst%3DD.%2BJ.%26atitle%3DRegulatory%2520functions%2520of%2520the%2520mediator%2520kinases%2520CDK8%2520and%2520CDK19%26jtitle%3DTranscription.%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D76%26epage%3D90%26doi%3D10.1080%2F21541264.2018.1556915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Overview of CDK9 as a target in cancer research</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1080/15384101.2016.1138186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F15384101.2016.1138186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26766294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=519-527&author=F.+Moralesauthor=A.+Giordano&title=Overview+of+CDK9+as+a+target+in+cancer+research&doi=10.1080%2F15384101.2016.1138186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of CDK9 as a target in cancer research</span></div><div class="casAuthors">Morales, Fatima; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">CDK9 is a protein in const. development in cancer therapy.  Herein we present an overview of the enzyme as a target for cancer therapy.  We provide data on its characteristics and mechanism of action.  In recent years, CDK9 inhibitors that have been designed with mol. modeling have demonstrated good antitumoral activity in vitro.  Clin. studies of the drugs flavopiridol, dinaciclib, seliciclib, SNS-032 and RGB-286638 used as CDK9 inhibitors are also reviewed, with their addnl. targets and their relative IC50 values.  Unfortunately, treatment with these drugs remains unsuccessful and involves many adverse effects.  We could conclude that there are many small mols. that bind to CDK9, but their lack of selectivity against other CDKs do not allow them to get to the clin. use.  However, drug designers currently have the tools needed to improve the selectivity of CDK9 inhibitors and to make successful treatment available to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTT9RDBXneVrVg90H21EOLACvtfcHk0lhtiksM1p0pZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D&md5=4380763f74e91d5ea6d2d9b38ec6fd5e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F15384101.2016.1138186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2016.1138186%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DF.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DOverview%2520of%2520CDK9%2520as%2520a%2520target%2520in%2520cancer%2520research%26jtitle%3DCell%2520Cycle%26date%3D2016%26volume%3D15%26spage%3D519%26epage%3D527%26doi%3D10.1080%2F15384101.2016.1138186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. P.</span></span> <span> </span><span class="NLM_article-title">The HIV-1 tat protein: mechanism of action and target for HIV-1 cure strategies</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">4098</span>– <span class="NLM_lpage">4102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.2174%2F1381612823666170704130635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28677507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWktLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4098-4102&issue=28&author=A.+P.+Rice&title=The+HIV-1+tat+protein%3A+mechanism+of+action+and+target+for+HIV-1+cure+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies</span></div><div class="casAuthors">Rice, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">4098-4102</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The general mechanism involved in Tat activation of RNA Polymerase II (RNAP II) elongation of the integrated HIV-1 was elucidated over 20 years ago.  This mechanism involves Tat binding to the TAR RNA element that forms at the 5' end of viral transcripts and recruiting a general RNAP II elongation factor termed as PTEFb.  This elongation factor consists of CDK9 and Cyclin T1, and when recruited by Tat to TAR RNA, CDK9 was proposed to phosphorylate the carboxyl terminal domain of RNAP II and thereby activate elongation.  Research in the past two decades has shown that the mechanism of Tat action is considerably more complicated than this simple model.  In metabolically active cells, CDK9 and Cyclin T1 are now known to be largely sequestered in a RNA-protein complex termed the 7SK RNP.  CDK9 and Cyclin T1 are released from the 7SK RNP by mechanisms not yet fully elucidated and along with Tat, bind to TAR RNA and orchestrate the assembly of a Super Elongation Complex (SEC) contg. several addnl. proteins.  CDK9 in the SEC then phosphorylates multiple substrates in the RNAP II complex to activate elongation.  Importantly for therapeutic strategies, CDK9 and Cyclin T1 functions are down-regulated in resting CD4+ T cells that harbor latent HIV-1, and their up-regulation is required for reactivation of latent virus.  Current strategies for a functional cure of HIV-1 infection therefore are likely to require development of latency reversal agents that up-regulate CDK9 and Cyclin T1 function in resting CD4+ T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy7nvbcmhpXbVg90H21EOLACvtfcHk0lhNpG_74DywWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWktLzI&md5=89b886a6ed7dc3cb3b4ae186c57d8a22</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F1381612823666170704130635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612823666170704130635%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DA.%2BP.%26atitle%3DThe%2520HIV-1%2520tat%2520protein%253A%2520mechanism%2520of%2520action%2520and%2520target%2520for%2520HIV-1%2520cure%2520strategies%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2017%26volume%3D23%26issue%3D28%26spage%3D4098%26epage%3D4102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornicek, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Z. F.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">5990</span>– <span class="NLM_lpage">6000</span>, <span class="refDoi"> DOI: 10.1096/fj.201801789RR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1096%2Ffj.201801789RR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30726104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFChs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=5990-6000&author=J.+L.+Wangauthor=D.+C.+Deanauthor=F.+J.+Hornicekauthor=H.+R.+Shiauthor=Z.+F.+Duan&title=Cyclin-dependent+kinase+9+%28CDK9%29+is+a+novel+prognostic+marker+and+therapeutic+target+in+ovarian+cancer&doi=10.1096%2Ffj.201801789RR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer</span></div><div class="casAuthors">Wang, Jinglu; Dean, Dylan C.; Hornicek, Francis J.; Shi, Huirong; Duan, Zhenfeng</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">5990-6000</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Despite surgical and chemotherapeutic advances over the past few decades, the prognosis for ovarian cancer remains very poor.  Although cyclin-dependent kinase (CDK) 9 has an established pathogenic role in various cancers, its function in ovarian cancer remains poorly defined.  The purpose of this study was to evaluate the expression of CDK9 and its therapeutic potential in ovarian cancer.  CDK9 expression was detd. by immunohistochem. in a unique ovarian cancer tissue microarray constructed with paired primary, metastatic, and recurrent tumor tissues from 26 ovarian cancer patients.  CDK9 was highly expressed in human ovarian cancer cell lines and was also elevated in metastatic and recurrent ovarian tumor tissue compared with patient-matched primary ovarian tumor tissue.  In addn., increased CDK9 significantly correlated with poor patient prognosis.  Inhibition of CDK9 by small interfering RNA or CDK9 inhibitor functionally suppressed RNA transcription elongation, induced apoptosis, and reduced proliferation of ovarian cancer cells.  Inhibition of CDK9 also suppressed ovarian cancer cell spheroid growth, clonogenicity formation, and migration activity.  Our results reveal CDK9 as a novel prognostic biomarker and a promising therapeutic target for preventing metastasis and recurrence while also improving the overall clin. outcome for ovarian cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTuSeIUOKO-LVg90H21EOLACvtfcHk0lhNpG_74DywWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFChs7zO&md5=cc691e71c659a48477b30130ccf6cd24</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1096%2Ffj.201801789RR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201801789RR%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BL.%26aulast%3DDean%26aufirst%3DD.%2BC.%26aulast%3DHornicek%26aufirst%3DF.%2BJ.%26aulast%3DShi%26aufirst%3DH.%2BR.%26aulast%3DDuan%26aufirst%3DZ.%2BF.%26atitle%3DCyclin-dependent%2520kinase%25209%2520%2528CDK9%2529%2520is%2520a%2520novel%2520prognostic%2520marker%2520and%2520therapeutic%2520target%2520in%2520ovarian%2520cancer%26jtitle%3DFASEB%2520J.%26date%3D2019%26volume%3D33%26spage%3D5990%26epage%3D6000%26doi%3D10.1096%2Ffj.201801789RR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidner, J. F.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1080/13543784.2019.1678583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F13543784.2019.1678583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31612739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVaisbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=989-1001&author=D.+J.+Leeauthor=J.+F.+Zeidner&title=Cyclin-dependent+kinase+%28CDK%29+9+and+4%2F6+inhibitors+in+acute+myeloid+leukemia+%28AML%29%3A+a+promising+therapeutic+approach&doi=10.1080%2F13543784.2019.1678583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach</span></div><div class="casAuthors">Lee, Daniel J.; Zeidner, Joshua F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">989-1001</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite advancements over the last 2 years, outcomes for acute myeloid leukemia (AML) are poor; however, a greater comprehension of disease mechanisms has driven the investigation of new targeted treatments.  Cyclin-dependent kinases (CDKs) regulate cell cycle progression, transcription and DNA repair, and are aberrantly expressed in AML.  Targeting the CDK pathway is an emerging promising therapeutic strategy in AML.  We describe the rationale for targeting CDK9 and CDK4/6, the ongoing preclin. and clin. trials and the potential of these inhibitors in AML.  Our anal. included an extensive literature search via the Pubmed database and clinicaltrials.gov (March to August, 2019).: While CDK4/6 inhibitors are early in development for AML, CDK9 inhibition with alvocidib has encouraging clin. activity in newly diagnosed and relapsed/refractory AML.  Preclin. data suggests that leukemic MCL-1 dependence may predict response to alvocidib.  Moreover, MCL-1 plays a key role in resistance to BCL-2 inhibition with venetoclax.  Investigational strategies of concomitant BCL-2 and CDK9 inhibition represent a promising therapeutic platform for AML.  Furthermore, preclin. data suggests that CDK4/6 inhibition has selective activity in patients with KMT2A-rearrangements and FLT3 mutations.  Incorporation of CDK9 and 4/6 inhibitors into the existing therapeutic armamentarium may improve outcomes in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokA26-dFEujbVg90H21EOLACvtfcHk0lhNpG_74DywWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVaisbvN&md5=84506de1d15d850dec22ac62d457fd53</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1080%2F13543784.2019.1678583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2019.1678583%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BJ.%26aulast%3DZeidner%26aufirst%3DJ.%2BF.%26atitle%3DCyclin-dependent%2520kinase%2520%2528CDK%2529%25209%2520and%25204%252F6%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%253A%2520a%2520promising%2520therapeutic%2520approach%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2019%26volume%3D28%26spage%3D989%26epage%3D1001%26doi%3D10.1080%2F13543784.2019.1678583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khowsathit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Leal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrero, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merali, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garriga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanu, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simithy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynal, N. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadoch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Gharbia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanicolas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahnow, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelinek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grana, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J. P. J.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK9 reactivates epigenetically silenced genes in cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1244</span>– <span class="NLM_lpage">1258</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.09.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.cell.2018.09.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30454645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWju7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=1244-1258&issue=5&author=H.+H.+Zhangauthor=S.+Pandeyauthor=M.+Traversauthor=H.+X.+Sunauthor=G.+Mortonauthor=J.+Madzoauthor=W.+Chungauthor=J.+Khowsathitauthor=O.+Perez-Lealauthor=C.+A.+Barreroauthor=C.+Meraliauthor=Y.+Okamotoauthor=T.+Satoauthor=J.+Panauthor=J.+Garrigaauthor=N.+V.+Bhanuauthor=J.+Simithyauthor=B.+Patelauthor=J.+Huangauthor=N.+J.+M.+Raynalauthor=B.+A.+Garciaauthor=M.+A.+Jacobsonauthor=C.+Kadochauthor=S.+Meraliauthor=Y.+Zhangauthor=W.+Childersauthor=M.+Abou-Gharbiaauthor=J.+Karanicolasauthor=S.+B.+Baylinauthor=C.+A.+Zahnowauthor=J.+Jelinekauthor=X.+Granaauthor=J.+P.+J.+Issa&title=Targeting+CDK9+reactivates+epigenetically+silenced+genes+in+cancer&doi=10.1016%2Fj.cell.2018.09.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK9 reactivates epigenetically silenced genes in cancer</span></div><div class="casAuthors">Zhang, Hanghang; Pandey, Somnath; Travers, Meghan; Sun, Hongxing; Morton, George; Madzo, Jozef; Chung, Woonbok; Khowsathit, Jittasak; Perez-Leal, Oscar; Barrero, Carlos A.; Merali, Carmen; Okamoto, Yasuyuki; Sato, Takahiro; Pan, Joshua; Garriga, Judit; Bhanu, Natarajan V.; Simithy, Johayra; Patel, Bela; Huang, Jian; Raynal, Noel J.-M.; Garcia, Benjamin A.; Jacobson, Marlene A.; Kadoch, Cigall; Merali, Salim; Zhang, Yi; Childers, Wayne; Abou-Gharbia, Magid; Karanicolas, John; Baylin, Stephen B.; Zahnow, Cynthia A.; Jelinek, Jaroslav; Grana, Xavier; Issa, Jean-Pierre J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1244-1258.e26</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9) promotes transcriptional elongation through RNAPII pause release.  We now report that CDK9 is also essential for maintaining gene silencing at heterochromatic loci.  Through a live cell drug screen with genetic confirmation, we discovered that CDK9 inhibition reactivates epigenetically silenced genes in cancer, leading to restored tumor suppressor gene expression, cell differentiation, and activation of endogenous retrovirus genes.  CDK9 inhibition dephosphorylates the SWI/SNF protein BRG1, which contributes to gene reactivation.  By optimization through gene expression, we developed a highly selective CDK9 inhibitor (MC180295, IC50 = 5 nM) that has broad anti-cancer activity in vitro and is effective in in vivo cancer models.  Addnl., CDK9 inhibition sensitizes to the immune checkpoint inhibitor α-PD-1 in vivo, making it an excellent target for epigenetic therapy of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCzCPV7XrawLVg90H21EOLACvtfcHk0ljkSqqWNX_amQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWju7jE&md5=830a035304148e0529c072965f9c8fa8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.09.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.09.051%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BH.%26aulast%3DPandey%26aufirst%3DS.%26aulast%3DTravers%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%2BX.%26aulast%3DMorton%26aufirst%3DG.%26aulast%3DMadzo%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DW.%26aulast%3DKhowsathit%26aufirst%3DJ.%26aulast%3DPerez-Leal%26aufirst%3DO.%26aulast%3DBarrero%26aufirst%3DC.%2BA.%26aulast%3DMerali%26aufirst%3DC.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DGarriga%26aufirst%3DJ.%26aulast%3DBhanu%26aufirst%3DN.%2BV.%26aulast%3DSimithy%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DRaynal%26aufirst%3DN.%2BJ.%2BM.%26aulast%3DGarcia%26aufirst%3DB.%2BA.%26aulast%3DJacobson%26aufirst%3DM.%2BA.%26aulast%3DKadoch%26aufirst%3DC.%26aulast%3DMerali%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChilders%26aufirst%3DW.%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26aulast%3DKaranicolas%26aufirst%3DJ.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DZahnow%26aufirst%3DC.%2BA.%26aulast%3DJelinek%26aufirst%3DJ.%26aulast%3DGrana%26aufirst%3DX.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%2BJ.%26atitle%3DTargeting%2520CDK9%2520reactivates%2520epigenetically%2520silenced%2520genes%2520in%2520cancer%26jtitle%3DCell%26date%3D2018%26volume%3D175%26issue%3D5%26spage%3D1244%26epage%3D1258%26doi%3D10.1016%2Fj.cell.2018.09.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl) amino) cyclohexyl) amino) pyridin-4-yl) thiazol-2-yl) amino) methyl) tetrahydro-2h-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">896</span>– <span class="NLM_lpage">916</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2018.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30253346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOksbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=896-916&author=B.+L.+Wangauthor=J.+X.+Wuauthor=Y.+Wuauthor=C.+Chenauthor=F.+M.+Zouauthor=A.+L.+Wangauthor=H.+Wuauthor=Z.+Q.+Huauthor=Z.+R.+Jiangauthor=Q.+W.+Liuauthor=W.+Wangauthor=Y.+C.+Zhangauthor=F.+Y.+Liuauthor=M.+Zhaoauthor=J.+Huauthor=T.+Huangauthor=J.+Geauthor=L.+Wangauthor=T.+Renauthor=Y.+X.+Wangauthor=J.+Liuauthor=Q.+S.+Liu&title=Discovery+of+4-%28%28%284-%285-chloro-2-%28%28%281s%2C4s%29-4-%28%282-methoxyethyl%29+amino%29+cyclohexyl%29+amino%29+pyridin-4-yl%29+thiazol-2-yl%29+amino%29+methyl%29+tetrahydro-2h-pyran-4-carbonitrile+%28JSH-150%29+as+a+novel+highly+selective+and+potent+CDK9+kinase+inhibitor&doi=10.1016%2Fj.ejmech.2018.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor</span></div><div class="casAuthors">Wang, Beilei; Wu, Jiaxin; Wu, Yun; Chen, Cheng; Zou, Fengming; Wang, Aoli; Wu, Hong; Hu, Zhenquan; Jiang, Zongru; Liu, Qingwang; Wang, Wei; Zhang, Yicong; Liu, Feiyang; Zhao, Ming; Hu, Jie; Huang, Tao; Ge, Juan; Wang, Li; Ren, Tao; Wang, Yuxin; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">896-916</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compd. 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochem. assay and achieved around 300-10000-fold selectivity over other CDK kinase family members.  In addn., it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01).  Compd. 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines.  It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells.  In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression.  The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacol. tool to study CDK9-mediated physiol. and pathol. as well as a potential drug candidate for leukemia and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_sWKyk4YTnbVg90H21EOLACvtfcHk0lg3AQpcnwSqCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOksbnM&md5=c0b4a5d7ab3d6a088874c2b9ea1a4620</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZou%26aufirst%3DF.%2BM.%26aulast%3DWang%26aufirst%3DA.%2BL.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%2BQ.%26aulast%3DJiang%26aufirst%3DZ.%2BR.%26aulast%3DLiu%26aufirst%3DQ.%2BW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%2BC.%26aulast%3DLiu%26aufirst%3DF.%2BY.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26atitle%3DDiscovery%2520of%25204-%2528%2528%25284-%25285-chloro-2-%2528%2528%25281s%252C4s%2529-4-%2528%25282-methoxyethyl%2529%2520amino%2529%2520cyclohexyl%2529%2520amino%2529%2520pyridin-4-yl%2529%2520thiazol-2-yl%2529%2520amino%2529%2520methyl%2529%2520tetrahydro-2h-pyran-4-carbonitrile%2520%2528JSH-150%2529%2520as%2520a%2520novel%2520highly%2520selective%2520and%2520potent%2520CDK9%2520kinase%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D896%26epage%3D916%26doi%3D10.1016%2Fj.ejmech.2018.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of cyclin-dependent kinases as cancer therapeutics</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.pharmthera.2017.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28174091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=83-105&author=S.+R.+Whittakerauthor=A.+Mallingerauthor=P.+Workmanauthor=P.+A.+Clarke&title=Inhibitors+of+cyclin-dependent+kinases+as+cancer+therapeutics&doi=10.1016%2Fj.pharmthera.2017.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cyclin-dependent kinases as cancer therapeutics</span></div><div class="casAuthors">Whittaker, Steven R.; Mallinger, Aurelie; Workman, Paul; Clarke, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs).  This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer.  CDKs have now been shown to regulate other processes, particularly various aspects of transcription.  The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers.  The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors.  However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest.  Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER +/HER2- advanced breast cancer.  Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compds. that have allowed exploration of individual CDKs as cancer targets and the detn. of their potential therapeutic windows.  Biomarkers that allow the selection of patients likely to respond are now being discovered.  Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors.  This suggests that the selective inhibitors may be best used combined with std. of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5gsvVBhpMEbVg90H21EOLACvtfcHk0lg3AQpcnwSqCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D&md5=933364a96089bc4c47e15bddb412bd53</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%2BR.%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520cyclin-dependent%2520kinases%2520as%2520cancer%2520therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D83%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2017.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhász, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadranel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drews, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span> <span> </span><span class="NLM_article-title">Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in patients with extensive-disease small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">701</span>– <span class="NLM_lpage">711</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.jtho.2019.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30677506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemtLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=701-711&author=M.+Reckauthor=L.+Hornauthor=S.+Novelloauthor=F.+Barlesiauthor=I.+Albertauthor=E.+Juh%C3%A1szauthor=D.+Kowalskiauthor=G.+Robinetauthor=G.+Cadranelauthor=P.+Bidoliauthor=J.+Chungauthor=A.+Fritschauthor=U.+Drewsauthor=A.+Wagnerauthor=R.+Govindan&title=Phase+II+study+of+roniciclib+in+combination+with+cisplatin%2Fetoposide+or+carboplatin%2Fetoposide+as+first-line+therapy+in+patients+with+extensive-disease+small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2019.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer</span></div><div class="casAuthors">Reck, Martin; Horn, Leora; Novello, Silvia; Barlesi, Fabrice; Albert, Istvan; Juhasz, Erzsebet; Kowalski, Dariusz; Robinet, Gilles; Cadranel, Jacques; Bidoli, Paolo; Chung, John; Fritsch, Arno; Drews, Uta; Wagner, Andrea; Govindan, Ramaswamy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">701-711</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">This phase II study evaluated the efficacy and safety of the pan-cyclin-dependent kinase inhibitor roniciclib with platinum-based chemotherapy in patients with extensive-disease SCLC.  In this randomized, double-blind study, unselected patients with previously untreated extensive-disease SCLC received roniciclib, 5 mg, or placebo twice daily according to a 3 days-on, 4 days-off schedule in 21-day cycles, with concomitant cisplatin or carboplatin on day 1 and etoposide on days 1 to 3.  The primary end point was progression-free survival.  Other end points included overall survival, objective response rate, and safety.  A total of 140 patients received treatment: 70 with roniciclib plus chemotherapy and 70 with placebo plus chemotherapy.  Median overall survival times was 9.7 mo (95% CI: 7.9-11.1) with roniciclib plus chemotherapy and 10.3 mo (95% CI: 8.7-11.9) with placebo plus chemotherapy (HR = 1.281, 95% CI: 0.776-1.912, p = 0.7858).  The objective response rates were 60.6% with roniciclib plus chemotherapy and 74.6% with placebo plus chemotherapy.  Common treatment-emergent adverse events in both groups included nausea, vomiting, and fatigue.  Serious treatment-emergent adverse events were more common with roniciclib plus chemotherapy (57.1%) than with placebo plus chemotherapy (38.6%).  Roniciclib combined with chemotherapy demonstrated an unfavorable risk-benefit profile in patients with extensive-disease SCLC, and the study was prematurely terminated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMO5HC1HHvgrVg90H21EOLACvtfcHk0lg3AQpcnwSqCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemtLjM&md5=82e47fb569099724b143175abbc7c648</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DReck%26aufirst%3DM.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DAlbert%26aufirst%3DI.%26aulast%3DJuh%25C3%25A1sz%26aufirst%3DE.%26aulast%3DKowalski%26aufirst%3DD.%26aulast%3DRobinet%26aufirst%3DG.%26aulast%3DCadranel%26aufirst%3DG.%26aulast%3DBidoli%26aufirst%3DP.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DDrews%26aufirst%3DU.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DGovindan%26aufirst%3DR.%26atitle%3DPhase%2520II%2520study%2520of%2520roniciclib%2520in%2520combination%2520with%2520cisplatin%252Fetoposide%2520or%2520carboplatin%252Fetoposide%2520as%2520first-line%2520therapy%2520in%2520patients%2520with%2520extensive-disease%2520small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26spage%3D701%26epage%3D711%26doi%3D10.1016%2Fj.jtho.2019.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">The history and future of targeting cyclin-dependent kinases in cancer therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&issue=2&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+history+and+future+of+targeting+cyclin-dependent+kinases+in+cancer+therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0lhxmy1W210udQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520history%2520and%2520future%2520of%2520targeting%2520cyclin-dependent%2520kinases%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D2%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napoleon, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin dependent kinase 9 inhibitors for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8667</span>– <span class="NLM_lpage">8684</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00150</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00150" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslGjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8667-8684&author=Y.+A.+Sonawaneauthor=M.+A.+Taylorauthor=J.+V.+Napoleonauthor=S.+Ranaauthor=J.+I.+Contrerasauthor=A.+Natarajan&title=Cyclin+dependent+kinase+9+inhibitors+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.6b00150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy</span></div><div class="casAuthors">Sonawane, Yogesh A.; Taylor, Margaret A.; Napoleon, John Victor; Rana, Sandeep; Contreras, Jacob I.; Natarajan, Amarnath</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8667-8684</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly 2 decades due to their widely varied and crit. functions within the cell.  Recently CDK9 has emerged as a druggable target for the development of cancer therapeutics.  CDK9 plays a crucial role in transcription regulation; specifically, CDK9 mediated transcriptional regulation of short-lived antiapoptotic proteins is crit. for the survival of transformed cells.  Focused chem. libraries based on a plethora of scaffolds have resulted in mixed success with regard to the development of selective CDK9 inhibitors.  Here we review the regulation of CDK9, its cellular functions, and common core structures used to target CDK9, along with their selectivity profile and efficacy in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOIqU9uSujdrVg90H21EOLACvtfcHk0lhxmy1W210udQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslGjsLo%253D&md5=0910a61f9c915002ff1073b22b5e20d6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00150%26sid%3Dliteratum%253Aachs%26aulast%3DSonawane%26aufirst%3DY.%2BA.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DNapoleon%26aufirst%3DJ.%2BV.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DContreras%26aufirst%3DJ.%2BI.%26aulast%3DNatarajan%26aufirst%3DA.%26atitle%3DCyclin%2520dependent%2520kinase%25209%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8667%26epage%3D8684%26doi%3D10.1021%2Facs.jmedchem.6b00150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paparidis, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durvale, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canduri, F.</span></span> <span> </span><span class="NLM_article-title">The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1039/C6MB00387G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1039%2FC6MB00387G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27833949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2snltVOlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=246-276&issue=2&author=N.+F.+Paparidisauthor=M.+C.+Durvaleauthor=F.+Canduri&title=The+emerging+picture+of+CDK9%2FP-TEFb%3A+more+than+20+years+of+advances+since+PITALRE&doi=10.1039%2FC6MB00387G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE</span></div><div class="casAuthors">Paparidis Nikolas Ferreira Dos Santos; Canduri Fernanda; Durvale Maxwell Castro</div><div class="citationInfo"><span class="NLM_cas:title">Molecular bioSystems</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-276</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CDK9 is a prominent member of the transcriptional CDKs subfamily, a group of kinases whose function is to control the primary steps of mRNA synthesis and processing by eukaryotic RNA polymerase II.  As a cyclin-dependent kinase, CDK9 activation in vivo depends upon its association with T-type cyclins to assemble the positive transcription elongation factor (P-TEFb).  Although CDK9/P-TEFb phosphorylates the C-terminal domain of RNAP II in the same positions targeted by CDK7 (TFIIH) and CDK8 (Mediator), the former does not participate in the transcription initiation, but rather plays a unique role by driving the polymerase to productive elongation.  In addition to RNAP II CTD, the negative transcription elongation factors DSIF and NELF also represent major CDK9 substrates, whose phosphorylation is required to overcome the proximal pause of the polymerase.  CDK9 is recruited to specific genes through proteins that interact with both P-TEFb and distinct elements in DNA, RNA or chromatin, where it modulates the activity of individual RNAP II transcription complexes.  The regulation of CDK9 function is an intricate network that includes post-translational modifications (phosphorylation/dephosphorylation and acetylation/deacetylation of key residues) as well as the association of P-TEFb with various proteins that can stimulate or inhibit its kinase activity.  Several cases of CDK9 deregulation have been linked to important human diseases, including various types of cancer and also AIDS (due to its essential role in HIV replication).  Not only HIV, but also many other human viruses have been shown to depend strongly on CDK9 activity to be transcribed within host cells.  This review summarizes the main advances made on CDK9/P-TEFb field in more than 20 years, introducing the structural, functional and genetic aspects that have been elucidated ever since.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJulYHhsNcnUmhnSqMnvzDfW6udTcc2eYxpWjt1zW1fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snltVOlsA%253D%253D&md5=eb1290cacb40f5c4c7158199fe513b14</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2FC6MB00387G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MB00387G%26sid%3Dliteratum%253Aachs%26aulast%3DPaparidis%26aufirst%3DN.%2BF.%26aulast%3DDurvale%26aufirst%3DM.%2BC.%26aulast%3DCanduri%26aufirst%3DF.%26atitle%3DThe%2520emerging%2520picture%2520of%2520CDK9%252FP-TEFb%253A%2520more%2520than%252020%2520years%2520of%2520advances%2520since%2520PITALRE%26jtitle%3DMol.%2520BioSyst.%26date%3D2017%26volume%3D13%26issue%3D2%26spage%3D246%26epage%3D276%26doi%3D10.1039%2FC6MB00387G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bacon, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Orso, I.</span></span> <span> </span><span class="NLM_article-title">CDK9: a signaling hub for transcriptional control</span>. <i>Transcription.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1080/21541264.2018.1523668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F21541264.2018.1523668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30227759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFSru7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=57-75&author=C.+W.+Baconauthor=I.+D%E2%80%99Orso&title=CDK9%3A+a+signaling+hub+for+transcriptional+control&doi=10.1080%2F21541264.2018.1523668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9: a signaling hub for transcriptional control</span></div><div class="casAuthors">Bacon, Curtis W.; D'Orso, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">57-75</span>CODEN:
                <span class="NLM_cas:coden">TRANH2</span>;
        ISSN:<span class="NLM_cas:issn">2154-1272</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9) is crit. for RNA Polymerase II (Pol II) transcription initiation, elongation, and termination in several key biol. processes including development, differentiation, and cell fate responses.  A broad range of diseases are characterized by CDK9 malfunction, illustrating its importance in maintaining transcriptional homeostasis in basal- and signal-regulated conditions.  Here we provide a historical recount of CDK9 discovery and the current models suggesting CDK9 is a central hub necessary for proper execution of different steps in the transcription cycle.  Finally, we discuss the current therapeutic strategies to treat CDK9 malfunction in several disease states.  CDK: Cyclin-dependent kinase; Pol II: RNA Polymerase II; PIC: Pre-initiation Complex; TFIIH: Transcription Factor-II H; snoRNA: small nucleolar RNA; CycT: CyclinT1/T2; P-TEFb: Pos. Transcription Elongation Factor Complex; snRNP: small nuclear ribonucleo-protein; HEXIM: Hexamethylene Bis-acetamide-inducible Protein 1/2; LARP7: La-related Protein 7; MePCE: Methylphosphate Capping Enzyme; HIV: human immunodeficiency virus; TAT: trans-activator of transcription; TAR: Trans-activation response element; Hsp70: Heat Shock Protein 70; Hsp90/Cdc37: Hsp90- Hsp90 co-chaperone Cdc37; DSIF: DRB Sensitivity Inducing Factor; NELF: Neg. Elongation Factor; CPSF: cleavage and polyadenylation-specific factor; CSTF: cleavage-stimulatory factor; eRNA: enhancer RNA; BRD4: Bromodomain-contg. protein 4; JMJD6: Jumonji C-domain-contg. protein 6; SEC: Super Elongation Complex; ELL: eleven-nineteen Lys-rich leukemia; ENL: eleven-nineteen leukemia; MLL: mixed lineage leukemia; BEC: BRD4-contg. Elongation Complex; SEC-L2/L3: SEC-like complexes; KAP1: Kruppel-assocd. box-protein 1; KEC: KAP1-7SK Elongation Complex; DRB: Dichloro-1-ss-D-Ribofuranosylbenzimidazole; H2Bub1: H2B mono-ubiquitination; KM: KM05382; PP1: Protein Phosphatase 1; CDK9i: CDK9 inhibitor; SHAPE: Selective 2'-hydroxyl acylation analyzed by primer extension; TE: Typical enhancer; SE : Super enhancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7KDxTlKPy47Vg90H21EOLACvtfcHk0lhWL18bN2-XTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFSru7bJ&md5=5977b1ea4f425dc8a2d0c39f98ef0e7d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1080%2F21541264.2018.1523668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2018.1523668%26sid%3Dliteratum%253Aachs%26aulast%3DBacon%26aufirst%3DC.%2BW.%26aulast%3DD%25E2%2580%2599Orso%26aufirst%3DI.%26atitle%3DCDK9%253A%2520a%2520signaling%2520hub%2520for%2520transcriptional%2520control%26jtitle%3DTranscription.%26date%3D2019%26volume%3D10%26spage%3D57%26epage%3D75%26doi%3D10.1080%2F21541264.2018.1523668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donehower, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. P.</span></span> <span> </span><span class="NLM_article-title">55k isoform of CDK9 associates with ku70 and is involved in DNA repair</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>397</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2010.05.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bbrc.2010.05.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=20493174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVChu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=397&publication_year=2010&pages=245-250&author=H.+B.+Liuauthor=C.+H.+Herrmannauthor=K.+R.+Chiangauthor=T.+L.+Sungauthor=S.+H.+Moonauthor=L.+A.+Donehowerauthor=A.+P.+Rice&title=55k+isoform+of+CDK9+associates+with+ku70+and+is+involved+in+DNA+repair&doi=10.1016%2Fj.bbrc.2010.05.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">55K isoform of CDK9 associates with Ku70 and is involved in DNA repair</span></div><div class="casAuthors">Liu, Hongbing; Herrmann, Christine H.; Chiang, Karen; Sung, Tzu-Ling; Moon, Sung-Hwan; Donehower, Lawrence A.; Rice, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">397</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-250</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pos. elongation factor b (P-TEFb) is a cellular protein kinase that is required for RNA polymerase II (RNAP II) transcriptional elongation of protein coding genes.  P-TEFb is a set of different mol. complexes, each contg. CDK9 as the catalytic subunit.  There are two isoforms of the CDK9 protein - the major 42 KDa CDK9 isoform and the minor 55KDa isoform that is translated from an in-frame mRNA that arises from an upstream transcriptional start site.  We found that shRNA depletion of the 55K CDK9 protein in HeLa cells induces apoptosis and double-strand DNA breaks (DSBs).  The levels of apoptosis and DSBs induced by the depletion were reduced by expression of a 55K CDK9 protein variant resistant to the shRNA, indicating that these phenotypes are the consequence of depletion of the 55K protein and not off-target effects.  We also found that the 55K CDK9 protein, but not the 42K CDK9 protein, specifically assocs. with Ku70, a protein involved in DSB repair.  Our findings suggest that the 55K CDK9 protein may function in repair of DNA through an assocn. with Ku70.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLqsE7-4wvgbVg90H21EOLACvtfcHk0lhWL18bN2-XTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVChu7Y%253D&md5=109c0d1320181f4784cdd94cbd553145</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2010.05.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2010.05.092%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%2BB.%26aulast%3DHerrmann%26aufirst%3DC.%2BH.%26aulast%3DChiang%26aufirst%3DK.%2BR.%26aulast%3DSung%26aufirst%3DT.%2BL.%26aulast%3DMoon%26aufirst%3DS.%2BH.%26aulast%3DDonehower%26aufirst%3DL.%2BA.%26aulast%3DRice%26aufirst%3DA.%2BP.%26atitle%3D55k%2520isoform%2520of%2520CDK9%2520associates%2520with%2520ku70%2520and%2520is%2520involved%2520in%2520DNA%2520repair%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2010%26volume%3D397%26spage%3D245%26epage%3D250%26doi%3D10.1016%2Fj.bbrc.2010.05.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lis, J. T.</span></span> <span> </span><span class="NLM_article-title">Genome-wide dynamics of pol II elongation and its interplay with promoter proximal pausing, chromatin, and exons</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e02407</span>, <span class="refDoi"> DOI: 10.7554/eLife.02407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.7554%2FeLife.02407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24843027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=e02407&author=I.+Jonkersauthor=H.+Kwakauthor=J.+T.+Lis&title=Genome-wide+dynamics+of+pol+II+elongation+and+its+interplay+with+promoter+proximal+pausing%2C+chromatin%2C+and+exons&doi=10.7554%2FeLife.02407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide dynamics of Pol II elongation and its interplay with promoter proximal pausing, chromatin, and exons</span></div><div class="casAuthors">Jonkers, Iris; Kwak, Hojoong; Lis, John T.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e02407/1-e02407/25, 25 pp.</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Prodn. of mRNA depends critically on the rate of RNA polymerase II (Pol II) elongation.  To dissect Pol II dynamics in mouse ES cells, we inhibited Pol II transcription at either initiation or promoter-proximal pause escape with Triptolide or Flavopiridol, and tracked Pol II kinetically using GRO-seq.  Both inhibitors block transcription of more than 95% of genes, showing that pause escape, like initiation, is a ubiquitous and crucial step within the transcription cycle.  Moreover, paused Pol II is relatively stable, as evidenced from half-life measurements at ∼3200 genes.  Finally, tracking the progression of Pol II after drug treatment establishes Pol II elongation rates at over 1000 genes.  Notably, Pol II accelerates dramatically while transcribing through genes, but slows at exons.  Furthermore, intergenic variance in elongation rates is substantial, and is influenced by a pos. effect of H3K79me2 and neg. effects of exon d. and CG content within genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjNRAyzNYAlrVg90H21EOLACvtfcHk0lhWL18bN2-XTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksLbI&md5=f8b3fb84eaa5711ee79819c66f8a4682</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.7554%2FeLife.02407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.02407%26sid%3Dliteratum%253Aachs%26aulast%3DJonkers%26aufirst%3DI.%26aulast%3DKwak%26aufirst%3DH.%26aulast%3DLis%26aufirst%3DJ.%2BT.%26atitle%3DGenome-wide%2520dynamics%2520of%2520pol%2520II%2520elongation%2520and%2520its%2520interplay%2520with%2520promoter%2520proximal%2520pausing%252C%2520chromatin%252C%2520and%2520exons%26jtitle%3DeLife%26date%3D2014%26volume%3D3%26spage%3De02407%26doi%3D10.7554%2FeLife.02407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover-Cutter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansó, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1108</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnsmb.2399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=23064645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2rsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1108-1115&issue=11&author=S.+Larochelleauthor=R.+Amatauthor=K.+Glover-Cutterauthor=M.+Sans%C3%B3author=C.+Zhangauthor=J.+J.+Allenauthor=K.+M.+Shokatauthor=D.+L.+Bentleyauthor=R.+P.+Fisher&title=Cyclin-dependent+kinase+control+of+the+initiation-to-elongation+switch+of+RNA+polymerase+II&doi=10.1038%2Fnsmb.2399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II</span></div><div class="casAuthors">Larochelle, Stephane; Amat, Ramon; Glover-Cutter, Kira; Sanso, Miriam; Zhang, Chao; Allen, Jasmina J.; Shokat, Kevan M.; Bentley, David L.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1108-1115</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Promoter-proximal pausing by RNA polymerase II (Pol II) ensures gene-specific regulation and RNA quality control.  Structural considerations suggested a requirement for initiation-factor eviction in elongation-factor engagement and pausing of transcription complexes.  Here we show that selective inhibition of Cdk7-part of TFIIH-increases TFIIE retention, prevents DRB sensitivity-inducing factor (DSIF) recruitment and attenuates pausing in human cells.  Pause release depends on Cdk9-cyclin T1 (P-TEFb); Cdk7 is also required for Cdk9-activating phosphorylation and Cdk9-dependent downstream events-Pol II C-terminal domain Ser2 phosphorylation and histone H2B ubiquitylation-in vivo.  Cdk7 inhibition, moreover, impairs Pol II transcript 3'-end formation.  Cdk7 thus acts through TFIIE and DSIF to establish, and through P-TEFb to relieve, barriers to elongation: incoherent feedforward that might create a window to recruit RNA-processing machinery.  Therefore, cyclin-dependent kinases govern Pol II handoff from initiation to elongation factors and cotranscriptional RNA maturation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUhQtYIcdjLbVg90H21EOLACvtfcHk0lh-x6IkPijyeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2rsLvI&md5=e483e572df1f8645db9da40800dffe4d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2399%26sid%3Dliteratum%253Aachs%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DAmat%26aufirst%3DR.%26aulast%3DGlover-Cutter%26aufirst%3DK.%26aulast%3DSans%25C3%25B3%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DAllen%26aufirst%3DJ.%2BJ.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DBentley%26aufirst%3DD.%2BL.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DCyclin-dependent%2520kinase%2520control%2520of%2520the%2520initiation-to-elongation%2520switch%2520of%2520RNA%2520polymerase%2520II%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26issue%3D11%26spage%3D1108%26epage%3D1115%26doi%3D10.1038%2Fnsmb.2399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Storch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordes, N.</span></span> <span> </span><span class="NLM_article-title">The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.3892/ijo.2015.3246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.3892%2Fijo.2015.3246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26573875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVGrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=191-198&issue=1&author=K.+Storchauthor=N.+Cordes&title=The+impact+of+CDK9+on+radiosensitivity%2C+DNA+damage+repair+and+cell+cycling+of+HNSCC+cancer+cells&doi=10.3892%2Fijo.2015.3246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells</span></div><div class="casAuthors">Storch, Katja; Cordes, Nils</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">191-198</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9), mainly involved in regulation of transcription, has recently been shown to impact on cell cycling and DNA repair.  Despite the fact that CDK9 has been proposed as potential cancer target, it remains largely elusive whether CDK9 targeting alters tumor cell radiosensitivity.  Five human head and neck squamous cell carcinoma (HNSCC) cell lines (SAS, FaDu, HSC4, Cal33, UTSCC5) as well as SAS cells stably transfected with CDK9-EGFP-N1 plasmid or empty vector controls were used.  Upon either CDK9 small interfering RNA knockdown or treatment with a pan-CDK inhibitor (ZK304709), colony formation, DNA double strand breaks (DSBs), apoptosis, cell cycling, and expression and phosphorylation of major cell cycle and DNA damage repair proteins were examd.  While CDK9 overexpression mediated radioprotection, CDK9 depletion clearly enhanced the radiosensitivity of HNSCC cells without an induction of apoptosis.  While the cell cycle and cell cycle proteins were significantly modulated by CDK9 depletion, no further alterations in these parameters were obsd. after combined CDK9 knockdown with irradn.  ZK304709 showed concn.-dependent cytotoxicity but failed to radiosensitize HNSCC cells.  Our findings suggest a potential role of CDK9 in the radiation response of HNSCC cells.  Addnl. studies are warranted to clarify the usefulness to target CDK9 in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDuDnye_D2t7Vg90H21EOLACvtfcHk0lh-x6IkPijyeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVGrsg%253D%253D&md5=bcecc7eca11a3d578dbba12ada463d4f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3892%2Fijo.2015.3246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2015.3246%26sid%3Dliteratum%253Aachs%26aulast%3DStorch%26aufirst%3DK.%26aulast%3DCordes%26aufirst%3DN.%26atitle%3DThe%2520impact%2520of%2520CDK9%2520on%2520radiosensitivity%252C%2520DNA%2520damage%2520repair%2520and%2520cell%2520cycling%2520of%2520HNSCC%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2016%26volume%3D48%26issue%3D1%26spage%3D191%26epage%3D198%26doi%3D10.3892%2Fijo.2015.3246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-19-0528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F2159-8290.CD-19-0528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=32071145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVyrs7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=351-370&author=J.+Chouauthor=D.+A.+Quigleyauthor=T.+M.+Robinsonauthor=F.+Y.+Fengauthor=A.+Ashworth&title=Transcription-associated+cyclin-dependent+kinases+as+targets+and+biomarkers+for+cancer+therapy&doi=10.1158%2F2159-8290.CD-19-0528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy</span></div><div class="casAuthors">Chou, Jonathan; Quigley, David A.; Robinson, Troy M.; Feng, Felix Y.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-370</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Drugs targeting the cell cycle-regulatory cyclin-dependent kinase (CDK) 4 and 6 have been approved for the treatment of hormone receptor-pos. breast cancer, and inhibitors targeting other cell-cycle CDKs are currently in clin. trials.  Another class of CDKs, the transcription-assocd. CDKs, including CDK7, CDK8, CDK9, CDK12 and CDK13, are crit. regulators of gene expression.  Recent evidence suggests several novel functions of these CDKs, including regulation of epigenetic modifications, intronic polyadenylation, DNA-damage responses, and genomic stability.  Here, we summarize our current understanding of the transcriptional CDKs, their utility as biomarkers, and their potential as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKsOxtaonQb7Vg90H21EOLACvtfcHk0lh-x6IkPijyeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVyrs7fM&md5=5fe5acb1fc8190ded5b14e6e44741df3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-0528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-0528%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DJ.%26aulast%3DQuigley%26aufirst%3DD.%2BA.%26aulast%3DRobinson%26aufirst%3DT.%2BM.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTranscription-associated%2520cyclin-dependent%2520kinases%2520as%2520targets%2520and%2520biomarkers%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2020%26volume%3D10%26spage%3D351%26epage%3D370%26doi%3D10.1158%2F2159-8290.CD-19-0528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nekhai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuer, D.</span></span> <span> </span><span class="NLM_article-title">Regulation of CDK9 activity by phosphorylation and dephosphorylation</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1155/2014/964964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1155%2F2014%2F964964" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=1&author=S.+Nekhaiauthor=M.+Petukhovauthor=D.+Breuer&title=Regulation+of+CDK9+activity+by+phosphorylation+and+dephosphorylation&doi=10.1155%2F2014%2F964964"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1155%2F2014%2F964964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F964964%26sid%3Dliteratum%253Aachs%26aulast%3DNekhai%26aufirst%3DS.%26aulast%3DPetukhov%26aufirst%3DM.%26aulast%3DBreuer%26aufirst%3DD.%26atitle%3DRegulation%2520of%2520CDK9%2520activity%2520by%2520phosphorylation%2520and%2520dephosphorylation%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2014%26volume%3D2014%26spage%3D1%26doi%3D10.1155%2F2014%2F964964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahaman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumarasiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekonnen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. D.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK9: a promising therapeutic opportunity in prostate cancer</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">T211</span>– <span class="NLM_lpage">T226</span>, <span class="refDoi"> DOI: 10.1530/ERC-16-0299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1530%2FERC-16-0299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27582311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=T211-T226&author=M.+H.+Rahamanauthor=M.+Kumarasiriauthor=L.+B.+Mekonnenauthor=M.+F.+Yuauthor=S.+Diabauthor=H.+Albrechtauthor=R.+W.+Milneauthor=S.+D.+Wang&title=Targeting+CDK9%3A+a+promising+therapeutic+opportunity+in+prostate+cancer&doi=10.1530%2FERC-16-0299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK9: a promising therapeutic opportunity in prostate cancer</span></div><div class="casAuthors">Rahaman, Muhammed H.; Kumarasiri, Malika; Mekonnen, Laychiluh B.; Yu, Mingfeng; Diab, Sarah; Albrecht, Hugo; Milne, Robert W.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">T211-T226</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9) is a key transcriptional regulator and a lucrative target for cancer treatment.  Targeting CDK9 can effectively confine the hyperactivity of androgen receptor and the constitutive expression of anti-apoptotic proteins; both being main causes of prostate cancer (PCa) development and progression.  In castrate-resistant PCa, traditional therapies that only target androgen receptor (AR) have become obsolete due to reprograming in AR activity to make the cells independent of androgen.  CDK9 inhibitors may provide a new and better therapeutic opportunity over traditional treatment options by targeting both androgen receptor activity and antiapoptotic proteins, improving the chances of pos. outcomes, esp. in patients with the advanced disease.  This review focuses on biol. functions of CDK9, its involvement with AR and the potential for therapeutic opportunities in PCa treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJmSh9D9_op7Vg90H21EOLACvtfcHk0liWA7_zJK61tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSlu78%253D&md5=cea302eeb765840884f60cb170ec1640</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1530%2FERC-16-0299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-16-0299%26sid%3Dliteratum%253Aachs%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DMekonnen%26aufirst%3DL.%2BB.%26aulast%3DYu%26aufirst%3DM.%2BF.%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DS.%2BD.%26atitle%3DTargeting%2520CDK9%253A%2520a%2520promising%2520therapeutic%2520opportunity%2520in%2520prostate%2520cancer%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2016%26volume%3D23%26spage%3DT211%26epage%3DT226%26doi%3D10.1530%2FERC-16-0299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisburd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e06535</span>, <span class="refDoi"> DOI: 10.7554/eLife.06535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.7554%2FeLife.06535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26083714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVylsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=e06535&author=H.+S.+Luauthor=Y.+H.+Xueauthor=G.+K.+Y.+Yuauthor=C.+Ariasauthor=J.+L.+Linauthor=S.+Fongauthor=M.+Faureauthor=B.+Weisburdauthor=X.+D.+Jiauthor=A.+Mercierauthor=J.+Suttonauthor=K.+X.+Luoauthor=Z.+H.+Gaoauthor=Q.+Zhou&title=Compensatory+induction+of+MYC+expression+by+sustained+CDK9+inhibition+via+a+BRD4-dependent+mechanism&doi=10.7554%2FeLife.06535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism</span></div><div class="casAuthors">Lu, Huasong; Xue, Yuahua; Yu, Guoying K.; Arias, Carolina; Lin, Julie; Fong, Susan; Faure, Michel; Weisburd, Ben; Ji, Xiaodan; Mercier, Alexandre; Sutton, James; Luo, Kunxin; Gao, Zhenhai; Zhou, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e06535/1-e06535/26</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">CDK9 is the kinase subunit of pos. transcription elongation factor b (P-TEFb) that enables RNA polymerase (Pol) II's transition from promoter-proximal pausing to productive elongation.  Although considerable interest exists in CDK9 as a therapeutic target, little progress has been made due to lack of highly selective inhibitors.  Here, we describe the development of i-CDK9 as such an inhibitor that potently suppresses CDK9 phosphorylation of substrates and causes genome-wide Pol II pausing.  While most genes experience reduced expression, MYC and other primary response genes increase expression upon sustained i-CDK9 treatment.  Essential for this increase, the bromodomain protein BRD4 captures P-TEFb from 7SK snRNP to deliver to target genes and also enhances CDK9's activity and resistance to inhibition.  Because the i-CDK9-induced MYC expression and binding to P-TEFb compensate for P-TEFb's loss of activity, only simultaneously inhibiting CDK9 and MYC/BRD4 can efficiently induce growth arrest and apoptosis of cancer cells, suggesting the potential of a combinatorial treatment strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqDVbCbzgrtLVg90H21EOLACvtfcHk0liWA7_zJK61tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVylsL4%253D&md5=d08929101f4e3603306ccdc8642c19b4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.7554%2FeLife.06535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.06535%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%2BS.%26aulast%3DXue%26aufirst%3DY.%2BH.%26aulast%3DYu%26aufirst%3DG.%2BK.%2BY.%26aulast%3DArias%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%2BL.%26aulast%3DFong%26aufirst%3DS.%26aulast%3DFaure%26aufirst%3DM.%26aulast%3DWeisburd%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DX.%2BD.%26aulast%3DMercier%26aufirst%3DA.%26aulast%3DSutton%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DK.%2BX.%26aulast%3DGao%26aufirst%3DZ.%2BH.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DCompensatory%2520induction%2520of%2520MYC%2520expression%2520by%2520sustained%2520CDK9%2520inhibition%2520via%2520a%2520BRD4-dependent%2520mechanism%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26spage%3De06535%26doi%3D10.7554%2FeLife.06535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaori-Kondo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, S.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase 9 is a novel specific molecular target in adult t-cell leukemia/lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">1114</span>– <span class="NLM_lpage">1124</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-09-741983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1182%2Fblood-2016-09-741983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28646117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=1114-1124&author=T.+Naritaauthor=T.+Ishidaauthor=A.+Itoauthor=A.+Masakiauthor=S.+Kinoshitaauthor=S.+Suzukiauthor=H.+Takinoauthor=T.+Yoshidaauthor=M.+Riauthor=S.+Kusumotoauthor=H.+Komatsuauthor=K.+Imadaauthor=Y.+Tanakaauthor=A.+Takaori-Kondoauthor=H.+Inagakiauthor=A.+Scholzauthor=P.+Lienauauthor=T.+Kurodaauthor=R.+Uedaauthor=S.+Iida&title=Cyclin-dependent+kinase+9+is+a+novel+specific+molecular+target+in+adult+t-cell+leukemia%2Flymphoma&doi=10.1182%2Fblood-2016-09-741983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma</span></div><div class="casAuthors">Narita, Tomoko; Ishida, Takashi; Ito, Asahi; Masaki, Ayako; Kinoshita, Shiori; Suzuki, Susumu; Takino, Hisashi; Yoshida, Takashi; Ri, Masaki; Kusumoto, Shigeru; Komatsu, Hirokazu; Imada, Kazunori; Tanaka, Yuetsu; Takaori-Kondo, Akifumi; Inagaki, Hiroshi; Scholz, Arne; Lienau, Philip; Kuroda, Taruho; Ueda, Ryuzo; Iida, Shinsuke</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1114-1124</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9), a subunit of the pos. transcription elongation factor b (P-TEFb) complex, regulates gene transcription elongation by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (RNAPII).  The deregulation of CDK9/PTEFb has important implications for many cancer types.  BAY 1143572 is a novel and highly selective CDK9/P-TEFb inhibitor currently being investigated in phase 1 studies.  We evaluated the therapeutic potential of BAY1143572 in adult T-cell leukemia/lymphoma (ATL).  As a result of CDK9 inhibition and subsequent inhibition of phosphorylation at serine 2 of the RNAPII CTD, BAY1143572 decreased c-Myc and Mcl-1 levels in ATL-derived or human T-cell lymphotropic virus type-1 (HTLV-1)-transformed lines and primary ATL cells tested, leading to their growth inhibition and apoptosis.  Median inhibitory concns. for BAY 1143572 in ATL-derived or HTLV-1-transformed lines (n 5 8), primary ATL cells (n511), and CD4+ cells fromhealthy volunteers (n55) were 0.535, 0.30, and 0.36 mM, resp.  Next, NOG mice were used as recipients of tumor cells from an ATL patient.  BAY 1143572-treated ATL-bearing mice (once daily 12.5 mg/kg oral application) demonstrated significantly decreased ATL cell infiltration of the liver and bone marrow, as well as decreased human sol. interleukin-2 receptor levels in serum (reflecting the ATL tumor burden), compared with untreated mice (n 5 8 for both).  BAY 1143572-treated ATL-bearingmice demonstrated significantly prolonged survival compared with untreated ATL-bearing mice (n57 for both).  Collectively, this study indicates that BAY1143572 showed strong potential as a novel treatment of ATL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOnbRIEdnT27Vg90H21EOLACvtfcHk0liWA7_zJK61tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsrc%253D&md5=dfea5c427ed9963db1cb6203a784d017</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-09-741983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-09-741983%26sid%3Dliteratum%253Aachs%26aulast%3DNarita%26aufirst%3DT.%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DMasaki%26aufirst%3DA.%26aulast%3DKinoshita%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DTakino%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DRi%26aufirst%3DM.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DImada%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DTakaori-Kondo%26aufirst%3DA.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DKuroda%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DR.%26aulast%3DIida%26aufirst%3DS.%26atitle%3DCyclin-dependent%2520kinase%25209%2520is%2520a%2520novel%2520specific%2520molecular%2520target%2520in%2520adult%2520t-cell%2520leukemia%252Flymphoma%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D1114%26epage%3D1124%26doi%3D10.1182%2Fblood-2016-09-741983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trounson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouillet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span> <span> </span><span class="NLM_article-title">Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1101/gad.182980.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1101%2Fgad.182980.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=22279045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFOjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=120-125&issue=2&author=S.+P.+Glaserauthor=E.+F.+Leeauthor=E.+Trounsonauthor=P.+Bouilletauthor=A.+Weiauthor=W.+D.+Fairlieauthor=D.+J.+Izonauthor=J.+Zuberauthor=A.+R.+Rappaportauthor=M.+J.+Heroldauthor=W.+S.+Alexanderauthor=S.+W.+Loweauthor=L.+Robbauthor=A.+Strasser&title=Anti-apoptotic+Mcl-1+is+essential+for+the+development+and+sustained+growth+of+acute+myeloid+leukemia&doi=10.1101%2Fgad.182980.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia</span></div><div class="casAuthors">Glaser, Stefan P.; Lee, Erinna F.; Trounson, Evelyn; Bouillet, Philippe; Wei, Andrew; Fairlie, W. Douglas; Izon, David J.; Zuber, Johannes; Rappaport, Amy R.; Herold, Marco J.; Alexander, Warren S.; Lowe, Scott W.; Robb, Lorraine; Strasser, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-125</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) frequently relapses after initial treatment.  Drug resistance in AML has been attributed to high levels of the anti-apoptotic Bcl-2 family members Bcl-xL and Mcl-1.  Here we report that removal of Mcl-1, but not loss or pharmacol. blockade of Bcl-xL, Bcl-2, or Bcl-w, caused the death of transformed AML and could cure disease in AML-afflicted mice.  Enforced expression of selective inhibitors of prosurvival Bcl-2 family members revealed that Mcl-1 is crit. for survival of human AML cells.  Thus, targeting of Mcl-1 or regulators of its expression may be a useful strategy for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6z2Lgi2YuK7Vg90H21EOLACvtfcHk0lhMdVW08AaJPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFOjs78%253D&md5=5f0cc61da50fddb262d30e243a7e6837</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1101%2Fgad.182980.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.182980.111%26sid%3Dliteratum%253Aachs%26aulast%3DGlaser%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DE.%2BF.%26aulast%3DTrounson%26aufirst%3DE.%26aulast%3DBouillet%26aufirst%3DP.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DFairlie%26aufirst%3DW.%2BD.%26aulast%3DIzon%26aufirst%3DD.%2BJ.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DRappaport%26aufirst%3DA.%2BR.%26aulast%3DHerold%26aufirst%3DM.%2BJ.%26aulast%3DAlexander%26aufirst%3DW.%2BS.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DRobb%26aufirst%3DL.%26aulast%3DStrasser%26aufirst%3DA.%26atitle%3DAnti-apoptotic%2520Mcl-1%2520is%2520essential%2520for%2520the%2520development%2520and%2520sustained%2520growth%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26issue%3D2%26spage%3D120%26epage%3D125%26doi%3D10.1101%2Fgad.182980.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawtin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plunkett, W.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4637</span>– <span class="NLM_lpage">4645</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-12-190256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1182%2Fblood-2008-12-190256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=19234140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvVyquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4637-4645&issue=19&author=R.+Chenauthor=W.+G.+Wierdaauthor=S.+Chubbauthor=R.+E.+Hawtinauthor=J.+A.+Foxauthor=M.+J.+Keatingauthor=V.+Gandhiauthor=W.+Plunkett&title=Mechanism+of+action+of+SNS-032%2C+a+novel+cyclin-dependent+kinase+inhibitor%2C+in+chronic+lymphocytic+leukemia&doi=10.1182%2Fblood-2008-12-190256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia</span></div><div class="casAuthors">Chen, Rong; Wierda, William G.; Chubb, Sherri; Hawtin, Rachael E.; Fox, Judith A.; Keating, Michael J.; Gandhi, Varsha; Plunkett, William</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4637-4645</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Inhibitors of cyclin-dependent kinases (Cdks) were reported to have activities in chronic lymphocytic leukemia cells by inhibiting Cdk7 and Cdk9, which control transcription.  Here we studied the novel Cdk inhibitor SNS-032, which exhibits potent and selective inhibitory activity against Cdk2, Cdk7, and Cdk9.  We hypothesized that transient inhibition of transcription by SNS-032 would decrease antiapoptotic proteins, resulting in cell death.  SNS-032 effectively killed chronic lymphocytic leukemia cells in vitro regardless of prognostic indicators and treatment history.  This was assocd. with inhibition of phosphorylation of RNA polymerase II and inhibition of RNA synthesis.  Consistent with the intrinsic turnover rates of their transcripts and proteins, antiapoptotic proteins, such as Mcl-1 and X-linked inhibitor of apoptosis protein (XIAP), were rapidly reduced on exposure to SNS-032, whereas Bcl-2 protein was not affected.  The initial decrease of Mcl-1 protein was the result of transcriptional inhibition rather than cleavage by caspase.  Compared with flavopiridol and roscovitine, SNS-032 was more potent, both in inhibition of RNA synthesis and at induction of apoptosis.  SNS-032 activity was readily reversible; removal of SNS-032 reactivated RNA polymerase II, which led to resynthesis of Mcl-1 and cell survival.  Thus, these data support the clin. development of SNS-032 in diseases that require short-lived oncoproteins for survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrosg5a-0E_5LVg90H21EOLACvtfcHk0lhMdVW08AaJPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvVyquro%253D&md5=b27a303a6ec8a28aefe720e981ed3c27</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-12-190256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-12-190256%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DR.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DChubb%26aufirst%3DS.%26aulast%3DHawtin%26aufirst%3DR.%2BE.%26aulast%3DFox%26aufirst%3DJ.%2BA.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DPlunkett%26aufirst%3DW.%26atitle%3DMechanism%2520of%2520action%2520of%2520SNS-032%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520in%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26issue%3D19%26spage%3D4637%26epage%3D4645%26doi%3D10.1182%2Fblood-2008-12-190256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathos, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, K. S.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitor, P276–00 induces apoptosis in multiple myeloma cells by inhibition of CDK9-T1 and RNA polymerase II-dependent transcription</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2010.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.leukres.2010.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=21216463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVSrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2011&pages=821-830&issue=6&author=S.+M.+Manoharauthor=M.+J.+Rathosauthor=V.+Sonawaneauthor=S.+V.+Raoauthor=K.+S.+Joshi&title=Cyclin-dependent+kinase+inhibitor%2C+P276%E2%80%9300+induces+apoptosis+in+multiple+myeloma+cells+by+inhibition+of+CDK9-T1+and+RNA+polymerase+II-dependent+transcription&doi=10.1016%2Fj.leukres.2010.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription</span></div><div class="casAuthors">Manohar, Sonal M.; Rathos, Maggie J.; Sonawane, Vinay; Rao, Shalini V.; Joshi, Kalpana S.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">821-830</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">P276-00 is a novel cyclin-dependent kinase inhibitor esp. potent for Cdk9-T1, Cdk4-D1 and Cdk1-B.  Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of malignant plasma cells.  Treatment of MM cell lines with P276-00 resulted in apoptosis that correlated with transcription inhibition and a significant decline in Mcl-1 protein levels with the appearance of cleaved PARP in these cells.  In vivo studies of P276-00 confirmed antitumor activity in RPMI-8226 xenograft.  These results suggest that P276-00 causes multiple myeloma cell death by disrupting the balance between cell survival and apoptosis through inhibition of transcription and downregulation of Mcl-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvm8H-guEyqrVg90H21EOLACvtfcHk0lhMdVW08AaJPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVSrtbs%253D&md5=792626fe7d151b94be7d0048a4e5dff8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2010.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2010.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DManohar%26aufirst%3DS.%2BM.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DSonawane%26aufirst%3DV.%26aulast%3DRao%26aufirst%3DS.%2BV.%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitor%252C%2520P276%25E2%2580%259300%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%2520by%2520inhibition%2520of%2520CDK9-T1%2520and%2520RNA%2520polymerase%2520II-dependent%2520transcription%26jtitle%3DLeuk.%2520Res.%26date%3D2011%26volume%3D35%26issue%3D6%26spage%3D821%26epage%3D830%26doi%3D10.1016%2Fj.leukres.2010.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, S.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma</span>. <i>Haematologica.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2059</span>– <span class="NLM_lpage">2068</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.191395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.3324%2Fhaematol.2018.191395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30076184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFynsrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=2059-2068&issue=12&author=S.+Kinoshitaauthor=T.+Ishidaauthor=A.+Itoauthor=T.+Naritaauthor=A.+Masakiauthor=S.+Suzukiauthor=T.+Yoshidaauthor=M.+Riauthor=S.+Kusumotoauthor=H.+Komatsuauthor=N.+Shimizuauthor=H.+Inagakiauthor=T.+Kurodaauthor=A.+Scholzauthor=R.+Uedaauthor=T.+Sandaauthor=S.+Iida&title=Cyclin-dependent+kinase+9+as+a+potential+specific+molecular+target+in+NK-cell+leukemia%2Flymphoma&doi=10.3324%2Fhaematol.2018.191395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma</span></div><div class="casAuthors">Kinoshita, Shiori; Ishida, Takashi; Ito, Asahi; Narita, Tomoko; Masaki, Ayako; Suzuki, Susumu; Yoshida, Takashi; Ri, Masaki; Kusumoto, Shigeru; Komatsu, Hirokazu; Shimizu, Norio; Inagaki, Hiroshi; Kuroda, Taruho; Scholz, Arne; Ueda, Ryuzo; Sanda, Takaomi; Iida, Shinsuke</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2059-2068</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">BAY 1143572 is a highly selective inhibitor of cyclin-dependent kinase 9/pos. transcription elongation factor b.  It has entered phase I clin. studies.  Here, we have assessed the utility of BAY 1143572 for treating natural killer (NK) cell leukemias/lymphomas that have a poor prognosis, namely extranodal NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia, in a preclin. mouse model in vivo as well as in tissue culture models in vitro.  Seven NK-cell leukemia/lymphoma lines and primary aggressive NK-cell leukemia cells from two individual patients were treated with BAY 1143572 in vitro.  Primary tumor cells from an aggressive NK-cell leukemia patient were used to establish a xenogeneic murine model for testing BAY 1143572 therapy.  Cyclin-dependent kinase 9 inhibition by BAY 1143572 resulted in prevention of phosphorylation at the serine 2 site of the C-terminal domain of RNA polymerase II.  This resulted in lower c-Myc and Mcl-1 levels in the cell lines, causing growth inhibition and apoptosis.  In aggressive NK-cell leukemia primary tumor cells, exposure to BAY 1143572 in vitro resulted in decreased Mcl-1 protein levels resulting from inhibition of RNA polymerase II C-terminal domain phosphorylation at the serine 2 site.  Orally administering BAY 1143572 once per day to aggressive NK-cell leukemia-bearing mice resulted in lower tumor cell infiltration into the bone marrow, liver, and spleen, with less export to the periphery relative to control mice.  The treated mice also had a survival advantage over the untreated controls.  The specific small mol. targeting agent BAY1143572 has potential for treating NK-cell leukemia/lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw1ARkWiEOirVg90H21EOLACvtfcHk0ljJQMgoIsWiSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFynsrvN&md5=39663108ae318d64625dcbca58c56ea4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.191395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.191395%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DS.%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNarita%26aufirst%3DT.%26aulast%3DMasaki%26aufirst%3DA.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DRi%26aufirst%3DM.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DKuroda%26aufirst%3DT.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DUeda%26aufirst%3DR.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DIida%26aufirst%3DS.%26atitle%3DCyclin-dependent%2520kinase%25209%2520as%2520a%2520potential%2520specific%2520molecular%2520target%2520in%2520NK-cell%2520leukemia%252Flymphoma%26jtitle%3DHaematologica.%26date%3D2018%26volume%3D103%26issue%3D12%26spage%3D2059%26epage%3D2068%26doi%3D10.3324%2Fhaematol.2018.191395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9</span>. <i>Artif. Cells, Nanomed., Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">980</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1080/21691401.2017.1351983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F21691401.2017.1351983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28701053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOrt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=980-984&author=Y.+B.+Luauthor=L.+Tangauthor=Q.+Zhangauthor=Z.+P.+Zhangauthor=W.+Wei&title=MicroRNA-613+inhibits+the+progression+of+gastric+cancer+by+targeting+CDK9&doi=10.1080%2F21691401.2017.1351983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9</span></div><div class="casAuthors">Lu, Yebin; Tang, Ling; Zhang, Qi; Zhang, Zhipeng; Wei, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Artificial Cells, Nanomedicine, and Biotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">980-984</span>CODEN:
                <span class="NLM_cas:coden">ACNBCI</span>;
        ISSN:<span class="NLM_cas:issn">2169-141X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">MicroRNAs (miRNAs) play an important role in the development and progression of human malignancy. miR-613, as a tumor suppressor, was reported to decrease in several tumors.  However, the expression levels and role of miR-613 in gastric cancer remain unknown.  In this study, we found that miR-613 was evidently downregulated in gastric cancer tissue and cell.  The functional anal. showed that miR-613 suppressed cell proliferation and migration in gastric cancer.  Next, the dual-luciferase reporter system supported CDK9 as a direct target gene of miR-613. miR-613 mimics evidently repressed CDK9 expression in gastric cancer cells.  Furthermore, we found that CDK9 in upregulated in gastric cancer and the CDK9 expression levels were inversely correlated with that of miR-613 in gastric cancer tissues.  Overall, the results revealed that miR-613, as a tumor suppressor, involves in gastric cancer progression and metastasis by targeting CDK9, implying a novel potential therapeutic target for the treatment of gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBDPuYFtGGCLVg90H21EOLACvtfcHk0ljJQMgoIsWiSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOrt7fF&md5=2bb6c8710a92e16d3cd201a00a8b2b98</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1080%2F21691401.2017.1351983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21691401.2017.1351983%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%2BB.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DZ.%2BP.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DMicroRNA-613%2520inhibits%2520the%2520progression%2520of%2520gastric%2520cancer%2520by%2520targeting%2520CDK9%26jtitle%3DArtif.%2520Cells%252C%2520Nanomed.%252C%2520Biotechnol.%26date%3D2018%26volume%3D46%26spage%3D980%26epage%3D984%26doi%3D10.1080%2F21691401.2017.1351983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornicek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Z.</span></span> <span> </span><span class="NLM_article-title">Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.7150/jca.35426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.7150%2Fjca.35426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31892980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVSltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=132-141&author=S.+Shenauthor=D.+C.+Deanauthor=Z.+Yuauthor=F.+Hornicekauthor=Q.+Kanauthor=Z.+Duan&title=Aberrant+CDK9+expression+within+chordoma+tissues+and+the+therapeutic+potential+of+a+selective+CDK9+inhibitor+LDC000067&doi=10.7150%2Fjca.35426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067</span></div><div class="casAuthors">Shen, Shen; Dean, Dylan C.; Yu, Zujiang; Hornicek, Francis; Kan, Quancheng; Duan, Zhenfeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer (Wyoming, Australia)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">132-141</span>CODEN:
                <span class="NLM_cas:coden">JCWAAL</span>;
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher Pty Ltd.</span>)
        </div><div class="casAbstract">Objectives: Chordomas are slow-growing malignancies that commonly affect vital neurol. structures.  These neoplasms are highly resistant to current chemotherapeutic regimens and often recur after surgical intervention.  Therefore, there is an urgent need to identify mol. targets and more robust drugs to improve chordoma patient outcomes.  It is well accepted that cyclin-dependent protein kinase 9 (CDK9) has tumorigenic roles in various cancers; however, the expression and significance of CDK9 in chordoma remains unknown.  Methods: Expression of CDK9 in chordoma cell lines and tumor tissues was examd. by Western blot and immunohistochem. (IHC).  The correlation between CDK9 expression in patient tissues and clin. prognosis was analyzed.  The functional roles of CDK9 in chordoma were investigated after the addn. of small interfering RNA (siRNA) and CDK9 inhibitor (LDC000067).  Cell growth and proliferation were assessed with MTT and clonogenic assays.  The effect of CDK9 inhibition on chordoma cells was further evaluated with a three-dimensional (3D) cell culture model which mimics the in vivo environment.  Results: CDK9 was expressed in both chordoma cell lines and chordoma tissues.  High- expression of CDK9 correlated with recurrence and poor outcomes for chordoma patients.  CDK9 silencing with siRNA decreased growth and proliferation of chordoma cells and lowered levels of Mcl-1 and RNA polymerase II (RNAP II) phosphorylation.  Pharmacol. inhibition of CDK9 with the small mol. inhibitor LDC000067 reduced cell growth, supported apoptosis, suppressed cell colony formation in a clonogenic assay, and decreased spheroid growth in 3D culture.  Conclusion: We demonstrate that CDK9 expression in chordoma correlates with patient outcome, and, when inhibited, chordoma cell growth and proliferation significantly decreases.  Taken together, these results support CDK9 as an emerging potential target in chordoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv8b4mxaKrd7Vg90H21EOLACvtfcHk0ljJQMgoIsWiSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVSltLs%253D&md5=5e1b393e63b83609d5a37e6debea188d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.7150%2Fjca.35426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.35426%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DDean%26aufirst%3DD.%2BC.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DHornicek%26aufirst%3DF.%26aulast%3DKan%26aufirst%3DQ.%26aulast%3DDuan%26aufirst%3DZ.%26atitle%3DAberrant%2520CDK9%2520expression%2520within%2520chordoma%2520tissues%2520and%2520the%2520therapeutic%2520potential%2520of%2520a%2520selective%2520CDK9%2520inhibitor%2520LDC000067%26jtitle%3DJ.%2520Cancer%26date%3D2020%26volume%3D11%26spage%3D132%26epage%3D141%26doi%3D10.7150%2Fjca.35426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharifnia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wawer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sizemore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawlor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogswell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornicek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Root, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Small-molecule targeting of brachyury transcription factor addiction in chordoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0312-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fs41591-018-0312-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30664779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFGru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=292-300&issue=2&author=T.+Sharifniaauthor=M.+J.+Wawerauthor=T.+Chenauthor=Q.+Y.+Huangauthor=B.+A.+Weirauthor=A.+Sizemoreauthor=M.+A.+Lawlorauthor=A.+Goodaleauthor=G.+S.+Cowleyauthor=F.+Vazquezauthor=C.+J.+Ottauthor=J.+M.+Francisauthor=S.+Sassiauthor=P.+Cogswellauthor=H.+E.+Sheppardauthor=T.+Zhangauthor=N.+S.+Grayauthor=P.+A.+Clarkeauthor=J.+Blaggauthor=P.+Workmanauthor=J.+Sommerauthor=F.+Hornicekauthor=D.+E.+Rootauthor=W.+C.+Hahnauthor=J.+E.+Bradnerauthor=K.+K.+Wongauthor=P.+A.+Clemonsauthor=C.+Y.+Linauthor=J.+D.+Kotzauthor=S.+L.+Schreiber&title=Small-molecule+targeting+of+brachyury+transcription+factor+addiction+in+chordoma&doi=10.1038%2Fs41591-018-0312-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule targeting of brachyury transcription factor addiction in chordoma</span></div><div class="casAuthors">Sharifnia, Tanaz; Wawer, Mathias J.; Chen, Ting; Huang, Qing-Yuan; Weir, Barbara A.; Sizemore, Ann; Lawlor, Matthew A.; Goodale, Amy; Cowley, Glenn S.; Vazquez, Francisca; Ott, Christopher J.; Francis, Joshua M.; Sassi, Slim; Cogswell, Patricia; Sheppard, Hadley E.; Zhang, Tinghu; Gray, Nathanael S.; Clarke, Paul A.; Blagg, Julian; Workman, Paul; Sommer, Josh; Hornicek, Francis; Root, David E.; Hahn, William C.; Bradner, James E.; Wong, Kwok K.; Clemons, Paul A.; Lin, Charles Y.; Kotz, Joanne D.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">292-300</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Chordoma is a primary bone cancer with no approved therapy1.  The identification of therapeutic targets in this disease has been challenging due to the infrequent occurrence of clin. actionable somatic mutations in chordoma tumors2,3.  Here we describe the discovery of therapeutically targetable chordoma dependencies via genome-scale CRISPR-Cas9 screening and focused small-mol. sensitivity profiling.  These systematic approaches reveal that the developmental transcription factor T (brachyury; TBXT) is the top selectively essential gene in chordoma, and that transcriptional cyclin-dependent kinase (CDK) inhibitors targeting CDK7/12/13 and CDK9 potently suppress chordoma cell proliferation.  In other cancer types, transcriptional CDK inhibitors have been obsd. to downregulate highly expressed, enhancer-assocd. oncogenic transcription factors4,5.  In chordoma, we find that T is assocd. with a 1.5-Mb region contg. 'super-enhancers' and is the most highly expressed super-enhancer-assocd. transcription factor.  Notably, transcriptional CDK inhibition leads to preferential and concn.-dependent downregulation of cellular brachyury protein levels in all models tested.  In vivo, CDK7/12/13-inhibitor treatment substantially reduces tumor growth.  Together, these data demonstrate small-mol. targeting of brachyury transcription factor addiction in chordoma, identify a mechanism of T gene regulation that underlies this therapeutic strategy, and provide a blueprint for applying systematic genetic and chem. screening approaches to discover vulnerabilities in genomically quiet cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2B8MeRhHUNrVg90H21EOLACvtfcHk0lj7XZINis_Rbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFGru7o%253D&md5=c69a979a760a679c8051f9b1f308d61a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0312-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0312-3%26sid%3Dliteratum%253Aachs%26aulast%3DSharifnia%26aufirst%3DT.%26aulast%3DWawer%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DQ.%2BY.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DSizemore%26aufirst%3DA.%26aulast%3DLawlor%26aufirst%3DM.%2BA.%26aulast%3DGoodale%26aufirst%3DA.%26aulast%3DCowley%26aufirst%3DG.%2BS.%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DFrancis%26aufirst%3DJ.%2BM.%26aulast%3DSassi%26aufirst%3DS.%26aulast%3DCogswell%26aufirst%3DP.%26aulast%3DSheppard%26aufirst%3DH.%2BE.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DSommer%26aufirst%3DJ.%26aulast%3DHornicek%26aufirst%3DF.%26aulast%3DRoot%26aufirst%3DD.%2BE.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DKotz%26aufirst%3DJ.%2BD.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DSmall-molecule%2520targeting%2520of%2520brachyury%2520transcription%2520factor%2520addiction%2520in%2520chordoma%26jtitle%3DNat.%2520Med.%26date%3D2019%26volume%3D25%26issue%3D2%26spage%3D292%26epage%3D300%26doi%3D10.1038%2Fs41591-018-0312-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borowczak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczerbowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzanka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szylberg, Ł.</span></span> <span> </span><span class="NLM_article-title">CDK9: therapeutic perspective in HCC therapy</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.2174/1568009620666200212124357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.2174%2F1568009620666200212124357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=32048975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOqsL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=318-324&issue=5&author=J.+Borowczakauthor=K.+Szczerbowskiauthor=E.+Stecauthor=D.+Grzankaauthor=%C5%81.+Szylberg&title=CDK9%3A+therapeutic+perspective+in+HCC+therapy&doi=10.2174%2F1568009620666200212124357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9: Therapeutic Perspective in HCC Therapy</span></div><div class="casAuthors">Borowczak, Jedrzej; Szczerbowski, Krzysztof; Stec, Ewa; Grzanka, Dariusz; Szylberg, Lukasz</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">318-324</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  CDK9 is an important cell-cycle control enzyme essential in transcription, elongation, and mRNA maturation.  Overexpression of CDK9 has been reported in several diseases, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and malignant melanoma.  Recent research revealed that CDK9-inhibitors have a major impact on the induction of apoptosis in hepatocellular carcinoma (HCC) cell lines.  Despite surprisingly promising results in in vitro and in vivo research, no CDK9 related therapy is currently allowed in cases of HCC.  Furthermore, due to their high specificity, the inhibitors had no effects on unaltered hepatocytes and no toxic effects were shown.  Considering that they were well tolerated and showed relatively few severe side-effects in mice, CDK9- inhibitors would seem to be promising targets in HCC biomarker-guided immunotherapy.  Studies have verified that CDK9 has a pivotal role in c-Myc-mediated tumor growth and CDK9 inhibitors inhibit not only its progression but diametrically decrease both the mass and size of HCC nodules.  CDK9-inhibitors seem to be a promising target in HCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHITSDgNzV4bVg90H21EOLACvtfcHk0lj7XZINis_Rbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOqsL7F&md5=ffba883e93f84117c7d6f827e48d3932</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2174%2F1568009620666200212124357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009620666200212124357%26sid%3Dliteratum%253Aachs%26aulast%3DBorowczak%26aufirst%3DJ.%26aulast%3DSzczerbowski%26aufirst%3DK.%26aulast%3DStec%26aufirst%3DE.%26aulast%3DGrzanka%26aufirst%3DD.%26aulast%3DSzylberg%26aufirst%3D%25C5%2581.%26atitle%3DCDK9%253A%2520therapeutic%2520perspective%2520in%2520HCC%2520therapy%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2020%26volume%3D20%26issue%3D5%26spage%3D318%26epage%3D324%26doi%3D10.2174%2F1568009620666200212124357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span> <span> </span><span class="NLM_article-title">Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111535</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2019.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31376566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111535&author=X.+Wangauthor=C.+Yuauthor=C.+Wangauthor=Y.+Maauthor=T.+Wangauthor=Y.+Liauthor=Z.+Huangauthor=M.+Zhouauthor=P.+Sunauthor=J.+Zhengauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=Novel+cyclin-dependent+kinase+9+%28CDK9%29+inhibitor+with+suppression+of+cancer+stemness+activity+against+non-small-cell+lung+cancer&doi=10.1016%2Fj.ejmech.2019.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer</span></div><div class="casAuthors">Wang, Xin; Yu, Chenhua; Wang, Cheng; Ma, Yakun; Wang, Tianqi; Li, Yao; Huang, Zhi; Zhou, Manqian; Sun, Peiqing; Zheng, Jianyu; Yang, Shengyong; Fan, Yan; Xiang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111535</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel, highly potent, selective CDK9 inhibitors with cancer stem cells (CSCs) inhibition activity were designed and synthesized for non-small-cell lung cancer (NSCLC) therapy.  Structure-activity relationship anal. based on enzymic and cellular activities led to the discovery of a promising inhibitor 21e(I).  I potently inhibited CDK9 with IC50 value of 11 nM and suppressed the stemness properties of NSCLC effectively.  It could decrease the stemness phenotypes of NSCLC cells, including tumor sphere formation, side-population and stemness markers abundance.  I displayed good selectivity over the CDK family kinases and kinase profiling assay against 381 kinases.  In addn., I inhibited cell proliferation, colony-formation, and cell cycle progression and induced apoptosis in NSCLC.  In H1299 xenograft mouse model, a once-daily dose of I at 20 mg/kg significantly suppressed the tumor growth without obvious toxicity.  Studies of mechanisms of action indicated that I efficiently inhibited CDK9 signaling pathway and stemness both in vitro and in vivo.  Collectively, I as a novel CDK9 inhibitor with CSCs inhibition properties could be a promising agent for the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_2AOdlSLbIrVg90H21EOLACvtfcHk0ljmGIX5-GiZJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3N&md5=b088226c0d124c27c921c2504a16a665</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DNovel%2520cyclin-dependent%2520kinase%25209%2520%2528CDK9%2529%2520inhibitor%2520with%2520suppression%2520of%2520cancer%2520stemness%2520activity%2520against%2520non-small-cell%2520lung%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111535%26doi%3D10.1016%2Fj.ejmech.2019.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Karstedt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abd El Hay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arce, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montinaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papenfuss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Bahrawy, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walczak, H.</span></span> <span> </span><span class="NLM_article-title">Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/cdd.2013.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fcdd.2013.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24362439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvF2rtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=491-502&issue=3&author=J.+Lemkeauthor=S.+von+Karstedtauthor=M.+Abd+El+Hayauthor=A.+Contiauthor=F.+Arceauthor=A.+Montinaroauthor=K.+Papenfussauthor=M.+A.+El-Bahrawyauthor=H.+Walczak&title=Selective+CDK9+inhibition+overcomes+TRAIL+resistance+by+concomitant+suppression+of+cFlip+and+Mcl-1&doi=10.1038%2Fcdd.2013.179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1</span></div><div class="casAuthors">Lemke, J.; von Karstedt, S.; Abd El Hay, M.; Conti, A.; Arce, F.; Montinaro, A.; Papenfuss, K.; El-Bahrawy, M. A.; Walczak, H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">491-502</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in many cancer cells without causing toxicity in vivo.  However, to date, TRAIL-receptor agonists have only shown limited therapeutic benefit in clin. trials.  This can, most likely, be attributed to the fact that 50% of all cancer cell lines and most primary human cancers are TRAIL resistant.  Consequently, future TRAIL-based therapies will require the addn. of sensitizing agents that remove crucial blocks in the TRAIL apoptosis pathway.  Here, we identify PIK-75, a small mol. inhibitor of the p110α isoform of phosphoinositide-3 kinase (PI3K), as an exceptionally potent TRAIL apoptosis sensitizer.  Surprisingly, PI3K inhibition was not responsible for this activity.  A kinome-wide in vitro screen revealed that PIK-75 strongly inhibits a panel of 27 kinases in addn. to p110α.  Within this panel, we identified cyclin-dependent kinase 9 (CDK9) as responsible for TRAIL resistance of cancer cells.  Combination of CDK9 inhibition with TRAIL effectively induced apoptosis even in highly TRAIL-resistant cancer cells.  Mechanistically, CDK9 inhibition resulted in downregulation of cellular FLICE-like inhibitory protein (cFlip) and Mcl-1 at both the mRNA and protein levels.  Concomitant cFlip and Mcl-1 downregulation was required and sufficient for TRAIL sensitization by CDK9 inhibition.  When evaluating cancer selectivity of TRAIL combined with SNS-032, the most selective and clin. used inhibitor of CDK9, we found that a panel of mostly TRAIL-resistant non-small cell lung cancer cell lines was readily killed, even at low concns. of TRAIL.  Primary human hepatocytes did not succumb to the same treatment regime, defining a therapeutic window.  Importantly, TRAIL in combination with SNS-032 eradicated established, orthotopic lung cancer xenografts in vivo.  Based on the high potency of CDK9 inhibition as a cancer cell-selective TRAIL-sensitizing strategy, we envisage the development of new, highly effective cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdFS2sPKgO2rVg90H21EOLACvtfcHk0ljmGIX5-GiZJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvF2rtrjM&md5=bfbbd7988333ff709670786628d2b62c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2013.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2013.179%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DJ.%26aulast%3Dvon%2BKarstedt%26aufirst%3DS.%26aulast%3DAbd%2BEl%2BHay%26aufirst%3DM.%26aulast%3DConti%26aufirst%3DA.%26aulast%3DArce%26aufirst%3DF.%26aulast%3DMontinaro%26aufirst%3DA.%26aulast%3DPapenfuss%26aufirst%3DK.%26aulast%3DEl-Bahrawy%26aufirst%3DM.%2BA.%26aulast%3DWalczak%26aufirst%3DH.%26atitle%3DSelective%2520CDK9%2520inhibition%2520overcomes%2520TRAIL%2520resistance%2520by%2520concomitant%2520suppression%2520of%2520cFlip%2520and%2520Mcl-1%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2014%26volume%3D21%26issue%3D3%26spage%3D491%26epage%3D502%26doi%3D10.1038%2Fcdd.2013.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajput, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoog, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C. X.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer</span>. <i>Oncotarget.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">56864</span>– <span class="NLM_lpage">56875</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.10870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.18632%2Foncotarget.10870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27486754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ntFSguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=56864-56875&issue=35&author=S.+Rajputauthor=N.+Kheraauthor=Z.+Guoauthor=J.+Hoogauthor=S.+Liauthor=C.+X.+Ma&title=Inhibition+of+cyclin+dependent+kinase+9+by+dinaciclib+suppresses+cyclin+B1+expression+and+tumor+growth+in+triple+negative+breast+cancer&doi=10.18632%2Foncotarget.10870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer</span></div><div class="casAuthors">Rajput Sandeep; Khera Nimmish; Guo Zhanfang; Hoog Jeremy; Li Shunqiang; Ma Cynthia X; Li Shunqiang; Ma Cynthia X</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">56864-56875</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are potential cancer therapeutic targets because of their critical role in promoting cell growth.  Dinaciclib is a novel CDK inhibitor currently under clinical evaluation for the treatment of advanced malignancies.  In this study, we demonstrated the anti-tumor activity of dinaciclib in triple negative breast cancer (TNBC) patient derived xenograft (PDX) and cell lines in vitro and in vivo.  Treatment with dinaciclib induced cell cycle arrest at G2/M phase and marked apoptosis.  These changes were accompanied by reduced phosphorylation of CDK1 and retinoblastoma (Rb) protein and decreased protein levels of cyclin B1, cMYC and survivin.  We further demonstrated that siRNA knockdown of CDK9, the kinase subunit of positive transcription elongation factor b (P-TEFb), instead of CDK1 or CDK2, reduced the levels of cyclin B1 and MYC in TNBC cell lines.  These data support the importance of CDK9, in addition to CDK1, in mediating the growth inhibitory effect of dinaciclib in TNBC.  Further investigation of CDK9 as a therapeutic target in TNBC is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2TNpFAv5mrtbHMBt0mMIXfW6udTcc2eZsJUn8UNJZl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ntFSguw%253D%253D&md5=766c27ec2b0a446f4e9a35b2a922edb6</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10870%26sid%3Dliteratum%253Aachs%26aulast%3DRajput%26aufirst%3DS.%26aulast%3DKhera%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DHoog%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DC.%2BX.%26atitle%3DInhibition%2520of%2520cyclin%2520dependent%2520kinase%25209%2520by%2520dinaciclib%2520suppresses%2520cyclin%2520B1%2520expression%2520and%2520tumor%2520growth%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DOncotarget.%26date%3D2016%26volume%3D7%26issue%3D35%26spage%3D56864%26epage%3D56875%26doi%3D10.18632%2Foncotarget.10870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Göthert, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imsak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möllmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göbel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dührsen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choidas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dürig, J.</span></span> <span> </span><span class="NLM_article-title">Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia</span>. <i>Oncotarget.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">41</span>),  <span class="NLM_fpage">26353</span>– <span class="NLM_lpage">26369</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.18632%2Foncotarget.25293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29899864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC1MbntVGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=26353-26369&issue=41&author=J.+R.+G%C3%B6thertauthor=R.+Imsakauthor=M.+M%C3%B6llmannauthor=S.+Kesperauthor=M.+G%C3%B6belauthor=U.+D%C3%BChrsenauthor=A.+Scholzauthor=U.+L%C3%BCckingauthor=M.+Baumannauthor=A.+Ungerauthor=C.+Schultz-Fademrechtauthor=B.+Kleblauthor=J.+Eickhoffauthor=A.+Choidasauthor=J.+D%C3%BCrig&title=Potent+anti-leukemic+activity+of+a+specific+cyclin-dependent+kinase+9+inhibitor+in+mouse+models+of+chronic+lymphocytic+leukemia&doi=10.18632%2Foncotarget.25293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia</span></div><div class="casAuthors">Gothert Joachim R; Imsak Roze; Mollmann Michael; Kesper Stefanie; Gobel Maria; Duhrsen Ulrich; Durig Jan; Scholz Arne; Lucking Ulrich; Baumann Matthias; Unger Anke; Schultz-Fademrecht Carsten; Klebl Bert; Eickhoff Jan; Choidas Axel</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">26353-26369</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Onset of progression even during therapy with novel drugs remains an issue in chronic lymphocytic leukemia (CLL).  Thus, there is ongoing demand for novel agents.  Approaches targeting cyclin-dependent kinases (CDK) have reached the clinical trial stage.  CDK9 mediating RNA transcriptional elongation is the evolving pivotal CLL CDK inhibitor target.  However, more CDK9 selective compounds are desirable.  Here, we describe the CDK9 inhibitor LDC526 displaying a low nanomolar biochemical activity against CDK9 and an at least 50-fold selectivity against other CDKs.  After demonstrating in vitro MEC-1 cell line and primary human CLL cell cytotoxicity we evaluated the LDC526 in vivo effect on human CLL cells transplanted into NOD/scid/γc(null) (NSG) mice.  LDC526 administration (75 mg/kg) for 5 days resulted in a 77% reduction of human CLL cells in NSG spleens compared to carrier control treatment.  Next, we longitudinally studied the LDC526 impact on circulating CLL cells in the TCL1 transgenic mouse model.  LDC526 (50 mg/kg) administration for two days led to a 16-fold reduction of blood CLL cell numbers.  Remarkably, residual CLL cells exhibited significantly increased intracellular BCL-2 levels.  However, the LDC526 cytotoxic effect was not restricted to CLL cells as also declining numbers of normal B and T lymphocytes were observed in LDC526 treated TCL1 mice.  Taken together, our in vivo data provide a strong rational for continued LDC526 development in CLL therapy and argue for the combination with BCL-2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFHuzsbtBNX11C8OJBvdfbfW6udTcc2ebgUFKO6llGR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbntVGrtA%253D%253D&md5=3f8862deb166fb1e343f0714a538a13b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25293%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B6thert%26aufirst%3DJ.%2BR.%26aulast%3DImsak%26aufirst%3DR.%26aulast%3DM%25C3%25B6llmann%26aufirst%3DM.%26aulast%3DKesper%26aufirst%3DS.%26aulast%3DG%25C3%25B6bel%26aufirst%3DM.%26aulast%3DD%25C3%25BChrsen%26aufirst%3DU.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DD%25C3%25BCrig%26aufirst%3DJ.%26atitle%3DPotent%2520anti-leukemic%2520activity%2520of%2520a%2520specific%2520cyclin-dependent%2520kinase%25209%2520inhibitor%2520in%2520mouse%2520models%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DOncotarget.%26date%3D2018%26volume%3D9%26issue%3D41%26spage%3D26353%26epage%3D26369%26doi%3D10.18632%2Foncotarget.25293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kats, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidacs, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortt, J.</span></span> <span> </span><span class="NLM_article-title">CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1437</span>– <span class="NLM_lpage">1441</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fleu.2015.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25578475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOjt7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=1437-1441&issue=6&author=G.+P.+Gregoryauthor=S.+J.+Hoggauthor=L.+M.+Katsauthor=E.+Vidacsauthor=A.+J.+Bakerauthor=O.+Gilanauthor=M.+Lefebureauthor=B.+P.+Martinauthor=M.+A.+Dawsonauthor=R.+W.+Johnstoneauthor=J.+Shortt&title=CDK9+inhibition+by+dinaciclib+potently+suppresses+Mcl-1+to+induce+durable+apoptotic+responses+in+aggressive+MYC-driven+B-cell+lymphoma+in+vivo&doi=10.1038%2Fleu.2015.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo</span></div><div class="casAuthors">Gregory, G. P.; Hogg, S. J.; Kats, L. M.; Vidacs, E.; Baker, A. J.; Gilan, O.; Lefebure, M.; Martin, B. P.; Dawson, M. A.; Johnstone, R. W.; Shortt, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1437-1441</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8lI6Bulr7brVg90H21EOLACvtfcHk0lhmQTEScWrawg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOjt7bI&md5=2eb8703bec387077e5b2e506b6d281f8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.10%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DG.%2BP.%26aulast%3DHogg%26aufirst%3DS.%2BJ.%26aulast%3DKats%26aufirst%3DL.%2BM.%26aulast%3DVidacs%26aufirst%3DE.%26aulast%3DBaker%26aufirst%3DA.%2BJ.%26aulast%3DGilan%26aufirst%3DO.%26aulast%3DLefebure%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DB.%2BP.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DShortt%26aufirst%3DJ.%26atitle%3DCDK9%2520inhibition%2520by%2520dinaciclib%2520potently%2520suppresses%2520Mcl-1%2520to%2520induce%2520durable%2520apoptotic%2520responses%2520in%2520aggressive%2520MYC-driven%2520B-cell%2520lymphoma%2520in%2520vivo%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26issue%3D6%26spage%3D1437%26epage%3D1441%26doi%3D10.1038%2Fleu.2015.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahaman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokman, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehler, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK9 for treatment of colorectal cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2178</span>– <span class="NLM_lpage">2193</span>, <span class="refDoi"> DOI: 10.1002/1878-0261.12559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1002%2F1878-0261.12559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31398271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXms1Sgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=2178-2193&issue=10&author=M.+H.+Rahamanauthor=F.+Lamauthor=L.+Zhongauthor=T.+Teoauthor=J.+Adamsauthor=M.+Yuauthor=R.+W.+Milneauthor=C.+Pepperauthor=N.+A.+Lokmanauthor=C.+Ricciardelliauthor=M.+K.+Oehlerauthor=S.+Wang&title=Targeting+CDK9+for+treatment+of+colorectal+cancer&doi=10.1002%2F1878-0261.12559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK9 for treatment of colorectal cancer</span></div><div class="casAuthors">Rahaman, Muhammed H.; Lam, Frankie; Zhong, Longjin; Teo, Theodosia; Adams, Julian; Yu, Mingfeng; Milne, Robert W.; Pepper, Chris; Lokman, Noor A.; Ricciardelli, Carmela; Oehler, Martin K.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2178-2193</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1878-0261</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Colorectal cancer (CRC) remains one of the most lethal human malignancies, and pursuit of new therapeutic targets for treatment has been a major research focus.  Cyclin-dependent kinase 9 (CDK9), which plays a crucial role in transcription, has emerged as a target for cancer treatment.  CDKI-73, one of the most potent and pharmacol. superior CDK9 inhibitors, has demonstrated excellent anti-tumor efficacy against several types of cancers.  In this study, we evaluated its therapeutic potential against CRC.  CDKI-73 elicited high cytotoxicity against all colon cancer cell lines tested.  Cell cycle and apoptosis anal. in HCT 116 and HT29 cells revealed that CDKI-73 induced cell death without accumulation of DNA at any phase of the cell cycle.  Moreover, it caused depolarization of mitochondrial membrane, leading to caspase-independent apoptosis.  Knockdown by shRNA demonstrated the CDK9-targeted mechanism of CDKI-73, which also affected the Mnk/eIF4E signaling axis.  In addn., RT-qPCR anal. showed that CDKI-73 down-regulated multiple pro-survival factors at the mRNA level.  Its in vivo anti-tumor efficacy was further evaluated in Balb/c nude mice bearing HCT 116 xenograft tumors.  CDKI-73 significantly inhibited tumor growth (***P < 0.001) without overt toxicity.  Anal. of the tumor tissues collected from the xenografted animals confirmed that the in vivo anti-tumor efficacy was assocd. with CDK9 targeting of CDKI-73.  Overall, this study provides compelling evidence that CDKI-73 is a promising drug candidate for treating colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm7AJZ0UvI1LVg90H21EOLACvtfcHk0lhmQTEScWrawg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXms1Sgt7s%253D&md5=8d8ca95e8950eda3588ae729d4447916</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2F1878-0261.12559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1878-0261.12559%26sid%3Dliteratum%253Aachs%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DLokman%26aufirst%3DN.%2BA.%26aulast%3DRicciardelli%26aufirst%3DC.%26aulast%3DOehler%26aufirst%3DM.%2BK.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520CDK9%2520for%2520treatment%2520of%2520colorectal%2520cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2019%26volume%3D13%26issue%3D10%26spage%3D2178%26epage%3D2193%26doi%3D10.1002%2F1878-0261.12559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieerkehazhi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">29090</span>, <span class="refDoi"> DOI: 10.1038/srep29090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fsrep29090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27378523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFahtL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=29090&author=Z.+Chenauthor=Z.+Wangauthor=J.+C.+Pangauthor=Y.+Yuauthor=S.+Bieerkehazhiauthor=J.+Luauthor=T.+Huauthor=Y.+Zhaoauthor=X.+Xuauthor=H.+Zhangauthor=J.+S.+Yiauthor=S.+Liuauthor=J.+Yang&title=Multiple+CDK+inhibitor+dinaciclib+suppresses+neuroblastoma+growth+via+inhibiting+CDK2+and+CDK9+activity&doi=10.1038%2Fsrep29090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity</span></div><div class="casAuthors">Chen, Zhenghu; Wang, Zhenyu; Pang, Jonathan C.; Yu, Yang; Bieerkehazhi, Shayahati; Lu, Jiaxiong; Hu, Ting; Zhao, Yanling; Xu, Xin; Zhang, Hong; Yi, Joanna S.; Liu, Shangfeng; Yang, Jianhua</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29090</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma (NB), the most common extracranial solid tumor of childhood, is responsible for approx. 15% of cancer-related mortality in children.  Aberrant activation of cyclin-dependent kinases (CDKs) has been shown to contribute to tumor cell progression in many cancers including NB.  Therefore, small mol. inhibitors of CDKs comprise a strategic option in cancer therapy.  Here we show that a novel multiple-CDK inhibitor, dinaciclib (SCH727965, MK-7965), exhibits potent anti-proliferative effects on a panel of NB cell lines by blocking the activity of CDK2 and CDK9.  Dinaciclib also significantly sensitized NB cell lines to the treatment of chemotherapeutic agents such as doxorubicin (Dox) and etoposide (VP-16).  Furthermore, dinaciclib revealed in vivo antitumor efficacy in an orthotopic xenograft mouse model of two NB cell lines and blocked tumor development in the TH-MYCN transgenic NB mouse model.  Taken together, this study suggests that CDK2 and CDK9 are potential therapeutic targets in NB and that abrogating CDK2 and CDK9 activity by small mols. like dinaciclib is a promising strategy and a treatment option for NB patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpobqy7FGRmgLVg90H21EOLACvtfcHk0lh7GlbnP7D5sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFahtL7M&md5=056d13b71230bd6cbe127371ea5ca3f3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fsrep29090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep29090%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DPang%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DBieerkehazhi%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYi%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DMultiple%2520CDK%2520inhibitor%2520dinaciclib%2520suppresses%2520neuroblastoma%2520growth%2520via%2520inhibiting%2520CDK2%2520and%2520CDK9%2520activity%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D29090%26doi%3D10.1038%2Fsrep29090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span> </span><span class="NLM_article-title">Clarivate Analytics Integrity</span>. <a href="https://integrity.clarivate.com" class="extLink">https://integrity.clarivate.com</a> (accessed April 10, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clarivate+Analytics+Integrity.+https%3A%2F%2Fintegrity.clarivate.com+%28accessed+April+10%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DClarivate%2520Analytics%2520Integrity" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanasa, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andritsos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilove, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligaris-Cappio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblond, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bühler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grever, M. R.</span></span> <span> </span><span class="NLM_article-title">Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2015.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.leukres.2015.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25804339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFCis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=495-500&issue=5&author=M.+C.+Lanasaauthor=L.+Andritsosauthor=J.+R.+Brownauthor=J.+Gabriloveauthor=F.+Caligaris-Cappioauthor=P.+Ghiaauthor=R.+A.+Larsonauthor=T.+J.+Kippsauthor=V.+Leblondauthor=D.+W.+Milliganauthor=A.+Janssensauthor=A.+J.+Johnsonauthor=N.+A.+Heeremaauthor=A.+B%C3%BChlerauthor=S.+Stilgenbauerauthor=J.+Devinauthor=M.+Hallekauthor=J.+C.+Byrdauthor=M.+R.+Grever&title=Final+results+of+EFC6663%3A+a+multicenter%2C+international%2C+phase+2+study+of+alvocidib+for+patients+with+fludarabine-refractory+chronic+lymphocytic+leukemia&doi=10.1016%2Fj.leukres.2015.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia</span></div><div class="casAuthors">Lanasa, Mark C.; Andritsos, Leslie; Brown, Jennifer R.; Gabrilove, Janice; Caligaris-Cappio, Federico; Ghia, Paolo; Larson, Richard A.; Kipps, Thomas J.; Leblond, Veronique; Milligan, Donald W.; Janssens, Ann; Johnson, Amy J.; Heerema, Nyla A.; Buhler, Andreas; Stilgenbauer, Stephan; Devin, Jeanne; Hallek, Michael; Byrd, John C.; Grever, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">495-500</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Early phase studies of alvocidib showed activity in relapsed CLL including patients with high risk genomic features and those refractory to fludarabine.  A multi-center, international, phase II study of alvocidib in fludarabine refractory CLL was undertaken to validate these early results.  Patients with fludarabine refractory CLL or prolymphocytic leukemia arising from CLL were treated with single agent alvocidib.  The primary outcome measure was overall response rate, with secondary outcomes including survival, toxicity, and response duration.  One hundred and sixty five patients were enrolled and 159 patients were treated.  The median age was 61 years, the median no. of prior therapies was 4, and 96% of patients were fludarabine refractory.  The investigator-assessed overall response rate was 25%; the majority of responses were partial.  Response rates were lower among patients with del(17p) (14%), but equiv. in patients with del(11q) or bulky lymphadenopathy.  Median progression free and overall survival were 7.6 and 14.6 mo, resp.  Tumor lysis occurred in 39 patients (25%), and 13 received hemodialysis.  Diarrhea, fatigue, and hematol. toxicities were common.  Alvocidib has clin. activity in patients with advanced, fludarabine refractory CLL.  Future studies should focus on discovery of biomarkers of clin. response and tumor lysis, and enhanced supportive care measures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNLlMqLBd2m7Vg90H21EOLACvtfcHk0lhab7W0ajRp_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFCis7c%253D&md5=3f3c902b0c772666192142ffd71d1c4f</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2015.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2015.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DLanasa%26aufirst%3DM.%2BC.%26aulast%3DAndritsos%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DGabrilove%26aufirst%3DJ.%26aulast%3DCaligaris-Cappio%26aufirst%3DF.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DLeblond%26aufirst%3DV.%26aulast%3DMilligan%26aufirst%3DD.%2BW.%26aulast%3DJanssens%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DB%25C3%25BChler%26aufirst%3DA.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDevin%26aufirst%3DJ.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26atitle%3DFinal%2520results%2520of%2520EFC6663%253A%2520a%2520multicenter%252C%2520international%252C%2520phase%25202%2520study%2520of%2520alvocidib%2520for%2520patients%2520with%2520fludarabine-refractory%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26issue%3D5%26spage%3D495%26epage%3D500%26doi%3D10.1016%2Fj.leukres.2015.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steward, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bono, J.</span></span> <span> </span><span class="NLM_article-title">A phase I dose escalation study of the pharmacokinetics and tolerability of ZK304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.1007/s00280-009-0968-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs00280-009-0968-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=19280191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1agurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2009&pages=425-429&issue=2&author=E.+N.+Scottauthor=A.+L.+Thomasauthor=L.+R.+Molifeauthor=S.+Ahmedauthor=S.+Blagdenauthor=P.+C.+Fongauthor=K.+Kowalauthor=C.+McCoyauthor=H.+Wiesingerauthor=W.+Stewardauthor=J.+De+Bono&title=A+phase+I+dose+escalation+study+of+the+pharmacokinetics+and+tolerability+of+ZK304709%2C+an+oral+multi-targeted+growth+inhibitor+%28MTGI%29%2C+in+patients+with+advanced+solid+tumours&doi=10.1007%2Fs00280-009-0968-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours</span></div><div class="casAuthors">Scott, Edwina N.; Thomas, Anne L.; Molife, L. Rhoda; Ahmed, Samreen; Blagden, Sarah; Fong, Peter C.; Kowal, Kristin; McCoy, Candice; Wiesinger, Herbert; Steward, Will; De Bono, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">425-429</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The toxicities, pharmacokinetics and recommended dose of oral once daily ZK 304709, a novel multi-targeted growth inhibitor (MTGI) with activity against cell-cycle progression and angiogenesis, was investigated in patients by administration for 14 consecutive days followed by 14 days recovery.  Methods: Patients with solid tumors resistant to std. treatments were enrolled in an accelerated titrn. design.  Results: Thirty-seven patients received ZK 304709 from 15 to 285 mg daily.  The most common drug-related adverse events were vomiting, diarrhea and fatigue.  Systemic exposure to ZK 304709 increased with dose up to 90 mg daily but plateaued thereafter, with high inter-individual variability at all doses.  Thirteen patients had stable disease as best response as per RECIST criteria.  Conclusions: There was no increase in exposure to ZK 304709 with dose escalation above 90 mg, and the MTD was not detd.  This study illustrates the importance of phase I pharmacokinetic data to guide dose escalation and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWHmxGlOkQx7Vg90H21EOLACvtfcHk0lhab7W0ajRp_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1agurk%253D&md5=fe0e50036e3fc15838425c5f52e30426</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2Fs00280-009-0968-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-009-0968-y%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DE.%2BN.%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DBlagden%26aufirst%3DS.%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DKowal%26aufirst%3DK.%26aulast%3DMcCoy%26aufirst%3DC.%26aulast%3DWiesinger%26aufirst%3DH.%26aulast%3DSteward%26aufirst%3DW.%26aulast%3DDe%2BBono%26aufirst%3DJ.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520the%2520pharmacokinetics%2520and%2520tolerability%2520of%2520ZK304709%252C%2520an%2520oral%2520multi-targeted%2520growth%2520inhibitor%2520%2528MTGI%2529%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D64%26issue%3D2%26spage%3D425%26epage%3D429%26doi%3D10.1007%2Fs00280-009-0968-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dy, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span> <span> </span><span class="NLM_article-title">Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.lungcan.2018.04.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30089585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BB3c7mt1yrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2018&pages=14-21&author=B.+C.+Choauthor=G.+K.+Dyauthor=R.+Govindanauthor=D.+W.+Kimauthor=N.+A.+Pennellauthor=G.+Zalcmanauthor=B.+Besseauthor=J.+H.+Kimauthor=G.+Kocaauthor=P.+Rajagopalanauthor=S.+Langerauthor=M.+Ockerauthor=H.+Nogaiauthor=F.+Barlesi&title=Phase+Ib%2FII+study+of+the+pan-cyclin-dependent+kinase+inhibitor+roniciclib+in+combination+with+chemotherapy+in+patients+with+extensive-disease+small-cell+lung+cancer&doi=10.1016%2Fj.lungcan.2018.04.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer</span></div><div class="casAuthors">Cho Byoung Chul; Dy Grace K; Govindan Ramaswamy; Kim Dong-Wan; Pennell Nathan A; Zalcman Gerard; Besse Benjamin; Kim Joo-Hang; Koca Goekben; Ocker Matthias; Nogai Hendrik; Rajagopalan Prabhu; Langer Simon; Barlesi Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  This phase Ib/II study evaluated safety, pharmacokinetics, maximum tolerated dose (MTD), and efficacy of the pan-cyclin-dependent kinase inhibitor roniciclib with cisplatin-etoposide (CIS-ETOP) or carboplatin-etoposide (CARBO-ETOP) in patients with extensive-disease small-cell lung cancer (ED-SCLC).  PATIENTS AND METHODS:  In this open-label, non-randomized study, patients with previously untreated ED-SCLC received roniciclib twice daily (BID) in a 3 days on/4 days off schedule.  Cisplatin 75 mg/m(2) or carboplatin (AUC5) dose was administered on day 1, and etoposide 100 mg/m(2) on days 1-3, of 21-day cycles.  Phase Ib used a dose-escalation design to define the MTD for phase II.  Pharmacokinetics were assessed.  RESULTS:  Forty-three patients received treatment (roniciclib 2.5 mg BID [+ CARBO-ETOP, n = 4; + CIS-ETOP, n = 3] and roniciclib 5 mg BID [+ CARBO-ETOP, n = 24; + CIS-ETOP, n = 12]).  The MTD of roniciclib was 5 mg BID with CARBO-ETOP or CIS-ETOP.  Common adverse events were nausea (90.7%) and vomiting (69.8%).  Roniciclib was readily absorbed following oral administration at the MTD (median tmax 0.5-1 h), with a 30-40% reduction in exposure when co-administered with CARBO-ETOP or CIS-ETOP; administration of roniciclib had no effect on etoposide or platinum pharmacokinetics.  The response rate was 81.4% (35/43) overall and 86.1% (31/36) in the pooled roniciclib 5 mg BID population (all partial responses).  CONCLUSION:  Roniciclib co-administered with chemotherapy in patients with ED-SCLC demonstrated tolerability, acceptable pharmacokinetics, and promising efficacy.  An observed safety signal in a related phase II study resulted in discontinuation of the present study and termination of further roniciclib development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS891qx-r3xr-b6AVA-44PTfW6udTcc2eaMRDyaTKohoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7mt1yrtg%253D%253D&md5=ec4e685886d5caf2a6db31b0364cdc2b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DDy%26aufirst%3DG.%2BK.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DPennell%26aufirst%3DN.%2BA.%26aulast%3DZalcman%26aufirst%3DG.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKoca%26aufirst%3DG.%26aulast%3DRajagopalan%26aufirst%3DP.%26aulast%3DLanger%26aufirst%3DS.%26aulast%3DOcker%26aufirst%3DM.%26aulast%3DNogai%26aufirst%3DH.%26aulast%3DBarlesi%26aufirst%3DF.%26atitle%3DPhase%2520Ib%252FII%2520study%2520of%2520the%2520pan-cyclin-dependent%2520kinase%2520inhibitor%2520roniciclib%2520in%2520combination%2520with%2520chemotherapy%2520in%2520patients%2520with%2520extensive-disease%2520small-cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer.%26date%3D2018%26volume%3D123%26spage%3D14%26epage%3D21%26doi%3D10.1016%2Fj.lungcan.2018.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPlant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callander, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlichman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span> <span> </span><span class="NLM_article-title">Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-05-573741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1182%2Fblood-2014-05-573741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25395429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=443-448&issue=3&author=S.+K.+Kumarauthor=B.+LaPlantauthor=W.+J.+Chngauthor=J.+Zonderauthor=N.+Callanderauthor=R.+Fonsecaauthor=B.+Fruthauthor=V.+Royauthor=C.+Erlichmanauthor=A.+K.+Stewart&title=Dinaciclib%2C+a+novel+CDK+inhibitor%2C+demonstrates+encouraging+single-agent+activity+in+patients+with+relapsed+multiple+myeloma&doi=10.1182%2Fblood-2014-05-573741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma</span></div><div class="casAuthors">Kumar, Shaji K.; La Plant, Betsy; Chng, Wee Joo; Zonder, Jeffrey; Callander, Natalie; Fonseca, Rafael; Fruth, Briant; Roy, Vivek; Erlichman, Charles; Stewart, A. Keith</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-448</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Dysregulation of cyclin-dependent kinases is a hallmark of myeloma, and specifically, cdk5 inhibition can enhance the activity of proteasome inhibitors in vitro.  Dinaciclib is a novel potent small mol. inhibitor of cyclin-dependent kinases (CDK)1, CDK2, CDK5, and CDK9.  Patients with relapsed multiple myeloma and ≤5 prior lines of therapy, with measurable disease, were enrolled.  Dinaciclib was administered on day 1 of a 21-day cycle at doses of 30 to 50 mg/m2.  Overall, 27 evaluable patients were accrued; the median no. of prior therapies was 4.  The dose level of 50 mg/m2 was detd. to be the maximally tolerated dose.  The overall confirmed partial response rate (PR) was 3 of 27 (11%), including 1 patient at the 30 mg/m2 dose (1 very good PR [VGPR]) and 2 patients at the 40 mg/m2 dose (1 VGPR and 1 PR).  In addn., 2 patients at the 50 mg/mg2 dose achieved a minimal response (clin. benefit rate, 19%).  Leukopenia, thrombocytopenia, gastrointestinal symptoms, alopecia, and fatigue were the most common adverse events.  The current study demonstrates single agent activity of dinaciclib in relapsed myeloma, with 2 patients achieving a deep response (VGPR) and 10 patients obtaining some degree of M protein stabilization or decrease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEP0lWUMq1_LVg90H21EOLACvtfcHk0lhk2_qXw97ysw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWms7k%253D&md5=22197956e071e38d29efb7c2fdcd707a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-05-573741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-05-573741%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%2BK.%26aulast%3DLaPlant%26aufirst%3DB.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DZonder%26aufirst%3DJ.%26aulast%3DCallander%26aufirst%3DN.%26aulast%3DFonseca%26aufirst%3DR.%26aulast%3DFruth%26aufirst%3DB.%26aulast%3DRoy%26aufirst%3DV.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26atitle%3DDinaciclib%252C%2520a%2520novel%2520CDK%2520inhibitor%252C%2520demonstrates%2520encouraging%2520single-agent%2520activity%2520in%2520patients%2520with%2520relapsed%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26issue%3D3%26spage%3D443%26epage%3D448%26doi%3D10.1182%2Fblood-2014-05-573741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankhala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jou, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statkevich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, C. L.</span></span> <span> </span><span class="NLM_article-title">Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2013.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.clbc.2013.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24393852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVWrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=169-176&issue=3&author=M.+M.+Mitaauthor=A.+A.+Joyauthor=A.+Mitaauthor=K.+Sankhalaauthor=Y.+M.+Jouauthor=D.+Zhangauthor=P.+Statkevichauthor=Y.+Zhuauthor=S.+L.+Yaoauthor=K.+Smallauthor=R.+Bannerjiauthor=C.+L.+Shapiro&title=Randomized+phase+II+trial+of+the+cyclin-dependent+kinase+inhibitor+dinaciclib+%28MK-7965%29+versus+capecitabine+in+patients+with+advanced+breast+cancer&doi=10.1016%2Fj.clbc.2013.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer</span></div><div class="casAuthors">Mita, Monica M.; Joy, Anil A.; Mita, Alain; Sankhala, Kamalesh; Jou, Ying-Ming; Zhang, Da; Statkevich, Paul; Zhu, Yali; Yao, Siu-Long; Small, Karen; Bannerji, Rajat; Shapiro, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-176</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: Effective therapies after failure of treatment with anthracyclines and taxanes are needed for patients with metastatic breast cancer.  Dinaciclib (MK-7965, formerly SCH727965), a small-mol. cyclin-dependent kinase inhibitor, has demonstrated antitumor activity in phase I studies with solid-tumor patients.  This phase II trial was designed to assess the efficacy and safety of dinaciclib compared with that of capecitabine in women with previously treated advanced breast cancer.  Patients and Methods: Patients were randomized to receive either dinaciclib at 50 mg/m2, administered as a 2-h infusion every 21 days, or 1250 mg/m2 capecitabine, administered orally twice daily in 21-day cycles.  Results: An unplanned interim anal. showed that the time to disease progression was inferior with dinaciclib treatment compared with capecitabine treatment; therefore, the trial was stopped after 30 patients were randomized.  Dinaciclib treatment demonstrated antitumor activity in 2 of 7 patients with estrogen receptor-pos. and human epidermal growth factor receptor 2-neg. metastatic breast cancer (1 confirmed and 1 unconfirmed partial response), as well as acceptable safety and tolerability.  Grade 3 or 4 treatment-related adverse events were common and included neutropenia, leukopenia, increase in aspartate aminotransferase, and febrile neutropenia.  Population pharmacokinetic model-predicted mean dinaciclib exposure (area under the concn.-time curve extrapolated to infinity [AUC[I]]) at 50 mg/m2 was similar to that obsd. in a previous phase I trial, and no drug accumulation was obsd. after multiple-dose administration.  Conclusion: Although dinaciclib monotherapy demonstrated some antitumor activity and was generally tolerated, efficacy was not superior to capecitabine.  Future studies may be considered to evaluate dinaciclib in select patient populations with metastatic breast cancer and in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetvZlPAou-LVg90H21EOLACvtfcHk0liBIAk3v9DVhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVWrtQ%253D%253D&md5=5f91dd3e13e17bac5c9bbb227ed1a107</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2013.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2013.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DJoy%26aufirst%3DA.%2BA.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DSankhala%26aufirst%3DK.%26aulast%3DJou%26aufirst%3DY.%2BM.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DS.%2BL.%26aulast%3DSmall%26aufirst%3DK.%26aulast%3DBannerji%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DC.%2BL.%26atitle%3DRandomized%2520phase%2520II%2520trial%2520of%2520the%2520cyclin-dependent%2520kinase%2520inhibitor%2520dinaciclib%2520%2528MK-7965%2529%2520versus%2520capecitabine%2520in%2520patients%2520with%2520advanced%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D3%26spage%3D169%26epage%3D176%26doi%3D10.1016%2Fj.clbc.2013.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemunaitis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jou, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statkevich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, M. J.</span></span> <span> </span><span class="NLM_article-title">Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinibin patients with non-small cell lung cancer</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2013.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.lungcan.2013.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24388167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2czhslKktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=219-223&issue=2&author=J.+J.+Stephensonauthor=J.+Nemunaitisauthor=A.+A.+Joyauthor=J.+C.+Martinauthor=Y.+M.+Jouauthor=D.+Zhangauthor=P.+Statkevichauthor=S.+L.+Yaoauthor=Y.+Zhuauthor=H.+Zhouauthor=K.+Smallauthor=R.+Bannerjiauthor=M.+J.+Edelman&title=Randomized+phase+2+study+of+the+cyclin-dependent+kinase+inhibitor+dinaciclib+%28MK-7965%29+versus+erlotinibin+patients+with+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2013.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer</span></div><div class="casAuthors">Stephenson Joe J; Martin Julie C; Nemunaitis John; Joy Anil A; Jou Ying-Ming; Zhang Da; Statkevich Paul; Yao Siu-Long; Zhu Yali; Zhou Honghong; Small Karen; Bannerji Rajat; Edelman Martin J</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclin-dependent kinases, has been shown to induce apoptosis in preclinical studies of human tumor cell lines, including non-small cell lung cancer (NSCLC) cells.  Erlotinib, an epidermal growth factor receptor inhibitor, is approved for the treatment of advanced NSCLC as second- or third-line therapy.  This phase 2, randomized, multicenter, open-label study compared dinaciclib with erlotinib in patients with previously treated NSCLC.  MATERIALS AND METHODS:  The study was comprised of 2 parts: in part 1, patients were randomized to either intravenous (IV) dinaciclib (50 mg/m2) or oral erlotinib (150 mg) using an adaptive Bayesian design that adjusted the randomization ratio in favor of the more active arm, and in part 2, patients who had progressed on erlotinib were permitted to cross over to receive dinaciclib at the same dosage as in part 1.  Patients were followed until disease progression or death, initiation of nonstudy cancer treatment, discontinuation, or withdrawal of consent.  The primary efficacy end point was time-to-progression (TTP) in part 1 and objective response rate (ORR) in part 2.  RESULTS:  Based on Kaplan-Meier estimates, the median TTP was 1.49 months (95% confidence interval [CI]: 1.31, 2.63) following initial treatment with dinaciclib, compared with 1.58 months (95% CI: 1.38, 2.83) with erlotinib.  No objective responses were observed following initial treatment with dinaciclib.  Common severe (grade 3 or 4) drug-related adverse effects included neutropenia, leukopenia, vomiting, and diarrhea.  CONCLUSIONS:  Dinaciclib, administered IV, was well tolerated at the 50 mg/m2 dose, but does not have activity as monotherapy in previously treated NSCLC.  Evaluation of dinaciclib in combination with other agents for other indications including breast cancer and multiple myeloma is in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRk6FO2RHT0FysZ1x6zOs0vfW6udTcc2eY1iuP3OqvLeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czhslKktQ%253D%253D&md5=684ef1bc79de64b1b0c7f9427ffe0c27</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2013.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2013.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DStephenson%26aufirst%3DJ.%2BJ.%26aulast%3DNemunaitis%26aufirst%3DJ.%26aulast%3DJoy%26aufirst%3DA.%2BA.%26aulast%3DMartin%26aufirst%3DJ.%2BC.%26aulast%3DJou%26aufirst%3DY.%2BM.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DYao%26aufirst%3DS.%2BL.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSmall%26aufirst%3DK.%26aulast%3DBannerji%26aufirst%3DR.%26aulast%3DEdelman%26aufirst%3DM.%2BJ.%26atitle%3DRandomized%2520phase%25202%2520study%2520of%2520the%2520cyclin-dependent%2520kinase%2520inhibitor%2520dinaciclib%2520%2528MK-7965%2529%2520versus%2520erlotinibin%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer.%26date%3D2014%26volume%3D83%26issue%3D2%26spage%3D219%26epage%3D223%26doi%3D10.1016%2Fj.lungcan.2013.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gojo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jou, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerji, R.</span></span> <span> </span><span class="NLM_article-title">Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) in acute leukemias</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2249-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs00280-013-2249-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=23949430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12ju73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=897-908&issue=4&author=I.+Gojoauthor=M.+Sadowskaauthor=A.+Walkerauthor=E.+J.+Feldmanauthor=S.+P.+Iyerauthor=M.+R.+Baerauthor=E.+A.+Sausvilleauthor=R.+G.+Lapidusauthor=D.+Zhangauthor=Y.+Zhuauthor=Y.+M.+Jouauthor=J.+Poonauthor=K.+Smallauthor=R.+Bannerji&title=Clinical+and+laboratory+studies+of+the+novel+cyclin-dependent+kinase+inhibitor+dinaciclib+%28SCH727965%29+in+acute+leukemias&doi=10.1007%2Fs00280-013-2249-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias</span></div><div class="casAuthors">Gojo, Ivana; Sadowska, Mariola; Walker, Alison; Feldman, Eric J.; Iyer, Swaminathan Padmanabhan; Baer, Maria R.; Sausville, Edward A.; Lapidus, Rena G.; Zhang, Da; Zhu, Yali; Jou, Ying-Ming; Poon, Jennifer; Small, Karen; Bannerji, Rajat</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">897-908</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Dinaciclib inhibits cyclin-dependent kinases 1, 2, 5, and 9 with a better therapeutic index than flavopiridol in preclin. studies.  This study assessed the activity of dinaciclib in acute leukemia both in the clinic and in vitro.  Methods: Adults with relapsed/refractory acute myeloid leukemia (n = 14) and acute lymphoid leukemia (n = 6) were treated with dinaciclib 50 mg/m2 given as a 2-h infusion every 21 days.  Results: Most patients had dramatic but transient redn. in circulating blasts; however, no remissions were achieved on this schedule.  The most common toxicities were gastrointestinal, fatigue, transaminitis, and clin. and lab. manifestations of tumor lysis syndrome, including one patient who died of acute renal failure.  Dinaciclib pharmacokinetics showed rapid (2 h) achievement of max. concn. and a short elimination/distribution phase.  Pharmacodynamic studies demonstrated in vivo inhibition of Mcl-1 expression and induction of PARP cleavage in patients' peripheral blood mononuclear cells 4 h after dinaciclib infusion, but the effects were lost by 24 h and did not correlate with clin. outcome.  Correlative in vitro studies showed that prolonged exposures to dinaciclib, at clin. attainable concns., result in improved leukemia cell kill.  Conclusions: While dinaciclib given as a 2-h bolus did not exhibit durable clin. activity, pharmacokinetic and pharmacodynamic data support the exploration of prolonged infusion schedules in future trials in patients with acute leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-GXoS2RFuB7Vg90H21EOLACvtfcHk0liBIAk3v9DVhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12ju73N&md5=1a89e1dc02b664e76472cd7d197a029f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2249-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2249-z%26sid%3Dliteratum%253Aachs%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DSadowska%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DFeldman%26aufirst%3DE.%2BJ.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DJou%26aufirst%3DY.%2BM.%26aulast%3DPoon%26aufirst%3DJ.%26aulast%3DSmall%26aufirst%3DK.%26aulast%3DBannerji%26aufirst%3DR.%26atitle%3DClinical%2520and%2520laboratory%2520studies%2520of%2520the%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%2520dinaciclib%2520%2528SCH727965%2529%2520in%2520acute%2520leukemias%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D72%26issue%3D4%26spage%3D897%26epage%3D908%26doi%3D10.1007%2Fs00280-013-2249-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bible, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martell, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelman, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorusso, P. M.</span></span> <span> </span><span class="NLM_article-title">A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1007/s10637-007-9090-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs10637-007-9090-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=17938863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1aruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=59-65&issue=1&author=E.+I.+Heathauthor=K.+Bibleauthor=R.+E.+Martellauthor=D.+C.+Adelmanauthor=P.+M.+Lorusso&title=A+phase+1+study+of+SNS-032+%28formerly+BMS-387032%29%2C+a+potent+inhibitor+of+cyclin-dependent+kinases+2%2C+7+and+9+administered+as+a+single+oral+dose+and+weekly+infusion+in+patients+with+metastatic+refractory+solid+tumors&doi=10.1007%2Fs10637-007-9090-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors</span></div><div class="casAuthors">Heath, Elisabeth I.; Bible, Keith; Martell, Robert E.; Adelman, Daniel C.; LoRusso, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-65</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: SNS-032, (formerly BMS-387032) is a potent and selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9.  The primary objective of the study was to establish the max. tolerated dose (MTD), the max. administered dose (MAD), dose limiting toxicity (DLT), and the recommended phase 2 dose for SNS-032 when administered as a weekly 1-h infusion.  The secondary objective was to assess the safety and tolerability of SNS-032 and to evaluate its bioavailability as an oral soln.  Methods: Patients with metastatic solid tumors or refractory lymphoma were treated with a starting dose of 4 mg/m2 i.v. administered over 1-h with a cycle defined as 3 weekly doses of SNS-032 every 21 days.  Three patient cohorts were utilized in the dose-escalation schema.  Pharmacokinetic studies were performed.  For the 13 and 16 mg/m2 dose cohorts, the first dose of cycle 2 was given as an oral soln. to est. the oral bioavailability of the drug in humans.  Results: A total of 21 patients were enrolled.  Twenty treated patients received a total of 39 cycles of treatment.  The most common treatment-related adverse events occurring with greater than 20% incidence were fatigue (25%) and nausea (20%).  Following i.v. administration, plasma concns. declined in a biphasic manner, resulting in mean terminal half-lives between 5 and 10 h.  The mean Cmax and AUC0-inf increased nearly linearly with dose, ranging from 0.067 to 0.287 μg/mL and 0.103 to 0.553 μg h/mL, resp.  The CL and Vss remained unchanged with increasing dose levels, averaging 38 l/h/m2 and 212 l/m2, resp.  Av. oral bioavailability was 19% (range: 4-33%).  Three (15%) patients experienced a best response of stable disease.  Study enrollment was terminated during dose-escalation due to a change in the development strategy for the study drug.  Conclusions: SNS-032 administered as a weekly 1-h infusion was well tolerated, although study enrollment was terminated during dose-escalation and the MTD of SNS-032 administered i.v. on days 1, 8, and 15 of each treatment cycle was not reached.  Tumor progression or stable disease was detd. to be the best response in all evaluable patients.  At the dose levels tested, the oral bioavailability of SNS-032 ranged from 4-33%.  The data suggest that oral administration of SNS-032 may be feasible, though the tolerability and bioavailability of the oral formulation would have to be formally assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUIS2yPNOYJLVg90H21EOLACvtfcHk0lgObNbVNEB3Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1aruw%253D%253D&md5=bb1a9d0365b230fc2408b957a692a2e8</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs10637-007-9090-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-007-9090-3%26sid%3Dliteratum%253Aachs%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DBible%26aufirst%3DK.%26aulast%3DMartell%26aufirst%3DR.%2BE.%26aulast%3DAdelman%26aufirst%3DD.%2BC.%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26atitle%3DA%2520phase%25201%2520study%2520of%2520SNS-032%2520%2528formerly%2520BMS-387032%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520cyclin-dependent%2520kinases%25202%252C%25207%2520and%25209%2520administered%2520as%2520a%2520single%2520oral%2520dose%2520and%2520weekly%2520infusion%2520in%2520patients%2520with%2520metastatic%2520refractory%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26issue%3D1%26spage%3D59%26epage%3D65%26doi%3D10.1007%2Fs10637-007-9090-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantzaris, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wermke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordoba, R.</span></span> <span> </span><span class="NLM_article-title">Phase I study of the P-TEFb inhibitor BAY 1251152 in patients with acute myelogenous leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">4055</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-99-117257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1182%2Fblood-2018-99-117257" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=4055&author=M.+Byrneauthor=M.+G.+Frattiniauthor=O.+G.+Ottmannauthor=I.+Mantzarisauthor=M.+Wermkeauthor=D.+J.+Leeauthor=D.+Morilloauthor=A.+Scholzauthor=S.+Inceauthor=R.+Valenciaauthor=F.+Souzaauthor=R.+Cordoba&title=Phase+I+study+of+the+P-TEFb+inhibitor+BAY+1251152+in+patients+with+acute+myelogenous+leukemia&doi=10.1182%2Fblood-2018-99-117257"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-99-117257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-99-117257%26sid%3Dliteratum%253Aachs%26aulast%3DByrne%26aufirst%3DM.%26aulast%3DFrattini%26aufirst%3DM.%2BG.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DMantzaris%26aufirst%3DI.%26aulast%3DWermke%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DD.%2BJ.%26aulast%3DMorillo%26aufirst%3DD.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DInce%26aufirst%3DS.%26aulast%3DValencia%26aufirst%3DR.%26aulast%3DSouza%26aufirst%3DF.%26aulast%3DCordoba%26aufirst%3DR.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520P-TEFb%2520inhibitor%2520BAY%25201251152%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26spage%3D4055%26doi%3D10.1182%2Fblood-2018-99-117257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troiani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span> <span> </span><span class="NLM_article-title">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1907</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.1038/emboj.2008.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Femboj.2008.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=18566585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1907-1918&author=S.+Baumliauthor=G.+Lolliauthor=E.+D.+Loweauthor=S.+Troianiauthor=L.+Rusconiauthor=A.+N.+Bullockauthor=J.+E.+Debreczeniauthor=S.+Knappauthor=L.+N.+Johnson&title=The+structure+of+P-TEFb+%28CDK9%2Fcyclin+T1%29%2C+its+complex+with+flavopiridol+and+regulation+by+phosphorylation&doi=10.1038%2Femboj.2008.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span></div><div class="casAuthors">Baumli, Sonja; Lolli, Graziano; Lowe, Edward D.; Troiani, Sonia; Rusconi, Luisa; Bullock, Alex N.; Debreczeni, Judit E.; Knapp, Stefan; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1907-1918</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pos. transcription elongation factor b (P-TEFb) (CDK9/cyclin T (CycT)) promotes mRNA transcriptional elongation through phosphorylation of elongation repressors and RNA polymerase II.  To understand the regulation of a transcriptional CDK by its cognate cyclin, we have detd. the structures of the CDK9/CycT1 and free cyclin T2.  There are distinct differences between CDK9/CycT1 and the cell cycle CDK CDK2/CycA manifested by a relative rotation of 26° of CycT1 with respect to the CDK, showing for the first time plasticity in CDK cyclin interactions.  The CDK9/CycT1 interface is relatively sparse but retains some core CDK-cyclin interactions.  The CycT1 C-terminal helix shows flexibility that may be important for the interaction of this region with HIV TAT and HEXIM.  Flavopiridol, an anticancer drug in phase II clin. trials, binds to the ATP site of CDK9, inducing unanticipated structural changes that bury the inhibitor.  CDK9 activity and recognition of regulatory proteins are governed by autophosphorylation.  We show that CDK9/CycT1 autophosphorylates on Thr186 in the activation segment and three C-terminal phosphorylation sites.  Autophosphorylation on all sites occurs in cis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG2808s0tnBrVg90H21EOLACvtfcHk0lgObNbVNEB3Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D&md5=c28cc6d1c178c79a12cfab03da9c45dc</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Femboj.2008.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2008.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLolli%26aufirst%3DG.%26aulast%3DLowe%26aufirst%3DE.%2BD.%26aulast%3DTroiani%26aufirst%3DS.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520structure%2520of%2520P-TEFb%2520%2528CDK9%252Fcyclin%2520T1%2529%252C%2520its%2520complex%2520with%2520flavopiridol%2520and%2520regulation%2520by%2520phosphorylation%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D1907%26epage%3D1918%26doi%3D10.1038%2Femboj.2008.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deep, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marwaha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marwaha, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jyoti</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. K.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review</span>. <i>New J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">18500</span>– <span class="NLM_lpage">18507</span>, <span class="refDoi"> DOI: 10.1039/C8NJ04306J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1039%2FC8NJ04306J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCjsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2018&pages=18500-18507&issue=23&author=A.+Deepauthor=R.+K.+Marwahaauthor=M.+G.+Marwahaauthor=+Jyotiauthor=R.+Nandalauthor=A.+K.+Sharma&title=Flavopiridol+as+cyclin+dependent+kinase+%28CDK%29+inhibitor%3A+a+review&doi=10.1039%2FC8NJ04306J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review</span></div><div class="casAuthors">Deep, Aakash; Marwaha, Rakesh Kumar; Marwaha, Minakshi Gupta; Jyoti; Nandal, Rimmy; Sharma, Arun Kumar</div><div class="citationInfo"><span class="NLM_cas:title">New Journal of Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">18500-18507</span>CODEN:
                <span class="NLM_cas:coden">NJCHE5</span>;
        ISSN:<span class="NLM_cas:issn">1144-0546</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Flavopiridol (alvocidib) is a synthetic flavonoid based on the ext. from an Indian plant developed for potential treatment of cancer whose first clin. trials were initiated in 1994 as a frontline combination therapy for leukemia.  It is a potent Cyclin Dependent Kinase (CDK) inhibitor with preferential activity against CDK9.  Several phase I and II trials using flavopiridol as a single agent and in combination with std. chemotherapeutic regimens and various tumor types are ongoing.  Moreover, the combination of flavopiridol with gemcitabine, imatinib mesylate, SN-38 (the active metabolite of CPT-11) and doxorubicin show synergistic therapeutic effect in inducing mortality of cancer cells.  Present study enlightens the individual and combined therapeutic and toxic profiles of flavopiridol.  The synthesis, mechanism of action, preclin. and clin. outcomes of flavopiridol till date have been discussed in the current study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoue28qb_LpSLVg90H21EOLACvtfcHk0lhz56kOEJf16Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCjsrrI&md5=369de8cacbf78af0e858a2324969ce9a</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1039%2FC8NJ04306J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8NJ04306J%26sid%3Dliteratum%253Aachs%26aulast%3DDeep%26aufirst%3DA.%26aulast%3DMarwaha%26aufirst%3DR.%2BK.%26aulast%3DMarwaha%26aufirst%3DM.%2BG.%26aulast%3DJyoti%26aulast%3DNandal%26aufirst%3DR.%26aulast%3DSharma%26aufirst%3DA.%2BK.%26atitle%3DFlavopiridol%2520as%2520cyclin%2520dependent%2520kinase%2520%2528CDK%2529%2520inhibitor%253A%2520a%2520review%26jtitle%3DNew%2520J.%2520Chem.%26date%3D2018%26volume%3D42%26issue%3D23%26spage%3D18500%26epage%3D18507%26doi%3D10.1039%2FC8NJ04306J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srikumar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, J.</span></span> <span> </span><span class="NLM_article-title">Potential use of flavopiridol in treatment of chronic diseases</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>929</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-41342-6_9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2F978-3-319-41342-6_9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27771926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1artr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=929&publication_year=2016&pages=209-228&author=T.+Srikumarauthor=J.+Padmanabhan&title=Potential+use+of+flavopiridol+in+treatment+of+chronic+diseases&doi=10.1007%2F978-3-319-41342-6_9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Potential Use of Flavopiridol in Treatment of Chronic Diseases</span></div><div class="casAuthors">Srikumar, Thejal; Padmanabhan, Jaya</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">929</span>
        (<span class="NLM_cas:issue">Drug Discovery from Mother Nature</span>),
    <span class="NLM_cas:pages">209-228</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This chapter describes the potential use of flavopiridol, a CDK inhibitor with anti-inflammatory and anti-proliferative activities, in the treatment of various chronic diseases.  Flavopiridol arrests cell cycle progression in the G1 or G2 phase by inhibiting the kinase activities of CDK1, CDK2, CDK4/6, and CDK7.  Addnl., it binds tightly to CDK9, a component of the P-TEFb complex (CDK9/cyclin T), and interferes with RNA polymerase II activation and assocd. transcription.  This in turn inhibits expression of several pro-survival and anti-apoptotic genes, and enhances cytotoxicity in transformed cells or differentiation in growth-arrested cells.  Recent studies indicate that flavopiridol elicits anti-inflammatory activity via CDK9 and NFκB-dependent signaling.  Overall, these effects of flavopiridol potentiate its ability to overcome aberrant cell cycle activation and/or inflammatory stimuli, which are mediators of various chronic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobJrum2VChk7Vg90H21EOLACvtfcHk0lhz56kOEJf16Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1artr%252FP&md5=1a4de78c8b6c7c47f042fc5da4279a8a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-41342-6_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-41342-6_9%26sid%3Dliteratum%253Aachs%26aulast%3DSrikumar%26aufirst%3DT.%26aulast%3DPadmanabhan%26aufirst%3DJ.%26atitle%3DPotential%2520use%2520of%2520flavopiridol%2520in%2520treatment%2520of%2520chronic%2520diseases%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2016%26volume%3D929%26spage%3D209%26epage%3D228%26doi%3D10.1007%2F978-3-319-41342-6_9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grever, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plunkett, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span> <span> </span><span class="NLM_article-title">Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia</span>. <i>Oncotarget.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2667</span>– <span class="NLM_lpage">2679</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.18632%2Foncotarget.2096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25596730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2Mvnt1ertQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=2667-2679&issue=5&author=Y.+Y.+Yehauthor=R.+Chenauthor=J.+Hesslerauthor=E.+Mahoneyauthor=A.+M.+Lehmanauthor=N.+A.+Heeremaauthor=M.+R.+Greverauthor=W.+Plunkettauthor=J.+C.+Byrdauthor=A.+J.+Johnson&title=Up-regulation+of+CDK9+kinase+activity+and+Mcl-1+stability+contributes+to+the+acquired+resistance+to+cyclin-dependent+kinase+inhibitors+in+leukemia&doi=10.18632%2Foncotarget.2096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia</span></div><div class="casAuthors">Yeh Yuh-Ying; Hessler Joshua; Mahoney Emilia; Grever Michael R; Byrd John C; Johnson Amy J; Chen Rong; Plunkett William; Lehman Amy M; Heerema Nyla A; Byrd John C; Johnson Amy J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2667-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Flavopiridol is a small molecule inhibitor of cyclin-dependent kinases (CDK) known to impair global transcription via inactivation of positive transcription elongation factor b.  It has been demonstrated to have significant activity predominantly in chronic lymphocytic leukemia and acute myeloid leukemia in phase I/II clinical trials while other similar CDK inhibitors are vigorously being pursued in pre-clinical and clinical studies.  Although flavopiridol is a potent therapeutic agent against blood diseases, some patients still have primary or acquired resistance throughout their clinical course.  Considering the limited knowledge of resistance mechanisms of flavopiridol, we investigated the potential mechanisms of resistance to flavopiridol in a cell line system, which gradually acquired resistance to flavopiridol in vitro, and then confirmed the mechanism in patient samples.  Herein, we present that this resistant cell line developed resistance through up-regulation of phosphorylation of RNA polymerase II C-terminal domain, activation of CDK9 kinase activity, and prolonged Mcl-1 stability to counter flavopiridol's drug actions.  Further analyses suggest MAPK/ERK activation-mediated Mcl-1 stabilization contributes to the resistance and knockdown of Mcl-1 in part restores sensitivity to flavopiridol-induced cytotoxicity.  Altogether, these findings demonstrate that CDK9 is the most relevant target of flavopiridol and provide avenues to improve the therapeutic strategies in blood malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-c1g_ogLWk_x2phytoz6_fW6udTcc2eb04-e3RPC-4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mvnt1ertQ%253D%253D&md5=1911709d5379ee0b254645433abb91c4</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2096%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DHessler%26aufirst%3DJ.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DLehman%26aufirst%3DA.%2BM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DPlunkett%26aufirst%3DW.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26atitle%3DUp-regulation%2520of%2520CDK9%2520kinase%2520activity%2520and%2520Mcl-1%2520stability%2520contributes%2520to%2520the%2520acquired%2520resistance%2520to%2520cyclin-dependent%2520kinase%2520inhibitors%2520in%2520leukemia%26jtitle%3DOncotarget.%26date%3D2015%26volume%3D6%26issue%3D5%26spage%3D2667%26epage%3D2679%26doi%3D10.18632%2Foncotarget.2096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Tolero Pharmaceuticals</span>. <a href="https://www.toleropharma.com/our-research/alvocidib" class="extLink">https://www.toleropharma.com/our-research/alvocidib</a> (accessed
April 15, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Tolero+Pharmaceuticals.+https%3A%2F%2Fwww.toleropharma.com%2Four-research%2Falvocidib+%28accessed%0AApril+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumara, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soujanya, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravikanth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudeva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganeshaiah, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaanker, R. U.</span></span> <span> </span><span class="NLM_article-title">Rohitukine, a chromone alkaloid and a precursor of flavopiridol, is produced by endophytic fungi isolated from dysoxylum binectariferum hook.f and amoora rohituka (Roxb).Wight & Arn</span>. <i>Phytomedicine</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1016/j.phymed.2013.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.phymed.2013.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24215673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGmu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=541-546&issue=4&author=P.+M.+Kumaraauthor=K.+N.+Soujanyaauthor=G.+Ravikanthauthor=R.+Vasudevaauthor=K.+N.+Ganeshaiahauthor=R.+U.+Shaanker&title=Rohitukine%2C+a+chromone+alkaloid+and+a+precursor+of+flavopiridol%2C+is+produced+by+endophytic+fungi+isolated+from+dysoxylum+binectariferum+hook.f+and+amoora+rohituka+%28Roxb%29.Wight+%26+Arn&doi=10.1016%2Fj.phymed.2013.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Rohitukine, a chromone alkaloid and a precursor of flavopiridol, is produced by endophytic fungi isolated from Dysoxylum binectariferum Hook.f and Amoora rohituka (Roxb).Wight & Arn</span></div><div class="casAuthors">Kumara, P. Mohana; Soujanya, K. N.; Ravikanth, G.; Vasudeva, R.; Ganeshaiah, K. N.; Shaanker, R. Uma</div><div class="citationInfo"><span class="NLM_cas:title">Phytomedicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">541-546</span>CODEN:
                <span class="NLM_cas:coden">PYTOEY</span>;
        ISSN:<span class="NLM_cas:issn">0944-7113</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Rohitukine, a chromone alkaloid, has gained considerable international attention in recent years because of its novel semi-synthetic deriv., flavopiridol and P-276-00.  Both these mols. are in advanced stages of clin. development and trial for cancer treatment.  Recently, flavopiridol was approved as an orphan drug for treatment of chronic lymphocytic leukemia cancer.  The natural occurrence of rohitukine is restricted to only four plant species, Amoora rohituka and Dysoxylum binectariferum (both from the Meliaceae family) and from Schumanniophyton magnificum and Schumanniophyton problematicum (both from the Rubiaceae family).  Recently, an endophytic fungi isolated from D. binectariferum was reported to produce rohitukine in culture.  In this study, we report the prodn. of rohitukine and its subsequent attenuation by endophytic fungi, Fusarium oxysporum (MTCC-11383), Fusarium oxysporum (MTCC-11384) and Fusarium solani (MTCC-11385), all isolated from D. binectariferum and Gibberella fujikuroi (MTCC-11382) isolated from Amoora rohituka.  The fungal rohitukine which was analyzed by HPLC, LC-MS and LC-MS/MS was identical to ref. rohitukine and that produced by the plant.  The rohitukine content in the mycelial samples ranged from 192.78 μg to 359.55 μg 100 g-1 of dry wt. of and in broth it ranged from 14.10 to 71.90 μg 100 mL-1.  In all the fungal cultures, the prodn. declined from first to fourth sub-culture.  Studies are underway to unravel the mechanism by which the fungi produce the host metabolite in culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNZ9s4yF6ZArVg90H21EOLACvtfcHk0lh0-CFPbFR0PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGmu7vJ&md5=b32b67ab5e9d32726f80b1efa5d54338</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.phymed.2013.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phymed.2013.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DKumara%26aufirst%3DP.%2BM.%26aulast%3DSoujanya%26aufirst%3DK.%2BN.%26aulast%3DRavikanth%26aufirst%3DG.%26aulast%3DVasudeva%26aufirst%3DR.%26aulast%3DGaneshaiah%26aufirst%3DK.%2BN.%26aulast%3DShaanker%26aufirst%3DR.%2BU.%26atitle%3DRohitukine%252C%2520a%2520chromone%2520alkaloid%2520and%2520a%2520precursor%2520of%2520flavopiridol%252C%2520is%2520produced%2520by%2520endophytic%2520fungi%2520isolated%2520from%2520dysoxylum%2520binectariferum%2520hook.f%2520and%2520amoora%2520rohituka%2520%2528Roxb%2529.Wight%2520%2526%2520Arn%26jtitle%3DPhytomedicine%26date%3D2014%26volume%3D21%26issue%3D4%26spage%3D541%26epage%3D546%26doi%3D10.1016%2Fj.phymed.2013.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiernik, P. H.</span></span> <span> </span><span class="NLM_article-title">Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">729</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1517/13543784.2016.1169273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1517%2F13543784.2016.1169273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26998706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1GisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=729-734&issue=6&author=P.+H.+Wiernik&title=Alvocidib+%28flavopiridol%29+for+the+treatment+of+chronic+lymphocytic+leukemia&doi=10.1517%2F13543784.2016.1169273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia</span></div><div class="casAuthors">Wiernik, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">729-734</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Alvocidib, which has orphan drug designation in chronic lymphocytic leukemia (CLL) from the FDA and the EMA, is a plant-derived semisynthetic flavone that acts as a cyclin-dependent kinase inhibitor.  It induces apoptosis in CLL cells in vitro and was introduced into clin. trials in CLL as an i.v. infusion in 1997, which proved disappointing.  Since the drug avidly binds to plasma proteins, higher serum concns. were required for clin. antileukemia activity than those suggested by in vitro studies.  Subsequent studies utilizing bolus plus infusional doses revealed significant activity against CLL, even in patients with unfavorable characteristics.  However, significant toxicity including high rates of major tumor lysis syndrome, cytokine release syndrome and secretory diarrhea were also obsd.  The chem., pharmacodynamics, pharmacokinetics and metab. of alvocidib are briefly discussed and phase I-II studies in CLL are discussed in detail.  To date, no phase III studies in CLL have been reported.  A no. of much less toxic drugs with similar efficacy against CLL both with and without unfavorable cytogenetics have come to market.  Furthermore, enthusiasm for the development of alvocidib as a single agent for the treatment of CLL has waned, primarily due to its toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWT5FoLZipWbVg90H21EOLACvtfcHk0lh0-CFPbFR0PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1GisL8%253D&md5=485e42cb368b87299eca0e2231eb0d3f</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1517%2F13543784.2016.1169273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2016.1169273%26sid%3Dliteratum%253Aachs%26aulast%3DWiernik%26aufirst%3DP.%2BH.%26atitle%3DAlvocidib%2520%2528flavopiridol%2529%2520for%2520the%2520treatment%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26issue%3D6%26spage%3D729%26epage%3D734%26doi%3D10.1517%2F13543784.2016.1169273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">U.S. National Library of Medicine:
ClinicalTrials.gov</span>, <a href="https://www.clinicaltrials.gov" class="extLink">https://www.clinicaltrials.gov</a> (accessed April 10, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+National+Library+of+Medicine%3A%0AClinicalTrials.gov%2C+https%3A%2F%2Fwww.clinicaltrials.gov+%28accessed+April+10%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haws, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whatcott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui-Jain, A.</span></span> <span> </span><span class="NLM_article-title">TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5133</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-5133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1538-7445.AM2017-5133" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=5133&author=W.+Kimauthor=H.+Hawsauthor=P.+Petersonauthor=C.+J.+Whatcottauthor=S.+Weitmanauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=A.+Siddiqui-Jain&title=TP-1287%2C+an+oral+prodrug+of+the+cyclin-dependent+kinase-9+inhibitor+alvocidib&doi=10.1158%2F1538-7445.AM2017-5133"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-5133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-5133%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%26aulast%3DHaws%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DP.%26aulast%3DWhatcott%26aufirst%3DC.%2BJ.%26aulast%3DWeitman%26aufirst%3DS.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DSiddiqui-Jain%26aufirst%3DA.%26atitle%3DTP-1287%252C%2520an%2520oral%2520prodrug%2520of%2520the%2520cyclin-dependent%2520kinase-9%2520inhibitor%2520alvocidib%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D5133%26doi%3D10.1158%2F1538-7445.AM2017-5133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintoo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guru, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuthakki, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondhe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, R. A.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical development of IIIM-290, an orally active potent cyclin-dependent kinase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1664</span>– <span class="NLM_lpage">1687</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsl2js7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1664-1687&issue=4&author=S.+B.+Bharateauthor=V.+Kumarauthor=S.+K.+Jainauthor=M.+J.+Mintooauthor=S.+K.+Guruauthor=V.+K.+Nuthakkiauthor=M.+Sharmaauthor=S.+S.+Bharateauthor=S.+G.+Gandhiauthor=D.+M.+Mondheauthor=S.+Bhushanauthor=R.+A.+Vishwakarma&title=Discovery+and+preclinical+development+of+IIIM-290%2C+an+orally+active+potent+cyclin-dependent+kinase+inhibitor&doi=10.1021%2Facs.jmedchem.7b01765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor</span></div><div class="casAuthors">Bharate, Sandip B.; Kumar, Vikas; Jain, Shreyans K.; Mintoo, Mubashir J.; Guru, Santosh K.; Nuthakki, Vijay K.; Sharma, Mohit; Bharate, Sonali S.; Gandhi, Sumit G.; Mondhe, Dilip M.; Bhushan, Shashi; Vishwakarma, Ram A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1664-1687</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rohitukine (1), a chromone alkaloid isolated from Indian medicinal plant Dysoxylum binectariferum, has inspired the discovery of flavopiridol and riviciclib, both of which are bioavailable only via i.v. route.  With the objective to address the oral bioavailability issue of this scaffold, four series of rohitukine derivs. were prepd. and screened for Cdk inhibition and cellular antiproliferative activity.  The 2,6-dichloro-styryl deriv. IIIM-290 (11d) showed strong inhibition of Cdk-9/T1 (IC50 1.9 nM) kinase and Molt-4/MIAPaCa-2 cell growth (GI50 < 1.0 μM) and was found to be highly selective for cancer cells over normal fibroblast cells.  It inhibited the cell growth of MIAPaCa-2 cells via caspase-dependent apoptosis.  It achieved 71% oral bioavailability with in vivo efficacy in pancreatic, colon, and leukemia xenografts at 50 mg/kg, po.  It did not have CYP/efflux-pump liability, was not mutagenic/genotoxic or cardiotoxic, and was metabolically stable.  The preclin. data presented herein indicates the potential of 11d for advancement in clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeRTRG-f8KqLVg90H21EOLACvtfcHk0li6Bj-PJWkqHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsl2js7k%253D&md5=13b67cdf1db966e2a414b64cd82a98e8</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01765%26sid%3Dliteratum%253Aachs%26aulast%3DBharate%26aufirst%3DS.%2BB.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DJain%26aufirst%3DS.%2BK.%26aulast%3DMintoo%26aufirst%3DM.%2BJ.%26aulast%3DGuru%26aufirst%3DS.%2BK.%26aulast%3DNuthakki%26aufirst%3DV.%2BK.%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DGandhi%26aufirst%3DS.%2BG.%26aulast%3DMondhe%26aufirst%3DD.%2BM.%26aulast%3DBhushan%26aufirst%3DS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DDiscovery%2520and%2520preclinical%2520development%2520of%2520IIIM-290%252C%2520an%2520orally%2520active%2520potent%2520cyclin-dependent%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1664%26epage%3D1687%26doi%3D10.1021%2Facs.jmedchem.7b01765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brion, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrat, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levaique, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josselin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messaoudi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamze, A.</span></span> <span> </span><span class="NLM_article-title">Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">112355</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2020.112355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=32402934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpt1Grtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2020&pages=112355&author=N.+Ibrahimauthor=P.+Bonnetauthor=J.+D.+Brionauthor=J.+F.+Peyratauthor=J.+Bignonauthor=H.+Levaiqueauthor=B.+Josselinauthor=T.+Robertauthor=P.+Colasauthor=S.+Bachauthor=S.+Messaoudiauthor=M.+Alamiauthor=A.+Hamze&title=Identification+of+a+new+series+of+flavopiridol-like+structures+as+kinase+inhibitors+with+high+cytotoxic+potency&doi=10.1016%2Fj.ejmech.2020.112355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency</span></div><div class="casAuthors">Ibrahim, Nada; Bonnet, Pascal; Brion, Jean-Daniel; Peyrat, Jean-Francois; Bignon, Jerome; Levaique, Helene; Josselin, Beatrice; Robert, Thomas; Colas, Pierre; Bach, Stephane; Messaoudi, Samir; Alami, Mouad; Hamze, Abdallah</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112355</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">An unique flavopiridol analogs bearing thiosugars, amino acids and heterocyclic moieties I [X = H, R = PhNH, 2-pyrimidylthio, HONHC(O)CH2CH2S, peracetyl-β-D-galactosylthio, etc.; X = Cl, R = benzimidazol-2-ylthio, peracetyl-β-D-glycosylthio] tethered to the flavopiridol via thioether and amine bonds mainly on its C ring was prepd.  The analogs bearing benzimidazolylthio substituents have demonstrated high cytotoxic activity in-vitro against up to seven cancer cell lines.  Their cytotoxic effects were comparable to those of flavopiridol.  The most active compd. I [X = Cl; R = 1-methylbenzimidazol-2-ylthio; (II)] resulting from a structure-activity relationship (SAR) study and in silico docking showed the best antiproliferative activity and was more efficient than the ref. compd.  In addn., the compd. II showed significant nanomolar inhibition against CDK9, CDK10 and GSK3β protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJpwVY4RdHLVg90H21EOLACvtfcHk0li6Bj-PJWkqHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpt1Grtbo%253D&md5=8c555b1f4db21d90dd5d467df77b7321</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112355%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DBrion%26aufirst%3DJ.%2BD.%26aulast%3DPeyrat%26aufirst%3DJ.%2BF.%26aulast%3DBignon%26aufirst%3DJ.%26aulast%3DLevaique%26aufirst%3DH.%26aulast%3DJosselin%26aufirst%3DB.%26aulast%3DRobert%26aufirst%3DT.%26aulast%3DColas%26aufirst%3DP.%26aulast%3DBach%26aufirst%3DS.%26aulast%3DMessaoudi%26aufirst%3DS.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DHamze%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520a%2520new%2520series%2520of%2520flavopiridol-like%2520structures%2520as%2520kinase%2520inhibitors%2520with%2520high%2520cytotoxic%2520potency%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D199%26spage%3D112355%26doi%3D10.1016%2Fj.ejmech.2020.112355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathos, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivakumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276–00</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">918</span>– <span class="NLM_lpage">925</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1535-7163.MCT-06-0613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=17363486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=918-925&issue=3&author=K.+S.+Joshiauthor=M.+J.+Rathosauthor=R.+D.+Joshiauthor=M.+Sivakumarauthor=M.+Mascarenhasauthor=S.+Kambleauthor=B.+Lalauthor=S.+Sharma&title=In+vitro+antitumor+properties+of+a+novel+cyclin-dependent+kinase+inhibitor%2C+P276%E2%80%9300&doi=10.1158%2F1535-7163.MCT-06-0613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Joshi, Rajendra D.; Sivakumar, Meenakshi; Mascarenhas, Malcolm; Kamble, Shrikant; Lal, Bansi; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">918-925</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (Cdk) and their assocd. pathways represent some of the most attractive targets for the development of anticancer therapeutics.  Based on antitumor activity in animal models, a variety of Cdk inhibitors are undergoing clin. evaluation either as a single agent or in combination with other approved drugs.  In our anticancer drug discovery program, a novel series of flavones were synthesized for evaluation against the activity of Cdk4-D1.  This enzyme catalyzes the phosphorylation of retinoblastoma protein, thus inhibiting its function.  We have identified a series of potent Cdk4-D1 inhibitors with IC50 below 250 nmol/L.  In this report, we have described the properties of one of the best compd., P276-00 of the flavone's series.  P276-00 shows 40-fold selectivity toward Cdk4-D1, compared with Cdk2-E.  The specificity toward 14 other related and unrelated kinases was also detd.  P276-00 was found to be more selective with IC50s <100 nmol/L for Cdk4-D1, Cdk1-B, and Cdk9-T1, as compared with other Cdks, and less selective for non-Cdk kinases.  It showed potent antiproliferative effects against various human cancer cell lines, with an IC50 ranging from 300 to 800 nmol/L and was further compared for its antiproliferative activity against cancer and normal fibroblast cell lines.  P276-00 was found to be highly selective for cancer cells as compared with normal fibroblast cells.  To delineate its mechanism of action, the effect of P276-00 on cell cycle proteins was studied in human breast cancer cell line (MCF-7) and human non-small cell lung carcinoma (H-460).  A significant down-regulation of cyclin D1 and Cdk4 and a decrease in Cdk4-specific pRb Ser780 phosphorylation was obsd.  P276-00 produced potent inhibition of Cdk4-D1 activity that was found to be competitive with ATP and not with retinoblastoma protein.  The compd. also induced apoptosis in human promyelocytic leukemia (HL-60) cells, as evidenced by the induction of caspase-3 and DNA ladder studies.  These data suggest that P276-00 has the potential to be developed as an anti-Cdk chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0IzehRnQJk7Vg90H21EOLACvtfcHk0li6Bj-PJWkqHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D&md5=7cc9256a1cd7a960e5e5497ad409a18b</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0613%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DJoshi%26aufirst%3DR.%2BD.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMascarenhas%26aufirst%3DM.%26aulast%3DKamble%26aufirst%3DS.%26aulast%3DLal%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520antitumor%2520properties%2520of%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520P276%25E2%2580%259300%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26issue%3D3%26spage%3D918%26epage%3D925%26doi%3D10.1158%2F1535-7163.MCT-06-0613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cassaday, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chawla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachankar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, A. K.</span></span> <span> </span><span class="NLM_article-title">A phase II, single-arm, open-label, multicenter sudy to evaluate the efficacy and safety of P276–00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma</span>. <i>Clin Lymphoma Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">392</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2015.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.clml.2015.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25816934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnos1Wlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=392-397&issue=7&author=R.+D.+Cassadayauthor=A.+Goyauthor=S.+Advaniauthor=P.+Chawlaauthor=R.+Nachankarauthor=M.+Gandhiauthor=A.+K.+Gopal&title=A+phase+II%2C+single-arm%2C+open-label%2C+multicenter+sudy+to+evaluate+the+efficacy+and+safety+of+P276%E2%80%9300%2C+a+cyclin-dependent+kinase+inhibitor%2C+in+patients+with+relapsed+or+refractory+mantle+cell+lymphoma&doi=10.1016%2Fj.clml.2015.02.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma</span></div><div class="casAuthors">Cassaday Ryan D; Goy Andre; Advani Suresh; Chawla Purvi; Nachankar Rajesh; Gandhi Mansi; Gopal Ajay K</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma, myeloma & leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">392-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Overexpression of cyclin D1 is a hallmark feature of mantle cell lymphoma (MCL).  Many of the oncogenic effects of cyclin D1 are mediated through cyclin-dependent kinases (CDKs).  P276-00 is a potent small molecule inhibitor of CDK4-D1, CDK1-B, and CDK9-T, with promising activity in preclinical models.  In phase I studies of P276-00 in patients with refractory solid neoplasms, it was well-tolerated with a mild trend toward single-agent efficacy.  PATIENTS AND METHODS:  A phase II study of P276-00 was conducted in patients with relapsed or refractory MCL at the recommended dose of 185 mg/m(2)/day from days 1 to 5 of a 21-day cycle.  Thirteen patients were enrolled in the present study.  RESULTS:  Of the 13 patients, 11 experienced disease progression, 1 patient was withdrawn because of an adverse event (AE), and 1 patient died.  Also, 11 patients (84.6%) experienced a treatment-emergent AE deemed related to P276-00.  Of the 13 patients, 9 (69.2%) received ≥ 2 cycles of treatment, which was the predefined threshold to be evaluable for efficacy.  Treatment was discontinued early in 2 patients because of AEs (1 of which was attributed to P276-00 administration) and in 2 patients because of disease progression.  Finally, 2 patients experienced stable disease for an estimated median duration of 60.5 days (range, 58-63 days).  The estimated median time to progression for the predefined efficacy population was 43 days (range, 38-58 days).  CONCLUSION:  Given the results observed in the present study, if evaluation of CDK inhibition in MCL continues, it should be considered earlier in the disease course or as a part of combination strategies for relapsed or refractory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9BvQqGeRc9p6KlWarZTAzfW6udTcc2eaI62SemRvenrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnos1Wlsw%253D%253D&md5=b1062faa6262674828e4338d26e66e00</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2015.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2015.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DCassaday%26aufirst%3DR.%2BD.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DS.%26aulast%3DChawla%26aufirst%3DP.%26aulast%3DNachankar%26aufirst%3DR.%26aulast%3DGandhi%26aufirst%3DM.%26aulast%3DGopal%26aufirst%3DA.%2BK.%26atitle%3DA%2520phase%2520II%252C%2520single-arm%252C%2520open-label%252C%2520multicenter%2520sudy%2520to%2520evaluate%2520the%2520efficacy%2520and%2520safety%2520of%2520P276%25E2%2580%259300%252C%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520mantle%2520cell%2520lymphoma%26jtitle%3DClin%2520Lymphoma%2520Myeloma%2520Leuk.%26date%3D2015%26volume%3D15%26issue%3D7%26spage%3D392%26epage%3D397%26doi%3D10.1016%2Fj.clml.2015.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deckwerth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwin, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalini, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenley, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditzler, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beirne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinman, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghoffer, R. A.</span></span> <span> </span><span class="NLM_article-title">Voruciclib, a clinical stage oral CDK9 inhibitor, represses Mcl-1 and sensitizes high-risk diffuse large B-cell lymphoma to BCL2 inhibition</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-18368-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fs41598-017-18368-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28127051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsl2is7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=1-17&author=J.+Deyauthor=T.+L.+Deckwerthauthor=W.+S.+Kerwinauthor=J.+R.+Casaliniauthor=A.+J.+Merrellauthor=M.+O.+Grenleyauthor=C.+Burnsauthor=S.+H.+Ditzlerauthor=C.+P.+Dixonauthor=E.+Beirneauthor=K.+C.+Gillespieauthor=E.+F.+Kleinmanauthor=R.+A.+Klinghoffer&title=Voruciclib%2C+a+clinical+stage+oral+CDK9+inhibitor%2C+represses+Mcl-1+and+sensitizes+high-risk+diffuse+large+B-cell+lymphoma+to+BCL2+inhibition&doi=10.1038%2Fs41598-017-18368-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial</span></div><div class="casAuthors">Sharma, Surendra K.; Katoch, Kiran; Sarin, Rohit; Balambal, Raman; Kumar Jain, Nirmal; Patel, Naresh; Murthy, Kolluri J. R.; Singla, Neeta; Saha, P. K.; Khanna, Ashwani; Singh, Urvashi; Kumar, Sanjiv; Sengupta, A.; Banavaliker, J. N.; Chauhan, D. S.; Sachan, Shailendra; Wasim, Mohammad; Tripathi, Sanjay; Dutt, Nilesh; Jain, Nitin; Joshi, Nalin; Penmesta, Sita Ram Raju; Gaddam, Sumanlatha; Gupta, Sanjay; Khamar, Bakulesh; Dey, Bindu; Mitra, Dipendra K.; Arora, Sunil K.; Bhaskar, Sangeeta; Rani, Rajni</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prolonged treatment of tuberculosis (TB) often leads to poor compliance, default and relapse, converting primary TB patients into category II TB (Cat IITB) cases, many of whom may convert to multi-drug resistant TB (MDR-TB).  We have evaluated the immunotherapeutic potential of Mycobacterium indicus pranii (MIP) as an adjunct to Anti-Tubercular Treatment (ATT) in Cat II pulmonary TB (PTB) patients in a prospective, randomized, double blind, placebo controlled, multicentric clin. trial. 890 sputum smear pos. Cat II PTB patients were randomized to receive either six intra-dermal injections (2 + 4) of heat-killed MIP at a dose of 5 × 108 bacilli or placebo once in 2 wk for 2 mo.  Sputum smear and culture examns. were performed at different time points.  MIP was safe with no adverse effects.  While sputum smear conversion did not show any statistically significant difference, significantly higher no. of patients (67.1%) in the MIP group achieved sputum culture conversion at fourth week compared to the placebo (57%) group (p = 0.0002), suggesting a role of MIP in clearance of the bacilli.  Since live bacteria are the major contributors for sustained incidence of TB, the potential of MIP in clearance of the bacilli has far reaching implications in controlling the spread of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpny4F2vXMSeLVg90H21EOLACvtfcHk0ljUHlKNh7Iv8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsl2is7zL&md5=a1808af8583b7c02e66c7a32369d5727</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-18368-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-18368-w%26sid%3Dliteratum%253Aachs%26aulast%3DDey%26aufirst%3DJ.%26aulast%3DDeckwerth%26aufirst%3DT.%2BL.%26aulast%3DKerwin%26aufirst%3DW.%2BS.%26aulast%3DCasalini%26aufirst%3DJ.%2BR.%26aulast%3DMerrell%26aufirst%3DA.%2BJ.%26aulast%3DGrenley%26aufirst%3DM.%2BO.%26aulast%3DBurns%26aufirst%3DC.%26aulast%3DDitzler%26aufirst%3DS.%2BH.%26aulast%3DDixon%26aufirst%3DC.%2BP.%26aulast%3DBeirne%26aufirst%3DE.%26aulast%3DGillespie%26aufirst%3DK.%2BC.%26aulast%3DKleinman%26aufirst%3DE.%2BF.%26aulast%3DKlinghoffer%26aufirst%3DR.%2BA.%26atitle%3DVoruciclib%252C%2520a%2520clinical%2520stage%2520oral%2520CDK9%2520inhibitor%252C%2520represses%2520Mcl-1%2520and%2520sensitizes%2520high-risk%2520diffuse%2520large%2520B-cell%2520lymphoma%2520to%2520BCL2%2520inhibition%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D1%26epage%3D17%26doi%3D10.1038%2Fs41598-017-18368-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paiva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godbersen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soderquist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilmarx, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasa, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilov, A. V.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-Cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0143685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1371%2Fjournal.pone.0143685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVWjtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1-16&issue=11&author=C.+Paivaauthor=J.+C.+Godbersenauthor=R.+S.+Soderquistauthor=T.+Rowlandauthor=S.+Kilmarxauthor=S.+E.+Spurgeonauthor=J.+R.+Brownauthor=S.+P.+Srinivasaauthor=A.+V.+Danilov&title=Cyclin-dependent+kinase+inhibitor+P1446A+induces+apoptosis+in+a+JNK%2Fp38+MAPK-dependent+manner+in+chronic+lymphocytic+leukemia+B-Cells&doi=10.1371%2Fjournal.pone.0143685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A role for microRNA-155 expression in microenvironment associated to HPV-induced carcinogenesis in K14-HPV16 transgenic mice [Erratum to document cited in CA163:328997]</span></div><div class="casAuthors">Paiva, Isabel; Gil da Costa, Rui M.; Ribeiro, Joana; Sousa, Hugo; Bastos, Margarida; Faustino-Rocha, Ana; Lopes, Carlos; Oliveira, Paula A.; Medeiros, Rui</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">This article was published with typog. errors in the authors list causing further errors to appear in the author affiliations and the article citation; the correct authors list, author affiliations, and article citation are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ5pr8BgKr9rVg90H21EOLACvtfcHk0lj6JcXz5m-TKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVWjtLzI&md5=a924751dca66e595d6e43261ce14884e</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0143685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0143685%26sid%3Dliteratum%253Aachs%26aulast%3DPaiva%26aufirst%3DC.%26aulast%3DGodbersen%26aufirst%3DJ.%2BC.%26aulast%3DSoderquist%26aufirst%3DR.%2BS.%26aulast%3DRowland%26aufirst%3DT.%26aulast%3DKilmarx%26aufirst%3DS.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DSrinivasa%26aufirst%3DS.%2BP.%26aulast%3DDanilov%26aufirst%3DA.%2BV.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitor%2520P1446A%2520induces%2520apoptosis%2520in%2520a%2520JNK%252Fp38%2520MAPK-dependent%2520manner%2520in%2520chronic%2520lymphocytic%2520leukemia%2520B-Cells%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D11%26spage%3D1%26epage%3D16%26doi%3D10.1371%2Fjournal.pone.0143685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span> <span> </span><span class="NLM_article-title">Voruciclib, a potent CDK4/6 inhibitor, antagonizes ABCB<sub>1</sub> and ABCG<sub>2</sub>-mediated multi-drug resistance in cancer cells</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1528</span>, <span class="refDoi"> DOI: 10.1159/000487578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1159%2F000487578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29486476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlOgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=1515-1528&issue=4&author=P.+Guptaauthor=Y.+K.+Zhangauthor=X.+Y.+Zhangauthor=Y.+J.+Wangauthor=K.+W.+Luauthor=T.+Hallauthor=R.+Pengauthor=D.+H.+Yangauthor=N.+Xieauthor=Z.+S.+Chen&title=Voruciclib%2C+a+potent+CDK4%2F6+inhibitor%2C+antagonizes+ABCB1+and+ABCG2-mediated+multi-drug+resistance+in+cancer+cells&doi=10.1159%2F000487578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells</span></div><div class="casAuthors">Gupta, Pranav; Zhang, Yun-Kai; Zhang, Xiao-Yu; Wang, Yi-Jun; Lu, Kimberly W.; Hall, Timothy; Peng, Richard; Yang, Dong-Hua; Xie, Ni; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1515-1528</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background/Aims: The overexpression of ATP-Binding Cassette (ABC) transporters has known to be one of the major obstacles impeding the success of chemotherapy in drug resistant cancers.  In this study, we evaluated voruciclib, a CDK 4/6 inhibitor, for its chemo-sensitizing activity in ABCB1- and ABCG2- overexpressing cells.  Methods: Cytotoxicity and reversal effect of voruciclib was detd. by MTT assay.  The intracellular accumulation and efflux of ABCB1 and ABCG2 substrates were measured by scintillation counter.  The effects on expression and intracellular localization of ABCB1 and ABCG2 proteins were detd. by Western blotting and immunofluorescence, resp.  Vanadate-sensitive ATPase assay was done to det. the effect of voruciclib on the ATPase activity of ABCB1 and ABCG2.  Flow cytometric anal. was done to det. the effect of voruciclib on apoptosis of ABCB1 and ABCG2-overexpressing cells and docking anal. was done to det. the interaction of voruciclib with ABCB1 and ACBG2 protein.  Results: Voruciclib significantly potentiated the effect of paclitaxel and doxorubicin in ABCB1-overexpressing cells, as well as mitoxantrone and SN-38 in ABCG2-overexpressing cells.  Voruciclib moderately sensitized ABCC10- overexpressing cells to paclitaxel, whereas it did not alter the cytotoxicity of substrates of ABCC1.  Furthermore, voruciclib increased the intracellular accumulation and decreased the efflux of substrate anti-cancer drugs from ABCB1- or ABCG2-overexpressing cells.  However, voruciclib did not alter the expression or the sub-cellular localization of ABCB1 or ABCG2.  Voruciclib stimulated the ATPase activity of both ABCB1 and ABCG2 in a concn.-dependent manner.  Lastly, voruciclib exhibited a drug-induced apoptotic effect in ABCB1- or ABCG2- overexpressing cells.  Conclusion: Voruciclib is currently a phase I clin. trial drug.  Our findings strongly support its potential use in combination with conventional anti-cancer drugs for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoyadf1NgenrVg90H21EOLACvtfcHk0lj6JcXz5m-TKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlOgtLo%253D&md5=03b4795bd5a136b1ea91f0403ee8fb5a</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1159%2F000487578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000487578%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DZhang%26aufirst%3DX.%2BY.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DLu%26aufirst%3DK.%2BW.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DD.%2BH.%26aulast%3DXie%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26atitle%3DVoruciclib%252C%2520a%2520potent%2520CDK4%252F6%2520inhibitor%252C%2520antagonizes%2520ABCB1%2520and%2520ABCG2-mediated%2520multi-drug%2520resistance%2520in%2520cancer%2520cells%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2018%26volume%3D45%26issue%3D4%26spage%3D1515%26epage%3D1528%26doi%3D10.1159%2F000487578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and synthesis of novel wogonin derivatives with potent antitumor activity in vitro</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.09.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2017.09.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28987604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1egsLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=421-434&author=J.+Wangauthor=R.+Geauthor=X.+Qiuauthor=X.+Xuauthor=L.+Weiauthor=Z.+Liauthor=J.+Bian&title=Discovery+and+synthesis+of+novel+wogonin+derivatives+with+potent+antitumor+activity+in+vitro&doi=10.1016%2Fj.ejmech.2017.09.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity in vitro</span></div><div class="casAuthors">Wang, Jubo; Ge, Raoling; Qiu, Xiaqiu; Xu, Xi; Wei, Libin; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">421-434</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Phenotypic screening of high quality compd. library is one of the most effective strategy to obtain novel bioactive compds.  Recently, the authors' group have constructed a Wogonin-scaffold library with substituents diversity and successfully obtained a series of potent compds.  Herein, the authors reported the synthesis of these compds. and evaluated the in vitro antitumor activity against a panel of human tumor cell lines.  Most of them showed good activity with a broad spectrum and preliminary structure-activity relationship for the substitutions were obtained.  Further biol. assays showed that the most potent compds. 18n (7-(benzyloxy)-5-hydroxy-8-(4-(4-methylpiperazin-1-yl)butoxy)-2-phenyl-4H-chromen-4-one) and 20b (7-(4-cyanobenzyloxy)-8-(4-(4-methylpiperazin-1-yl)butoxy)-5-hydroxy-2-phenyl-4H-chromen-4-one) could significantly enhance the intracellular ROS level and induce the cell apoptosis at low micromole level.  Through similarity searching, CDK9 was identified as the potential target for 20b, which could be a start point for next structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe__G_FQ4ourVg90H21EOLACvtfcHk0lj6JcXz5m-TKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1egsLfL&md5=c782025d03a8fe855039eaee0b0c734e</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.09.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.09.046%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DR.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520novel%2520wogonin%2520derivatives%2520with%2520potent%2520antitumor%2520activity%2520in%2520vitro%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D140%26spage%3D421%26epage%3D434%26doi%3D10.1016%2Fj.ejmech.2017.09.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">801</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2019.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31238183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Kjs77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=782-801&author=J.+Wangauthor=T.+Liauthor=T.+Zhaoauthor=T.+Wuauthor=C.+Liuauthor=H.+Dingauthor=Z.+Liauthor=J.+Bian&title=Design+of+wogonin-inspired+selective+cyclin-dependent+kinase+9+%28CDK9%29+inhibitors+with+potent+in+vitro+and+in+vivo+antitumor+activity&doi=10.1016%2Fj.ejmech.2019.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity</span></div><div class="casAuthors">Wang, Jubo; Li, Tinghan; Zhao, Tengteng; Wu, Tizhi; Liu, Chuang; Ding, Hong; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">782-801</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Wogonin, a natural product isolated from the plant Scutellaria baicalensis, has been shown to be a potent and selective inhibitor of CDK9.  With the purpose of investigating the activity and selectivity of this chem. scaffold, several series of wogonin derivs. were prepd. and screened for CDK9 inhibition and cellular antiproliferative activity.  Among these compds., the drug-like compd. 51 (I) showed potent activity against CDK9 (IC50 = 19.9 nM) and MV4-11 cell growth (IC50 = 20 nM).  In addn., compd. 51 showed much improved physicochem. properties, such as water soly., compared with the parent compd. wogonin.  The follow-up studies showed that the compd. 51 is selective toward CDK9-overexpressing cancer cells over normal cells.  Preliminary mechanism studies on the anticancer effect indicated that 51 inhibited the proliferation of MV4-11 cells via caspase-dependent apoptosis.  In addn., highlighted compd. 51 showed significant antitumor activity in mouse acute myeloid leukemia (AML) models without producing apparent toxic effects in vivo, which gave us a new tool for further investigation of CDK9-targeted inhibitor as a potential antitumor drug esp. for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMD5_MDU-cl7Vg90H21EOLACvtfcHk0ljvmS5KW9JZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Kjs77P&md5=5718b8c461f761ca8217b7b782dc7dec</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DDesign%2520of%2520wogonin-inspired%2520selective%2520cyclin-dependent%2520kinase%25209%2520%2528CDK9%2529%2520inhibitors%2520with%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D178%26spage%3D782%26epage%3D801%26doi%3D10.1016%2Fj.ejmech.2019.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3)</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1007/s00894-012-1528-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs00894-012-1528-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=22820730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=119-130&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=H.+Nagarajauthor=M.+Williamsauthor=H.+Wangauthor=A.+Leeauthor=E.+Sunauthor=E.+L.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-based+design+of+nitrogen-linked+macrocyclic+kinase+inhibitors+leading+to+the+clinical+candidate+SB1317%2FTG02%2C+a+potent+inhibitor+of+cyclin+dependant+kinases+%28CDKs%29%2C+janus+kinase+2+%28JAK2%29%2C+and+fms-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1007%2Fs00894-012-1528-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Poulsen, Anders; William, Anthony; Blanchard, Stephanie; Nagaraj, Harish; Williams, Meredith; Wang, Haishan; Lee, Angeline; Sun, Eric; Teo, Ee-Ling; Tan, Evelyn; Goh, Kee Chuan; Dymock, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-130</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A high-throughput screen against Aurora A kinase revealed several promising submicromolar pyrimidine-aniline leads.  The bioactive conformation found by docking these leads into the Aurora A ATP-binding site had a semicircular shape.  Macrocycle formation was proposed to achieve novelty and selectivity via ring-closing metathesis of a diene precursor.  The nature of the optimal linker and its size was directed by docking.  In a kinase panel screen, selected macrocycles were active on other kinase targets, mainly FLT3, JAK2, and CDKs.  These compds. then became leads in a CDK/FLT3/JAK2 inhibitor project.  Macrocycles with a basic nitrogen in the linker form a salt bridge with Asp86 in CDK2 and Asp698 in FLT3.  Interaction with this residue explains the obsd. selectivity.  The Asp86 residue is conserved in most CDKs, resulting in potent pan-CDK inhibition by these compds.  Optimized macrocycles generally have good DMPK properties, and are efficacious in mouse models of cancer.  Compd. 5 (SB1317/TG02), a pan-CDK/FLT3/JAK2 inhibitor, was selected for preclin. development, and is now in phase 1 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnGiv82CuwbVg90H21EOLACvtfcHk0ljvmS5KW9JZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D&md5=3f65c0a7f61329cabb9e85656a2c3dcf</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2Fs00894-012-1528-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-012-1528-7%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-based%2520design%2520of%2520nitrogen-linked%2520macrocyclic%2520kinase%2520inhibitors%2520leading%2520to%2520the%2520clinical%2520candidate%2520SB1317%252FTG02%252C%2520a%2520potent%2520inhibitor%2520of%2520cyclin%2520dependant%2520kinases%2520%2528CDKs%2529%252C%2520janus%2520kinase%25202%2520%2528JAK2%2529%252C%2520and%2520fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2013%26volume%3D19%26spage%3D119%26epage%3D130%26doi%3D10.1007%2Fs00894-012-1528-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfeliciano, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: recent advances (2015–2019)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126637</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bmcl.2019.126637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31477350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWjs73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126637&author=C.+Sanchez-Martinezauthor=M.+J.+Lallenaauthor=S.+G.+Sanfelicianoauthor=A.+de+Dios&title=Cyclin+dependent+kinase+%28CDK%29+inhibitors+as+anticancer+drugs%3A+recent+advances+%282015%E2%80%932019%29&doi=10.1016%2Fj.bmcl.2019.126637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019)</span></div><div class="casAuthors">Sanchez-Martinez, Concepcion; Lallena, Maria Jose; Sanfeliciano, Sonia Gutierrez; de Dios, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">126637</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sustained proliferative capacity and gene dysregulation are hallmarks of cancer.  In mammalian cells, cyclin-dependent kinases (CDKs) control crit. cell cycle checkpoints and key transcriptional events in response to extracellular and intracellular signals leading to proliferation.  Significant clin. activity for the treatment of hormone receptor pos. metastatic breast cancer has been demonstrated by palbociclib, ribociclib and abemaciclib, dual CDK4/6 inhibitors recently FDA-approved.  SY-1365, a CDK7 inhibitor has shown initial encouraging data in phase I for solid tumors treatment.  These results have rejuvenated the CDKs research field.  This review provides an overview of relevant advances on CDK inhibitor research since 2015 to 2019, with special emphasis on transcriptional CDK inhibitors, new emerging strategies such as target protein degrdn. and compds. under clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcZ4sKIv0DfrVg90H21EOLACvtfcHk0ljvmS5KW9JZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWjs73N&md5=2808e04d5c09daad462133bcf9b9cb3d</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126637%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Martinez%26aufirst%3DC.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3DSanfeliciano%26aufirst%3DS.%2BG.%26aulast%3Dde%2BDios%26aufirst%3DA.%26atitle%3DCyclin%2520dependent%2520kinase%2520%2528CDK%2529%2520inhibitors%2520as%2520anticancer%2520drugs%253A%2520recent%2520advances%2520%25282015%25E2%2580%25932019%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126637%26doi%3D10.1016%2Fj.bmcl.2019.126637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pallis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Aziz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seedhouse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N.</span></span> <span> </span><span class="NLM_article-title">The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1111/bjh.12018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1111%2Fbjh.12018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=22934750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2qs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2012&pages=191-203&author=M.+Pallisauthor=A.+Abdul-Azizauthor=F.+Burrowsauthor=C.+Seedhouseauthor=M.+Grundyauthor=N.+Russell&title=The+multi-kinase+inhibitor+TG02+overcomes+signalling+activation+by+survival+factors+to+deplete+MCL1+and+XIAP+and+induce+cell+death+in+primary+acute+myeloid+leukaemia+cells&doi=10.1111%2Fbjh.12018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells</span></div><div class="casAuthors">Pallis, Monica; Abdul-Aziz, Amina; Burrows, Francis; Seedhouse, Claire; Grundy, Martin; Russell, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-203</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summmary : The novel multi-kinase inhibitor TG02 has selectivity against cell cycle and transcriptional cyclin dependent kinases (CDKs) as well as fms-like tyrosine kinase receptor-3 (FLT3).  Inhibition of transcriptional CDKs preferentially depletes short-lived proteins such as MCL1.  We evaluated the in vitro toxicity of TG02 to primary acute myeloid leukemia (AML) cells in the presence of survival signalling pathway activation by cytokines and fibronectin.  One hundred nanomolar TG02 induced a median decrease of 40% in bulk cell survival and 43% in the CD34+CD38-CD123+subset.  A 90% inhibitory concn. of 500 nmol/l indicated that TG02 toxicity is not halted by protective cell cycle arrest.  Samples with FLT3 internal tandem duplication were not preferentially targeted.  By flow cytometry, TG02 treatment caused loss of RNA Polymerase II serine 2 phosphorylation in patient samples, which correlated strongly with BAX activation (R2=0·89), suggesting these as potential biomarkers for clin. studies.  MCL1 and XIAP expression also decreased.  Repeated brief exposure to TG02 in MOLM-13 cells did not result in compensatory up-regulation of survival protein expression.  In conclusion, TG02 is potently cytotoxic towards CD34+CD38-CD123+ and bulk AML cells, despite protective signalling pathway activation.  This antitumor activity is most likely mediated by dephosphorylation of RNA Polymerase II leading to depletion of survival mols. such as MCL1 and XIAP, with subsequent BAX activation and apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3mvr_3yc0bVg90H21EOLACvtfcHk0ljfsd9vGZZtdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2qs73J&md5=e8da0f2e7a1a5fcf03f90e68311ab294</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12018%26sid%3Dliteratum%253Aachs%26aulast%3DPallis%26aufirst%3DM.%26aulast%3DAbdul-Aziz%26aufirst%3DA.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DSeedhouse%26aufirst%3DC.%26aulast%3DGrundy%26aufirst%3DM.%26aulast%3DRussell%26aufirst%3DN.%26atitle%3DThe%2520multi-kinase%2520inhibitor%2520TG02%2520overcomes%2520signalling%2520activation%2520by%2520survival%2520factors%2520to%2520deplete%2520MCL1%2520and%2520XIAP%2520and%2520induce%2520cell%2520death%2520in%2520primary%2520acute%2520myeloid%2520leukaemia%2520cells%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2012%26volume%3D159%26spage%3D191%26epage%3D203%26doi%3D10.1111%2Fbjh.12018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Discovery and sars of 5-chloro-n(4)-phenyl-n(2)-(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as oral available and dual CDK6 and 9 inhibitors with potent antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3327</span>– <span class="NLM_lpage">3347</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02121</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02121" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlOgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3327-3347&author=Y.+Wangauthor=X.+Chenauthor=Y.+Yanauthor=X.+Zhuauthor=M.+Liuauthor=X.+Liu&title=Discovery+and+sars+of+5-chloro-n%284%29-phenyl-n%282%29-%28pyridin-2-yl%29pyrimidine-2%2C4-diamine+derivatives+as+oral+available+and+dual+CDK6+and+9+inhibitors+with+potent+antitumor+activity&doi=10.1021%2Facs.jmedchem.9b02121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SARs of 5-Chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity</span></div><div class="casAuthors">Wang, Yang; Chen, Xing; Yan, Yaoyao; Zhu, Xiaochen; Liu, Mingming; Liu, Xinhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3327-3347</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are promising therapeutic targets for cancer therapy.  Herein, we describe our efforts toward the discovery of a series of 5-chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine derivs. as dual CDK6 and 9 inhibitors.  Intensive structural modifications lead to the identification of compd. 66 as the most active dual CDK6/9 inhibitor with balancing potency against these two targets and good selectivity over CDK2.  Further biol. studies revealed that compd. 66 was directly bound to CDK6/9, resulting in suppression of their downstream signaling pathway and inhibition of cell proliferation by blocking cell cycle progression and inducing cellular apoptosis.  More importantly, compd. 66 significantly inhibited tumor growth in a xenograft mouse model with no obvious toxicity, indicating the promising therapeutic potential of CDK6/9 dual inhibitors for cancer treatment.  Therefore, the above results are of great importance in the development of dual CDK6/9 inhibitors for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp0hGRgNOM4LVg90H21EOLACvtfcHk0ljfsd9vGZZtdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlOgs70%253D&md5=151501473ce1ccd19bc8cc488286201d</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02121%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DDiscovery%2520and%2520sars%2520of%25205-chloro-n%25284%2529-phenyl-n%25282%2529-%2528pyridin-2-yl%2529pyrimidine-2%252C4-diamine%2520derivatives%2520as%2520oral%2520available%2520and%2520dual%2520CDK6%2520and%25209%2520inhibitors%2520with%2520potent%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3327%26epage%3D3347%26doi%3D10.1021%2Facs.jmedchem.9b02121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huff, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span> <span> </span><span class="NLM_article-title">Variolins and related alkaloids</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3080</span>– <span class="NLM_lpage">3098</span>, <span class="refDoi"> DOI: 10.1021/cr900032s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr900032s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1ensL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=3080-3098&issue=7&author=S.+R.+Walkerauthor=E.+J.+Carterauthor=B.+C.+Huffauthor=J.+C.+Morris&title=Variolins+and+related+alkaloids&doi=10.1021%2Fcr900032s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Variolins and Related Alkaloids</span></div><div class="casAuthors">Walker, Scott R.; Carter, Erin J.; Huff, Belinda C.; Morris, Jonathan C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3080-3098</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review was presented that summarized the isolation, structure detn., synthetic studies and biol. activities of the variolins, meridianins, and meriolins.  The identification and development of new cyclin-dependent kinase (CDK) inhibitors is an important area of research, particularly in the area of cancer chemotherapeutics.  The isolation of variolin B and the meridianins has resulted in a new scaffold being identified.  However, access to these compds. from their natural source, particularly in the case of variolin B, is very difficult, and as such, total synthesis was required to restore access.  This has allowed for more thorough biol. testing and allowed insights into the mode of action of these compds.  It is difficult to say whether variolin B or its deoxy analog will make it to clin. trials because there are issues with their soly. in water and their pharmacokinetic behavior.  However, work on these natural products has led to the discovery that the meriolins, synthetic hybrids that contain common structural features from each family, possess biol. activities that surpass those of either class of natural products.  Work by Meijer and co-workers suggests that the meriolins constitute a potent kinase inhibitory scaffold, and as such, these compds. may in turn inform the development of the next generation of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHctKcp2TF0bVg90H21EOLACvtfcHk0lgy5AvTqf_sMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1ensL8%253D&md5=7e617c38d72081988898dae97a40c3d8</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fcr900032s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900032s%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DS.%2BR.%26aulast%3DCarter%26aufirst%3DE.%2BJ.%26aulast%3DHuff%26aufirst%3DB.%2BC.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26atitle%3DVariolins%2520and%2520related%2520alkaloids%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26issue%3D7%26spage%3D3080%26epage%3D3098%26doi%3D10.1021%2Fcr900032s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marionneau-Lambot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo-Lozano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schächtele, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubbutat, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notario, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">8325</span>– <span class="NLM_lpage">8334</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1826</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F0008-5472.CAN-07-1826" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=17804748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFKju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=8325-8334&issue=17&author=K.+Bettayebauthor=O.+M.+Tiradoauthor=S.+Marionneau-Lambotauthor=Y.+Ferandinauthor=O.+Lozachauthor=J.+C.+Morrisauthor=S.+Mateo-Lozanoauthor=P.+Drueckesauthor=C.+Sch%C3%A4chteleauthor=M.+H.+Kubbutatauthor=F.+Ligerauthor=B.+Marquetauthor=B.+Josephauthor=A.+Echalierauthor=J.+A.+Endicottauthor=V.+Notarioauthor=L.+Meijer&title=Meriolins%2C+a+new+class+of+cell+death+inducing+kinase+inhibitors+with+enhanced+selectivity+for+cyclin-dependent+kinases&doi=10.1158%2F0008-5472.CAN-07-1826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Meriolins, a New Class of Cell Death-Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin-Dependent Kinases</span></div><div class="casAuthors">Bettayeb, Karima; Tirado, Oscar M.; Marionneau-Lambot, Severine; Ferandin, Yoan; Lozach, Olivier; Morris, Jonathan C.; Mateo-Lozano, Silvia; Drueckes, Peter; Schaechtele, Christoph; Kubbutat, Michael H. G.; Liger, Francois; Marquet, Bernard; Joseph, Benoit; Echalier, Aude; Endicott, Jane A.; Notario, Vicente; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8325-8334</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Protein kinases represent promising anticancer drug targets.  We describe here the meriolins, a new family of inhibitors of cyclin-dependent kinases (CDK).  Meriolins represent a chem. structural hybrid between meridianins and variolins, two families of kinase inhibitors extd. from various marine invertebrates.  Variolin B is currently in preclin. evaluation as an antitumor agent.  A selectivity study done on 32 kinases showed that, compared with variolin B, meriolins display enhanced specificity toward CDKs, with marked potency on CDK2 and CDK9.  The structures of pCDK2/cyclin A/variolin B and pCDK2/cyclin A/meriolin 3 complexes reveal that the two inhibitors bind within the ATP binding site of the kinase, but in different orientations.  Meriolins display better antiproliferative and proapoptotic properties in human tumor cell cultures than their parent mols., meridianins and variolins.  Phosphorylation at CDK1, CDK4, and CDK9 sites on, resp., protein phosphatase 1α, retinoblastoma protein, and RNA polymerase II is inhibited in neuroblastoma SH-SY5Y cells exposed to meriolins.  Apoptosis triggered by meriolins is accompanied by rapid Mcl-1 down-regulation, cytochrome c release, and activation of caspases.  Meriolin 3 potently inhibits tumor growth in two mouse xenograft cancer models, namely, Ewing's sarcoma and LS174T colorectal carcinoma.  Meriolins thus constitute a new CDK inhibitory scaffold, with promising antitumor activity, derived from mols. initially isolated from marine organisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopZcnwG1KL77Vg90H21EOLACvtfcHk0lgy5AvTqf_sMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFKju7g%253D&md5=651f574186c0ff8f13db4edf47220e89</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1826%26sid%3Dliteratum%253Aachs%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DTirado%26aufirst%3DO.%2BM.%26aulast%3DMarionneau-Lambot%26aufirst%3DS.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26aulast%3DMateo-Lozano%26aufirst%3DS.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DSch%25C3%25A4chtele%26aufirst%3DC.%26aulast%3DKubbutat%26aufirst%3DM.%2BH.%26aulast%3DLiger%26aufirst%3DF.%26aulast%3DMarquet%26aufirst%3DB.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNotario%26aufirst%3DV.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DMeriolins%252C%2520a%2520new%2520class%2520of%2520cell%2520death%2520inducing%2520kinase%2520inhibitors%2520with%2520enhanced%2520selectivity%2520for%2520cyclin-dependent%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D17%26spage%3D8325%26epage%3D8334%26doi%3D10.1158%2F0008-5472.CAN-07-1826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clément, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1021/jm700940h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm700940h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2msL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=737-751&issue=4&author=A.+Echalierauthor=K.+Bettayebauthor=Y.+Ferandinauthor=O.+Lozachauthor=M.+Cl%C3%A9mentauthor=A.+Valetteauthor=F.+Ligerauthor=B.+Marquetauthor=J.+C.+Morrisauthor=J.+A.+Endicottauthor=B.+Josephauthor=L.+Meijer&title=Meriolins+%283-%28pyrimidin-4-yl%29-7-azaindoles%29%3A+synthesis%2C+kinase+inhibitory+activity%2C+cellular+effects%2C+and+structure+of+a+CDK2%2Fcyclin+A%2Fmeriolin+complex&doi=10.1021%2Fjm700940h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Meriolins (3-(Pyrimidin-4-yl)-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/Cyclin A/Meriolin Complex</span></div><div class="casAuthors">Echalier, Aude; Bettayeb, Karima; Ferandin, Yoan; Lozach, Olivier; Clelment, Monique; Valette, Annie; Liger, Francois; Marquet, Bernard; Morris, Jonathan C.; Endicott, Jane A.; Joseph, Benoit; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">737-751</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis and biol. characterization of 3-(pyrimidin-4-yl)-7-azaindoles (meriolins), a chem. hybrid between the natural products meridianins and variolins, derived from marine organisms.  Meriolins display potent inhibitory activities toward cyclin-dependent kinases (CDKs) and, to a lesser extent, other kinases (GSK-3, DYRK1A).  The crystal structures of I (meriolin 5) and variolin B in complex with CDK2/cyclin A reveal that the two inhibitors are oriented in very different ways inside the ATP-binding pocket of the kinase.  A structure-activity relationship provides further insight into the mol. mechanism of action of this family of kinase inhibitors.  Meriolins are also potent antiproliferative and proapoptotic agents in cells cultured either as monolayers or in spheroids.  Proapoptotic efficacy of meriolins correlates best with their CDK2 and CDK9 inhibitory activity.  Meriolins thus constitute a promising class of pharmacol. agents to be further evaluated against the numerous human diseases that imply abnormal regulation of CDKs including cancers, neurodegenerative disorders, and polycystic kidney disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJgno3A1_7LVg90H21EOLACvtfcHk0li6DKQ_JCkBKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2msL8%253D&md5=1bfb3d02c6894c04237eee27bbccaa5b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm700940h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm700940h%26sid%3Dliteratum%253Aachs%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DM.%26aulast%3DValette%26aufirst%3DA.%26aulast%3DLiger%26aufirst%3DF.%26aulast%3DMarquet%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DMeriolins%2520%25283-%2528pyrimidin-4-yl%2529-7-azaindoles%2529%253A%2520synthesis%252C%2520kinase%2520inhibitory%2520activity%252C%2520cellular%2520effects%252C%2520and%2520structure%2520of%2520a%2520CDK2%252Fcyclin%2520A%252Fmeriolin%2520complex%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D4%26spage%3D737%26epage%3D751%26doi%3D10.1021%2Fjm700940h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chashoo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargotra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintoo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guru, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aruri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatikonda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibber, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mir, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madishetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondhe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. P.</span></span> <span> </span><span class="NLM_article-title">Design of novel 3-pyrimidinylazaindole CDK2/9 inhibitors with potent in vitro and in vivo antitumor efficacy in a triple-negative breast cancer model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">9470</span>– <span class="NLM_lpage">9489</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00663</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00663" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9470-9489&issue=23&author=U.+Singhauthor=G.+Chashooauthor=S.+U.+Khanauthor=P.+Mahajanauthor=A.+Nargotraauthor=G.+Mahajanauthor=A.+Singhauthor=A.+Sharmaauthor=M.+J.+Mintooauthor=S.+K.+Guruauthor=H.+Aruriauthor=T.+Thatikondaauthor=P.+Sahuauthor=P.+Chibberauthor=V.+Kumarauthor=S.+A.+Mirauthor=S.+S.+Bharateauthor=S.+Madishettiauthor=U.+Nandiauthor=G.+Singhauthor=D.+M.+Mondheauthor=S.+Bhushanauthor=F.+Malikauthor=S.+Mignaniauthor=R.+A.+Vishwakarmaauthor=P.+P.+Singh&title=Design+of+novel+3-pyrimidinylazaindole+CDK2%2F9+inhibitors+with+potent+in+vitro+and+in+vivo+antitumor+efficacy+in+a+triple-negative+breast+cancer+model&doi=10.1021%2Facs.jmedchem.7b00663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model</span></div><div class="casAuthors">Singh, Umed; Chashoo, Gousia; Khan, Sameer U.; Mahajan, Priya; Nargotra, Amit; Mahajan, Girish; Singh, Amarinder; Sharma, Anjna; Mintoo, Mubashir J.; Guru, Santosh Kumar; Aruri, Hariprasad; Thatikonda, Thanusha; Sahu, Promod; Chibber, Pankaj; Kumar, Vikas; Mir, Sameer A.; Bharate, Sonali S.; Madishetti, Sreedhar; Nandi, Utpal; Singh, Gurdarshan; Mondhe, Dilip Manikrao; Bhushan, Shashi; Malik, Fayaz; Mignani, Serge; Vishwakarma, Ram A.; Singh, Parvinder Pal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9470-9489</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present study, novel series of 3-pyrimidinylazaindoles were designed and synthesized using bioinformatics strategy as cyclin-dependent kinases CDK2 and CDK9 inhibitors, which play crit. roles in cell-cycle control and regulation of cell transcription.  The present approach has given new dimensions to existing SAR and opens the new opportunity for lead optimization from comparatively inexpensive starting materials.  The study led to the identification of alternative lead candidate I with nanomolar potency against CDK2 and CDK9 and potent anti-proliferative activities against a panel of tested tumor cell lines along better safety ratio of ∼30 in comparison to reported leads.  In addn., the identified lead I has demonstrated good soly. and acceptable in vivo PK profile.  The identified lead I has also shown in vivo efficacy in mouse triple neg. breast cancer (TNBC) syngeneic model with TGI of 90% without any mortality growth inhibition in comparison to reported leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvqLjfKAkGYbVg90H21EOLACvtfcHk0li6DKQ_JCkBKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbnL&md5=5f6edf3003a3a7b2e9b29d51c68846d1</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00663%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DU.%26aulast%3DChashoo%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DS.%2BU.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DNargotra%26aufirst%3DA.%26aulast%3DMahajan%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DMintoo%26aufirst%3DM.%2BJ.%26aulast%3DGuru%26aufirst%3DS.%2BK.%26aulast%3DAruri%26aufirst%3DH.%26aulast%3DThatikonda%26aufirst%3DT.%26aulast%3DSahu%26aufirst%3DP.%26aulast%3DChibber%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMir%26aufirst%3DS.%2BA.%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DMadishetti%26aufirst%3DS.%26aulast%3DNandi%26aufirst%3DU.%26aulast%3DSingh%26aufirst%3DG.%26aulast%3DMondhe%26aufirst%3DD.%2BM.%26aulast%3DBhushan%26aufirst%3DS.%26aulast%3DMalik%26aufirst%3DF.%26aulast%3DMignani%26aufirst%3DS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DSingh%26aufirst%3DP.%2BP.%26atitle%3DDesign%2520of%2520novel%25203-pyrimidinylazaindole%2520CDK2%252F9%2520inhibitors%2520with%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520efficacy%2520in%2520a%2520triple-negative%2520breast%2520cancer%2520model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D23%26spage%3D9470%26epage%3D9489%26doi%3D10.1021%2Facs.jmedchem.7b00663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of N1-(4-((7-cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a novel inhibitor targeting cyclin-dependent kinase 4/9 (CDK4/9) and histone deacetlyase1 (HDAC1) against malignant cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3166</span>– <span class="NLM_lpage">3192</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00209</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00209" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFWgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3166-3192&issue=7&author=Y.+Liauthor=X.+Luoauthor=Q.+Guoauthor=Y.+Nieauthor=T.+Wangauthor=C.+Zhangauthor=Z.+Huangauthor=X.+Wangauthor=Y.+Liuauthor=Y.+Chenauthor=J.+Zhengauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=Discovery+of+N1-%284-%28%287-cyclopentyl-6-%28dimethylcarbamoyl%29-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-2-yl%29amino%29phenyl%29-N8-hydroxyoctanediamide+as+a+novel+inhibitor+targeting+cyclin-dependent+kinase+4%2F9+%28CDK4%2F9%29+and+histone+deacetlyase1+%28HDAC1%29+against+malignant+cancer&doi=10.1021%2Facs.jmedchem.8b00209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetylase 1 (HDAC1) against Malignant Cancer</span></div><div class="casAuthors">Li, Yongtao; Luo, Xiaohe; Guo, Qingxiang; Nie, Yongwei; Wang, Tianqi; Zhang, Chao; Huang, Zhi; Wang, Xin; Liu, Yanhua; Chen, Yanan; Zheng, Jianyu; Yang, Shengyong; Fan, Yan; Xiang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3166-3192</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of highly potent, selective inhibitors targeting both CDK4/9 and HDAC1 have been designed and synthesized.  N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide (I) was discovered.  The lead compd. I with excellent CDK4/9 and HDAC1 inhibitory activity of IC50 = 8.8, 12, and 2.2 nM, resp., can effectively induce apoptosis of cancer cell lines.  The kinase profiling of compd. I showed excellent selectivity and specificity.  Compd. I induces G2/M arrest in high concn. and G0/G1 arrest in low concn. to prevent the proliferation and differentiation of cancer cells.  Mice bared-breast cancer treated with I showed significant antitumor efficacy.  The insight into mechanisms of I indicated that it could induce cancer cell death via cell apoptosis based on CDK4/9 and HDAC1 repression and phosphorylation of p53.  The data demonstrated the compd. I could be a promising drug candidate for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4B7BpJ-foDbVg90H21EOLACvtfcHk0li6DKQ_JCkBKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFWgs7c%253D&md5=b1ca389e67a3ccd3fe5c005cb547e369</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00209%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DNie%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520N1-%25284-%2528%25287-cyclopentyl-6-%2528dimethylcarbamoyl%2529-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-2-yl%2529amino%2529phenyl%2529-N8-hydroxyoctanediamide%2520as%2520a%2520novel%2520inhibitor%2520targeting%2520cyclin-dependent%2520kinase%25204%252F9%2520%2528CDK4%252F9%2529%2520and%2520histone%2520deacetlyase1%2520%2528HDAC1%2529%2520against%2520malignant%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D3166%26epage%3D3192%26doi%3D10.1021%2Facs.jmedchem.8b00209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3231</span>– <span class="NLM_lpage">3237</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.06.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bmcl.2017.06.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28651979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKhs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=3231-3237&issue=15&author=Y.+Liauthor=Q.+Guoauthor=C.+Zhangauthor=Z.+Huangauthor=T.+Wangauthor=X.+Wangauthor=X.+Wangauthor=G.+Xuauthor=Y.+Liuauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=Discovery+of+a+highly+potent%2C+selective+and+novel+CDK9+inhibitor+as+an+anticancer+drug+candidate&doi=10.1016%2Fj.bmcl.2017.06.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate</span></div><div class="casAuthors">Li, Yongtao; Guo, Qingxiang; Zhang, Chao; Huang, Zhi; Wang, Tianqi; Wang, Xin; Wang, Xiang; Xu, Guangwei; Liu, Yanhua; Yang, Shengyong; Fan, Yan; Xiang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3231-3237</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arylaminocarbonylcyclopropanecarbonylaminophenylamino pyrrolopyridiminecarboxamide hybrids of the antitumor CDK inhibitor LEE011 and the antitumor VEGFR2 inhibitor cabozantinib such as I were prepd. as potential antitumor agents.  I inhibited CDK9 with an IC50 value of 12 nM, induced apoptosis in breast and lung cancer cell lines at nanomolar concns., and suppressed the growth of breast cancer xenografts in mice without causing significant wt. loss.  Mol. docking calcns. of I bound to the ATP binding site of CDK9 kinase demonstrated the formation of a hydrogen bond between the fluorine atom of the fluorobenzyloxy group and ASN116 not seen in mol. docking calcns. of LEE011.  I blocked cancer cell replication in the G0/G1 and G2/M phases and induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrylmH0vyLZuLVg90H21EOLACvtfcHk0liOkjM8iuPWnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKhs7nP&md5=58f48a7866815b6b6935100d2ddd9e4e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.06.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.06.041%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520potent%252C%2520selective%2520and%2520novel%2520CDK9%2520inhibitor%2520as%2520an%2520anticancer%2520drug%2520candidate%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D15%26spage%3D3231%26epage%3D3237%26doi%3D10.1016%2Fj.bmcl.2017.06.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosemund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terebesi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bömer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choidas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaumer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rühter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span> <span> </span><span class="NLM_article-title">Identification of atuveciclib (BAY1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">1776</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1002%2Fcmdc.201700447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28961375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1776-1793&issue=21&author=U.+L%C3%BCckingauthor=A.+Scholzauthor=P.+Lienauauthor=G.+Siemeisterauthor=D.+Kosemundauthor=R.+Bohlmannauthor=H.+Briemauthor=I.+Terebesiauthor=K.+Meyerauthor=K.+Prelleauthor=K.+Dennerauthor=U.+B%C3%B6merauthor=M.+Sch%C3%A4ferauthor=K.+Eisauthor=R.+Valenciaauthor=S.+Inceauthor=F.+von+Nussbaumauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=B.+Kleblauthor=A.+Choidasauthor=P.+Nussbaumerauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=G.+R%C3%BChterauthor=J.+Eickhoffauthor=M.+Brands&title=Identification+of+atuveciclib+%28BAY1143572%29%2C+the+first+highly+selective%2C+clinical+PTEFb%2FCDK9+inhibitor+for+the+treatment+of+cancer&doi=10.1002%2Fcmdc.201700447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Luecking, Ulrich; Scholz, Arne; Lienau, Philip; Siemeister, Gerhard; Kosemund, Dirk; Bohlmann, Rolf; Briem, Hans; Terebesi, Ildiko; Meyer, Kirstin; Prelle, Katja; Denner, Karsten; Boemer, Ulf; Schaefer, Martina; Eis, Knut; Valencia, Ray; Ince, Stuart; von Nussbaum, Franz; Mumberg, Dominik; Ziegelbauer, Karl; Klebl, Bert; Choidas, Axel; Nussbaumer, Peter; Baumann, Matthias; Schultz-Fademrecht, Carsten; Ruehter, Gerd; Eickhoff, Jan; Brands, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1776-1793</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy.  Starting from lead compd. BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochem. and DMPK properties finally led to the identification of the orally available clin. candidate atuveciclib (BAY 1143572).  Structurally characterized by an unusual benzyl sulfoximine group, BAY 1143572 exhibited the best overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats.  BAY 1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypgkxBuypa7Vg90H21EOLACvtfcHk0liOkjM8iuPWnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ&md5=04fb5dae9956246889e1313c87339990</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700447%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DBohlmann%26aufirst%3DR.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DTerebesi%26aufirst%3DI.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DPrelle%26aufirst%3DK.%26aulast%3DDenner%26aufirst%3DK.%26aulast%3DB%25C3%25B6mer%26aufirst%3DU.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DEis%26aufirst%3DK.%26aulast%3DValencia%26aufirst%3DR.%26aulast%3DInce%26aufirst%3DS.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DNussbaumer%26aufirst%3DP.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DR%25C3%25BChter%26aufirst%3DG.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DBrands%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520atuveciclib%2520%2528BAY1143572%2529%252C%2520the%2520first%2520highly%2520selective%252C%2520clinical%2520PTEFb%252FCDK9%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26issue%3D21%26spage%3D1776%26epage%3D1793%26doi%3D10.1002%2Fcmdc.201700447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luecking, U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosemund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terebesi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaum, F. v.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span> <span> </span><span class="NLM_article-title">Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from P.O. to I.V. application via scaffold hops</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">984</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1538-7445.AM2017-984" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=984&author=U.+T.+Lueckingauthor=A.+Scholzauthor=D.+Kosemundauthor=R.+Bohlmannauthor=H.+Briemauthor=P.+Lienauauthor=G.+Siemeisterauthor=I.+Terebesiauthor=K.+Meyerauthor=K.+Prelleauthor=R.+Valenciaauthor=S.+Inceauthor=F.+v.+Nussbaumauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=M.+Brands&title=Identification+of+potent+and+highly+selective+PTEFb+inhibitor+BAY+1251152+for+the+treatment+of+cancer%3A+from+P.O.+to+I.V.+application+via+scaffold+hops&doi=10.1158%2F1538-7445.AM2017-984"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-984%26sid%3Dliteratum%253Aachs%26aulast%3DLuecking%26aufirst%3DU.%2BT.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DBohlmann%26aufirst%3DR.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DTerebesi%26aufirst%3DI.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DPrelle%26aufirst%3DK.%26aulast%3DValencia%26aufirst%3DR.%26aulast%3DInce%26aufirst%3DS.%26aulast%3DNussbaum%26aufirst%3DF.%2Bv.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DBrands%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520potent%2520and%2520highly%2520selective%2520PTEFb%2520inhibitor%2520BAY%25201251152%2520for%2520the%2520treatment%2520of%2520cancer%253A%2520from%2520P.O.%2520to%2520I.V.%2520application%2520via%2520scaffold%2520hops%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D984%26doi%3D10.1158%2F1538-7445.AM2017-984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cidado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boiko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span> <span> </span><span class="NLM_article-title">AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3572</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-3572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1538-7445.AM2016-3572" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=3572&author=J.+Cidadoauthor=M.+Shenauthor=M.+Grondineauthor=S.+Boikoauthor=H.+Wangauthor=A.+Borodovskyauthor=A.+M.+Mazzolaauthor=A.+Wuauthor=D.+Lawsonauthor=D.+Fergusonauthor=B.+Gaoauthor=A.+Cuiauthor=C.+D%E2%80%99Cruzauthor=L.+Drew&title=AZ5576%2C+a+novel+potent+and+selective+CDK9+inhibitor%2C+induces+rapid+cell+death+and+achieves+efficacy+in+multiple+preclinical+hematological+models&doi=10.1158%2F1538-7445.AM2016-3572"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-3572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-3572%26sid%3Dliteratum%253Aachs%26aulast%3DCidado%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DGrondine%26aufirst%3DM.%26aulast%3DBoiko%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBorodovsky%26aufirst%3DA.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DLawson%26aufirst%3DD.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DB.%26aulast%3DCui%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Cruz%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26atitle%3DAZ5576%252C%2520a%2520novel%2520potent%2520and%2520selective%2520CDK9%2520inhibitor%252C%2520induces%2520rapid%2520cell%2520death%2520and%2520achieves%2520efficacy%2520in%2520multiple%2520preclinical%2520hematological%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D14%26spage%3D3572%26doi%3D10.1158%2F1538-7445.AM2016-3572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cidado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boiko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criscione, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pop-Damkov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roamio Franklin, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekhar Reddy Chilamakuri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Santos, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span> <span> </span><span class="NLM_article-title">AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematologic cancer cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-1853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1078-0432.CCR-19-1853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31699827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslylsLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=922-934&author=J.+Cidadoauthor=S.+Boikoauthor=T.+Proiaauthor=D.+Fergusonauthor=S.+W.+Criscioneauthor=M.+San+Martinauthor=P.+Pop-Damkovauthor=N.+Suauthor=V.+N.+Roamio+Franklinauthor=C.+Sekhar+Reddy+Chilamakuriauthor=C.+S.+D%E2%80%99Santosauthor=W.+Shaoauthor=J.+C.+Saehauthor=R.+Kochauthor=D.+M.+Weinstockauthor=M.+Zindaauthor=S.+E.+Fawellauthor=L.+Drew&title=AZD4573+is+a+highly+selective+CDK9+inhibitor+that+suppresses+Mcl-1+and+induces+apoptosis+in+hematologic+cancer+cells&doi=10.1158%2F1078-0432.CCR-19-1853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells</span></div><div class="casAuthors">Cidado, Justin; Boiko, Scott; Proia, Theresa; Ferguson, Douglas; Criscione, Steven W.; Martin, Maryann San; Pop-Damkov, Petar; Su, Nancy; Franklin, Valar Nila Roamio; Chilamakuri, Chandra Sekhar Reddy; D'Santos, Clive S.; Shao, Wenlin; Saeh, Jamal C.; Koch, Raphael; Weinstock, David M.; Zinda, Michael; Fawell, Stephen E.; Drew, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">922-934</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CDK9 is a transcriptional regulator and potential therapeutic target for many cancers.  Multiple nonselective CDK9 inhibitors have progressed clin. but were limited by a narrow therapeutic window.  This work describes a novel, potent, and highly selective CDK9 inhibitor, AZD4573.  The antitumor activity of AZD4573 was detd. across broad cancer cell line panels in vitro as well as cell line- and patient-derived xenograft models in vivo.  Multiple approaches, including integrated transcriptomic and proteomic analyses, loss-of-function pathway interrogation, and pharmacol. comparisons, were employed to further understand the major mechanism driving AZD4573 activity and to establish an exposure/effect relationship.  AZD4573 is a highly selective and potent CDK9 inhibitor.  It demonstrated rapid induction of apoptosis and subsequent cell death broadly across hematol. cancer models in vitro, and MCL-1 depletion in a dose- and time-dependent manner was identified as a major mechanism through which AZD4573 induces cell death in tumor cells.  This understanding of the mechanism, exposure, and antitumor activity of AZD4573 facilitated development of a robust pharmacokinetic/PD/efficacy model used to inform the clin. trial design.  Selective targeting of CDK9 enables the indirect inhibition of MCL-1, providing a therapeutic option for MCL-1-dependent diseases.  Accordingly, AZD4573 is currently being evaluated in a phase I clin. trial for patients with hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp213MDHb0Y7rVg90H21EOLACvtfcHk0lhW_E0dZ-PoZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslylsLrK&md5=18be82de651b9be77a95f3d7c423b6aa</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-1853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-1853%26sid%3Dliteratum%253Aachs%26aulast%3DCidado%26aufirst%3DJ.%26aulast%3DBoiko%26aufirst%3DS.%26aulast%3DProia%26aufirst%3DT.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DCriscione%26aufirst%3DS.%2BW.%26aulast%3DSan%2BMartin%26aufirst%3DM.%26aulast%3DPop-Damkov%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DN.%26aulast%3DRoamio%2BFranklin%26aufirst%3DV.%2BN.%26aulast%3DSekhar%2BReddy%2BChilamakuri%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Santos%26aufirst%3DC.%2BS.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DKoch%26aufirst%3DR.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DDrew%26aufirst%3DL.%26atitle%3DAZD4573%2520is%2520a%2520highly%2520selective%2520CDK9%2520inhibitor%2520that%2520suppresses%2520Mcl-1%2520and%2520induces%2520apoptosis%2520in%2520hematologic%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D922%26epage%3D934%26doi%3D10.1158%2F1078-0432.CCR-19-1853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaxman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidiqi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertz, M.</span></span> <span> </span><span class="NLM_article-title">Venetoclax for the treatment of multiple myeloma</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">915</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1080/17474086.2018.1548931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F17474086.2018.1548931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30428277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKit7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=915-920&author=I.+Vaxmanauthor=M.+H.+Sidiqiauthor=M.+Gertz&title=Venetoclax+for+the+treatment+of+multiple+myeloma&doi=10.1080%2F17474086.2018.1548931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Venetoclax for the treatment of multiple myeloma</span></div><div class="casAuthors">Vaxman, Iuliana; Sidiqi, M. Hasib; Gertz, Morie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">915-920</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Treatment of multiple myeloma (MM) in the relapsed setting remains challenging, despite recent impressive advances in the management of these patients.  Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration for treatment of chronic lymphocytic leukemia but the drug has shown activity in a no. of hematol. malignancies.  Venetoclax has broadened the treatment options for patients with relapsed or refractory MM.  Approx., 20% of myeloma patients will exhibit t (11;14) assocd. with high BCL-2 expression making venetoclax an attractive therapeutic option.  The efficacy of venetoclax is not uniquely restricted to this population.  This review will summarize the mechanism of action, toxicity profile, and published data on venetoclax use in MM, moving the field toward personalized medicine in the treatment of myeloma.  Numerous phase 1/2 clin. trials are evaluating the efficacy and safety of venetoclax monotherapy and in combinations in the relapse setting.  These trials show better outcomes in the subgroup of patients harboring t(11;14).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrbEBbpXasZLVg90H21EOLACvtfcHk0lh9IN2ejwo6uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKit7vF&md5=5ecd31654e1af8b8bb5cc4c73a2eaef3</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1080%2F17474086.2018.1548931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2018.1548931%26sid%3Dliteratum%253Aachs%26aulast%3DVaxman%26aufirst%3DI.%26aulast%3DSidiqi%26aufirst%3DM.%2BH.%26aulast%3DGertz%26aufirst%3DM.%26atitle%3DVenetoclax%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2018%26volume%3D11%26spage%3D915%26epage%3D920%26doi%3D10.1080%2F17474086.2018.1548931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.1021/jm301495v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301495v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=660-670&author=A.+J.+Holeauthor=S.+Baumliauthor=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wangauthor=J.+A.+Endicottauthor=M.+E.+Noble&title=Comparative+structural+and+functional+studies+of+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidine-5-carbonitrile+CDK9+inhibitors+suggest+the+basis+for+isotype+selectivity&doi=10.1021%2Fjm301495v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span></div><div class="casAuthors">Hole, Alison J.; Baumli, Sonja; Shao, Hao; Shi, Shenhua; Huang, Shiliang; Pepper, Chris; Fischer, Peter M.; Wang, Shudong; Endicott, Jane A.; Noble, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">660-670</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9/cyclin T, the protein kinase heterodimer that constitutes pos. transcription elongation factor b, is a well-validated target for treatment of several diseases, including cancer and cardiac hypertrophy.  In order to aid inhibitor design and rationalize the basis for CDK9 selectivity, we have studied the CDK-binding properties of six different members of a 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series that bind to both CDK9/cyclin T and CDK2/cyclin A.  We find that for a given CDK, the melting temp. of a CDK/cyclin/inhibitor complex correlates well with inhibitor potency, suggesting that differential scanning fluorometry (DSF) is a useful orthogonal measure of inhibitory activity for this series.  We have used DSF to demonstrate that the binding of these compds. is independent of the presence or absence of the C-terminal tail region of CDK9, unlike the binding of the CDK9-selective inhibitor 5,6-dichlorobenzimidazone-1-β-D-ribofuranoside (DRB).  Finally, on the basis of 11 cocrystal structures bound to CDK9/cyclin T or CDK2/cyclin A, we conclude that selective inhibition of CDK9/cyclin T by members of the 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series results from the relative malleability of the CDK9 active site rather than from the formation of specific polar contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGJy-t5isJBbVg90H21EOLACvtfcHk0lh9IN2ejwo6uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE&md5=8c09b13b5f828b7a013607cab64b0b80</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm301495v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301495v%26sid%3Dliteratum%253Aachs%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DComparative%2520structural%2520and%2520functional%2520studies%2520of%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidine-5-carbonitrile%2520CDK9%2520inhibitors%2520suggest%2520the%2520basis%2520for%2520isotype%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D660%26epage%3D670%26doi%3D10.1021%2Fjm301495v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erb, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doctor, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boukhali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnchembio.2538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29251720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFyrsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=163-170&author=C.+M.+Olsonauthor=B.+Jiangauthor=M.+A.+Erbauthor=Y.+Liangauthor=Z.+M.+Doctorauthor=Z.+Zhangauthor=T.+Zhangauthor=N.+Kwiatkowskiauthor=M.+Boukhaliauthor=J.+L.+Greenauthor=W.+Haasauthor=T.+Nomanbhoyauthor=E.+S.+Fischerauthor=R.+A.+Youngauthor=J.+E.+Bradnerauthor=G.+E.+Winterauthor=N.+S.+Gray&title=Pharmacological+perturbation+of+CDK9+using+selective+CDK9+inhibition+or+degradation&doi=10.1038%2Fnchembio.2538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation</span></div><div class="casAuthors">Olson, Calla M.; Jiang, Baishan; Erb, Michael A.; Liang, Yanke; Doctor, Zainab M.; Zhang, Zinan; Zhang, Tinghu; Kwiatkowski, Nicholas; Boukhali, Myriam; Green, Jennifer L.; Haas, Wilhelm; Nomanbhoy, Tyzoon; Fischer, Eric S.; Young, Richard A.; Bradner, James E.; Winter, Georg E.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-170</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation.  The authors characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 degrader consisting of a CDK-binding SNS-032 ligand linked to a thalidomide deriv. that binds the E3 ubiquitin ligase Cereblon (CRBN).  To the authors' surprise, THAL-SNS-032 induced rapid degrdn. of CDK9 without affecting the levels of other SNS-032 targets.  Moreover, the transcriptional changes elicited by THAL-SNS-032 were more like those caused by NVP-2 than those induced by SNS-032.  Notably, compd. washout did not significantly reduce levels of THAL-SNS-032-induced apoptosis, suggesting that CDK9 degrdn. had prolonged cytotoxic effects compared with CDK9 inhibition.  Thus, the authors' findings suggest that thalidomide conjugation represents a promising strategy for converting multi-targeted inhibitors into selective degraders and reveal that kinase degrdn. can induce distinct pharmacol. effects compared with inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWnT9r0GIlmbVg90H21EOLACvtfcHk0lgcRwSWsI5uqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFyrsr7O&md5=88aabb209b4cb7516a652d6c75a35667</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2538%26sid%3Dliteratum%253Aachs%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DErb%26aufirst%3DM.%2BA.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DDoctor%26aufirst%3DZ.%2BM.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DBoukhali%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DJ.%2BL.%26aulast%3DHaas%26aufirst%3DW.%26aulast%3DNomanbhoy%26aufirst%3DT.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DPharmacological%2520perturbation%2520of%2520CDK9%2520using%2520selective%2520CDK9%2520inhibition%2520or%2520degradation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D163%26epage%3D170%26doi%3D10.1038%2Fnchembio.2538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">112424</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2020.112424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=32447197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVWitr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2020&pages=112424&author=J.+Xuauthor=H.+Liauthor=X.+Wangauthor=J.+Huangauthor=S.+Liauthor=C.+Liuauthor=R.+Dongauthor=G.+Zhuauthor=C.+Duanauthor=F.+Jiangauthor=Y.+Zhangauthor=Y.+Zhuauthor=T.+Zhangauthor=Y.+Chenauthor=W.+Tangauthor=T.+Lu&title=Discovery+of+coumarin+derivatives+as+potent+and+selective+cyclin-dependent+kinase+9+%28CDK9%29+inhibitors+with+high+antitumour+activity&doi=10.1016%2Fj.ejmech.2020.112424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumor activity</span></div><div class="casAuthors">Xu, Junyu; Li, Hongmei; Wang, Xinren; Huang, Jianhang; Li, Shuwen; Liu, Chenhe; Dong, Ruinan; Zhu, Gaoyuan; Duan, Chunqi; Jiang, Fei; Zhang, Yanmin; Zhu, Yuqin; Zhang, Tianyi; Chen, Yadong; Tang, Weifang; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112424</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Specific inhibition of CDK9 is considered a promising strategy for developing effective anticancer therapeutics.  However, most of the reported CDK9 inhibitors are still at an early stage of development and lack selectivity against other CDKs.  Herein, we discovered coumarin deriv. 30i(I) as a potent CDK9 inhibitor with high selectivity (8300-fold over CDK7).  Binding mode anal. illustrated that the substituent coumarin moiety is a crit. group for CDK9 selectivity by occupying a flexible hinge/αD region, which is sterically hindered in other CDKs.  Compd. 30i showed excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition.  Moreover, 30i significantly induced tumor growth inhibition in a dose-dependent manner without causing an obvious loss of body wt. in an MV4-11 xenograft mice model.  Altogether, these results suggest that 30i may serve as a potential acute myeloid leukemia (AML) therapeutics by selectively targeting CDK9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSaq963s3BbVg90H21EOLACvtfcHk0lgcRwSWsI5uqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVWitr3N&md5=aeb59372b32a4acc1189bad3ccd506ff</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112424%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DDong%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DG.%26aulast%3DDuan%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520coumarin%2520derivatives%2520as%2520potent%2520and%2520selective%2520cyclin-dependent%2520kinase%25209%2520%2528CDK9%2529%2520inhibitors%2520with%2520high%2520antitumour%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D200%26spage%3D112424%26doi%3D10.1016%2Fj.ejmech.2020.112424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahir, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penning, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devlin, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsi, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souers, A. J.</span></span> <span> </span><span class="NLM_article-title">A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1646</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1038/s41375-019-0652-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fs41375-019-0652-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31827241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSltL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=1646-1657&author=D.+C.+Phillipsauthor=S.+Jinauthor=G.+P.+Gregoryauthor=Q.+Zhangauthor=J.+Xueauthor=X.+Zhaoauthor=J.+Chenauthor=Y.+Tongauthor=H.+Zhangauthor=M.+Smithauthor=S.+K.+Tahirauthor=R.+F.+Clarkauthor=T.+D.+Penningauthor=J.+R.+Devlinauthor=J.+Shorttauthor=E.+D.+Hsiauthor=D.+H.+Albertauthor=M.+Konoplevaauthor=R.+W.+Johnstoneauthor=J.+D.+Leversonauthor=A.+J.+Souers&title=A+novel+CDK9+inhibitor+increases+the+efficacy+of+venetoclax+%28ABT-199%29+in+multiple+models+of+hematologic+malignancies&doi=10.1038%2Fs41375-019-0652-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies</span></div><div class="casAuthors">Phillips, Darren C.; Jin, Sha; Gregory, Gareth P.; Zhang, Qi; Xue, John; Zhao, Xiaoxian; Chen, Jun; Tong, Yunsong; Zhang, Haichao; Smith, Morey; Tahir, Stephen K.; Clark, Rick F.; Penning, Thomas D.; Devlin, Jennifer R.; Shortt, Jake; Hsi, Eric D.; Albert, Daniel H.; Konopleva, Marina; Johnstone, Ricky W.; Leverson, Joel D.; Souers, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1646-1657</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">MCL-1 is one of the most frequently amplified genes in cancer, facilitating tumor initiation and maintenance and enabling resistance to anti-tumorigenic agents including the BCL-2 selective inhibitor venetoclax.  The expression of MCL-1 is maintained via P-TEFb-mediated transcription, where the kinase CDK9 is a crit. component.  Consequently, we developed a series of potent small-mol. inhibitors of CDK9, exemplified by the orally active A-1592668, with CDK selectivity profiles that are distinct from related mols. that have been extensively studied clin.  Short-term treatment with A-1592668 rapidly downregulates RNA pol-II (Ser 2) phosphorylation resulting in the loss of MCL-1 protein and apoptosis in MCL-1-dependent hematol. tumor cell lines.  This cell death could be attenuated by either inhibiting caspases or overexpressing BCL-2 protein.  Synergistic cell killing was also obsd. between A-1592668 or the related analog A-1467729, and venetoclax in a no. of hematol. cell lines and primary NHL patient samples.  Importantly, the CDK9 inhibitor plus venetoclax combination was well tolerated in vivo and demonstrated efficacy superior to either agent alone in mouse models of lymphoma and AML.  These data indicate that CDK9 inhibitors could be highly efficacious in tumors that depend on MCL-1 for survival or when used in combination with venetoclax in malignancies dependent on MCL-1 and BCL-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphCp3ZfyvPi7Vg90H21EOLACvtfcHk0ljrYxwyNatsQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSltL3E&md5=1857f3731a7b2711d00444b65804aac4</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fs41375-019-0652-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-019-0652-0%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DD.%2BC.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DGregory%26aufirst%3DG.%2BP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DTahir%26aufirst%3DS.%2BK.%26aulast%3DClark%26aufirst%3DR.%2BF.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DDevlin%26aufirst%3DJ.%2BR.%26aulast%3DShortt%26aufirst%3DJ.%26aulast%3DHsi%26aufirst%3DE.%2BD.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DLeverson%26aufirst%3DJ.%2BD.%26aulast%3DSouers%26aufirst%3DA.%2BJ.%26atitle%3DA%2520novel%2520CDK9%2520inhibitor%2520increases%2520the%2520efficacy%2520of%2520venetoclax%2520%2528ABT-199%2529%2520in%2520multiple%2520models%2520of%2520hematologic%2520malignancies%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D1646%26epage%3D1657%26doi%3D10.1038%2Fs41375-019-0652-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu Jin, U.</span>; <span class="NLM_string-name">Geisler, J.</span>; <span class="NLM_string-name">Hogg, D.</span>; <span class="NLM_string-name">Scholz, A.</span>; <span class="NLM_string-name">Peterson, K.</span>; <span class="NLM_string-name">Linau, P.</span>; <span class="NLM_string-name">Stegman, C.</span>; <span class="NLM_string-name">Andres, D.</span></span> <span> </span><span class="NLM_article-title">New Macrocyclic Sulfonimide Compounds</span>. Patent <span class="NLM_patent">CN108290903</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=U.+Lu+Jin&author=J.+Geisler&author=D.+Hogg&author=A.+Scholz&author=K.+Peterson&author=P.+Linau&author=C.+Stegman&author=D.+Andres&title=New+Macrocyclic+Sulfonimide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLu%2BJin%26aufirst%3DU.%26atitle%3DNew%2520Macrocyclic%2520Sulfonimide%2520Compounds%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cozemont, D.</span>; <span class="NLM_string-name">Lu Jin, U.</span>; <span class="NLM_string-name">Simest, G.</span>; <span class="NLM_string-name">Scholz, A.</span>; <span class="NLM_string-name">Linau, P.</span></span> <span> </span><span class="NLM_article-title">Fluorinated Benzofuranyl-pyrimidine Derivatives Containing Sulfone Groups</span>. Patent <span class="NLM_patent">CN107207475A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+Cozemont&author=U.+Lu+Jin&author=G.+Simest&author=A.+Scholz&author=P.+Linau&title=Fluorinated+Benzofuranyl-pyrimidine+Derivatives+Containing+Sulfone+Groups"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCozemont%26aufirst%3DD.%26atitle%3DFluorinated%2520Benzofuranyl-pyrimidine%2520Derivatives%2520Containing%2520Sulfone%2520Groups%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span>; <span class="NLM_string-name">Tao, Z.</span>; <span class="NLM_string-name">Tong, Y.</span>; <span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">CDK9 Kinase Inhibitors with Pyrrolo [2,3-B] Pyridine</span>. Patent <span class="NLM_patent">CN105324380A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Gong&author=Z.+Tao&author=Y.+Tong&author=G.+Zhu&title=CDK9+Kinase+Inhibitors+with+Pyrrolo+%5B2%2C3-B%5D+Pyridine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26atitle%3DCDK9%2520Kinase%2520Inhibitors%2520with%2520Pyrrolo%2520%255B2%252C3-B%255D%2520Pyridine%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul A, B.</span>; <span class="NLM_string-name">Hu, C.</span>; <span class="NLM_string-name">Jin, X.</span>; <span class="NLM_string-name">Simon C, N. G.</span>; <span class="NLM_string-name">Keith B, P.</span>; <span class="NLM_string-name">Martin, S.</span>; <span class="NLM_string-name">James, S.</span></span> <span> </span><span class="NLM_article-title">N-Acyl Pyridine Biaryl Compounds and Their Uses</span>. Patent <span class="NLM_patent">WO2012/101063A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=B.+Paul+A&author=C.+Hu&author=X.+Jin&author=N.+G.+Simon+C&author=P.+Keith+B&author=S.+Martin&author=S.+James&title=N-Acyl+Pyridine+Biaryl+Compounds+and+Their+Uses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%2BA%26aufirst%3DB.%26atitle%3DN-Acyl%2520Pyridine%2520Biaryl%2520Compounds%2520and%2520Their%2520Uses%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Childers, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elokely, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Gharbia, A.</span></span> <span> </span><span class="NLM_article-title">The resurrection of phenotypic drug discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=W.+E.+Childersauthor=K.+M.+Elokelyauthor=A.+Abou-Gharbia&title=The+resurrection+of+phenotypic+drug+discovery&doi=10.1021%2Facsmedchemlett.0c00006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00006%26sid%3Dliteratum%253Aachs%26aulast%3DChilders%26aufirst%3DW.%2BE.%26aulast%3DElokely%26aufirst%3DK.%2BM.%26aulast%3DAbou-Gharbia%26aufirst%3DA.%26atitle%3DThe%2520resurrection%2520of%2520phenotypic%2520drug%2520discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26doi%3D10.1021%2Facsmedchemlett.0c00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis-targeting chimeras as therapeutics and tools for biological discovery</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.cell.2019.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31955850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=102-114&issue=1&author=G.+M.+Burslemauthor=C.+M.+Crews&title=Proteolysis-targeting+chimeras+as+therapeutics+and+tools+for+biological+discovery&doi=10.1016%2Fj.cell.2019.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery</span></div><div class="casAuthors">Burslem, George M.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-114</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  New biol. tools provide new techniques to probe fundamental biol. processes.  Here we describe the burgeoning field of proteolysis-targeting chimeras (PROTACs), which are capable of modulating protein concns. at a post-translational level by co-opting the ubiquitin-proteasome system.  We describe the PROTAC technol. and its application to drug discovery and provide examples where PROTACs have enabled novel biol. insights.  Furthermore, we provide a workflow for PROTAC development and use and discuss the benefits and issues assocd. with PROTACs.  Finally, we compare PROTAC-mediated protein-level modulation with other technologies, such as RNAi and genome editing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXgumsEakVWrVg90H21EOLACvtfcHk0liLm3R8Rd_xuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D&md5=3010929d2979cf04dc6003e66575f1b0</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DProteolysis-targeting%2520chimeras%2520as%2520therapeutics%2520and%2520tools%2520for%2520biological%2520discovery%26jtitle%3DCell%26date%3D2020%26volume%3D181%26issue%3D1%26spage%3D102%26epage%3D114%26doi%3D10.1016%2Fj.cell.2019.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, D.</span></span> <span> </span><span class="NLM_article-title">Phenotypic screening in cancer drug discovery-past, present and future</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/nrd4366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnrd4366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25033736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=588-602&issue=8&author=J.+G.+Moffatauthor=J.+Rudolphauthor=D.+Bailey&title=Phenotypic+screening+in+cancer+drug+discovery-past%2C+present+and+future&doi=10.1038%2Fnrd4366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening in cancer drug discovery - past, present and future</span></div><div class="casAuthors">Moffat, John G.; Rudolph, Joachim; Bailey, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-602</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches.  Given that oncol. is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncol. drug discovery by analyzing the origins of all new small-mol. cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clin. development.  Although the majority of these drugs originated from target-based discovery, we identified a significant no. whose discovery depended on phenotypic screening approaches.  We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes.  However, tech. and biol. advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTWtoTIgWqvbVg90H21EOLACvtfcHk0ljBBy9822n72A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L&md5=0e8efed90e5bc4b47f959b83a6ab5b96</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fnrd4366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4366%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DD.%26atitle%3DPhenotypic%2520screening%2520in%2520cancer%2520drug%2520discovery-past%252C%2520present%2520and%2520future%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D8%26spage%3D588%26epage%3D602%26doi%3D10.1038%2Fnrd4366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butera, J. A.</span></span> <span> </span><span class="NLM_article-title">Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents: an editorial miniperspectives series on phenotypic screening for antiinfective targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">7715</span>– <span class="NLM_lpage">7718</span>, <span class="refDoi"> DOI: 10.1021/jm400443k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400443k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Chs7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7715-7718&issue=20&author=J.+A.+Butera&title=Phenotypic+screening+as+a+strategic+component+of+drug+discovery+programs+targeting+novel+antiparasitic+and+antimycobacterial+agents%3A+an+editorial+miniperspectives+series+on+phenotypic+screening+for+antiinfective+targets&doi=10.1021%2Fjm400443k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic Screening as a Strategic Component of Drug Discovery Programs Targeting Novel Antiparasitic and Antimycobacterial Agents: An Editorial</span></div><div class="casAuthors">Butera, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7715-7718</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review. Drug development for neglected tropical diseases, defined as a collection of infectious diseases affecting over 4 billion people worldwide (esp. endemic to poverty-stricken populations in underdeveloped regions of Africa, Asia, the Pacific Rim, and Latin America), has been underfunded and stagnant.  A much needed resurgence of R&D activity in this area is currently developing.  Target-directed screening and whole-cell phenotypic screening represent two complementary approaches to discover viable new starting point scaffolds for medicinal chem. optimization.  This editorial will provide introductory comments to a series of six miniperspectives that focus on the special challenges faced by scientists in discovering potential new chem. leads that could be optimized into promising clin. candidates for neglected tropical diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocE0tu0F4KKbVg90H21EOLACvtfcHk0ljBBy9822n72A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Chs7fM&md5=53dd78afac8444f8739dfe03c25f41f5</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm400443k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400443k%26sid%3Dliteratum%253Aachs%26aulast%3DButera%26aufirst%3DJ.%2BA.%26atitle%3DPhenotypic%2520screening%2520as%2520a%2520strategic%2520component%2520of%2520drug%2520discovery%2520programs%2520targeting%2520novel%2520antiparasitic%2520and%2520antimycobacterial%2520agents%253A%2520an%2520editorial%2520miniperspectives%2520series%2520on%2520phenotypic%2520screening%2520for%2520antiinfective%2520targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D20%26spage%3D7715%26epage%3D7718%26doi%3D10.1021%2Fjm400443k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ali, H.</span></span> <span> </span><span class="NLM_article-title">The evolution of drug discovery: from phenotypes to targets, and back</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1039/C6MD00129G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1039%2FC6MD00129G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=788-798&author=H.+Al-Ali&title=The+evolution+of+drug+discovery%3A+from+phenotypes+to+targets%2C+and+back&doi=10.1039%2FC6MD00129G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of drug discovery: from phenotypes to targets, and back</span></div><div class="casAuthors">Al-Ali, Hassan</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">788-798</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cumulative scientific and technol. advances over the past two centuries have transformed drug discovery from a largely serendipitous process into the high tech pipelines of today.  For thousands of years, medicines were sourced directly from nature, through observing the phenotypic effects of substances on humans or animals.  Following the mol. biol. revolution and initiation of the human genome project in the 1990s, target-based screening gained popularity and soon came to dominate the pharmaceutical industry.  Two decades later, the phenotypic approach began to make a strong comeback, benefiting from the scalability and speed afforded by massive technol. advances.  This has ignited a debate over the relative productivities of phenotypic and target-based screening.  However, as more integrative technologies become available, the focus of the discussion should shift from prioritizing the different approaches to finding strategies that can combine their complementary strengths.  This review chronicles major trends and transformative events in the evolution of drug discovery, and underscores the importance of phenotypic approaches for past, and likely future, successes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeOAT0eQ1lu7Vg90H21EOLACvtfcHk0lgHfHV06g69Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVOjtbY%253D&md5=53787b4b2d5869bf857cf0e834c361bf</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1039%2FC6MD00129G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00129G%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Ali%26aufirst%3DH.%26atitle%3DThe%2520evolution%2520of%2520drug%2520discovery%253A%2520from%2520phenotypes%2520to%2520targets%252C%2520and%2520back%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D788%26epage%3D798%26doi%3D10.1039%2FC6MD00129G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J.-P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S.</span></span> <span> </span><span class="NLM_article-title">Targeting the cancer epigenome for therapy</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1038/nrg.2016.93</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnrg.2016.93" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27629931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWiu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=630-641&issue=10&author=P.+A.+Jonesauthor=J.-P.+J.+Issaauthor=S.+Baylin&title=Targeting+the+cancer+epigenome+for+therapy&doi=10.1038%2Fnrg.2016.93"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer epigenome for therapy</span></div><div class="casAuthors">Jones, Peter A.; Issa, Jean-Pierre J.; Baylin, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">630-641</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Next-generation sequencing has revealed that more than 50% of human cancers harbor mutations in enzymes that are involved in chromatin organization.  Tumor cells not only are activated by genetic and epigenetic alterations, but also routinely use epigenetic processes to ensure their escape from chemotherapy and host immune surveillance.  Hence, a growing emphasis of recent drug discovery efforts has been on targeting the epigenome, including DNA methylation and histone modifications, with several new drugs being tested and some already approved by the US Food and Drug Administration (FDA).  The future will see the increasing success of combining epigenetic drugs with other therapies.  As epigenetic drugs target the epigenome as a whole, these true 'genomic medicines' lessen the need for precision approaches to individualized therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5pfbPOnZMtbVg90H21EOLACvtfcHk0lgHfHV06g69Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWiu77O&md5=22d98e58a4637d61af34a382e92adace</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fnrg.2016.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg.2016.93%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BA.%26aulast%3DIssa%26aufirst%3DJ.-P.%2BJ.%26aulast%3DBaylin%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520cancer%2520epigenome%2520for%2520therapy%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2016%26volume%3D17%26issue%3D10%26spage%3D630%26epage%3D641%26doi%3D10.1038%2Fnrg.2016.93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bewersdorf, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shallis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidan, A. M.</span></span> <span> </span><span class="NLM_article-title">Epigenetic therapy combinations in acute myeloid leukemia: what are the options?</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1177/2040620718816698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1177%2F2040620718816698" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1-19&author=J.+P.+Bewersdorfauthor=R.+Shallisauthor=M.+Stahlauthor=A.+M.+Zeidan&title=Epigenetic+therapy+combinations+in+acute+myeloid+leukemia%3A+what+are+the+options%3F&doi=10.1177%2F2040620718816698"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1177%2F2040620718816698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620718816698%26sid%3Dliteratum%253Aachs%26aulast%3DBewersdorf%26aufirst%3DJ.%2BP.%26aulast%3DShallis%26aufirst%3DR.%26aulast%3DStahl%26aufirst%3DM.%26aulast%3DZeidan%26aufirst%3DA.%2BM.%26atitle%3DEpigenetic%2520therapy%2520combinations%2520in%2520acute%2520myeloid%2520leukemia%253A%2520what%2520are%2520the%2520options%253F%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2019%26volume%3D10%26spage%3D1%26epage%3D19%26doi%3D10.1177%2F2040620718816698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hausheer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahnow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span> <span> </span><span class="NLM_article-title">A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3834</span>– <span class="NLM_lpage">3843</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-2287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F0008-5472.CAN-13-2287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24876104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFCqsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3834-3843&author=Y.+Cuiauthor=F.+Hausheerauthor=R.+Beatyauthor=C.+Zahnowauthor=J.+P.+Issaauthor=F.+Bunzauthor=S.+B.+Baylin&title=A+recombinant+reporter+system+for+monitoring+reactivation+of+an+endogenously+DNA+hypermethylated+gene&doi=10.1158%2F0008-5472.CAN-13-2287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene</span></div><div class="casAuthors">Cui, Ying; Hausheer, Frederick; Beaty, Robert; Zahnow, Cynthia; Issa, Jean Pierre; Bunz, Frederick; Baylin, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3834-3843</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversing abnormal gene silencing in cancer cells due to DNA hypermethylation of promoter CpG islands may offer new cancer prevention or therapeutic approaches.  Here, the authors demonstrate the powerful utility of a novel gene reporter system to permit studies of the dynamics, mechanisms, and translational relevance of candidate therapies of this type in human colon cancer cells.  The reporter system is based on in situ modification of the endogenous locus of the tumor-suppressor gene SFRP1, a pivotal regulator of the Wnt pathway that is silenced by DNA hypermethylation in many colon cancers.  The modified SFRP1-GFP reporter allele used remained basally silent, like the unaltered allele, and it was activated only by drug treatments that derepress gene silencing by reversing DNA hypermethylation.  The authors used the established DNA methyltransferase inhibitor (DNMTi) 5-aza-deoxycytidine (DAC) to show how this system can be used to address key questions in the clin. development of epigenetic cancer therapies.  First, the authors defined conditions for which clin. relevant dosing could induce sustained induction of RNA and protein.  Second, they found that, in vivo, a more prolonged drug exposure than anticipated was essential to derepress gene silencing in significant cell nos., and this has implications for generating effective anticancer responses in patients with hematopoietic or solid tumors.  Finally, they discovered how histone deacetylase inhibitors (HDACi) alone, when administered to cells actively replicating DNA, can robustly reexpress the silenced gene with no change in promoter methylation status.  These findings offer a new tool and insights for devising optimal clin. expts. to evaluate epigenetic therapies aimed at improving the management and prevention of cancer.  Derived from Cancer Res; 74(14); 3834-43. © 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5emVpnjouObVg90H21EOLACvtfcHk0ljlaGA57tDTnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFCqsL7E&md5=309f342799bd9a838aa23d21c5b5b66c</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-2287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-2287%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DY.%26aulast%3DHausheer%26aufirst%3DF.%26aulast%3DBeaty%26aufirst%3DR.%26aulast%3DZahnow%26aufirst%3DC.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%26aulast%3DBunz%26aufirst%3DF.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26atitle%3DA%2520recombinant%2520reporter%2520system%2520for%2520monitoring%2520reactivation%2520of%2520an%2520endogenously%2520DNA%2520hypermethylated%2520gene%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3834%26epage%3D3843%26doi%3D10.1158%2F0008-5472.CAN-13-2287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rye, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessum, N. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeritt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaac, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boros, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Billy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">te Poele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fee, L. O’</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1580</span>, <span class="refDoi"> DOI: 10.1039/C6MD00159A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1039%2FC6MD00159A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27746890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps12itLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1580&author=C.+S.+Ryeauthor=N.+E.+A.+Chessumauthor=S.+Lamontauthor=K.+G.+Pikeauthor=P.+Faulderauthor=J.+Demerittauthor=P.+Kemmittauthor=J.+Tuckerauthor=L.+Zaniauthor=M.+D.+Cheesemanauthor=R.+Isaacauthor=L.+Goodwinauthor=J.+Borosauthor=F.+Raynaudauthor=A.+Hayesauthor=A.+T.+Henleyauthor=E.+de+Billyauthor=C.+J.+Lynchauthor=S.+Y.+Sharpauthor=R.+te+Poeleauthor=L.+O%E2%80%99+Feeauthor=K.+M.+Footeauthor=S.+Greenauthor=P.+Workmanauthor=K.+Jones&title=Discovery+of+4%2C6-disubstituted+pyrimidines+as+potent+inhibitors+of+the+heat+shock+factor+1+%28HSF1%29+stress+pathway+and+CDK9&doi=10.1039%2FC6MD00159A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9</span></div><div class="casAuthors">Rye, Carl S.; Chessum, Nicola E. A.; Lamont, Scott; Pike, Kurt G.; Faulder, Paul; Demeritt, Julie; Kemmitt, Paul; Tucker, Julie; Zani, Lorenzo; Cheeseman, Matthew D.; Isaac, Rosie; Goodwin, Louise; Boros, Joanna; Raynaud, Florence; Hayes, Angela; Henley, Alan T.; de Billy, Emmanuel; Lynch, Christopher J.; Sharp, Swee Y.; te Poele, Robert; Fee, Lisa O'; Foote, Kevin M.; Green, Stephen; Workman, Paul; Jones, Keith</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1580-1586</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Heat shock factor 1 (HSF1) is a transcription factor that plays key roles in cancer, including providing a mechanism for cell survival under proteotoxic stress.  Therefore, inhibition of the HSF1-stress pathway represents an exciting new opportunity in cancer treatment.  We employed an unbiased phenotypic screen to discover inhibitors of the HSF1-stress pathway.  Using this approach we identified an initial hit (1) based on a 4,6-pyrimidine scaffold (2.00 μM).  Optimization of cellular SAR led to an inhibitor with improved potency (25, 15 nM) in the HSF1 phenotypic assay.  The 4,6-pyrimidine 25 was also shown to have high potency against the CDK9 enzyme (3 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp16iro0pz-9bVg90H21EOLACvtfcHk0ljlaGA57tDTnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps12itLo%253D&md5=23592e20ebd11fe41f80d9d4101b9c4e</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1039%2FC6MD00159A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00159A%26sid%3Dliteratum%253Aachs%26aulast%3DRye%26aufirst%3DC.%2BS.%26aulast%3DChessum%26aufirst%3DN.%2BE.%2BA.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DFaulder%26aufirst%3DP.%26aulast%3DDemeritt%26aufirst%3DJ.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DTucker%26aufirst%3DJ.%26aulast%3DZani%26aufirst%3DL.%26aulast%3DCheeseman%26aufirst%3DM.%2BD.%26aulast%3DIsaac%26aufirst%3DR.%26aulast%3DGoodwin%26aufirst%3DL.%26aulast%3DBoros%26aufirst%3DJ.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3Dde%2BBilly%26aufirst%3DE.%26aulast%3DLynch%26aufirst%3DC.%2BJ.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3Dte%2BPoele%26aufirst%3DR.%26aulast%3DFee%26aufirst%3DL.%2BO%25E2%2580%2599%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25204%252C6-disubstituted%2520pyrimidines%2520as%2520potent%2520inhibitors%2520of%2520the%2520heat%2520shock%2520factor%25201%2520%2528HSF1%2529%2520stress%2520pathway%2520and%2520CDK9%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D1580%26doi%3D10.1039%2FC6MD00159A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">The PROTAC technology in drug development</span>. <i>Cell Biochem Funct.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1002/cbf.3369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1002%2Fcbf.3369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30604499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslygsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=21-30&issue=1&author=Y.+Zouauthor=D.+Maauthor=Y.+Wang&title=The+PROTAC+technology+in+drug+development&doi=10.1002%2Fcbf.3369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The PROTAC technology in drug development</span></div><div class="casAuthors">Zou, Yutian; Ma, Danhui; Wang, Yinyin</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Function</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">CBFUDH</span>;
        ISSN:<span class="NLM_cas:issn">1099-0844</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Currently, a new technol. termed PROTAC, proteolysis targeting chimera, has been developed for inducing the protein degrdn. by a targeting mol.  This technol. takes advantage of a moiety of targeted protein and a moiety of recognizing E3 ubiquitin ligase and produces a hybrid mol. to specifically knock down a targeted protein.  During the first decade, three pedigreed groups worked on the development of this technol.  To date, this technol. has been extended by different groups, aiming to develop new drugs against different diseases including cancers.  This review summarizes the contributions of the groups for the development of PROTAC.  Significance of the study : This review summarized the development of the PROTAC technol. for readers and also presented the author's opinions on the application of the technol. in tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprT1CUHOqrfbVg90H21EOLACvtfcHk0liwsratJeAcaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslygsQ%253D%253D&md5=2a7417e2c385d01f7eaef52a72c7ea52</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1002%2Fcbf.3369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbf.3369%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DThe%2520PROTAC%2520technology%2520in%2520drug%2520development%26jtitle%3DCell%2520Biochem%2520Funct.%26date%3D2019%26volume%3D37%26issue%3D1%26spage%3D21%26epage%3D30%26doi%3D10.1002%2Fcbf.3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span> <span> </span><span class="NLM_article-title">Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=444-452&issue=2&author=I.+Churcher&title=Protac-induced+protein+degradation+in+drug+discovery%3A+breaking+the+rules+or+just+making+new+ones%3F&doi=10.1021%2Facs.jmedchem.7b01272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?</span></div><div class="casAuthors">Churcher, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">444-452</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn., using bifunctional small mols. (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches.  In this perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degrdn. concepts, and their resulting applications to medicine discovery.  The approach has the potential to bring disruptive change to drug discovery - the many potential advantages and outstanding challenges which lie ahead of this technol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9n8I_0MhtkbVg90H21EOLACvtfcHk0liwsratJeAcaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ&md5=e60f1777de8bd860c5001137d8583f1f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01272%26sid%3Dliteratum%253Aachs%26aulast%3DChurcher%26aufirst%3DI.%26atitle%3DProtac-induced%2520protein%2520degradation%2520in%2520drug%2520discovery%253A%2520breaking%2520the%2520rules%2520or%2520just%2520making%2520new%2520ones%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D2%26spage%3D444%26epage%3D452%26doi%3D10.1021%2Facs.jmedchem.7b01272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delproposto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">62</span>),  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01631</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01631" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=941-964&issue=62&author=X.+Hanauthor=C.+Wangauthor=C.+Qinauthor=W.+Xiangauthor=E.+Fernandez-Salasauthor=C.+Y.+Yangauthor=M.+Wangauthor=L.+Zhaoauthor=T.+Xuauthor=K.+Chinnaswamyauthor=J.+Delpropostoauthor=J.+Stuckeyauthor=S.+Wang&title=Discovery+of+ARD-69+as+a+highly+potent+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+androgen+receptor+%28AR%29+for+the+treatment+of+prostate+cancer&doi=10.1021%2Facs.jmedchem.8b01631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span></div><div class="casAuthors">Han, Xin; Wang, Chao; Qin, Chong; Xiang, Weiguo; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Mi; Zhao, Lijie; Xu, Tianfeng; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">941-964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by IARD-69.  I induces degrdn. of AR protein in AR-pos. prostate cancer cell lines in a dose- and time-dependent manner.  I achieves DC50 values of 0.86, 0.76, and 10.4 nM in LNCaP, VCaP, and 22Rv1 AR+ prostate cancer cell lines, resp.  I is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.  I potently inhibits cell growth in these AR-pos. prostate cancer cell lines and is >100 times more potent than AR antagonists.  A single dose of I effectively reduces the level of AR protein in xenograft tumor tissue in mice.  Further optimization of I may ultimately lead to a new therapy for AR+, castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTlOD69tfhtbVg90H21EOLACvtfcHk0liwsratJeAcaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D&md5=2376573fb1a1e19c517d64c70199700a</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01631%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DDelproposto%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520ARD-69%2520as%2520a%2520highly%2520potent%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520androgen%2520receptor%2520%2528AR%2529%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D62%26spage%3D941%26epage%3D964%26doi%3D10.1021%2Facs.jmedchem.8b01631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2018.03.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29627725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=304-314&author=C.+Zhangauthor=X.+R.+Hanauthor=X.+Yangauthor=B.+Jiangauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Proteolysis+targeting+chimeras+%28PROTACs%29+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1016%2Fj.ejmech.2018.03.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) activation has been assocd. with many types of human cancer.  Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK.  Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-pos. nonsmall cell lung cancers (NSCLC).  However, drug resistance has been obsd. in the majority of patients treated with these inhibitors.  New therapeutic strategies (e.g., compds. with novel mechanisms of action) are needed to overcome the drug resistance issue.  The emerging PROTAC (Proteolysis Targeting Chimera) technol. has been successfully applied to selective degrdn. of multiple protein targets, but not ALK.  Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity.  Here the authors report the design, synthesis and biol. evaluation of novel PROTACs (degraders) of ALK.  MS4077 (I) and MS4078 (II) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concn.- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells.  The ALK protein degrdn. induced by compds. I and II was cereblon and proteasome dependent.  In addn., compds. I and II potently inhibited proliferation of SU-DHL-1 cells.  Furthermore, compd. II displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies.  The authors also developed MS4748 and MS4740 , very close analogs of I and II resp., which are incapable to degrade the ALK fusion proteins, as neg. controls.  All 4 compds. are valuable chem. tools for investigating effects of ALK pharmacol. degrdn.  The study paved the way for developing the next generation of ALK PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGM3aAZZ6h7Vg90H21EOLACvtfcHk0lgrfZwhJn3g4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D&md5=804324b95034f38b46e45f89e18e55be</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.%2BR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D304%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2018.03.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morreale, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, H.</span></span> <span> </span><span class="NLM_article-title">Types of ubiquitin ligases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.cell.2016.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27015313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVamurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=248-248&issue=1&author=F.+E.+Morrealeauthor=H.+Walden&title=Types+of+ubiquitin+ligases&doi=10.1016%2Fj.cell.2016.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Types of ubiquitin ligases</span></div><div class="casAuthors">Morreale, Francesca Ester; Walden, Helen</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">248-248.e1</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Ubiquitination is a post-translational modification of proteins involved in a variety of cellular processes.  Ubiquitination requires the sequential action of 3 enzymes: E1 (ubiquitin-activating enzymes), E2 (ubiquitin-conjugating enzymes), and E3 (ubiquitin ligases).  Here, the authors highlight the main types of E3 ubiquitin ligases, which can be classified in 3 families depending on the presence of characteristic domains and on the mechanism of ubiquitin transfer to the substrate protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaGjtLCe1p8LVg90H21EOLACvtfcHk0lgrfZwhJn3g4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVamurg%253D&md5=f819525b60b95ed16340612d6bf51a13</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DMorreale%26aufirst%3DF.%2BE.%26aulast%3DWalden%26aufirst%3DH.%26atitle%3DTypes%2520of%2520ubiquitin%2520ligases%26jtitle%3DCell%26date%3D2016%26volume%3D165%26issue%3D1%26spage%3D248%26epage%3D248%26doi%3D10.1016%2Fj.cell.2016.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">First targeted protein degrader hits the clinic</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=237-239&author=A.+Mullard&title=First+targeted+protein+degrader+hits+the+clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DFirst%2520targeted%2520protein%2520degrader%2520hits%2520the%2520clinic%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D237%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petzold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoma, N. H.</span></span> <span> </span><span class="NLM_article-title">Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span> (<span class="NLM_issue">7597</span>),  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1038/nature16979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnature16979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26909574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=127-130&issue=7597&author=G.+Petzoldauthor=E.+S.+Fischerauthor=N.+H.+Thoma&title=Structural+basis+of+lenalidomide-induced+CK1%CE%B1+degradation+by+the+CRL4%28CRBN%29+ubiquitin+ligase&doi=10.1038%2Fnature16979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Petzold, Georg; Fischer, Eric S.; Thoma, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7597</span>),
    <span class="NLM_cas:pages">127-130</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thalidomide and its derivs., lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of hematol. malignancies.  IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4CRBN) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous CRL4CRBN substrates.  Unexpectedly, IMiDs also repurpose the ligase to target new proteins for degrdn.  Lenalidomide induces degrdn. of the lymphoid transcription factors Ikaros and Aiolos (also known as IKZF1 and IKZF3), and casein kinase 1α (CK1α), which contributes to its clin. efficacy in the treatment of multiple myeloma and 5q-deletion assocd. myelodysplastic syndrome (del(5q) MDS), resp.  How lenalidomide alters the specificity of the ligase to degrade these proteins remains elusive.  Here we present the 2.45 Å crystal structure of DDB1-CRBN bound to lenalidomide and CK1α.  CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop located in the kinase N-lobe.  We show that CK1α binding to CRL4CRBN is strictly dependent on the presence of an IMiD.  Binding of IKZF1 to CRBN similarly requires the compd. and both, IKZF1 and CK1α, use a related binding mode.  Our study provides a mechanistic explanation for the selective efficacy of lenalidomide in del(5q) MDS therapy.  We anticipate that high-affinity protein-protein interactions induced by small mols. will provide opportunities for drug development, particularly for targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs4FxWriI1ObVg90H21EOLACvtfcHk0lglG1iRoxFFDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D&md5=320fc6ff811da335fa8e02feab2d702d</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnature16979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16979%26sid%3Dliteratum%253Aachs%26aulast%3DPetzold%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DThoma%26aufirst%3DN.%2BH.%26atitle%3DStructural%2520basis%2520of%2520lenalidomide-induced%2520CK1%25CE%25B1%2520degradation%2520by%2520the%2520CRL4%2528CRBN%2529%2520ubiquitin%2520ligase%26jtitle%3DNature%26date%3D2016%26volume%3D532%26issue%3D7597%26spage%3D127%26epage%3D130%26doi%3D10.1038%2Fnature16979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robb, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kour, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murry, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span> <span> </span><span class="NLM_article-title">Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">54</span>),  <span class="NLM_fpage">7577</span>– <span class="NLM_lpage">7580</span>, <span class="refDoi"> DOI: 10.1039/C7CC03879H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1039%2FC7CC03879H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28636052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFyjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=7577-7580&issue=54&author=C.+M.+Robbauthor=J.+I.+Contrerasauthor=S.+Kourauthor=M.+A.+Taylorauthor=M.+Abidauthor=Y.+A.+Sonawaneauthor=M.+Zahidauthor=D.+J.+Murryauthor=A.+Natarajanauthor=S.+Rana&title=Chemically+induced+degradation+of+CDK9+by+a+proteolysis+targeting+chimera+%28PROTAC%29&doi=10.1039%2FC7CC03879H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Robb, Caroline M.; Contreras, Jacob I.; Kour, Smit; Taylor, Margaret A.; Abid, Mohammad; Sonawane, Yogesh A.; Zahid, Muhammad; Murry, Daryl J.; Natarajan, Amarnath; Rana, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">54</span>),
    <span class="NLM_cas:pages">7577-7580</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9), a member of the cyclin-dependent protein kinase (CDK) family, is involved in transcriptional elongation of several target genes.  CDK9 is ubiquitously expressed and has been shown to contribute to a variety of malignancies such as pancreatic, prostate and breast cancers.  Here we report the development of a heterobifunctional small mol. proteolysis targeting chimera (PROTAC) capable of cereblon (CRBN)-mediated proteasomal degrdn. of CDK9.  In HCT116 cells, it selectively degrades CDK9 while sparing other CDK family members.  This is the first example of a PROTAC that selectively degrades CDK9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXgLtOTwvlnbVg90H21EOLACvtfcHk0lglG1iRoxFFDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFyjsLw%253D&md5=a9aa8ebf8109f11206740efd1b5e09a2</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1039%2FC7CC03879H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CC03879H%26sid%3Dliteratum%253Aachs%26aulast%3DRobb%26aufirst%3DC.%2BM.%26aulast%3DContreras%26aufirst%3DJ.%2BI.%26aulast%3DKour%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DAbid%26aufirst%3DM.%26aulast%3DSonawane%26aufirst%3DY.%2BA.%26aulast%3DZahid%26aufirst%3DM.%26aulast%3DMurry%26aufirst%3DD.%2BJ.%26aulast%3DNatarajan%26aufirst%3DA.%26aulast%3DRana%26aufirst%3DS.%26atitle%3DChemically%2520induced%2520degradation%2520of%2520CDK9%2520by%2520a%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26issue%3D54%26spage%3D7577%26epage%3D7580%26doi%3D10.1039%2FC7CC03879H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bioorg.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30196207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=373-381&author=J.+Bianauthor=J.+Renauthor=Y.+Liauthor=J.+Wangauthor=X.+Xuauthor=Y.+Fengauthor=H.+Tangauthor=Y.+Wangauthor=Z.+Li&title=Discovery+of+wogonin-based+PROTACs+against+CDK9+and+capable+of+achieving+antitumor+activity&doi=10.1016%2Fj.bioorg.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity</span></div><div class="casAuthors">Bian, Jinlei; Ren, Jie; Li, Yongren; Wang, Jubo; Xu, Xi; Feng, Yifan; Tang, Hui; Wang, Yajing; Li, Zhiyu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">373-381</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Wogonin is a natural product isolated from the Scutellaria baicalensis and has been proved to be a potent and selective inhibitor of CDK9.  Using this scaffold, we designed and synthesized a series of proteolysis targeting chimeras (PROTACs) targeting CDK9 by recruiting ubiquitin E3 ligase cereblon (CRBN).  For constructing diverse Wogonin-based PROTACs, a "click chem." approach was employed for the synthesis of CDK9-targeting PROTACs.  The results of western blotting assays showed that compds. contg. triazole group in the linker could selectively downregulate the intracellular CDK9 level.  Among these compds., 11c could selectively degrade CDK9 in a concn.-dependent manner.  In addn., the application of the proteasome inhibitor MG132 and CRBN siRNA silencing confirmed that 11c could promote the proteasome-dependent and CRBN-dependent degrdn.  Consistent with the degrdn. of the CDK9 protein, 11c selectively inhibits proliferation of CDK9-overexpressed cancer cells.  Thus, our Wogonin-based PROTAC would be an efficient probe that induces the degrdn. of CDK9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod4sLAWq5vMrVg90H21EOLACvtfcHk0lgk753JwM4TmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7bE&md5=6a7158be1fce50296d6d0ec9160db0fc</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520wogonin-based%2520PROTACs%2520against%2520CDK9%2520and%2520capable%2520of%2520achieving%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D373%26epage%3D381%26doi%3D10.1016%2Fj.bioorg.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockett, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawtin, R. E.</span></span> <span> </span><span class="NLM_article-title">SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1007/s00280-008-0921-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs00280-008-0921-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=19169685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFCksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2009&pages=723-732&issue=4&author=A.+Conroyauthor=D.+E.+Stockettauthor=D.+Walkerauthor=M.+R.+Arkinauthor=U.+Hochauthor=J.+A.+Foxauthor=R.+E.+Hawtin&title=SNS-032+is+a+potent+and+selective+CDK+2%2C+7+and+9+inhibitor+that+drives+target+modulation+in+patient+samples&doi=10.1007%2Fs00280-008-0921-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples</span></div><div class="casAuthors">Conroy, Andrew; Stockett, David E.; Walker, Duncan; Arkin, Michelle R.; Hoch, Ute; Fox, Judith A.; Hawtin, Rachael Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">723-732</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">SNS-032 (formerly BMS-387032) is a potent, selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9, currently in phase 1 clin. trial for chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).  We used the MM cell line RPMI-8226 to evaluate the relationship between duration of SNS-032 exposure, target modulation of CDKs 2, 7 and 9, and induction of apoptosis.  We also assessed target modulation in patient peripheral blood mononuclear cells (PBMCs) from phase 1 solid tumor patients treated with SNS-032.  Proliferation and colony forming assays were used to evaluate cytotoxicity, Western blot analyses to evaluate target modulation, FACS anal. to assess cell cycle distribution, RT-PCR to evaluate transcriptional inhibition.  SNS-032 blocks the cell cycle via inhibition of CDKs 2 and 7, and transcription via inhibition of CDKs 7 and 9.  Treatment of RPMI-8226 MM cells at 300 nM (IC90) for 6 h was sufficient for commitment to apoptosis.  This correlated with inhibition of CDKs 2, 7 and 9, as reflected in substrate signaling mols.  SNS-032 activity was unaffected by human serum.  Target modulation was obsd. in PBMC from treated patients.  These results demonstrate SNS-032 target modulation of CDKs 2, 7 and 9, and establish 6 h exposure as sufficient to commit RPMI-8226 MM cells to apoptosis.  Combined with the demonstration of target modulation in PBMC from phase 1 solid tumor patients treated with SNS-032, these data support the ongoing clin. study of SNS-032 in MM and CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMlNcab7zzo7Vg90H21EOLACvtfcHk0lgk753JwM4TmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFCksLY%253D&md5=231b8ddb93821ba00d912ed28dbc1ccb</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1007%2Fs00280-008-0921-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-008-0921-5%26sid%3Dliteratum%253Aachs%26aulast%3DConroy%26aufirst%3DA.%26aulast%3DStockett%26aufirst%3DD.%2BE.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DHoch%26aufirst%3DU.%26aulast%3DFox%26aufirst%3DJ.%2BA.%26aulast%3DHawtin%26aufirst%3DR.%2BE.%26atitle%3DSNS-032%2520is%2520a%2520potent%2520and%2520selective%2520CDK%25202%252C%25207%2520and%25209%2520inhibitor%2520that%2520drives%2520target%2520modulation%2520in%2520patient%2520samples%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D64%26issue%3D4%26spage%3D723%26epage%3D732%26doi%3D10.1007%2Fs00280-008-0921-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span> <span> </span><span class="NLM_article-title">Halogen bonds form the basis for selective P-TEFb inhibition by DRB</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.chembiol.2010.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=20851342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=931-936&author=S.+Baumliauthor=J.+A.+Endicottauthor=L.+N.+Johnson&title=Halogen+bonds+form+the+basis+for+selective+P-TEFb+inhibition+by+DRB&doi=10.1016%2Fj.chembiol.2010.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen Bonds Form the Basis for Selective P-TEFb Inhibition by DRB</span></div><div class="casAuthors">Baumli, Sonja; Endicott, Jane A.; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">931-936</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Cdk9, the kinase of the pos. transcription elongation factor b, is required for processive transcription elongation by RNA polymerase II.  Cdk9 inhibition contributes to the anticancer activity of many Cdk inhibitors under clin. investigation and hence there is interest in selective Cdk9 inhibitors.  DRB (5,6-dichlorobenzimidazone-1-β-D-ribofuranoside) is a commonly used reagent for Cdk9 inhibition in cell biol. studies.  The crystal structures of Cdk9 and Cdk2 in complex with DRB reported here describe the mol. basis for the DRB selectivity toward Cdk9.  The DRB chlorine atoms form halogen bonds that are specific for the Cdk9 kinase hinge region.  Kinetic and thermodn. expts. validate the structural findings and implicate the C-terminal residues of Cdk9 in contributing to the affinity for DRB.  These results open the possibility to exploit halogen atoms in inhibitor design to specifically target Cdk9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMj3v7EG7-1LVg90H21EOLACvtfcHk0lgk753JwM4TmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fN&md5=88686dcae3c6943da8a05e463d4fd419</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DHalogen%2520bonds%2520form%2520the%2520basis%2520for%2520selective%2520P-TEFb%2520inhibition%2520by%2520DRB%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D931%26epage%3D936%26doi%3D10.1016%2Fj.chembiol.2010.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span> <span> </span><span class="NLM_article-title">The CDK9 c-helix exhibits conformational plasticity that may explain the selectivity of CAN508</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">816</span>, <span class="refDoi"> DOI: 10.1021/cb2004516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb2004516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVGlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=811-816&author=S.+Baumliauthor=A.+J.+Holeauthor=M.+E.+M.+Nobleauthor=J.+A.+Endicott&title=The+CDK9+c-helix+exhibits+conformational+plasticity+that+may+explain+the+selectivity+of+CAN508&doi=10.1021%2Fcb2004516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508</span></div><div class="casAuthors">Baumli, Sonja; Hole, Alison J.; Noble, Martin E. M.; Endicott, Jane A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">811-816</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CDK9 is the kinase of pos. transcription elongation factor b and facilitates the transition of paused RNA polymerase II to processive transcription elongation.  CDK9 is a validated target for the treatment of cancer, cardiac hypertrophy, and human immunodeficiency virus.  Here we analyze different CDK9/cyclin T variants to identify a form of the complex amenable to use in inhibitor design.  To demonstrate the utility of this system, we have detd. the crystal structures of CDK9/cyclin T and CDK2/cyclin A bound to the CDK9-specific inhibitor CAN508.  Comparison of the structures reveals CDK9-specific conformational changes and identifies a CDK9-specific hydrophobic pocket, adjacent to the αC-helix.  By comparison with a previously published structure of CDK9/cyclin T/human immunodeficiency virus TAT we find that the CDK9 αC-helix has a degree of conformational variability that has the potential to be exploited for inhibitor design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6zu3z8kUuhrVg90H21EOLACvtfcHk0li5auEaDxd0CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVGlsro%253D&md5=32dc86d1d1b8ff619446a4d6a6773341</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fcb2004516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb2004516%26sid%3Dliteratum%253Aachs%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520CDK9%2520c-helix%2520exhibits%2520conformational%2520plasticity%2520that%2520may%2520explain%2520the%2520selectivity%2520of%2520CAN508%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D811%26epage%3D816%26doi%3D10.1021%2Fcb2004516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: novel potential CDK9 inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">104064</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2020.104064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bioorg.2020.104064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=32653610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlyisLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2020&pages=104064&author=H.+Huauthor=J.+Wuauthor=M.+Aoauthor=X.+Zhouauthor=B.+Liauthor=Z.+Cuiauthor=T.+Wuauthor=L.+Wangauthor=Y.+Xueauthor=Z.+Wuauthor=M.+Fang&title=Design%2C+synthesis+and+biological+evaluation+of+methylenehydrazine-1-carboxamide+derivatives+with+%285-%28%284-%28pyridin-3-yl%29pyrimidin-2-yl%29amino%29-1H-indole+scaffold%3A+novel+potential+CDK9+inhibitors&doi=10.1016%2Fj.bioorg.2020.104064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors</span></div><div class="casAuthors">Hu, Hongyu; Wu, Jun; Ao, Mingtao; Zhou, Xiaoping; Li, Boqun; Cui, Zhenzhen; Wu, Tong; Wang, Lijuan; Xue, Yuhua; Wu, Zhen; Fang, Meijuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104064</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Design and synthesis of N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-2-methylenehydrazine-1-carboxamide derivs. I [R1 = n-Pr, 2-thienyl, Ph, etc.] and methylenehydrazine-1-carboxamide derivs. with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino))-1H-indole scaffold I [R2 = 4-pyridyl, 4-MeSC6H4, 1H-indol-3-yl, etc.] as novel potential CDK9 inhibitors was repoted.  Biol. activity results demonstrated that most of these derivs. I and II possessed good inhibitory on the kinase activity of CDK9 such as blocking its phosphorylation function and inhibiting HIV-1 transcription.  Compd. II [R2 = 1H-indol-3-yl] was found to be the most potent CDK9 inhibitor and exhibited excellent anticancer activity against HepG2, A375, MCF-7, and A549, but low toxic on normal cells including HaCaT and MCF-10A.  Further studies revealed that as a result of CDK9 inhibition and subsequent inhibition of phosphorylation at Serine 2 of the RNAPII CTD, the representative compd. II [R2 = 1H-indol-3-yl] dose-dependently increased cleaved PARP level, exerting its antiproliferative effect through induction of apoptosis in cancer cells.  Finally, the mol. docking anal. implied that compd. II [R2 = 1H-indol-3-yl] had a good binding affinity with CDK9.  In summary, compd. II [R2 = 1H-indol-3-yl] was a potent CDK9 inhibitor and could be considered as a good lead-candidate for developing potential anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUUGqHUrrS37Vg90H21EOLACvtfcHk0li5auEaDxd0CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlyisLbE&md5=54bf245213ae9e856cfaad2758c190bc</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.104064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.104064%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DAo%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520methylenehydrazine-1-carboxamide%2520derivatives%2520with%2520%25285-%2528%25284-%2528pyridin-3-yl%2529pyrimidin-2-yl%2529amino%2529-1H-indole%2520scaffold%253A%2520novel%2520potential%2520CDK9%2520inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D102%26spage%3D104064%26doi%3D10.1016%2Fj.bioorg.2020.104064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khedkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutinho, E. C.</span></span> <span> </span><span class="NLM_article-title">3D-QSAR in drug design--a review</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.2174/156802610790232260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.2174%2F156802610790232260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=19929826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFWqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=95-115&author=J.+Vermaauthor=V.+M.+Khedkarauthor=E.+C.+Coutinho&title=3D-QSAR+in+drug+design%2D%2Da+review&doi=10.2174%2F156802610790232260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">3D-QSAR in drug design - a review</span></div><div class="casAuthors">Verma, Jitender; Khedkar, Vijay M.; Coutinho, Evans C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-115</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Quant. structure-activity relationships (QSAR) have been applied for decades in the development of relationships between physicochem. properties of chem. substances and their biol. activities to obtain a reliable statistical model for prediction of the activities of new chem. entities.  The fundamental principle underlying the formalism is that the difference in structural properties is responsible for the variations in biol. activities of the compds.  In the classical QSAR studies, affinities of ligands to their binding sites, inhibition consts., rate consts., and other biol. end points, with at., group or mol. properties such as lipophilicity, polarizability, electronic and steric properties (Hansch anal.) or with certain structural features (Free-Wilson anal.) have been correlated.  However such an approach has only a limited utility for designing a new mol. due to the lack of consideration of the 3D structure of the mols.  3D-QSAR has emerged as a natural extension to the classical Hansch and Free-Wilson approaches, which exploits the three-dimensional properties of the ligands to predict their biol. activities using robust chemometric techniques such as PLS, G/PLS, ANN etc.  It has served as a valuable predictive tool in the design of pharmaceuticals and agrochems.  Although the trial and error factor involved in the development of a new drug cannot be ignored completely, QSAR certainly decreases the no. of compds. to be synthesized by facilitating the selection of the most promising candidates.  Several success stories of QSAR have attracted the medicinal chemists to investigate the relationships of structural properties with biol. activity.  This review seeks to provide a bird's eye view of the different 3D-QSAR approaches employed within the current drug discovery community to construct predictive structure-activity relationships and also discusses the limitations that are fundamental to these approaches, as well as those that might be overcome with the improved strategies.  The components involved in building a useful 3D-QSAR model are discussed, including the validation techniques available for this purpose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIsS98xZ6vS7Vg90H21EOLACvtfcHk0liaMWSTu0pfJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFWqu7c%253D&md5=b3fc197c2730da3b7bb806366ef25c46</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.2174%2F156802610790232260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610790232260%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DJ.%26aulast%3DKhedkar%26aufirst%3DV.%2BM.%26aulast%3DCoutinho%26aufirst%3DE.%2BC.%26atitle%3D3D-QSAR%2520in%2520drug%2520design--a%2520review%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D95%26epage%3D115%26doi%3D10.2174%2F156802610790232260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kent, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, G.</span></span> <span> </span><span class="NLM_article-title">The broken cycle: E2F dysfunction in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1038/s41568-019-0143-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fs41568-019-0143-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31053804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptFSqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=326-338&author=L.+N.+Kentauthor=G.+Leone&title=The+broken+cycle%3A+E2F+dysfunction+in+cancer&doi=10.1038%2Fs41568-019-0143-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">The broken cycle: E2F dysfunction in cancer</span></div><div class="casAuthors">Kent, Lindsey N.; Leone, Gustavo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">326-338</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The cyclin-dependent kinase (CDK)-RB-E2F axis forms the core transcriptional machinery driving cell cycle progression, dictating the timing and fidelity of genome replication and ensuring genetic material is accurately passed through each cell division cycle.  The ultimate effectors of this axis are members of a family of eight distinct E2F genes encoding transcriptional activators and repressors.  E2F transcriptional activity is tightly regulated throughout the cell cycle via transcriptional and translational regulation, post-translational modifications, protein degrdn., binding to cofactors and subcellular localization.  Alterations in one or more key components of this axis (CDKs, cyclins, CDK inhibitors and the RB family of proteins) occur in virtually all cancers and result in heightened oncogenic E2F activity, leading to uncontrolled proliferation.  In this Review, we discuss the activities of E2F proteins with an emphasis on the newest atypical E2F family members, the specific and redundant functions of E2F proteins, how misexpression of E2F transcriptional targets promotes cancer and both current and developing therapeutic strategies being used to target this oncogenic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZOonvudzTx7Vg90H21EOLACvtfcHk0liaMWSTu0pfJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptFSqt7k%253D&md5=8f9b774c2dbdfee74823ab5a8f14b4cc</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fs41568-019-0143-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-019-0143-7%26sid%3Dliteratum%253Aachs%26aulast%3DKent%26aufirst%3DL.%2BN.%26aulast%3DLeone%26aufirst%3DG.%26atitle%3DThe%2520broken%2520cycle%253A%2520E2F%2520dysfunction%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2019%26volume%3D19%26spage%3D326%26epage%3D338%26doi%3D10.1038%2Fs41568-019-0143-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Condorelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailleux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span> <span> </span><span class="NLM_article-title">Polyclonal RB1 mutations and acquired resistance to CDK4/6 inhibitors in patients with metastatic breast cancer</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1093%2Fannonc%2Fmdx784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29236940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC1MzhtFWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=640-645&author=R.+Condorelliauthor=L.+Springauthor=J.+O%E2%80%99Shaughnessyauthor=L.+Lacroixauthor=C.+Bailleuxauthor=V.+Scottauthor=J.+Duboisauthor=R.+J.+Nagyauthor=R.+B.+Lanmanauthor=A.+J.+Iafrateauthor=F.+Andreauthor=A.+Bardia&title=Polyclonal+RB1+mutations+and+acquired+resistance+to+CDK4%2F6+inhibitors+in+patients+with+metastatic+breast+cancer&doi=10.1093%2Fannonc%2Fmdx784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer</span></div><div class="casAuthors">Condorelli R; Lacroix L; Bailleux C; Scott V; Andre F; Spring L; Dubois J; Iafrate A J; O'Shaughnessy J; Nagy R J; Lanman R B; Bardia A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">640-645</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  While deregulation of the cyclin D1-CDK4/6-retinoblastoma pathway is common in hormone receptor positive (HR+) breast cancer, Rb is usually intact in HR+ breast cancer, and targeted CDK 4/6 inhibitors that act upstream of Rb, are routinely being utilized in clinical practice.  However, factors that can lead to clinical resistance to CDK 4/6 inhibitors are not known.  Patients and methods:  We identified patients who had pre- and post-genotyping in tissue and peripheral blood samples after receiving CDK 4/6 inhibitors.  Genotyping was carried out in tumor tissue or blood collected before start of CDK 4/6 inhibitor and after disease progression on CDK 4/6 inhibitor, covering more than 90% of the coding region in RB1.  Results:  We identified detectable acquired RB1 mutations in circulating tumor DNA (ctDNA) after exposure to CDK4/6 inhibitor (palbociclib, palbociclib, ribociclib) for 5, 8, and 13 months, respectively, in three patients.  The RB1 mutations included substitution in donor splicing site of exon 8 of the RB1 gene in patient #1; substitution in donor splicing site of exon 22 of RB1 gene, exon 19 deletion, exon 3 insertion in patient #2; and RB1 exon 16 H483Y mutation in patient #3.  None of these RB1 mutations were present in the pre-CDK 4/6 specimen highlighting these molecular alterations, which lead to functional loss of Rb1, likely emerged under selective pressure from the CDK4/6 inhibitor potentially confering therapeutic resistance.  Conclusion:  This is the first clinical report to describe the emergence of somatic RB1 mutations after exposure to palbociclib or ribociclib, in patients with metastatic breast cancer.  Further research is needed to validate these findings, identify how these mutations temporally emerge under selective pressure of CDK 4/6 inhibitor, and develop rational therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT57Ei4We3h7fIW7hznt0zpfW6udTcc2eZvkdkNY0kNZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzhtFWisw%253D%253D&md5=0f659618552c56fdc7b21f50bbb7c0cf</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx784%26sid%3Dliteratum%253Aachs%26aulast%3DCondorelli%26aufirst%3DR.%26aulast%3DSpring%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DBailleux%26aufirst%3DC.%26aulast%3DScott%26aufirst%3DV.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DNagy%26aufirst%3DR.%2BJ.%26aulast%3DLanman%26aufirst%3DR.%2BB.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DBardia%26aufirst%3DA.%26atitle%3DPolyclonal%2520RB1%2520mutations%2520and%2520acquired%2520resistance%2520to%2520CDK4%252F6%2520inhibitors%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3D640%26epage%3D645%26doi%3D10.1093%2Fannonc%2Fmdx784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del Re, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crucitta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rofi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diodati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianfilippo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvadori, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scatena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naccarato, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danesi, R.</span></span> <span> </span><span class="NLM_article-title">Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1007/s10549-019-05365-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs10549-019-05365-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31346846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVGrtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=57-62&issue=1&author=M.+Del+Reauthor=I.+Bertoliniauthor=S.+Crucittaauthor=L.+Fontanelliauthor=E.+Rofiauthor=C.+De+Angelisauthor=L.+Diodatiauthor=D.+Cavalleroauthor=G.+Gianfilippoauthor=B.+Salvadoriauthor=S.+Fogliauthor=A.+Falconeauthor=C.+Scatenaauthor=A.+G.+Naccaratoauthor=M.+Roncellaauthor=M.+Ghilliauthor=R.+Morgantiauthor=A.+Fontanaauthor=R.+Danesi&title=Overexpression+of+TK1+and+CDK9+in+plasma-derived+exosomes+is+associated+with+clinical+resistance+to+CDK4%2F6+inhibitors+in+metastatic+breast+cancer+patients&doi=10.1007%2Fs10549-019-05365-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients</span></div><div class="casAuthors">Del Re, Marzia; Bertolini, Ilaria; Crucitta, Stefania; Fontanelli, Lorenzo; Rofi, Eleonora; De Angelis, Claudia; Diodati, Lucrezia; Cavallero, Diletta; Gianfilippo, Giulia; Salvadori, Barbara; Fogli, Stefano; Falcone, Alfredo; Scatena, Cristian; Naccarato, Antonio Giuseppe; Roncella, Manuela; Ghilli, Matteo; Morganti, Riccardo; Fontana, Andrea; Danesi, Romano</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-62</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The present article addresses the role of the mRNA expression of thymidine kinase 1 (TK1), CDK4, 6 and 9 in plasma-derived exosomes and their relevance in the pharmacol. activity of CDK4/6i.  Methods: Blood samples of 40 HR+/HER2- advanced breast cancer patients were collected before (T0) the administration of palbociclib plus hormonal therapy and after 3 mo (T1).  RNA was isolated from exosomes and analyzed for the expression of TK1, CDK 4, 6 and 9 by digital droplet PCR (ddPCR).  Results: A higher value of TK1 copies/mL at baseline (T0) was significantly assocd. with the no. of previous lines of chemotherapy (p = 0.009).  In patients with PD, a significant increase was obsd. in the no. of copies/mL of TK1 (p = 0.01) and CDK9 (p = 0.03) comparing T1 vs.  T0 values. No significant correlations between response to treatment and clin. parameters were found at univariate anal.  High baseline CDK4 expression was significantly correlated with longer PFS in patients treated with fulvestrant + palbociclib (low vs. high: 6.45 mo vs. not reached, p = 0.01).  Conclusions: The present study demonstrates that, in plasma-derived exosomes, high baseline CDK4 mRNA levels are assocd. with response to palbociclib plus hormonal therapy, while the increase in TK1 and CDK9 mRNA copies/mL is assocd. with clin. resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAoJIlNIJ7NLVg90H21EOLACvtfcHk0lg5ZjQCHE5GAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVGrtbzM&md5=e5684c7965c4527fe92c7c5c9869e428</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1007%2Fs10549-019-05365-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-019-05365-y%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BRe%26aufirst%3DM.%26aulast%3DBertolini%26aufirst%3DI.%26aulast%3DCrucitta%26aufirst%3DS.%26aulast%3DFontanelli%26aufirst%3DL.%26aulast%3DRofi%26aufirst%3DE.%26aulast%3DDe%2BAngelis%26aufirst%3DC.%26aulast%3DDiodati%26aufirst%3DL.%26aulast%3DCavallero%26aufirst%3DD.%26aulast%3DGianfilippo%26aufirst%3DG.%26aulast%3DSalvadori%26aufirst%3DB.%26aulast%3DFogli%26aufirst%3DS.%26aulast%3DFalcone%26aufirst%3DA.%26aulast%3DScatena%26aufirst%3DC.%26aulast%3DNaccarato%26aufirst%3DA.%2BG.%26aulast%3DRoncella%26aufirst%3DM.%26aulast%3DGhilli%26aufirst%3DM.%26aulast%3DMorganti%26aufirst%3DR.%26aulast%3DFontana%26aufirst%3DA.%26aulast%3DDanesi%26aufirst%3DR.%26atitle%3DOverexpression%2520of%2520TK1%2520and%2520CDK9%2520in%2520plasma-derived%2520exosomes%2520is%2520associated%2520with%2520clinical%2520resistance%2520to%2520CDK4%252F6%2520inhibitors%2520in%2520metastatic%2520breast%2520cancer%2520patients%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2019%26volume%3D178%26issue%3D1%26spage%3D57%26epage%3D62%26doi%3D10.1007%2Fs10549-019-05365-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minzel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatachalam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachya, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burstain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdman, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushansky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shlush, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikarsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snir-Alkalay, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Neriah, Y.</span></span> <span> </span><span class="NLM_article-title">Small molecules co-targeting CKIα and the transcriptional kinases CDK7/9 control AML in preclinical models</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.cell.2018.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30146162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyktbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=171-185&issue=1&author=W.+Minzelauthor=A.+Venkatachalamauthor=A.+Finkauthor=E.+Hungauthor=G.+Brachyaauthor=I.+Burstainauthor=M.+Shahamauthor=A.+Rivlinauthor=I.+Omerauthor=A.+Zingerauthor=S.+Eliasauthor=E.+Winterauthor=P.+E.+Erdmanauthor=R.+W.+Sullivanauthor=L.+Fungauthor=F.+Mercurioauthor=D.+Liauthor=J.+Vaccaauthor=N.+Kaushanskyauthor=L.+Shlushauthor=M.+Orenauthor=R.+Levineauthor=E.+Pikarskyauthor=I.+Snir-Alkalayauthor=Y.+Ben-Neriah&title=Small+molecules+co-targeting+CKI%CE%B1+and+the+transcriptional+kinases+CDK7%2F9+control+AML+in+preclinical+models&doi=10.1016%2Fj.cell.2018.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models</span></div><div class="casAuthors">Minzel, Waleed; Venkatachalam, Avanthika; Fink, Avner; Hung, Eric; Brachya, Guy; Burstain, Ido; Shaham, Maya; Rivlin, Amitai; Omer, Itay; Zinger, Adar; Elias, Shlomo; Winter, Eitan; Erdman, Paul E.; Sullivan, Robert W.; Fung, Leah; Mercurio, Frank; Li, Dansu; Vacca, Joseph; Kaushansky, Nathali; Shlush, Liran; Oren, Moshe; Levine, Ross; Pikarsky, Eli; Snir-Alkalay, Irit; Ben-Neriah, Yinon</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-185.e25</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">CKIα ablation induces p53 activation, and CKIα degrdn. underlies the therapeutic effect of lenalidomide in a pre-leukemia syndrome.  Here we describe the development of CKIα inhibitors, which co-target the transcriptional kinases CDK7 and CDK9, thereby augmenting CKIα-induced p53 activation and its anti-leukemic activity.  Oncogene-driving super-enhancers (SEs) are highly sensitive to CDK7/9 inhibition.  We identified multiple newly gained SEs in primary mouse acute myeloid leukemia (AML) cells and demonstrate that the inhibitors abolish many SEs and preferentially suppress the transcription elongation of SE-driven oncogenes.  We show that blocking CKIα together with CDK7 and/or CDK9 synergistically stabilize p53, deprive leukemia cells of survival and proliferation-maintaining SE-driven oncogenes, and induce apoptosis.  Leukemia progenitors are selectively eliminated by the inhibitors, explaining their therapeutic efficacy with preserved hematopoiesis and leukemia cure potential; they eradicate leukemia in MLL-AF9 and Tet2-/-;Flt3ITD AML mouse models and in several patient-derived AML xenograft models, supporting their potential efficacy in curing human leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg4QEH6R_ll7Vg90H21EOLACvtfcHk0lggdTC4S5gQrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyktbvF&md5=b3e088a6b262dc8998ff334867102aa5</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DMinzel%26aufirst%3DW.%26aulast%3DVenkatachalam%26aufirst%3DA.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHung%26aufirst%3DE.%26aulast%3DBrachya%26aufirst%3DG.%26aulast%3DBurstain%26aufirst%3DI.%26aulast%3DShaham%26aufirst%3DM.%26aulast%3DRivlin%26aufirst%3DA.%26aulast%3DOmer%26aufirst%3DI.%26aulast%3DZinger%26aufirst%3DA.%26aulast%3DElias%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DE.%26aulast%3DErdman%26aufirst%3DP.%2BE.%26aulast%3DSullivan%26aufirst%3DR.%2BW.%26aulast%3DFung%26aufirst%3DL.%26aulast%3DMercurio%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DKaushansky%26aufirst%3DN.%26aulast%3DShlush%26aufirst%3DL.%26aulast%3DOren%26aufirst%3DM.%26aulast%3DLevine%26aufirst%3DR.%26aulast%3DPikarsky%26aufirst%3DE.%26aulast%3DSnir-Alkalay%26aufirst%3DI.%26aulast%3DBen-Neriah%26aufirst%3DY.%26atitle%3DSmall%2520molecules%2520co-targeting%2520CKI%25CE%25B1%2520and%2520the%2520transcriptional%2520kinases%2520CDK7%252F9%2520control%2520AML%2520in%2520preclinical%2520models%26jtitle%3DCell%26date%3D2018%26volume%3D175%26issue%3D1%26spage%3D171%26epage%3D185%26doi%3D10.1016%2Fj.cell.2018.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span>; <span class="NLM_string-name">Justin, C. D.</span>; <span class="NLM_string-name">Lisa, D.</span>; <span class="NLM_string-name">Theresa, P.</span>; <span class="NLM_string-name">Maryann, S. M.</span></span> <span> </span><span class="NLM_article-title">Combination of A BTK Inhibitor of CDK9 to Treat Cancer</span>. Patent <span class="NLM_patent">WO2019/058348A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=B.+Scott&author=C.+D.+Justin&author=D.+Lisa&author=P.+Theresa&author=S.+M.+Maryann&title=Combination+of+A+BTK+Inhibitor+of+CDK9+to+Treat+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DB.%26atitle%3DCombination%2520of%2520A%2520BTK%2520Inhibitor%2520of%2520CDK9%2520to%2520Treat%2520Cancer%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veeranki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solis, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kathkuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstetter, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maru, D. M.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK9 and MCL-1 by a new CDK9/P-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma</span>. <i>Ther Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1177/1758835919864850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1177%2F1758835919864850" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1-17&author=Z.+Tongauthor=A.+Mejiaauthor=O.+Veerankiauthor=A.+Vermaauthor=A.+M.+Correaauthor=R.+Dokeyauthor=V.+Patelauthor=L.+M.+Solisauthor=B.+Minoauthor=R.+Kathkudaauthor=J.+Rodriguez-Canalesauthor=S.+H.+Linauthor=S.+Krishnanauthor=S.+Kopetzauthor=M.+Blumauthor=J.+A.+Ajaniauthor=W.+L.+Hofstetterauthor=D.+M.+Maru&title=Targeting+CDK9+and+MCL-1+by+a+new+CDK9%2FP-TEFb+inhibitor+with+and+without+5-fluorouracil+in+esophageal+adenocarcinoma&doi=10.1177%2F1758835919864850"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1177%2F1758835919864850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758835919864850%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DMejia%26aufirst%3DA.%26aulast%3DVeeranki%26aufirst%3DO.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DCorrea%26aufirst%3DA.%2BM.%26aulast%3DDokey%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DSolis%26aufirst%3DL.%2BM.%26aulast%3DMino%26aufirst%3DB.%26aulast%3DKathkuda%26aufirst%3DR.%26aulast%3DRodriguez-Canales%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%2BH.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DBlum%26aufirst%3DM.%26aulast%3DAjani%26aufirst%3DJ.%2BA.%26aulast%3DHofstetter%26aufirst%3DW.%2BL.%26aulast%3DMaru%26aufirst%3DD.%2BM.%26atitle%3DTargeting%2520CDK9%2520and%2520MCL-1%2520by%2520a%2520new%2520CDK9%252FP-TEFb%2520inhibitor%2520with%2520and%2520without%25205-fluorouracil%2520in%2520esophageal%2520adenocarcinoma%26jtitle%3DTher%2520Adv.%2520Med.%2520Oncol.%26date%3D2019%26volume%3D11%26spage%3D1%26epage%3D17%26doi%3D10.1177%2F1758835919864850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCalmont, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toubia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casolari, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayoh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samaraweera, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, R. J.</span></span> <span> </span><span class="NLM_article-title">Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2019000586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1182%2Fbloodadvances.2019000586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31971998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FjsFeguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=296-300&author=H.+McCalmontauthor=K.+L.+Liauthor=L.+Jonesauthor=J.+Toubiaauthor=S.+C.+Brayauthor=D.+A.+Casolariauthor=C.+Mayohauthor=S.+E.+Samaraweeraauthor=I.+D.+Lewisauthor=R.+K.+Prinjhaauthor=N.+Smithersauthor=S.+Wangauthor=R.+B.+Lockauthor=R.+J.+D%E2%80%99Andrea&title=Efficacy+of+combined+CDK9%2FBET+inhibition+in+preclinical+models+of+MLL-rearranged+acute+leukemia&doi=10.1182%2Fbloodadvances.2019000586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia</span></div><div class="casAuthors">McCalmont Hannah; Jones Luke; Mayoh Chelsea; Lock Richard B; Li Ka Leung; Toubia John; Casolari Debora A; Samaraweera Saumya E; D'Andrea Richard J; Bray Sarah C; Lewis Ian D; Prinjha Rab K; Smithers Nicholas; Wang Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Blood advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">296-300</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGEj1qON9AKbt7lRqEFUJVfW6udTcc2eZ3ti2CMqUms7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FjsFeguw%253D%253D&md5=3a266c0e3f97b0238fa22cc5b7b97089</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2019000586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2019000586%26sid%3Dliteratum%253Aachs%26aulast%3DMcCalmont%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DK.%2BL.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DToubia%26aufirst%3DJ.%26aulast%3DBray%26aufirst%3DS.%2BC.%26aulast%3DCasolari%26aufirst%3DD.%2BA.%26aulast%3DMayoh%26aufirst%3DC.%26aulast%3DSamaraweera%26aufirst%3DS.%2BE.%26aulast%3DLewis%26aufirst%3DI.%2BD.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DSmithers%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DR.%2BJ.%26atitle%3DEfficacy%2520of%2520combined%2520CDK9%252FBET%2520inhibition%2520in%2520preclinical%2520models%2520of%2520MLL-rearranged%2520acute%2520leukemia%26jtitle%3DBlood%2520Adv.%26date%3D2020%26volume%3D4%26spage%3D296%26epage%3D300%26doi%3D10.1182%2Fbloodadvances.2019000586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Yu</span>, <span class="hlFld-ContribAuthor ">Ming  Cai</span>, <span class="hlFld-ContribAuthor ">Liang  Shao</span>, <span class="hlFld-ContribAuthor ">Jihong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Protein Kinases Degradation by PROTACs. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fchem.2021.679120" title="DOI URL">https://doi.org/10.3389/fchem.2021.679120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2021.679120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2021.679120%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DTargeting%252BProtein%252BKinases%252BDegradation%252Bby%252BPROTACs%26aulast%3DYu%26aufirst%3DFei%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephin J.  Vervoort</span>, <span class="hlFld-ContribAuthor ">Sarah A.  Welsh</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Devlin</span>, <span class="hlFld-ContribAuthor ">Elisa  Barbieri</span>, <span class="hlFld-ContribAuthor ">Deborah A.  Knight</span>, <span class="hlFld-ContribAuthor ">Sarah  Offley</span>, <span class="hlFld-ContribAuthor ">Stefan  Bjelosevic</span>, <span class="hlFld-ContribAuthor ">Matteo  Costacurta</span>, <span class="hlFld-ContribAuthor ">Izabela  Todorovski</span>, <span class="hlFld-ContribAuthor ">Conor J.  Kearney</span>, <span class="hlFld-ContribAuthor ">Jarrod J.  Sandow</span>, <span class="hlFld-ContribAuthor ">Zheng  Fan</span>, <span class="hlFld-ContribAuthor ">Benjamin  Blyth</span>, <span class="hlFld-ContribAuthor ">Victoria  McLeod</span>, <span class="hlFld-ContribAuthor ">Joseph H.A.  Vissers</span>, <span class="hlFld-ContribAuthor ">Karolina  Pavic</span>, <span class="hlFld-ContribAuthor ">Ben P.  Martin</span>, <span class="hlFld-ContribAuthor ">Gareth  Gregory</span>, <span class="hlFld-ContribAuthor ">Elena  Demosthenous</span>, <span class="hlFld-ContribAuthor ">Magnus  Zethoven</span>, <span class="hlFld-ContribAuthor ">Isabella Y.  Kong</span>, <span class="hlFld-ContribAuthor ">Edwin D.  Hawkins</span>, <span class="hlFld-ContribAuthor ">Simon J.  Hogg</span>, <span class="hlFld-ContribAuthor ">Madison J.  Kelly</span>, <span class="hlFld-ContribAuthor ">Andrea  Newbold</span>, <span class="hlFld-ContribAuthor ">Kaylene J.  Simpson</span>, <span class="hlFld-ContribAuthor ">Otto  Kauko</span>, <span class="hlFld-ContribAuthor ">Kieran F.  Harvey</span>, <span class="hlFld-ContribAuthor ">Michael  Ohlmeyer</span>, <span class="hlFld-ContribAuthor ">Jukka  Westermarck</span>, <span class="hlFld-ContribAuthor ">Nathanael  Gray</span>, <span class="hlFld-ContribAuthor ">Alessandro  Gardini</span>, <span class="hlFld-ContribAuthor ">Ricky W.  Johnstone</span>. </span><span class="cited-content_cbyCitation_article-title">The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. </span><span class="cited-content_cbyCitation_journal-name">Cell</span><span> <strong>2021,</strong> <em>184 </em>
                                    (12)
                                     , 3143-3162.e32. <a href="https://doi.org/10.1016/j.cell.2021.04.022" title="DOI URL">https://doi.org/10.1016/j.cell.2021.04.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cell.2021.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cell.2021.04.022%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%26atitle%3DThe%252BPP2A-Integrator-CDK9%252Baxis%252Bfine-tunes%252Btranscription%252Band%252Bcan%252Bbe%252Btargeted%252Btherapeutically%252Bin%252Bcancer%26aulast%3DVervoort%26aufirst%3DStephin%2BJ.%26date%3D2021%26volume%3D184%26issue%3D12%26spage%3D3143%26epage%3D3162.e32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alice  Ranjan</span>, <span class="hlFld-ContribAuthor ">Ying  Pang</span>, <span class="hlFld-ContribAuthor ">Madison  Butler</span>, <span class="hlFld-ContribAuthor ">Mythili  Merchant</span>, <span class="hlFld-ContribAuthor ">Olga  Kim</span>, <span class="hlFld-ContribAuthor ">Guangyang  Yu</span>, <span class="hlFld-ContribAuthor ">Yu-Ting  Su</span>, <span class="hlFld-ContribAuthor ">Mark R.  Gilbert</span>, <span class="hlFld-ContribAuthor ">David  Levens</span>, <span class="hlFld-ContribAuthor ">Jing  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting CDK9 for the Treatment of Glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (12)
                                     , 3039. <a href="https://doi.org/10.3390/cancers13123039" title="DOI URL">https://doi.org/10.3390/cancers13123039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13123039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13123039%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeting%252BCDK9%252Bfor%252Bthe%252BTreatment%252Bof%252BGlioblastoma%26aulast%3DRanjan%26aufirst%3DAlice%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D12%26spage%3D3039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott  Boiko</span>, <span class="hlFld-ContribAuthor ">Theresa  Proia</span>, <span class="hlFld-ContribAuthor ">Maryann  San Martin</span>, <span class="hlFld-ContribAuthor ">Gareth P.  Gregory</span>, <span class="hlFld-ContribAuthor ">Michelle Min  Wu</span>, <span class="hlFld-ContribAuthor ">Neeraj  Aryal</span>, <span class="hlFld-ContribAuthor ">Maureen  Hattersley</span>, <span class="hlFld-ContribAuthor ">Wenlin  Shao</span>, <span class="hlFld-ContribAuthor ">Jamal C.  Saeh</span>, <span class="hlFld-ContribAuthor ">Stephen E.  Fawell</span>, <span class="hlFld-ContribAuthor ">Ricky W.  Johnstone</span>, <span class="hlFld-ContribAuthor ">Lisa  Drew</span>, <span class="hlFld-ContribAuthor ">Justin  Cidado</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2021,</strong> <em>137 </em>
                                    (21)
                                     , 2947-2957. <a href="https://doi.org/10.1182/blood.2020008528" title="DOI URL">https://doi.org/10.1182/blood.2020008528</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood.2020008528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood.2020008528%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DTargeting%252BBfl-1%252Bvia%252Bacute%252BCDK9%252Binhibition%252Bovercomes%252Bintrinsic%252BBH3-mimetic%252Bresistance%252Bin%252Blymphomas%26aulast%3DBoiko%26aufirst%3DScott%26date%3D2021%26volume%3D137%26issue%3D21%26spage%3D2947%26epage%3D2957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Shao</span>, <span class="hlFld-ContribAuthor ">David W.  Foley</span>, <span class="hlFld-ContribAuthor ">Shiliang  Huang</span>, <span class="hlFld-ContribAuthor ">Abdullahi Y.  Abbas</span>, <span class="hlFld-ContribAuthor ">Frankie  Lam</span>, <span class="hlFld-ContribAuthor ">Pavel  Gershkovich</span>, <span class="hlFld-ContribAuthor ">Tracey D.  Bradshaw</span>, <span class="hlFld-ContribAuthor ">Chris  Pepper</span>, <span class="hlFld-ContribAuthor ">Peter M.  Fischer</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113244. <a href="https://doi.org/10.1016/j.ejmech.2021.113244" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113244</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113244%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Bof%252Bhighly%252Bselective%252B2%25252C4%25252C5-trisubstituted%252Bpyrimidine%252BCDK9%252Binhibitors%252Bas%252Banti-cancer%252Bagents%26aulast%3DShao%26aufirst%3DHao%26date%3D2021%26volume%3D214%26spage%3D113244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Role of CDKs and their corresponding cyclins in the regulation of cell cycle and transcription. Cell cycle-related CDKs: Binding of CDK4/6 to cyclin D releases the E2F transcription factor and starts the cell cycle by phosphorylating the retinoblastoma protein (Rb). Inhibitors of CDK4 (INK4) proteins (p15<sup>INK4B</sup>, p16<sup>INK4A</sup>, p18<sup>INK4C</sup>, and p19<sup>INK4D</sup>) inhibit CDK4/6 activation. The CDK2-cyclin E complex maintains the phosphorylation of Rb, while the CDK2-cyclin A complex regulates DNA replication in the S phase, and their activities are modulated by the CDK inhibitors P21<sup>CIP1</sup> and P27<sup>KIP1</sup>. CDK1 formed an active complex with cyclin A or cyclin B that can prevent Rb phosphorylation and regulate the progression of the late S phase and entire G2 phase. Checkpoint signaling kinases such as CHK1 and WEE1 can inactivate CDK1. Transcription-related CDKs: As a component of the transcription factor IIH (TFIIH), CDK7 is mainly responsible for the initiation of transcription. CDK8 phosphorylates the CTD of RNAPII and activates transcription by forming the mediator complex with cyclin C and mediator complex subunits (Med12 and Med13). In addition, CDK8 can inhibit transcription initiation by phosphorylation of the cyclin H of TFIIH. The CDK9–cyclin T complex phosphorylates the negative elongation factor (NELF) complex, DRB-sensitivity inducing factor (DSIF), and the Ser2 of the CTD of RNAPII, which leads to the removal of elongation blocks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Role of CDK9 in mRNA transcription. CDK7 phosphorylates the CTD of RNAPII for transcription initiation, promoting the release of RNAPII from the preinitiation complex (PIC). The NELF complex and DSIF lead to the formation of the paused transcription complex. With the help of bromodomain-containing protein 4 (BRD4), the CDK9–cyclin T complex is recruited and phosphorylates DISF, NELF, and the CTD of RNAPII, which releases the paused RNAPII into the productive elongation phase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure analysis of CDK9/cyclin T (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>). According to the crystal structure, the structural features of CDK9 mainly include a glycine-rich G loop, an αC-helix and a hinge in the N-terminal, as well as an activation loop and catalytic loop in the C-terminal. The interactions with amino acid residues in the hinge significantly contribute to the potent inhibition of CDK9. Some less conserved regions, including a hydrophobic region, a solvent-exposed region, and the G loop, may provide an opportunity to design selective inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CDK9 inhibitors that have been or are currently being evaluated in various clinical trials. Atoms participating in binding to the hinge region of the active site are shown in red with dashed lines for putative hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) The crystal structure of flavopiridol (<b>1</b>) and CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>). The hydrogen bonds are depicted by red dotted lines. (B) The development of CDK9 inhibitors with a flavonoid scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Design of CDK9 inhibitor <b>21</b> with high activity and selectivity based on the natural product wogonin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) The docking model of compound <b>21</b> and CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>). (B) The docking model of compound <b>21</b> and CDK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCP">4BCP</a>). The hydrogen bonds are depicted by red dotted lines. The steric hindrance of Gly112 and Lys89 is shown on the surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Development of CDK9 inhibitor <b>28</b> with high activity and selectivity based on compound <b>22</b>. According to the docking model of compound <b>48</b>-CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>), two hydrogen bonds were formed between 2-amino pyrimidine and the key residue Cys106 (the interactions between compound <b>22</b> and CDK6 are not shown). The hydrogen bonds are depicted by red dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Discovery of compound <b>32</b>. The docking models of <b>31</b>-CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>) and <b>31</b>-CDK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>) reveal that 7-azaindole of <b>31</b> forms two hydrogen bonds with the hinge residues Cys106 and Asp104 in CDK9 (Glu81 and Leu83 in CDK2). The hydrogen bonds are depicted by red dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) The design of selective CDK9 inhibitors by structural hybridization. (B) The overlay docking model of <b>34</b> and <b>35</b> in CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF">4BCF</a>). (C) The overlay docking model of <b>34</b> and <b>39</b> in CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>). The hydrogen bonds are depicted by red dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) The development of BAY-1143572 (<b>7</b>) and BAY-1251152 (<b>8</b>) based on compound <b>40</b>. According to the docking model of <b>40</b>-CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG">4BCG</a>), two hydrogen bonds were formed between the hinge region of CDK9 and the triazine core as well as the aniline NH group. The benzyl sulfonamide moiety interacted with Glu107 and was directed toward the exit of the ATP-binding pocket. The hydrogen bonds are depicted by red dotted lines. (B) The structure of AZ-5576 (<b>44</b>) and AZD-4573 (<b>16</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Cocrystal structures of <b>45</b> bound to CDK9 (A and C, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG">4BCG</a>) and CDK2 (B and D, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCP">4BCP</a>). The steric hindrance of Lys89 leads to compound <b>45</b> showing “inward” or “outward” conformations in CDK2 (D), which does not exist in CDK9 (C). The hydrogen bonds are depicted by red dotted lines. The steric hindrance of Gly112 and Lys89 is shown on the surface and depicted by yellow dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Development of CDK9 inhibitor <b>58</b> with high activity and selectivity based on compound <b>45</b> and the structure of compound <b>59</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) The binding mode of compound <b>58</b> and CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG">4BCG</a>). (B) The overlay model of CDK7 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UA2">1UA2</a>) and <b>58</b>-CDK9.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. (A) The discovery of a selective CDK9 inhibitor. (B) The docking model between compound <b>61</b> and CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG">4BCG</a>). (C) The docking model between compound <b>61</b> and CDK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCP">4BCP</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Report of the selective CDK9 inhibitors A-1467729 (<b>62</b>) and A-1592688 (<b>63</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of compounds <b>64</b>–<b>69</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. (A) Drug screening workflow utilizing YB5 as a phenotypic-based screening system. (B) Development of the novel CDK9 inhibitor <b>71</b> by gene expression-based SAR discovery.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. 4,6-Disubstituted pyrimidine derivatives obtained by using the HSF1-stress pathway as a phenotypic-based screening system. The CDK9 inhibitor dinaciclib (<b>12</b>) and SNS-032 (<b>13</b>) also showed potent inhibition of the HSF1-stress pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Composition and degradation mechanism of PROTACs. The PROTAC molecule (<b>78</b>) is composed of a CDK9 inhibitor and a small molecule binding to E3 ligase, followed by polyubiquitination and proteasome degradation of CDK9.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structures of compounds <b>76</b>–<b>80</b>. The DC<sub>50</sub> values are estimated from the reported data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Overview of the structure of CDK9 inhibitors discussed in this review, which are divided into six categories according to their core scaffold, including flavonoids, aminopyridine (aminotriazine), aminopyrimidine, fused heterocycles, bipyridine, and aminothiazole (aminopyrazole). Compounds marked in blue are currently in clinical studies, while those marked in red are discontinued.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/medium/jm0c00744_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Binding mode of inhibitors in the ATP pocket of CDK9, which consists of A (cyan), B (blue), and C (turquois). CDK9 inhibitors including flavonoids, aminopyridine, aminopyrimidine, and a fused heterocycle are shown and color-coded by their binding mode. Part A is the core scaffold of CDK9 inhibitors and forms hydrogen bonds with the hinge residues of CDK9 (the interaction area is indicated in pink). Part C, extending into the hydrophilic region, may be used to further improve kinase activity, while part B, the adjacent solvent-exposed region, is usually used to improve the selectivity and physicochemical properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00744/20201120/images/large/jm0c00744_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00744&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35565" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35565" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 140 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedewa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manassaram-Baptiste, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saslow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wender, R. C.</span></span> <span> </span><span class="NLM_article-title">Cancer screening in the united states, 2019: a review of current American cancer society guidelines and current issues in cancer screening</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.3322/caac.21557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.3322%2Fcaac.21557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30875085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BB3cbksV2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=184-210&issue=3&author=R.+A.+Smithauthor=K.+S.+Andrewsauthor=D.+Brooksauthor=S.+A.+Fedewaauthor=D.+Manassaram-Baptisteauthor=D.+Saslowauthor=R.+C.+Wender&title=Cancer+screening+in+the+united+states%2C+2019%3A+a+review+of+current+American+cancer+society+guidelines+and+current+issues+in+cancer+screening&doi=10.3322%2Fcaac.21557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening</span></div><div class="casAuthors">Smith Robert A; Andrews Kimberly S; Manassaram-Baptiste Deana; Brooks Durado; Fedewa Stacey A; Saslow Debbie; Wender Richard C</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-210</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society publishes a summary of its guidelines for early cancer detection, data and trends in cancer screening rates, and select issues related to cancer screening.  In this issue of the journal, the current American Cancer Society cancer screening guidelines are summarized, and the most current data from the National Health Interview Survey are provided on the utilization of cancer screening for men and women and on the adherence of men and women to multiple recommended screening tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkwie6IygDLeIHSmpohpd0fW6udTcc2eY6uei4zqgKB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbksV2qtw%253D%253D&md5=e04fa8bf340b2cfda11d03cdf2afa95a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21557%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DAndrews%26aufirst%3DK.%2BS.%26aulast%3DBrooks%26aufirst%3DD.%26aulast%3DFedewa%26aufirst%3DS.%2BA.%26aulast%3DManassaram-Baptiste%26aufirst%3DD.%26aulast%3DSaslow%26aufirst%3DD.%26aulast%3DWender%26aufirst%3DR.%2BC.%26atitle%3DCancer%2520screening%2520in%2520the%2520united%2520states%252C%25202019%253A%2520a%2520review%2520of%2520current%2520American%2520cancer%2520society%2520guidelines%2520and%2520current%2520issues%2520in%2520cancer%2520screening%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2019%26volume%3D69%26issue%3D3%26spage%3D184%26epage%3D210%26doi%3D10.3322%2Fcaac.21557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tutone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almerico, A. M.</span></span> <span> </span><span class="NLM_article-title">Recent advances on CDK inhibitors: an insight by means of in silico methods</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">142</span>),  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2017.07.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=300-315&issue=142&author=M.+Tutoneauthor=A.+M.+Almerico&title=Recent+advances+on+CDK+inhibitors%3A+an+insight+by+means+of+in+silico+methods&doi=10.1016%2Fj.ejmech.2017.07.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.067%26sid%3Dliteratum%253Aachs%26aulast%3DTutone%26aufirst%3DM.%26aulast%3DAlmerico%26aufirst%3DA.%2BM.%26atitle%3DRecent%2520advances%2520on%2520CDK%2520inhibitors%253A%2520an%2520insight%2520by%2520means%2520of%2520in%2520silico%2520methods%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D15%26issue%3D142%26spage%3D300%26epage%3D315%26doi%3D10.1016%2Fj.ejmech.2017.07.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duronio, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span> <span> </span><span class="NLM_article-title">Signaling pathways that control cell proliferation</span>. <i>Cold Spring Harbor Perspect. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">a008904</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a008904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1101%2Fcshperspect.a008904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=23457258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVCit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=a008904&author=R.+J.+Duronioauthor=Y.+Xiong&title=Signaling+pathways+that+control+cell+proliferation&doi=10.1101%2Fcshperspect.a008904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling pathways that control cell proliferation</span></div><div class="casAuthors">Duronio, Robert J.; Xiong, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">a008904/1-a008904/12</span>CODEN:
                <span class="NLM_cas:coden">CSHPEU</span>;
        ISSN:<span class="NLM_cas:issn">1943-0264</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Cells decide to proliferate or remain quiescent using signaling pathways that link information about the cellular environment to the G1 phase of the cell cycle.  Progression through G1 phase is controlled by pRB proteins, which function to repress the activity of E2F transcription factors in cells exiting mitosis and in quiescent cells.  Phosphorylation of pRB proteins by the G1 cyclin-dependent kinases (CDKs) releases E2F factors, promoting the transition to S phase.  CDK activity is primarily regulated by the binding of CDK catalytic subunits to cyclin partners and CDK inhibitors.  Consequently, both mitogenic and antiproliferative signals exert their effects on cell proliferation through the transcriptional regulation and ubiquitin-dependent degrdn. of cyclins and CDK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprCm1Z75UpSrVg90H21EOLACvtfcHk0linvTu4Bpl_dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVCit7k%253D&md5=6f5a3dcca0bb636f013af03783d1fccd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a008904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a008904%26sid%3Dliteratum%253Aachs%26aulast%3DDuronio%26aufirst%3DR.%2BJ.%26aulast%3DXiong%26aufirst%3DY.%26atitle%3DSignaling%2520pathways%2520that%2520control%2520cell%2520proliferation%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2013%26volume%3D5%26spage%3Da008904%26doi%3D10.1101%2Fcshperspect.a008904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1535-7163.MCT-12-0286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=22821149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2265-2273&issue=10&author=G.+Siemeisterauthor=U.+Luckingauthor=A.+M.+Wengnerauthor=P.+Lienauauthor=W.+Steinkeauthor=C.+Schatzauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=BAY1000394%2C+a+novel+cyclin-dependent+kinase+inhibitor%2C+with+potent+antitumor+activity+in+mono-+and+in+combination+treatment+upon+oral+application&doi=10.1158%2F1535-7163.MCT-12-0286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application</span></div><div class="casAuthors">Siemeister, Gerhard; Luecking, Ulrich; Wengner, Antje M.; Lienau, Philip; Steinke, Wolfram; Schatz, Christoph; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2265-2273</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulated activity of cyclin-dependent kinases (CDK) results in loss of cell-cycle checkpoint function and increased expression of antiapoptotic proteins, which has been directly linked to the mol. pathol. of cancer.  BAY 1000394 inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC50 values in the range between 5 and 25 nmol/L.  Cell proliferation was inhibited at low nanomolar concn. in a broad spectrum of human cancer cell lines.  In cell-based assays, the inhibition of phosphorylation of the CDK substrates retinoblastoma protein, nucleophosmin, and RNA polymerase II was shown.  Cell-cycle profiles were consistent with inhibition of CDK 1, 2, and 4 as shown in cell-cycle block and release expts.  The physicochem. and pharmacokinetic properties of BAY 1000394 facilitate rapid absorption and moderate oral bioavailability.  The compd. potently inhibits growth of various human tumor xenografts on athymic mice including models of chemotherapy resistance upon oral dosing.  Furthermore, BAY 1000394 shows more than additive efficacy when combined with cisplatin and etoposide.  These results suggest that BAY 1000394 is a potent pan-CDK inhibitor and a novel oral cytotoxic agent currently in phase I clin. trials.  Mol Cancer Ther; 11(10); 2265-73. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBMnyCrxDjqbVg90H21EOLACvtfcHk0linvTu4Bpl_dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK&md5=c175eacd5440b59b113a78a61a89a4b5</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0286%26sid%3Dliteratum%253Aachs%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DLucking%26aufirst%3DU.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSteinke%26aufirst%3DW.%26aulast%3DSchatz%26aufirst%3DC.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DBAY1000394%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520with%2520potent%2520antitumor%2520activity%2520in%2520mono-%2520and%2520in%2520combination%2520treatment%2520upon%2520oral%2520application%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D10%26spage%3D2265%26epage%3D2273%26doi%3D10.1158%2F1535-7163.MCT-12-0286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnum, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, M. J.</span></span> <span> </span><span class="NLM_article-title">Cell cycle regulation by checkpoints</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1170</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-0888-2_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2F978-1-4939-0888-2_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24906307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2cfgsFeqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1170&publication_year=2014&pages=29-40&author=K.+J.+Barnumauthor=M.+J.+O%E2%80%99Connell&title=Cell+cycle+regulation+by+checkpoints&doi=10.1007%2F978-1-4939-0888-2_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle regulation by checkpoints</span></div><div class="casAuthors">Barnum Kevin J; O'Connell Matthew J</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cell cycle checkpoints are surveillance mechanisms that monitor the order, integrity, and fidelity of the major events of the cell cycle.  These include growth to the appropriate cell size, the replication and integrity of the chromosomes, and their accurate segregation at mitosis.  Many of these mechanisms are ancient in origin and highly conserved, and hence have been heavily informed by studies in simple organisms such as the yeasts.  Others have evolved in higher organisms, and control alternative cell fates with significant impact on tumor suppression.  Here, we consider these different checkpoint pathways and the consequences of their dysfunction on cell fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3b8IASWHSOg8IxFYvehhofW6udTcc2eYyAKxiDxEMaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfgsFeqtA%253D%253D&md5=b5572013941fc639faddf9d9813ec0e3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-0888-2_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-0888-2_2%26sid%3Dliteratum%253Aachs%26aulast%3DBarnum%26aufirst%3DK.%2BJ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DM.%2BJ.%26atitle%3DCell%2520cycle%2520regulation%2520by%2520checkpoints%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2014%26volume%3D1170%26spage%3D29%26epage%3D40%26doi%3D10.1007%2F978-1-4939-0888-2_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of cyclin-dependent protein kinase inhibitors</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1042/EBC20170040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1042%2FEBC20170040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29118092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC1M7pt1Gmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=439-452&issue=5&author=M.+P.+Martinauthor=J.+A.+Endicottauthor=M.+E.+M.+Noble&title=Structure-based+discovery+of+cyclin-dependent+protein+kinase+inhibitors&doi=10.1042%2FEBC20170040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of cyclin-dependent protein kinase inhibitors</span></div><div class="casAuthors">Martin Mathew P; Endicott Jane A; Noble Martin E M</div><div class="citationInfo"><span class="NLM_cas:title">Essays in biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">439-452</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The cell fate-determining roles played by members of the cyclin-dependent protein kinase (CDK) family explain why their dysregulation can promote proliferative diseases, and identify them as potential targets for drug discovery in oncology and beyond.  After many years of research, the first efficacious CDK inhibitors have now been registered for clinical use in a defined segment of breast cancer.  Research is underway to identify inhibitors with appropriate CDK-inhibitory profiles to recapitulate this success in other disease settings.  Here, we review the structural data that illustrate the interactions and properties that confer upon inhibitors affinity and/or selectivity toward different CDK family members.  We conclude that where CDK inhibitors display selectivity, that selectivity derives from exploiting active site sequence peculiarities and/or from the capacity of the target CDK(s) to access conformations compatible with optimizing inhibitor-target interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqZGQ3bfUY0XELvajU9pjPfW6udTcc2eYyAKxiDxEMaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7pt1Gmtg%253D%253D&md5=7795a97e063f43e77499e9a03020d6cb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1042%2FEBC20170040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FEBC20170040%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26atitle%3DStructure-based%2520discovery%2520of%2520cyclin-dependent%2520protein%2520kinase%2520inhibitors%26jtitle%3DEssays%2520Biochem.%26date%3D2017%26volume%3D61%26issue%3D5%26spage%3D439%26epage%3D452%26doi%3D10.1042%2FEBC20170040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, E. L.</span></span> <span> </span><span class="NLM_article-title">Targeting breast cancer with CDK inhibitors</span>. <i>Curr. Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">443</span>, <span class="refDoi"> DOI: 10.1007/s11912-015-0443-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs11912-015-0443-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25716100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2MrptVantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=443&issue=5&author=E.+L.+Mayer&title=Targeting+breast+cancer+with+CDK+inhibitors&doi=10.1007%2Fs11912-015-0443-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting breast cancer with CDK inhibitors</span></div><div class="casAuthors">Mayer Erica L</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">443</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dysregulation of the cell cycle is a classic hallmark of cancer growth and metastatic potential.  Re-establishing cell cycle control through CDK inhibition has emerged as an attractive option in the development of targeted cancer therapy.  Three oral agents selectively targeting CDK4/6 have been developed: palbociclib, abemaciclib, and LEE011.  Preclinical models show optimal activity in hormone receptor positive breast cancer, which may display biologic features suggesting particular dependence on the CDK4/cyclin D1/Rb interaction.  Palbociclib has been studied in a randomized phase 2 clinical trial in metastatic hormone receptor positive breast cancer in which the combination of palbociclib and endocrine therapy significantly prolonged progression-free survival over endocrine therapy alone.  The toxicity profile of palbociclib and the other CDK 4/6 inhibitors in early phase I and II trials has been predominantly hematologic, characterized by limited neutropenia, as well as variable gastrointestinal toxicity.  Multiple phase II and III studies are ongoing with all three agents, and are designed to explore the role of CDK 4/6 inhibition in metastatic hormone receptor positive breast cancer.  The next wave of studies will examine further clinical and scientific topics, including the role of CDK 4/6 inhibition in the neo/adjuvant setting, the combination of CDK 4/6 inhibitors with other targeted therapies, and the activity of CDK 4/6 inhibitors in the HER2 positive subset of breast cancer, as well as in other cancer subtypes.  Should ongoing study confirm benefits and tolerability of CDK 4/6 inhibition, combination therapy with endocrine agents may become a new standard of care for hormone receptor positive breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBpxScH0UYfUh5eUSa2oe_fW6udTcc2eaiBrcZzdrSPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrptVantw%253D%253D&md5=01eda5d08847dab9cc5386e44daa00a9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs11912-015-0443-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-015-0443-3%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DE.%2BL.%26atitle%3DTargeting%2520breast%2520cancer%2520with%2520CDK%2520inhibitors%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2015%26volume%3D17%26issue%3D5%26spage%3D443%26doi%3D10.1007%2Fs11912-015-0443-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vora, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino-Kenudson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinzon-Ortiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ccr.2014.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25002028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFans7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=136-149&issue=1&author=S.+R.+Voraauthor=D.+Juricauthor=N.+Kimauthor=M.+Mino-Kenudsonauthor=T.+Huynhauthor=C.+Costaauthor=E.+L.+Lockermanauthor=S.+F.+Pollackauthor=M.+Liuauthor=X.+Y.+Liauthor=J.+Leharauthor=M.+Wiesmannauthor=M.+Wartmannauthor=Y.+Chenauthor=Z.+A.+Caoauthor=M.+Pinzon-Ortizauthor=S.+Kimauthor=R.+Schlegelauthor=A.+Huangauthor=J.+A.+Engelman&title=CDK+4%2F6+inhibitors+sensitize+PIK3CA+mutant+breast+cancer+to+PI3K+inhibitors&doi=10.1016%2Fj.ccr.2014.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors</span></div><div class="casAuthors">Vora, Sadhna R.; Juric, Dejan; Kim, Nayoon; Mino-Kenudson, Mari; Huynh, Tiffany; Costa, Carlotta; Lockerman, Elizabeth L.; Pollack, Sarah F.; Liu, Manway; Li, Xiaoyan; Lehar, Joseph; Wiesmann, Marion; Wartmann, Markus; Chen, Yan; Cao, Z. Alexander; Pinzon-Ortiz, Maria; Kim, Sunkyu; Schlegel, Robert; Huang, Alan; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-149</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast cancer.  However, clin. results of single-agent PI3K inhibitors have been modest to date.  A combinatorial drug screen on multiple PIK3CA mutant cancers with decreased sensitivity to PI3K inhibitors revealed that combined CDK 4/6-PI3K inhibition synergistically reduces cell viability.  Lab. studies revealed that sensitive cancers suppress RB phosphorylation upon treatment with single-agent PI3K inhibitors but cancers with reduced sensitivity fail to do so.  Similarly, patients' tumors that responded to the PI3K inhibitor BYL719 demonstrated suppression of pRB, while nonresponding tumors showed sustained or increased levels of pRB.  Importantly, the combination of PI3K and CDK 4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions in PIK3CA mutant xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwXkjWvgTQGrVg90H21EOLACvtfcHk0lgWtd8w_DF84Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFans7rE&md5=493e85e43bf363ffcf301968df772b85</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DVora%26aufirst%3DS.%2BR.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DHuynh%26aufirst%3DT.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DPollack%26aufirst%3DS.%2BF.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%2BY.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DZ.%2BA.%26aulast%3DPinzon-Ortiz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DCDK%25204%252F6%2520inhibitors%2520sensitize%2520PIK3CA%2520mutant%2520breast%2520cancer%2520to%2520PI3K%2520inhibitors%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26issue%3D1%26spage%3D136%26epage%3D149%26doi%3D10.1016%2Fj.ccr.2014.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boye, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grallert, B.</span></span> <span> </span><span class="NLM_article-title">Consequences of abnormal CDK activity in S phase</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">973</span>, <span class="refDoi"> DOI: 10.1080/15384101.2016.1152423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F15384101.2016.1152423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26918805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFeit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=963-973&issue=7&author=S.+Andaauthor=C.+Rotheauthor=E.+Boyeauthor=B.+Grallert&title=Consequences+of+abnormal+CDK+activity+in+S+phase&doi=10.1080%2F15384101.2016.1152423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Consequences of abnormal CDK activity in S phase</span></div><div class="casAuthors">Anda, Silje; Rothe, Christiane; Boye, Erik; Grallert, Beata</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">963-973</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cyclin Dependent Kinases (CDKs) are important regulators of DNA replication.  In this work we have investigated the consequences of increasing or decreasing the CDK activity in S phase.  To this end we identified S-phase regulators of the fission yeast CDK, Cdc2, and used appropriate mutants to modulate Cdc2 activity.  In fission yeast Mik1 has been thought to be the main regulator of Cdc2 activity in S phase.  However, we find that Wee1 has a major function in S phase and thus we used wee1 mutants to investigate the consequences of increased Cdc2 activity.  These wee1 mutants display increased replication stress and, particularly in the absence of the S-phase checkpoint, accumulate DNA damage.  Notably, more cells incorporate EdU in a wee1- strain as compared to wildtype, suggesting altered regulation of DNA replication.  In addn., a higher no. of cells contain chromatin-bound Cdc45, an indicator of active replication forks.  In addn., we found that Cdc25 is required to activate Cdc2 in S phase and used a cdc25 mutant to explore a situation where Cdc2 activity is reduced.  Interestingly, a cdc25 mutant has a higher tolerance for replication stress than wild-type cells, suggesting that reduced CDK activity in S phase confers resistance to at least some forms of replication stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro8l9RISwz0rVg90H21EOLACvtfcHk0lgWqdgyCyC6fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFeit74%253D&md5=79f38e52076ea0bd77b5268e4d2c48a7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1080%2F15384101.2016.1152423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2016.1152423%26sid%3Dliteratum%253Aachs%26aulast%3DAnda%26aufirst%3DS.%26aulast%3DRothe%26aufirst%3DC.%26aulast%3DBoye%26aufirst%3DE.%26aulast%3DGrallert%26aufirst%3DB.%26atitle%3DConsequences%2520of%2520abnormal%2520CDK%2520activity%2520in%2520S%2520phase%26jtitle%3DCell%2520Cycle%26date%3D2016%26volume%3D15%26issue%3D7%26spage%3D963%26epage%3D973%26doi%3D10.1080%2F15384101.2016.1152423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumarasiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK6 in cancer: state of the art and new insights</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3220</span>– <span class="NLM_lpage">3230</span>, <span class="refDoi"> DOI: 10.1080/15384101.2015.1084445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F15384101.2015.1084445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26315616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=3220-3230&issue=20&author=S.+Tadesseauthor=M.+Yuauthor=M.+Kumarasiriauthor=B.+T.+Leauthor=S.+Wang&title=Targeting+CDK6+in+cancer%3A+state+of+the+art+and+new+insights&doi=10.1080%2F15384101.2015.1084445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK6 in cancer: State of the art and new insights</span></div><div class="casAuthors">Tadesse, Solomon; Yu, Mingfeng; Kumarasiri, Malika; Le, Bich Thuy; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3220-3230</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 6 (CDK6) plays a vital role in regulating the progression of the cell cycle.  More recently, CDK6 has also been shown to have a transcriptional role in tumor angiogenesis.  Up-regulated CDK6 activity is assocd. with the development of several types of cancers.  While CDK6 is over-expressed in cancer cells, it has a low detectable level in non-cancerous cells and CDK6-null mice develop normally, suggesting a specific oncogenic role of CDK6, and that its inhibition may represent an ideal mechanism-based and low toxic therapeutic strategy in cancer treatment.  Identification of selective small mol. inhibitors of CDK6 is thus needed for drug development.  Herein, we review the latest understandings of the biol. regulation and oncogenic roles of CDK6.  The potential clin. relevance of CDK6 inhibition, the progress in the development of small-mol. CDK6 inhibitors and the rational design of potential selective CDK6 inhibitors are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV1uu9UWb3XrVg90H21EOLACvtfcHk0lhFVzs_ub7IgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsbrN&md5=eefeeab43ed50693886447c122e5002d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1084445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1084445%26sid%3Dliteratum%253Aachs%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DB.%2BT.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520CDK6%2520in%2520cancer%253A%2520state%2520of%2520the%2520art%2520and%2520new%2520insights%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26issue%3D20%26spage%3D3220%26epage%3D3230%26doi%3D10.1080%2F15384101.2015.1084445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span> <span> </span><span class="NLM_article-title">Phylogenetic analysis of CDK and cyclin proteins in premetazoan lineages</span>. <i>BMC Evol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1186/1471-2148-14-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1186%2F1471-2148-14-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24433236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsFKlsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=10-16&issue=1&author=L.+Caoauthor=F.+Chenauthor=X.+Yangauthor=W.+Xuauthor=J.+Xieauthor=L.+Yu&title=Phylogenetic+analysis+of+CDK+and+cyclin+proteins+in+premetazoan+lineages&doi=10.1186%2F1471-2148-14-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Phylogenetic analysis of CDK and cyclin proteins in premetazoan lineages</span></div><div class="casAuthors">Cao, Lihuan; Chen, Fang; Yang, Xianmei; Xu, Weijin; Xie, Jun; Yu, Long</div><div class="citationInfo"><span class="NLM_cas:title">BMC Evolutionary Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10/1-10/16, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">BEBMCG</span>;
        ISSN:<span class="NLM_cas:issn">1471-2148</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The mol. history of animal evolution from single-celled ancestors remains a major question in biol., and little is known regarding the evolution of cell cycle regulation during animal emergence.  In this study, we conducted a comprehensive evolutionary anal. of CDK and cyclin proteins in metazoans and their unicellular relatives.  Results: Our anal. divided the CDK family into eight subfamilies.  Seven subfamilies (CDK1/2/3, CDK5, CDK7, CDK 20, CDK8/19, CDK9 and CDK10/11) are conserved in metazoans and fungi, with the remaining subfamily, CDK4/6, found only in eumetazoans.  With respect to cyclins, cyclin C, H, L, Y subfamilies, and cyclin K and T as a whole subfamily, are generally conserved in animal, fungi, and amoeba Dictyostelium discoideum.  In contrast, cyclin subfamilies B, A, E, and D, which are cell cycle-related, have distinct evolutionary histories.  The cyclin B subfamily is generally conserved in D. discoideum, fungi, and animals, whereas cyclin A and E subfamilies are both present in animals and their unicellular relatives such as choanoflagellate Monosiga brevicollis and filasterean Capsaspora owczarzaki, but are absent in fungi and D. discoideum.  Although absent in fungi and D. discoideum, cyclin D subfamily orthologs can be found in the early-emerging, non-opisthokont apusozoan Thecamonas trahens.  Within opisthokonta, the cyclin D subfamily is conserved only in eumetazoans, and is absent in fungi, choanoflagellates, and the basal metazoan Amphimedon queenslandica.  Conclusions: Our data indicate that the CDK4/6 subfamily and eumetazoans emerged simultaneously, with the evolutionary conservation of the cyclin D subfamily also tightly linked with eumetazoan appearance.  Establishment of the CDK4/6-cyclin D complex may have been the key step in the evolution of cell cycle control during eumetazoan emergence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopxivYNpVsqLVg90H21EOLACvtfcHk0lhFVzs_ub7IgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsFKlsL0%253D&md5=9220ce7f96250958f4c040dda377c99d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2F1471-2148-14-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2148-14-10%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DL.%26atitle%3DPhylogenetic%2520analysis%2520of%2520CDK%2520and%2520cyclin%2520proteins%2520in%2520premetazoan%2520lineages%26jtitle%3DBMC%2520Evol.%2520Biol.%26date%3D2014%26volume%3D14%26issue%3D1%26spage%3D10%26epage%3D16%26doi%3D10.1186%2F1471-2148-14-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galbraith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, J. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of transcriptional cyclin-dependent kinases</span>. <i>Transcription.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/21541264.2018.1539615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F21541264.2018.1539615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30409083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKjs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=118-136&issue=2&author=M.+D.+Galbraithauthor=H.+Benderauthor=J.+M.+Espinosa&title=Therapeutic+targeting+of+transcriptional+cyclin-dependent+kinases&doi=10.1080%2F21541264.2018.1539615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of transcriptional cyclin-dependent kinases</span></div><div class="casAuthors">Galbraith, Matthew D.; Bender, Heather; Espinosa, Joaquin M.</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-136</span>CODEN:
                <span class="NLM_cas:coden">TRANH2</span>;
        ISSN:<span class="NLM_cas:issn">2154-1272</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  The fact that many cancer types display transcriptional addiction driven by dysregulation of oncogenic enhancers and transcription factors has led to increased interest in a group of protein kinases, known as transcriptional cyclin dependent kinases (tCDKs), as potential therapeutic targets.  Despite early reservations about targeting a process that is essential to healthy cell types, there is now evidence that targeting tCDKs could provide enough therapeutic window to be effective in the clinic.  Here, we discuss recent developments in this field, with an emphasis on highly-selective inhibitors and the challenges to be addressed before these inhibitors could be used for therapeutic purposes.: CAK: CDK-activating kinase;CDK: cyclin-dependent kinase;CMGC group: CDK-, MAPK-, GSK3-, and CLK-like;CTD: C-terminal repeat domain of the RPB1 subunit of RNA polymerase II;DRB: 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole;mCRPC: metastatic castration-resistant prostate cancer;NSCLC: non-small cell lung cancer;P-TEFb: pos. elongation factor b;RNAPII: RNA polymerase II;S2: serine-2 of CTD repeats;S5: serine-5 of CTD repeats;S7: serine-7 of CTD repeats;SEC: super elongation complex;tCDK: transcriptional cyclin-dependent kinase;TNBC: triple-neg. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptgAOjkQMqqbVg90H21EOLACvtfcHk0lhFVzs_ub7IgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKjs7vP&md5=1700138890acfc08ad2ab2a81f62c476</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F21541264.2018.1539615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2018.1539615%26sid%3Dliteratum%253Aachs%26aulast%3DGalbraith%26aufirst%3DM.%2BD.%26aulast%3DBender%26aufirst%3DH.%26aulast%3DEspinosa%26aufirst%3DJ.%2BM.%26atitle%3DTherapeutic%2520targeting%2520of%2520transcriptional%2520cyclin-dependent%2520kinases%26jtitle%3DTranscription.%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D118%26epage%3D136%26doi%3D10.1080%2F21541264.2018.1539615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korolchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moukhametzianov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span> <span> </span><span class="NLM_article-title">CDK1 structures reveal conserved and unique features of the essential cell cycle CDK</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/ncomms7769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fncomms7769" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1-12&issue=1&author=N.+R.+Brownauthor=S.+Korolchukauthor=M.+P.+Martinauthor=W.+A.+Stanleyauthor=R.+Moukhametzianovauthor=M.+E.+M.+Nobleauthor=J.+A.+Endicott&title=CDK1+structures+reveal+conserved+and+unique+features+of+the+essential+cell+cycle+CDK&doi=10.1038%2Fncomms7769"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fncomms7769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7769%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%2BR.%26aulast%3DKorolchuk%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DStanley%26aufirst%3DW.%2BA.%26aulast%3DMoukhametzianov%26aufirst%3DR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26atitle%3DCDK1%2520structures%2520reveal%2520conserved%2520and%2520unique%2520features%2520of%2520the%2520essential%2520cell%2520cycle%2520CDK%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26issue%3D1%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fncomms7769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherukupalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleti, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayyad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampannavar, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merugu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachamalla, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpoormath, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 4,6-disubstituted pyrazolo[3,4-d]pyrimidine analogues: cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation</span>. <i>J. Mol. Struct.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1176</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1016/j.molstruc.2018.08.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.molstruc.2018.08.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWis7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1176&publication_year=2019&pages=538-551&author=S.+Cherukupalliauthor=B.+Chandrasekaranauthor=R.+R.+Aletiauthor=N.+Sayyadauthor=G.+A.+Hampannavarauthor=S.+R.+Meruguauthor=H.+R.+Rachamallaauthor=R.+Banerjeeauthor=R.+Karpoormath&title=Synthesis+of+4%2C6-disubstituted+pyrazolo%5B3%2C4-d%5Dpyrimidine+analogues%3A+cyclin-dependent+kinase+2+%28CDK2%29+inhibition%2C+molecular+docking+and+anticancer+evaluation&doi=10.1016%2Fj.molstruc.2018.08.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 4,6-disubstituted pyrazolo[3,4-d]pyrimidine analogues: Cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation</span></div><div class="casAuthors">Cherukupalli, Srinivasulu; Chandrasekaran, Balakumar; Aleti, Rajeshwar Reddy; Sayyad, Nisar; Hampannavar, Girish A.; Merugu, Srinivas Reddy; Rachamalla, Harikrishna Reddy; Banerjee, Rajkumar; Karpoormath, Rajshekhar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Structure</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">538-551</span>CODEN:
                <span class="NLM_cas:coden">JMOSB4</span>;
        ISSN:<span class="NLM_cas:issn">0022-2860</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cyclin-dependent kinases (CDKs) play a crucial role in cell cycle progression and are validated targets of cancer therapy.  Pyrazolopyrimidines are versatile scaffolds, which have been exploited for developing potential anticancer agents.  We herein report the synthesis and in vitro CDK2/cyclin E kinase inhibitory activity of 34 novel 4,6-disubstituted pyrazolo [3,4-d]pyrimidines.  The structure-activity relationship (SAR) studies revealed that compds. with thiopentane/thiophenethyl group at C-6 and heteroatom-contg. bicyclic moiety (benzofuran) at C-4 exhibited good CDK2 inhibitory activity.  Further, the binding energies obtained for the active compds. from in silico mol. docking studies with CDK2 were found to be in consonance with the obsd. SAR and exptl. results.  In addn., some of the synthesized compds. showed anti-proliferative activity against K-562 (chronic myelogenous leukemia) and MCF-7 (breast adenocarcinoma) cell lines in micromolar ranges.  Further, the cytotoxicity studies on CHO cell line revealed that all the compds. are non-toxic to normal cells and are safe.  Thus, the research findings revealed the anticancer potential of 4,6-disubstituted pyrazolo [3,4-d]pyrimidine derivs. which could be further considered for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpukE_bBmZt-LVg90H21EOLACvtfcHk0lhoa36PJx5aOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWis7%252FJ&md5=2c3f2ca5d72af3e4614ad3a214cf1104</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.molstruc.2018.08.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molstruc.2018.08.104%26sid%3Dliteratum%253Aachs%26aulast%3DCherukupalli%26aufirst%3DS.%26aulast%3DChandrasekaran%26aufirst%3DB.%26aulast%3DAleti%26aufirst%3DR.%2BR.%26aulast%3DSayyad%26aufirst%3DN.%26aulast%3DHampannavar%26aufirst%3DG.%2BA.%26aulast%3DMerugu%26aufirst%3DS.%2BR.%26aulast%3DRachamalla%26aufirst%3DH.%2BR.%26aulast%3DBanerjee%26aufirst%3DR.%26aulast%3DKarpoormath%26aufirst%3DR.%26atitle%3DSynthesis%2520of%25204%252C6-disubstituted%2520pyrazolo%255B3%252C4-d%255Dpyrimidine%2520analogues%253A%2520cyclin-dependent%2520kinase%25202%2520%2528CDK2%2529%2520inhibition%252C%2520molecular%2520docking%2520and%2520anticancer%2520evaluation%26jtitle%3DJ.%2520Mol.%2520Struct.%26date%3D2019%26volume%3D1176%26spage%3D538%26epage%3D551%26doi%3D10.1016%2Fj.molstruc.2018.08.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of NFAT3 by CDK3 induces cell transformation and promotes tumor growth in skin cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2835</span>– <span class="NLM_lpage">2845</span>, <span class="refDoi"> DOI: 10.1038/onc.2016.434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fonc.2016.434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27893713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCnu7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=2835-2845&issue=20&author=T.+Xiaoauthor=J.+J.+Zhuauthor=S.+Huangauthor=C.+Pengauthor=S.+Heauthor=J.+Duauthor=R.+Hongauthor=X.+Chenauthor=A.+M.+Bodeauthor=W.+Jiangauthor=Z.+Dongauthor=D.+Zheng&title=Phosphorylation+of+NFAT3+by+CDK3+induces+cell+transformation+and+promotes+tumor+growth+in+skin+cancer&doi=10.1038%2Fonc.2016.434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of NFAT3 by CDK3 induces cell transformation and promotes tumor growth in skin cancer</span></div><div class="casAuthors">Xiao, T.; Zhu, J. J.; Huang, S.; Peng, C.; He, S.; Du, J.; Hong, R.; Chen, X.; Bode, A. M.; Jiang, W.; Dong, Z.; Zheng, D.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2835-2845</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The nuclear factor of activated T cells (NFAT) family proteins are transcription factors that regulate the expression of pro-inflammatory cytokines and other genes during the immune response.  Although the NFAT proteins have been extensively investigated in the immune system, their role in cancer progression remains controversial.  Here, we report that NFAT3 is highly expressed in various skin cancer cell lines and tumor tissues.  Knockdown of endogenous NFAT3 expression by short hairpin RNA (shRNA) significantly inhibited tumor cell proliferation, colony formation and anchorage-independent cell growth.  Furthermore, results of the mammalian two-hybrid assay showed that cyclin-dependent kinase 3 (CDK3) directly interacted with NFAT3 and phosphorylated NFAT3 at serine 259 (Ser259), which enhanced the transactivation and transcriptional activity of NFAT3.  The phosphorylation site of NFAT3 was crit. for epidermal growth factor (EGF)-stimulated cell transformation of the HaCaT immortalized skin cell line and mutation of NFAT3 at Ser259 led to a redn. of colony formation in soft agar.  We also found that overexpressing wildtype NFAT3, but not mutant NFAT3-S259A, promoted A431 xenograft tumor growth.  Importantly, we showed that CDK3, NFAT3 and phosphorylated NFAT3-Ser259 were highly expressed in skin cancer compared with normal skin tissues.  These results provided evidence supporting the oncogenic potential of NFAT3 and suggested that CDK3-mediated phosphorylation of NFAT3 has an important role in skin tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4PbBstnK9LLVg90H21EOLACvtfcHk0ljjKwQs58F8Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCnu7vO&md5=01d3620d159057585f5d2177309f36e3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fonc.2016.434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2016.434%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DBode%26aufirst%3DA.%2BM.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DD.%26atitle%3DPhosphorylation%2520of%2520NFAT3%2520by%2520CDK3%2520induces%2520cell%2520transformation%2520and%2520promotes%2520tumor%2520growth%2520in%2520skin%2520cancer%26jtitle%3DOncogene%26date%3D2017%26volume%3D36%26issue%3D20%26spage%3D2835%26epage%3D2845%26doi%3D10.1038%2Fonc.2016.434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaganathan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overstreet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, E.</span></span> <span> </span><span class="NLM_article-title">Improving breast cancer therapy with CDK4/6 inhibitors</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2014.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.clbc.2014.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25457990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2MzkslCisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=379-380&author=H.+Jaganathanauthor=K.+Overstreetauthor=E.+Reed&title=Improving+breast+cancer+therapy+with+CDK4%2F6+inhibitors&doi=10.1016%2Fj.clbc.2014.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Improving breast cancer therapy with CDK4/6 inhibitors</span></div><div class="casAuthors">Jaganathan Hamsa; Overstreet Karen; Reed Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Clinical breast cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">379-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsa0Hvb5m_-GHOrQ6qeX-mfW6udTcc2ebE6B_GuIZuA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzkslCisw%253D%253D&md5=7212a5d3482aef9e55605bbb7c743251</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2014.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2014.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DJaganathan%26aufirst%3DH.%26aulast%3DOverstreet%26aufirst%3DK.%26aulast%3DReed%26aufirst%3DE.%26atitle%3DImproving%2520breast%2520cancer%2520therapy%2520with%2520CDK4%252F6%2520inhibitors%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D379%26epage%3D380%26doi%3D10.1016%2Fj.clbc.2014.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shupp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestell, R. G.</span></span> <span> </span><span class="NLM_article-title">Biological functions of CDK5 and potential CDK5 targeted clinical treatments</span>. <i>Oncotarget.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">17373</span>– <span class="NLM_lpage">17382</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.18632%2Foncotarget.14538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28077789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC1c7kslOqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=17373-17382&issue=10&author=A.+Shuppauthor=M.+C.+Casimiroauthor=R.+G.+Pestell&title=Biological+functions+of+CDK5+and+potential+CDK5+targeted+clinical+treatments&doi=10.18632%2Foncotarget.14538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biological functions of CDK5 and potential CDK5 targeted clinical treatments</span></div><div class="casAuthors">Shupp Alison; Casimiro Mathew C; Pestell Richard G</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">17373-17382</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin dependent kinases are proline-directed serine/threonine protein kinases that are traditionally activated upon association with a regulatory subunit.  For most CDKs, activation by a cyclin occurs through association and phosphorylation of the CDK's T-loop.  CDK5 is unusual because it is not typically activated upon binding with a cyclin and does not require T-loop phosphorylation for activation, even though it has high amino acid sequence homology with other CDKs.  While it was previously thought that CDK5 only interacted with p35 or p39 and their cleaved counterparts, Recent evidence suggests that CDK5 can interact with certain cylins, amongst other proteins, which modulate CDK5 activity levels.  This review discusses recent findings of molecular interactions that regulate CDK5 activity and CDK5 associated pathways that are implicated in various diseases.  Also covered herein is the growing body of evidence for CDK5 in contributing to the onset and progression of tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIIzpNr4o8O-RS7coPn-RtfW6udTcc2ebE6B_GuIZuA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7kslOqug%253D%253D&md5=a18a8cf007ba65b165d690e4a7f6bb1a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14538%26sid%3Dliteratum%253Aachs%26aulast%3DShupp%26aufirst%3DA.%26aulast%3DCasimiro%26aufirst%3DM.%2BC.%26aulast%3DPestell%26aufirst%3DR.%2BG.%26atitle%3DBiological%2520functions%2520of%2520CDK5%2520and%2520potential%2520CDK5%2520targeted%2520clinical%2520treatments%26jtitle%3DOncotarget.%26date%3D2017%26volume%3D8%26issue%3D10%26spage%3D17373%26epage%3D17382%26doi%3D10.18632%2Foncotarget.14538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK7 increases the stability of snail to promote the dissemination of colorectal cancer</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1442</span>– <span class="NLM_lpage">1452</span>, <span class="refDoi"> DOI: 10.1038/s41418-018-0222-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fs41418-018-0222-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30451989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegtrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1442-1452&issue=8&author=Y.+Zhouauthor=L.+Luauthor=G.+Jiangauthor=Z.+Chenauthor=J.+Liauthor=P.+Anauthor=L.+Chenauthor=J.+Duauthor=H.+Wang&title=Targeting+CDK7+increases+the+stability+of+snail+to+promote+the+dissemination+of+colorectal+cancer&doi=10.1038%2Fs41418-018-0222-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer</span></div><div class="casAuthors">Zhou, Yan; Lu, Linlin; Jiang, Guanmin; Chen, Zhuojia; Li, Jiexin; An, Panpan; Chen, Likun; Du, Jun; Wang, Hongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1442-1452</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Targeted inhibition of cyclin-dependent kinase 7 (CDK7) via its covalent inhibitor THZ1 can suppress the growth of various cancers, while its roles on colorectal cancer (CRC) remain obscure.  Here we report that the expression of CDK7 is upregulated in CRC cells and tissues.  THZ1 exhibits high potency and selectivity against CRC cells both in vitro and in vivo via induction of cell apoptosis rather than cell cycle disruption.  Intriguingly, THZ1 treatment increases the ability of epithelial mesenchymal transition (EMT) and in vivo metastasis to liver of CRC cells.  Mechanistical studies reveal that THZ1 increases the expression of Snail, while not other EMT-transcription factors, via enhancing its protein stability rather than mRNA expression or translation.  By screening Snail stability related factors via qRT-PCR, results indicate THZ1 and si-CDK7 decrease the expression of protein kinase D1 (PKD1) in CRC cells.  Down regulation of PKD1 mediates THZ1 up regulated Snail via dephosphorylation of Snail Ser 11 and prevention of proteasome mediated degrdn.  Clin. anal. confirms that CDK7 is significantly (p < 0.05) neg. correlated with the expression of mesenchymal markers including FN1, VIM, and MMP2.  CRC patients whose tumors expressing less CDK7/SNAI1 or PKD1/SNAI1 showed significant (p < 0.05) poorer overall survival (OS) rate as compared with those with greater levels.  Collectively, our data suggest that targeted inhibition of CDK7 can trigger the metastasis of CRC during cancer development via PKD1/Snail axis, which imposes great challenge that inhibition of CDK7 is a potential approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy89Fkw4m-F7Vg90H21EOLACvtfcHk0liqHJN_hLNx-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegtrzJ&md5=6674d36ade83d70a05060d69632d3737</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fs41418-018-0222-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41418-018-0222-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DAn%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DTargeting%2520CDK7%2520increases%2520the%2520stability%2520of%2520snail%2520to%2520promote%2520the%2520dissemination%2520of%2520colorectal%2520cancer%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2019%26volume%3D26%26issue%3D8%26spage%3D1442%26epage%3D1452%26doi%3D10.1038%2Fs41418-018-0222-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective CDK8 inhibitors through FBDD approach</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4488</span>– <span class="NLM_lpage">4492</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.07.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bmcl.2017.07.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28802632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlarsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4488-4492&author=X.+C.+Hanauthor=M.+Jiangauthor=C.+G.+Zhouauthor=Z.+Zhouauthor=Z.+H.+Xuauthor=L.+S.+Wangauthor=A.+V.+Maywegauthor=R.+Niuauthor=T.+G.+Jinauthor=S.+Yang&title=Discovery+of+potent+and+selective+CDK8+inhibitors+through+FBDD+approach&doi=10.1016%2Fj.bmcl.2017.07.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective CDK8 inhibitors through FBDD approach</span></div><div class="casAuthors">Han, Xingchun; Jiang, Min; Zhou, Chengang; Zhou, Zheng; Xu, Zhiheng; Wang, Lisha; Mayweg, Alexander V.; Niu, Rui; Jin, Tai-Guang; Yang, Song</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4488-4492</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A fragment library screen was carried out to identify starting points for novel CDK8 inhibitors.  Optimization of a fragment hit guided by co-crystal structures led to identification of a novel series of potent CDK8 inhibitors which are highly ligand efficient, kinase selective and cellular active.  Compd. I was progressed to a mouse pharmacokinetic study and showed good oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLEnv4NnOEZ7Vg90H21EOLACvtfcHk0liqHJN_hLNx-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlarsrrM&md5=23b49ed1f18b508afde0847db8027a81</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.07.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.07.080%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%2BC.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DC.%2BG.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DZ.%2BH.%26aulast%3DWang%26aufirst%3DL.%2BS.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DNiu%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DT.%2BG.%26aulast%3DYang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520CDK8%2520inhibitors%2520through%2520FBDD%2520approach%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4488%26epage%3D4492%26doi%3D10.1016%2Fj.bmcl.2017.07.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franco, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boffo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">CDK9: a key player in cancer and other diseases</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">1273</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1002/jcb.26293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1002%2Fjcb.26293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28722178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1SksbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=1273-1284&issue=2&author=L.+C.+Francoauthor=F.+Moralesauthor=S.+Boffoauthor=A.+Giordano&title=CDK9%3A+a+key+player+in+cancer+and+other+diseases&doi=10.1002%2Fjcb.26293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9: A key player in cancer and other diseases</span></div><div class="casAuthors">Franco, Lia Carolina; Morales, Fatima; Boffo, Silvia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1273-1284</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cyclin-Dependent Kinase 9 (CDK9) is part of a functional diverse group of enzymes responsible for cell cycle control and progression.  It assocs. mainly with Cyclin T1 and forms the Pos. Transcription Elongation Factor b (p-TEFb) complex responsible for regulation of transcription elongation and mRNA maturation.  Recent studies have highlighted the importance of CDK9 in many relevant pathol. processes, like cancer, cardiovascular diseases, and viral replication.  Herein we provide an overview of the different pathways in which CDK9 is directly and indirectly involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-mhEa2vTa8LVg90H21EOLACvtfcHk0lhMGMATft0zcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1SksbzI&md5=769d1349ea4079406fd15ec6746d2522</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fjcb.26293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.26293%26sid%3Dliteratum%253Aachs%26aulast%3DFranco%26aufirst%3DL.%2BC.%26aulast%3DMorales%26aufirst%3DF.%26aulast%3DBoffo%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCDK9%253A%2520a%2520key%2520player%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2018%26volume%3D119%26issue%3D2%26spage%3D1273%26epage%3D1284%26doi%3D10.1002%2Fjcb.26293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dos
Santos Paparidis, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canduri, F.</span></span> <span> </span><span class="NLM_article-title">The emerging picture of CDK11: genetic, functional and medicinal aspects</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170815102036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.2174%2F0929867324666170815102036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28814241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC1cfovFOntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=880-888&issue=8&author=N.+F.+Dos%0ASantos+Paparidisauthor=F.+Canduri&title=The+emerging+picture+of+CDK11%3A+genetic%2C+functional+and+medicinal+aspects&doi=10.2174%2F0929867324666170815102036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Emerging Picture of CDK11: Genetic, Functional and Medicinal Aspects</span></div><div class="casAuthors">Dos Santos Paparidis Nikolas Ferreira; Canduri Fernanda</div><div class="citationInfo"><span class="NLM_cas:title">Current medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">880-888</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinase 11 is a relatively neglected member of the transcriptional CDKs subfamily, despite possibly being the most versatile CDK in this group.  Different CDK11 variants are known to play essential roles in major cellular processes as mRNA transcription (CDK11p110), mitosis (CDK11p58), and apoptosis (CDK11p46 and CDK11p60).  Each CDK11 species targets a particular set of substrates related to its functional background, but all isoforms originate from the CDC2L gene complex in human chromosome 1p36.2.  CDK11p110 is synthesized through regular cap-dependent translation of CDK11 mRNA, whereas CDK11p58 translation is initiated through an IRES, and occurs only at G2 and M phases.  CDK11p46 and CDK11p60, in turn, are the products of caspase cleavage of the larger isoforms during apoptosis.  L-type cyclins are the main partners of CDK11, although CDK11p58 species interacts specifically with cyclin D3.  The link between CDK11 dysfunction and cancer has been known for a long time, and critical roles in the proliferation of different cancer cell lines have been assigned to CDK11.  This review summarizes more than 25 years of studies that unraveled CDK11 genetic and functional aspects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3qfv6I-cXX2Gmni0r9GoKfW6udTcc2ea6nAT-7e7rdbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfovFOntA%253D%253D&md5=e16097c1b50b5c24f91f734ef28d21b7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170815102036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170815102036%26sid%3Dliteratum%253Aachs%26aulast%3DDos%2BSantos%2BPaparidis%26aufirst%3DN.%2BF.%26aulast%3DCanduri%26aufirst%3DF.%26atitle%3DThe%2520emerging%2520picture%2520of%2520CDK11%253A%2520genetic%252C%2520functional%2520and%2520medicinal%2520aspects%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2018%26volume%3D25%26issue%3D8%26spage%3D880%26epage%3D888%26doi%3D10.2174%2F0929867324666170815102036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriplani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moseley, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Fatah, T. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhusudan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhaka, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natrajan, R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of CDK12 protein expression as a potential novel biomarker for dna damage response-targeted therapies in breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1535-7163.MCT-17-0760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29133620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Gitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=306-315&issue=1&author=K.+Naidooauthor=P.+T.+Waiauthor=S.+L.+Maguireauthor=F.+Daleyauthor=S.+Haiderauthor=D.+Kriplaniauthor=J.+Campbellauthor=H.+Mirzaauthor=A.+Grigoriadisauthor=A.+Tuttauthor=P.+M.+Moseleyauthor=T.+M.+A.+Abdel-Fatahauthor=S.+Y.+T.+Chanauthor=S.+Madhusudanauthor=E.+A.+Rhakaauthor=I.+O.+Ellisauthor=C.+J.+Lordauthor=Y.+Y.+Yuanauthor=A.+R.+Greenauthor=R.+Natrajan&title=Evaluation+of+CDK12+protein+expression+as+a+potential+novel+biomarker+for+dna+damage+response-targeted+therapies+in+breast+cancer&doi=10.1158%2F1535-7163.MCT-17-0760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer</span></div><div class="casAuthors">Naidoo, Kalnisha; Wai, Patty T.; Maguire, Sarah L.; Daley, Frances; Haider, Syed; Kriplani, Divya; Campbell, James; Mirza, Hasan; Grigoriadis, Anita; Tutt, Andrew; Moseley, Paul M.; Abdel-Fatah, Tarek M. A.; Chan, Stephen Y. T.; Madhusudan, Srinivasan; Rhaka, Emad A.; Ellis, Ian O.; Lord, Christopher J.; Yuan, Yinyin; Green, Andrew R.; Natrajan, Rachael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">306-315</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors.  However, CDK12 has also been proposed as an oncogene in breast cancer.  We therefore aimed to assess the frequency and distribution of CDK12 protein expression by IHC in independent cohorts of breast cancer and correlate this with outcome and genomic status.  We found that 21% of primary unselected breast cancers were CDK12 high, and 10.5% were absent, by IHC.  CDK12 positivity correlated with HER2 positivity but was not an independent predictor of breast cancer-specific survival taking HER2 status into account; however, absent CDK12 protein expression significantly correlated with a triple-neg. phenotype.  Interestingly, CDK12 protein absence was assocd. with reduced expression of a no. of DDR proteins including ATR, Ku70/Ku80, PARP1, DNA-PK, and γH2AX, suggesting a novel mechanism of CDK12-assocd. DDR dysregulation in breast cancer.  Our data suggest that diagnostic IHC quantification of CDK12 in breast cancer is feasible, with CDK12 absence possibly signifying defective DDR function.  This may have important therapeutic implications, particularly for triple-neg. breast cancers.  Mol Cancer Ther; 17(1); 306-15. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK7g_s8kIxRrVg90H21EOLACvtfcHk0lhMGMATft0zcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Gitw%253D%253D&md5=66790735980e31d1736272e2c20be108</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0760%26sid%3Dliteratum%253Aachs%26aulast%3DNaidoo%26aufirst%3DK.%26aulast%3DWai%26aufirst%3DP.%2BT.%26aulast%3DMaguire%26aufirst%3DS.%2BL.%26aulast%3DDaley%26aufirst%3DF.%26aulast%3DHaider%26aufirst%3DS.%26aulast%3DKriplani%26aufirst%3DD.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DMirza%26aufirst%3DH.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DMoseley%26aufirst%3DP.%2BM.%26aulast%3DAbdel-Fatah%26aufirst%3DT.%2BM.%2BA.%26aulast%3DChan%26aufirst%3DS.%2BY.%2BT.%26aulast%3DMadhusudan%26aufirst%3DS.%26aulast%3DRhaka%26aufirst%3DE.%2BA.%26aulast%3DEllis%26aufirst%3DI.%2BO.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DYuan%26aufirst%3DY.%2BY.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26aulast%3DNatrajan%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520CDK12%2520protein%2520expression%2520as%2520a%2520potential%2520novel%2520biomarker%2520for%2520dna%2520damage%2520response-targeted%2520therapies%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D306%26epage%3D315%26doi%3D10.1158%2F1535-7163.MCT-17-0760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fant, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taatjes, D. J.</span></span> <span> </span><span class="NLM_article-title">Regulatory functions of the mediator kinases CDK8 and CDK19</span>. <i>Transcription.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1080/21541264.2018.1556915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F21541264.2018.1556915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30585107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BB3cnlsFKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=76-90&issue=2&author=C.+B.+Fantauthor=D.+J.+Taatjes&title=Regulatory+functions+of+the+mediator+kinases+CDK8+and+CDK19&doi=10.1080%2F21541264.2018.1556915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory functions of the Mediator kinases CDK8 and CDK19</span></div><div class="casAuthors">Fant Charli B; Taatjes Dylan J</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">76-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Mediator-associated kinases CDK8 and CDK19 function in the context of three additional proteins: CCNC and MED12, which activate CDK8/CDK19 kinase function, and MED13, which enables their association with the Mediator complex.  The Mediator kinases affect RNA polymerase II (pol II) transcription indirectly, through phosphorylation of transcription factors and by controlling Mediator structure and function.  In this review, we discuss cellular roles of the Mediator kinases and mechanisms that enable their biological functions.  We focus on sequence-specific, DNA-binding transcription factors and other Mediator kinase substrates, and how CDK8 or CDK19 may enable metabolic and transcriptional reprogramming through enhancers and chromatin looping.  We also summarize Mediator kinase inhibitors and their therapeutic potential.  Throughout, we note conserved and divergent functions between yeast and mammalian CDK8, and highlight many aspects of kinase module function that remain enigmatic, ranging from potential roles in pol II promoter-proximal pausing to liquid-liquid phase separation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQbbey-l8f0QpJitSxOdIlfW6udTcc2eYhar7-KrMMWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnlsFKksQ%253D%253D&md5=356eb2f7adf7ec40e8fcd0a02cdaed69</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1080%2F21541264.2018.1556915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2018.1556915%26sid%3Dliteratum%253Aachs%26aulast%3DFant%26aufirst%3DC.%2BB.%26aulast%3DTaatjes%26aufirst%3DD.%2BJ.%26atitle%3DRegulatory%2520functions%2520of%2520the%2520mediator%2520kinases%2520CDK8%2520and%2520CDK19%26jtitle%3DTranscription.%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D76%26epage%3D90%26doi%3D10.1080%2F21541264.2018.1556915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Overview of CDK9 as a target in cancer research</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1080/15384101.2016.1138186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F15384101.2016.1138186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26766294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=519-527&author=F.+Moralesauthor=A.+Giordano&title=Overview+of+CDK9+as+a+target+in+cancer+research&doi=10.1080%2F15384101.2016.1138186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of CDK9 as a target in cancer research</span></div><div class="casAuthors">Morales, Fatima; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">CDK9 is a protein in const. development in cancer therapy.  Herein we present an overview of the enzyme as a target for cancer therapy.  We provide data on its characteristics and mechanism of action.  In recent years, CDK9 inhibitors that have been designed with mol. modeling have demonstrated good antitumoral activity in vitro.  Clin. studies of the drugs flavopiridol, dinaciclib, seliciclib, SNS-032 and RGB-286638 used as CDK9 inhibitors are also reviewed, with their addnl. targets and their relative IC50 values.  Unfortunately, treatment with these drugs remains unsuccessful and involves many adverse effects.  We could conclude that there are many small mols. that bind to CDK9, but their lack of selectivity against other CDKs do not allow them to get to the clin. use.  However, drug designers currently have the tools needed to improve the selectivity of CDK9 inhibitors and to make successful treatment available to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTT9RDBXneVrVg90H21EOLACvtfcHk0liwIse-PbH01w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D&md5=4380763f74e91d5ea6d2d9b38ec6fd5e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F15384101.2016.1138186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2016.1138186%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DF.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DOverview%2520of%2520CDK9%2520as%2520a%2520target%2520in%2520cancer%2520research%26jtitle%3DCell%2520Cycle%26date%3D2016%26volume%3D15%26spage%3D519%26epage%3D527%26doi%3D10.1080%2F15384101.2016.1138186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. P.</span></span> <span> </span><span class="NLM_article-title">The HIV-1 tat protein: mechanism of action and target for HIV-1 cure strategies</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">4098</span>– <span class="NLM_lpage">4102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.2174%2F1381612823666170704130635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28677507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWktLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4098-4102&issue=28&author=A.+P.+Rice&title=The+HIV-1+tat+protein%3A+mechanism+of+action+and+target+for+HIV-1+cure+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies</span></div><div class="casAuthors">Rice, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">4098-4102</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The general mechanism involved in Tat activation of RNA Polymerase II (RNAP II) elongation of the integrated HIV-1 was elucidated over 20 years ago.  This mechanism involves Tat binding to the TAR RNA element that forms at the 5' end of viral transcripts and recruiting a general RNAP II elongation factor termed as PTEFb.  This elongation factor consists of CDK9 and Cyclin T1, and when recruited by Tat to TAR RNA, CDK9 was proposed to phosphorylate the carboxyl terminal domain of RNAP II and thereby activate elongation.  Research in the past two decades has shown that the mechanism of Tat action is considerably more complicated than this simple model.  In metabolically active cells, CDK9 and Cyclin T1 are now known to be largely sequestered in a RNA-protein complex termed the 7SK RNP.  CDK9 and Cyclin T1 are released from the 7SK RNP by mechanisms not yet fully elucidated and along with Tat, bind to TAR RNA and orchestrate the assembly of a Super Elongation Complex (SEC) contg. several addnl. proteins.  CDK9 in the SEC then phosphorylates multiple substrates in the RNAP II complex to activate elongation.  Importantly for therapeutic strategies, CDK9 and Cyclin T1 functions are down-regulated in resting CD4+ T cells that harbor latent HIV-1, and their up-regulation is required for reactivation of latent virus.  Current strategies for a functional cure of HIV-1 infection therefore are likely to require development of latency reversal agents that up-regulate CDK9 and Cyclin T1 function in resting CD4+ T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy7nvbcmhpXbVg90H21EOLACvtfcHk0liwIse-PbH01w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWktLzI&md5=89b886a6ed7dc3cb3b4ae186c57d8a22</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F1381612823666170704130635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612823666170704130635%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DA.%2BP.%26atitle%3DThe%2520HIV-1%2520tat%2520protein%253A%2520mechanism%2520of%2520action%2520and%2520target%2520for%2520HIV-1%2520cure%2520strategies%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2017%26volume%3D23%26issue%3D28%26spage%3D4098%26epage%3D4102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornicek, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Z. F.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">5990</span>– <span class="NLM_lpage">6000</span>, <span class="refDoi"> DOI: 10.1096/fj.201801789RR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1096%2Ffj.201801789RR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30726104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFChs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=5990-6000&author=J.+L.+Wangauthor=D.+C.+Deanauthor=F.+J.+Hornicekauthor=H.+R.+Shiauthor=Z.+F.+Duan&title=Cyclin-dependent+kinase+9+%28CDK9%29+is+a+novel+prognostic+marker+and+therapeutic+target+in+ovarian+cancer&doi=10.1096%2Ffj.201801789RR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer</span></div><div class="casAuthors">Wang, Jinglu; Dean, Dylan C.; Hornicek, Francis J.; Shi, Huirong; Duan, Zhenfeng</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">5990-6000</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Despite surgical and chemotherapeutic advances over the past few decades, the prognosis for ovarian cancer remains very poor.  Although cyclin-dependent kinase (CDK) 9 has an established pathogenic role in various cancers, its function in ovarian cancer remains poorly defined.  The purpose of this study was to evaluate the expression of CDK9 and its therapeutic potential in ovarian cancer.  CDK9 expression was detd. by immunohistochem. in a unique ovarian cancer tissue microarray constructed with paired primary, metastatic, and recurrent tumor tissues from 26 ovarian cancer patients.  CDK9 was highly expressed in human ovarian cancer cell lines and was also elevated in metastatic and recurrent ovarian tumor tissue compared with patient-matched primary ovarian tumor tissue.  In addn., increased CDK9 significantly correlated with poor patient prognosis.  Inhibition of CDK9 by small interfering RNA or CDK9 inhibitor functionally suppressed RNA transcription elongation, induced apoptosis, and reduced proliferation of ovarian cancer cells.  Inhibition of CDK9 also suppressed ovarian cancer cell spheroid growth, clonogenicity formation, and migration activity.  Our results reveal CDK9 as a novel prognostic biomarker and a promising therapeutic target for preventing metastasis and recurrence while also improving the overall clin. outcome for ovarian cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTuSeIUOKO-LVg90H21EOLACvtfcHk0ljCaAYgYiBAJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFChs7zO&md5=cc691e71c659a48477b30130ccf6cd24</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1096%2Ffj.201801789RR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201801789RR%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BL.%26aulast%3DDean%26aufirst%3DD.%2BC.%26aulast%3DHornicek%26aufirst%3DF.%2BJ.%26aulast%3DShi%26aufirst%3DH.%2BR.%26aulast%3DDuan%26aufirst%3DZ.%2BF.%26atitle%3DCyclin-dependent%2520kinase%25209%2520%2528CDK9%2529%2520is%2520a%2520novel%2520prognostic%2520marker%2520and%2520therapeutic%2520target%2520in%2520ovarian%2520cancer%26jtitle%3DFASEB%2520J.%26date%3D2019%26volume%3D33%26spage%3D5990%26epage%3D6000%26doi%3D10.1096%2Ffj.201801789RR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidner, J. F.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1080/13543784.2019.1678583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F13543784.2019.1678583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31612739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVaisbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=989-1001&author=D.+J.+Leeauthor=J.+F.+Zeidner&title=Cyclin-dependent+kinase+%28CDK%29+9+and+4%2F6+inhibitors+in+acute+myeloid+leukemia+%28AML%29%3A+a+promising+therapeutic+approach&doi=10.1080%2F13543784.2019.1678583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach</span></div><div class="casAuthors">Lee, Daniel J.; Zeidner, Joshua F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">989-1001</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite advancements over the last 2 years, outcomes for acute myeloid leukemia (AML) are poor; however, a greater comprehension of disease mechanisms has driven the investigation of new targeted treatments.  Cyclin-dependent kinases (CDKs) regulate cell cycle progression, transcription and DNA repair, and are aberrantly expressed in AML.  Targeting the CDK pathway is an emerging promising therapeutic strategy in AML.  We describe the rationale for targeting CDK9 and CDK4/6, the ongoing preclin. and clin. trials and the potential of these inhibitors in AML.  Our anal. included an extensive literature search via the Pubmed database and clinicaltrials.gov (March to August, 2019).: While CDK4/6 inhibitors are early in development for AML, CDK9 inhibition with alvocidib has encouraging clin. activity in newly diagnosed and relapsed/refractory AML.  Preclin. data suggests that leukemic MCL-1 dependence may predict response to alvocidib.  Moreover, MCL-1 plays a key role in resistance to BCL-2 inhibition with venetoclax.  Investigational strategies of concomitant BCL-2 and CDK9 inhibition represent a promising therapeutic platform for AML.  Furthermore, preclin. data suggests that CDK4/6 inhibition has selective activity in patients with KMT2A-rearrangements and FLT3 mutations.  Incorporation of CDK9 and 4/6 inhibitors into the existing therapeutic armamentarium may improve outcomes in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokA26-dFEujbVg90H21EOLACvtfcHk0ljCaAYgYiBAJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVaisbvN&md5=84506de1d15d850dec22ac62d457fd53</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1080%2F13543784.2019.1678583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2019.1678583%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BJ.%26aulast%3DZeidner%26aufirst%3DJ.%2BF.%26atitle%3DCyclin-dependent%2520kinase%2520%2528CDK%2529%25209%2520and%25204%252F6%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%253A%2520a%2520promising%2520therapeutic%2520approach%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2019%26volume%3D28%26spage%3D989%26epage%3D1001%26doi%3D10.1080%2F13543784.2019.1678583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khowsathit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Leal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrero, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merali, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garriga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanu, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simithy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynal, N. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadoch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Gharbia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanicolas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahnow, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelinek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grana, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J. P. J.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK9 reactivates epigenetically silenced genes in cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1244</span>– <span class="NLM_lpage">1258</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.09.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.cell.2018.09.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30454645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWju7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=1244-1258&issue=5&author=H.+H.+Zhangauthor=S.+Pandeyauthor=M.+Traversauthor=H.+X.+Sunauthor=G.+Mortonauthor=J.+Madzoauthor=W.+Chungauthor=J.+Khowsathitauthor=O.+Perez-Lealauthor=C.+A.+Barreroauthor=C.+Meraliauthor=Y.+Okamotoauthor=T.+Satoauthor=J.+Panauthor=J.+Garrigaauthor=N.+V.+Bhanuauthor=J.+Simithyauthor=B.+Patelauthor=J.+Huangauthor=N.+J.+M.+Raynalauthor=B.+A.+Garciaauthor=M.+A.+Jacobsonauthor=C.+Kadochauthor=S.+Meraliauthor=Y.+Zhangauthor=W.+Childersauthor=M.+Abou-Gharbiaauthor=J.+Karanicolasauthor=S.+B.+Baylinauthor=C.+A.+Zahnowauthor=J.+Jelinekauthor=X.+Granaauthor=J.+P.+J.+Issa&title=Targeting+CDK9+reactivates+epigenetically+silenced+genes+in+cancer&doi=10.1016%2Fj.cell.2018.09.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK9 reactivates epigenetically silenced genes in cancer</span></div><div class="casAuthors">Zhang, Hanghang; Pandey, Somnath; Travers, Meghan; Sun, Hongxing; Morton, George; Madzo, Jozef; Chung, Woonbok; Khowsathit, Jittasak; Perez-Leal, Oscar; Barrero, Carlos A.; Merali, Carmen; Okamoto, Yasuyuki; Sato, Takahiro; Pan, Joshua; Garriga, Judit; Bhanu, Natarajan V.; Simithy, Johayra; Patel, Bela; Huang, Jian; Raynal, Noel J.-M.; Garcia, Benjamin A.; Jacobson, Marlene A.; Kadoch, Cigall; Merali, Salim; Zhang, Yi; Childers, Wayne; Abou-Gharbia, Magid; Karanicolas, John; Baylin, Stephen B.; Zahnow, Cynthia A.; Jelinek, Jaroslav; Grana, Xavier; Issa, Jean-Pierre J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1244-1258.e26</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9) promotes transcriptional elongation through RNAPII pause release.  We now report that CDK9 is also essential for maintaining gene silencing at heterochromatic loci.  Through a live cell drug screen with genetic confirmation, we discovered that CDK9 inhibition reactivates epigenetically silenced genes in cancer, leading to restored tumor suppressor gene expression, cell differentiation, and activation of endogenous retrovirus genes.  CDK9 inhibition dephosphorylates the SWI/SNF protein BRG1, which contributes to gene reactivation.  By optimization through gene expression, we developed a highly selective CDK9 inhibitor (MC180295, IC50 = 5 nM) that has broad anti-cancer activity in vitro and is effective in in vivo cancer models.  Addnl., CDK9 inhibition sensitizes to the immune checkpoint inhibitor α-PD-1 in vivo, making it an excellent target for epigenetic therapy of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCzCPV7XrawLVg90H21EOLACvtfcHk0ljCaAYgYiBAJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWju7jE&md5=830a035304148e0529c072965f9c8fa8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.09.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.09.051%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BH.%26aulast%3DPandey%26aufirst%3DS.%26aulast%3DTravers%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%2BX.%26aulast%3DMorton%26aufirst%3DG.%26aulast%3DMadzo%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DW.%26aulast%3DKhowsathit%26aufirst%3DJ.%26aulast%3DPerez-Leal%26aufirst%3DO.%26aulast%3DBarrero%26aufirst%3DC.%2BA.%26aulast%3DMerali%26aufirst%3DC.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DGarriga%26aufirst%3DJ.%26aulast%3DBhanu%26aufirst%3DN.%2BV.%26aulast%3DSimithy%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DRaynal%26aufirst%3DN.%2BJ.%2BM.%26aulast%3DGarcia%26aufirst%3DB.%2BA.%26aulast%3DJacobson%26aufirst%3DM.%2BA.%26aulast%3DKadoch%26aufirst%3DC.%26aulast%3DMerali%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChilders%26aufirst%3DW.%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26aulast%3DKaranicolas%26aufirst%3DJ.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DZahnow%26aufirst%3DC.%2BA.%26aulast%3DJelinek%26aufirst%3DJ.%26aulast%3DGrana%26aufirst%3DX.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%2BJ.%26atitle%3DTargeting%2520CDK9%2520reactivates%2520epigenetically%2520silenced%2520genes%2520in%2520cancer%26jtitle%3DCell%26date%3D2018%26volume%3D175%26issue%3D5%26spage%3D1244%26epage%3D1258%26doi%3D10.1016%2Fj.cell.2018.09.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl) amino) cyclohexyl) amino) pyridin-4-yl) thiazol-2-yl) amino) methyl) tetrahydro-2h-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">896</span>– <span class="NLM_lpage">916</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2018.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30253346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOksbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=896-916&author=B.+L.+Wangauthor=J.+X.+Wuauthor=Y.+Wuauthor=C.+Chenauthor=F.+M.+Zouauthor=A.+L.+Wangauthor=H.+Wuauthor=Z.+Q.+Huauthor=Z.+R.+Jiangauthor=Q.+W.+Liuauthor=W.+Wangauthor=Y.+C.+Zhangauthor=F.+Y.+Liuauthor=M.+Zhaoauthor=J.+Huauthor=T.+Huangauthor=J.+Geauthor=L.+Wangauthor=T.+Renauthor=Y.+X.+Wangauthor=J.+Liuauthor=Q.+S.+Liu&title=Discovery+of+4-%28%28%284-%285-chloro-2-%28%28%281s%2C4s%29-4-%28%282-methoxyethyl%29+amino%29+cyclohexyl%29+amino%29+pyridin-4-yl%29+thiazol-2-yl%29+amino%29+methyl%29+tetrahydro-2h-pyran-4-carbonitrile+%28JSH-150%29+as+a+novel+highly+selective+and+potent+CDK9+kinase+inhibitor&doi=10.1016%2Fj.ejmech.2018.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor</span></div><div class="casAuthors">Wang, Beilei; Wu, Jiaxin; Wu, Yun; Chen, Cheng; Zou, Fengming; Wang, Aoli; Wu, Hong; Hu, Zhenquan; Jiang, Zongru; Liu, Qingwang; Wang, Wei; Zhang, Yicong; Liu, Feiyang; Zhao, Ming; Hu, Jie; Huang, Tao; Ge, Juan; Wang, Li; Ren, Tao; Wang, Yuxin; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">896-916</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compd. 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochem. assay and achieved around 300-10000-fold selectivity over other CDK kinase family members.  In addn., it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01).  Compd. 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines.  It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells.  In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression.  The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacol. tool to study CDK9-mediated physiol. and pathol. as well as a potential drug candidate for leukemia and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_sWKyk4YTnbVg90H21EOLACvtfcHk0lifCEi6WG9ePA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOksbnM&md5=c0b4a5d7ab3d6a088874c2b9ea1a4620</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZou%26aufirst%3DF.%2BM.%26aulast%3DWang%26aufirst%3DA.%2BL.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%2BQ.%26aulast%3DJiang%26aufirst%3DZ.%2BR.%26aulast%3DLiu%26aufirst%3DQ.%2BW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%2BC.%26aulast%3DLiu%26aufirst%3DF.%2BY.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%2BS.%26atitle%3DDiscovery%2520of%25204-%2528%2528%25284-%25285-chloro-2-%2528%2528%25281s%252C4s%2529-4-%2528%25282-methoxyethyl%2529%2520amino%2529%2520cyclohexyl%2529%2520amino%2529%2520pyridin-4-yl%2529%2520thiazol-2-yl%2529%2520amino%2529%2520methyl%2529%2520tetrahydro-2h-pyran-4-carbonitrile%2520%2528JSH-150%2529%2520as%2520a%2520novel%2520highly%2520selective%2520and%2520potent%2520CDK9%2520kinase%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D896%26epage%3D916%26doi%3D10.1016%2Fj.ejmech.2018.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of cyclin-dependent kinases as cancer therapeutics</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.pharmthera.2017.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28174091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=83-105&author=S.+R.+Whittakerauthor=A.+Mallingerauthor=P.+Workmanauthor=P.+A.+Clarke&title=Inhibitors+of+cyclin-dependent+kinases+as+cancer+therapeutics&doi=10.1016%2Fj.pharmthera.2017.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cyclin-dependent kinases as cancer therapeutics</span></div><div class="casAuthors">Whittaker, Steven R.; Mallinger, Aurelie; Workman, Paul; Clarke, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs).  This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer.  CDKs have now been shown to regulate other processes, particularly various aspects of transcription.  The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers.  The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors.  However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest.  Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER +/HER2- advanced breast cancer.  Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compds. that have allowed exploration of individual CDKs as cancer targets and the detn. of their potential therapeutic windows.  Biomarkers that allow the selection of patients likely to respond are now being discovered.  Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors.  This suggests that the selective inhibitors may be best used combined with std. of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5gsvVBhpMEbVg90H21EOLACvtfcHk0lifCEi6WG9ePA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D&md5=933364a96089bc4c47e15bddb412bd53</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%2BR.%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520cyclin-dependent%2520kinases%2520as%2520cancer%2520therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D83%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2017.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhász, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadranel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drews, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span> <span> </span><span class="NLM_article-title">Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in patients with extensive-disease small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">701</span>– <span class="NLM_lpage">711</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2019.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.jtho.2019.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30677506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemtLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=701-711&author=M.+Reckauthor=L.+Hornauthor=S.+Novelloauthor=F.+Barlesiauthor=I.+Albertauthor=E.+Juh%C3%A1szauthor=D.+Kowalskiauthor=G.+Robinetauthor=G.+Cadranelauthor=P.+Bidoliauthor=J.+Chungauthor=A.+Fritschauthor=U.+Drewsauthor=A.+Wagnerauthor=R.+Govindan&title=Phase+II+study+of+roniciclib+in+combination+with+cisplatin%2Fetoposide+or+carboplatin%2Fetoposide+as+first-line+therapy+in+patients+with+extensive-disease+small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2019.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer</span></div><div class="casAuthors">Reck, Martin; Horn, Leora; Novello, Silvia; Barlesi, Fabrice; Albert, Istvan; Juhasz, Erzsebet; Kowalski, Dariusz; Robinet, Gilles; Cadranel, Jacques; Bidoli, Paolo; Chung, John; Fritsch, Arno; Drews, Uta; Wagner, Andrea; Govindan, Ramaswamy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">701-711</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">This phase II study evaluated the efficacy and safety of the pan-cyclin-dependent kinase inhibitor roniciclib with platinum-based chemotherapy in patients with extensive-disease SCLC.  In this randomized, double-blind study, unselected patients with previously untreated extensive-disease SCLC received roniciclib, 5 mg, or placebo twice daily according to a 3 days-on, 4 days-off schedule in 21-day cycles, with concomitant cisplatin or carboplatin on day 1 and etoposide on days 1 to 3.  The primary end point was progression-free survival.  Other end points included overall survival, objective response rate, and safety.  A total of 140 patients received treatment: 70 with roniciclib plus chemotherapy and 70 with placebo plus chemotherapy.  Median overall survival times was 9.7 mo (95% CI: 7.9-11.1) with roniciclib plus chemotherapy and 10.3 mo (95% CI: 8.7-11.9) with placebo plus chemotherapy (HR = 1.281, 95% CI: 0.776-1.912, p = 0.7858).  The objective response rates were 60.6% with roniciclib plus chemotherapy and 74.6% with placebo plus chemotherapy.  Common treatment-emergent adverse events in both groups included nausea, vomiting, and fatigue.  Serious treatment-emergent adverse events were more common with roniciclib plus chemotherapy (57.1%) than with placebo plus chemotherapy (38.6%).  Roniciclib combined with chemotherapy demonstrated an unfavorable risk-benefit profile in patients with extensive-disease SCLC, and the study was prematurely terminated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMO5HC1HHvgrVg90H21EOLACvtfcHk0liygdDV0597RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemtLjM&md5=82e47fb569099724b143175abbc7c648</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2019.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2019.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DReck%26aufirst%3DM.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DAlbert%26aufirst%3DI.%26aulast%3DJuh%25C3%25A1sz%26aufirst%3DE.%26aulast%3DKowalski%26aufirst%3DD.%26aulast%3DRobinet%26aufirst%3DG.%26aulast%3DCadranel%26aufirst%3DG.%26aulast%3DBidoli%26aufirst%3DP.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DDrews%26aufirst%3DU.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DGovindan%26aufirst%3DR.%26atitle%3DPhase%2520II%2520study%2520of%2520roniciclib%2520in%2520combination%2520with%2520cisplatin%252Fetoposide%2520or%2520carboplatin%252Fetoposide%2520as%2520first-line%2520therapy%2520in%2520patients%2520with%2520extensive-disease%2520small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2019%26volume%3D14%26spage%3D701%26epage%3D711%26doi%3D10.1016%2Fj.jtho.2019.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">The history and future of targeting cyclin-dependent kinases in cancer therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&issue=2&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+history+and+future+of+targeting+cyclin-dependent+kinases+in+cancer+therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0liygdDV0597RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520history%2520and%2520future%2520of%2520targeting%2520cyclin-dependent%2520kinases%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D2%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napoleon, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin dependent kinase 9 inhibitors for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8667</span>– <span class="NLM_lpage">8684</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00150</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00150" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslGjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8667-8684&author=Y.+A.+Sonawaneauthor=M.+A.+Taylorauthor=J.+V.+Napoleonauthor=S.+Ranaauthor=J.+I.+Contrerasauthor=A.+Natarajan&title=Cyclin+dependent+kinase+9+inhibitors+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.6b00150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy</span></div><div class="casAuthors">Sonawane, Yogesh A.; Taylor, Margaret A.; Napoleon, John Victor; Rana, Sandeep; Contreras, Jacob I.; Natarajan, Amarnath</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8667-8684</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly 2 decades due to their widely varied and crit. functions within the cell.  Recently CDK9 has emerged as a druggable target for the development of cancer therapeutics.  CDK9 plays a crucial role in transcription regulation; specifically, CDK9 mediated transcriptional regulation of short-lived antiapoptotic proteins is crit. for the survival of transformed cells.  Focused chem. libraries based on a plethora of scaffolds have resulted in mixed success with regard to the development of selective CDK9 inhibitors.  Here we review the regulation of CDK9, its cellular functions, and common core structures used to target CDK9, along with their selectivity profile and efficacy in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOIqU9uSujdrVg90H21EOLACvtfcHk0liygdDV0597RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslGjsLo%253D&md5=0910a61f9c915002ff1073b22b5e20d6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00150%26sid%3Dliteratum%253Aachs%26aulast%3DSonawane%26aufirst%3DY.%2BA.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DNapoleon%26aufirst%3DJ.%2BV.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DContreras%26aufirst%3DJ.%2BI.%26aulast%3DNatarajan%26aufirst%3DA.%26atitle%3DCyclin%2520dependent%2520kinase%25209%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8667%26epage%3D8684%26doi%3D10.1021%2Facs.jmedchem.6b00150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paparidis, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durvale, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canduri, F.</span></span> <span> </span><span class="NLM_article-title">The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1039/C6MB00387G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1039%2FC6MB00387G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27833949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2snltVOlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=246-276&issue=2&author=N.+F.+Paparidisauthor=M.+C.+Durvaleauthor=F.+Canduri&title=The+emerging+picture+of+CDK9%2FP-TEFb%3A+more+than+20+years+of+advances+since+PITALRE&doi=10.1039%2FC6MB00387G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE</span></div><div class="casAuthors">Paparidis Nikolas Ferreira Dos Santos; Canduri Fernanda; Durvale Maxwell Castro</div><div class="citationInfo"><span class="NLM_cas:title">Molecular bioSystems</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-276</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CDK9 is a prominent member of the transcriptional CDKs subfamily, a group of kinases whose function is to control the primary steps of mRNA synthesis and processing by eukaryotic RNA polymerase II.  As a cyclin-dependent kinase, CDK9 activation in vivo depends upon its association with T-type cyclins to assemble the positive transcription elongation factor (P-TEFb).  Although CDK9/P-TEFb phosphorylates the C-terminal domain of RNAP II in the same positions targeted by CDK7 (TFIIH) and CDK8 (Mediator), the former does not participate in the transcription initiation, but rather plays a unique role by driving the polymerase to productive elongation.  In addition to RNAP II CTD, the negative transcription elongation factors DSIF and NELF also represent major CDK9 substrates, whose phosphorylation is required to overcome the proximal pause of the polymerase.  CDK9 is recruited to specific genes through proteins that interact with both P-TEFb and distinct elements in DNA, RNA or chromatin, where it modulates the activity of individual RNAP II transcription complexes.  The regulation of CDK9 function is an intricate network that includes post-translational modifications (phosphorylation/dephosphorylation and acetylation/deacetylation of key residues) as well as the association of P-TEFb with various proteins that can stimulate or inhibit its kinase activity.  Several cases of CDK9 deregulation have been linked to important human diseases, including various types of cancer and also AIDS (due to its essential role in HIV replication).  Not only HIV, but also many other human viruses have been shown to depend strongly on CDK9 activity to be transcribed within host cells.  This review summarizes the main advances made on CDK9/P-TEFb field in more than 20 years, introducing the structural, functional and genetic aspects that have been elucidated ever since.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJulYHhsNcnUmhnSqMnvzDfW6udTcc2eZFfxyQRK0SsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snltVOlsA%253D%253D&md5=eb1290cacb40f5c4c7158199fe513b14</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2FC6MB00387G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MB00387G%26sid%3Dliteratum%253Aachs%26aulast%3DPaparidis%26aufirst%3DN.%2BF.%26aulast%3DDurvale%26aufirst%3DM.%2BC.%26aulast%3DCanduri%26aufirst%3DF.%26atitle%3DThe%2520emerging%2520picture%2520of%2520CDK9%252FP-TEFb%253A%2520more%2520than%252020%2520years%2520of%2520advances%2520since%2520PITALRE%26jtitle%3DMol.%2520BioSyst.%26date%3D2017%26volume%3D13%26issue%3D2%26spage%3D246%26epage%3D276%26doi%3D10.1039%2FC6MB00387G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bacon, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Orso, I.</span></span> <span> </span><span class="NLM_article-title">CDK9: a signaling hub for transcriptional control</span>. <i>Transcription.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1080/21541264.2018.1523668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F21541264.2018.1523668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30227759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFSru7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=57-75&author=C.+W.+Baconauthor=I.+D%E2%80%99Orso&title=CDK9%3A+a+signaling+hub+for+transcriptional+control&doi=10.1080%2F21541264.2018.1523668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9: a signaling hub for transcriptional control</span></div><div class="casAuthors">Bacon, Curtis W.; D'Orso, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">57-75</span>CODEN:
                <span class="NLM_cas:coden">TRANH2</span>;
        ISSN:<span class="NLM_cas:issn">2154-1272</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9) is crit. for RNA Polymerase II (Pol II) transcription initiation, elongation, and termination in several key biol. processes including development, differentiation, and cell fate responses.  A broad range of diseases are characterized by CDK9 malfunction, illustrating its importance in maintaining transcriptional homeostasis in basal- and signal-regulated conditions.  Here we provide a historical recount of CDK9 discovery and the current models suggesting CDK9 is a central hub necessary for proper execution of different steps in the transcription cycle.  Finally, we discuss the current therapeutic strategies to treat CDK9 malfunction in several disease states.  CDK: Cyclin-dependent kinase; Pol II: RNA Polymerase II; PIC: Pre-initiation Complex; TFIIH: Transcription Factor-II H; snoRNA: small nucleolar RNA; CycT: CyclinT1/T2; P-TEFb: Pos. Transcription Elongation Factor Complex; snRNP: small nuclear ribonucleo-protein; HEXIM: Hexamethylene Bis-acetamide-inducible Protein 1/2; LARP7: La-related Protein 7; MePCE: Methylphosphate Capping Enzyme; HIV: human immunodeficiency virus; TAT: trans-activator of transcription; TAR: Trans-activation response element; Hsp70: Heat Shock Protein 70; Hsp90/Cdc37: Hsp90- Hsp90 co-chaperone Cdc37; DSIF: DRB Sensitivity Inducing Factor; NELF: Neg. Elongation Factor; CPSF: cleavage and polyadenylation-specific factor; CSTF: cleavage-stimulatory factor; eRNA: enhancer RNA; BRD4: Bromodomain-contg. protein 4; JMJD6: Jumonji C-domain-contg. protein 6; SEC: Super Elongation Complex; ELL: eleven-nineteen Lys-rich leukemia; ENL: eleven-nineteen leukemia; MLL: mixed lineage leukemia; BEC: BRD4-contg. Elongation Complex; SEC-L2/L3: SEC-like complexes; KAP1: Kruppel-assocd. box-protein 1; KEC: KAP1-7SK Elongation Complex; DRB: Dichloro-1-ss-D-Ribofuranosylbenzimidazole; H2Bub1: H2B mono-ubiquitination; KM: KM05382; PP1: Protein Phosphatase 1; CDK9i: CDK9 inhibitor; SHAPE: Selective 2'-hydroxyl acylation analyzed by primer extension; TE: Typical enhancer; SE : Super enhancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7KDxTlKPy47Vg90H21EOLACvtfcHk0lh9R9DCNpXNnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFSru7bJ&md5=5977b1ea4f425dc8a2d0c39f98ef0e7d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1080%2F21541264.2018.1523668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2018.1523668%26sid%3Dliteratum%253Aachs%26aulast%3DBacon%26aufirst%3DC.%2BW.%26aulast%3DD%25E2%2580%2599Orso%26aufirst%3DI.%26atitle%3DCDK9%253A%2520a%2520signaling%2520hub%2520for%2520transcriptional%2520control%26jtitle%3DTranscription.%26date%3D2019%26volume%3D10%26spage%3D57%26epage%3D75%26doi%3D10.1080%2F21541264.2018.1523668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donehower, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. P.</span></span> <span> </span><span class="NLM_article-title">55k isoform of CDK9 associates with ku70 and is involved in DNA repair</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>397</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2010.05.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bbrc.2010.05.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=20493174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVChu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=397&publication_year=2010&pages=245-250&author=H.+B.+Liuauthor=C.+H.+Herrmannauthor=K.+R.+Chiangauthor=T.+L.+Sungauthor=S.+H.+Moonauthor=L.+A.+Donehowerauthor=A.+P.+Rice&title=55k+isoform+of+CDK9+associates+with+ku70+and+is+involved+in+DNA+repair&doi=10.1016%2Fj.bbrc.2010.05.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">55K isoform of CDK9 associates with Ku70 and is involved in DNA repair</span></div><div class="casAuthors">Liu, Hongbing; Herrmann, Christine H.; Chiang, Karen; Sung, Tzu-Ling; Moon, Sung-Hwan; Donehower, Lawrence A.; Rice, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">397</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-250</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pos. elongation factor b (P-TEFb) is a cellular protein kinase that is required for RNA polymerase II (RNAP II) transcriptional elongation of protein coding genes.  P-TEFb is a set of different mol. complexes, each contg. CDK9 as the catalytic subunit.  There are two isoforms of the CDK9 protein - the major 42 KDa CDK9 isoform and the minor 55KDa isoform that is translated from an in-frame mRNA that arises from an upstream transcriptional start site.  We found that shRNA depletion of the 55K CDK9 protein in HeLa cells induces apoptosis and double-strand DNA breaks (DSBs).  The levels of apoptosis and DSBs induced by the depletion were reduced by expression of a 55K CDK9 protein variant resistant to the shRNA, indicating that these phenotypes are the consequence of depletion of the 55K protein and not off-target effects.  We also found that the 55K CDK9 protein, but not the 42K CDK9 protein, specifically assocs. with Ku70, a protein involved in DSB repair.  Our findings suggest that the 55K CDK9 protein may function in repair of DNA through an assocn. with Ku70.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLqsE7-4wvgbVg90H21EOLACvtfcHk0lh9R9DCNpXNnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVChu7Y%253D&md5=109c0d1320181f4784cdd94cbd553145</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2010.05.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2010.05.092%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%2BB.%26aulast%3DHerrmann%26aufirst%3DC.%2BH.%26aulast%3DChiang%26aufirst%3DK.%2BR.%26aulast%3DSung%26aufirst%3DT.%2BL.%26aulast%3DMoon%26aufirst%3DS.%2BH.%26aulast%3DDonehower%26aufirst%3DL.%2BA.%26aulast%3DRice%26aufirst%3DA.%2BP.%26atitle%3D55k%2520isoform%2520of%2520CDK9%2520associates%2520with%2520ku70%2520and%2520is%2520involved%2520in%2520DNA%2520repair%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2010%26volume%3D397%26spage%3D245%26epage%3D250%26doi%3D10.1016%2Fj.bbrc.2010.05.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lis, J. T.</span></span> <span> </span><span class="NLM_article-title">Genome-wide dynamics of pol II elongation and its interplay with promoter proximal pausing, chromatin, and exons</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e02407</span>, <span class="refDoi"> DOI: 10.7554/eLife.02407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.7554%2FeLife.02407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24843027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=e02407&author=I.+Jonkersauthor=H.+Kwakauthor=J.+T.+Lis&title=Genome-wide+dynamics+of+pol+II+elongation+and+its+interplay+with+promoter+proximal+pausing%2C+chromatin%2C+and+exons&doi=10.7554%2FeLife.02407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide dynamics of Pol II elongation and its interplay with promoter proximal pausing, chromatin, and exons</span></div><div class="casAuthors">Jonkers, Iris; Kwak, Hojoong; Lis, John T.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e02407/1-e02407/25, 25 pp.</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Prodn. of mRNA depends critically on the rate of RNA polymerase II (Pol II) elongation.  To dissect Pol II dynamics in mouse ES cells, we inhibited Pol II transcription at either initiation or promoter-proximal pause escape with Triptolide or Flavopiridol, and tracked Pol II kinetically using GRO-seq.  Both inhibitors block transcription of more than 95% of genes, showing that pause escape, like initiation, is a ubiquitous and crucial step within the transcription cycle.  Moreover, paused Pol II is relatively stable, as evidenced from half-life measurements at ∼3200 genes.  Finally, tracking the progression of Pol II after drug treatment establishes Pol II elongation rates at over 1000 genes.  Notably, Pol II accelerates dramatically while transcribing through genes, but slows at exons.  Furthermore, intergenic variance in elongation rates is substantial, and is influenced by a pos. effect of H3K79me2 and neg. effects of exon d. and CG content within genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjNRAyzNYAlrVg90H21EOLACvtfcHk0lgsRDUOpYUNHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksLbI&md5=f8b3fb84eaa5711ee79819c66f8a4682</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.7554%2FeLife.02407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.02407%26sid%3Dliteratum%253Aachs%26aulast%3DJonkers%26aufirst%3DI.%26aulast%3DKwak%26aufirst%3DH.%26aulast%3DLis%26aufirst%3DJ.%2BT.%26atitle%3DGenome-wide%2520dynamics%2520of%2520pol%2520II%2520elongation%2520and%2520its%2520interplay%2520with%2520promoter%2520proximal%2520pausing%252C%2520chromatin%252C%2520and%2520exons%26jtitle%3DeLife%26date%3D2014%26volume%3D3%26spage%3De02407%26doi%3D10.7554%2FeLife.02407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover-Cutter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansó, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1108</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnsmb.2399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=23064645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2rsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1108-1115&issue=11&author=S.+Larochelleauthor=R.+Amatauthor=K.+Glover-Cutterauthor=M.+Sans%C3%B3author=C.+Zhangauthor=J.+J.+Allenauthor=K.+M.+Shokatauthor=D.+L.+Bentleyauthor=R.+P.+Fisher&title=Cyclin-dependent+kinase+control+of+the+initiation-to-elongation+switch+of+RNA+polymerase+II&doi=10.1038%2Fnsmb.2399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II</span></div><div class="casAuthors">Larochelle, Stephane; Amat, Ramon; Glover-Cutter, Kira; Sanso, Miriam; Zhang, Chao; Allen, Jasmina J.; Shokat, Kevan M.; Bentley, David L.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1108-1115</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Promoter-proximal pausing by RNA polymerase II (Pol II) ensures gene-specific regulation and RNA quality control.  Structural considerations suggested a requirement for initiation-factor eviction in elongation-factor engagement and pausing of transcription complexes.  Here we show that selective inhibition of Cdk7-part of TFIIH-increases TFIIE retention, prevents DRB sensitivity-inducing factor (DSIF) recruitment and attenuates pausing in human cells.  Pause release depends on Cdk9-cyclin T1 (P-TEFb); Cdk7 is also required for Cdk9-activating phosphorylation and Cdk9-dependent downstream events-Pol II C-terminal domain Ser2 phosphorylation and histone H2B ubiquitylation-in vivo.  Cdk7 inhibition, moreover, impairs Pol II transcript 3'-end formation.  Cdk7 thus acts through TFIIE and DSIF to establish, and through P-TEFb to relieve, barriers to elongation: incoherent feedforward that might create a window to recruit RNA-processing machinery.  Therefore, cyclin-dependent kinases govern Pol II handoff from initiation to elongation factors and cotranscriptional RNA maturation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUhQtYIcdjLbVg90H21EOLACvtfcHk0lgsRDUOpYUNHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2rsLvI&md5=e483e572df1f8645db9da40800dffe4d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2399%26sid%3Dliteratum%253Aachs%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DAmat%26aufirst%3DR.%26aulast%3DGlover-Cutter%26aufirst%3DK.%26aulast%3DSans%25C3%25B3%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DAllen%26aufirst%3DJ.%2BJ.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DBentley%26aufirst%3DD.%2BL.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DCyclin-dependent%2520kinase%2520control%2520of%2520the%2520initiation-to-elongation%2520switch%2520of%2520RNA%2520polymerase%2520II%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26issue%3D11%26spage%3D1108%26epage%3D1115%26doi%3D10.1038%2Fnsmb.2399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Storch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordes, N.</span></span> <span> </span><span class="NLM_article-title">The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.3892/ijo.2015.3246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.3892%2Fijo.2015.3246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26573875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVGrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=191-198&issue=1&author=K.+Storchauthor=N.+Cordes&title=The+impact+of+CDK9+on+radiosensitivity%2C+DNA+damage+repair+and+cell+cycling+of+HNSCC+cancer+cells&doi=10.3892%2Fijo.2015.3246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells</span></div><div class="casAuthors">Storch, Katja; Cordes, Nils</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">191-198</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9), mainly involved in regulation of transcription, has recently been shown to impact on cell cycling and DNA repair.  Despite the fact that CDK9 has been proposed as potential cancer target, it remains largely elusive whether CDK9 targeting alters tumor cell radiosensitivity.  Five human head and neck squamous cell carcinoma (HNSCC) cell lines (SAS, FaDu, HSC4, Cal33, UTSCC5) as well as SAS cells stably transfected with CDK9-EGFP-N1 plasmid or empty vector controls were used.  Upon either CDK9 small interfering RNA knockdown or treatment with a pan-CDK inhibitor (ZK304709), colony formation, DNA double strand breaks (DSBs), apoptosis, cell cycling, and expression and phosphorylation of major cell cycle and DNA damage repair proteins were examd.  While CDK9 overexpression mediated radioprotection, CDK9 depletion clearly enhanced the radiosensitivity of HNSCC cells without an induction of apoptosis.  While the cell cycle and cell cycle proteins were significantly modulated by CDK9 depletion, no further alterations in these parameters were obsd. after combined CDK9 knockdown with irradn.  ZK304709 showed concn.-dependent cytotoxicity but failed to radiosensitize HNSCC cells.  Our findings suggest a potential role of CDK9 in the radiation response of HNSCC cells.  Addnl. studies are warranted to clarify the usefulness to target CDK9 in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDuDnye_D2t7Vg90H21EOLACvtfcHk0lgsRDUOpYUNHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVGrsg%253D%253D&md5=bcecc7eca11a3d578dbba12ada463d4f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3892%2Fijo.2015.3246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2015.3246%26sid%3Dliteratum%253Aachs%26aulast%3DStorch%26aufirst%3DK.%26aulast%3DCordes%26aufirst%3DN.%26atitle%3DThe%2520impact%2520of%2520CDK9%2520on%2520radiosensitivity%252C%2520DNA%2520damage%2520repair%2520and%2520cell%2520cycling%2520of%2520HNSCC%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2016%26volume%3D48%26issue%3D1%26spage%3D191%26epage%3D198%26doi%3D10.3892%2Fijo.2015.3246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-19-0528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F2159-8290.CD-19-0528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=32071145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVyrs7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=351-370&author=J.+Chouauthor=D.+A.+Quigleyauthor=T.+M.+Robinsonauthor=F.+Y.+Fengauthor=A.+Ashworth&title=Transcription-associated+cyclin-dependent+kinases+as+targets+and+biomarkers+for+cancer+therapy&doi=10.1158%2F2159-8290.CD-19-0528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy</span></div><div class="casAuthors">Chou, Jonathan; Quigley, David A.; Robinson, Troy M.; Feng, Felix Y.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-370</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Drugs targeting the cell cycle-regulatory cyclin-dependent kinase (CDK) 4 and 6 have been approved for the treatment of hormone receptor-pos. breast cancer, and inhibitors targeting other cell-cycle CDKs are currently in clin. trials.  Another class of CDKs, the transcription-assocd. CDKs, including CDK7, CDK8, CDK9, CDK12 and CDK13, are crit. regulators of gene expression.  Recent evidence suggests several novel functions of these CDKs, including regulation of epigenetic modifications, intronic polyadenylation, DNA-damage responses, and genomic stability.  Here, we summarize our current understanding of the transcriptional CDKs, their utility as biomarkers, and their potential as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKsOxtaonQb7Vg90H21EOLACvtfcHk0liAcsa7TLGw6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVyrs7fM&md5=5fe5acb1fc8190ded5b14e6e44741df3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-0528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-0528%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DJ.%26aulast%3DQuigley%26aufirst%3DD.%2BA.%26aulast%3DRobinson%26aufirst%3DT.%2BM.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTranscription-associated%2520cyclin-dependent%2520kinases%2520as%2520targets%2520and%2520biomarkers%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2020%26volume%3D10%26spage%3D351%26epage%3D370%26doi%3D10.1158%2F2159-8290.CD-19-0528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nekhai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuer, D.</span></span> <span> </span><span class="NLM_article-title">Regulation of CDK9 activity by phosphorylation and dephosphorylation</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1155/2014/964964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1155%2F2014%2F964964" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=1&author=S.+Nekhaiauthor=M.+Petukhovauthor=D.+Breuer&title=Regulation+of+CDK9+activity+by+phosphorylation+and+dephosphorylation&doi=10.1155%2F2014%2F964964"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1155%2F2014%2F964964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F964964%26sid%3Dliteratum%253Aachs%26aulast%3DNekhai%26aufirst%3DS.%26aulast%3DPetukhov%26aufirst%3DM.%26aulast%3DBreuer%26aufirst%3DD.%26atitle%3DRegulation%2520of%2520CDK9%2520activity%2520by%2520phosphorylation%2520and%2520dephosphorylation%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2014%26volume%3D2014%26spage%3D1%26doi%3D10.1155%2F2014%2F964964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahaman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumarasiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekonnen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. D.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK9: a promising therapeutic opportunity in prostate cancer</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">T211</span>– <span class="NLM_lpage">T226</span>, <span class="refDoi"> DOI: 10.1530/ERC-16-0299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1530%2FERC-16-0299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27582311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=T211-T226&author=M.+H.+Rahamanauthor=M.+Kumarasiriauthor=L.+B.+Mekonnenauthor=M.+F.+Yuauthor=S.+Diabauthor=H.+Albrechtauthor=R.+W.+Milneauthor=S.+D.+Wang&title=Targeting+CDK9%3A+a+promising+therapeutic+opportunity+in+prostate+cancer&doi=10.1530%2FERC-16-0299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK9: a promising therapeutic opportunity in prostate cancer</span></div><div class="casAuthors">Rahaman, Muhammed H.; Kumarasiri, Malika; Mekonnen, Laychiluh B.; Yu, Mingfeng; Diab, Sarah; Albrecht, Hugo; Milne, Robert W.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">T211-T226</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9) is a key transcriptional regulator and a lucrative target for cancer treatment.  Targeting CDK9 can effectively confine the hyperactivity of androgen receptor and the constitutive expression of anti-apoptotic proteins; both being main causes of prostate cancer (PCa) development and progression.  In castrate-resistant PCa, traditional therapies that only target androgen receptor (AR) have become obsolete due to reprograming in AR activity to make the cells independent of androgen.  CDK9 inhibitors may provide a new and better therapeutic opportunity over traditional treatment options by targeting both androgen receptor activity and antiapoptotic proteins, improving the chances of pos. outcomes, esp. in patients with the advanced disease.  This review focuses on biol. functions of CDK9, its involvement with AR and the potential for therapeutic opportunities in PCa treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJmSh9D9_op7Vg90H21EOLACvtfcHk0liAcsa7TLGw6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSlu78%253D&md5=cea302eeb765840884f60cb170ec1640</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1530%2FERC-16-0299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-16-0299%26sid%3Dliteratum%253Aachs%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DMekonnen%26aufirst%3DL.%2BB.%26aulast%3DYu%26aufirst%3DM.%2BF.%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DS.%2BD.%26atitle%3DTargeting%2520CDK9%253A%2520a%2520promising%2520therapeutic%2520opportunity%2520in%2520prostate%2520cancer%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2016%26volume%3D23%26spage%3DT211%26epage%3DT226%26doi%3D10.1530%2FERC-16-0299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisburd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e06535</span>, <span class="refDoi"> DOI: 10.7554/eLife.06535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.7554%2FeLife.06535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26083714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVylsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=e06535&author=H.+S.+Luauthor=Y.+H.+Xueauthor=G.+K.+Y.+Yuauthor=C.+Ariasauthor=J.+L.+Linauthor=S.+Fongauthor=M.+Faureauthor=B.+Weisburdauthor=X.+D.+Jiauthor=A.+Mercierauthor=J.+Suttonauthor=K.+X.+Luoauthor=Z.+H.+Gaoauthor=Q.+Zhou&title=Compensatory+induction+of+MYC+expression+by+sustained+CDK9+inhibition+via+a+BRD4-dependent+mechanism&doi=10.7554%2FeLife.06535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism</span></div><div class="casAuthors">Lu, Huasong; Xue, Yuahua; Yu, Guoying K.; Arias, Carolina; Lin, Julie; Fong, Susan; Faure, Michel; Weisburd, Ben; Ji, Xiaodan; Mercier, Alexandre; Sutton, James; Luo, Kunxin; Gao, Zhenhai; Zhou, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e06535/1-e06535/26</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">CDK9 is the kinase subunit of pos. transcription elongation factor b (P-TEFb) that enables RNA polymerase (Pol) II's transition from promoter-proximal pausing to productive elongation.  Although considerable interest exists in CDK9 as a therapeutic target, little progress has been made due to lack of highly selective inhibitors.  Here, we describe the development of i-CDK9 as such an inhibitor that potently suppresses CDK9 phosphorylation of substrates and causes genome-wide Pol II pausing.  While most genes experience reduced expression, MYC and other primary response genes increase expression upon sustained i-CDK9 treatment.  Essential for this increase, the bromodomain protein BRD4 captures P-TEFb from 7SK snRNP to deliver to target genes and also enhances CDK9's activity and resistance to inhibition.  Because the i-CDK9-induced MYC expression and binding to P-TEFb compensate for P-TEFb's loss of activity, only simultaneously inhibiting CDK9 and MYC/BRD4 can efficiently induce growth arrest and apoptosis of cancer cells, suggesting the potential of a combinatorial treatment strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqDVbCbzgrtLVg90H21EOLACvtfcHk0lhxKd4eVgKmTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVylsL4%253D&md5=d08929101f4e3603306ccdc8642c19b4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.7554%2FeLife.06535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.06535%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%2BS.%26aulast%3DXue%26aufirst%3DY.%2BH.%26aulast%3DYu%26aufirst%3DG.%2BK.%2BY.%26aulast%3DArias%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%2BL.%26aulast%3DFong%26aufirst%3DS.%26aulast%3DFaure%26aufirst%3DM.%26aulast%3DWeisburd%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DX.%2BD.%26aulast%3DMercier%26aufirst%3DA.%26aulast%3DSutton%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DK.%2BX.%26aulast%3DGao%26aufirst%3DZ.%2BH.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DCompensatory%2520induction%2520of%2520MYC%2520expression%2520by%2520sustained%2520CDK9%2520inhibition%2520via%2520a%2520BRD4-dependent%2520mechanism%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26spage%3De06535%26doi%3D10.7554%2FeLife.06535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaori-Kondo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, S.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase 9 is a novel specific molecular target in adult t-cell leukemia/lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">1114</span>– <span class="NLM_lpage">1124</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-09-741983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1182%2Fblood-2016-09-741983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28646117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=1114-1124&author=T.+Naritaauthor=T.+Ishidaauthor=A.+Itoauthor=A.+Masakiauthor=S.+Kinoshitaauthor=S.+Suzukiauthor=H.+Takinoauthor=T.+Yoshidaauthor=M.+Riauthor=S.+Kusumotoauthor=H.+Komatsuauthor=K.+Imadaauthor=Y.+Tanakaauthor=A.+Takaori-Kondoauthor=H.+Inagakiauthor=A.+Scholzauthor=P.+Lienauauthor=T.+Kurodaauthor=R.+Uedaauthor=S.+Iida&title=Cyclin-dependent+kinase+9+is+a+novel+specific+molecular+target+in+adult+t-cell+leukemia%2Flymphoma&doi=10.1182%2Fblood-2016-09-741983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma</span></div><div class="casAuthors">Narita, Tomoko; Ishida, Takashi; Ito, Asahi; Masaki, Ayako; Kinoshita, Shiori; Suzuki, Susumu; Takino, Hisashi; Yoshida, Takashi; Ri, Masaki; Kusumoto, Shigeru; Komatsu, Hirokazu; Imada, Kazunori; Tanaka, Yuetsu; Takaori-Kondo, Akifumi; Inagaki, Hiroshi; Scholz, Arne; Lienau, Philip; Kuroda, Taruho; Ueda, Ryuzo; Iida, Shinsuke</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1114-1124</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9), a subunit of the pos. transcription elongation factor b (P-TEFb) complex, regulates gene transcription elongation by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (RNAPII).  The deregulation of CDK9/PTEFb has important implications for many cancer types.  BAY 1143572 is a novel and highly selective CDK9/P-TEFb inhibitor currently being investigated in phase 1 studies.  We evaluated the therapeutic potential of BAY1143572 in adult T-cell leukemia/lymphoma (ATL).  As a result of CDK9 inhibition and subsequent inhibition of phosphorylation at serine 2 of the RNAPII CTD, BAY1143572 decreased c-Myc and Mcl-1 levels in ATL-derived or human T-cell lymphotropic virus type-1 (HTLV-1)-transformed lines and primary ATL cells tested, leading to their growth inhibition and apoptosis.  Median inhibitory concns. for BAY 1143572 in ATL-derived or HTLV-1-transformed lines (n 5 8), primary ATL cells (n511), and CD4+ cells fromhealthy volunteers (n55) were 0.535, 0.30, and 0.36 mM, resp.  Next, NOG mice were used as recipients of tumor cells from an ATL patient.  BAY 1143572-treated ATL-bearing mice (once daily 12.5 mg/kg oral application) demonstrated significantly decreased ATL cell infiltration of the liver and bone marrow, as well as decreased human sol. interleukin-2 receptor levels in serum (reflecting the ATL tumor burden), compared with untreated mice (n 5 8 for both).  BAY 1143572-treated ATL-bearingmice demonstrated significantly prolonged survival compared with untreated ATL-bearing mice (n57 for both).  Collectively, this study indicates that BAY1143572 showed strong potential as a novel treatment of ATL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOnbRIEdnT27Vg90H21EOLACvtfcHk0lhxKd4eVgKmTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsrc%253D&md5=dfea5c427ed9963db1cb6203a784d017</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-09-741983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-09-741983%26sid%3Dliteratum%253Aachs%26aulast%3DNarita%26aufirst%3DT.%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DMasaki%26aufirst%3DA.%26aulast%3DKinoshita%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DTakino%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DRi%26aufirst%3DM.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DImada%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DTakaori-Kondo%26aufirst%3DA.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DKuroda%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DR.%26aulast%3DIida%26aufirst%3DS.%26atitle%3DCyclin-dependent%2520kinase%25209%2520is%2520a%2520novel%2520specific%2520molecular%2520target%2520in%2520adult%2520t-cell%2520leukemia%252Flymphoma%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D1114%26epage%3D1124%26doi%3D10.1182%2Fblood-2016-09-741983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trounson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouillet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span> <span> </span><span class="NLM_article-title">Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1101/gad.182980.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1101%2Fgad.182980.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=22279045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFOjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=120-125&issue=2&author=S.+P.+Glaserauthor=E.+F.+Leeauthor=E.+Trounsonauthor=P.+Bouilletauthor=A.+Weiauthor=W.+D.+Fairlieauthor=D.+J.+Izonauthor=J.+Zuberauthor=A.+R.+Rappaportauthor=M.+J.+Heroldauthor=W.+S.+Alexanderauthor=S.+W.+Loweauthor=L.+Robbauthor=A.+Strasser&title=Anti-apoptotic+Mcl-1+is+essential+for+the+development+and+sustained+growth+of+acute+myeloid+leukemia&doi=10.1101%2Fgad.182980.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia</span></div><div class="casAuthors">Glaser, Stefan P.; Lee, Erinna F.; Trounson, Evelyn; Bouillet, Philippe; Wei, Andrew; Fairlie, W. Douglas; Izon, David J.; Zuber, Johannes; Rappaport, Amy R.; Herold, Marco J.; Alexander, Warren S.; Lowe, Scott W.; Robb, Lorraine; Strasser, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-125</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) frequently relapses after initial treatment.  Drug resistance in AML has been attributed to high levels of the anti-apoptotic Bcl-2 family members Bcl-xL and Mcl-1.  Here we report that removal of Mcl-1, but not loss or pharmacol. blockade of Bcl-xL, Bcl-2, or Bcl-w, caused the death of transformed AML and could cure disease in AML-afflicted mice.  Enforced expression of selective inhibitors of prosurvival Bcl-2 family members revealed that Mcl-1 is crit. for survival of human AML cells.  Thus, targeting of Mcl-1 or regulators of its expression may be a useful strategy for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6z2Lgi2YuK7Vg90H21EOLACvtfcHk0lglkeLOMOaKFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFOjs78%253D&md5=5f0cc61da50fddb262d30e243a7e6837</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1101%2Fgad.182980.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.182980.111%26sid%3Dliteratum%253Aachs%26aulast%3DGlaser%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DE.%2BF.%26aulast%3DTrounson%26aufirst%3DE.%26aulast%3DBouillet%26aufirst%3DP.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DFairlie%26aufirst%3DW.%2BD.%26aulast%3DIzon%26aufirst%3DD.%2BJ.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DRappaport%26aufirst%3DA.%2BR.%26aulast%3DHerold%26aufirst%3DM.%2BJ.%26aulast%3DAlexander%26aufirst%3DW.%2BS.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DRobb%26aufirst%3DL.%26aulast%3DStrasser%26aufirst%3DA.%26atitle%3DAnti-apoptotic%2520Mcl-1%2520is%2520essential%2520for%2520the%2520development%2520and%2520sustained%2520growth%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26issue%3D2%26spage%3D120%26epage%3D125%26doi%3D10.1101%2Fgad.182980.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawtin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plunkett, W.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4637</span>– <span class="NLM_lpage">4645</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-12-190256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1182%2Fblood-2008-12-190256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=19234140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvVyquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4637-4645&issue=19&author=R.+Chenauthor=W.+G.+Wierdaauthor=S.+Chubbauthor=R.+E.+Hawtinauthor=J.+A.+Foxauthor=M.+J.+Keatingauthor=V.+Gandhiauthor=W.+Plunkett&title=Mechanism+of+action+of+SNS-032%2C+a+novel+cyclin-dependent+kinase+inhibitor%2C+in+chronic+lymphocytic+leukemia&doi=10.1182%2Fblood-2008-12-190256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia</span></div><div class="casAuthors">Chen, Rong; Wierda, William G.; Chubb, Sherri; Hawtin, Rachael E.; Fox, Judith A.; Keating, Michael J.; Gandhi, Varsha; Plunkett, William</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4637-4645</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Inhibitors of cyclin-dependent kinases (Cdks) were reported to have activities in chronic lymphocytic leukemia cells by inhibiting Cdk7 and Cdk9, which control transcription.  Here we studied the novel Cdk inhibitor SNS-032, which exhibits potent and selective inhibitory activity against Cdk2, Cdk7, and Cdk9.  We hypothesized that transient inhibition of transcription by SNS-032 would decrease antiapoptotic proteins, resulting in cell death.  SNS-032 effectively killed chronic lymphocytic leukemia cells in vitro regardless of prognostic indicators and treatment history.  This was assocd. with inhibition of phosphorylation of RNA polymerase II and inhibition of RNA synthesis.  Consistent with the intrinsic turnover rates of their transcripts and proteins, antiapoptotic proteins, such as Mcl-1 and X-linked inhibitor of apoptosis protein (XIAP), were rapidly reduced on exposure to SNS-032, whereas Bcl-2 protein was not affected.  The initial decrease of Mcl-1 protein was the result of transcriptional inhibition rather than cleavage by caspase.  Compared with flavopiridol and roscovitine, SNS-032 was more potent, both in inhibition of RNA synthesis and at induction of apoptosis.  SNS-032 activity was readily reversible; removal of SNS-032 reactivated RNA polymerase II, which led to resynthesis of Mcl-1 and cell survival.  Thus, these data support the clin. development of SNS-032 in diseases that require short-lived oncoproteins for survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrosg5a-0E_5LVg90H21EOLACvtfcHk0lglkeLOMOaKFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvVyquro%253D&md5=b27a303a6ec8a28aefe720e981ed3c27</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-12-190256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-12-190256%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DR.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DChubb%26aufirst%3DS.%26aulast%3DHawtin%26aufirst%3DR.%2BE.%26aulast%3DFox%26aufirst%3DJ.%2BA.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DPlunkett%26aufirst%3DW.%26atitle%3DMechanism%2520of%2520action%2520of%2520SNS-032%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520in%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26issue%3D19%26spage%3D4637%26epage%3D4645%26doi%3D10.1182%2Fblood-2008-12-190256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathos, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, K. S.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitor, P276–00 induces apoptosis in multiple myeloma cells by inhibition of CDK9-T1 and RNA polymerase II-dependent transcription</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2010.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.leukres.2010.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=21216463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVSrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2011&pages=821-830&issue=6&author=S.+M.+Manoharauthor=M.+J.+Rathosauthor=V.+Sonawaneauthor=S.+V.+Raoauthor=K.+S.+Joshi&title=Cyclin-dependent+kinase+inhibitor%2C+P276%E2%80%9300+induces+apoptosis+in+multiple+myeloma+cells+by+inhibition+of+CDK9-T1+and+RNA+polymerase+II-dependent+transcription&doi=10.1016%2Fj.leukres.2010.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription</span></div><div class="casAuthors">Manohar, Sonal M.; Rathos, Maggie J.; Sonawane, Vinay; Rao, Shalini V.; Joshi, Kalpana S.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">821-830</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">P276-00 is a novel cyclin-dependent kinase inhibitor esp. potent for Cdk9-T1, Cdk4-D1 and Cdk1-B.  Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of malignant plasma cells.  Treatment of MM cell lines with P276-00 resulted in apoptosis that correlated with transcription inhibition and a significant decline in Mcl-1 protein levels with the appearance of cleaved PARP in these cells.  In vivo studies of P276-00 confirmed antitumor activity in RPMI-8226 xenograft.  These results suggest that P276-00 causes multiple myeloma cell death by disrupting the balance between cell survival and apoptosis through inhibition of transcription and downregulation of Mcl-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvm8H-guEyqrVg90H21EOLACvtfcHk0lglkeLOMOaKFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVSrtbs%253D&md5=792626fe7d151b94be7d0048a4e5dff8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2010.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2010.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DManohar%26aufirst%3DS.%2BM.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DSonawane%26aufirst%3DV.%26aulast%3DRao%26aufirst%3DS.%2BV.%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitor%252C%2520P276%25E2%2580%259300%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%2520by%2520inhibition%2520of%2520CDK9-T1%2520and%2520RNA%2520polymerase%2520II-dependent%2520transcription%26jtitle%3DLeuk.%2520Res.%26date%3D2011%26volume%3D35%26issue%3D6%26spage%3D821%26epage%3D830%26doi%3D10.1016%2Fj.leukres.2010.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, S.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma</span>. <i>Haematologica.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2059</span>– <span class="NLM_lpage">2068</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.191395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.3324%2Fhaematol.2018.191395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30076184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFynsrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=2059-2068&issue=12&author=S.+Kinoshitaauthor=T.+Ishidaauthor=A.+Itoauthor=T.+Naritaauthor=A.+Masakiauthor=S.+Suzukiauthor=T.+Yoshidaauthor=M.+Riauthor=S.+Kusumotoauthor=H.+Komatsuauthor=N.+Shimizuauthor=H.+Inagakiauthor=T.+Kurodaauthor=A.+Scholzauthor=R.+Uedaauthor=T.+Sandaauthor=S.+Iida&title=Cyclin-dependent+kinase+9+as+a+potential+specific+molecular+target+in+NK-cell+leukemia%2Flymphoma&doi=10.3324%2Fhaematol.2018.191395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma</span></div><div class="casAuthors">Kinoshita, Shiori; Ishida, Takashi; Ito, Asahi; Narita, Tomoko; Masaki, Ayako; Suzuki, Susumu; Yoshida, Takashi; Ri, Masaki; Kusumoto, Shigeru; Komatsu, Hirokazu; Shimizu, Norio; Inagaki, Hiroshi; Kuroda, Taruho; Scholz, Arne; Ueda, Ryuzo; Sanda, Takaomi; Iida, Shinsuke</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2059-2068</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">BAY 1143572 is a highly selective inhibitor of cyclin-dependent kinase 9/pos. transcription elongation factor b.  It has entered phase I clin. studies.  Here, we have assessed the utility of BAY 1143572 for treating natural killer (NK) cell leukemias/lymphomas that have a poor prognosis, namely extranodal NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia, in a preclin. mouse model in vivo as well as in tissue culture models in vitro.  Seven NK-cell leukemia/lymphoma lines and primary aggressive NK-cell leukemia cells from two individual patients were treated with BAY 1143572 in vitro.  Primary tumor cells from an aggressive NK-cell leukemia patient were used to establish a xenogeneic murine model for testing BAY 1143572 therapy.  Cyclin-dependent kinase 9 inhibition by BAY 1143572 resulted in prevention of phosphorylation at the serine 2 site of the C-terminal domain of RNA polymerase II.  This resulted in lower c-Myc and Mcl-1 levels in the cell lines, causing growth inhibition and apoptosis.  In aggressive NK-cell leukemia primary tumor cells, exposure to BAY 1143572 in vitro resulted in decreased Mcl-1 protein levels resulting from inhibition of RNA polymerase II C-terminal domain phosphorylation at the serine 2 site.  Orally administering BAY 1143572 once per day to aggressive NK-cell leukemia-bearing mice resulted in lower tumor cell infiltration into the bone marrow, liver, and spleen, with less export to the periphery relative to control mice.  The treated mice also had a survival advantage over the untreated controls.  The specific small mol. targeting agent BAY1143572 has potential for treating NK-cell leukemia/lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw1ARkWiEOirVg90H21EOLACvtfcHk0lgVx2zBwExJyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFynsrvN&md5=39663108ae318d64625dcbca58c56ea4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.191395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.191395%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DS.%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNarita%26aufirst%3DT.%26aulast%3DMasaki%26aufirst%3DA.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DRi%26aufirst%3DM.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DKuroda%26aufirst%3DT.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DUeda%26aufirst%3DR.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DIida%26aufirst%3DS.%26atitle%3DCyclin-dependent%2520kinase%25209%2520as%2520a%2520potential%2520specific%2520molecular%2520target%2520in%2520NK-cell%2520leukemia%252Flymphoma%26jtitle%3DHaematologica.%26date%3D2018%26volume%3D103%26issue%3D12%26spage%3D2059%26epage%3D2068%26doi%3D10.3324%2Fhaematol.2018.191395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9</span>. <i>Artif. Cells, Nanomed., Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">980</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1080/21691401.2017.1351983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F21691401.2017.1351983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28701053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOrt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=980-984&author=Y.+B.+Luauthor=L.+Tangauthor=Q.+Zhangauthor=Z.+P.+Zhangauthor=W.+Wei&title=MicroRNA-613+inhibits+the+progression+of+gastric+cancer+by+targeting+CDK9&doi=10.1080%2F21691401.2017.1351983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9</span></div><div class="casAuthors">Lu, Yebin; Tang, Ling; Zhang, Qi; Zhang, Zhipeng; Wei, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Artificial Cells, Nanomedicine, and Biotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">980-984</span>CODEN:
                <span class="NLM_cas:coden">ACNBCI</span>;
        ISSN:<span class="NLM_cas:issn">2169-141X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">MicroRNAs (miRNAs) play an important role in the development and progression of human malignancy. miR-613, as a tumor suppressor, was reported to decrease in several tumors.  However, the expression levels and role of miR-613 in gastric cancer remain unknown.  In this study, we found that miR-613 was evidently downregulated in gastric cancer tissue and cell.  The functional anal. showed that miR-613 suppressed cell proliferation and migration in gastric cancer.  Next, the dual-luciferase reporter system supported CDK9 as a direct target gene of miR-613. miR-613 mimics evidently repressed CDK9 expression in gastric cancer cells.  Furthermore, we found that CDK9 in upregulated in gastric cancer and the CDK9 expression levels were inversely correlated with that of miR-613 in gastric cancer tissues.  Overall, the results revealed that miR-613, as a tumor suppressor, involves in gastric cancer progression and metastasis by targeting CDK9, implying a novel potential therapeutic target for the treatment of gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBDPuYFtGGCLVg90H21EOLACvtfcHk0lgVx2zBwExJyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOrt7fF&md5=2bb6c8710a92e16d3cd201a00a8b2b98</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1080%2F21691401.2017.1351983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21691401.2017.1351983%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%2BB.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DZ.%2BP.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DMicroRNA-613%2520inhibits%2520the%2520progression%2520of%2520gastric%2520cancer%2520by%2520targeting%2520CDK9%26jtitle%3DArtif.%2520Cells%252C%2520Nanomed.%252C%2520Biotechnol.%26date%3D2018%26volume%3D46%26spage%3D980%26epage%3D984%26doi%3D10.1080%2F21691401.2017.1351983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornicek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Z.</span></span> <span> </span><span class="NLM_article-title">Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.7150/jca.35426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.7150%2Fjca.35426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31892980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVSltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=132-141&author=S.+Shenauthor=D.+C.+Deanauthor=Z.+Yuauthor=F.+Hornicekauthor=Q.+Kanauthor=Z.+Duan&title=Aberrant+CDK9+expression+within+chordoma+tissues+and+the+therapeutic+potential+of+a+selective+CDK9+inhibitor+LDC000067&doi=10.7150%2Fjca.35426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067</span></div><div class="casAuthors">Shen, Shen; Dean, Dylan C.; Yu, Zujiang; Hornicek, Francis; Kan, Quancheng; Duan, Zhenfeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer (Wyoming, Australia)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">132-141</span>CODEN:
                <span class="NLM_cas:coden">JCWAAL</span>;
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher Pty Ltd.</span>)
        </div><div class="casAbstract">Objectives: Chordomas are slow-growing malignancies that commonly affect vital neurol. structures.  These neoplasms are highly resistant to current chemotherapeutic regimens and often recur after surgical intervention.  Therefore, there is an urgent need to identify mol. targets and more robust drugs to improve chordoma patient outcomes.  It is well accepted that cyclin-dependent protein kinase 9 (CDK9) has tumorigenic roles in various cancers; however, the expression and significance of CDK9 in chordoma remains unknown.  Methods: Expression of CDK9 in chordoma cell lines and tumor tissues was examd. by Western blot and immunohistochem. (IHC).  The correlation between CDK9 expression in patient tissues and clin. prognosis was analyzed.  The functional roles of CDK9 in chordoma were investigated after the addn. of small interfering RNA (siRNA) and CDK9 inhibitor (LDC000067).  Cell growth and proliferation were assessed with MTT and clonogenic assays.  The effect of CDK9 inhibition on chordoma cells was further evaluated with a three-dimensional (3D) cell culture model which mimics the in vivo environment.  Results: CDK9 was expressed in both chordoma cell lines and chordoma tissues.  High- expression of CDK9 correlated with recurrence and poor outcomes for chordoma patients.  CDK9 silencing with siRNA decreased growth and proliferation of chordoma cells and lowered levels of Mcl-1 and RNA polymerase II (RNAP II) phosphorylation.  Pharmacol. inhibition of CDK9 with the small mol. inhibitor LDC000067 reduced cell growth, supported apoptosis, suppressed cell colony formation in a clonogenic assay, and decreased spheroid growth in 3D culture.  Conclusion: We demonstrate that CDK9 expression in chordoma correlates with patient outcome, and, when inhibited, chordoma cell growth and proliferation significantly decreases.  Taken together, these results support CDK9 as an emerging potential target in chordoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv8b4mxaKrd7Vg90H21EOLACvtfcHk0liCNEnOHg70PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVSltLs%253D&md5=5e1b393e63b83609d5a37e6debea188d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.7150%2Fjca.35426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.35426%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DDean%26aufirst%3DD.%2BC.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DHornicek%26aufirst%3DF.%26aulast%3DKan%26aufirst%3DQ.%26aulast%3DDuan%26aufirst%3DZ.%26atitle%3DAberrant%2520CDK9%2520expression%2520within%2520chordoma%2520tissues%2520and%2520the%2520therapeutic%2520potential%2520of%2520a%2520selective%2520CDK9%2520inhibitor%2520LDC000067%26jtitle%3DJ.%2520Cancer%26date%3D2020%26volume%3D11%26spage%3D132%26epage%3D141%26doi%3D10.7150%2Fjca.35426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharifnia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wawer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sizemore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawlor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogswell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornicek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Root, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Small-molecule targeting of brachyury transcription factor addiction in chordoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0312-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fs41591-018-0312-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30664779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFGru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=292-300&issue=2&author=T.+Sharifniaauthor=M.+J.+Wawerauthor=T.+Chenauthor=Q.+Y.+Huangauthor=B.+A.+Weirauthor=A.+Sizemoreauthor=M.+A.+Lawlorauthor=A.+Goodaleauthor=G.+S.+Cowleyauthor=F.+Vazquezauthor=C.+J.+Ottauthor=J.+M.+Francisauthor=S.+Sassiauthor=P.+Cogswellauthor=H.+E.+Sheppardauthor=T.+Zhangauthor=N.+S.+Grayauthor=P.+A.+Clarkeauthor=J.+Blaggauthor=P.+Workmanauthor=J.+Sommerauthor=F.+Hornicekauthor=D.+E.+Rootauthor=W.+C.+Hahnauthor=J.+E.+Bradnerauthor=K.+K.+Wongauthor=P.+A.+Clemonsauthor=C.+Y.+Linauthor=J.+D.+Kotzauthor=S.+L.+Schreiber&title=Small-molecule+targeting+of+brachyury+transcription+factor+addiction+in+chordoma&doi=10.1038%2Fs41591-018-0312-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule targeting of brachyury transcription factor addiction in chordoma</span></div><div class="casAuthors">Sharifnia, Tanaz; Wawer, Mathias J.; Chen, Ting; Huang, Qing-Yuan; Weir, Barbara A.; Sizemore, Ann; Lawlor, Matthew A.; Goodale, Amy; Cowley, Glenn S.; Vazquez, Francisca; Ott, Christopher J.; Francis, Joshua M.; Sassi, Slim; Cogswell, Patricia; Sheppard, Hadley E.; Zhang, Tinghu; Gray, Nathanael S.; Clarke, Paul A.; Blagg, Julian; Workman, Paul; Sommer, Josh; Hornicek, Francis; Root, David E.; Hahn, William C.; Bradner, James E.; Wong, Kwok K.; Clemons, Paul A.; Lin, Charles Y.; Kotz, Joanne D.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">292-300</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Chordoma is a primary bone cancer with no approved therapy1.  The identification of therapeutic targets in this disease has been challenging due to the infrequent occurrence of clin. actionable somatic mutations in chordoma tumors2,3.  Here we describe the discovery of therapeutically targetable chordoma dependencies via genome-scale CRISPR-Cas9 screening and focused small-mol. sensitivity profiling.  These systematic approaches reveal that the developmental transcription factor T (brachyury; TBXT) is the top selectively essential gene in chordoma, and that transcriptional cyclin-dependent kinase (CDK) inhibitors targeting CDK7/12/13 and CDK9 potently suppress chordoma cell proliferation.  In other cancer types, transcriptional CDK inhibitors have been obsd. to downregulate highly expressed, enhancer-assocd. oncogenic transcription factors4,5.  In chordoma, we find that T is assocd. with a 1.5-Mb region contg. 'super-enhancers' and is the most highly expressed super-enhancer-assocd. transcription factor.  Notably, transcriptional CDK inhibition leads to preferential and concn.-dependent downregulation of cellular brachyury protein levels in all models tested.  In vivo, CDK7/12/13-inhibitor treatment substantially reduces tumor growth.  Together, these data demonstrate small-mol. targeting of brachyury transcription factor addiction in chordoma, identify a mechanism of T gene regulation that underlies this therapeutic strategy, and provide a blueprint for applying systematic genetic and chem. screening approaches to discover vulnerabilities in genomically quiet cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2B8MeRhHUNrVg90H21EOLACvtfcHk0liCNEnOHg70PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFGru7o%253D&md5=c69a979a760a679c8051f9b1f308d61a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0312-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0312-3%26sid%3Dliteratum%253Aachs%26aulast%3DSharifnia%26aufirst%3DT.%26aulast%3DWawer%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DQ.%2BY.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DSizemore%26aufirst%3DA.%26aulast%3DLawlor%26aufirst%3DM.%2BA.%26aulast%3DGoodale%26aufirst%3DA.%26aulast%3DCowley%26aufirst%3DG.%2BS.%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DFrancis%26aufirst%3DJ.%2BM.%26aulast%3DSassi%26aufirst%3DS.%26aulast%3DCogswell%26aufirst%3DP.%26aulast%3DSheppard%26aufirst%3DH.%2BE.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DSommer%26aufirst%3DJ.%26aulast%3DHornicek%26aufirst%3DF.%26aulast%3DRoot%26aufirst%3DD.%2BE.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DKotz%26aufirst%3DJ.%2BD.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DSmall-molecule%2520targeting%2520of%2520brachyury%2520transcription%2520factor%2520addiction%2520in%2520chordoma%26jtitle%3DNat.%2520Med.%26date%3D2019%26volume%3D25%26issue%3D2%26spage%3D292%26epage%3D300%26doi%3D10.1038%2Fs41591-018-0312-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borowczak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczerbowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzanka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szylberg, Ł.</span></span> <span> </span><span class="NLM_article-title">CDK9: therapeutic perspective in HCC therapy</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.2174/1568009620666200212124357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.2174%2F1568009620666200212124357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=32048975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOqsL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=318-324&issue=5&author=J.+Borowczakauthor=K.+Szczerbowskiauthor=E.+Stecauthor=D.+Grzankaauthor=%C5%81.+Szylberg&title=CDK9%3A+therapeutic+perspective+in+HCC+therapy&doi=10.2174%2F1568009620666200212124357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9: Therapeutic Perspective in HCC Therapy</span></div><div class="casAuthors">Borowczak, Jedrzej; Szczerbowski, Krzysztof; Stec, Ewa; Grzanka, Dariusz; Szylberg, Lukasz</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">318-324</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  CDK9 is an important cell-cycle control enzyme essential in transcription, elongation, and mRNA maturation.  Overexpression of CDK9 has been reported in several diseases, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and malignant melanoma.  Recent research revealed that CDK9-inhibitors have a major impact on the induction of apoptosis in hepatocellular carcinoma (HCC) cell lines.  Despite surprisingly promising results in in vitro and in vivo research, no CDK9 related therapy is currently allowed in cases of HCC.  Furthermore, due to their high specificity, the inhibitors had no effects on unaltered hepatocytes and no toxic effects were shown.  Considering that they were well tolerated and showed relatively few severe side-effects in mice, CDK9- inhibitors would seem to be promising targets in HCC biomarker-guided immunotherapy.  Studies have verified that CDK9 has a pivotal role in c-Myc-mediated tumor growth and CDK9 inhibitors inhibit not only its progression but diametrically decrease both the mass and size of HCC nodules.  CDK9-inhibitors seem to be a promising target in HCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHITSDgNzV4bVg90H21EOLACvtfcHk0lhrUXwgplfKrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOqsL7F&md5=ffba883e93f84117c7d6f827e48d3932</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2174%2F1568009620666200212124357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009620666200212124357%26sid%3Dliteratum%253Aachs%26aulast%3DBorowczak%26aufirst%3DJ.%26aulast%3DSzczerbowski%26aufirst%3DK.%26aulast%3DStec%26aufirst%3DE.%26aulast%3DGrzanka%26aufirst%3DD.%26aulast%3DSzylberg%26aufirst%3D%25C5%2581.%26atitle%3DCDK9%253A%2520therapeutic%2520perspective%2520in%2520HCC%2520therapy%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2020%26volume%3D20%26issue%3D5%26spage%3D318%26epage%3D324%26doi%3D10.2174%2F1568009620666200212124357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span> <span> </span><span class="NLM_article-title">Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111535</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2019.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31376566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111535&author=X.+Wangauthor=C.+Yuauthor=C.+Wangauthor=Y.+Maauthor=T.+Wangauthor=Y.+Liauthor=Z.+Huangauthor=M.+Zhouauthor=P.+Sunauthor=J.+Zhengauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=Novel+cyclin-dependent+kinase+9+%28CDK9%29+inhibitor+with+suppression+of+cancer+stemness+activity+against+non-small-cell+lung+cancer&doi=10.1016%2Fj.ejmech.2019.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer</span></div><div class="casAuthors">Wang, Xin; Yu, Chenhua; Wang, Cheng; Ma, Yakun; Wang, Tianqi; Li, Yao; Huang, Zhi; Zhou, Manqian; Sun, Peiqing; Zheng, Jianyu; Yang, Shengyong; Fan, Yan; Xiang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111535</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel, highly potent, selective CDK9 inhibitors with cancer stem cells (CSCs) inhibition activity were designed and synthesized for non-small-cell lung cancer (NSCLC) therapy.  Structure-activity relationship anal. based on enzymic and cellular activities led to the discovery of a promising inhibitor 21e(I).  I potently inhibited CDK9 with IC50 value of 11 nM and suppressed the stemness properties of NSCLC effectively.  It could decrease the stemness phenotypes of NSCLC cells, including tumor sphere formation, side-population and stemness markers abundance.  I displayed good selectivity over the CDK family kinases and kinase profiling assay against 381 kinases.  In addn., I inhibited cell proliferation, colony-formation, and cell cycle progression and induced apoptosis in NSCLC.  In H1299 xenograft mouse model, a once-daily dose of I at 20 mg/kg significantly suppressed the tumor growth without obvious toxicity.  Studies of mechanisms of action indicated that I efficiently inhibited CDK9 signaling pathway and stemness both in vitro and in vivo.  Collectively, I as a novel CDK9 inhibitor with CSCs inhibition properties could be a promising agent for the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_2AOdlSLbIrVg90H21EOLACvtfcHk0lhrUXwgplfKrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3N&md5=b088226c0d124c27c921c2504a16a665</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DNovel%2520cyclin-dependent%2520kinase%25209%2520%2528CDK9%2529%2520inhibitor%2520with%2520suppression%2520of%2520cancer%2520stemness%2520activity%2520against%2520non-small-cell%2520lung%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111535%26doi%3D10.1016%2Fj.ejmech.2019.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Karstedt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abd El Hay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arce, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montinaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papenfuss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Bahrawy, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walczak, H.</span></span> <span> </span><span class="NLM_article-title">Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/cdd.2013.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fcdd.2013.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24362439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvF2rtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=491-502&issue=3&author=J.+Lemkeauthor=S.+von+Karstedtauthor=M.+Abd+El+Hayauthor=A.+Contiauthor=F.+Arceauthor=A.+Montinaroauthor=K.+Papenfussauthor=M.+A.+El-Bahrawyauthor=H.+Walczak&title=Selective+CDK9+inhibition+overcomes+TRAIL+resistance+by+concomitant+suppression+of+cFlip+and+Mcl-1&doi=10.1038%2Fcdd.2013.179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1</span></div><div class="casAuthors">Lemke, J.; von Karstedt, S.; Abd El Hay, M.; Conti, A.; Arce, F.; Montinaro, A.; Papenfuss, K.; El-Bahrawy, M. A.; Walczak, H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">491-502</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in many cancer cells without causing toxicity in vivo.  However, to date, TRAIL-receptor agonists have only shown limited therapeutic benefit in clin. trials.  This can, most likely, be attributed to the fact that 50% of all cancer cell lines and most primary human cancers are TRAIL resistant.  Consequently, future TRAIL-based therapies will require the addn. of sensitizing agents that remove crucial blocks in the TRAIL apoptosis pathway.  Here, we identify PIK-75, a small mol. inhibitor of the p110α isoform of phosphoinositide-3 kinase (PI3K), as an exceptionally potent TRAIL apoptosis sensitizer.  Surprisingly, PI3K inhibition was not responsible for this activity.  A kinome-wide in vitro screen revealed that PIK-75 strongly inhibits a panel of 27 kinases in addn. to p110α.  Within this panel, we identified cyclin-dependent kinase 9 (CDK9) as responsible for TRAIL resistance of cancer cells.  Combination of CDK9 inhibition with TRAIL effectively induced apoptosis even in highly TRAIL-resistant cancer cells.  Mechanistically, CDK9 inhibition resulted in downregulation of cellular FLICE-like inhibitory protein (cFlip) and Mcl-1 at both the mRNA and protein levels.  Concomitant cFlip and Mcl-1 downregulation was required and sufficient for TRAIL sensitization by CDK9 inhibition.  When evaluating cancer selectivity of TRAIL combined with SNS-032, the most selective and clin. used inhibitor of CDK9, we found that a panel of mostly TRAIL-resistant non-small cell lung cancer cell lines was readily killed, even at low concns. of TRAIL.  Primary human hepatocytes did not succumb to the same treatment regime, defining a therapeutic window.  Importantly, TRAIL in combination with SNS-032 eradicated established, orthotopic lung cancer xenografts in vivo.  Based on the high potency of CDK9 inhibition as a cancer cell-selective TRAIL-sensitizing strategy, we envisage the development of new, highly effective cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdFS2sPKgO2rVg90H21EOLACvtfcHk0liZZZpGxyB1pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvF2rtrjM&md5=bfbbd7988333ff709670786628d2b62c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2013.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2013.179%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DJ.%26aulast%3Dvon%2BKarstedt%26aufirst%3DS.%26aulast%3DAbd%2BEl%2BHay%26aufirst%3DM.%26aulast%3DConti%26aufirst%3DA.%26aulast%3DArce%26aufirst%3DF.%26aulast%3DMontinaro%26aufirst%3DA.%26aulast%3DPapenfuss%26aufirst%3DK.%26aulast%3DEl-Bahrawy%26aufirst%3DM.%2BA.%26aulast%3DWalczak%26aufirst%3DH.%26atitle%3DSelective%2520CDK9%2520inhibition%2520overcomes%2520TRAIL%2520resistance%2520by%2520concomitant%2520suppression%2520of%2520cFlip%2520and%2520Mcl-1%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2014%26volume%3D21%26issue%3D3%26spage%3D491%26epage%3D502%26doi%3D10.1038%2Fcdd.2013.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajput, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoog, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C. X.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer</span>. <i>Oncotarget.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">56864</span>– <span class="NLM_lpage">56875</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.10870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.18632%2Foncotarget.10870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27486754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ntFSguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=56864-56875&issue=35&author=S.+Rajputauthor=N.+Kheraauthor=Z.+Guoauthor=J.+Hoogauthor=S.+Liauthor=C.+X.+Ma&title=Inhibition+of+cyclin+dependent+kinase+9+by+dinaciclib+suppresses+cyclin+B1+expression+and+tumor+growth+in+triple+negative+breast+cancer&doi=10.18632%2Foncotarget.10870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer</span></div><div class="casAuthors">Rajput Sandeep; Khera Nimmish; Guo Zhanfang; Hoog Jeremy; Li Shunqiang; Ma Cynthia X; Li Shunqiang; Ma Cynthia X</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">56864-56875</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are potential cancer therapeutic targets because of their critical role in promoting cell growth.  Dinaciclib is a novel CDK inhibitor currently under clinical evaluation for the treatment of advanced malignancies.  In this study, we demonstrated the anti-tumor activity of dinaciclib in triple negative breast cancer (TNBC) patient derived xenograft (PDX) and cell lines in vitro and in vivo.  Treatment with dinaciclib induced cell cycle arrest at G2/M phase and marked apoptosis.  These changes were accompanied by reduced phosphorylation of CDK1 and retinoblastoma (Rb) protein and decreased protein levels of cyclin B1, cMYC and survivin.  We further demonstrated that siRNA knockdown of CDK9, the kinase subunit of positive transcription elongation factor b (P-TEFb), instead of CDK1 or CDK2, reduced the levels of cyclin B1 and MYC in TNBC cell lines.  These data support the importance of CDK9, in addition to CDK1, in mediating the growth inhibitory effect of dinaciclib in TNBC.  Further investigation of CDK9 as a therapeutic target in TNBC is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2TNpFAv5mrtbHMBt0mMIXfW6udTcc2eZKJ3WSiBi3crntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ntFSguw%253D%253D&md5=766c27ec2b0a446f4e9a35b2a922edb6</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10870%26sid%3Dliteratum%253Aachs%26aulast%3DRajput%26aufirst%3DS.%26aulast%3DKhera%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DHoog%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DC.%2BX.%26atitle%3DInhibition%2520of%2520cyclin%2520dependent%2520kinase%25209%2520by%2520dinaciclib%2520suppresses%2520cyclin%2520B1%2520expression%2520and%2520tumor%2520growth%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DOncotarget.%26date%3D2016%26volume%3D7%26issue%3D35%26spage%3D56864%26epage%3D56875%26doi%3D10.18632%2Foncotarget.10870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Göthert, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imsak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möllmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göbel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dührsen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choidas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dürig, J.</span></span> <span> </span><span class="NLM_article-title">Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia</span>. <i>Oncotarget.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">41</span>),  <span class="NLM_fpage">26353</span>– <span class="NLM_lpage">26369</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.18632%2Foncotarget.25293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29899864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC1MbntVGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=26353-26369&issue=41&author=J.+R.+G%C3%B6thertauthor=R.+Imsakauthor=M.+M%C3%B6llmannauthor=S.+Kesperauthor=M.+G%C3%B6belauthor=U.+D%C3%BChrsenauthor=A.+Scholzauthor=U.+L%C3%BCckingauthor=M.+Baumannauthor=A.+Ungerauthor=C.+Schultz-Fademrechtauthor=B.+Kleblauthor=J.+Eickhoffauthor=A.+Choidasauthor=J.+D%C3%BCrig&title=Potent+anti-leukemic+activity+of+a+specific+cyclin-dependent+kinase+9+inhibitor+in+mouse+models+of+chronic+lymphocytic+leukemia&doi=10.18632%2Foncotarget.25293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia</span></div><div class="casAuthors">Gothert Joachim R; Imsak Roze; Mollmann Michael; Kesper Stefanie; Gobel Maria; Duhrsen Ulrich; Durig Jan; Scholz Arne; Lucking Ulrich; Baumann Matthias; Unger Anke; Schultz-Fademrecht Carsten; Klebl Bert; Eickhoff Jan; Choidas Axel</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">26353-26369</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Onset of progression even during therapy with novel drugs remains an issue in chronic lymphocytic leukemia (CLL).  Thus, there is ongoing demand for novel agents.  Approaches targeting cyclin-dependent kinases (CDK) have reached the clinical trial stage.  CDK9 mediating RNA transcriptional elongation is the evolving pivotal CLL CDK inhibitor target.  However, more CDK9 selective compounds are desirable.  Here, we describe the CDK9 inhibitor LDC526 displaying a low nanomolar biochemical activity against CDK9 and an at least 50-fold selectivity against other CDKs.  After demonstrating in vitro MEC-1 cell line and primary human CLL cell cytotoxicity we evaluated the LDC526 in vivo effect on human CLL cells transplanted into NOD/scid/γc(null) (NSG) mice.  LDC526 administration (75 mg/kg) for 5 days resulted in a 77% reduction of human CLL cells in NSG spleens compared to carrier control treatment.  Next, we longitudinally studied the LDC526 impact on circulating CLL cells in the TCL1 transgenic mouse model.  LDC526 (50 mg/kg) administration for two days led to a 16-fold reduction of blood CLL cell numbers.  Remarkably, residual CLL cells exhibited significantly increased intracellular BCL-2 levels.  However, the LDC526 cytotoxic effect was not restricted to CLL cells as also declining numbers of normal B and T lymphocytes were observed in LDC526 treated TCL1 mice.  Taken together, our in vivo data provide a strong rational for continued LDC526 development in CLL therapy and argue for the combination with BCL-2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFHuzsbtBNX11C8OJBvdfbfW6udTcc2eb6DZs_lNb3S7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbntVGrtA%253D%253D&md5=3f8862deb166fb1e343f0714a538a13b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25293%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B6thert%26aufirst%3DJ.%2BR.%26aulast%3DImsak%26aufirst%3DR.%26aulast%3DM%25C3%25B6llmann%26aufirst%3DM.%26aulast%3DKesper%26aufirst%3DS.%26aulast%3DG%25C3%25B6bel%26aufirst%3DM.%26aulast%3DD%25C3%25BChrsen%26aufirst%3DU.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DD%25C3%25BCrig%26aufirst%3DJ.%26atitle%3DPotent%2520anti-leukemic%2520activity%2520of%2520a%2520specific%2520cyclin-dependent%2520kinase%25209%2520inhibitor%2520in%2520mouse%2520models%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DOncotarget.%26date%3D2018%26volume%3D9%26issue%3D41%26spage%3D26353%26epage%3D26369%26doi%3D10.18632%2Foncotarget.25293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kats, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidacs, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortt, J.</span></span> <span> </span><span class="NLM_article-title">CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1437</span>– <span class="NLM_lpage">1441</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fleu.2015.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25578475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOjt7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=1437-1441&issue=6&author=G.+P.+Gregoryauthor=S.+J.+Hoggauthor=L.+M.+Katsauthor=E.+Vidacsauthor=A.+J.+Bakerauthor=O.+Gilanauthor=M.+Lefebureauthor=B.+P.+Martinauthor=M.+A.+Dawsonauthor=R.+W.+Johnstoneauthor=J.+Shortt&title=CDK9+inhibition+by+dinaciclib+potently+suppresses+Mcl-1+to+induce+durable+apoptotic+responses+in+aggressive+MYC-driven+B-cell+lymphoma+in+vivo&doi=10.1038%2Fleu.2015.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo</span></div><div class="casAuthors">Gregory, G. P.; Hogg, S. J.; Kats, L. M.; Vidacs, E.; Baker, A. J.; Gilan, O.; Lefebure, M.; Martin, B. P.; Dawson, M. A.; Johnstone, R. W.; Shortt, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1437-1441</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8lI6Bulr7brVg90H21EOLACvtfcHk0lhYETJaHjPxuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOjt7bI&md5=2eb8703bec387077e5b2e506b6d281f8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.10%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DG.%2BP.%26aulast%3DHogg%26aufirst%3DS.%2BJ.%26aulast%3DKats%26aufirst%3DL.%2BM.%26aulast%3DVidacs%26aufirst%3DE.%26aulast%3DBaker%26aufirst%3DA.%2BJ.%26aulast%3DGilan%26aufirst%3DO.%26aulast%3DLefebure%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DB.%2BP.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DShortt%26aufirst%3DJ.%26atitle%3DCDK9%2520inhibition%2520by%2520dinaciclib%2520potently%2520suppresses%2520Mcl-1%2520to%2520induce%2520durable%2520apoptotic%2520responses%2520in%2520aggressive%2520MYC-driven%2520B-cell%2520lymphoma%2520in%2520vivo%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26issue%3D6%26spage%3D1437%26epage%3D1441%26doi%3D10.1038%2Fleu.2015.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahaman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokman, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehler, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK9 for treatment of colorectal cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2178</span>– <span class="NLM_lpage">2193</span>, <span class="refDoi"> DOI: 10.1002/1878-0261.12559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1002%2F1878-0261.12559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31398271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXms1Sgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=2178-2193&issue=10&author=M.+H.+Rahamanauthor=F.+Lamauthor=L.+Zhongauthor=T.+Teoauthor=J.+Adamsauthor=M.+Yuauthor=R.+W.+Milneauthor=C.+Pepperauthor=N.+A.+Lokmanauthor=C.+Ricciardelliauthor=M.+K.+Oehlerauthor=S.+Wang&title=Targeting+CDK9+for+treatment+of+colorectal+cancer&doi=10.1002%2F1878-0261.12559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK9 for treatment of colorectal cancer</span></div><div class="casAuthors">Rahaman, Muhammed H.; Lam, Frankie; Zhong, Longjin; Teo, Theodosia; Adams, Julian; Yu, Mingfeng; Milne, Robert W.; Pepper, Chris; Lokman, Noor A.; Ricciardelli, Carmela; Oehler, Martin K.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2178-2193</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1878-0261</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Colorectal cancer (CRC) remains one of the most lethal human malignancies, and pursuit of new therapeutic targets for treatment has been a major research focus.  Cyclin-dependent kinase 9 (CDK9), which plays a crucial role in transcription, has emerged as a target for cancer treatment.  CDKI-73, one of the most potent and pharmacol. superior CDK9 inhibitors, has demonstrated excellent anti-tumor efficacy against several types of cancers.  In this study, we evaluated its therapeutic potential against CRC.  CDKI-73 elicited high cytotoxicity against all colon cancer cell lines tested.  Cell cycle and apoptosis anal. in HCT 116 and HT29 cells revealed that CDKI-73 induced cell death without accumulation of DNA at any phase of the cell cycle.  Moreover, it caused depolarization of mitochondrial membrane, leading to caspase-independent apoptosis.  Knockdown by shRNA demonstrated the CDK9-targeted mechanism of CDKI-73, which also affected the Mnk/eIF4E signaling axis.  In addn., RT-qPCR anal. showed that CDKI-73 down-regulated multiple pro-survival factors at the mRNA level.  Its in vivo anti-tumor efficacy was further evaluated in Balb/c nude mice bearing HCT 116 xenograft tumors.  CDKI-73 significantly inhibited tumor growth (***P < 0.001) without overt toxicity.  Anal. of the tumor tissues collected from the xenografted animals confirmed that the in vivo anti-tumor efficacy was assocd. with CDK9 targeting of CDKI-73.  Overall, this study provides compelling evidence that CDKI-73 is a promising drug candidate for treating colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm7AJZ0UvI1LVg90H21EOLACvtfcHk0lhRP5Dvt1tb-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXms1Sgt7s%253D&md5=8d8ca95e8950eda3588ae729d4447916</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2F1878-0261.12559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1878-0261.12559%26sid%3Dliteratum%253Aachs%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DLokman%26aufirst%3DN.%2BA.%26aulast%3DRicciardelli%26aufirst%3DC.%26aulast%3DOehler%26aufirst%3DM.%2BK.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520CDK9%2520for%2520treatment%2520of%2520colorectal%2520cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2019%26volume%3D13%26issue%3D10%26spage%3D2178%26epage%3D2193%26doi%3D10.1002%2F1878-0261.12559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieerkehazhi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">29090</span>, <span class="refDoi"> DOI: 10.1038/srep29090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fsrep29090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27378523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFahtL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=29090&author=Z.+Chenauthor=Z.+Wangauthor=J.+C.+Pangauthor=Y.+Yuauthor=S.+Bieerkehazhiauthor=J.+Luauthor=T.+Huauthor=Y.+Zhaoauthor=X.+Xuauthor=H.+Zhangauthor=J.+S.+Yiauthor=S.+Liuauthor=J.+Yang&title=Multiple+CDK+inhibitor+dinaciclib+suppresses+neuroblastoma+growth+via+inhibiting+CDK2+and+CDK9+activity&doi=10.1038%2Fsrep29090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity</span></div><div class="casAuthors">Chen, Zhenghu; Wang, Zhenyu; Pang, Jonathan C.; Yu, Yang; Bieerkehazhi, Shayahati; Lu, Jiaxiong; Hu, Ting; Zhao, Yanling; Xu, Xin; Zhang, Hong; Yi, Joanna S.; Liu, Shangfeng; Yang, Jianhua</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29090</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma (NB), the most common extracranial solid tumor of childhood, is responsible for approx. 15% of cancer-related mortality in children.  Aberrant activation of cyclin-dependent kinases (CDKs) has been shown to contribute to tumor cell progression in many cancers including NB.  Therefore, small mol. inhibitors of CDKs comprise a strategic option in cancer therapy.  Here we show that a novel multiple-CDK inhibitor, dinaciclib (SCH727965, MK-7965), exhibits potent anti-proliferative effects on a panel of NB cell lines by blocking the activity of CDK2 and CDK9.  Dinaciclib also significantly sensitized NB cell lines to the treatment of chemotherapeutic agents such as doxorubicin (Dox) and etoposide (VP-16).  Furthermore, dinaciclib revealed in vivo antitumor efficacy in an orthotopic xenograft mouse model of two NB cell lines and blocked tumor development in the TH-MYCN transgenic NB mouse model.  Taken together, this study suggests that CDK2 and CDK9 are potential therapeutic targets in NB and that abrogating CDK2 and CDK9 activity by small mols. like dinaciclib is a promising strategy and a treatment option for NB patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpobqy7FGRmgLVg90H21EOLACvtfcHk0lhRP5Dvt1tb-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFahtL7M&md5=056d13b71230bd6cbe127371ea5ca3f3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fsrep29090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep29090%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DPang%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DBieerkehazhi%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYi%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DMultiple%2520CDK%2520inhibitor%2520dinaciclib%2520suppresses%2520neuroblastoma%2520growth%2520via%2520inhibiting%2520CDK2%2520and%2520CDK9%2520activity%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D29090%26doi%3D10.1038%2Fsrep29090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span> </span><span class="NLM_article-title">Clarivate Analytics Integrity</span>. <a href="https://integrity.clarivate.com" class="extLink">https://integrity.clarivate.com</a> (accessed April 10, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clarivate+Analytics+Integrity.+https%3A%2F%2Fintegrity.clarivate.com+%28accessed+April+10%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DClarivate%2520Analytics%2520Integrity" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanasa, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andritsos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilove, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligaris-Cappio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblond, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bühler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grever, M. R.</span></span> <span> </span><span class="NLM_article-title">Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2015.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.leukres.2015.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25804339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFCis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=495-500&issue=5&author=M.+C.+Lanasaauthor=L.+Andritsosauthor=J.+R.+Brownauthor=J.+Gabriloveauthor=F.+Caligaris-Cappioauthor=P.+Ghiaauthor=R.+A.+Larsonauthor=T.+J.+Kippsauthor=V.+Leblondauthor=D.+W.+Milliganauthor=A.+Janssensauthor=A.+J.+Johnsonauthor=N.+A.+Heeremaauthor=A.+B%C3%BChlerauthor=S.+Stilgenbauerauthor=J.+Devinauthor=M.+Hallekauthor=J.+C.+Byrdauthor=M.+R.+Grever&title=Final+results+of+EFC6663%3A+a+multicenter%2C+international%2C+phase+2+study+of+alvocidib+for+patients+with+fludarabine-refractory+chronic+lymphocytic+leukemia&doi=10.1016%2Fj.leukres.2015.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia</span></div><div class="casAuthors">Lanasa, Mark C.; Andritsos, Leslie; Brown, Jennifer R.; Gabrilove, Janice; Caligaris-Cappio, Federico; Ghia, Paolo; Larson, Richard A.; Kipps, Thomas J.; Leblond, Veronique; Milligan, Donald W.; Janssens, Ann; Johnson, Amy J.; Heerema, Nyla A.; Buhler, Andreas; Stilgenbauer, Stephan; Devin, Jeanne; Hallek, Michael; Byrd, John C.; Grever, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">495-500</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Early phase studies of alvocidib showed activity in relapsed CLL including patients with high risk genomic features and those refractory to fludarabine.  A multi-center, international, phase II study of alvocidib in fludarabine refractory CLL was undertaken to validate these early results.  Patients with fludarabine refractory CLL or prolymphocytic leukemia arising from CLL were treated with single agent alvocidib.  The primary outcome measure was overall response rate, with secondary outcomes including survival, toxicity, and response duration.  One hundred and sixty five patients were enrolled and 159 patients were treated.  The median age was 61 years, the median no. of prior therapies was 4, and 96% of patients were fludarabine refractory.  The investigator-assessed overall response rate was 25%; the majority of responses were partial.  Response rates were lower among patients with del(17p) (14%), but equiv. in patients with del(11q) or bulky lymphadenopathy.  Median progression free and overall survival were 7.6 and 14.6 mo, resp.  Tumor lysis occurred in 39 patients (25%), and 13 received hemodialysis.  Diarrhea, fatigue, and hematol. toxicities were common.  Alvocidib has clin. activity in patients with advanced, fludarabine refractory CLL.  Future studies should focus on discovery of biomarkers of clin. response and tumor lysis, and enhanced supportive care measures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNLlMqLBd2m7Vg90H21EOLACvtfcHk0lhwjBpfGsTnig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFCis7c%253D&md5=3f3c902b0c772666192142ffd71d1c4f</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2015.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2015.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DLanasa%26aufirst%3DM.%2BC.%26aulast%3DAndritsos%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DGabrilove%26aufirst%3DJ.%26aulast%3DCaligaris-Cappio%26aufirst%3DF.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DLeblond%26aufirst%3DV.%26aulast%3DMilligan%26aufirst%3DD.%2BW.%26aulast%3DJanssens%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DB%25C3%25BChler%26aufirst%3DA.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDevin%26aufirst%3DJ.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26atitle%3DFinal%2520results%2520of%2520EFC6663%253A%2520a%2520multicenter%252C%2520international%252C%2520phase%25202%2520study%2520of%2520alvocidib%2520for%2520patients%2520with%2520fludarabine-refractory%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26issue%3D5%26spage%3D495%26epage%3D500%26doi%3D10.1016%2Fj.leukres.2015.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steward, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bono, J.</span></span> <span> </span><span class="NLM_article-title">A phase I dose escalation study of the pharmacokinetics and tolerability of ZK304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.1007/s00280-009-0968-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs00280-009-0968-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=19280191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1agurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2009&pages=425-429&issue=2&author=E.+N.+Scottauthor=A.+L.+Thomasauthor=L.+R.+Molifeauthor=S.+Ahmedauthor=S.+Blagdenauthor=P.+C.+Fongauthor=K.+Kowalauthor=C.+McCoyauthor=H.+Wiesingerauthor=W.+Stewardauthor=J.+De+Bono&title=A+phase+I+dose+escalation+study+of+the+pharmacokinetics+and+tolerability+of+ZK304709%2C+an+oral+multi-targeted+growth+inhibitor+%28MTGI%29%2C+in+patients+with+advanced+solid+tumours&doi=10.1007%2Fs00280-009-0968-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours</span></div><div class="casAuthors">Scott, Edwina N.; Thomas, Anne L.; Molife, L. Rhoda; Ahmed, Samreen; Blagden, Sarah; Fong, Peter C.; Kowal, Kristin; McCoy, Candice; Wiesinger, Herbert; Steward, Will; De Bono, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">425-429</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The toxicities, pharmacokinetics and recommended dose of oral once daily ZK 304709, a novel multi-targeted growth inhibitor (MTGI) with activity against cell-cycle progression and angiogenesis, was investigated in patients by administration for 14 consecutive days followed by 14 days recovery.  Methods: Patients with solid tumors resistant to std. treatments were enrolled in an accelerated titrn. design.  Results: Thirty-seven patients received ZK 304709 from 15 to 285 mg daily.  The most common drug-related adverse events were vomiting, diarrhea and fatigue.  Systemic exposure to ZK 304709 increased with dose up to 90 mg daily but plateaued thereafter, with high inter-individual variability at all doses.  Thirteen patients had stable disease as best response as per RECIST criteria.  Conclusions: There was no increase in exposure to ZK 304709 with dose escalation above 90 mg, and the MTD was not detd.  This study illustrates the importance of phase I pharmacokinetic data to guide dose escalation and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWHmxGlOkQx7Vg90H21EOLACvtfcHk0ljgwI0qd6DelA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1agurk%253D&md5=fe0e50036e3fc15838425c5f52e30426</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2Fs00280-009-0968-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-009-0968-y%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DE.%2BN.%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DBlagden%26aufirst%3DS.%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DKowal%26aufirst%3DK.%26aulast%3DMcCoy%26aufirst%3DC.%26aulast%3DWiesinger%26aufirst%3DH.%26aulast%3DSteward%26aufirst%3DW.%26aulast%3DDe%2BBono%26aufirst%3DJ.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520the%2520pharmacokinetics%2520and%2520tolerability%2520of%2520ZK304709%252C%2520an%2520oral%2520multi-targeted%2520growth%2520inhibitor%2520%2528MTGI%2529%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D64%26issue%3D2%26spage%3D425%26epage%3D429%26doi%3D10.1007%2Fs00280-009-0968-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dy, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span> <span> </span><span class="NLM_article-title">Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.lungcan.2018.04.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30089585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BB3c7mt1yrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2018&pages=14-21&author=B.+C.+Choauthor=G.+K.+Dyauthor=R.+Govindanauthor=D.+W.+Kimauthor=N.+A.+Pennellauthor=G.+Zalcmanauthor=B.+Besseauthor=J.+H.+Kimauthor=G.+Kocaauthor=P.+Rajagopalanauthor=S.+Langerauthor=M.+Ockerauthor=H.+Nogaiauthor=F.+Barlesi&title=Phase+Ib%2FII+study+of+the+pan-cyclin-dependent+kinase+inhibitor+roniciclib+in+combination+with+chemotherapy+in+patients+with+extensive-disease+small-cell+lung+cancer&doi=10.1016%2Fj.lungcan.2018.04.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer</span></div><div class="casAuthors">Cho Byoung Chul; Dy Grace K; Govindan Ramaswamy; Kim Dong-Wan; Pennell Nathan A; Zalcman Gerard; Besse Benjamin; Kim Joo-Hang; Koca Goekben; Ocker Matthias; Nogai Hendrik; Rajagopalan Prabhu; Langer Simon; Barlesi Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  This phase Ib/II study evaluated safety, pharmacokinetics, maximum tolerated dose (MTD), and efficacy of the pan-cyclin-dependent kinase inhibitor roniciclib with cisplatin-etoposide (CIS-ETOP) or carboplatin-etoposide (CARBO-ETOP) in patients with extensive-disease small-cell lung cancer (ED-SCLC).  PATIENTS AND METHODS:  In this open-label, non-randomized study, patients with previously untreated ED-SCLC received roniciclib twice daily (BID) in a 3 days on/4 days off schedule.  Cisplatin 75 mg/m(2) or carboplatin (AUC5) dose was administered on day 1, and etoposide 100 mg/m(2) on days 1-3, of 21-day cycles.  Phase Ib used a dose-escalation design to define the MTD for phase II.  Pharmacokinetics were assessed.  RESULTS:  Forty-three patients received treatment (roniciclib 2.5 mg BID [+ CARBO-ETOP, n = 4; + CIS-ETOP, n = 3] and roniciclib 5 mg BID [+ CARBO-ETOP, n = 24; + CIS-ETOP, n = 12]).  The MTD of roniciclib was 5 mg BID with CARBO-ETOP or CIS-ETOP.  Common adverse events were nausea (90.7%) and vomiting (69.8%).  Roniciclib was readily absorbed following oral administration at the MTD (median tmax 0.5-1 h), with a 30-40% reduction in exposure when co-administered with CARBO-ETOP or CIS-ETOP; administration of roniciclib had no effect on etoposide or platinum pharmacokinetics.  The response rate was 81.4% (35/43) overall and 86.1% (31/36) in the pooled roniciclib 5 mg BID population (all partial responses).  CONCLUSION:  Roniciclib co-administered with chemotherapy in patients with ED-SCLC demonstrated tolerability, acceptable pharmacokinetics, and promising efficacy.  An observed safety signal in a related phase II study resulted in discontinuation of the present study and termination of further roniciclib development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS891qx-r3xr-b6AVA-44PTfW6udTcc2eZBOQCoct9iPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7mt1yrtg%253D%253D&md5=ec4e685886d5caf2a6db31b0364cdc2b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DDy%26aufirst%3DG.%2BK.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DPennell%26aufirst%3DN.%2BA.%26aulast%3DZalcman%26aufirst%3DG.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKoca%26aufirst%3DG.%26aulast%3DRajagopalan%26aufirst%3DP.%26aulast%3DLanger%26aufirst%3DS.%26aulast%3DOcker%26aufirst%3DM.%26aulast%3DNogai%26aufirst%3DH.%26aulast%3DBarlesi%26aufirst%3DF.%26atitle%3DPhase%2520Ib%252FII%2520study%2520of%2520the%2520pan-cyclin-dependent%2520kinase%2520inhibitor%2520roniciclib%2520in%2520combination%2520with%2520chemotherapy%2520in%2520patients%2520with%2520extensive-disease%2520small-cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer.%26date%3D2018%26volume%3D123%26spage%3D14%26epage%3D21%26doi%3D10.1016%2Fj.lungcan.2018.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPlant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callander, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlichman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span> <span> </span><span class="NLM_article-title">Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-05-573741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1182%2Fblood-2014-05-573741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25395429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=443-448&issue=3&author=S.+K.+Kumarauthor=B.+LaPlantauthor=W.+J.+Chngauthor=J.+Zonderauthor=N.+Callanderauthor=R.+Fonsecaauthor=B.+Fruthauthor=V.+Royauthor=C.+Erlichmanauthor=A.+K.+Stewart&title=Dinaciclib%2C+a+novel+CDK+inhibitor%2C+demonstrates+encouraging+single-agent+activity+in+patients+with+relapsed+multiple+myeloma&doi=10.1182%2Fblood-2014-05-573741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma</span></div><div class="casAuthors">Kumar, Shaji K.; La Plant, Betsy; Chng, Wee Joo; Zonder, Jeffrey; Callander, Natalie; Fonseca, Rafael; Fruth, Briant; Roy, Vivek; Erlichman, Charles; Stewart, A. Keith</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-448</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Dysregulation of cyclin-dependent kinases is a hallmark of myeloma, and specifically, cdk5 inhibition can enhance the activity of proteasome inhibitors in vitro.  Dinaciclib is a novel potent small mol. inhibitor of cyclin-dependent kinases (CDK)1, CDK2, CDK5, and CDK9.  Patients with relapsed multiple myeloma and ≤5 prior lines of therapy, with measurable disease, were enrolled.  Dinaciclib was administered on day 1 of a 21-day cycle at doses of 30 to 50 mg/m2.  Overall, 27 evaluable patients were accrued; the median no. of prior therapies was 4.  The dose level of 50 mg/m2 was detd. to be the maximally tolerated dose.  The overall confirmed partial response rate (PR) was 3 of 27 (11%), including 1 patient at the 30 mg/m2 dose (1 very good PR [VGPR]) and 2 patients at the 40 mg/m2 dose (1 VGPR and 1 PR).  In addn., 2 patients at the 50 mg/mg2 dose achieved a minimal response (clin. benefit rate, 19%).  Leukopenia, thrombocytopenia, gastrointestinal symptoms, alopecia, and fatigue were the most common adverse events.  The current study demonstrates single agent activity of dinaciclib in relapsed myeloma, with 2 patients achieving a deep response (VGPR) and 10 patients obtaining some degree of M protein stabilization or decrease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEP0lWUMq1_LVg90H21EOLACvtfcHk0ljgwI0qd6DelA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWms7k%253D&md5=22197956e071e38d29efb7c2fdcd707a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-05-573741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-05-573741%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%2BK.%26aulast%3DLaPlant%26aufirst%3DB.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DZonder%26aufirst%3DJ.%26aulast%3DCallander%26aufirst%3DN.%26aulast%3DFonseca%26aufirst%3DR.%26aulast%3DFruth%26aufirst%3DB.%26aulast%3DRoy%26aufirst%3DV.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26atitle%3DDinaciclib%252C%2520a%2520novel%2520CDK%2520inhibitor%252C%2520demonstrates%2520encouraging%2520single-agent%2520activity%2520in%2520patients%2520with%2520relapsed%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26issue%3D3%26spage%3D443%26epage%3D448%26doi%3D10.1182%2Fblood-2014-05-573741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankhala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jou, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statkevich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, C. L.</span></span> <span> </span><span class="NLM_article-title">Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2013.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.clbc.2013.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24393852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVWrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=169-176&issue=3&author=M.+M.+Mitaauthor=A.+A.+Joyauthor=A.+Mitaauthor=K.+Sankhalaauthor=Y.+M.+Jouauthor=D.+Zhangauthor=P.+Statkevichauthor=Y.+Zhuauthor=S.+L.+Yaoauthor=K.+Smallauthor=R.+Bannerjiauthor=C.+L.+Shapiro&title=Randomized+phase+II+trial+of+the+cyclin-dependent+kinase+inhibitor+dinaciclib+%28MK-7965%29+versus+capecitabine+in+patients+with+advanced+breast+cancer&doi=10.1016%2Fj.clbc.2013.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer</span></div><div class="casAuthors">Mita, Monica M.; Joy, Anil A.; Mita, Alain; Sankhala, Kamalesh; Jou, Ying-Ming; Zhang, Da; Statkevich, Paul; Zhu, Yali; Yao, Siu-Long; Small, Karen; Bannerji, Rajat; Shapiro, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-176</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: Effective therapies after failure of treatment with anthracyclines and taxanes are needed for patients with metastatic breast cancer.  Dinaciclib (MK-7965, formerly SCH727965), a small-mol. cyclin-dependent kinase inhibitor, has demonstrated antitumor activity in phase I studies with solid-tumor patients.  This phase II trial was designed to assess the efficacy and safety of dinaciclib compared with that of capecitabine in women with previously treated advanced breast cancer.  Patients and Methods: Patients were randomized to receive either dinaciclib at 50 mg/m2, administered as a 2-h infusion every 21 days, or 1250 mg/m2 capecitabine, administered orally twice daily in 21-day cycles.  Results: An unplanned interim anal. showed that the time to disease progression was inferior with dinaciclib treatment compared with capecitabine treatment; therefore, the trial was stopped after 30 patients were randomized.  Dinaciclib treatment demonstrated antitumor activity in 2 of 7 patients with estrogen receptor-pos. and human epidermal growth factor receptor 2-neg. metastatic breast cancer (1 confirmed and 1 unconfirmed partial response), as well as acceptable safety and tolerability.  Grade 3 or 4 treatment-related adverse events were common and included neutropenia, leukopenia, increase in aspartate aminotransferase, and febrile neutropenia.  Population pharmacokinetic model-predicted mean dinaciclib exposure (area under the concn.-time curve extrapolated to infinity [AUC[I]]) at 50 mg/m2 was similar to that obsd. in a previous phase I trial, and no drug accumulation was obsd. after multiple-dose administration.  Conclusion: Although dinaciclib monotherapy demonstrated some antitumor activity and was generally tolerated, efficacy was not superior to capecitabine.  Future studies may be considered to evaluate dinaciclib in select patient populations with metastatic breast cancer and in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetvZlPAou-LVg90H21EOLACvtfcHk0ljDULHdJcvD9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVWrtQ%253D%253D&md5=5f91dd3e13e17bac5c9bbb227ed1a107</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2013.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2013.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DJoy%26aufirst%3DA.%2BA.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DSankhala%26aufirst%3DK.%26aulast%3DJou%26aufirst%3DY.%2BM.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DS.%2BL.%26aulast%3DSmall%26aufirst%3DK.%26aulast%3DBannerji%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DC.%2BL.%26atitle%3DRandomized%2520phase%2520II%2520trial%2520of%2520the%2520cyclin-dependent%2520kinase%2520inhibitor%2520dinaciclib%2520%2528MK-7965%2529%2520versus%2520capecitabine%2520in%2520patients%2520with%2520advanced%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D3%26spage%3D169%26epage%3D176%26doi%3D10.1016%2Fj.clbc.2013.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemunaitis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jou, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statkevich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, M. J.</span></span> <span> </span><span class="NLM_article-title">Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinibin patients with non-small cell lung cancer</span>. <i>Lung Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2013.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.lungcan.2013.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24388167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2czhslKktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=219-223&issue=2&author=J.+J.+Stephensonauthor=J.+Nemunaitisauthor=A.+A.+Joyauthor=J.+C.+Martinauthor=Y.+M.+Jouauthor=D.+Zhangauthor=P.+Statkevichauthor=S.+L.+Yaoauthor=Y.+Zhuauthor=H.+Zhouauthor=K.+Smallauthor=R.+Bannerjiauthor=M.+J.+Edelman&title=Randomized+phase+2+study+of+the+cyclin-dependent+kinase+inhibitor+dinaciclib+%28MK-7965%29+versus+erlotinibin+patients+with+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2013.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer</span></div><div class="casAuthors">Stephenson Joe J; Martin Julie C; Nemunaitis John; Joy Anil A; Jou Ying-Ming; Zhang Da; Statkevich Paul; Yao Siu-Long; Zhu Yali; Zhou Honghong; Small Karen; Bannerji Rajat; Edelman Martin J</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclin-dependent kinases, has been shown to induce apoptosis in preclinical studies of human tumor cell lines, including non-small cell lung cancer (NSCLC) cells.  Erlotinib, an epidermal growth factor receptor inhibitor, is approved for the treatment of advanced NSCLC as second- or third-line therapy.  This phase 2, randomized, multicenter, open-label study compared dinaciclib with erlotinib in patients with previously treated NSCLC.  MATERIALS AND METHODS:  The study was comprised of 2 parts: in part 1, patients were randomized to either intravenous (IV) dinaciclib (50 mg/m2) or oral erlotinib (150 mg) using an adaptive Bayesian design that adjusted the randomization ratio in favor of the more active arm, and in part 2, patients who had progressed on erlotinib were permitted to cross over to receive dinaciclib at the same dosage as in part 1.  Patients were followed until disease progression or death, initiation of nonstudy cancer treatment, discontinuation, or withdrawal of consent.  The primary efficacy end point was time-to-progression (TTP) in part 1 and objective response rate (ORR) in part 2.  RESULTS:  Based on Kaplan-Meier estimates, the median TTP was 1.49 months (95% confidence interval [CI]: 1.31, 2.63) following initial treatment with dinaciclib, compared with 1.58 months (95% CI: 1.38, 2.83) with erlotinib.  No objective responses were observed following initial treatment with dinaciclib.  Common severe (grade 3 or 4) drug-related adverse effects included neutropenia, leukopenia, vomiting, and diarrhea.  CONCLUSIONS:  Dinaciclib, administered IV, was well tolerated at the 50 mg/m2 dose, but does not have activity as monotherapy in previously treated NSCLC.  Evaluation of dinaciclib in combination with other agents for other indications including breast cancer and multiple myeloma is in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRk6FO2RHT0FysZ1x6zOs0vfW6udTcc2eZM9WVQM-HhlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czhslKktQ%253D%253D&md5=684ef1bc79de64b1b0c7f9427ffe0c27</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2013.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2013.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DStephenson%26aufirst%3DJ.%2BJ.%26aulast%3DNemunaitis%26aufirst%3DJ.%26aulast%3DJoy%26aufirst%3DA.%2BA.%26aulast%3DMartin%26aufirst%3DJ.%2BC.%26aulast%3DJou%26aufirst%3DY.%2BM.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DYao%26aufirst%3DS.%2BL.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSmall%26aufirst%3DK.%26aulast%3DBannerji%26aufirst%3DR.%26aulast%3DEdelman%26aufirst%3DM.%2BJ.%26atitle%3DRandomized%2520phase%25202%2520study%2520of%2520the%2520cyclin-dependent%2520kinase%2520inhibitor%2520dinaciclib%2520%2528MK-7965%2529%2520versus%2520erlotinibin%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer.%26date%3D2014%26volume%3D83%26issue%3D2%26spage%3D219%26epage%3D223%26doi%3D10.1016%2Fj.lungcan.2013.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gojo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jou, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerji, R.</span></span> <span> </span><span class="NLM_article-title">Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) in acute leukemias</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2249-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs00280-013-2249-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=23949430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12ju73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=897-908&issue=4&author=I.+Gojoauthor=M.+Sadowskaauthor=A.+Walkerauthor=E.+J.+Feldmanauthor=S.+P.+Iyerauthor=M.+R.+Baerauthor=E.+A.+Sausvilleauthor=R.+G.+Lapidusauthor=D.+Zhangauthor=Y.+Zhuauthor=Y.+M.+Jouauthor=J.+Poonauthor=K.+Smallauthor=R.+Bannerji&title=Clinical+and+laboratory+studies+of+the+novel+cyclin-dependent+kinase+inhibitor+dinaciclib+%28SCH727965%29+in+acute+leukemias&doi=10.1007%2Fs00280-013-2249-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias</span></div><div class="casAuthors">Gojo, Ivana; Sadowska, Mariola; Walker, Alison; Feldman, Eric J.; Iyer, Swaminathan Padmanabhan; Baer, Maria R.; Sausville, Edward A.; Lapidus, Rena G.; Zhang, Da; Zhu, Yali; Jou, Ying-Ming; Poon, Jennifer; Small, Karen; Bannerji, Rajat</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">897-908</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Dinaciclib inhibits cyclin-dependent kinases 1, 2, 5, and 9 with a better therapeutic index than flavopiridol in preclin. studies.  This study assessed the activity of dinaciclib in acute leukemia both in the clinic and in vitro.  Methods: Adults with relapsed/refractory acute myeloid leukemia (n = 14) and acute lymphoid leukemia (n = 6) were treated with dinaciclib 50 mg/m2 given as a 2-h infusion every 21 days.  Results: Most patients had dramatic but transient redn. in circulating blasts; however, no remissions were achieved on this schedule.  The most common toxicities were gastrointestinal, fatigue, transaminitis, and clin. and lab. manifestations of tumor lysis syndrome, including one patient who died of acute renal failure.  Dinaciclib pharmacokinetics showed rapid (2 h) achievement of max. concn. and a short elimination/distribution phase.  Pharmacodynamic studies demonstrated in vivo inhibition of Mcl-1 expression and induction of PARP cleavage in patients' peripheral blood mononuclear cells 4 h after dinaciclib infusion, but the effects were lost by 24 h and did not correlate with clin. outcome.  Correlative in vitro studies showed that prolonged exposures to dinaciclib, at clin. attainable concns., result in improved leukemia cell kill.  Conclusions: While dinaciclib given as a 2-h bolus did not exhibit durable clin. activity, pharmacokinetic and pharmacodynamic data support the exploration of prolonged infusion schedules in future trials in patients with acute leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-GXoS2RFuB7Vg90H21EOLACvtfcHk0lgP7m3JFPD1jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12ju73N&md5=1a89e1dc02b664e76472cd7d197a029f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2249-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2249-z%26sid%3Dliteratum%253Aachs%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DSadowska%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DFeldman%26aufirst%3DE.%2BJ.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DJou%26aufirst%3DY.%2BM.%26aulast%3DPoon%26aufirst%3DJ.%26aulast%3DSmall%26aufirst%3DK.%26aulast%3DBannerji%26aufirst%3DR.%26atitle%3DClinical%2520and%2520laboratory%2520studies%2520of%2520the%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%2520dinaciclib%2520%2528SCH727965%2529%2520in%2520acute%2520leukemias%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D72%26issue%3D4%26spage%3D897%26epage%3D908%26doi%3D10.1007%2Fs00280-013-2249-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bible, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martell, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelman, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorusso, P. M.</span></span> <span> </span><span class="NLM_article-title">A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1007/s10637-007-9090-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs10637-007-9090-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=17938863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1aruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=59-65&issue=1&author=E.+I.+Heathauthor=K.+Bibleauthor=R.+E.+Martellauthor=D.+C.+Adelmanauthor=P.+M.+Lorusso&title=A+phase+1+study+of+SNS-032+%28formerly+BMS-387032%29%2C+a+potent+inhibitor+of+cyclin-dependent+kinases+2%2C+7+and+9+administered+as+a+single+oral+dose+and+weekly+infusion+in+patients+with+metastatic+refractory+solid+tumors&doi=10.1007%2Fs10637-007-9090-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors</span></div><div class="casAuthors">Heath, Elisabeth I.; Bible, Keith; Martell, Robert E.; Adelman, Daniel C.; LoRusso, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-65</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: SNS-032, (formerly BMS-387032) is a potent and selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9.  The primary objective of the study was to establish the max. tolerated dose (MTD), the max. administered dose (MAD), dose limiting toxicity (DLT), and the recommended phase 2 dose for SNS-032 when administered as a weekly 1-h infusion.  The secondary objective was to assess the safety and tolerability of SNS-032 and to evaluate its bioavailability as an oral soln.  Methods: Patients with metastatic solid tumors or refractory lymphoma were treated with a starting dose of 4 mg/m2 i.v. administered over 1-h with a cycle defined as 3 weekly doses of SNS-032 every 21 days.  Three patient cohorts were utilized in the dose-escalation schema.  Pharmacokinetic studies were performed.  For the 13 and 16 mg/m2 dose cohorts, the first dose of cycle 2 was given as an oral soln. to est. the oral bioavailability of the drug in humans.  Results: A total of 21 patients were enrolled.  Twenty treated patients received a total of 39 cycles of treatment.  The most common treatment-related adverse events occurring with greater than 20% incidence were fatigue (25%) and nausea (20%).  Following i.v. administration, plasma concns. declined in a biphasic manner, resulting in mean terminal half-lives between 5 and 10 h.  The mean Cmax and AUC0-inf increased nearly linearly with dose, ranging from 0.067 to 0.287 μg/mL and 0.103 to 0.553 μg h/mL, resp.  The CL and Vss remained unchanged with increasing dose levels, averaging 38 l/h/m2 and 212 l/m2, resp.  Av. oral bioavailability was 19% (range: 4-33%).  Three (15%) patients experienced a best response of stable disease.  Study enrollment was terminated during dose-escalation due to a change in the development strategy for the study drug.  Conclusions: SNS-032 administered as a weekly 1-h infusion was well tolerated, although study enrollment was terminated during dose-escalation and the MTD of SNS-032 administered i.v. on days 1, 8, and 15 of each treatment cycle was not reached.  Tumor progression or stable disease was detd. to be the best response in all evaluable patients.  At the dose levels tested, the oral bioavailability of SNS-032 ranged from 4-33%.  The data suggest that oral administration of SNS-032 may be feasible, though the tolerability and bioavailability of the oral formulation would have to be formally assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUIS2yPNOYJLVg90H21EOLACvtfcHk0lgP7m3JFPD1jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1aruw%253D%253D&md5=bb1a9d0365b230fc2408b957a692a2e8</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs10637-007-9090-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-007-9090-3%26sid%3Dliteratum%253Aachs%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DBible%26aufirst%3DK.%26aulast%3DMartell%26aufirst%3DR.%2BE.%26aulast%3DAdelman%26aufirst%3DD.%2BC.%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26atitle%3DA%2520phase%25201%2520study%2520of%2520SNS-032%2520%2528formerly%2520BMS-387032%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520cyclin-dependent%2520kinases%25202%252C%25207%2520and%25209%2520administered%2520as%2520a%2520single%2520oral%2520dose%2520and%2520weekly%2520infusion%2520in%2520patients%2520with%2520metastatic%2520refractory%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26issue%3D1%26spage%3D59%26epage%3D65%26doi%3D10.1007%2Fs10637-007-9090-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantzaris, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wermke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordoba, R.</span></span> <span> </span><span class="NLM_article-title">Phase I study of the P-TEFb inhibitor BAY 1251152 in patients with acute myelogenous leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">4055</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-99-117257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1182%2Fblood-2018-99-117257" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=4055&author=M.+Byrneauthor=M.+G.+Frattiniauthor=O.+G.+Ottmannauthor=I.+Mantzarisauthor=M.+Wermkeauthor=D.+J.+Leeauthor=D.+Morilloauthor=A.+Scholzauthor=S.+Inceauthor=R.+Valenciaauthor=F.+Souzaauthor=R.+Cordoba&title=Phase+I+study+of+the+P-TEFb+inhibitor+BAY+1251152+in+patients+with+acute+myelogenous+leukemia&doi=10.1182%2Fblood-2018-99-117257"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-99-117257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-99-117257%26sid%3Dliteratum%253Aachs%26aulast%3DByrne%26aufirst%3DM.%26aulast%3DFrattini%26aufirst%3DM.%2BG.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DMantzaris%26aufirst%3DI.%26aulast%3DWermke%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DD.%2BJ.%26aulast%3DMorillo%26aufirst%3DD.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DInce%26aufirst%3DS.%26aulast%3DValencia%26aufirst%3DR.%26aulast%3DSouza%26aufirst%3DF.%26aulast%3DCordoba%26aufirst%3DR.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520P-TEFb%2520inhibitor%2520BAY%25201251152%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26spage%3D4055%26doi%3D10.1182%2Fblood-2018-99-117257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troiani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span> <span> </span><span class="NLM_article-title">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1907</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.1038/emboj.2008.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Femboj.2008.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=18566585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1907-1918&author=S.+Baumliauthor=G.+Lolliauthor=E.+D.+Loweauthor=S.+Troianiauthor=L.+Rusconiauthor=A.+N.+Bullockauthor=J.+E.+Debreczeniauthor=S.+Knappauthor=L.+N.+Johnson&title=The+structure+of+P-TEFb+%28CDK9%2Fcyclin+T1%29%2C+its+complex+with+flavopiridol+and+regulation+by+phosphorylation&doi=10.1038%2Femboj.2008.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span></div><div class="casAuthors">Baumli, Sonja; Lolli, Graziano; Lowe, Edward D.; Troiani, Sonia; Rusconi, Luisa; Bullock, Alex N.; Debreczeni, Judit E.; Knapp, Stefan; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1907-1918</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pos. transcription elongation factor b (P-TEFb) (CDK9/cyclin T (CycT)) promotes mRNA transcriptional elongation through phosphorylation of elongation repressors and RNA polymerase II.  To understand the regulation of a transcriptional CDK by its cognate cyclin, we have detd. the structures of the CDK9/CycT1 and free cyclin T2.  There are distinct differences between CDK9/CycT1 and the cell cycle CDK CDK2/CycA manifested by a relative rotation of 26° of CycT1 with respect to the CDK, showing for the first time plasticity in CDK cyclin interactions.  The CDK9/CycT1 interface is relatively sparse but retains some core CDK-cyclin interactions.  The CycT1 C-terminal helix shows flexibility that may be important for the interaction of this region with HIV TAT and HEXIM.  Flavopiridol, an anticancer drug in phase II clin. trials, binds to the ATP site of CDK9, inducing unanticipated structural changes that bury the inhibitor.  CDK9 activity and recognition of regulatory proteins are governed by autophosphorylation.  We show that CDK9/CycT1 autophosphorylates on Thr186 in the activation segment and three C-terminal phosphorylation sites.  Autophosphorylation on all sites occurs in cis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG2808s0tnBrVg90H21EOLACvtfcHk0ljLbboFqrsJtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D&md5=c28cc6d1c178c79a12cfab03da9c45dc</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Femboj.2008.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2008.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLolli%26aufirst%3DG.%26aulast%3DLowe%26aufirst%3DE.%2BD.%26aulast%3DTroiani%26aufirst%3DS.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520structure%2520of%2520P-TEFb%2520%2528CDK9%252Fcyclin%2520T1%2529%252C%2520its%2520complex%2520with%2520flavopiridol%2520and%2520regulation%2520by%2520phosphorylation%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D1907%26epage%3D1918%26doi%3D10.1038%2Femboj.2008.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deep, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marwaha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marwaha, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jyoti</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. K.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review</span>. <i>New J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">18500</span>– <span class="NLM_lpage">18507</span>, <span class="refDoi"> DOI: 10.1039/C8NJ04306J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1039%2FC8NJ04306J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCjsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2018&pages=18500-18507&issue=23&author=A.+Deepauthor=R.+K.+Marwahaauthor=M.+G.+Marwahaauthor=+Jyotiauthor=R.+Nandalauthor=A.+K.+Sharma&title=Flavopiridol+as+cyclin+dependent+kinase+%28CDK%29+inhibitor%3A+a+review&doi=10.1039%2FC8NJ04306J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review</span></div><div class="casAuthors">Deep, Aakash; Marwaha, Rakesh Kumar; Marwaha, Minakshi Gupta; Jyoti; Nandal, Rimmy; Sharma, Arun Kumar</div><div class="citationInfo"><span class="NLM_cas:title">New Journal of Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">18500-18507</span>CODEN:
                <span class="NLM_cas:coden">NJCHE5</span>;
        ISSN:<span class="NLM_cas:issn">1144-0546</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Flavopiridol (alvocidib) is a synthetic flavonoid based on the ext. from an Indian plant developed for potential treatment of cancer whose first clin. trials were initiated in 1994 as a frontline combination therapy for leukemia.  It is a potent Cyclin Dependent Kinase (CDK) inhibitor with preferential activity against CDK9.  Several phase I and II trials using flavopiridol as a single agent and in combination with std. chemotherapeutic regimens and various tumor types are ongoing.  Moreover, the combination of flavopiridol with gemcitabine, imatinib mesylate, SN-38 (the active metabolite of CPT-11) and doxorubicin show synergistic therapeutic effect in inducing mortality of cancer cells.  Present study enlightens the individual and combined therapeutic and toxic profiles of flavopiridol.  The synthesis, mechanism of action, preclin. and clin. outcomes of flavopiridol till date have been discussed in the current study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoue28qb_LpSLVg90H21EOLACvtfcHk0ljLbboFqrsJtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCjsrrI&md5=369de8cacbf78af0e858a2324969ce9a</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1039%2FC8NJ04306J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8NJ04306J%26sid%3Dliteratum%253Aachs%26aulast%3DDeep%26aufirst%3DA.%26aulast%3DMarwaha%26aufirst%3DR.%2BK.%26aulast%3DMarwaha%26aufirst%3DM.%2BG.%26aulast%3DJyoti%26aulast%3DNandal%26aufirst%3DR.%26aulast%3DSharma%26aufirst%3DA.%2BK.%26atitle%3DFlavopiridol%2520as%2520cyclin%2520dependent%2520kinase%2520%2528CDK%2529%2520inhibitor%253A%2520a%2520review%26jtitle%3DNew%2520J.%2520Chem.%26date%3D2018%26volume%3D42%26issue%3D23%26spage%3D18500%26epage%3D18507%26doi%3D10.1039%2FC8NJ04306J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srikumar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, J.</span></span> <span> </span><span class="NLM_article-title">Potential use of flavopiridol in treatment of chronic diseases</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>929</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-41342-6_9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2F978-3-319-41342-6_9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27771926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1artr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=929&publication_year=2016&pages=209-228&author=T.+Srikumarauthor=J.+Padmanabhan&title=Potential+use+of+flavopiridol+in+treatment+of+chronic+diseases&doi=10.1007%2F978-3-319-41342-6_9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Potential Use of Flavopiridol in Treatment of Chronic Diseases</span></div><div class="casAuthors">Srikumar, Thejal; Padmanabhan, Jaya</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">929</span>
        (<span class="NLM_cas:issue">Drug Discovery from Mother Nature</span>),
    <span class="NLM_cas:pages">209-228</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This chapter describes the potential use of flavopiridol, a CDK inhibitor with anti-inflammatory and anti-proliferative activities, in the treatment of various chronic diseases.  Flavopiridol arrests cell cycle progression in the G1 or G2 phase by inhibiting the kinase activities of CDK1, CDK2, CDK4/6, and CDK7.  Addnl., it binds tightly to CDK9, a component of the P-TEFb complex (CDK9/cyclin T), and interferes with RNA polymerase II activation and assocd. transcription.  This in turn inhibits expression of several pro-survival and anti-apoptotic genes, and enhances cytotoxicity in transformed cells or differentiation in growth-arrested cells.  Recent studies indicate that flavopiridol elicits anti-inflammatory activity via CDK9 and NFκB-dependent signaling.  Overall, these effects of flavopiridol potentiate its ability to overcome aberrant cell cycle activation and/or inflammatory stimuli, which are mediators of various chronic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobJrum2VChk7Vg90H21EOLACvtfcHk0ljw0eO8fFIj5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1artr%252FP&md5=1a4de78c8b6c7c47f042fc5da4279a8a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-41342-6_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-41342-6_9%26sid%3Dliteratum%253Aachs%26aulast%3DSrikumar%26aufirst%3DT.%26aulast%3DPadmanabhan%26aufirst%3DJ.%26atitle%3DPotential%2520use%2520of%2520flavopiridol%2520in%2520treatment%2520of%2520chronic%2520diseases%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2016%26volume%3D929%26spage%3D209%26epage%3D228%26doi%3D10.1007%2F978-3-319-41342-6_9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grever, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plunkett, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span> <span> </span><span class="NLM_article-title">Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia</span>. <i>Oncotarget.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2667</span>– <span class="NLM_lpage">2679</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.18632%2Foncotarget.2096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25596730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2Mvnt1ertQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=2667-2679&issue=5&author=Y.+Y.+Yehauthor=R.+Chenauthor=J.+Hesslerauthor=E.+Mahoneyauthor=A.+M.+Lehmanauthor=N.+A.+Heeremaauthor=M.+R.+Greverauthor=W.+Plunkettauthor=J.+C.+Byrdauthor=A.+J.+Johnson&title=Up-regulation+of+CDK9+kinase+activity+and+Mcl-1+stability+contributes+to+the+acquired+resistance+to+cyclin-dependent+kinase+inhibitors+in+leukemia&doi=10.18632%2Foncotarget.2096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia</span></div><div class="casAuthors">Yeh Yuh-Ying; Hessler Joshua; Mahoney Emilia; Grever Michael R; Byrd John C; Johnson Amy J; Chen Rong; Plunkett William; Lehman Amy M; Heerema Nyla A; Byrd John C; Johnson Amy J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2667-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Flavopiridol is a small molecule inhibitor of cyclin-dependent kinases (CDK) known to impair global transcription via inactivation of positive transcription elongation factor b.  It has been demonstrated to have significant activity predominantly in chronic lymphocytic leukemia and acute myeloid leukemia in phase I/II clinical trials while other similar CDK inhibitors are vigorously being pursued in pre-clinical and clinical studies.  Although flavopiridol is a potent therapeutic agent against blood diseases, some patients still have primary or acquired resistance throughout their clinical course.  Considering the limited knowledge of resistance mechanisms of flavopiridol, we investigated the potential mechanisms of resistance to flavopiridol in a cell line system, which gradually acquired resistance to flavopiridol in vitro, and then confirmed the mechanism in patient samples.  Herein, we present that this resistant cell line developed resistance through up-regulation of phosphorylation of RNA polymerase II C-terminal domain, activation of CDK9 kinase activity, and prolonged Mcl-1 stability to counter flavopiridol's drug actions.  Further analyses suggest MAPK/ERK activation-mediated Mcl-1 stabilization contributes to the resistance and knockdown of Mcl-1 in part restores sensitivity to flavopiridol-induced cytotoxicity.  Altogether, these findings demonstrate that CDK9 is the most relevant target of flavopiridol and provide avenues to improve the therapeutic strategies in blood malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-c1g_ogLWk_x2phytoz6_fW6udTcc2eYuteZWVmik5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mvnt1ertQ%253D%253D&md5=1911709d5379ee0b254645433abb91c4</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2096%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DHessler%26aufirst%3DJ.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DLehman%26aufirst%3DA.%2BM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DPlunkett%26aufirst%3DW.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26atitle%3DUp-regulation%2520of%2520CDK9%2520kinase%2520activity%2520and%2520Mcl-1%2520stability%2520contributes%2520to%2520the%2520acquired%2520resistance%2520to%2520cyclin-dependent%2520kinase%2520inhibitors%2520in%2520leukemia%26jtitle%3DOncotarget.%26date%3D2015%26volume%3D6%26issue%3D5%26spage%3D2667%26epage%3D2679%26doi%3D10.18632%2Foncotarget.2096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Tolero Pharmaceuticals</span>. <a href="https://www.toleropharma.com/our-research/alvocidib" class="extLink">https://www.toleropharma.com/our-research/alvocidib</a> (accessed
April 15, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Tolero+Pharmaceuticals.+https%3A%2F%2Fwww.toleropharma.com%2Four-research%2Falvocidib+%28accessed%0AApril+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumara, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soujanya, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravikanth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudeva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganeshaiah, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaanker, R. U.</span></span> <span> </span><span class="NLM_article-title">Rohitukine, a chromone alkaloid and a precursor of flavopiridol, is produced by endophytic fungi isolated from dysoxylum binectariferum hook.f and amoora rohituka (Roxb).Wight & Arn</span>. <i>Phytomedicine</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1016/j.phymed.2013.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.phymed.2013.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24215673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGmu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=541-546&issue=4&author=P.+M.+Kumaraauthor=K.+N.+Soujanyaauthor=G.+Ravikanthauthor=R.+Vasudevaauthor=K.+N.+Ganeshaiahauthor=R.+U.+Shaanker&title=Rohitukine%2C+a+chromone+alkaloid+and+a+precursor+of+flavopiridol%2C+is+produced+by+endophytic+fungi+isolated+from+dysoxylum+binectariferum+hook.f+and+amoora+rohituka+%28Roxb%29.Wight+%26+Arn&doi=10.1016%2Fj.phymed.2013.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Rohitukine, a chromone alkaloid and a precursor of flavopiridol, is produced by endophytic fungi isolated from Dysoxylum binectariferum Hook.f and Amoora rohituka (Roxb).Wight & Arn</span></div><div class="casAuthors">Kumara, P. Mohana; Soujanya, K. N.; Ravikanth, G.; Vasudeva, R.; Ganeshaiah, K. N.; Shaanker, R. Uma</div><div class="citationInfo"><span class="NLM_cas:title">Phytomedicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">541-546</span>CODEN:
                <span class="NLM_cas:coden">PYTOEY</span>;
        ISSN:<span class="NLM_cas:issn">0944-7113</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Rohitukine, a chromone alkaloid, has gained considerable international attention in recent years because of its novel semi-synthetic deriv., flavopiridol and P-276-00.  Both these mols. are in advanced stages of clin. development and trial for cancer treatment.  Recently, flavopiridol was approved as an orphan drug for treatment of chronic lymphocytic leukemia cancer.  The natural occurrence of rohitukine is restricted to only four plant species, Amoora rohituka and Dysoxylum binectariferum (both from the Meliaceae family) and from Schumanniophyton magnificum and Schumanniophyton problematicum (both from the Rubiaceae family).  Recently, an endophytic fungi isolated from D. binectariferum was reported to produce rohitukine in culture.  In this study, we report the prodn. of rohitukine and its subsequent attenuation by endophytic fungi, Fusarium oxysporum (MTCC-11383), Fusarium oxysporum (MTCC-11384) and Fusarium solani (MTCC-11385), all isolated from D. binectariferum and Gibberella fujikuroi (MTCC-11382) isolated from Amoora rohituka.  The fungal rohitukine which was analyzed by HPLC, LC-MS and LC-MS/MS was identical to ref. rohitukine and that produced by the plant.  The rohitukine content in the mycelial samples ranged from 192.78 μg to 359.55 μg 100 g-1 of dry wt. of and in broth it ranged from 14.10 to 71.90 μg 100 mL-1.  In all the fungal cultures, the prodn. declined from first to fourth sub-culture.  Studies are underway to unravel the mechanism by which the fungi produce the host metabolite in culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNZ9s4yF6ZArVg90H21EOLACvtfcHk0liTSPJWTDqgFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGmu7vJ&md5=b32b67ab5e9d32726f80b1efa5d54338</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.phymed.2013.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phymed.2013.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DKumara%26aufirst%3DP.%2BM.%26aulast%3DSoujanya%26aufirst%3DK.%2BN.%26aulast%3DRavikanth%26aufirst%3DG.%26aulast%3DVasudeva%26aufirst%3DR.%26aulast%3DGaneshaiah%26aufirst%3DK.%2BN.%26aulast%3DShaanker%26aufirst%3DR.%2BU.%26atitle%3DRohitukine%252C%2520a%2520chromone%2520alkaloid%2520and%2520a%2520precursor%2520of%2520flavopiridol%252C%2520is%2520produced%2520by%2520endophytic%2520fungi%2520isolated%2520from%2520dysoxylum%2520binectariferum%2520hook.f%2520and%2520amoora%2520rohituka%2520%2528Roxb%2529.Wight%2520%2526%2520Arn%26jtitle%3DPhytomedicine%26date%3D2014%26volume%3D21%26issue%3D4%26spage%3D541%26epage%3D546%26doi%3D10.1016%2Fj.phymed.2013.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiernik, P. H.</span></span> <span> </span><span class="NLM_article-title">Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">729</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1517/13543784.2016.1169273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1517%2F13543784.2016.1169273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26998706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1GisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=729-734&issue=6&author=P.+H.+Wiernik&title=Alvocidib+%28flavopiridol%29+for+the+treatment+of+chronic+lymphocytic+leukemia&doi=10.1517%2F13543784.2016.1169273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia</span></div><div class="casAuthors">Wiernik, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">729-734</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Alvocidib, which has orphan drug designation in chronic lymphocytic leukemia (CLL) from the FDA and the EMA, is a plant-derived semisynthetic flavone that acts as a cyclin-dependent kinase inhibitor.  It induces apoptosis in CLL cells in vitro and was introduced into clin. trials in CLL as an i.v. infusion in 1997, which proved disappointing.  Since the drug avidly binds to plasma proteins, higher serum concns. were required for clin. antileukemia activity than those suggested by in vitro studies.  Subsequent studies utilizing bolus plus infusional doses revealed significant activity against CLL, even in patients with unfavorable characteristics.  However, significant toxicity including high rates of major tumor lysis syndrome, cytokine release syndrome and secretory diarrhea were also obsd.  The chem., pharmacodynamics, pharmacokinetics and metab. of alvocidib are briefly discussed and phase I-II studies in CLL are discussed in detail.  To date, no phase III studies in CLL have been reported.  A no. of much less toxic drugs with similar efficacy against CLL both with and without unfavorable cytogenetics have come to market.  Furthermore, enthusiasm for the development of alvocidib as a single agent for the treatment of CLL has waned, primarily due to its toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWT5FoLZipWbVg90H21EOLACvtfcHk0liTSPJWTDqgFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1GisL8%253D&md5=485e42cb368b87299eca0e2231eb0d3f</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1517%2F13543784.2016.1169273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2016.1169273%26sid%3Dliteratum%253Aachs%26aulast%3DWiernik%26aufirst%3DP.%2BH.%26atitle%3DAlvocidib%2520%2528flavopiridol%2529%2520for%2520the%2520treatment%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26issue%3D6%26spage%3D729%26epage%3D734%26doi%3D10.1517%2F13543784.2016.1169273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">U.S. National Library of Medicine:
ClinicalTrials.gov</span>, <a href="https://www.clinicaltrials.gov" class="extLink">https://www.clinicaltrials.gov</a> (accessed April 10, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+National+Library+of+Medicine%3A%0AClinicalTrials.gov%2C+https%3A%2F%2Fwww.clinicaltrials.gov+%28accessed+April+10%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haws, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whatcott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui-Jain, A.</span></span> <span> </span><span class="NLM_article-title">TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5133</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-5133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1538-7445.AM2017-5133" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=5133&author=W.+Kimauthor=H.+Hawsauthor=P.+Petersonauthor=C.+J.+Whatcottauthor=S.+Weitmanauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=A.+Siddiqui-Jain&title=TP-1287%2C+an+oral+prodrug+of+the+cyclin-dependent+kinase-9+inhibitor+alvocidib&doi=10.1158%2F1538-7445.AM2017-5133"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-5133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-5133%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%26aulast%3DHaws%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DP.%26aulast%3DWhatcott%26aufirst%3DC.%2BJ.%26aulast%3DWeitman%26aufirst%3DS.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DSiddiqui-Jain%26aufirst%3DA.%26atitle%3DTP-1287%252C%2520an%2520oral%2520prodrug%2520of%2520the%2520cyclin-dependent%2520kinase-9%2520inhibitor%2520alvocidib%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D5133%26doi%3D10.1158%2F1538-7445.AM2017-5133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintoo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guru, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuthakki, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondhe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, R. A.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical development of IIIM-290, an orally active potent cyclin-dependent kinase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1664</span>– <span class="NLM_lpage">1687</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsl2js7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1664-1687&issue=4&author=S.+B.+Bharateauthor=V.+Kumarauthor=S.+K.+Jainauthor=M.+J.+Mintooauthor=S.+K.+Guruauthor=V.+K.+Nuthakkiauthor=M.+Sharmaauthor=S.+S.+Bharateauthor=S.+G.+Gandhiauthor=D.+M.+Mondheauthor=S.+Bhushanauthor=R.+A.+Vishwakarma&title=Discovery+and+preclinical+development+of+IIIM-290%2C+an+orally+active+potent+cyclin-dependent+kinase+inhibitor&doi=10.1021%2Facs.jmedchem.7b01765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor</span></div><div class="casAuthors">Bharate, Sandip B.; Kumar, Vikas; Jain, Shreyans K.; Mintoo, Mubashir J.; Guru, Santosh K.; Nuthakki, Vijay K.; Sharma, Mohit; Bharate, Sonali S.; Gandhi, Sumit G.; Mondhe, Dilip M.; Bhushan, Shashi; Vishwakarma, Ram A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1664-1687</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rohitukine (1), a chromone alkaloid isolated from Indian medicinal plant Dysoxylum binectariferum, has inspired the discovery of flavopiridol and riviciclib, both of which are bioavailable only via i.v. route.  With the objective to address the oral bioavailability issue of this scaffold, four series of rohitukine derivs. were prepd. and screened for Cdk inhibition and cellular antiproliferative activity.  The 2,6-dichloro-styryl deriv. IIIM-290 (11d) showed strong inhibition of Cdk-9/T1 (IC50 1.9 nM) kinase and Molt-4/MIAPaCa-2 cell growth (GI50 < 1.0 μM) and was found to be highly selective for cancer cells over normal fibroblast cells.  It inhibited the cell growth of MIAPaCa-2 cells via caspase-dependent apoptosis.  It achieved 71% oral bioavailability with in vivo efficacy in pancreatic, colon, and leukemia xenografts at 50 mg/kg, po.  It did not have CYP/efflux-pump liability, was not mutagenic/genotoxic or cardiotoxic, and was metabolically stable.  The preclin. data presented herein indicates the potential of 11d for advancement in clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeRTRG-f8KqLVg90H21EOLACvtfcHk0lgV5fYK1tSkNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsl2js7k%253D&md5=13b67cdf1db966e2a414b64cd82a98e8</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01765%26sid%3Dliteratum%253Aachs%26aulast%3DBharate%26aufirst%3DS.%2BB.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DJain%26aufirst%3DS.%2BK.%26aulast%3DMintoo%26aufirst%3DM.%2BJ.%26aulast%3DGuru%26aufirst%3DS.%2BK.%26aulast%3DNuthakki%26aufirst%3DV.%2BK.%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DGandhi%26aufirst%3DS.%2BG.%26aulast%3DMondhe%26aufirst%3DD.%2BM.%26aulast%3DBhushan%26aufirst%3DS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DDiscovery%2520and%2520preclinical%2520development%2520of%2520IIIM-290%252C%2520an%2520orally%2520active%2520potent%2520cyclin-dependent%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1664%26epage%3D1687%26doi%3D10.1021%2Facs.jmedchem.7b01765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brion, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrat, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levaique, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josselin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messaoudi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamze, A.</span></span> <span> </span><span class="NLM_article-title">Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">112355</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2020.112355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=32402934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpt1Grtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2020&pages=112355&author=N.+Ibrahimauthor=P.+Bonnetauthor=J.+D.+Brionauthor=J.+F.+Peyratauthor=J.+Bignonauthor=H.+Levaiqueauthor=B.+Josselinauthor=T.+Robertauthor=P.+Colasauthor=S.+Bachauthor=S.+Messaoudiauthor=M.+Alamiauthor=A.+Hamze&title=Identification+of+a+new+series+of+flavopiridol-like+structures+as+kinase+inhibitors+with+high+cytotoxic+potency&doi=10.1016%2Fj.ejmech.2020.112355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency</span></div><div class="casAuthors">Ibrahim, Nada; Bonnet, Pascal; Brion, Jean-Daniel; Peyrat, Jean-Francois; Bignon, Jerome; Levaique, Helene; Josselin, Beatrice; Robert, Thomas; Colas, Pierre; Bach, Stephane; Messaoudi, Samir; Alami, Mouad; Hamze, Abdallah</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112355</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">An unique flavopiridol analogs bearing thiosugars, amino acids and heterocyclic moieties I [X = H, R = PhNH, 2-pyrimidylthio, HONHC(O)CH2CH2S, peracetyl-β-D-galactosylthio, etc.; X = Cl, R = benzimidazol-2-ylthio, peracetyl-β-D-glycosylthio] tethered to the flavopiridol via thioether and amine bonds mainly on its C ring was prepd.  The analogs bearing benzimidazolylthio substituents have demonstrated high cytotoxic activity in-vitro against up to seven cancer cell lines.  Their cytotoxic effects were comparable to those of flavopiridol.  The most active compd. I [X = Cl; R = 1-methylbenzimidazol-2-ylthio; (II)] resulting from a structure-activity relationship (SAR) study and in silico docking showed the best antiproliferative activity and was more efficient than the ref. compd.  In addn., the compd. II showed significant nanomolar inhibition against CDK9, CDK10 and GSK3β protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJpwVY4RdHLVg90H21EOLACvtfcHk0lgV5fYK1tSkNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpt1Grtbo%253D&md5=8c555b1f4db21d90dd5d467df77b7321</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112355%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DBrion%26aufirst%3DJ.%2BD.%26aulast%3DPeyrat%26aufirst%3DJ.%2BF.%26aulast%3DBignon%26aufirst%3DJ.%26aulast%3DLevaique%26aufirst%3DH.%26aulast%3DJosselin%26aufirst%3DB.%26aulast%3DRobert%26aufirst%3DT.%26aulast%3DColas%26aufirst%3DP.%26aulast%3DBach%26aufirst%3DS.%26aulast%3DMessaoudi%26aufirst%3DS.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DHamze%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520a%2520new%2520series%2520of%2520flavopiridol-like%2520structures%2520as%2520kinase%2520inhibitors%2520with%2520high%2520cytotoxic%2520potency%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D199%26spage%3D112355%26doi%3D10.1016%2Fj.ejmech.2020.112355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathos, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivakumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276–00</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">918</span>– <span class="NLM_lpage">925</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1535-7163.MCT-06-0613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=17363486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=918-925&issue=3&author=K.+S.+Joshiauthor=M.+J.+Rathosauthor=R.+D.+Joshiauthor=M.+Sivakumarauthor=M.+Mascarenhasauthor=S.+Kambleauthor=B.+Lalauthor=S.+Sharma&title=In+vitro+antitumor+properties+of+a+novel+cyclin-dependent+kinase+inhibitor%2C+P276%E2%80%9300&doi=10.1158%2F1535-7163.MCT-06-0613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Joshi, Rajendra D.; Sivakumar, Meenakshi; Mascarenhas, Malcolm; Kamble, Shrikant; Lal, Bansi; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">918-925</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (Cdk) and their assocd. pathways represent some of the most attractive targets for the development of anticancer therapeutics.  Based on antitumor activity in animal models, a variety of Cdk inhibitors are undergoing clin. evaluation either as a single agent or in combination with other approved drugs.  In our anticancer drug discovery program, a novel series of flavones were synthesized for evaluation against the activity of Cdk4-D1.  This enzyme catalyzes the phosphorylation of retinoblastoma protein, thus inhibiting its function.  We have identified a series of potent Cdk4-D1 inhibitors with IC50 below 250 nmol/L.  In this report, we have described the properties of one of the best compd., P276-00 of the flavone's series.  P276-00 shows 40-fold selectivity toward Cdk4-D1, compared with Cdk2-E.  The specificity toward 14 other related and unrelated kinases was also detd.  P276-00 was found to be more selective with IC50s <100 nmol/L for Cdk4-D1, Cdk1-B, and Cdk9-T1, as compared with other Cdks, and less selective for non-Cdk kinases.  It showed potent antiproliferative effects against various human cancer cell lines, with an IC50 ranging from 300 to 800 nmol/L and was further compared for its antiproliferative activity against cancer and normal fibroblast cell lines.  P276-00 was found to be highly selective for cancer cells as compared with normal fibroblast cells.  To delineate its mechanism of action, the effect of P276-00 on cell cycle proteins was studied in human breast cancer cell line (MCF-7) and human non-small cell lung carcinoma (H-460).  A significant down-regulation of cyclin D1 and Cdk4 and a decrease in Cdk4-specific pRb Ser780 phosphorylation was obsd.  P276-00 produced potent inhibition of Cdk4-D1 activity that was found to be competitive with ATP and not with retinoblastoma protein.  The compd. also induced apoptosis in human promyelocytic leukemia (HL-60) cells, as evidenced by the induction of caspase-3 and DNA ladder studies.  These data suggest that P276-00 has the potential to be developed as an anti-Cdk chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0IzehRnQJk7Vg90H21EOLACvtfcHk0lhq04aqi5-z_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D&md5=7cc9256a1cd7a960e5e5497ad409a18b</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0613%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DJoshi%26aufirst%3DR.%2BD.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMascarenhas%26aufirst%3DM.%26aulast%3DKamble%26aufirst%3DS.%26aulast%3DLal%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520antitumor%2520properties%2520of%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520P276%25E2%2580%259300%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26issue%3D3%26spage%3D918%26epage%3D925%26doi%3D10.1158%2F1535-7163.MCT-06-0613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cassaday, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chawla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachankar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, A. K.</span></span> <span> </span><span class="NLM_article-title">A phase II, single-arm, open-label, multicenter sudy to evaluate the efficacy and safety of P276–00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma</span>. <i>Clin Lymphoma Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">392</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2015.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.clml.2015.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25816934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnos1Wlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=392-397&issue=7&author=R.+D.+Cassadayauthor=A.+Goyauthor=S.+Advaniauthor=P.+Chawlaauthor=R.+Nachankarauthor=M.+Gandhiauthor=A.+K.+Gopal&title=A+phase+II%2C+single-arm%2C+open-label%2C+multicenter+sudy+to+evaluate+the+efficacy+and+safety+of+P276%E2%80%9300%2C+a+cyclin-dependent+kinase+inhibitor%2C+in+patients+with+relapsed+or+refractory+mantle+cell+lymphoma&doi=10.1016%2Fj.clml.2015.02.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma</span></div><div class="casAuthors">Cassaday Ryan D; Goy Andre; Advani Suresh; Chawla Purvi; Nachankar Rajesh; Gandhi Mansi; Gopal Ajay K</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma, myeloma & leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">392-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Overexpression of cyclin D1 is a hallmark feature of mantle cell lymphoma (MCL).  Many of the oncogenic effects of cyclin D1 are mediated through cyclin-dependent kinases (CDKs).  P276-00 is a potent small molecule inhibitor of CDK4-D1, CDK1-B, and CDK9-T, with promising activity in preclinical models.  In phase I studies of P276-00 in patients with refractory solid neoplasms, it was well-tolerated with a mild trend toward single-agent efficacy.  PATIENTS AND METHODS:  A phase II study of P276-00 was conducted in patients with relapsed or refractory MCL at the recommended dose of 185 mg/m(2)/day from days 1 to 5 of a 21-day cycle.  Thirteen patients were enrolled in the present study.  RESULTS:  Of the 13 patients, 11 experienced disease progression, 1 patient was withdrawn because of an adverse event (AE), and 1 patient died.  Also, 11 patients (84.6%) experienced a treatment-emergent AE deemed related to P276-00.  Of the 13 patients, 9 (69.2%) received ≥ 2 cycles of treatment, which was the predefined threshold to be evaluable for efficacy.  Treatment was discontinued early in 2 patients because of AEs (1 of which was attributed to P276-00 administration) and in 2 patients because of disease progression.  Finally, 2 patients experienced stable disease for an estimated median duration of 60.5 days (range, 58-63 days).  The estimated median time to progression for the predefined efficacy population was 43 days (range, 38-58 days).  CONCLUSION:  Given the results observed in the present study, if evaluation of CDK inhibition in MCL continues, it should be considered earlier in the disease course or as a part of combination strategies for relapsed or refractory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9BvQqGeRc9p6KlWarZTAzfW6udTcc2eb2InBVfy4o_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnos1Wlsw%253D%253D&md5=b1062faa6262674828e4338d26e66e00</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2015.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2015.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DCassaday%26aufirst%3DR.%2BD.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DS.%26aulast%3DChawla%26aufirst%3DP.%26aulast%3DNachankar%26aufirst%3DR.%26aulast%3DGandhi%26aufirst%3DM.%26aulast%3DGopal%26aufirst%3DA.%2BK.%26atitle%3DA%2520phase%2520II%252C%2520single-arm%252C%2520open-label%252C%2520multicenter%2520sudy%2520to%2520evaluate%2520the%2520efficacy%2520and%2520safety%2520of%2520P276%25E2%2580%259300%252C%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520mantle%2520cell%2520lymphoma%26jtitle%3DClin%2520Lymphoma%2520Myeloma%2520Leuk.%26date%3D2015%26volume%3D15%26issue%3D7%26spage%3D392%26epage%3D397%26doi%3D10.1016%2Fj.clml.2015.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deckwerth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwin, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalini, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenley, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditzler, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beirne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinman, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghoffer, R. A.</span></span> <span> </span><span class="NLM_article-title">Voruciclib, a clinical stage oral CDK9 inhibitor, represses Mcl-1 and sensitizes high-risk diffuse large B-cell lymphoma to BCL2 inhibition</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-18368-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fs41598-017-18368-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28127051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsl2is7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=1-17&author=J.+Deyauthor=T.+L.+Deckwerthauthor=W.+S.+Kerwinauthor=J.+R.+Casaliniauthor=A.+J.+Merrellauthor=M.+O.+Grenleyauthor=C.+Burnsauthor=S.+H.+Ditzlerauthor=C.+P.+Dixonauthor=E.+Beirneauthor=K.+C.+Gillespieauthor=E.+F.+Kleinmanauthor=R.+A.+Klinghoffer&title=Voruciclib%2C+a+clinical+stage+oral+CDK9+inhibitor%2C+represses+Mcl-1+and+sensitizes+high-risk+diffuse+large+B-cell+lymphoma+to+BCL2+inhibition&doi=10.1038%2Fs41598-017-18368-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial</span></div><div class="casAuthors">Sharma, Surendra K.; Katoch, Kiran; Sarin, Rohit; Balambal, Raman; Kumar Jain, Nirmal; Patel, Naresh; Murthy, Kolluri J. R.; Singla, Neeta; Saha, P. K.; Khanna, Ashwani; Singh, Urvashi; Kumar, Sanjiv; Sengupta, A.; Banavaliker, J. N.; Chauhan, D. S.; Sachan, Shailendra; Wasim, Mohammad; Tripathi, Sanjay; Dutt, Nilesh; Jain, Nitin; Joshi, Nalin; Penmesta, Sita Ram Raju; Gaddam, Sumanlatha; Gupta, Sanjay; Khamar, Bakulesh; Dey, Bindu; Mitra, Dipendra K.; Arora, Sunil K.; Bhaskar, Sangeeta; Rani, Rajni</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prolonged treatment of tuberculosis (TB) often leads to poor compliance, default and relapse, converting primary TB patients into category II TB (Cat IITB) cases, many of whom may convert to multi-drug resistant TB (MDR-TB).  We have evaluated the immunotherapeutic potential of Mycobacterium indicus pranii (MIP) as an adjunct to Anti-Tubercular Treatment (ATT) in Cat II pulmonary TB (PTB) patients in a prospective, randomized, double blind, placebo controlled, multicentric clin. trial. 890 sputum smear pos. Cat II PTB patients were randomized to receive either six intra-dermal injections (2 + 4) of heat-killed MIP at a dose of 5 × 108 bacilli or placebo once in 2 wk for 2 mo.  Sputum smear and culture examns. were performed at different time points.  MIP was safe with no adverse effects.  While sputum smear conversion did not show any statistically significant difference, significantly higher no. of patients (67.1%) in the MIP group achieved sputum culture conversion at fourth week compared to the placebo (57%) group (p = 0.0002), suggesting a role of MIP in clearance of the bacilli.  Since live bacteria are the major contributors for sustained incidence of TB, the potential of MIP in clearance of the bacilli has far reaching implications in controlling the spread of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpny4F2vXMSeLVg90H21EOLACvtfcHk0lhq04aqi5-z_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsl2is7zL&md5=a1808af8583b7c02e66c7a32369d5727</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-18368-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-18368-w%26sid%3Dliteratum%253Aachs%26aulast%3DDey%26aufirst%3DJ.%26aulast%3DDeckwerth%26aufirst%3DT.%2BL.%26aulast%3DKerwin%26aufirst%3DW.%2BS.%26aulast%3DCasalini%26aufirst%3DJ.%2BR.%26aulast%3DMerrell%26aufirst%3DA.%2BJ.%26aulast%3DGrenley%26aufirst%3DM.%2BO.%26aulast%3DBurns%26aufirst%3DC.%26aulast%3DDitzler%26aufirst%3DS.%2BH.%26aulast%3DDixon%26aufirst%3DC.%2BP.%26aulast%3DBeirne%26aufirst%3DE.%26aulast%3DGillespie%26aufirst%3DK.%2BC.%26aulast%3DKleinman%26aufirst%3DE.%2BF.%26aulast%3DKlinghoffer%26aufirst%3DR.%2BA.%26atitle%3DVoruciclib%252C%2520a%2520clinical%2520stage%2520oral%2520CDK9%2520inhibitor%252C%2520represses%2520Mcl-1%2520and%2520sensitizes%2520high-risk%2520diffuse%2520large%2520B-cell%2520lymphoma%2520to%2520BCL2%2520inhibition%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D1%26epage%3D17%26doi%3D10.1038%2Fs41598-017-18368-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paiva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godbersen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soderquist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilmarx, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasa, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilov, A. V.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-Cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0143685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1371%2Fjournal.pone.0143685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVWjtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1-16&issue=11&author=C.+Paivaauthor=J.+C.+Godbersenauthor=R.+S.+Soderquistauthor=T.+Rowlandauthor=S.+Kilmarxauthor=S.+E.+Spurgeonauthor=J.+R.+Brownauthor=S.+P.+Srinivasaauthor=A.+V.+Danilov&title=Cyclin-dependent+kinase+inhibitor+P1446A+induces+apoptosis+in+a+JNK%2Fp38+MAPK-dependent+manner+in+chronic+lymphocytic+leukemia+B-Cells&doi=10.1371%2Fjournal.pone.0143685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A role for microRNA-155 expression in microenvironment associated to HPV-induced carcinogenesis in K14-HPV16 transgenic mice [Erratum to document cited in CA163:328997]</span></div><div class="casAuthors">Paiva, Isabel; Gil da Costa, Rui M.; Ribeiro, Joana; Sousa, Hugo; Bastos, Margarida; Faustino-Rocha, Ana; Lopes, Carlos; Oliveira, Paula A.; Medeiros, Rui</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">This article was published with typog. errors in the authors list causing further errors to appear in the author affiliations and the article citation; the correct authors list, author affiliations, and article citation are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ5pr8BgKr9rVg90H21EOLACvtfcHk0liWoICEkVNquw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVWjtLzI&md5=a924751dca66e595d6e43261ce14884e</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0143685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0143685%26sid%3Dliteratum%253Aachs%26aulast%3DPaiva%26aufirst%3DC.%26aulast%3DGodbersen%26aufirst%3DJ.%2BC.%26aulast%3DSoderquist%26aufirst%3DR.%2BS.%26aulast%3DRowland%26aufirst%3DT.%26aulast%3DKilmarx%26aufirst%3DS.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DSrinivasa%26aufirst%3DS.%2BP.%26aulast%3DDanilov%26aufirst%3DA.%2BV.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitor%2520P1446A%2520induces%2520apoptosis%2520in%2520a%2520JNK%252Fp38%2520MAPK-dependent%2520manner%2520in%2520chronic%2520lymphocytic%2520leukemia%2520B-Cells%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D11%26spage%3D1%26epage%3D16%26doi%3D10.1371%2Fjournal.pone.0143685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span> <span> </span><span class="NLM_article-title">Voruciclib, a potent CDK4/6 inhibitor, antagonizes ABCB<sub>1</sub> and ABCG<sub>2</sub>-mediated multi-drug resistance in cancer cells</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1528</span>, <span class="refDoi"> DOI: 10.1159/000487578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1159%2F000487578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29486476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlOgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=1515-1528&issue=4&author=P.+Guptaauthor=Y.+K.+Zhangauthor=X.+Y.+Zhangauthor=Y.+J.+Wangauthor=K.+W.+Luauthor=T.+Hallauthor=R.+Pengauthor=D.+H.+Yangauthor=N.+Xieauthor=Z.+S.+Chen&title=Voruciclib%2C+a+potent+CDK4%2F6+inhibitor%2C+antagonizes+ABCB1+and+ABCG2-mediated+multi-drug+resistance+in+cancer+cells&doi=10.1159%2F000487578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells</span></div><div class="casAuthors">Gupta, Pranav; Zhang, Yun-Kai; Zhang, Xiao-Yu; Wang, Yi-Jun; Lu, Kimberly W.; Hall, Timothy; Peng, Richard; Yang, Dong-Hua; Xie, Ni; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1515-1528</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background/Aims: The overexpression of ATP-Binding Cassette (ABC) transporters has known to be one of the major obstacles impeding the success of chemotherapy in drug resistant cancers.  In this study, we evaluated voruciclib, a CDK 4/6 inhibitor, for its chemo-sensitizing activity in ABCB1- and ABCG2- overexpressing cells.  Methods: Cytotoxicity and reversal effect of voruciclib was detd. by MTT assay.  The intracellular accumulation and efflux of ABCB1 and ABCG2 substrates were measured by scintillation counter.  The effects on expression and intracellular localization of ABCB1 and ABCG2 proteins were detd. by Western blotting and immunofluorescence, resp.  Vanadate-sensitive ATPase assay was done to det. the effect of voruciclib on the ATPase activity of ABCB1 and ABCG2.  Flow cytometric anal. was done to det. the effect of voruciclib on apoptosis of ABCB1 and ABCG2-overexpressing cells and docking anal. was done to det. the interaction of voruciclib with ABCB1 and ACBG2 protein.  Results: Voruciclib significantly potentiated the effect of paclitaxel and doxorubicin in ABCB1-overexpressing cells, as well as mitoxantrone and SN-38 in ABCG2-overexpressing cells.  Voruciclib moderately sensitized ABCC10- overexpressing cells to paclitaxel, whereas it did not alter the cytotoxicity of substrates of ABCC1.  Furthermore, voruciclib increased the intracellular accumulation and decreased the efflux of substrate anti-cancer drugs from ABCB1- or ABCG2-overexpressing cells.  However, voruciclib did not alter the expression or the sub-cellular localization of ABCB1 or ABCG2.  Voruciclib stimulated the ATPase activity of both ABCB1 and ABCG2 in a concn.-dependent manner.  Lastly, voruciclib exhibited a drug-induced apoptotic effect in ABCB1- or ABCG2- overexpressing cells.  Conclusion: Voruciclib is currently a phase I clin. trial drug.  Our findings strongly support its potential use in combination with conventional anti-cancer drugs for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoyadf1NgenrVg90H21EOLACvtfcHk0liWoICEkVNquw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlOgtLo%253D&md5=03b4795bd5a136b1ea91f0403ee8fb5a</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1159%2F000487578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000487578%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DZhang%26aufirst%3DX.%2BY.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DLu%26aufirst%3DK.%2BW.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DD.%2BH.%26aulast%3DXie%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26atitle%3DVoruciclib%252C%2520a%2520potent%2520CDK4%252F6%2520inhibitor%252C%2520antagonizes%2520ABCB1%2520and%2520ABCG2-mediated%2520multi-drug%2520resistance%2520in%2520cancer%2520cells%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2018%26volume%3D45%26issue%3D4%26spage%3D1515%26epage%3D1528%26doi%3D10.1159%2F000487578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and synthesis of novel wogonin derivatives with potent antitumor activity in vitro</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.09.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2017.09.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28987604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1egsLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=421-434&author=J.+Wangauthor=R.+Geauthor=X.+Qiuauthor=X.+Xuauthor=L.+Weiauthor=Z.+Liauthor=J.+Bian&title=Discovery+and+synthesis+of+novel+wogonin+derivatives+with+potent+antitumor+activity+in+vitro&doi=10.1016%2Fj.ejmech.2017.09.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity in vitro</span></div><div class="casAuthors">Wang, Jubo; Ge, Raoling; Qiu, Xiaqiu; Xu, Xi; Wei, Libin; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">421-434</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Phenotypic screening of high quality compd. library is one of the most effective strategy to obtain novel bioactive compds.  Recently, the authors' group have constructed a Wogonin-scaffold library with substituents diversity and successfully obtained a series of potent compds.  Herein, the authors reported the synthesis of these compds. and evaluated the in vitro antitumor activity against a panel of human tumor cell lines.  Most of them showed good activity with a broad spectrum and preliminary structure-activity relationship for the substitutions were obtained.  Further biol. assays showed that the most potent compds. 18n (7-(benzyloxy)-5-hydroxy-8-(4-(4-methylpiperazin-1-yl)butoxy)-2-phenyl-4H-chromen-4-one) and 20b (7-(4-cyanobenzyloxy)-8-(4-(4-methylpiperazin-1-yl)butoxy)-5-hydroxy-2-phenyl-4H-chromen-4-one) could significantly enhance the intracellular ROS level and induce the cell apoptosis at low micromole level.  Through similarity searching, CDK9 was identified as the potential target for 20b, which could be a start point for next structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe__G_FQ4ourVg90H21EOLACvtfcHk0liWoICEkVNquw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1egsLfL&md5=c782025d03a8fe855039eaee0b0c734e</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.09.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.09.046%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DR.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520novel%2520wogonin%2520derivatives%2520with%2520potent%2520antitumor%2520activity%2520in%2520vitro%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D140%26spage%3D421%26epage%3D434%26doi%3D10.1016%2Fj.ejmech.2017.09.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">801</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2019.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31238183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Kjs77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=782-801&author=J.+Wangauthor=T.+Liauthor=T.+Zhaoauthor=T.+Wuauthor=C.+Liuauthor=H.+Dingauthor=Z.+Liauthor=J.+Bian&title=Design+of+wogonin-inspired+selective+cyclin-dependent+kinase+9+%28CDK9%29+inhibitors+with+potent+in+vitro+and+in+vivo+antitumor+activity&doi=10.1016%2Fj.ejmech.2019.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity</span></div><div class="casAuthors">Wang, Jubo; Li, Tinghan; Zhao, Tengteng; Wu, Tizhi; Liu, Chuang; Ding, Hong; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">782-801</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Wogonin, a natural product isolated from the plant Scutellaria baicalensis, has been shown to be a potent and selective inhibitor of CDK9.  With the purpose of investigating the activity and selectivity of this chem. scaffold, several series of wogonin derivs. were prepd. and screened for CDK9 inhibition and cellular antiproliferative activity.  Among these compds., the drug-like compd. 51 (I) showed potent activity against CDK9 (IC50 = 19.9 nM) and MV4-11 cell growth (IC50 = 20 nM).  In addn., compd. 51 showed much improved physicochem. properties, such as water soly., compared with the parent compd. wogonin.  The follow-up studies showed that the compd. 51 is selective toward CDK9-overexpressing cancer cells over normal cells.  Preliminary mechanism studies on the anticancer effect indicated that 51 inhibited the proliferation of MV4-11 cells via caspase-dependent apoptosis.  In addn., highlighted compd. 51 showed significant antitumor activity in mouse acute myeloid leukemia (AML) models without producing apparent toxic effects in vivo, which gave us a new tool for further investigation of CDK9-targeted inhibitor as a potential antitumor drug esp. for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMD5_MDU-cl7Vg90H21EOLACvtfcHk0lifGnkvjP7AuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Kjs77P&md5=5718b8c461f761ca8217b7b782dc7dec</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DDesign%2520of%2520wogonin-inspired%2520selective%2520cyclin-dependent%2520kinase%25209%2520%2528CDK9%2529%2520inhibitors%2520with%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D178%26spage%3D782%26epage%3D801%26doi%3D10.1016%2Fj.ejmech.2019.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3)</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1007/s00894-012-1528-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs00894-012-1528-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=22820730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=119-130&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=H.+Nagarajauthor=M.+Williamsauthor=H.+Wangauthor=A.+Leeauthor=E.+Sunauthor=E.+L.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-based+design+of+nitrogen-linked+macrocyclic+kinase+inhibitors+leading+to+the+clinical+candidate+SB1317%2FTG02%2C+a+potent+inhibitor+of+cyclin+dependant+kinases+%28CDKs%29%2C+janus+kinase+2+%28JAK2%29%2C+and+fms-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1007%2Fs00894-012-1528-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Poulsen, Anders; William, Anthony; Blanchard, Stephanie; Nagaraj, Harish; Williams, Meredith; Wang, Haishan; Lee, Angeline; Sun, Eric; Teo, Ee-Ling; Tan, Evelyn; Goh, Kee Chuan; Dymock, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-130</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A high-throughput screen against Aurora A kinase revealed several promising submicromolar pyrimidine-aniline leads.  The bioactive conformation found by docking these leads into the Aurora A ATP-binding site had a semicircular shape.  Macrocycle formation was proposed to achieve novelty and selectivity via ring-closing metathesis of a diene precursor.  The nature of the optimal linker and its size was directed by docking.  In a kinase panel screen, selected macrocycles were active on other kinase targets, mainly FLT3, JAK2, and CDKs.  These compds. then became leads in a CDK/FLT3/JAK2 inhibitor project.  Macrocycles with a basic nitrogen in the linker form a salt bridge with Asp86 in CDK2 and Asp698 in FLT3.  Interaction with this residue explains the obsd. selectivity.  The Asp86 residue is conserved in most CDKs, resulting in potent pan-CDK inhibition by these compds.  Optimized macrocycles generally have good DMPK properties, and are efficacious in mouse models of cancer.  Compd. 5 (SB1317/TG02), a pan-CDK/FLT3/JAK2 inhibitor, was selected for preclin. development, and is now in phase 1 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnGiv82CuwbVg90H21EOLACvtfcHk0lifGnkvjP7AuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D&md5=3f65c0a7f61329cabb9e85656a2c3dcf</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2Fs00894-012-1528-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-012-1528-7%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-based%2520design%2520of%2520nitrogen-linked%2520macrocyclic%2520kinase%2520inhibitors%2520leading%2520to%2520the%2520clinical%2520candidate%2520SB1317%252FTG02%252C%2520a%2520potent%2520inhibitor%2520of%2520cyclin%2520dependant%2520kinases%2520%2528CDKs%2529%252C%2520janus%2520kinase%25202%2520%2528JAK2%2529%252C%2520and%2520fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2013%26volume%3D19%26spage%3D119%26epage%3D130%26doi%3D10.1007%2Fs00894-012-1528-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfeliciano, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: recent advances (2015–2019)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126637</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bmcl.2019.126637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31477350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWjs73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126637&author=C.+Sanchez-Martinezauthor=M.+J.+Lallenaauthor=S.+G.+Sanfelicianoauthor=A.+de+Dios&title=Cyclin+dependent+kinase+%28CDK%29+inhibitors+as+anticancer+drugs%3A+recent+advances+%282015%E2%80%932019%29&doi=10.1016%2Fj.bmcl.2019.126637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019)</span></div><div class="casAuthors">Sanchez-Martinez, Concepcion; Lallena, Maria Jose; Sanfeliciano, Sonia Gutierrez; de Dios, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">126637</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sustained proliferative capacity and gene dysregulation are hallmarks of cancer.  In mammalian cells, cyclin-dependent kinases (CDKs) control crit. cell cycle checkpoints and key transcriptional events in response to extracellular and intracellular signals leading to proliferation.  Significant clin. activity for the treatment of hormone receptor pos. metastatic breast cancer has been demonstrated by palbociclib, ribociclib and abemaciclib, dual CDK4/6 inhibitors recently FDA-approved.  SY-1365, a CDK7 inhibitor has shown initial encouraging data in phase I for solid tumors treatment.  These results have rejuvenated the CDKs research field.  This review provides an overview of relevant advances on CDK inhibitor research since 2015 to 2019, with special emphasis on transcriptional CDK inhibitors, new emerging strategies such as target protein degrdn. and compds. under clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcZ4sKIv0DfrVg90H21EOLACvtfcHk0lgEPhKmjjBupg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWjs73N&md5=2808e04d5c09daad462133bcf9b9cb3d</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126637%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Martinez%26aufirst%3DC.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3DSanfeliciano%26aufirst%3DS.%2BG.%26aulast%3Dde%2BDios%26aufirst%3DA.%26atitle%3DCyclin%2520dependent%2520kinase%2520%2528CDK%2529%2520inhibitors%2520as%2520anticancer%2520drugs%253A%2520recent%2520advances%2520%25282015%25E2%2580%25932019%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126637%26doi%3D10.1016%2Fj.bmcl.2019.126637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pallis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Aziz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seedhouse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N.</span></span> <span> </span><span class="NLM_article-title">The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1111/bjh.12018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1111%2Fbjh.12018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=22934750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2qs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2012&pages=191-203&author=M.+Pallisauthor=A.+Abdul-Azizauthor=F.+Burrowsauthor=C.+Seedhouseauthor=M.+Grundyauthor=N.+Russell&title=The+multi-kinase+inhibitor+TG02+overcomes+signalling+activation+by+survival+factors+to+deplete+MCL1+and+XIAP+and+induce+cell+death+in+primary+acute+myeloid+leukaemia+cells&doi=10.1111%2Fbjh.12018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells</span></div><div class="casAuthors">Pallis, Monica; Abdul-Aziz, Amina; Burrows, Francis; Seedhouse, Claire; Grundy, Martin; Russell, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-203</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summmary : The novel multi-kinase inhibitor TG02 has selectivity against cell cycle and transcriptional cyclin dependent kinases (CDKs) as well as fms-like tyrosine kinase receptor-3 (FLT3).  Inhibition of transcriptional CDKs preferentially depletes short-lived proteins such as MCL1.  We evaluated the in vitro toxicity of TG02 to primary acute myeloid leukemia (AML) cells in the presence of survival signalling pathway activation by cytokines and fibronectin.  One hundred nanomolar TG02 induced a median decrease of 40% in bulk cell survival and 43% in the CD34+CD38-CD123+subset.  A 90% inhibitory concn. of 500 nmol/l indicated that TG02 toxicity is not halted by protective cell cycle arrest.  Samples with FLT3 internal tandem duplication were not preferentially targeted.  By flow cytometry, TG02 treatment caused loss of RNA Polymerase II serine 2 phosphorylation in patient samples, which correlated strongly with BAX activation (R2=0·89), suggesting these as potential biomarkers for clin. studies.  MCL1 and XIAP expression also decreased.  Repeated brief exposure to TG02 in MOLM-13 cells did not result in compensatory up-regulation of survival protein expression.  In conclusion, TG02 is potently cytotoxic towards CD34+CD38-CD123+ and bulk AML cells, despite protective signalling pathway activation.  This antitumor activity is most likely mediated by dephosphorylation of RNA Polymerase II leading to depletion of survival mols. such as MCL1 and XIAP, with subsequent BAX activation and apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3mvr_3yc0bVg90H21EOLACvtfcHk0lgEPhKmjjBupg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2qs73J&md5=e8da0f2e7a1a5fcf03f90e68311ab294</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12018%26sid%3Dliteratum%253Aachs%26aulast%3DPallis%26aufirst%3DM.%26aulast%3DAbdul-Aziz%26aufirst%3DA.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DSeedhouse%26aufirst%3DC.%26aulast%3DGrundy%26aufirst%3DM.%26aulast%3DRussell%26aufirst%3DN.%26atitle%3DThe%2520multi-kinase%2520inhibitor%2520TG02%2520overcomes%2520signalling%2520activation%2520by%2520survival%2520factors%2520to%2520deplete%2520MCL1%2520and%2520XIAP%2520and%2520induce%2520cell%2520death%2520in%2520primary%2520acute%2520myeloid%2520leukaemia%2520cells%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2012%26volume%3D159%26spage%3D191%26epage%3D203%26doi%3D10.1111%2Fbjh.12018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Discovery and sars of 5-chloro-n(4)-phenyl-n(2)-(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as oral available and dual CDK6 and 9 inhibitors with potent antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3327</span>– <span class="NLM_lpage">3347</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02121</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02121" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlOgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3327-3347&author=Y.+Wangauthor=X.+Chenauthor=Y.+Yanauthor=X.+Zhuauthor=M.+Liuauthor=X.+Liu&title=Discovery+and+sars+of+5-chloro-n%284%29-phenyl-n%282%29-%28pyridin-2-yl%29pyrimidine-2%2C4-diamine+derivatives+as+oral+available+and+dual+CDK6+and+9+inhibitors+with+potent+antitumor+activity&doi=10.1021%2Facs.jmedchem.9b02121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SARs of 5-Chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity</span></div><div class="casAuthors">Wang, Yang; Chen, Xing; Yan, Yaoyao; Zhu, Xiaochen; Liu, Mingming; Liu, Xinhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3327-3347</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are promising therapeutic targets for cancer therapy.  Herein, we describe our efforts toward the discovery of a series of 5-chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine derivs. as dual CDK6 and 9 inhibitors.  Intensive structural modifications lead to the identification of compd. 66 as the most active dual CDK6/9 inhibitor with balancing potency against these two targets and good selectivity over CDK2.  Further biol. studies revealed that compd. 66 was directly bound to CDK6/9, resulting in suppression of their downstream signaling pathway and inhibition of cell proliferation by blocking cell cycle progression and inducing cellular apoptosis.  More importantly, compd. 66 significantly inhibited tumor growth in a xenograft mouse model with no obvious toxicity, indicating the promising therapeutic potential of CDK6/9 dual inhibitors for cancer treatment.  Therefore, the above results are of great importance in the development of dual CDK6/9 inhibitors for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp0hGRgNOM4LVg90H21EOLACvtfcHk0lgEPhKmjjBupg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlOgs70%253D&md5=151501473ce1ccd19bc8cc488286201d</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02121%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DDiscovery%2520and%2520sars%2520of%25205-chloro-n%25284%2529-phenyl-n%25282%2529-%2528pyridin-2-yl%2529pyrimidine-2%252C4-diamine%2520derivatives%2520as%2520oral%2520available%2520and%2520dual%2520CDK6%2520and%25209%2520inhibitors%2520with%2520potent%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3327%26epage%3D3347%26doi%3D10.1021%2Facs.jmedchem.9b02121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huff, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span> <span> </span><span class="NLM_article-title">Variolins and related alkaloids</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3080</span>– <span class="NLM_lpage">3098</span>, <span class="refDoi"> DOI: 10.1021/cr900032s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr900032s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1ensL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=3080-3098&issue=7&author=S.+R.+Walkerauthor=E.+J.+Carterauthor=B.+C.+Huffauthor=J.+C.+Morris&title=Variolins+and+related+alkaloids&doi=10.1021%2Fcr900032s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Variolins and Related Alkaloids</span></div><div class="casAuthors">Walker, Scott R.; Carter, Erin J.; Huff, Belinda C.; Morris, Jonathan C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3080-3098</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review was presented that summarized the isolation, structure detn., synthetic studies and biol. activities of the variolins, meridianins, and meriolins.  The identification and development of new cyclin-dependent kinase (CDK) inhibitors is an important area of research, particularly in the area of cancer chemotherapeutics.  The isolation of variolin B and the meridianins has resulted in a new scaffold being identified.  However, access to these compds. from their natural source, particularly in the case of variolin B, is very difficult, and as such, total synthesis was required to restore access.  This has allowed for more thorough biol. testing and allowed insights into the mode of action of these compds.  It is difficult to say whether variolin B or its deoxy analog will make it to clin. trials because there are issues with their soly. in water and their pharmacokinetic behavior.  However, work on these natural products has led to the discovery that the meriolins, synthetic hybrids that contain common structural features from each family, possess biol. activities that surpass those of either class of natural products.  Work by Meijer and co-workers suggests that the meriolins constitute a potent kinase inhibitory scaffold, and as such, these compds. may in turn inform the development of the next generation of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHctKcp2TF0bVg90H21EOLACvtfcHk0lgNXE8Lni85Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1ensL8%253D&md5=7e617c38d72081988898dae97a40c3d8</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fcr900032s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900032s%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DS.%2BR.%26aulast%3DCarter%26aufirst%3DE.%2BJ.%26aulast%3DHuff%26aufirst%3DB.%2BC.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26atitle%3DVariolins%2520and%2520related%2520alkaloids%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26issue%3D7%26spage%3D3080%26epage%3D3098%26doi%3D10.1021%2Fcr900032s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marionneau-Lambot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo-Lozano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schächtele, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubbutat, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notario, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">8325</span>– <span class="NLM_lpage">8334</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1826</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F0008-5472.CAN-07-1826" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=17804748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFKju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=8325-8334&issue=17&author=K.+Bettayebauthor=O.+M.+Tiradoauthor=S.+Marionneau-Lambotauthor=Y.+Ferandinauthor=O.+Lozachauthor=J.+C.+Morrisauthor=S.+Mateo-Lozanoauthor=P.+Drueckesauthor=C.+Sch%C3%A4chteleauthor=M.+H.+Kubbutatauthor=F.+Ligerauthor=B.+Marquetauthor=B.+Josephauthor=A.+Echalierauthor=J.+A.+Endicottauthor=V.+Notarioauthor=L.+Meijer&title=Meriolins%2C+a+new+class+of+cell+death+inducing+kinase+inhibitors+with+enhanced+selectivity+for+cyclin-dependent+kinases&doi=10.1158%2F0008-5472.CAN-07-1826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Meriolins, a New Class of Cell Death-Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin-Dependent Kinases</span></div><div class="casAuthors">Bettayeb, Karima; Tirado, Oscar M.; Marionneau-Lambot, Severine; Ferandin, Yoan; Lozach, Olivier; Morris, Jonathan C.; Mateo-Lozano, Silvia; Drueckes, Peter; Schaechtele, Christoph; Kubbutat, Michael H. G.; Liger, Francois; Marquet, Bernard; Joseph, Benoit; Echalier, Aude; Endicott, Jane A.; Notario, Vicente; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8325-8334</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Protein kinases represent promising anticancer drug targets.  We describe here the meriolins, a new family of inhibitors of cyclin-dependent kinases (CDK).  Meriolins represent a chem. structural hybrid between meridianins and variolins, two families of kinase inhibitors extd. from various marine invertebrates.  Variolin B is currently in preclin. evaluation as an antitumor agent.  A selectivity study done on 32 kinases showed that, compared with variolin B, meriolins display enhanced specificity toward CDKs, with marked potency on CDK2 and CDK9.  The structures of pCDK2/cyclin A/variolin B and pCDK2/cyclin A/meriolin 3 complexes reveal that the two inhibitors bind within the ATP binding site of the kinase, but in different orientations.  Meriolins display better antiproliferative and proapoptotic properties in human tumor cell cultures than their parent mols., meridianins and variolins.  Phosphorylation at CDK1, CDK4, and CDK9 sites on, resp., protein phosphatase 1α, retinoblastoma protein, and RNA polymerase II is inhibited in neuroblastoma SH-SY5Y cells exposed to meriolins.  Apoptosis triggered by meriolins is accompanied by rapid Mcl-1 down-regulation, cytochrome c release, and activation of caspases.  Meriolin 3 potently inhibits tumor growth in two mouse xenograft cancer models, namely, Ewing's sarcoma and LS174T colorectal carcinoma.  Meriolins thus constitute a new CDK inhibitory scaffold, with promising antitumor activity, derived from mols. initially isolated from marine organisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopZcnwG1KL77Vg90H21EOLACvtfcHk0lgNXE8Lni85Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFKju7g%253D&md5=651f574186c0ff8f13db4edf47220e89</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1826%26sid%3Dliteratum%253Aachs%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DTirado%26aufirst%3DO.%2BM.%26aulast%3DMarionneau-Lambot%26aufirst%3DS.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26aulast%3DMateo-Lozano%26aufirst%3DS.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DSch%25C3%25A4chtele%26aufirst%3DC.%26aulast%3DKubbutat%26aufirst%3DM.%2BH.%26aulast%3DLiger%26aufirst%3DF.%26aulast%3DMarquet%26aufirst%3DB.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNotario%26aufirst%3DV.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DMeriolins%252C%2520a%2520new%2520class%2520of%2520cell%2520death%2520inducing%2520kinase%2520inhibitors%2520with%2520enhanced%2520selectivity%2520for%2520cyclin-dependent%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D17%26spage%3D8325%26epage%3D8334%26doi%3D10.1158%2F0008-5472.CAN-07-1826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clément, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1021/jm700940h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm700940h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2msL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=737-751&issue=4&author=A.+Echalierauthor=K.+Bettayebauthor=Y.+Ferandinauthor=O.+Lozachauthor=M.+Cl%C3%A9mentauthor=A.+Valetteauthor=F.+Ligerauthor=B.+Marquetauthor=J.+C.+Morrisauthor=J.+A.+Endicottauthor=B.+Josephauthor=L.+Meijer&title=Meriolins+%283-%28pyrimidin-4-yl%29-7-azaindoles%29%3A+synthesis%2C+kinase+inhibitory+activity%2C+cellular+effects%2C+and+structure+of+a+CDK2%2Fcyclin+A%2Fmeriolin+complex&doi=10.1021%2Fjm700940h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Meriolins (3-(Pyrimidin-4-yl)-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/Cyclin A/Meriolin Complex</span></div><div class="casAuthors">Echalier, Aude; Bettayeb, Karima; Ferandin, Yoan; Lozach, Olivier; Clelment, Monique; Valette, Annie; Liger, Francois; Marquet, Bernard; Morris, Jonathan C.; Endicott, Jane A.; Joseph, Benoit; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">737-751</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis and biol. characterization of 3-(pyrimidin-4-yl)-7-azaindoles (meriolins), a chem. hybrid between the natural products meridianins and variolins, derived from marine organisms.  Meriolins display potent inhibitory activities toward cyclin-dependent kinases (CDKs) and, to a lesser extent, other kinases (GSK-3, DYRK1A).  The crystal structures of I (meriolin 5) and variolin B in complex with CDK2/cyclin A reveal that the two inhibitors are oriented in very different ways inside the ATP-binding pocket of the kinase.  A structure-activity relationship provides further insight into the mol. mechanism of action of this family of kinase inhibitors.  Meriolins are also potent antiproliferative and proapoptotic agents in cells cultured either as monolayers or in spheroids.  Proapoptotic efficacy of meriolins correlates best with their CDK2 and CDK9 inhibitory activity.  Meriolins thus constitute a promising class of pharmacol. agents to be further evaluated against the numerous human diseases that imply abnormal regulation of CDKs including cancers, neurodegenerative disorders, and polycystic kidney disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJgno3A1_7LVg90H21EOLACvtfcHk0lheL-cZZyPlAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2msL8%253D&md5=1bfb3d02c6894c04237eee27bbccaa5b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm700940h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm700940h%26sid%3Dliteratum%253Aachs%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DM.%26aulast%3DValette%26aufirst%3DA.%26aulast%3DLiger%26aufirst%3DF.%26aulast%3DMarquet%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DMeriolins%2520%25283-%2528pyrimidin-4-yl%2529-7-azaindoles%2529%253A%2520synthesis%252C%2520kinase%2520inhibitory%2520activity%252C%2520cellular%2520effects%252C%2520and%2520structure%2520of%2520a%2520CDK2%252Fcyclin%2520A%252Fmeriolin%2520complex%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D4%26spage%3D737%26epage%3D751%26doi%3D10.1021%2Fjm700940h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chashoo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargotra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintoo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guru, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aruri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatikonda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibber, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mir, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madishetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondhe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. P.</span></span> <span> </span><span class="NLM_article-title">Design of novel 3-pyrimidinylazaindole CDK2/9 inhibitors with potent in vitro and in vivo antitumor efficacy in a triple-negative breast cancer model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">9470</span>– <span class="NLM_lpage">9489</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00663</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00663" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9470-9489&issue=23&author=U.+Singhauthor=G.+Chashooauthor=S.+U.+Khanauthor=P.+Mahajanauthor=A.+Nargotraauthor=G.+Mahajanauthor=A.+Singhauthor=A.+Sharmaauthor=M.+J.+Mintooauthor=S.+K.+Guruauthor=H.+Aruriauthor=T.+Thatikondaauthor=P.+Sahuauthor=P.+Chibberauthor=V.+Kumarauthor=S.+A.+Mirauthor=S.+S.+Bharateauthor=S.+Madishettiauthor=U.+Nandiauthor=G.+Singhauthor=D.+M.+Mondheauthor=S.+Bhushanauthor=F.+Malikauthor=S.+Mignaniauthor=R.+A.+Vishwakarmaauthor=P.+P.+Singh&title=Design+of+novel+3-pyrimidinylazaindole+CDK2%2F9+inhibitors+with+potent+in+vitro+and+in+vivo+antitumor+efficacy+in+a+triple-negative+breast+cancer+model&doi=10.1021%2Facs.jmedchem.7b00663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model</span></div><div class="casAuthors">Singh, Umed; Chashoo, Gousia; Khan, Sameer U.; Mahajan, Priya; Nargotra, Amit; Mahajan, Girish; Singh, Amarinder; Sharma, Anjna; Mintoo, Mubashir J.; Guru, Santosh Kumar; Aruri, Hariprasad; Thatikonda, Thanusha; Sahu, Promod; Chibber, Pankaj; Kumar, Vikas; Mir, Sameer A.; Bharate, Sonali S.; Madishetti, Sreedhar; Nandi, Utpal; Singh, Gurdarshan; Mondhe, Dilip Manikrao; Bhushan, Shashi; Malik, Fayaz; Mignani, Serge; Vishwakarma, Ram A.; Singh, Parvinder Pal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9470-9489</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present study, novel series of 3-pyrimidinylazaindoles were designed and synthesized using bioinformatics strategy as cyclin-dependent kinases CDK2 and CDK9 inhibitors, which play crit. roles in cell-cycle control and regulation of cell transcription.  The present approach has given new dimensions to existing SAR and opens the new opportunity for lead optimization from comparatively inexpensive starting materials.  The study led to the identification of alternative lead candidate I with nanomolar potency against CDK2 and CDK9 and potent anti-proliferative activities against a panel of tested tumor cell lines along better safety ratio of ∼30 in comparison to reported leads.  In addn., the identified lead I has demonstrated good soly. and acceptable in vivo PK profile.  The identified lead I has also shown in vivo efficacy in mouse triple neg. breast cancer (TNBC) syngeneic model with TGI of 90% without any mortality growth inhibition in comparison to reported leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvqLjfKAkGYbVg90H21EOLACvtfcHk0lheL-cZZyPlAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbnL&md5=5f6edf3003a3a7b2e9b29d51c68846d1</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00663%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DU.%26aulast%3DChashoo%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DS.%2BU.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DNargotra%26aufirst%3DA.%26aulast%3DMahajan%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DMintoo%26aufirst%3DM.%2BJ.%26aulast%3DGuru%26aufirst%3DS.%2BK.%26aulast%3DAruri%26aufirst%3DH.%26aulast%3DThatikonda%26aufirst%3DT.%26aulast%3DSahu%26aufirst%3DP.%26aulast%3DChibber%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMir%26aufirst%3DS.%2BA.%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DMadishetti%26aufirst%3DS.%26aulast%3DNandi%26aufirst%3DU.%26aulast%3DSingh%26aufirst%3DG.%26aulast%3DMondhe%26aufirst%3DD.%2BM.%26aulast%3DBhushan%26aufirst%3DS.%26aulast%3DMalik%26aufirst%3DF.%26aulast%3DMignani%26aufirst%3DS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DSingh%26aufirst%3DP.%2BP.%26atitle%3DDesign%2520of%2520novel%25203-pyrimidinylazaindole%2520CDK2%252F9%2520inhibitors%2520with%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520efficacy%2520in%2520a%2520triple-negative%2520breast%2520cancer%2520model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D23%26spage%3D9470%26epage%3D9489%26doi%3D10.1021%2Facs.jmedchem.7b00663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of N1-(4-((7-cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a novel inhibitor targeting cyclin-dependent kinase 4/9 (CDK4/9) and histone deacetlyase1 (HDAC1) against malignant cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3166</span>– <span class="NLM_lpage">3192</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00209</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00209" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFWgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3166-3192&issue=7&author=Y.+Liauthor=X.+Luoauthor=Q.+Guoauthor=Y.+Nieauthor=T.+Wangauthor=C.+Zhangauthor=Z.+Huangauthor=X.+Wangauthor=Y.+Liuauthor=Y.+Chenauthor=J.+Zhengauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=Discovery+of+N1-%284-%28%287-cyclopentyl-6-%28dimethylcarbamoyl%29-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-2-yl%29amino%29phenyl%29-N8-hydroxyoctanediamide+as+a+novel+inhibitor+targeting+cyclin-dependent+kinase+4%2F9+%28CDK4%2F9%29+and+histone+deacetlyase1+%28HDAC1%29+against+malignant+cancer&doi=10.1021%2Facs.jmedchem.8b00209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetylase 1 (HDAC1) against Malignant Cancer</span></div><div class="casAuthors">Li, Yongtao; Luo, Xiaohe; Guo, Qingxiang; Nie, Yongwei; Wang, Tianqi; Zhang, Chao; Huang, Zhi; Wang, Xin; Liu, Yanhua; Chen, Yanan; Zheng, Jianyu; Yang, Shengyong; Fan, Yan; Xiang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3166-3192</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of highly potent, selective inhibitors targeting both CDK4/9 and HDAC1 have been designed and synthesized.  N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide (I) was discovered.  The lead compd. I with excellent CDK4/9 and HDAC1 inhibitory activity of IC50 = 8.8, 12, and 2.2 nM, resp., can effectively induce apoptosis of cancer cell lines.  The kinase profiling of compd. I showed excellent selectivity and specificity.  Compd. I induces G2/M arrest in high concn. and G0/G1 arrest in low concn. to prevent the proliferation and differentiation of cancer cells.  Mice bared-breast cancer treated with I showed significant antitumor efficacy.  The insight into mechanisms of I indicated that it could induce cancer cell death via cell apoptosis based on CDK4/9 and HDAC1 repression and phosphorylation of p53.  The data demonstrated the compd. I could be a promising drug candidate for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4B7BpJ-foDbVg90H21EOLACvtfcHk0lhfNkDfS-jwnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFWgs7c%253D&md5=b1ca389e67a3ccd3fe5c005cb547e369</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00209%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DNie%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520N1-%25284-%2528%25287-cyclopentyl-6-%2528dimethylcarbamoyl%2529-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-2-yl%2529amino%2529phenyl%2529-N8-hydroxyoctanediamide%2520as%2520a%2520novel%2520inhibitor%2520targeting%2520cyclin-dependent%2520kinase%25204%252F9%2520%2528CDK4%252F9%2529%2520and%2520histone%2520deacetlyase1%2520%2528HDAC1%2529%2520against%2520malignant%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D3166%26epage%3D3192%26doi%3D10.1021%2Facs.jmedchem.8b00209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3231</span>– <span class="NLM_lpage">3237</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.06.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bmcl.2017.06.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28651979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKhs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=3231-3237&issue=15&author=Y.+Liauthor=Q.+Guoauthor=C.+Zhangauthor=Z.+Huangauthor=T.+Wangauthor=X.+Wangauthor=X.+Wangauthor=G.+Xuauthor=Y.+Liuauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=Discovery+of+a+highly+potent%2C+selective+and+novel+CDK9+inhibitor+as+an+anticancer+drug+candidate&doi=10.1016%2Fj.bmcl.2017.06.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate</span></div><div class="casAuthors">Li, Yongtao; Guo, Qingxiang; Zhang, Chao; Huang, Zhi; Wang, Tianqi; Wang, Xin; Wang, Xiang; Xu, Guangwei; Liu, Yanhua; Yang, Shengyong; Fan, Yan; Xiang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3231-3237</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arylaminocarbonylcyclopropanecarbonylaminophenylamino pyrrolopyridiminecarboxamide hybrids of the antitumor CDK inhibitor LEE011 and the antitumor VEGFR2 inhibitor cabozantinib such as I were prepd. as potential antitumor agents.  I inhibited CDK9 with an IC50 value of 12 nM, induced apoptosis in breast and lung cancer cell lines at nanomolar concns., and suppressed the growth of breast cancer xenografts in mice without causing significant wt. loss.  Mol. docking calcns. of I bound to the ATP binding site of CDK9 kinase demonstrated the formation of a hydrogen bond between the fluorine atom of the fluorobenzyloxy group and ASN116 not seen in mol. docking calcns. of LEE011.  I blocked cancer cell replication in the G0/G1 and G2/M phases and induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrylmH0vyLZuLVg90H21EOLACvtfcHk0lhlQ5gfEajFVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKhs7nP&md5=58f48a7866815b6b6935100d2ddd9e4e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.06.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.06.041%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520potent%252C%2520selective%2520and%2520novel%2520CDK9%2520inhibitor%2520as%2520an%2520anticancer%2520drug%2520candidate%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D15%26spage%3D3231%26epage%3D3237%26doi%3D10.1016%2Fj.bmcl.2017.06.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosemund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terebesi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bömer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choidas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaumer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rühter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span> <span> </span><span class="NLM_article-title">Identification of atuveciclib (BAY1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">1776</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1002%2Fcmdc.201700447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28961375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1776-1793&issue=21&author=U.+L%C3%BCckingauthor=A.+Scholzauthor=P.+Lienauauthor=G.+Siemeisterauthor=D.+Kosemundauthor=R.+Bohlmannauthor=H.+Briemauthor=I.+Terebesiauthor=K.+Meyerauthor=K.+Prelleauthor=K.+Dennerauthor=U.+B%C3%B6merauthor=M.+Sch%C3%A4ferauthor=K.+Eisauthor=R.+Valenciaauthor=S.+Inceauthor=F.+von+Nussbaumauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=B.+Kleblauthor=A.+Choidasauthor=P.+Nussbaumerauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=G.+R%C3%BChterauthor=J.+Eickhoffauthor=M.+Brands&title=Identification+of+atuveciclib+%28BAY1143572%29%2C+the+first+highly+selective%2C+clinical+PTEFb%2FCDK9+inhibitor+for+the+treatment+of+cancer&doi=10.1002%2Fcmdc.201700447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Luecking, Ulrich; Scholz, Arne; Lienau, Philip; Siemeister, Gerhard; Kosemund, Dirk; Bohlmann, Rolf; Briem, Hans; Terebesi, Ildiko; Meyer, Kirstin; Prelle, Katja; Denner, Karsten; Boemer, Ulf; Schaefer, Martina; Eis, Knut; Valencia, Ray; Ince, Stuart; von Nussbaum, Franz; Mumberg, Dominik; Ziegelbauer, Karl; Klebl, Bert; Choidas, Axel; Nussbaumer, Peter; Baumann, Matthias; Schultz-Fademrecht, Carsten; Ruehter, Gerd; Eickhoff, Jan; Brands, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1776-1793</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy.  Starting from lead compd. BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochem. and DMPK properties finally led to the identification of the orally available clin. candidate atuveciclib (BAY 1143572).  Structurally characterized by an unusual benzyl sulfoximine group, BAY 1143572 exhibited the best overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats.  BAY 1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypgkxBuypa7Vg90H21EOLACvtfcHk0lhlQ5gfEajFVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ&md5=04fb5dae9956246889e1313c87339990</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700447%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DBohlmann%26aufirst%3DR.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DTerebesi%26aufirst%3DI.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DPrelle%26aufirst%3DK.%26aulast%3DDenner%26aufirst%3DK.%26aulast%3DB%25C3%25B6mer%26aufirst%3DU.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DEis%26aufirst%3DK.%26aulast%3DValencia%26aufirst%3DR.%26aulast%3DInce%26aufirst%3DS.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DNussbaumer%26aufirst%3DP.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DR%25C3%25BChter%26aufirst%3DG.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DBrands%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520atuveciclib%2520%2528BAY1143572%2529%252C%2520the%2520first%2520highly%2520selective%252C%2520clinical%2520PTEFb%252FCDK9%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26issue%3D21%26spage%3D1776%26epage%3D1793%26doi%3D10.1002%2Fcmdc.201700447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luecking, U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosemund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terebesi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaum, F. v.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span> <span> </span><span class="NLM_article-title">Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from P.O. to I.V. application via scaffold hops</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">984</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1538-7445.AM2017-984" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=984&author=U.+T.+Lueckingauthor=A.+Scholzauthor=D.+Kosemundauthor=R.+Bohlmannauthor=H.+Briemauthor=P.+Lienauauthor=G.+Siemeisterauthor=I.+Terebesiauthor=K.+Meyerauthor=K.+Prelleauthor=R.+Valenciaauthor=S.+Inceauthor=F.+v.+Nussbaumauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=M.+Brands&title=Identification+of+potent+and+highly+selective+PTEFb+inhibitor+BAY+1251152+for+the+treatment+of+cancer%3A+from+P.O.+to+I.V.+application+via+scaffold+hops&doi=10.1158%2F1538-7445.AM2017-984"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-984%26sid%3Dliteratum%253Aachs%26aulast%3DLuecking%26aufirst%3DU.%2BT.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DBohlmann%26aufirst%3DR.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DTerebesi%26aufirst%3DI.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DPrelle%26aufirst%3DK.%26aulast%3DValencia%26aufirst%3DR.%26aulast%3DInce%26aufirst%3DS.%26aulast%3DNussbaum%26aufirst%3DF.%2Bv.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DBrands%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520potent%2520and%2520highly%2520selective%2520PTEFb%2520inhibitor%2520BAY%25201251152%2520for%2520the%2520treatment%2520of%2520cancer%253A%2520from%2520P.O.%2520to%2520I.V.%2520application%2520via%2520scaffold%2520hops%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D984%26doi%3D10.1158%2F1538-7445.AM2017-984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cidado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boiko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span> <span> </span><span class="NLM_article-title">AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3572</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2016-3572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1538-7445.AM2016-3572" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=3572&author=J.+Cidadoauthor=M.+Shenauthor=M.+Grondineauthor=S.+Boikoauthor=H.+Wangauthor=A.+Borodovskyauthor=A.+M.+Mazzolaauthor=A.+Wuauthor=D.+Lawsonauthor=D.+Fergusonauthor=B.+Gaoauthor=A.+Cuiauthor=C.+D%E2%80%99Cruzauthor=L.+Drew&title=AZ5576%2C+a+novel+potent+and+selective+CDK9+inhibitor%2C+induces+rapid+cell+death+and+achieves+efficacy+in+multiple+preclinical+hematological+models&doi=10.1158%2F1538-7445.AM2016-3572"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-3572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-3572%26sid%3Dliteratum%253Aachs%26aulast%3DCidado%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DGrondine%26aufirst%3DM.%26aulast%3DBoiko%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBorodovsky%26aufirst%3DA.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DLawson%26aufirst%3DD.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DB.%26aulast%3DCui%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Cruz%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26atitle%3DAZ5576%252C%2520a%2520novel%2520potent%2520and%2520selective%2520CDK9%2520inhibitor%252C%2520induces%2520rapid%2520cell%2520death%2520and%2520achieves%2520efficacy%2520in%2520multiple%2520preclinical%2520hematological%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D14%26spage%3D3572%26doi%3D10.1158%2F1538-7445.AM2016-3572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cidado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boiko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criscione, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pop-Damkov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roamio Franklin, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekhar Reddy Chilamakuri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Santos, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span> <span> </span><span class="NLM_article-title">AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematologic cancer cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-1853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F1078-0432.CCR-19-1853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31699827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslylsLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=922-934&author=J.+Cidadoauthor=S.+Boikoauthor=T.+Proiaauthor=D.+Fergusonauthor=S.+W.+Criscioneauthor=M.+San+Martinauthor=P.+Pop-Damkovauthor=N.+Suauthor=V.+N.+Roamio+Franklinauthor=C.+Sekhar+Reddy+Chilamakuriauthor=C.+S.+D%E2%80%99Santosauthor=W.+Shaoauthor=J.+C.+Saehauthor=R.+Kochauthor=D.+M.+Weinstockauthor=M.+Zindaauthor=S.+E.+Fawellauthor=L.+Drew&title=AZD4573+is+a+highly+selective+CDK9+inhibitor+that+suppresses+Mcl-1+and+induces+apoptosis+in+hematologic+cancer+cells&doi=10.1158%2F1078-0432.CCR-19-1853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells</span></div><div class="casAuthors">Cidado, Justin; Boiko, Scott; Proia, Theresa; Ferguson, Douglas; Criscione, Steven W.; Martin, Maryann San; Pop-Damkov, Petar; Su, Nancy; Franklin, Valar Nila Roamio; Chilamakuri, Chandra Sekhar Reddy; D'Santos, Clive S.; Shao, Wenlin; Saeh, Jamal C.; Koch, Raphael; Weinstock, David M.; Zinda, Michael; Fawell, Stephen E.; Drew, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">922-934</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CDK9 is a transcriptional regulator and potential therapeutic target for many cancers.  Multiple nonselective CDK9 inhibitors have progressed clin. but were limited by a narrow therapeutic window.  This work describes a novel, potent, and highly selective CDK9 inhibitor, AZD4573.  The antitumor activity of AZD4573 was detd. across broad cancer cell line panels in vitro as well as cell line- and patient-derived xenograft models in vivo.  Multiple approaches, including integrated transcriptomic and proteomic analyses, loss-of-function pathway interrogation, and pharmacol. comparisons, were employed to further understand the major mechanism driving AZD4573 activity and to establish an exposure/effect relationship.  AZD4573 is a highly selective and potent CDK9 inhibitor.  It demonstrated rapid induction of apoptosis and subsequent cell death broadly across hematol. cancer models in vitro, and MCL-1 depletion in a dose- and time-dependent manner was identified as a major mechanism through which AZD4573 induces cell death in tumor cells.  This understanding of the mechanism, exposure, and antitumor activity of AZD4573 facilitated development of a robust pharmacokinetic/PD/efficacy model used to inform the clin. trial design.  Selective targeting of CDK9 enables the indirect inhibition of MCL-1, providing a therapeutic option for MCL-1-dependent diseases.  Accordingly, AZD4573 is currently being evaluated in a phase I clin. trial for patients with hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp213MDHb0Y7rVg90H21EOLACvtfcHk0lglO3-BukrFLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslylsLrK&md5=18be82de651b9be77a95f3d7c423b6aa</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-1853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-1853%26sid%3Dliteratum%253Aachs%26aulast%3DCidado%26aufirst%3DJ.%26aulast%3DBoiko%26aufirst%3DS.%26aulast%3DProia%26aufirst%3DT.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DCriscione%26aufirst%3DS.%2BW.%26aulast%3DSan%2BMartin%26aufirst%3DM.%26aulast%3DPop-Damkov%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DN.%26aulast%3DRoamio%2BFranklin%26aufirst%3DV.%2BN.%26aulast%3DSekhar%2BReddy%2BChilamakuri%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Santos%26aufirst%3DC.%2BS.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DKoch%26aufirst%3DR.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DDrew%26aufirst%3DL.%26atitle%3DAZD4573%2520is%2520a%2520highly%2520selective%2520CDK9%2520inhibitor%2520that%2520suppresses%2520Mcl-1%2520and%2520induces%2520apoptosis%2520in%2520hematologic%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D922%26epage%3D934%26doi%3D10.1158%2F1078-0432.CCR-19-1853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaxman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidiqi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertz, M.</span></span> <span> </span><span class="NLM_article-title">Venetoclax for the treatment of multiple myeloma</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">915</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1080/17474086.2018.1548931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1080%2F17474086.2018.1548931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30428277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKit7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=915-920&author=I.+Vaxmanauthor=M.+H.+Sidiqiauthor=M.+Gertz&title=Venetoclax+for+the+treatment+of+multiple+myeloma&doi=10.1080%2F17474086.2018.1548931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Venetoclax for the treatment of multiple myeloma</span></div><div class="casAuthors">Vaxman, Iuliana; Sidiqi, M. Hasib; Gertz, Morie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">915-920</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Treatment of multiple myeloma (MM) in the relapsed setting remains challenging, despite recent impressive advances in the management of these patients.  Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration for treatment of chronic lymphocytic leukemia but the drug has shown activity in a no. of hematol. malignancies.  Venetoclax has broadened the treatment options for patients with relapsed or refractory MM.  Approx., 20% of myeloma patients will exhibit t (11;14) assocd. with high BCL-2 expression making venetoclax an attractive therapeutic option.  The efficacy of venetoclax is not uniquely restricted to this population.  This review will summarize the mechanism of action, toxicity profile, and published data on venetoclax use in MM, moving the field toward personalized medicine in the treatment of myeloma.  Numerous phase 1/2 clin. trials are evaluating the efficacy and safety of venetoclax monotherapy and in combinations in the relapse setting.  These trials show better outcomes in the subgroup of patients harboring t(11;14).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrbEBbpXasZLVg90H21EOLACvtfcHk0ljvFgj3lwOfNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKit7vF&md5=5ecd31654e1af8b8bb5cc4c73a2eaef3</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1080%2F17474086.2018.1548931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2018.1548931%26sid%3Dliteratum%253Aachs%26aulast%3DVaxman%26aufirst%3DI.%26aulast%3DSidiqi%26aufirst%3DM.%2BH.%26aulast%3DGertz%26aufirst%3DM.%26atitle%3DVenetoclax%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2018%26volume%3D11%26spage%3D915%26epage%3D920%26doi%3D10.1080%2F17474086.2018.1548931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.1021/jm301495v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301495v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=660-670&author=A.+J.+Holeauthor=S.+Baumliauthor=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wangauthor=J.+A.+Endicottauthor=M.+E.+Noble&title=Comparative+structural+and+functional+studies+of+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidine-5-carbonitrile+CDK9+inhibitors+suggest+the+basis+for+isotype+selectivity&doi=10.1021%2Fjm301495v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span></div><div class="casAuthors">Hole, Alison J.; Baumli, Sonja; Shao, Hao; Shi, Shenhua; Huang, Shiliang; Pepper, Chris; Fischer, Peter M.; Wang, Shudong; Endicott, Jane A.; Noble, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">660-670</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9/cyclin T, the protein kinase heterodimer that constitutes pos. transcription elongation factor b, is a well-validated target for treatment of several diseases, including cancer and cardiac hypertrophy.  In order to aid inhibitor design and rationalize the basis for CDK9 selectivity, we have studied the CDK-binding properties of six different members of a 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series that bind to both CDK9/cyclin T and CDK2/cyclin A.  We find that for a given CDK, the melting temp. of a CDK/cyclin/inhibitor complex correlates well with inhibitor potency, suggesting that differential scanning fluorometry (DSF) is a useful orthogonal measure of inhibitory activity for this series.  We have used DSF to demonstrate that the binding of these compds. is independent of the presence or absence of the C-terminal tail region of CDK9, unlike the binding of the CDK9-selective inhibitor 5,6-dichlorobenzimidazone-1-β-D-ribofuranoside (DRB).  Finally, on the basis of 11 cocrystal structures bound to CDK9/cyclin T or CDK2/cyclin A, we conclude that selective inhibition of CDK9/cyclin T by members of the 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series results from the relative malleability of the CDK9 active site rather than from the formation of specific polar contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGJy-t5isJBbVg90H21EOLACvtfcHk0ljvFgj3lwOfNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE&md5=8c09b13b5f828b7a013607cab64b0b80</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm301495v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301495v%26sid%3Dliteratum%253Aachs%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DComparative%2520structural%2520and%2520functional%2520studies%2520of%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidine-5-carbonitrile%2520CDK9%2520inhibitors%2520suggest%2520the%2520basis%2520for%2520isotype%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D660%26epage%3D670%26doi%3D10.1021%2Fjm301495v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erb, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doctor, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boukhali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnchembio.2538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29251720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFyrsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=163-170&author=C.+M.+Olsonauthor=B.+Jiangauthor=M.+A.+Erbauthor=Y.+Liangauthor=Z.+M.+Doctorauthor=Z.+Zhangauthor=T.+Zhangauthor=N.+Kwiatkowskiauthor=M.+Boukhaliauthor=J.+L.+Greenauthor=W.+Haasauthor=T.+Nomanbhoyauthor=E.+S.+Fischerauthor=R.+A.+Youngauthor=J.+E.+Bradnerauthor=G.+E.+Winterauthor=N.+S.+Gray&title=Pharmacological+perturbation+of+CDK9+using+selective+CDK9+inhibition+or+degradation&doi=10.1038%2Fnchembio.2538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation</span></div><div class="casAuthors">Olson, Calla M.; Jiang, Baishan; Erb, Michael A.; Liang, Yanke; Doctor, Zainab M.; Zhang, Zinan; Zhang, Tinghu; Kwiatkowski, Nicholas; Boukhali, Myriam; Green, Jennifer L.; Haas, Wilhelm; Nomanbhoy, Tyzoon; Fischer, Eric S.; Young, Richard A.; Bradner, James E.; Winter, Georg E.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-170</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation.  The authors characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 degrader consisting of a CDK-binding SNS-032 ligand linked to a thalidomide deriv. that binds the E3 ubiquitin ligase Cereblon (CRBN).  To the authors' surprise, THAL-SNS-032 induced rapid degrdn. of CDK9 without affecting the levels of other SNS-032 targets.  Moreover, the transcriptional changes elicited by THAL-SNS-032 were more like those caused by NVP-2 than those induced by SNS-032.  Notably, compd. washout did not significantly reduce levels of THAL-SNS-032-induced apoptosis, suggesting that CDK9 degrdn. had prolonged cytotoxic effects compared with CDK9 inhibition.  Thus, the authors' findings suggest that thalidomide conjugation represents a promising strategy for converting multi-targeted inhibitors into selective degraders and reveal that kinase degrdn. can induce distinct pharmacol. effects compared with inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWnT9r0GIlmbVg90H21EOLACvtfcHk0ljvFgj3lwOfNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFyrsr7O&md5=88aabb209b4cb7516a652d6c75a35667</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2538%26sid%3Dliteratum%253Aachs%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DErb%26aufirst%3DM.%2BA.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DDoctor%26aufirst%3DZ.%2BM.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DBoukhali%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DJ.%2BL.%26aulast%3DHaas%26aufirst%3DW.%26aulast%3DNomanbhoy%26aufirst%3DT.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DPharmacological%2520perturbation%2520of%2520CDK9%2520using%2520selective%2520CDK9%2520inhibition%2520or%2520degradation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D163%26epage%3D170%26doi%3D10.1038%2Fnchembio.2538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">112424</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2020.112424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=32447197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVWitr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2020&pages=112424&author=J.+Xuauthor=H.+Liauthor=X.+Wangauthor=J.+Huangauthor=S.+Liauthor=C.+Liuauthor=R.+Dongauthor=G.+Zhuauthor=C.+Duanauthor=F.+Jiangauthor=Y.+Zhangauthor=Y.+Zhuauthor=T.+Zhangauthor=Y.+Chenauthor=W.+Tangauthor=T.+Lu&title=Discovery+of+coumarin+derivatives+as+potent+and+selective+cyclin-dependent+kinase+9+%28CDK9%29+inhibitors+with+high+antitumour+activity&doi=10.1016%2Fj.ejmech.2020.112424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumor activity</span></div><div class="casAuthors">Xu, Junyu; Li, Hongmei; Wang, Xinren; Huang, Jianhang; Li, Shuwen; Liu, Chenhe; Dong, Ruinan; Zhu, Gaoyuan; Duan, Chunqi; Jiang, Fei; Zhang, Yanmin; Zhu, Yuqin; Zhang, Tianyi; Chen, Yadong; Tang, Weifang; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112424</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Specific inhibition of CDK9 is considered a promising strategy for developing effective anticancer therapeutics.  However, most of the reported CDK9 inhibitors are still at an early stage of development and lack selectivity against other CDKs.  Herein, we discovered coumarin deriv. 30i(I) as a potent CDK9 inhibitor with high selectivity (8300-fold over CDK7).  Binding mode anal. illustrated that the substituent coumarin moiety is a crit. group for CDK9 selectivity by occupying a flexible hinge/αD region, which is sterically hindered in other CDKs.  Compd. 30i showed excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition.  Moreover, 30i significantly induced tumor growth inhibition in a dose-dependent manner without causing an obvious loss of body wt. in an MV4-11 xenograft mice model.  Altogether, these results suggest that 30i may serve as a potential acute myeloid leukemia (AML) therapeutics by selectively targeting CDK9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSaq963s3BbVg90H21EOLACvtfcHk0lgm2PSkA8QMLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVWitr3N&md5=aeb59372b32a4acc1189bad3ccd506ff</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112424%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DDong%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DG.%26aulast%3DDuan%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520coumarin%2520derivatives%2520as%2520potent%2520and%2520selective%2520cyclin-dependent%2520kinase%25209%2520%2528CDK9%2529%2520inhibitors%2520with%2520high%2520antitumour%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D200%26spage%3D112424%26doi%3D10.1016%2Fj.ejmech.2020.112424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahir, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penning, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devlin, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsi, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souers, A. J.</span></span> <span> </span><span class="NLM_article-title">A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1646</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1038/s41375-019-0652-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fs41375-019-0652-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31827241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSltL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=1646-1657&author=D.+C.+Phillipsauthor=S.+Jinauthor=G.+P.+Gregoryauthor=Q.+Zhangauthor=J.+Xueauthor=X.+Zhaoauthor=J.+Chenauthor=Y.+Tongauthor=H.+Zhangauthor=M.+Smithauthor=S.+K.+Tahirauthor=R.+F.+Clarkauthor=T.+D.+Penningauthor=J.+R.+Devlinauthor=J.+Shorttauthor=E.+D.+Hsiauthor=D.+H.+Albertauthor=M.+Konoplevaauthor=R.+W.+Johnstoneauthor=J.+D.+Leversonauthor=A.+J.+Souers&title=A+novel+CDK9+inhibitor+increases+the+efficacy+of+venetoclax+%28ABT-199%29+in+multiple+models+of+hematologic+malignancies&doi=10.1038%2Fs41375-019-0652-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies</span></div><div class="casAuthors">Phillips, Darren C.; Jin, Sha; Gregory, Gareth P.; Zhang, Qi; Xue, John; Zhao, Xiaoxian; Chen, Jun; Tong, Yunsong; Zhang, Haichao; Smith, Morey; Tahir, Stephen K.; Clark, Rick F.; Penning, Thomas D.; Devlin, Jennifer R.; Shortt, Jake; Hsi, Eric D.; Albert, Daniel H.; Konopleva, Marina; Johnstone, Ricky W.; Leverson, Joel D.; Souers, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1646-1657</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">MCL-1 is one of the most frequently amplified genes in cancer, facilitating tumor initiation and maintenance and enabling resistance to anti-tumorigenic agents including the BCL-2 selective inhibitor venetoclax.  The expression of MCL-1 is maintained via P-TEFb-mediated transcription, where the kinase CDK9 is a crit. component.  Consequently, we developed a series of potent small-mol. inhibitors of CDK9, exemplified by the orally active A-1592668, with CDK selectivity profiles that are distinct from related mols. that have been extensively studied clin.  Short-term treatment with A-1592668 rapidly downregulates RNA pol-II (Ser 2) phosphorylation resulting in the loss of MCL-1 protein and apoptosis in MCL-1-dependent hematol. tumor cell lines.  This cell death could be attenuated by either inhibiting caspases or overexpressing BCL-2 protein.  Synergistic cell killing was also obsd. between A-1592668 or the related analog A-1467729, and venetoclax in a no. of hematol. cell lines and primary NHL patient samples.  Importantly, the CDK9 inhibitor plus venetoclax combination was well tolerated in vivo and demonstrated efficacy superior to either agent alone in mouse models of lymphoma and AML.  These data indicate that CDK9 inhibitors could be highly efficacious in tumors that depend on MCL-1 for survival or when used in combination with venetoclax in malignancies dependent on MCL-1 and BCL-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphCp3ZfyvPi7Vg90H21EOLACvtfcHk0lgm2PSkA8QMLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSltL3E&md5=1857f3731a7b2711d00444b65804aac4</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fs41375-019-0652-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-019-0652-0%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DD.%2BC.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DGregory%26aufirst%3DG.%2BP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DTahir%26aufirst%3DS.%2BK.%26aulast%3DClark%26aufirst%3DR.%2BF.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DDevlin%26aufirst%3DJ.%2BR.%26aulast%3DShortt%26aufirst%3DJ.%26aulast%3DHsi%26aufirst%3DE.%2BD.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DLeverson%26aufirst%3DJ.%2BD.%26aulast%3DSouers%26aufirst%3DA.%2BJ.%26atitle%3DA%2520novel%2520CDK9%2520inhibitor%2520increases%2520the%2520efficacy%2520of%2520venetoclax%2520%2528ABT-199%2529%2520in%2520multiple%2520models%2520of%2520hematologic%2520malignancies%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D1646%26epage%3D1657%26doi%3D10.1038%2Fs41375-019-0652-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu Jin, U.</span>; <span class="NLM_string-name">Geisler, J.</span>; <span class="NLM_string-name">Hogg, D.</span>; <span class="NLM_string-name">Scholz, A.</span>; <span class="NLM_string-name">Peterson, K.</span>; <span class="NLM_string-name">Linau, P.</span>; <span class="NLM_string-name">Stegman, C.</span>; <span class="NLM_string-name">Andres, D.</span></span> <span> </span><span class="NLM_article-title">New Macrocyclic Sulfonimide Compounds</span>. Patent <span class="NLM_patent">CN108290903</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=U.+Lu+Jin&author=J.+Geisler&author=D.+Hogg&author=A.+Scholz&author=K.+Peterson&author=P.+Linau&author=C.+Stegman&author=D.+Andres&title=New+Macrocyclic+Sulfonimide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLu%2BJin%26aufirst%3DU.%26atitle%3DNew%2520Macrocyclic%2520Sulfonimide%2520Compounds%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cozemont, D.</span>; <span class="NLM_string-name">Lu Jin, U.</span>; <span class="NLM_string-name">Simest, G.</span>; <span class="NLM_string-name">Scholz, A.</span>; <span class="NLM_string-name">Linau, P.</span></span> <span> </span><span class="NLM_article-title">Fluorinated Benzofuranyl-pyrimidine Derivatives Containing Sulfone Groups</span>. Patent <span class="NLM_patent">CN107207475A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+Cozemont&author=U.+Lu+Jin&author=G.+Simest&author=A.+Scholz&author=P.+Linau&title=Fluorinated+Benzofuranyl-pyrimidine+Derivatives+Containing+Sulfone+Groups"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCozemont%26aufirst%3DD.%26atitle%3DFluorinated%2520Benzofuranyl-pyrimidine%2520Derivatives%2520Containing%2520Sulfone%2520Groups%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span>; <span class="NLM_string-name">Tao, Z.</span>; <span class="NLM_string-name">Tong, Y.</span>; <span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">CDK9 Kinase Inhibitors with Pyrrolo [2,3-B] Pyridine</span>. Patent <span class="NLM_patent">CN105324380A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Gong&author=Z.+Tao&author=Y.+Tong&author=G.+Zhu&title=CDK9+Kinase+Inhibitors+with+Pyrrolo+%5B2%2C3-B%5D+Pyridine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26atitle%3DCDK9%2520Kinase%2520Inhibitors%2520with%2520Pyrrolo%2520%255B2%252C3-B%255D%2520Pyridine%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul A, B.</span>; <span class="NLM_string-name">Hu, C.</span>; <span class="NLM_string-name">Jin, X.</span>; <span class="NLM_string-name">Simon C, N. G.</span>; <span class="NLM_string-name">Keith B, P.</span>; <span class="NLM_string-name">Martin, S.</span>; <span class="NLM_string-name">James, S.</span></span> <span> </span><span class="NLM_article-title">N-Acyl Pyridine Biaryl Compounds and Their Uses</span>. Patent <span class="NLM_patent">WO2012/101063A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=B.+Paul+A&author=C.+Hu&author=X.+Jin&author=N.+G.+Simon+C&author=P.+Keith+B&author=S.+Martin&author=S.+James&title=N-Acyl+Pyridine+Biaryl+Compounds+and+Their+Uses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%2BA%26aufirst%3DB.%26atitle%3DN-Acyl%2520Pyridine%2520Biaryl%2520Compounds%2520and%2520Their%2520Uses%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Childers, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elokely, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Gharbia, A.</span></span> <span> </span><span class="NLM_article-title">The resurrection of phenotypic drug discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=W.+E.+Childersauthor=K.+M.+Elokelyauthor=A.+Abou-Gharbia&title=The+resurrection+of+phenotypic+drug+discovery&doi=10.1021%2Facsmedchemlett.0c00006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00006%26sid%3Dliteratum%253Aachs%26aulast%3DChilders%26aufirst%3DW.%2BE.%26aulast%3DElokely%26aufirst%3DK.%2BM.%26aulast%3DAbou-Gharbia%26aufirst%3DA.%26atitle%3DThe%2520resurrection%2520of%2520phenotypic%2520drug%2520discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26doi%3D10.1021%2Facsmedchemlett.0c00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis-targeting chimeras as therapeutics and tools for biological discovery</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.cell.2019.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31955850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=102-114&issue=1&author=G.+M.+Burslemauthor=C.+M.+Crews&title=Proteolysis-targeting+chimeras+as+therapeutics+and+tools+for+biological+discovery&doi=10.1016%2Fj.cell.2019.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery</span></div><div class="casAuthors">Burslem, George M.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-114</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  New biol. tools provide new techniques to probe fundamental biol. processes.  Here we describe the burgeoning field of proteolysis-targeting chimeras (PROTACs), which are capable of modulating protein concns. at a post-translational level by co-opting the ubiquitin-proteasome system.  We describe the PROTAC technol. and its application to drug discovery and provide examples where PROTACs have enabled novel biol. insights.  Furthermore, we provide a workflow for PROTAC development and use and discuss the benefits and issues assocd. with PROTACs.  Finally, we compare PROTAC-mediated protein-level modulation with other technologies, such as RNAi and genome editing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXgumsEakVWrVg90H21EOLACvtfcHk0liRE8t5OAy4Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Sitrk%253D&md5=3010929d2979cf04dc6003e66575f1b0</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DProteolysis-targeting%2520chimeras%2520as%2520therapeutics%2520and%2520tools%2520for%2520biological%2520discovery%26jtitle%3DCell%26date%3D2020%26volume%3D181%26issue%3D1%26spage%3D102%26epage%3D114%26doi%3D10.1016%2Fj.cell.2019.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, D.</span></span> <span> </span><span class="NLM_article-title">Phenotypic screening in cancer drug discovery-past, present and future</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/nrd4366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnrd4366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=25033736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=588-602&issue=8&author=J.+G.+Moffatauthor=J.+Rudolphauthor=D.+Bailey&title=Phenotypic+screening+in+cancer+drug+discovery-past%2C+present+and+future&doi=10.1038%2Fnrd4366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening in cancer drug discovery - past, present and future</span></div><div class="casAuthors">Moffat, John G.; Rudolph, Joachim; Bailey, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-602</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches.  Given that oncol. is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncol. drug discovery by analyzing the origins of all new small-mol. cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clin. development.  Although the majority of these drugs originated from target-based discovery, we identified a significant no. whose discovery depended on phenotypic screening approaches.  We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes.  However, tech. and biol. advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTWtoTIgWqvbVg90H21EOLACvtfcHk0liRE8t5OAy4Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L&md5=0e8efed90e5bc4b47f959b83a6ab5b96</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fnrd4366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4366%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DD.%26atitle%3DPhenotypic%2520screening%2520in%2520cancer%2520drug%2520discovery-past%252C%2520present%2520and%2520future%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D8%26spage%3D588%26epage%3D602%26doi%3D10.1038%2Fnrd4366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butera, J. A.</span></span> <span> </span><span class="NLM_article-title">Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents: an editorial miniperspectives series on phenotypic screening for antiinfective targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">7715</span>– <span class="NLM_lpage">7718</span>, <span class="refDoi"> DOI: 10.1021/jm400443k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400443k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Chs7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7715-7718&issue=20&author=J.+A.+Butera&title=Phenotypic+screening+as+a+strategic+component+of+drug+discovery+programs+targeting+novel+antiparasitic+and+antimycobacterial+agents%3A+an+editorial+miniperspectives+series+on+phenotypic+screening+for+antiinfective+targets&doi=10.1021%2Fjm400443k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic Screening as a Strategic Component of Drug Discovery Programs Targeting Novel Antiparasitic and Antimycobacterial Agents: An Editorial</span></div><div class="casAuthors">Butera, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7715-7718</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review. Drug development for neglected tropical diseases, defined as a collection of infectious diseases affecting over 4 billion people worldwide (esp. endemic to poverty-stricken populations in underdeveloped regions of Africa, Asia, the Pacific Rim, and Latin America), has been underfunded and stagnant.  A much needed resurgence of R&D activity in this area is currently developing.  Target-directed screening and whole-cell phenotypic screening represent two complementary approaches to discover viable new starting point scaffolds for medicinal chem. optimization.  This editorial will provide introductory comments to a series of six miniperspectives that focus on the special challenges faced by scientists in discovering potential new chem. leads that could be optimized into promising clin. candidates for neglected tropical diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocE0tu0F4KKbVg90H21EOLACvtfcHk0lhjMzhljnABKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Chs7fM&md5=53dd78afac8444f8739dfe03c25f41f5</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm400443k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400443k%26sid%3Dliteratum%253Aachs%26aulast%3DButera%26aufirst%3DJ.%2BA.%26atitle%3DPhenotypic%2520screening%2520as%2520a%2520strategic%2520component%2520of%2520drug%2520discovery%2520programs%2520targeting%2520novel%2520antiparasitic%2520and%2520antimycobacterial%2520agents%253A%2520an%2520editorial%2520miniperspectives%2520series%2520on%2520phenotypic%2520screening%2520for%2520antiinfective%2520targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D20%26spage%3D7715%26epage%3D7718%26doi%3D10.1021%2Fjm400443k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ali, H.</span></span> <span> </span><span class="NLM_article-title">The evolution of drug discovery: from phenotypes to targets, and back</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1039/C6MD00129G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1039%2FC6MD00129G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=788-798&author=H.+Al-Ali&title=The+evolution+of+drug+discovery%3A+from+phenotypes+to+targets%2C+and+back&doi=10.1039%2FC6MD00129G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of drug discovery: from phenotypes to targets, and back</span></div><div class="casAuthors">Al-Ali, Hassan</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">788-798</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cumulative scientific and technol. advances over the past two centuries have transformed drug discovery from a largely serendipitous process into the high tech pipelines of today.  For thousands of years, medicines were sourced directly from nature, through observing the phenotypic effects of substances on humans or animals.  Following the mol. biol. revolution and initiation of the human genome project in the 1990s, target-based screening gained popularity and soon came to dominate the pharmaceutical industry.  Two decades later, the phenotypic approach began to make a strong comeback, benefiting from the scalability and speed afforded by massive technol. advances.  This has ignited a debate over the relative productivities of phenotypic and target-based screening.  However, as more integrative technologies become available, the focus of the discussion should shift from prioritizing the different approaches to finding strategies that can combine their complementary strengths.  This review chronicles major trends and transformative events in the evolution of drug discovery, and underscores the importance of phenotypic approaches for past, and likely future, successes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeOAT0eQ1lu7Vg90H21EOLACvtfcHk0lhjMzhljnABKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVOjtbY%253D&md5=53787b4b2d5869bf857cf0e834c361bf</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1039%2FC6MD00129G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00129G%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Ali%26aufirst%3DH.%26atitle%3DThe%2520evolution%2520of%2520drug%2520discovery%253A%2520from%2520phenotypes%2520to%2520targets%252C%2520and%2520back%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D788%26epage%3D798%26doi%3D10.1039%2FC6MD00129G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J.-P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S.</span></span> <span> </span><span class="NLM_article-title">Targeting the cancer epigenome for therapy</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1038/nrg.2016.93</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnrg.2016.93" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27629931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWiu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=630-641&issue=10&author=P.+A.+Jonesauthor=J.-P.+J.+Issaauthor=S.+Baylin&title=Targeting+the+cancer+epigenome+for+therapy&doi=10.1038%2Fnrg.2016.93"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer epigenome for therapy</span></div><div class="casAuthors">Jones, Peter A.; Issa, Jean-Pierre J.; Baylin, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">630-641</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Next-generation sequencing has revealed that more than 50% of human cancers harbor mutations in enzymes that are involved in chromatin organization.  Tumor cells not only are activated by genetic and epigenetic alterations, but also routinely use epigenetic processes to ensure their escape from chemotherapy and host immune surveillance.  Hence, a growing emphasis of recent drug discovery efforts has been on targeting the epigenome, including DNA methylation and histone modifications, with several new drugs being tested and some already approved by the US Food and Drug Administration (FDA).  The future will see the increasing success of combining epigenetic drugs with other therapies.  As epigenetic drugs target the epigenome as a whole, these true 'genomic medicines' lessen the need for precision approaches to individualized therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5pfbPOnZMtbVg90H21EOLACvtfcHk0lhjMzhljnABKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWiu77O&md5=22d98e58a4637d61af34a382e92adace</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fnrg.2016.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg.2016.93%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BA.%26aulast%3DIssa%26aufirst%3DJ.-P.%2BJ.%26aulast%3DBaylin%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520cancer%2520epigenome%2520for%2520therapy%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2016%26volume%3D17%26issue%3D10%26spage%3D630%26epage%3D641%26doi%3D10.1038%2Fnrg.2016.93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bewersdorf, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shallis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidan, A. M.</span></span> <span> </span><span class="NLM_article-title">Epigenetic therapy combinations in acute myeloid leukemia: what are the options?</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1177/2040620718816698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1177%2F2040620718816698" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1-19&author=J.+P.+Bewersdorfauthor=R.+Shallisauthor=M.+Stahlauthor=A.+M.+Zeidan&title=Epigenetic+therapy+combinations+in+acute+myeloid+leukemia%3A+what+are+the+options%3F&doi=10.1177%2F2040620718816698"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1177%2F2040620718816698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620718816698%26sid%3Dliteratum%253Aachs%26aulast%3DBewersdorf%26aufirst%3DJ.%2BP.%26aulast%3DShallis%26aufirst%3DR.%26aulast%3DStahl%26aufirst%3DM.%26aulast%3DZeidan%26aufirst%3DA.%2BM.%26atitle%3DEpigenetic%2520therapy%2520combinations%2520in%2520acute%2520myeloid%2520leukemia%253A%2520what%2520are%2520the%2520options%253F%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2019%26volume%3D10%26spage%3D1%26epage%3D19%26doi%3D10.1177%2F2040620718816698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hausheer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahnow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span> <span> </span><span class="NLM_article-title">A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3834</span>– <span class="NLM_lpage">3843</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-2287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1158%2F0008-5472.CAN-13-2287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=24876104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFCqsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3834-3843&author=Y.+Cuiauthor=F.+Hausheerauthor=R.+Beatyauthor=C.+Zahnowauthor=J.+P.+Issaauthor=F.+Bunzauthor=S.+B.+Baylin&title=A+recombinant+reporter+system+for+monitoring+reactivation+of+an+endogenously+DNA+hypermethylated+gene&doi=10.1158%2F0008-5472.CAN-13-2287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene</span></div><div class="casAuthors">Cui, Ying; Hausheer, Frederick; Beaty, Robert; Zahnow, Cynthia; Issa, Jean Pierre; Bunz, Frederick; Baylin, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3834-3843</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversing abnormal gene silencing in cancer cells due to DNA hypermethylation of promoter CpG islands may offer new cancer prevention or therapeutic approaches.  Here, the authors demonstrate the powerful utility of a novel gene reporter system to permit studies of the dynamics, mechanisms, and translational relevance of candidate therapies of this type in human colon cancer cells.  The reporter system is based on in situ modification of the endogenous locus of the tumor-suppressor gene SFRP1, a pivotal regulator of the Wnt pathway that is silenced by DNA hypermethylation in many colon cancers.  The modified SFRP1-GFP reporter allele used remained basally silent, like the unaltered allele, and it was activated only by drug treatments that derepress gene silencing by reversing DNA hypermethylation.  The authors used the established DNA methyltransferase inhibitor (DNMTi) 5-aza-deoxycytidine (DAC) to show how this system can be used to address key questions in the clin. development of epigenetic cancer therapies.  First, the authors defined conditions for which clin. relevant dosing could induce sustained induction of RNA and protein.  Second, they found that, in vivo, a more prolonged drug exposure than anticipated was essential to derepress gene silencing in significant cell nos., and this has implications for generating effective anticancer responses in patients with hematopoietic or solid tumors.  Finally, they discovered how histone deacetylase inhibitors (HDACi) alone, when administered to cells actively replicating DNA, can robustly reexpress the silenced gene with no change in promoter methylation status.  These findings offer a new tool and insights for devising optimal clin. expts. to evaluate epigenetic therapies aimed at improving the management and prevention of cancer.  Derived from Cancer Res; 74(14); 3834-43. © 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5emVpnjouObVg90H21EOLACvtfcHk0ljW5qO_7oA5lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFCqsL7E&md5=309f342799bd9a838aa23d21c5b5b66c</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-2287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-2287%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DY.%26aulast%3DHausheer%26aufirst%3DF.%26aulast%3DBeaty%26aufirst%3DR.%26aulast%3DZahnow%26aufirst%3DC.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%26aulast%3DBunz%26aufirst%3DF.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26atitle%3DA%2520recombinant%2520reporter%2520system%2520for%2520monitoring%2520reactivation%2520of%2520an%2520endogenously%2520DNA%2520hypermethylated%2520gene%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3834%26epage%3D3843%26doi%3D10.1158%2F0008-5472.CAN-13-2287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rye, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessum, N. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeritt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaac, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boros, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Billy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">te Poele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fee, L. O’</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1580</span>, <span class="refDoi"> DOI: 10.1039/C6MD00159A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1039%2FC6MD00159A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27746890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps12itLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1580&author=C.+S.+Ryeauthor=N.+E.+A.+Chessumauthor=S.+Lamontauthor=K.+G.+Pikeauthor=P.+Faulderauthor=J.+Demerittauthor=P.+Kemmittauthor=J.+Tuckerauthor=L.+Zaniauthor=M.+D.+Cheesemanauthor=R.+Isaacauthor=L.+Goodwinauthor=J.+Borosauthor=F.+Raynaudauthor=A.+Hayesauthor=A.+T.+Henleyauthor=E.+de+Billyauthor=C.+J.+Lynchauthor=S.+Y.+Sharpauthor=R.+te+Poeleauthor=L.+O%E2%80%99+Feeauthor=K.+M.+Footeauthor=S.+Greenauthor=P.+Workmanauthor=K.+Jones&title=Discovery+of+4%2C6-disubstituted+pyrimidines+as+potent+inhibitors+of+the+heat+shock+factor+1+%28HSF1%29+stress+pathway+and+CDK9&doi=10.1039%2FC6MD00159A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9</span></div><div class="casAuthors">Rye, Carl S.; Chessum, Nicola E. A.; Lamont, Scott; Pike, Kurt G.; Faulder, Paul; Demeritt, Julie; Kemmitt, Paul; Tucker, Julie; Zani, Lorenzo; Cheeseman, Matthew D.; Isaac, Rosie; Goodwin, Louise; Boros, Joanna; Raynaud, Florence; Hayes, Angela; Henley, Alan T.; de Billy, Emmanuel; Lynch, Christopher J.; Sharp, Swee Y.; te Poele, Robert; Fee, Lisa O'; Foote, Kevin M.; Green, Stephen; Workman, Paul; Jones, Keith</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1580-1586</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Heat shock factor 1 (HSF1) is a transcription factor that plays key roles in cancer, including providing a mechanism for cell survival under proteotoxic stress.  Therefore, inhibition of the HSF1-stress pathway represents an exciting new opportunity in cancer treatment.  We employed an unbiased phenotypic screen to discover inhibitors of the HSF1-stress pathway.  Using this approach we identified an initial hit (1) based on a 4,6-pyrimidine scaffold (2.00 μM).  Optimization of cellular SAR led to an inhibitor with improved potency (25, 15 nM) in the HSF1 phenotypic assay.  The 4,6-pyrimidine 25 was also shown to have high potency against the CDK9 enzyme (3 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp16iro0pz-9bVg90H21EOLACvtfcHk0liRaALADoe0Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps12itLo%253D&md5=23592e20ebd11fe41f80d9d4101b9c4e</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1039%2FC6MD00159A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00159A%26sid%3Dliteratum%253Aachs%26aulast%3DRye%26aufirst%3DC.%2BS.%26aulast%3DChessum%26aufirst%3DN.%2BE.%2BA.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DFaulder%26aufirst%3DP.%26aulast%3DDemeritt%26aufirst%3DJ.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DTucker%26aufirst%3DJ.%26aulast%3DZani%26aufirst%3DL.%26aulast%3DCheeseman%26aufirst%3DM.%2BD.%26aulast%3DIsaac%26aufirst%3DR.%26aulast%3DGoodwin%26aufirst%3DL.%26aulast%3DBoros%26aufirst%3DJ.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3Dde%2BBilly%26aufirst%3DE.%26aulast%3DLynch%26aufirst%3DC.%2BJ.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3Dte%2BPoele%26aufirst%3DR.%26aulast%3DFee%26aufirst%3DL.%2BO%25E2%2580%2599%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25204%252C6-disubstituted%2520pyrimidines%2520as%2520potent%2520inhibitors%2520of%2520the%2520heat%2520shock%2520factor%25201%2520%2528HSF1%2529%2520stress%2520pathway%2520and%2520CDK9%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D1580%26doi%3D10.1039%2FC6MD00159A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">The PROTAC technology in drug development</span>. <i>Cell Biochem Funct.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1002/cbf.3369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1002%2Fcbf.3369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30604499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslygsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=21-30&issue=1&author=Y.+Zouauthor=D.+Maauthor=Y.+Wang&title=The+PROTAC+technology+in+drug+development&doi=10.1002%2Fcbf.3369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The PROTAC technology in drug development</span></div><div class="casAuthors">Zou, Yutian; Ma, Danhui; Wang, Yinyin</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Function</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">CBFUDH</span>;
        ISSN:<span class="NLM_cas:issn">1099-0844</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Currently, a new technol. termed PROTAC, proteolysis targeting chimera, has been developed for inducing the protein degrdn. by a targeting mol.  This technol. takes advantage of a moiety of targeted protein and a moiety of recognizing E3 ubiquitin ligase and produces a hybrid mol. to specifically knock down a targeted protein.  During the first decade, three pedigreed groups worked on the development of this technol.  To date, this technol. has been extended by different groups, aiming to develop new drugs against different diseases including cancers.  This review summarizes the contributions of the groups for the development of PROTAC.  Significance of the study : This review summarized the development of the PROTAC technol. for readers and also presented the author's opinions on the application of the technol. in tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprT1CUHOqrfbVg90H21EOLACvtfcHk0liRaALADoe0Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslygsQ%253D%253D&md5=2a7417e2c385d01f7eaef52a72c7ea52</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1002%2Fcbf.3369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbf.3369%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DThe%2520PROTAC%2520technology%2520in%2520drug%2520development%26jtitle%3DCell%2520Biochem%2520Funct.%26date%3D2019%26volume%3D37%26issue%3D1%26spage%3D21%26epage%3D30%26doi%3D10.1002%2Fcbf.3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span> <span> </span><span class="NLM_article-title">Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=444-452&issue=2&author=I.+Churcher&title=Protac-induced+protein+degradation+in+drug+discovery%3A+breaking+the+rules+or+just+making+new+ones%3F&doi=10.1021%2Facs.jmedchem.7b01272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?</span></div><div class="casAuthors">Churcher, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">444-452</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn., using bifunctional small mols. (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches.  In this perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degrdn. concepts, and their resulting applications to medicine discovery.  The approach has the potential to bring disruptive change to drug discovery - the many potential advantages and outstanding challenges which lie ahead of this technol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9n8I_0MhtkbVg90H21EOLACvtfcHk0ljE7mDahGk4qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ&md5=e60f1777de8bd860c5001137d8583f1f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01272%26sid%3Dliteratum%253Aachs%26aulast%3DChurcher%26aufirst%3DI.%26atitle%3DProtac-induced%2520protein%2520degradation%2520in%2520drug%2520discovery%253A%2520breaking%2520the%2520rules%2520or%2520just%2520making%2520new%2520ones%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D2%26spage%3D444%26epage%3D452%26doi%3D10.1021%2Facs.jmedchem.7b01272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delproposto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">62</span>),  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01631</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01631" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=941-964&issue=62&author=X.+Hanauthor=C.+Wangauthor=C.+Qinauthor=W.+Xiangauthor=E.+Fernandez-Salasauthor=C.+Y.+Yangauthor=M.+Wangauthor=L.+Zhaoauthor=T.+Xuauthor=K.+Chinnaswamyauthor=J.+Delpropostoauthor=J.+Stuckeyauthor=S.+Wang&title=Discovery+of+ARD-69+as+a+highly+potent+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+androgen+receptor+%28AR%29+for+the+treatment+of+prostate+cancer&doi=10.1021%2Facs.jmedchem.8b01631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span></div><div class="casAuthors">Han, Xin; Wang, Chao; Qin, Chong; Xiang, Weiguo; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Mi; Zhao, Lijie; Xu, Tianfeng; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">941-964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by IARD-69.  I induces degrdn. of AR protein in AR-pos. prostate cancer cell lines in a dose- and time-dependent manner.  I achieves DC50 values of 0.86, 0.76, and 10.4 nM in LNCaP, VCaP, and 22Rv1 AR+ prostate cancer cell lines, resp.  I is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.  I potently inhibits cell growth in these AR-pos. prostate cancer cell lines and is >100 times more potent than AR antagonists.  A single dose of I effectively reduces the level of AR protein in xenograft tumor tissue in mice.  Further optimization of I may ultimately lead to a new therapy for AR+, castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTlOD69tfhtbVg90H21EOLACvtfcHk0ljE7mDahGk4qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D&md5=2376573fb1a1e19c517d64c70199700a</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01631%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DDelproposto%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520ARD-69%2520as%2520a%2520highly%2520potent%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520androgen%2520receptor%2520%2528AR%2529%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D62%26spage%3D941%26epage%3D964%26doi%3D10.1021%2Facs.jmedchem.8b01631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.ejmech.2018.03.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29627725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=304-314&author=C.+Zhangauthor=X.+R.+Hanauthor=X.+Yangauthor=B.+Jiangauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Proteolysis+targeting+chimeras+%28PROTACs%29+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1016%2Fj.ejmech.2018.03.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) activation has been assocd. with many types of human cancer.  Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK.  Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-pos. nonsmall cell lung cancers (NSCLC).  However, drug resistance has been obsd. in the majority of patients treated with these inhibitors.  New therapeutic strategies (e.g., compds. with novel mechanisms of action) are needed to overcome the drug resistance issue.  The emerging PROTAC (Proteolysis Targeting Chimera) technol. has been successfully applied to selective degrdn. of multiple protein targets, but not ALK.  Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity.  Here the authors report the design, synthesis and biol. evaluation of novel PROTACs (degraders) of ALK.  MS4077 (I) and MS4078 (II) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concn.- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells.  The ALK protein degrdn. induced by compds. I and II was cereblon and proteasome dependent.  In addn., compds. I and II potently inhibited proliferation of SU-DHL-1 cells.  Furthermore, compd. II displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies.  The authors also developed MS4748 and MS4740 , very close analogs of I and II resp., which are incapable to degrade the ALK fusion proteins, as neg. controls.  All 4 compds. are valuable chem. tools for investigating effects of ALK pharmacol. degrdn.  The study paved the way for developing the next generation of ALK PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGM3aAZZ6h7Vg90H21EOLACvtfcHk0ljE7mDahGk4qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D&md5=804324b95034f38b46e45f89e18e55be</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.%2BR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D304%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2018.03.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morreale, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, H.</span></span> <span> </span><span class="NLM_article-title">Types of ubiquitin ligases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.cell.2016.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=27015313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVamurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=248-248&issue=1&author=F.+E.+Morrealeauthor=H.+Walden&title=Types+of+ubiquitin+ligases&doi=10.1016%2Fj.cell.2016.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Types of ubiquitin ligases</span></div><div class="casAuthors">Morreale, Francesca Ester; Walden, Helen</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">248-248.e1</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Ubiquitination is a post-translational modification of proteins involved in a variety of cellular processes.  Ubiquitination requires the sequential action of 3 enzymes: E1 (ubiquitin-activating enzymes), E2 (ubiquitin-conjugating enzymes), and E3 (ubiquitin ligases).  Here, the authors highlight the main types of E3 ubiquitin ligases, which can be classified in 3 families depending on the presence of characteristic domains and on the mechanism of ubiquitin transfer to the substrate protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaGjtLCe1p8LVg90H21EOLACvtfcHk0lhrOmRPQCXJdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVamurg%253D&md5=f819525b60b95ed16340612d6bf51a13</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DMorreale%26aufirst%3DF.%2BE.%26aulast%3DWalden%26aufirst%3DH.%26atitle%3DTypes%2520of%2520ubiquitin%2520ligases%26jtitle%3DCell%26date%3D2016%26volume%3D165%26issue%3D1%26spage%3D248%26epage%3D248%26doi%3D10.1016%2Fj.cell.2016.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">First targeted protein degrader hits the clinic</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=237-239&author=A.+Mullard&title=First+targeted+protein+degrader+hits+the+clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DFirst%2520targeted%2520protein%2520degrader%2520hits%2520the%2520clinic%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D237%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petzold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoma, N. H.</span></span> <span> </span><span class="NLM_article-title">Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span> (<span class="NLM_issue">7597</span>),  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1038/nature16979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fnature16979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=26909574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=127-130&issue=7597&author=G.+Petzoldauthor=E.+S.+Fischerauthor=N.+H.+Thoma&title=Structural+basis+of+lenalidomide-induced+CK1%CE%B1+degradation+by+the+CRL4%28CRBN%29+ubiquitin+ligase&doi=10.1038%2Fnature16979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Petzold, Georg; Fischer, Eric S.; Thoma, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7597</span>),
    <span class="NLM_cas:pages">127-130</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thalidomide and its derivs., lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of hematol. malignancies.  IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4CRBN) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous CRL4CRBN substrates.  Unexpectedly, IMiDs also repurpose the ligase to target new proteins for degrdn.  Lenalidomide induces degrdn. of the lymphoid transcription factors Ikaros and Aiolos (also known as IKZF1 and IKZF3), and casein kinase 1α (CK1α), which contributes to its clin. efficacy in the treatment of multiple myeloma and 5q-deletion assocd. myelodysplastic syndrome (del(5q) MDS), resp.  How lenalidomide alters the specificity of the ligase to degrade these proteins remains elusive.  Here we present the 2.45 Å crystal structure of DDB1-CRBN bound to lenalidomide and CK1α.  CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop located in the kinase N-lobe.  We show that CK1α binding to CRL4CRBN is strictly dependent on the presence of an IMiD.  Binding of IKZF1 to CRBN similarly requires the compd. and both, IKZF1 and CK1α, use a related binding mode.  Our study provides a mechanistic explanation for the selective efficacy of lenalidomide in del(5q) MDS therapy.  We anticipate that high-affinity protein-protein interactions induced by small mols. will provide opportunities for drug development, particularly for targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs4FxWriI1ObVg90H21EOLACvtfcHk0lhrOmRPQCXJdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D&md5=320fc6ff811da335fa8e02feab2d702d</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnature16979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16979%26sid%3Dliteratum%253Aachs%26aulast%3DPetzold%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DThoma%26aufirst%3DN.%2BH.%26atitle%3DStructural%2520basis%2520of%2520lenalidomide-induced%2520CK1%25CE%25B1%2520degradation%2520by%2520the%2520CRL4%2528CRBN%2529%2520ubiquitin%2520ligase%26jtitle%3DNature%26date%3D2016%26volume%3D532%26issue%3D7597%26spage%3D127%26epage%3D130%26doi%3D10.1038%2Fnature16979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robb, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kour, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murry, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span> <span> </span><span class="NLM_article-title">Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">54</span>),  <span class="NLM_fpage">7577</span>– <span class="NLM_lpage">7580</span>, <span class="refDoi"> DOI: 10.1039/C7CC03879H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1039%2FC7CC03879H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=28636052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFyjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=7577-7580&issue=54&author=C.+M.+Robbauthor=J.+I.+Contrerasauthor=S.+Kourauthor=M.+A.+Taylorauthor=M.+Abidauthor=Y.+A.+Sonawaneauthor=M.+Zahidauthor=D.+J.+Murryauthor=A.+Natarajanauthor=S.+Rana&title=Chemically+induced+degradation+of+CDK9+by+a+proteolysis+targeting+chimera+%28PROTAC%29&doi=10.1039%2FC7CC03879H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Robb, Caroline M.; Contreras, Jacob I.; Kour, Smit; Taylor, Margaret A.; Abid, Mohammad; Sonawane, Yogesh A.; Zahid, Muhammad; Murry, Daryl J.; Natarajan, Amarnath; Rana, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">54</span>),
    <span class="NLM_cas:pages">7577-7580</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9), a member of the cyclin-dependent protein kinase (CDK) family, is involved in transcriptional elongation of several target genes.  CDK9 is ubiquitously expressed and has been shown to contribute to a variety of malignancies such as pancreatic, prostate and breast cancers.  Here we report the development of a heterobifunctional small mol. proteolysis targeting chimera (PROTAC) capable of cereblon (CRBN)-mediated proteasomal degrdn. of CDK9.  In HCT116 cells, it selectively degrades CDK9 while sparing other CDK family members.  This is the first example of a PROTAC that selectively degrades CDK9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXgLtOTwvlnbVg90H21EOLACvtfcHk0lggRblCuikq8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFyjsLw%253D&md5=a9aa8ebf8109f11206740efd1b5e09a2</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1039%2FC7CC03879H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CC03879H%26sid%3Dliteratum%253Aachs%26aulast%3DRobb%26aufirst%3DC.%2BM.%26aulast%3DContreras%26aufirst%3DJ.%2BI.%26aulast%3DKour%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DAbid%26aufirst%3DM.%26aulast%3DSonawane%26aufirst%3DY.%2BA.%26aulast%3DZahid%26aufirst%3DM.%26aulast%3DMurry%26aufirst%3DD.%2BJ.%26aulast%3DNatarajan%26aufirst%3DA.%26aulast%3DRana%26aufirst%3DS.%26atitle%3DChemically%2520induced%2520degradation%2520of%2520CDK9%2520by%2520a%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26issue%3D54%26spage%3D7577%26epage%3D7580%26doi%3D10.1039%2FC7CC03879H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bioorg.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30196207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=373-381&author=J.+Bianauthor=J.+Renauthor=Y.+Liauthor=J.+Wangauthor=X.+Xuauthor=Y.+Fengauthor=H.+Tangauthor=Y.+Wangauthor=Z.+Li&title=Discovery+of+wogonin-based+PROTACs+against+CDK9+and+capable+of+achieving+antitumor+activity&doi=10.1016%2Fj.bioorg.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity</span></div><div class="casAuthors">Bian, Jinlei; Ren, Jie; Li, Yongren; Wang, Jubo; Xu, Xi; Feng, Yifan; Tang, Hui; Wang, Yajing; Li, Zhiyu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">373-381</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Wogonin is a natural product isolated from the Scutellaria baicalensis and has been proved to be a potent and selective inhibitor of CDK9.  Using this scaffold, we designed and synthesized a series of proteolysis targeting chimeras (PROTACs) targeting CDK9 by recruiting ubiquitin E3 ligase cereblon (CRBN).  For constructing diverse Wogonin-based PROTACs, a "click chem." approach was employed for the synthesis of CDK9-targeting PROTACs.  The results of western blotting assays showed that compds. contg. triazole group in the linker could selectively downregulate the intracellular CDK9 level.  Among these compds., 11c could selectively degrade CDK9 in a concn.-dependent manner.  In addn., the application of the proteasome inhibitor MG132 and CRBN siRNA silencing confirmed that 11c could promote the proteasome-dependent and CRBN-dependent degrdn.  Consistent with the degrdn. of the CDK9 protein, 11c selectively inhibits proliferation of CDK9-overexpressed cancer cells.  Thus, our Wogonin-based PROTAC would be an efficient probe that induces the degrdn. of CDK9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod4sLAWq5vMrVg90H21EOLACvtfcHk0lggRblCuikq8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7bE&md5=6a7158be1fce50296d6d0ec9160db0fc</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520wogonin-based%2520PROTACs%2520against%2520CDK9%2520and%2520capable%2520of%2520achieving%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D373%26epage%3D381%26doi%3D10.1016%2Fj.bioorg.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockett, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawtin, R. E.</span></span> <span> </span><span class="NLM_article-title">SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1007/s00280-008-0921-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs00280-008-0921-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=19169685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFCksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2009&pages=723-732&issue=4&author=A.+Conroyauthor=D.+E.+Stockettauthor=D.+Walkerauthor=M.+R.+Arkinauthor=U.+Hochauthor=J.+A.+Foxauthor=R.+E.+Hawtin&title=SNS-032+is+a+potent+and+selective+CDK+2%2C+7+and+9+inhibitor+that+drives+target+modulation+in+patient+samples&doi=10.1007%2Fs00280-008-0921-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples</span></div><div class="casAuthors">Conroy, Andrew; Stockett, David E.; Walker, Duncan; Arkin, Michelle R.; Hoch, Ute; Fox, Judith A.; Hawtin, Rachael Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">723-732</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">SNS-032 (formerly BMS-387032) is a potent, selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9, currently in phase 1 clin. trial for chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).  We used the MM cell line RPMI-8226 to evaluate the relationship between duration of SNS-032 exposure, target modulation of CDKs 2, 7 and 9, and induction of apoptosis.  We also assessed target modulation in patient peripheral blood mononuclear cells (PBMCs) from phase 1 solid tumor patients treated with SNS-032.  Proliferation and colony forming assays were used to evaluate cytotoxicity, Western blot analyses to evaluate target modulation, FACS anal. to assess cell cycle distribution, RT-PCR to evaluate transcriptional inhibition.  SNS-032 blocks the cell cycle via inhibition of CDKs 2 and 7, and transcription via inhibition of CDKs 7 and 9.  Treatment of RPMI-8226 MM cells at 300 nM (IC90) for 6 h was sufficient for commitment to apoptosis.  This correlated with inhibition of CDKs 2, 7 and 9, as reflected in substrate signaling mols.  SNS-032 activity was unaffected by human serum.  Target modulation was obsd. in PBMC from treated patients.  These results demonstrate SNS-032 target modulation of CDKs 2, 7 and 9, and establish 6 h exposure as sufficient to commit RPMI-8226 MM cells to apoptosis.  Combined with the demonstration of target modulation in PBMC from phase 1 solid tumor patients treated with SNS-032, these data support the ongoing clin. study of SNS-032 in MM and CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMlNcab7zzo7Vg90H21EOLACvtfcHk0ljtiweiKUpGoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFCksLY%253D&md5=231b8ddb93821ba00d912ed28dbc1ccb</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1007%2Fs00280-008-0921-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-008-0921-5%26sid%3Dliteratum%253Aachs%26aulast%3DConroy%26aufirst%3DA.%26aulast%3DStockett%26aufirst%3DD.%2BE.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DHoch%26aufirst%3DU.%26aulast%3DFox%26aufirst%3DJ.%2BA.%26aulast%3DHawtin%26aufirst%3DR.%2BE.%26atitle%3DSNS-032%2520is%2520a%2520potent%2520and%2520selective%2520CDK%25202%252C%25207%2520and%25209%2520inhibitor%2520that%2520drives%2520target%2520modulation%2520in%2520patient%2520samples%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D64%26issue%3D4%26spage%3D723%26epage%3D732%26doi%3D10.1007%2Fs00280-008-0921-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span> <span> </span><span class="NLM_article-title">Halogen bonds form the basis for selective P-TEFb inhibition by DRB</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.chembiol.2010.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=20851342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=931-936&author=S.+Baumliauthor=J.+A.+Endicottauthor=L.+N.+Johnson&title=Halogen+bonds+form+the+basis+for+selective+P-TEFb+inhibition+by+DRB&doi=10.1016%2Fj.chembiol.2010.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen Bonds Form the Basis for Selective P-TEFb Inhibition by DRB</span></div><div class="casAuthors">Baumli, Sonja; Endicott, Jane A.; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">931-936</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Cdk9, the kinase of the pos. transcription elongation factor b, is required for processive transcription elongation by RNA polymerase II.  Cdk9 inhibition contributes to the anticancer activity of many Cdk inhibitors under clin. investigation and hence there is interest in selective Cdk9 inhibitors.  DRB (5,6-dichlorobenzimidazone-1-β-D-ribofuranoside) is a commonly used reagent for Cdk9 inhibition in cell biol. studies.  The crystal structures of Cdk9 and Cdk2 in complex with DRB reported here describe the mol. basis for the DRB selectivity toward Cdk9.  The DRB chlorine atoms form halogen bonds that are specific for the Cdk9 kinase hinge region.  Kinetic and thermodn. expts. validate the structural findings and implicate the C-terminal residues of Cdk9 in contributing to the affinity for DRB.  These results open the possibility to exploit halogen atoms in inhibitor design to specifically target Cdk9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMj3v7EG7-1LVg90H21EOLACvtfcHk0ljtiweiKUpGoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyit7fN&md5=88686dcae3c6943da8a05e463d4fd419</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DHalogen%2520bonds%2520form%2520the%2520basis%2520for%2520selective%2520P-TEFb%2520inhibition%2520by%2520DRB%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D931%26epage%3D936%26doi%3D10.1016%2Fj.chembiol.2010.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span> <span> </span><span class="NLM_article-title">The CDK9 c-helix exhibits conformational plasticity that may explain the selectivity of CAN508</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">816</span>, <span class="refDoi"> DOI: 10.1021/cb2004516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb2004516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVGlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=811-816&author=S.+Baumliauthor=A.+J.+Holeauthor=M.+E.+M.+Nobleauthor=J.+A.+Endicott&title=The+CDK9+c-helix+exhibits+conformational+plasticity+that+may+explain+the+selectivity+of+CAN508&doi=10.1021%2Fcb2004516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508</span></div><div class="casAuthors">Baumli, Sonja; Hole, Alison J.; Noble, Martin E. M.; Endicott, Jane A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">811-816</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CDK9 is the kinase of pos. transcription elongation factor b and facilitates the transition of paused RNA polymerase II to processive transcription elongation.  CDK9 is a validated target for the treatment of cancer, cardiac hypertrophy, and human immunodeficiency virus.  Here we analyze different CDK9/cyclin T variants to identify a form of the complex amenable to use in inhibitor design.  To demonstrate the utility of this system, we have detd. the crystal structures of CDK9/cyclin T and CDK2/cyclin A bound to the CDK9-specific inhibitor CAN508.  Comparison of the structures reveals CDK9-specific conformational changes and identifies a CDK9-specific hydrophobic pocket, adjacent to the αC-helix.  By comparison with a previously published structure of CDK9/cyclin T/human immunodeficiency virus TAT we find that the CDK9 αC-helix has a degree of conformational variability that has the potential to be exploited for inhibitor design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6zu3z8kUuhrVg90H21EOLACvtfcHk0ljmlNTioaKJpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVGlsro%253D&md5=32dc86d1d1b8ff619446a4d6a6773341</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fcb2004516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb2004516%26sid%3Dliteratum%253Aachs%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520CDK9%2520c-helix%2520exhibits%2520conformational%2520plasticity%2520that%2520may%2520explain%2520the%2520selectivity%2520of%2520CAN508%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D811%26epage%3D816%26doi%3D10.1021%2Fcb2004516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: novel potential CDK9 inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">104064</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2020.104064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.bioorg.2020.104064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=32653610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlyisLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2020&pages=104064&author=H.+Huauthor=J.+Wuauthor=M.+Aoauthor=X.+Zhouauthor=B.+Liauthor=Z.+Cuiauthor=T.+Wuauthor=L.+Wangauthor=Y.+Xueauthor=Z.+Wuauthor=M.+Fang&title=Design%2C+synthesis+and+biological+evaluation+of+methylenehydrazine-1-carboxamide+derivatives+with+%285-%28%284-%28pyridin-3-yl%29pyrimidin-2-yl%29amino%29-1H-indole+scaffold%3A+novel+potential+CDK9+inhibitors&doi=10.1016%2Fj.bioorg.2020.104064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors</span></div><div class="casAuthors">Hu, Hongyu; Wu, Jun; Ao, Mingtao; Zhou, Xiaoping; Li, Boqun; Cui, Zhenzhen; Wu, Tong; Wang, Lijuan; Xue, Yuhua; Wu, Zhen; Fang, Meijuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104064</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Design and synthesis of N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-2-methylenehydrazine-1-carboxamide derivs. I [R1 = n-Pr, 2-thienyl, Ph, etc.] and methylenehydrazine-1-carboxamide derivs. with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino))-1H-indole scaffold I [R2 = 4-pyridyl, 4-MeSC6H4, 1H-indol-3-yl, etc.] as novel potential CDK9 inhibitors was repoted.  Biol. activity results demonstrated that most of these derivs. I and II possessed good inhibitory on the kinase activity of CDK9 such as blocking its phosphorylation function and inhibiting HIV-1 transcription.  Compd. II [R2 = 1H-indol-3-yl] was found to be the most potent CDK9 inhibitor and exhibited excellent anticancer activity against HepG2, A375, MCF-7, and A549, but low toxic on normal cells including HaCaT and MCF-10A.  Further studies revealed that as a result of CDK9 inhibition and subsequent inhibition of phosphorylation at Serine 2 of the RNAPII CTD, the representative compd. II [R2 = 1H-indol-3-yl] dose-dependently increased cleaved PARP level, exerting its antiproliferative effect through induction of apoptosis in cancer cells.  Finally, the mol. docking anal. implied that compd. II [R2 = 1H-indol-3-yl] had a good binding affinity with CDK9.  In summary, compd. II [R2 = 1H-indol-3-yl] was a potent CDK9 inhibitor and could be considered as a good lead-candidate for developing potential anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUUGqHUrrS37Vg90H21EOLACvtfcHk0ljmlNTioaKJpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlyisLbE&md5=54bf245213ae9e856cfaad2758c190bc</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.104064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.104064%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DAo%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520methylenehydrazine-1-carboxamide%2520derivatives%2520with%2520%25285-%2528%25284-%2528pyridin-3-yl%2529pyrimidin-2-yl%2529amino%2529-1H-indole%2520scaffold%253A%2520novel%2520potential%2520CDK9%2520inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D102%26spage%3D104064%26doi%3D10.1016%2Fj.bioorg.2020.104064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khedkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutinho, E. C.</span></span> <span> </span><span class="NLM_article-title">3D-QSAR in drug design--a review</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.2174/156802610790232260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.2174%2F156802610790232260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=19929826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFWqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=95-115&author=J.+Vermaauthor=V.+M.+Khedkarauthor=E.+C.+Coutinho&title=3D-QSAR+in+drug+design%2D%2Da+review&doi=10.2174%2F156802610790232260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">3D-QSAR in drug design - a review</span></div><div class="casAuthors">Verma, Jitender; Khedkar, Vijay M.; Coutinho, Evans C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-115</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Quant. structure-activity relationships (QSAR) have been applied for decades in the development of relationships between physicochem. properties of chem. substances and their biol. activities to obtain a reliable statistical model for prediction of the activities of new chem. entities.  The fundamental principle underlying the formalism is that the difference in structural properties is responsible for the variations in biol. activities of the compds.  In the classical QSAR studies, affinities of ligands to their binding sites, inhibition consts., rate consts., and other biol. end points, with at., group or mol. properties such as lipophilicity, polarizability, electronic and steric properties (Hansch anal.) or with certain structural features (Free-Wilson anal.) have been correlated.  However such an approach has only a limited utility for designing a new mol. due to the lack of consideration of the 3D structure of the mols.  3D-QSAR has emerged as a natural extension to the classical Hansch and Free-Wilson approaches, which exploits the three-dimensional properties of the ligands to predict their biol. activities using robust chemometric techniques such as PLS, G/PLS, ANN etc.  It has served as a valuable predictive tool in the design of pharmaceuticals and agrochems.  Although the trial and error factor involved in the development of a new drug cannot be ignored completely, QSAR certainly decreases the no. of compds. to be synthesized by facilitating the selection of the most promising candidates.  Several success stories of QSAR have attracted the medicinal chemists to investigate the relationships of structural properties with biol. activity.  This review seeks to provide a bird's eye view of the different 3D-QSAR approaches employed within the current drug discovery community to construct predictive structure-activity relationships and also discusses the limitations that are fundamental to these approaches, as well as those that might be overcome with the improved strategies.  The components involved in building a useful 3D-QSAR model are discussed, including the validation techniques available for this purpose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIsS98xZ6vS7Vg90H21EOLACvtfcHk0ljmlNTioaKJpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFWqu7c%253D&md5=b3fc197c2730da3b7bb806366ef25c46</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.2174%2F156802610790232260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610790232260%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DJ.%26aulast%3DKhedkar%26aufirst%3DV.%2BM.%26aulast%3DCoutinho%26aufirst%3DE.%2BC.%26atitle%3D3D-QSAR%2520in%2520drug%2520design--a%2520review%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D95%26epage%3D115%26doi%3D10.2174%2F156802610790232260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kent, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, G.</span></span> <span> </span><span class="NLM_article-title">The broken cycle: E2F dysfunction in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1038/s41568-019-0143-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1038%2Fs41568-019-0143-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31053804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptFSqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=326-338&author=L.+N.+Kentauthor=G.+Leone&title=The+broken+cycle%3A+E2F+dysfunction+in+cancer&doi=10.1038%2Fs41568-019-0143-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">The broken cycle: E2F dysfunction in cancer</span></div><div class="casAuthors">Kent, Lindsey N.; Leone, Gustavo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">326-338</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The cyclin-dependent kinase (CDK)-RB-E2F axis forms the core transcriptional machinery driving cell cycle progression, dictating the timing and fidelity of genome replication and ensuring genetic material is accurately passed through each cell division cycle.  The ultimate effectors of this axis are members of a family of eight distinct E2F genes encoding transcriptional activators and repressors.  E2F transcriptional activity is tightly regulated throughout the cell cycle via transcriptional and translational regulation, post-translational modifications, protein degrdn., binding to cofactors and subcellular localization.  Alterations in one or more key components of this axis (CDKs, cyclins, CDK inhibitors and the RB family of proteins) occur in virtually all cancers and result in heightened oncogenic E2F activity, leading to uncontrolled proliferation.  In this Review, we discuss the activities of E2F proteins with an emphasis on the newest atypical E2F family members, the specific and redundant functions of E2F proteins, how misexpression of E2F transcriptional targets promotes cancer and both current and developing therapeutic strategies being used to target this oncogenic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZOonvudzTx7Vg90H21EOLACvtfcHk0lilTFb14uuwyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptFSqt7k%253D&md5=8f9b774c2dbdfee74823ab5a8f14b4cc</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fs41568-019-0143-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-019-0143-7%26sid%3Dliteratum%253Aachs%26aulast%3DKent%26aufirst%3DL.%2BN.%26aulast%3DLeone%26aufirst%3DG.%26atitle%3DThe%2520broken%2520cycle%253A%2520E2F%2520dysfunction%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2019%26volume%3D19%26spage%3D326%26epage%3D338%26doi%3D10.1038%2Fs41568-019-0143-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Condorelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailleux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span> <span> </span><span class="NLM_article-title">Polyclonal RB1 mutations and acquired resistance to CDK4/6 inhibitors in patients with metastatic breast cancer</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1093%2Fannonc%2Fmdx784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=29236940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BC1MzhtFWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=640-645&author=R.+Condorelliauthor=L.+Springauthor=J.+O%E2%80%99Shaughnessyauthor=L.+Lacroixauthor=C.+Bailleuxauthor=V.+Scottauthor=J.+Duboisauthor=R.+J.+Nagyauthor=R.+B.+Lanmanauthor=A.+J.+Iafrateauthor=F.+Andreauthor=A.+Bardia&title=Polyclonal+RB1+mutations+and+acquired+resistance+to+CDK4%2F6+inhibitors+in+patients+with+metastatic+breast+cancer&doi=10.1093%2Fannonc%2Fmdx784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer</span></div><div class="casAuthors">Condorelli R; Lacroix L; Bailleux C; Scott V; Andre F; Spring L; Dubois J; Iafrate A J; O'Shaughnessy J; Nagy R J; Lanman R B; Bardia A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">640-645</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  While deregulation of the cyclin D1-CDK4/6-retinoblastoma pathway is common in hormone receptor positive (HR+) breast cancer, Rb is usually intact in HR+ breast cancer, and targeted CDK 4/6 inhibitors that act upstream of Rb, are routinely being utilized in clinical practice.  However, factors that can lead to clinical resistance to CDK 4/6 inhibitors are not known.  Patients and methods:  We identified patients who had pre- and post-genotyping in tissue and peripheral blood samples after receiving CDK 4/6 inhibitors.  Genotyping was carried out in tumor tissue or blood collected before start of CDK 4/6 inhibitor and after disease progression on CDK 4/6 inhibitor, covering more than 90% of the coding region in RB1.  Results:  We identified detectable acquired RB1 mutations in circulating tumor DNA (ctDNA) after exposure to CDK4/6 inhibitor (palbociclib, palbociclib, ribociclib) for 5, 8, and 13 months, respectively, in three patients.  The RB1 mutations included substitution in donor splicing site of exon 8 of the RB1 gene in patient #1; substitution in donor splicing site of exon 22 of RB1 gene, exon 19 deletion, exon 3 insertion in patient #2; and RB1 exon 16 H483Y mutation in patient #3.  None of these RB1 mutations were present in the pre-CDK 4/6 specimen highlighting these molecular alterations, which lead to functional loss of Rb1, likely emerged under selective pressure from the CDK4/6 inhibitor potentially confering therapeutic resistance.  Conclusion:  This is the first clinical report to describe the emergence of somatic RB1 mutations after exposure to palbociclib or ribociclib, in patients with metastatic breast cancer.  Further research is needed to validate these findings, identify how these mutations temporally emerge under selective pressure of CDK 4/6 inhibitor, and develop rational therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT57Ei4We3h7fIW7hznt0zpfW6udTcc2ebvD4fAMR3I9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzhtFWisw%253D%253D&md5=0f659618552c56fdc7b21f50bbb7c0cf</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx784%26sid%3Dliteratum%253Aachs%26aulast%3DCondorelli%26aufirst%3DR.%26aulast%3DSpring%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DBailleux%26aufirst%3DC.%26aulast%3DScott%26aufirst%3DV.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DNagy%26aufirst%3DR.%2BJ.%26aulast%3DLanman%26aufirst%3DR.%2BB.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DBardia%26aufirst%3DA.%26atitle%3DPolyclonal%2520RB1%2520mutations%2520and%2520acquired%2520resistance%2520to%2520CDK4%252F6%2520inhibitors%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3D640%26epage%3D645%26doi%3D10.1093%2Fannonc%2Fmdx784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del Re, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crucitta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rofi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diodati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianfilippo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvadori, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scatena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naccarato, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danesi, R.</span></span> <span> </span><span class="NLM_article-title">Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1007/s10549-019-05365-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1007%2Fs10549-019-05365-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31346846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVGrtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=57-62&issue=1&author=M.+Del+Reauthor=I.+Bertoliniauthor=S.+Crucittaauthor=L.+Fontanelliauthor=E.+Rofiauthor=C.+De+Angelisauthor=L.+Diodatiauthor=D.+Cavalleroauthor=G.+Gianfilippoauthor=B.+Salvadoriauthor=S.+Fogliauthor=A.+Falconeauthor=C.+Scatenaauthor=A.+G.+Naccaratoauthor=M.+Roncellaauthor=M.+Ghilliauthor=R.+Morgantiauthor=A.+Fontanaauthor=R.+Danesi&title=Overexpression+of+TK1+and+CDK9+in+plasma-derived+exosomes+is+associated+with+clinical+resistance+to+CDK4%2F6+inhibitors+in+metastatic+breast+cancer+patients&doi=10.1007%2Fs10549-019-05365-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients</span></div><div class="casAuthors">Del Re, Marzia; Bertolini, Ilaria; Crucitta, Stefania; Fontanelli, Lorenzo; Rofi, Eleonora; De Angelis, Claudia; Diodati, Lucrezia; Cavallero, Diletta; Gianfilippo, Giulia; Salvadori, Barbara; Fogli, Stefano; Falcone, Alfredo; Scatena, Cristian; Naccarato, Antonio Giuseppe; Roncella, Manuela; Ghilli, Matteo; Morganti, Riccardo; Fontana, Andrea; Danesi, Romano</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-62</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The present article addresses the role of the mRNA expression of thymidine kinase 1 (TK1), CDK4, 6 and 9 in plasma-derived exosomes and their relevance in the pharmacol. activity of CDK4/6i.  Methods: Blood samples of 40 HR+/HER2- advanced breast cancer patients were collected before (T0) the administration of palbociclib plus hormonal therapy and after 3 mo (T1).  RNA was isolated from exosomes and analyzed for the expression of TK1, CDK 4, 6 and 9 by digital droplet PCR (ddPCR).  Results: A higher value of TK1 copies/mL at baseline (T0) was significantly assocd. with the no. of previous lines of chemotherapy (p = 0.009).  In patients with PD, a significant increase was obsd. in the no. of copies/mL of TK1 (p = 0.01) and CDK9 (p = 0.03) comparing T1 vs.  T0 values. No significant correlations between response to treatment and clin. parameters were found at univariate anal.  High baseline CDK4 expression was significantly correlated with longer PFS in patients treated with fulvestrant + palbociclib (low vs. high: 6.45 mo vs. not reached, p = 0.01).  Conclusions: The present study demonstrates that, in plasma-derived exosomes, high baseline CDK4 mRNA levels are assocd. with response to palbociclib plus hormonal therapy, while the increase in TK1 and CDK9 mRNA copies/mL is assocd. with clin. resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAoJIlNIJ7NLVg90H21EOLACvtfcHk0lgWU_ZXWhJMyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVGrtbzM&md5=e5684c7965c4527fe92c7c5c9869e428</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1007%2Fs10549-019-05365-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-019-05365-y%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BRe%26aufirst%3DM.%26aulast%3DBertolini%26aufirst%3DI.%26aulast%3DCrucitta%26aufirst%3DS.%26aulast%3DFontanelli%26aufirst%3DL.%26aulast%3DRofi%26aufirst%3DE.%26aulast%3DDe%2BAngelis%26aufirst%3DC.%26aulast%3DDiodati%26aufirst%3DL.%26aulast%3DCavallero%26aufirst%3DD.%26aulast%3DGianfilippo%26aufirst%3DG.%26aulast%3DSalvadori%26aufirst%3DB.%26aulast%3DFogli%26aufirst%3DS.%26aulast%3DFalcone%26aufirst%3DA.%26aulast%3DScatena%26aufirst%3DC.%26aulast%3DNaccarato%26aufirst%3DA.%2BG.%26aulast%3DRoncella%26aufirst%3DM.%26aulast%3DGhilli%26aufirst%3DM.%26aulast%3DMorganti%26aufirst%3DR.%26aulast%3DFontana%26aufirst%3DA.%26aulast%3DDanesi%26aufirst%3DR.%26atitle%3DOverexpression%2520of%2520TK1%2520and%2520CDK9%2520in%2520plasma-derived%2520exosomes%2520is%2520associated%2520with%2520clinical%2520resistance%2520to%2520CDK4%252F6%2520inhibitors%2520in%2520metastatic%2520breast%2520cancer%2520patients%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2019%26volume%3D178%26issue%3D1%26spage%3D57%26epage%3D62%26doi%3D10.1007%2Fs10549-019-05365-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minzel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatachalam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachya, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burstain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdman, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushansky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shlush, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikarsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snir-Alkalay, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Neriah, Y.</span></span> <span> </span><span class="NLM_article-title">Small molecules co-targeting CKIα and the transcriptional kinases CDK7/9 control AML in preclinical models</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1016%2Fj.cell.2018.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=30146162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyktbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=171-185&issue=1&author=W.+Minzelauthor=A.+Venkatachalamauthor=A.+Finkauthor=E.+Hungauthor=G.+Brachyaauthor=I.+Burstainauthor=M.+Shahamauthor=A.+Rivlinauthor=I.+Omerauthor=A.+Zingerauthor=S.+Eliasauthor=E.+Winterauthor=P.+E.+Erdmanauthor=R.+W.+Sullivanauthor=L.+Fungauthor=F.+Mercurioauthor=D.+Liauthor=J.+Vaccaauthor=N.+Kaushanskyauthor=L.+Shlushauthor=M.+Orenauthor=R.+Levineauthor=E.+Pikarskyauthor=I.+Snir-Alkalayauthor=Y.+Ben-Neriah&title=Small+molecules+co-targeting+CKI%CE%B1+and+the+transcriptional+kinases+CDK7%2F9+control+AML+in+preclinical+models&doi=10.1016%2Fj.cell.2018.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models</span></div><div class="casAuthors">Minzel, Waleed; Venkatachalam, Avanthika; Fink, Avner; Hung, Eric; Brachya, Guy; Burstain, Ido; Shaham, Maya; Rivlin, Amitai; Omer, Itay; Zinger, Adar; Elias, Shlomo; Winter, Eitan; Erdman, Paul E.; Sullivan, Robert W.; Fung, Leah; Mercurio, Frank; Li, Dansu; Vacca, Joseph; Kaushansky, Nathali; Shlush, Liran; Oren, Moshe; Levine, Ross; Pikarsky, Eli; Snir-Alkalay, Irit; Ben-Neriah, Yinon</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-185.e25</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">CKIα ablation induces p53 activation, and CKIα degrdn. underlies the therapeutic effect of lenalidomide in a pre-leukemia syndrome.  Here we describe the development of CKIα inhibitors, which co-target the transcriptional kinases CDK7 and CDK9, thereby augmenting CKIα-induced p53 activation and its anti-leukemic activity.  Oncogene-driving super-enhancers (SEs) are highly sensitive to CDK7/9 inhibition.  We identified multiple newly gained SEs in primary mouse acute myeloid leukemia (AML) cells and demonstrate that the inhibitors abolish many SEs and preferentially suppress the transcription elongation of SE-driven oncogenes.  We show that blocking CKIα together with CDK7 and/or CDK9 synergistically stabilize p53, deprive leukemia cells of survival and proliferation-maintaining SE-driven oncogenes, and induce apoptosis.  Leukemia progenitors are selectively eliminated by the inhibitors, explaining their therapeutic efficacy with preserved hematopoiesis and leukemia cure potential; they eradicate leukemia in MLL-AF9 and Tet2-/-;Flt3ITD AML mouse models and in several patient-derived AML xenograft models, supporting their potential efficacy in curing human leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg4QEH6R_ll7Vg90H21EOLACvtfcHk0licqaDQcOSK3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyktbvF&md5=b3e088a6b262dc8998ff334867102aa5</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DMinzel%26aufirst%3DW.%26aulast%3DVenkatachalam%26aufirst%3DA.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHung%26aufirst%3DE.%26aulast%3DBrachya%26aufirst%3DG.%26aulast%3DBurstain%26aufirst%3DI.%26aulast%3DShaham%26aufirst%3DM.%26aulast%3DRivlin%26aufirst%3DA.%26aulast%3DOmer%26aufirst%3DI.%26aulast%3DZinger%26aufirst%3DA.%26aulast%3DElias%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DE.%26aulast%3DErdman%26aufirst%3DP.%2BE.%26aulast%3DSullivan%26aufirst%3DR.%2BW.%26aulast%3DFung%26aufirst%3DL.%26aulast%3DMercurio%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DKaushansky%26aufirst%3DN.%26aulast%3DShlush%26aufirst%3DL.%26aulast%3DOren%26aufirst%3DM.%26aulast%3DLevine%26aufirst%3DR.%26aulast%3DPikarsky%26aufirst%3DE.%26aulast%3DSnir-Alkalay%26aufirst%3DI.%26aulast%3DBen-Neriah%26aufirst%3DY.%26atitle%3DSmall%2520molecules%2520co-targeting%2520CKI%25CE%25B1%2520and%2520the%2520transcriptional%2520kinases%2520CDK7%252F9%2520control%2520AML%2520in%2520preclinical%2520models%26jtitle%3DCell%26date%3D2018%26volume%3D175%26issue%3D1%26spage%3D171%26epage%3D185%26doi%3D10.1016%2Fj.cell.2018.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, B.</span>; <span class="NLM_string-name">Justin, C. D.</span>; <span class="NLM_string-name">Lisa, D.</span>; <span class="NLM_string-name">Theresa, P.</span>; <span class="NLM_string-name">Maryann, S. M.</span></span> <span> </span><span class="NLM_article-title">Combination of A BTK Inhibitor of CDK9 to Treat Cancer</span>. Patent <span class="NLM_patent">WO2019/058348A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=B.+Scott&author=C.+D.+Justin&author=D.+Lisa&author=P.+Theresa&author=S.+M.+Maryann&title=Combination+of+A+BTK+Inhibitor+of+CDK9+to+Treat+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DB.%26atitle%3DCombination%2520of%2520A%2520BTK%2520Inhibitor%2520of%2520CDK9%2520to%2520Treat%2520Cancer%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veeranki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solis, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kathkuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstetter, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maru, D. M.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK9 and MCL-1 by a new CDK9/P-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma</span>. <i>Ther Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1177/1758835919864850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1177%2F1758835919864850" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1-17&author=Z.+Tongauthor=A.+Mejiaauthor=O.+Veerankiauthor=A.+Vermaauthor=A.+M.+Correaauthor=R.+Dokeyauthor=V.+Patelauthor=L.+M.+Solisauthor=B.+Minoauthor=R.+Kathkudaauthor=J.+Rodriguez-Canalesauthor=S.+H.+Linauthor=S.+Krishnanauthor=S.+Kopetzauthor=M.+Blumauthor=J.+A.+Ajaniauthor=W.+L.+Hofstetterauthor=D.+M.+Maru&title=Targeting+CDK9+and+MCL-1+by+a+new+CDK9%2FP-TEFb+inhibitor+with+and+without+5-fluorouracil+in+esophageal+adenocarcinoma&doi=10.1177%2F1758835919864850"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1177%2F1758835919864850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758835919864850%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DMejia%26aufirst%3DA.%26aulast%3DVeeranki%26aufirst%3DO.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DCorrea%26aufirst%3DA.%2BM.%26aulast%3DDokey%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DSolis%26aufirst%3DL.%2BM.%26aulast%3DMino%26aufirst%3DB.%26aulast%3DKathkuda%26aufirst%3DR.%26aulast%3DRodriguez-Canales%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%2BH.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DBlum%26aufirst%3DM.%26aulast%3DAjani%26aufirst%3DJ.%2BA.%26aulast%3DHofstetter%26aufirst%3DW.%2BL.%26aulast%3DMaru%26aufirst%3DD.%2BM.%26atitle%3DTargeting%2520CDK9%2520and%2520MCL-1%2520by%2520a%2520new%2520CDK9%252FP-TEFb%2520inhibitor%2520with%2520and%2520without%25205-fluorouracil%2520in%2520esophageal%2520adenocarcinoma%26jtitle%3DTher%2520Adv.%2520Med.%2520Oncol.%26date%3D2019%26volume%3D11%26spage%3D1%26epage%3D17%26doi%3D10.1177%2F1758835919864850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCalmont, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toubia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casolari, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayoh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samaraweera, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, R. J.</span></span> <span> </span><span class="NLM_article-title">Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2019000586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=10.1182%2Fbloodadvances.2019000586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=31971998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FjsFeguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=296-300&author=H.+McCalmontauthor=K.+L.+Liauthor=L.+Jonesauthor=J.+Toubiaauthor=S.+C.+Brayauthor=D.+A.+Casolariauthor=C.+Mayohauthor=S.+E.+Samaraweeraauthor=I.+D.+Lewisauthor=R.+K.+Prinjhaauthor=N.+Smithersauthor=S.+Wangauthor=R.+B.+Lockauthor=R.+J.+D%E2%80%99Andrea&title=Efficacy+of+combined+CDK9%2FBET+inhibition+in+preclinical+models+of+MLL-rearranged+acute+leukemia&doi=10.1182%2Fbloodadvances.2019000586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia</span></div><div class="casAuthors">McCalmont Hannah; Jones Luke; Mayoh Chelsea; Lock Richard B; Li Ka Leung; Toubia John; Casolari Debora A; Samaraweera Saumya E; D'Andrea Richard J; Bray Sarah C; Lewis Ian D; Prinjha Rab K; Smithers Nicholas; Wang Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Blood advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">296-300</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGEj1qON9AKbt7lRqEFUJVfW6udTcc2eap2HwZZbn0XLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FjsFeguw%253D%253D&md5=3a266c0e3f97b0238fa22cc5b7b97089</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2019000586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2019000586%26sid%3Dliteratum%253Aachs%26aulast%3DMcCalmont%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DK.%2BL.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DToubia%26aufirst%3DJ.%26aulast%3DBray%26aufirst%3DS.%2BC.%26aulast%3DCasolari%26aufirst%3DD.%2BA.%26aulast%3DMayoh%26aufirst%3DC.%26aulast%3DSamaraweera%26aufirst%3DS.%2BE.%26aulast%3DLewis%26aufirst%3DI.%2BD.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DSmithers%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DR.%2BJ.%26atitle%3DEfficacy%2520of%2520combined%2520CDK9%252FBET%2520inhibition%2520in%2520preclinical%2520models%2520of%2520MLL-rearranged%2520acute%2520leukemia%26jtitle%3DBlood%2520Adv.%26date%3D2020%26volume%3D4%26spage%3D296%26epage%3D300%26doi%3D10.1182%2Fbloodadvances.2019000586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR','PDB','3BLR'); return false;">PDB: 3BLR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCP','PDB','4BCP'); return false;">PDB: 4BCP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3','PDB','2VU3'); return false;">PDB: 2VU3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF','PDB','4BCF'); return false;">PDB: 4BCF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCG','PDB','4BCG'); return false;">PDB: 4BCG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UA2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UA2','PDB','1UA2'); return false;">PDB: 1UA2</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i25"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00744">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_10853"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00744?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00744</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">The superimposition of the dominant conformation of CDK9 inhibitors in the binding site of CDK9 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00744/suppl_file/jm0c00744_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00744/suppl_file/jm0c00744_si_001.pdf">jm0c00744_si_001.pdf (255.51 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00744&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00744%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00744" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797fa138b6195b","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
